<SEC-DOCUMENT>0000914475-24-000054.txt : 20240209
<SEC-HEADER>0000914475-24-000054.hdr.sgml : 20240209
<ACCEPTANCE-DATETIME>20240209172913
ACCESSION NUMBER:		0000914475-24-000054
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240209
DATE AS OF CHANGE:		20240209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		24616306

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nbix-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:nbix="http://www.neurocrine.com/20231231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-32">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0000914475</ix:nonNumeric><ix:nonNumeric contextRef="c-30" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="f-208">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="c-52" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-374">P3Y</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-380">one</ix:nonFraction><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-381">one</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-155" decimals="8" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-627">0.00131711</ix:nonFraction><ix:nonNumeric contextRef="c-194" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-775">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-197" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-833">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1022">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-208" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1076">337</ix:nonNumeric><ix:nonNumeric contextRef="c-210" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1077">364</ix:nonNumeric><ix:nonNumeric contextRef="c-215" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1078">648</ix:nonNumeric><ix:nonNumeric contextRef="c-217" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1079">366</ix:nonNumeric><ix:nonNumeric contextRef="c-219" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1080">186</ix:nonNumeric><ix:nonNumeric contextRef="c-221" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1081">375</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestFourCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestFourCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nbix:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="non-clinicalstagecompound"><xbrli:measure>nbix:non-clinicalStageCompound</xbrli:measure></xbrli:unit><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="preclinicalcandidate"><xbrli:measure>nbix:preclinicalCandidate</xbrli:measure></xbrli:unit><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2019VoyagerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="undisclosedprogram"><xbrli:measure>nbix:undisclosedProgram</xbrli:measure></xbrli:unit><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2019VoyagerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2019VoyagerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2019VoyagerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2019VoyagerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2023VoyagerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="genetherapyprogram"><xbrli:measure>nbix:geneTherapyProgram</xbrli:measure></xbrli:unit><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2023VoyagerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2023VoyagerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:BIALPortelaCaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:ScientificEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:ScientificEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:Amended2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:Amended2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:TwoThousandAndElevenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:Amended2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-08</xbrli:startDate><xbrli:endDate>2022-02-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:GeorgeMorrowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:GeorgeMorrowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:EricBenevichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:EricBenevichMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nbix:EricBenevich2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:EricBenevichMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nbix:EricBenevich2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:EricBenevichMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nbix:EricBenevich2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:EricBenevichMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nbix:EricBenevich2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:IngridDelaetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:IngridDelaetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:LeslieNorwalkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:LeslieNorwalkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:ShaliniSharpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:ShaliniSharpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:RichardPopsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:RichardPopsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:EricBenevichMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">nbix:EricBenevich2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_1"></div><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:548.25pt"><tr><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:532.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:548.25pt"><tr><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:532.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from __________to__________</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission file number </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">0-22705</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:548.25pt"><tr><td style="width:1.0pt"/><td style="width:109.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:55.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:104.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:219.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">33-0525145</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">12780 El Camino Real,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">San&#160;Diego,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">92130</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">617-7600</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.140%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.141%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">NBIX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Title of each class)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Trading Symbol)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Name of each exchange on which registered)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Title of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">class</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric>&#160;&#160;&#9745;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;&#9745;&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;&#9745;&#160;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;&#9745;&#160;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.863%"><tr><td style="width:1.0%"/><td style="width:15.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.146%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9745;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;&#9744;&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9745;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric>&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b).&#160;&#160;&#9744;&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;No&#160;&#160;&#9745;&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of registrant&#8217;s common stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, June 30, 2023, was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="f-29">7.9</ix:nonFraction> billion.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of February&#160;5, 2024, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">99,507,490</ix:nonFraction> shares of the registrant&#8217;s common stock were outstanding.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days following the end of the registrant&#8217;s fiscal year ended December&#160;31, 2023 are incorporated by reference into Part III of this Form 10-K.</span></div></ix:nonNumeric><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_10">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_58">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_58">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_64">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_64">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1C.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_1809">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_1809">ybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_1809">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_67">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_67">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_70">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_70">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_73">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_73">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_76">PART&#160;II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_79">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_79">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_88">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_82">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_103">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_103">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_106">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_106">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_175">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_175">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_178">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_178">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_187">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_187">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_190">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_190">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_193">PART&#160;III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_196">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_196">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_199">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_199">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_202">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_202">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_205">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_205">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_208">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_208">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_211">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_214">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_214">97</a></span></div></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEUROCRINE, the Neurocrine logo, INGREZZA, the INGREZZA logo, and other Neurocrine Biosciences trademarks are the property of Neurocrine Biosciences, Inc. ALKINDI, EFMODY, and other Diurnal trademarks are the property of Diurnal Limited, a Neurocrine Biosciences company. Any other brand names or trademarks appearing in this Annual Report that are not the property of Neurocrine Biosciences, Inc. are the property of their respective holders.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_13"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form&#160;10-K and the information incorporated herein by reference contain forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;pro forma,&#8221; or &#8220;anticipates,&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as the development of new products, technology enhancements, possible changes in legislation and other statements that are not historical. These statements include but are not limited to statements under the captions &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business,&#8221; as well as other sections in this report. You should be aware that the occurrence of any of the events discussed under the heading in Part I titled &#8220;Item&#160;1A. Risk Factors&#8221; and elsewhere in this report could substantially harm our business, results of operations and financial condition and that if any of these events occurs, the trading price of our common stock could decline and you could lose all or a part of the value of your shares of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_19"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to advance medicines for the treatment of under-addressed neurological, neuroendocrine and neuropsychiatric disorders and we will continue to relentlessly pursue medicines to ease the burden of debilitating diseases and disorders.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched INGREZZA in the U.S. in May 2017 as the first U.S. Food and Drug Administration (FDA)-approved drug for the treatment of tardive dyskinesia and in August 2023 for the treatment of chorea associated with Huntington's disease. INGREZZA provides a once-daily dosing treatment option with a recommended dose of 40 mg taken for the first seven days of treatment for tardive dyskinesia and fourteen days for chorea associated with Huntington&#8217;s disease, and an option to take 40 mg, 60 mg, or 80 mg thereafter, depending on the patient&#8217;s dosing needs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, INGREZZA helped more people affected by tardive dyskinesia than ever before, reflecting higher prescription demand driven by increased commercial activities, including the continued investment in our branded direct-to-consumer INGREZZA advertising campaign and benefit from the expansion of our sales force completed in April 2022. Going forward, key elements of our commercial strategy include maximizing the opportunity in INGREZZA through consistent and effective commercial execution, continued development of valbenazine as the best-in-class treatment for new patient populations and to lead the evolving understanding of VMAT2 biology and its role in disease. INGREZZA net product sales totaled $1.8 billion for 2023, $1.4 billion for 2022 and $1.1 billion for 2021 and accounted for approximately 99% of our total net product sales for 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal research and development efforts are focused on innovative therapies with clear and defined clinical and regulatory paths to approval. From time to time, we supplement our internal research and development efforts by in-licensing the rights to certain clinical development programs or by acquiring businesses that synergize with and allow us to capitalize on our existing development and commercial capabilities.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercial Products</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Major Markets</span></td></tr><tr style="height:3pt"><td colspan="3" rowspan="4" style="border-top:1pt solid #000;padding:0 1pt"><div style="text-align:center"><img src="nbix-20231231_g1.jpg" alt="ingrezza2.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"/></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tardive Dyskinesia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S., Japan, Select Asian Markets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt dashed #929292;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chorea Associated with Huntington&#8217;s Disease</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #929292;padding:0 1pt"><div style="text-align:center"><img src="nbix-20231231_g2.jpg" alt="alkindi4.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"/></div></td><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adrenal Insufficiency</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S., United Kingdom, EU4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(3)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #929292;padding:0 1pt"><div style="text-align:center;text-indent:-4.5pt"><img src="nbix-20231231_g3.jpg" alt="efmody2.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"/></div></td><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classic Congenital Adrenal Hyperplasia</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom, EU4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(3)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #929292;padding:0 1pt"><div style="text-align:center;text-indent:-4.5pt"><img src="nbix-20231231_g4.jpg" alt="orilissa.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"/></div></td><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endometriosis</span></td><td colspan="3" style="padding:0 1pt 0 5.5pt;text-indent:-4.5pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(4)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:0 1pt"><div style="text-align:center;text-indent:-4.5pt"><img src="nbix-20231231_g5.jpg" alt="oriahnn.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"/></div></td><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uterine Fibroids</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(4)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #929292;padding:0 1pt 0 5.5pt;text-indent:-4.5pt"/><td colspan="3" style="border-bottom:1pt solid #929292;padding:0 1pt 0 5.5pt;text-indent:-4.5pt"/><td colspan="3" style="border-bottom:1pt solid #929292;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) INGREZZA is marketed as DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan and REMLEAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) ALKINDI is marketed as ALKINDI SPRINKLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (hydrocortisone) in the U.S., where Eton Pharmaceuticals, Inc. retains commercialization rights.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) The EU4 market is made up of the following countries: Germany, France, Italy and Spain.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) AbbVie Inc. retains global commercialization rights to elagolix.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Marketing and Distribution</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our specialty sales force consists of approximately 400 experienced sales professionals located in the U.S. and is divided into three dedicated sales teams focused on psychiatry, neurology and long-term care.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For INGREZZA, our customers in the U.S. consist of a limited network of specialty pharmacy providers that deliver INGREZZA to patients by mail, wholesale distributors that distribute INGREZZA primarily to certain specialty pharmacies, and specialty distributors that distribute INGREZZA primarily to closed-door pharmacies and government facilities. We rely on third-party service providers to perform a variety of functions related to the packaging, storage and distribution of INGREZZA.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_34"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on, and intend to continue to rely on, third-party manufacturers for the production of INGREZZA and our product candidates. Raw materials, active pharmaceutical ingredients (API) and other supplies required for the production of INGREZZA and our product candidates are sourced from various third-party manufacturers and suppliers in quantities adequate to meet our needs. Continuing adequate supply of such raw materials and API is assured through our long-term commercial supply and manufacturing agreements with multiple manufacturers and our continued focus on the expansion and diversification of our third-party manufacturing relationships.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our outsourced manufacturing strategy enables us to direct our financial resources to the maximization of our opportunity with INGREZZA, investment in our internal research and development programs and expansion of our clinical pipeline through business development opportunities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party manufacturers, suppliers and service providers may be subject to routine current Good Manufacturing Practice (cGMP) inspections by the FDA or comparable agencies in other jurisdictions. We depend on our third-party partners and our quality system oversight of them for continued compliance with cGMP requirements and applicable foreign standards.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_1099511629500"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Development Programs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table highlights our current clinical development programs and the current phase of development for such programs.</span></div><div style="margin-top:3pt"><img src="nbix-20231231_g6.jpg" alt="pipeline chart.jpg" style="height:448px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Mitsubishi Tanabe Pharma Corporation retains commercialization rights in Japan and other select Asian markets.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224; Heptares Therapeutics Limited retains commercialization rights in Japan, where Neurocrine Biosciences retains the right to opt in to a 50:50 profit sharing arrangement upon certain development events.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) This program was in-licensed from Heptares Therapeutics Limited.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) This program was in-licensed from Idorsia Pharmaceuticals Ltd.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) This program was in-licensed from Xenon Pharmaceuticals Inc.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) This program was in-licensed from Sanofi S.A.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) This program was in-licensed from Takeda Pharmaceutical Company Limited</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences retains global rights unless otherwise noted.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Neurology</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Valbenazine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Valbenazine is a highly selective VMAT2 inhibitor. VMAT2 is a protein concentrated in the human brain that is essential for the transmission of nerve impulses between neurons. VMAT2 is primarily responsible for packaging and transporting monoamines (dopamine, norepinephrine, serotonin and histamine) in neurons. Specifically, dopamine enables neurotransmission among nerve cells that are involved in voluntary and involuntary motor control.</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Dyskinetic Cerebral Palsy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Dyskinetic cerebral palsy is a non-progressive, permanent disorder marked by involuntary movement and is a result of damage to the fetal or infant brain&#8217;s basal ganglia. The basal ganglia are responsible for submitting messages to the body to help coordinate and control movements. When damaged, voluntary movements are compromised, resulting in involuntary and abnormal movements. It affects development and movement and has long term effects on patients&#8217; quality of life. The long-term outlook for patients with dyskinetic cerebral palsy will depend upon the severity of the brain damage and how well the treatment works. Dyskinetic cerebral palsy affects up to 15% of the estimated 500,000 to 1 million people affected by cerebral palsy in the U.S.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">NBI-921352. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NBI-921352 is a potent, highly selective Nav1.6 sodium channel inhibitor being developed to treat pediatric patients with SCN8A-DEE and other potential indications. We acquired the global rights to NBI-921352 in December 2019.</span></div></td><td colspan="3" style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">SCN8A Developmental and Epileptic Encephalopathy Syndrome, or SCN8A-DEE. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCN8A-DEE is a rare, extremely severe, single-gene epilepsy caused by mutations in the SCN8A gene that activates Nav1.6, the most highly expressed sodium channel in the excitatory pathways of the central nervous system. Children born with SCN8A-DEE typically start experiencing seizures between birth and 18 months of age, and most have multiple seizures per day. Other symptoms include learning difficulties, muscle spasms, low or high muscle tone, poor coordination, developmental delay and features similar to autism. As SCN8a mutations were discovered only recently, prevalence estimates will be determined in the future as awareness of and access to genetic surveillance increases. NBI-921352 has been granted orphan drug and rare pediatric disease designations for the treatment of SCN8A-DEE in the U.S.</span></div></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valbenazine in Pediatrics and Adults with Dyskinetic Cerebral Palsy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing Phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and tolerability of valbenazine for the treatment of dyskinetic cerebral palsy in pediatrics and adults (aged 6 to 70 years).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBI-921352 in Pediatrics and Adolescents with SCN8A-DEE. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have ongoing the KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> study, a Phase 2 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in adolescents (aged 12 to 21 years) with SCN8A-DEE. In January 2022, the study protocol was amended to include pediatrics (aged 2 to 11 years) with SCN8A-DEE.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Neuroendocrinology</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Crinecerfont.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Crinecerfont is an investigational, oral, selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist being developed to reduce and control excess adrenal androgens through a steroid-independent mechanism for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crinecerfont has received orphan drug designation in the U.S. from the FDA and in the European Union (EU) from the European Medicines Agency (EMA). Crinecerfont has also received Breakthrough Therapy designation in the U.S. from the FDA for the treatment of CAH due to 21-OHD in adults and pediatrics.</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Classic Congenital Adrenal Hyperplasia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAH is a genetic disorder that causes little to no cortisol production and increased secretion of adrenocorticotropic hormone (ACTH) and androgens. In approximately 75% of cases, the adrenal glands cannot produce aldosterone, which can result in salt wasting adrenal crisis, causing extreme weakness, low blood pressure, shock, and even death. There are currently no non-steroidal FDA-approved treatments for CAH. CAH affects up to an estimated 30,000 people in the U.S. and 50,000 people in Europe.</span></div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">EFMODY.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> EFMODY is a modified-release preparation of hydrocortisone that mimics the physiological circadian rhythm of cortisol and has been specifically designed for patients with diseases of cortisol deficiency, such as CAH and adrenal insufficiency.</span></div></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Classic Congenital Adrenal Hyperplasia.</span></div></td></tr><tr style="height:53pt"><td colspan="3" style="border-bottom:1pt solid #929292;border-top:1pt dashed #929292;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Adrenal Insufficiency.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Adrenal insufficiency is a rare condition caused by inadequate production of steroid hormones in the cortex of the adrenal glands. Adrenal insufficiency can result in severe fatigue and, if left untreated, adrenal crisis that may be life threatening.</span></div></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Crinecerfont in Adults with CAH.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we announced positive top-line data from the Phase 3 CAHtalyst&#8482; clinical study of crinecerfont in adults with CAH due to 21-OHD. The Phase 3 adult study met its primary endpoint at Week 24, demonstrating that treatment with crinecerfont resulted in a statistically significant percent reduction in daily glucocorticoid (GC) dose versus placebo while maintaining androgen control (p-value &lt;0.0001). The study also met important key secondary endpoints, with a statistically significant decrease in androstenedione at Week 4 versus placebo (p-value &lt;0.0001). At Week 24, approximately 63% of patients on crinecerfont achieved a reduction to a physiologic GC dose versus approximately 18% on placebo (p-value &lt;0.0001). The data from the Phase 3 adult study, including data from the open-label treatment period, will support New Drug Application (NDA) submission to the FDA in the second quarter of 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Crinecerfont in Pediatrics with CAH.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we announced positive top-line data from the Phase 3 CAHtalyst&#8482; clinical study of crinecerfont in pediatrics (aged 2 to 17 years) with CAH due to 21-OHD. The Phase 3 pediatric study met its primary endpoint, demonstrating that treatment with crinecerfont resulted in a statistically significant decrease in serum androstenedione from baseline at Week 4 versus placebo following a GC stable period (p = 0.0002). Consistent with the results from the Phase 3 adult study, crinecerfont treatment led to a statistically significant percent reduction from baseline in daily GC dose while maintaining androgen control at Week 28 versus placebo (p &lt; 0.0001). Approximately 30% of participants receiving crinecerfont achieved a reduction to a physiologic GC dose while maintaining androgen control compared to 0% of participants receiving placebo. The study also met the other key secondary endpoint demonstrating a statistically significant decrease in serum 17-hydroxyprogesterone from baseline at Week 4 versus placebo (p &lt; 0.0001). The data from the Phase 3 pediatric study, including data from the open-label treatment period, will support NDA submission to the FDA in the second quarter of 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EFMODY in Adolescents and Adults with CAH. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing Phase 2 randomized, double-blind, active-controlled clinical study to evaluate the efficacy, safety and tolerability of twice-daily EFMODY compared with twice-daily Cortef</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (immediate-release hydrocortisone tablets) in adolescents and adults (aged 16 years and older) with CAH. We anticipate having top-line data for this clinical study in the first half of 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EFMODY in Adults with Adrenal Insufficiency. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have ongoing the CHAMPAIN study, a Phase 2 randomized, double-blind, double-dummy, two-way crossover clinical study to evaluate the efficacy, safety and tolerability of twice-daily EFMODY compared with once-daily Plenadren</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (modified-release hydrocortisone tablets) in adults with primary adrenal insufficiency. We anticipate having top-line data for this clinical study in the first half of 2024.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Neuropsychiatry</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td></tr><tr style="height:93pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Valbenazine. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valbenazine is a highly selective VMAT2 inhibitor. VMAT2 is a protein concentrated in the human brain that is essential for the transmission of nerve impulses between neurons. VMAT2 is primarily responsible for packaging and transporting monoamines (dopamine, norepinephrine, serotonin and histamine) in neurons. Specifically, dopamine enables neurotransmission among nerve cells that are involved in voluntary and involuntary motor control.</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Schizophrenia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Schizophrenia is a spectrum of serious neuropsychiatric brain diseases in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions and extremely disordered thinking and behavior that impairs daily life. People with schizophrenia typically require lifelong treatment. Early treatment may help improve long-term prognosis and get symptoms under control before serious complications develop. Schizophrenia affects an estimated 3.5 million people in the U.S. All currently approved antipsychotic medications are believed to work through direct action on monoaminergic receptors, with approximately 40% of patients reporting negative side effects and approximately 30% not benefiting adequately from these medications.</span></div></td></tr><tr style="height:113pt"><td colspan="3" style="border-top:1pt dashed #929292;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">NBI-1117568. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NBI-1117568 is a potential first-in-class muscarinic M4 receptor agonist with the potential to be developed for the treatment of schizophrenia. As a selective M4 orthosteric agonist, NBI-1117568 offers the potential for an improved safety profile without the need for combination therapy to ameliorate off-target effects or for cooperativity with acetylcholine. Muscarinic receptors are central to brain function and validated as drug targets in psychosis and cognitive disorders. We acquired the global rights to NBI-1117568 in December 2021.</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Luvadaxistat. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luvadaxistat is a potential first-in-class D-Amino Acid Oxidase (DAAO) inhibitor with the potential to be developed for the treatment of cognitive impairment associated with schizophrenia. We acquired the global rights to luvadaxistat in June 2020.</span></div></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Cognitive Impairment Associated with Schizophrenia, or CIAS. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CIAS, which may include deficits in attention, working memory and executive function, has a negative impact on patients&#8217; quality of life and ability to function. Although cognitive symptoms in schizophrenia are well characterized, no formal diagnostic criteria exist. Furthermore, no pharmacological agents are approved to treat the condition, and no marketed therapy tested to date has established clear, meaningful efficacy, which underscores the difficulty of drug development in this arena and accentuates the unmet need for proven treatment options. Approximately 80% of the estimated 3.5 million people affected by schizophrenia in the U.S. experience clinically relevant cognitive impairment.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">NBI-1065845. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NBI-1065845 is a potential first-in-class Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA) potentiator with the potential to be developed for the treatment of inadequate response to treatment in major depressive disorder. We acquired the global rights to NBI-1065845 in June 2020. NBI-1065845 is currently designated as a 50:50 profit-share product with Takeda Pharmaceutical Company Limited, which retains a one-time opt-out right to convert the designation to a royalty-bearing product.</span></div></td><td colspan="3" style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Major Depressive Disorder. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Major depressive disorder is one of the leading causes of disability and is characterized by a persistently depressed mood or loss of interest in daily activities that is present most of the day in addition to other symptoms that can impact normal daily functioning, relationships and overall quality of life. Treatments range from selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, atypical antipsychotics, tricyclic antidepressants and psychotherapies, among others. Approximately 30% of the more than 16 million people affected by the disorder in the U.S. do not adequately respond to treatment.</span></div></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valbenazine in Adolescents and Adults with Schizophrenia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing Phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and tolerability of valbenazine when administered orally once daily as adjunctive treatment in adolescents and adults (aged 13 years and older) with schizophrenia who have had an inadequate response to antipsychotics.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBI-1117568 in Adults with Schizophrenia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing Phase 2 multi-center, randomized, double-blind, placebo-controlled, multi-arm, multi-stage clinical study to evaluate the efficacy, safety and tolerability of NBI-1117568 in adults with schizophrenia who are experiencing an acute exacerbation or relapse of symptoms. We anticipate having top-line data for this clinical study in the second half of 2024.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Luvadaxistat in Adults with CIAS.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have ongoing the ERUDITE&#8482; study, a Phase 2 randomized, double-blind, parallel, placebo-controlled clinical study to evaluate the efficacy, safety, tolerability and pharmacokinetics of luvadaxistat when administered orally once daily as adjunctive treatment in adults with CIAS. We anticipate having top-line data for this clinical study in the second half of 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBI-1065845 in Adults with Inadequate Response to Treatment in Major Depressive Disorder.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have ongoing the SAVITRI&#8482; study, a Phase 2 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of NBI-1065845 as adjunctive treatment in adults with inadequate response to treatment in major depressive disorder. We anticipate having top-line data for this clinical study in the first half of 2024.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_31"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek to protect our products, product candidates, and related inventions and improvements that we consider important to our business. We own a portfolio of U.S. and ex-U.S. patents and patent applications, and have also licensed rights to a number of U.S. and ex-U.S. patents and patent applications. Our owned and licensed patents and patent applications cover or relate to our products and product candidates, including certain formulations, uses to treat particular conditions, methods of administration, drug delivery technologies and delivery profiles, and methods of manufacturing.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a description of the U.S. and ex-U.S. patents to INGREZZA and crinecerfont:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INGREZZA, our highly selective VMAT2 inhibitor approved in the U.S. for the treatment of tardive dyskinesia and of chorea associated with Huntington&#8217;s disease, is covered by 22 issued, FDA Orange Book-listed U.S. patents which are set to expire between 2027 and 2040. Patent term extension corresponding to regulatory approval delay of 552 days has been received for U.S. Patent No. 8,039,627, which now expires in 2031 and covers valbenazine, the active pharmaceutical ingredient contained in INGREZZA. In Japan and in certain other East Asian markets, we are actively pursuing most of the patents corresponding to those listed in the FDA&#8217;s Orange Book entry for INGREZZA. In 2023, we entered into settlement agreements resolving all patent litigation brought by us against the companies that filed ANDAs seeking approval to market generic versions of INGREZZA, and all cases have been dismissed. Pursuant to the terms of the respective settlement agreements, such companies have the right to sell generic versions of INGREZZA in the U.S. beginning March 1, 2038, or earlier under certain circumstances. Refer to Note 13 to the consolidated financial statements for a more detailed description of these matters.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Crinecerfont, a CRF1 receptor antagonist under clinical development for the treatment of CAH in adults and children, is covered by U.S. Patent Nos. 10,905,690, 11,311,544, and 11,730,739, among other patents and pending patent applications, set to expire between 2035 and 2044 (not including any potential patent term extensions).</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own, or have licensed rights to, patents covering our other products and earlier stage product candidates. In addition to the potential patent term extensions referenced above, the products and product candidates in our pipeline may be subject to additional terms of exclusivity that we may obtain by future patent issuances.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the U.S., the EU, and Japan each provide data and marketing exclusivity for new medicinal compounds. If this protection is available, no competitor may use the original applicant&#8217;s data as the basis of a generic marketing application during the period of data and marketing exclusivity, which is measured from the date of marketing approval by the FDA or corresponding foreign regulatory authority. This period of exclusivity is generally five years in the U.S., six years in Japan and 10 years in the EU, except that for biologics, the period of exclusivity in the U.S. is 12 years under the Biologics Price Competition and Innovation Act. In addition, if granted orphan drug designation, certain of our product candidates, including, for example, crinecerfont, may also be eligible for marketing exclusivity in the U.S. for seven years and EU for 10 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Part I, Item 1A. Risk Factors for a discussion of the challenges we may face in obtaining or maintaining patent and/or trade secret protection and Note 13 to the consolidated financial statements f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a description of our legal proceedings related to intellectual property matters.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval and marketing than we do.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may also arise from, among other things, other drug development technologies, methods of preventing or reducing the incidence of disease, including vaccines, and new small molecule or other classes of therapeutic agents. Such developments by others (including the development of generic equivalents) may render our product candidates or technologies obsolete or noncompetitive.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INGREZZA competes with AUSTEDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (deutetrabenazine), marketed by Teva Pharmaceuticals Industries, for the treatment of tardive dyskinesia in adults and chorea associated with Huntington's disease. A once-daily dosing of AUSTEDO (AUSTEDO XR) was introduced in February 2023. Additionally, there are a number of commercially available medicines used to treat tardive dyskinesia off-label, such as XENAZINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tetrabenazine) and generic equivalents, and various antipsychotic medications (e.g., clozapine), anticholinergics, benzodiazepines (off-label), and botulinum toxin. In addition, there are several programs in clinical development by other companies targeting Huntington's disease.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORILISSA and ORIAHNN each compete with several FDA-approved products for the treatment of endometriosis, uterine fibroids, infertility and central precocious puberty. Additionally, there is also competition from surgical intervention, including hysterectomies and ablations. Separate from these options, there are many programs in clinical development which serve as potential future competition. Lastly, there are numerous medicines used to treat the symptoms of disease (vs. endometriosis or uterine fibroids directly) which may also serve as competition: oral contraceptives, NSAIDs and other pain medications, including opioids.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For CAH, high doses of corticosteroids are the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive ACTH levels. In the U.S. alone, there are more than two dozen companies manufacturing steroid-based products. In addition, there are several programs in clinical development by other companies targeting CAH with a variety of approaches including gene therapy.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in epilepsy may in the future compete with numerous approved anti-seizure medications and development-stage programs being pursued by several other companies. Commonly used anti-seizure medications include phenytoin, levetiracetam, brivaracetam, cenobamate, carbamazepine, clobazam, lamotrigine, valproate, oxcarbazepine, topiramate, lacosamide, perampanel and cannabidiol, among others. There are currently no FDA-approved treatments specifically indicated for the early infantile epileptic encephalopathy SCN8A-DEE; however, a number of different anti-seizure medications are currently used in these patient populations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in schizophrenia, anhedonia and depression may in the future compete with several development-stage programs being pursued by other companies. Currently, there are no FDA-approved treatments specifically indicated for anhedonia or CIAS; however, there are a number of different anti-psychotic medications currently used in these patient populations.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in neurology, neuroendocrinology and neuropsychiatry may in the future compete with numerous approved products and development-stage programs being pursued by several other companies.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_28"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration and License Agreements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2 to the consolidated financial statements for more information on our significant collaboration and license agreements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business activities are subject to extensive regulation by the U.S. and other countries. Regulation by government authorities in the U.S. and foreign countries is a significant factor in the development, manufacture, distribution, tracking, marketing and sale of our proposed products and in our ongoing research and product development activities. All of our products in development will require regulatory approval by government agencies prior to commercialization. The process of obtaining these approvals and the subsequent compliance with appropriate federal and state statutes and regulations require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, federal and state healthcare laws, and equivalent supranational and foreign laws, restrict business practices in the pharmaceutical industry. These laws include, without limitation, federal, state and foreign fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws and industry codes of conduct regarding payments or other items of value provided to healthcare providers. We have a comprehensive compliance program designed to ensure our business practices remain compliant.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal Anti-Kickback Statute and equivalent foreign laws makes it illegal for any person or entity to knowingly and willfully, directly or indirectly, solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, lease of any good, facility, item or service for which payment may be made under programs such as a federal healthcare program, such as Medicare or Medicaid in the U.S.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and equivalent foreign civil and criminal false claims laws and the federal civil monetary penalties law and equivalent foreign laws, which prohibit among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent or not provided as claimed and knowingly making, or causing to be made, a false record or to avoid or decrease an obligation to pay money to the federal government.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996 (HIPAA) created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services and equivalent foreign laws.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and their privacy and security regulations, which impose certain obligations, including the adoption of administrative, physical and technical safeguards to protect individually identifiable health information on covered entities subject to HIPAA (i.e., health plans, healthcare clearinghouses and certain healthcare providers) and their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information as well as their covered subcontractors.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare&#160;&amp; Medicaid Services (CMS) information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, many states have similar healthcare statutes or regulations that may be broader in scope and may apply regardless of payor. Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act (FCPA) prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The FCPA also imposes accounting standards and requirements on publicly traded U.S. corporations and their foreign affiliates, which are intended to prevent the diversion of corporate funds to the payment of bribes and other improper payments. Similar laws exist in other countries, such as the United Kingdom (UK) or in EU member states, that restrict improper payments to public and private parties. Many countries have laws prohibiting these types of payments within the respective country. In addition to these anti-corruption laws, we are subject to import and export control laws, tariffs, trade barriers, economic sanctions, and regulatory limitations on our ability to operate in certain foreign markets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these laws, where applicable, can result in significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal and equivalent foreign healthcare programs, and additional reporting requirements and regulatory oversight, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Marketing Approval for Products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies generally are conducted in laboratory animals to evaluate the potential safety and efficacy of a product. Drug developers submit the results of preclinical studies to the FDA as a part of an investigational new drug application (IND) and to equivalent foreign authorities before clinical trials can begin in humans. Typically, clinical evaluation involves a time consuming and costly multi-phase process.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials are conducted with a small number of subjects to determine the early safety profile, maximum tolerated dose and pharmacokinetic properties of the product in human volunteers or in patients with the target disease.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials are conducted with groups of patients afflicted with a specific disease in order to determine preliminary efficacy, optimal dosages and expanded evidence of safety.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Larger, multi-center, comparative clinical trials are conducted with patients afflicted with a specific disease in order to determine safety and efficacy as primary support for regulatory approval by the FDA, the European Commission, or equivalent foreign authorities, to market a product candidate for a specific disease.</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely monitors the progress of each of the three phases of clinical trials that are conducted in the U.S. and may, at its discretion, re-evaluate, alter, suspend or terminate the testing based upon the data accumulated to that point and the FDA&#8217;s assessment of the risk/benefit ratio to the patient. Institutional Review Boards, Institutional Ethics Committees and Data Safety Monitoring Boards also closely monitor the conduct of our trials and may also place holds on our clinical trials or recommend that we voluntarily do so. Clinical trials conducted in foreign countries are also subject to oversight by regulatory authorities in those countries.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once Phase&#160;3 trials are completed, drug developers submit the results of preclinical studies and clinical trials to the FDA in the form of a new drug application (NDA) for approval to commence commercial sales. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act (PDUFA), the FDA has a goal of 10 months from the date of filing of a standard NDA for a new molecular entity to review and act on the submission. The FDA generally has a six-month review goal of priority NDAs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act of 2003 as amended and reauthorized, certain applications or supplements to an application must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a risk evaluation and mitigation strategy to ensure that the benefits of the drug outweigh its risks. The risk evaluation and mitigation strategy could include medication guides, physician communication plans, assessment plans and/or additional elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an application for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective for its intended use and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with Good Clinical Practice (GCP) requirements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the application and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a risk evaluation and mitigation strategy, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also have to complete an approval process similar to that in the U.S. in order to commercialize our product candidates in each foreign country. The approval procedure and the time required for approval vary from country to country and may involve additional testing. Foreign approvals may not be granted on a timely basis, or at all. In addition, regulatory approval of prices is required in most countries other than the U.S., except for a certain limited number of drugs sold to certain Medicare beneficiaries beginning in 2023. The resulting prices may not be sufficient to generate an acceptable return to us or our corporate collaborators.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the U.S., or if it affects more than 200,000, there is no reasonable expectation that sales of the drug in the U.S. will be sufficient to offset the costs of developing and making the drug available in the U.S. Orphan drug designation must be requested before submitting an NDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a sponsor&#8217;s marketing application for a designated orphan drug for use in the rare disease or condition for which it was designated, the sponsor is eligible for a seven-year period of marketing exclusivity, during which the FDA may not approve another sponsor&#8217;s marketing application for a drug with the same active moiety and intended for the same use or indication as the approved orphan drug, except in limited circumstances, such as if a subsequent sponsor demonstrates its product is clinically superior. During a sponsor&#8217;s orphan drug exclusivity period, competitors, however, may receive approval for drugs with different active moieties for the same indication as the approved orphan drug, or for drugs with the same active moiety as the approved orphan drug, but for different indications. Orphan drug exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for a drug with the same active moiety intended for the same indication before we do, unless we are able to demonstrate that grounds for withdrawal of the orphan drug exclusivity exist, or that our product is clinically superior. Further, if a designated orphan drug receives marketing approval for an indication broader than the rare disease or condition for which it received orphan drug designation, it may not be entitled to exclusivity.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for any marketed products, as well as new application fees for supplemental applications with clinical data.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions. Other potential consequences include, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indication(s) and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting pre-approval promotion of investigational drugs, as well as the promotion of off-label uses of approved drugs, and a company may be subject to significant liability. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. The FDA does not regulate behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_43"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reimbursement</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the U.S. and other countries, sales of any products for which we receive regulatory approval will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such drug products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., third-party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers and other organizations. No uniform policy for coverage and reimbursement exists in the U.S., and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our drug products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained in the first instance or applied consistently.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of drug products and medical services, in addition to questioning their safety, efficacy and clinical appropriateness. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication.&#160;We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Nonetheless, our products or product candidates, including INGREZZA, may not be considered medically necessary or cost-effective.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the process for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party payor reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any product or product candidates for which we or our collaborators receive regulatory approval for commercial sale may suffer if third-party payors fail to provide coverage and adequate reimbursement. In addition, emphasis on managed care in the U.S. has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_46"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Healthcare Reform Measures</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and some foreign jurisdictions have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. In the U.S., the pharmaceutical industry and the cost of prescription drugs has been a continuous focus of these efforts and has been significantly affected by major legislative initiatives.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most recently, in August 2022, President Biden signed into law the Inflation Reduction Act of 2022 (IRA), which, among other things, (1) directs the Secretary of the U.S. Department of Health and Human Services (HHS) to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, (2) redesigns the Medicare Part D prescription drug benefit to lower patient out-of-pocket costs and increase manufacturer liability and (3) requires drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in the ACA marketplaces through plan year 2025 and eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost to $2,000 through a newly established manufacturer discount program. These provisions take effect progressively starting in 2023. On August 29, 2023, HHS announced the list of the first 10 drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be implemented; however, it is likely to have a significant impact on the pharmaceutical industry and prescription drug pricing. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the IRA targets high-expenditure drugs that have been on the market for several years without generic or biosimilar competition, we expect to qualify for the small biotech manufacturer exemption that is set to expire in 2029. However, the qualification for this exemption is subject to various requirements and there is no assurance that we will continue to qualify for this exemption in the future. Further, the loss of this exemption or the potential loss of this exemption, including as a result of a potential acquisition or strategic transaction, could have an adverse impact on our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant prior revisions to federal law governing the pharmaceutical industry and prescription drug pricing were enacted through the March 2010 Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the ACA). This</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">law was intended to broaden access to health insurance by reducing the number of uninsured persons, reducing or constraining the growth of healthcare spending, enhancing remedies against fraud and abuse, adding transparency requirements for the healthcare and health insurance industries, imposing taxes and fees on the health industry and imposing additional health policy reforms. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these health reform measures may result in more rigorous coverage criteria and lower reimbursement for prescription drugs, as well as result in additional downward pressure on any price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private third-party payors. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other significant legislative changes impacting the pharmaceutical industry and prescription drug pricing have been adopted since the ACA was enacted. These changes include, among others, aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments, including the Investment and Jobs Act, will remain in effect through 2032.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to examine and/or control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. Further, certain states through legislation have created a state prescription drug affordability board (PDAB) to help control costs of drugs for that state. The functions of the PDABs vary by state, and may include among others, negotiating the price the state pays for certain drugs, recommending or setting upper limits on drug prices, performing drug affordability reviews, and advising state lawmakers on additional ways to reduce the state&#8217;s drug spending. It is possible that the actions taken by the PDABs may result in lower prices for certain drug products sold in their states.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_1834"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Healthcare Reform Measures</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and some foreign jurisdictions are considering a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and may be significantly affected by major legislative initiatives.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently unable to predict what other additional legislation or regulation, if any, relating to the healthcare industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our business.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_1853"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulation and Procedures Governing Approval of Medicinal Products in the EU</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To market any product outside of the U.S., a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can initiate clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the EU generally aligns with the requirements in the U.S. It entails satisfactory completion of pharmaceutical development, nonclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the medicinal product for each proposed indication. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement may vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Medicines used in clinical trials must be manufactured in accordance with cGMP and in a GMP licensed facility, which can be subject to GMP inspections.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials in the EU.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the EU, the Clinical Trials Regulation (EU) No 536/2014 (CTR) entered into application on January 31, 2022 repealing and replacing the former Clinical Trials Directive 2001/20 (CTD). The regulation introduces a streamlined application procedure via a single entry point, the &#8220;EU portal&#8221;, the Clinical Trials Information System (CTIS); a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which on-going clinical trials will be governed by the CTR will depend on the duration of the individual clinical trial. For clinical trials in relation to which an application for approval was made on the basis of the CTD before January 31, 2023, the CTD will continue to apply on a transitional basis until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. The CTR will apply to clinical trials from an earlier date if the related clinical trial application was made on the basis of the CTR or if the clinical trial has already transitioned to the CTR framework before January 31, 2025.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketing Authorizations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the EU, medicinal products can only be commercialized after a related marketing authorization (MA) has been granted. To obtain an MA for a product in the EU, an applicant must submit a marketing authorization application (MAA) either under a centralized procedure administered by the EMA or one of the procedures administered by the competent authorities of EU Member States (decentralized procedure, national procedure or mutual recognition procedure). An MA may be granted only to an applicant established in the EU. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single MA by the European Commission that is valid throughout the European Economic Area (which is comprised of the 27 EU Member States plus Norway, Iceland and Liechtenstein). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for (i) medicinal products derived from biotechnological processes, (ii) products designated as orphan medicinal products, (iii) advanced therapy medicinal products (ATMPs), and (iv) products with a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, authorization through the centralized procedure is optional on related approval. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated assessment may be granted by the EMA&#8217;s Committee for Medicinal Products for Human Use (CHMP) in exceptional cases, when a medicinal product targeting an unmet medical need is expected to be of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts a request for accelerated assessment, the time limit of 210 days will be reduced to 150 days (excluding clock stops). The CHMP can, however, revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An MA has, in principle, an initial validity of five years. The MA may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State in which the original MA was granted. The European Commission or the competent authorities of the EU Member States may decide on justified grounds relating to pharmacovigilance, to proceed with one further five-year renewal period for the MA. Once subsequently definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (for a centralized MA) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause). </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon receiving an MA, innovative medicinal products are generally entitled to receive eight years of data exclusivity and 10 years of market exclusivity. Data exclusivity, if granted, prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall ten-year period may, occasionally, be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Designation and related Exclusivity in the EU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, Regulation (EC) No. 141 provides that a medicinal product can be designated as an orphan medicinal product by the European Commission if its sponsor can establish that: (i) the product is intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions; (ii) either (a) such conditions affect not more than five in 10,000 persons in the EU when the application is made, or (b) the product without the benefits derived from orphan status, would not generate sufficient return in the EU to justify the necessary investment in developing the medicinal product; and (iii) there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition that has been authorized in the EU, or even if such method exists, the product will be of significant benefit to those affected by that condition.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon grant of a marketing authorization, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication, which means that the EMA cannot accept another marketing authorization application or accept an application to extend for a similar product and the European Commission cannot grant a marketing authorization for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP. The period of market exclusivity may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria on the basis of which it received orphan medicinal product destination.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Authorization Obligations in the EU.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Where an MA is granted in relation to a medicinal product in the EU, the holder of the MA is required to comply with a range of regulatory requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. Similar to the U.S., both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the individual EU Member States. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports (PSURs).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, the advertising and promotion of medicinal products are subject to both EU and EU Member States&#8217; laws governing promotion of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. General requirements for advertising and promotion of medicinal products, such as direct-to-consumer advertising of prescription medicinal products are established in EU law. However, the details are governed by regulations in individual EU Member States and can differ from one country to another. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Brexit and the Regulatory Framework in the UK.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The UK&#8217;s withdrawal from the EU on January 31, 2020, commonly referred to as Brexit, has changed the regulatory relationship between the UK and the EU. The Medicines and Healthcare products Regulatory Agency (MHRA) is now the UK&#8217;s standalone regulator for medicinal products and medical devices. Great Britain (England, Scotland and Wales) is now a third country to the EU. Northern Ireland continues to follow the EU regulatory rules. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK regulatory framework in relation to clinical trials is governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is derived from the CTD, as implemented into UK national law through secondary legislation. In October 2023, the MHRA announced a new Notification Scheme for clinical trials which enables a more streamlined and risk-proportionate approach to initial clinical trial applications for Phase 4 and low-risk Phase 3 clinical trial applications.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing authorizations in the UK are governed by the Human Medicines Regulations (SI 2012/1916), as amended. This legislation includes procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment route, a rolling review procedure and the International Recognition Procedures (IRP) which entered into application on January 1, 2024. Since January 1, 2024, the MHRA may rely on the IRP when reviewing certain types of marketing authorization applications. There is no pre-marketing authorization orphan designation for medicinal products in the UK. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding marketing authorization application. The criteria are essentially the same as those in the EU but have been tailored for the market.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_52"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Employees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have grown to a team of more than 1,400 employees as of December&#160;31, 2023, primarily employed in the U.S. Our highly qualified and experienced team, which includes scientists, physicians and professionals across sales, marketing, manufacturing, regulatory, finance and other essential functions are critical to our success. We also leverage temporary workers to provide flexibility for our business needs. During 2023, we added approximately 200 new employees to our team.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to add additional employees in 2024 with a focus on expanding our research and development organization. We continually evaluate our business needs and opportunities and balance in-house with external expertise and capacity. Currently, we rely on third-party contract manufacturers.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Culture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our human capital management investments is evidenced by our low employee turnover, a number which is regularly reviewed by our Board of Directors as part of their oversight of our human capital strategy. In recognition of our efforts, in 2023, we were ranked #8 in Fortune Best Workplaces in Biopharma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Engagement, Talent Development &amp; Benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives, including healthcare, retirement planning and paid time off. As part of our promotion and retention efforts, we also invest in ongoing leadership development programs as well as offer tuition reimbursement. In addition, we regularly conduct employee surveys to gauge employee engagement and identify areas of focus.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity &amp; Inclusion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce. We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were originally incorporated in California in January 1992 and reincorporated in Delaware in May 1996. Our principal executive offices are located at 12780 El Camino Real, San Diego, California 92130. Our telephone number is (858) 617-7600.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and amendments to reports filed pursuant to Sections&#160;13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.neurocrine.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as soon as reasonably practicable after such reports are available on the Securities and Exchange Commission (SEC) website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, copies of our Annual Report will be made available, free of charge, upon written request. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this Annual Report on Form 10-K.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_58"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report on Form&#160;10-K and those we may make from time to time. If any of the following risks actually occur, our business, operating results, prospects or financial condition could be harmed. Additional risks not presently known to us, or that we currently deem immaterial, may also affect our business operations.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_61"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks and uncertainties related to our business, many of which are beyond our control.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, risks associated with our business include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to continue to successfully commercialize INGREZZA or any of our other products, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If physicians and patients do not continue to accept INGREZZA or do not accept any of our other products, or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enacted healthcare reform, drug pricing measures and other recent legislative initiatives, including the Inflation Reduction Act of 2022, could adversely affect our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be adversely affected by the effects of health pandemics or epidemics, which could also cause significant disruption in the operations of third-party manufacturers, contract research organizations (CROs), or other third parties upon whom we rely.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may be delayed for safety or other reasons, or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use of our approved products or those of our collaborators could be associated with side effects or adverse events.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to retain and recruit qualified scientists and other employees or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA or any of our other products, or any product candidate approved by the FDA in the future.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA or any of our other products, or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or any of our other products, could materially and adversely affect our ability to successfully commercialize INGREZZA or any of our other products.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Government and third-party payors may impose sales and pharmaceutical pricing controls on our products, or limit coverage and/or reimbursement for our products or impose policies and/or make decisions that regarding the status of our products that could limit our product revenues and delay sustained profitability.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our indebtedness could expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need additional capital in the future. If we cannot raise additional funding, we may be unable to fund our business plan and our future research, development, commercial and manufacturing efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Company</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to continue to successfully commercialize INGREZZA or any of our other products, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to produce INGREZZA revenues consistent with expectations ultimately depends on our ability to continue to successfully commercialize INGREZZA and secure adequate third-party reimbursement. Our experience in marketing and selling pharmaceutical products began with INGREZZA&#8217;s approval in 2017, when we hired our sales force and established our distribution and reimbursement capabilities, all of which are necessary to successfully commercialize our current and future products. We have continued to invest in our commercial infrastructure and distribution capabilities, including the expansion of our specialty sales force, which we announced in the third quarter of 2021 and completed in April 2022. While our team members and consultants have experience marketing and selling pharmaceutical products, we may face difficulties related to managing the rapid growth of our personnel and infrastructure, and there can be no guarantee that we will be able to maintain the personnel, systems, arrangements and capabilities necessary to continue to successfully commercialize INGREZZA or any of our other products, or any product candidate approved by the FDA, or equivalent foreign authorities, in the future. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business has been and may continue to be adversely affected by the effects of health pandemics or epidemics. In parts of the country, some hospitals, community mental health facilities, and other healthcare facilities continue to have policies that limit access of our sales representatives, medical affairs personnel and patients to such facilities. In addition, many healthcare practitioners have adopted telehealth for patient interactions, which may impact the ability of the healthcare practitioner to screen for and diagnose tardive dyskinesia or chorea associated with Huntington's disease.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If physicians and patients do not continue to accept INGREZZA or do not accept any of our other products, or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of INGREZZA or any of our other products will depend upon the acceptance of those products as safe and effective by the medical community and patients.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market acceptance of INGREZZA or any of our other products could be affected by a number of factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of receipt of marketing approvals for additional indications;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of the products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of healthcare payor coverage and adequate reimbursement for the products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public perception regarding any products we may develop;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of existing competitor products addressing our target markets or the emergence of equivalent or superior products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost-effectiveness of the products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the medical community, patients and payors do not continue to accept our products as being safe, effective, superior and/or cost-effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products or impose policies and/or make decisions regarding the status of our products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">that could limit our product revenues and delay sustained profitability. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to commercialize INGREZZA successfully or any of our other products will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available. The continuing efforts of government and third-party payors to contain or reduce the costs of healthcare and the price of prescription drugs through various means may impact our revenues. These payors&#8217; efforts could decrease the price that we receive for any products we may develop and sell in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the out-of-pocket cost of our products. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available regardless of whether they are approved by the FDA for that particular use. Coverage decisions by payors for our competitors' products may also impact coverage for our products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. In addition, communications from government officials, media outlets, and others regarding healthcare costs and pharmaceutical pricing could have a negative impact on our stock price, even if such communications do not ultimately impact coverage or reimbursement decisions for our products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may also be significant delays in obtaining coverage and reimbursement for newly approved drugs or indications, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. In addition, we could also be subject to amendments in our rebate agreements with pharmaceutical benefit managers that require us to pay larger rebate amounts or modify our formulary position, which could have a material adverse effect on our business. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. For example, government authorities could make a decision that adversely impacts the status of one of our products, which could impact the eligibility and/or the amount of government reimbursement for that product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a pharmaceutical manufacturer, we are subject to various federal statutes and regulations requiring the reporting of price data and the subsequent provision of concessions to certain purchasers/payors, including state Medicaid programs. Federal agencies issue guidance to manufacturers related to the interpretation of laws and regulations, and this guidance has changed and may change or be updated over time. In interpreting these laws, regulations and guidance, manufacturers may make reasonable assumptions to fill gaps, and these reasonable assumptions may need to be updated upon issuance of additional agency guidance.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may be unable to successfully commercialize INGREZZA or any of our other products, or any other product candidate for which we obtain marketing approval in the future. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. Further, a majority of our current revenue is derived from federal healthcare program payors, including Medicare and Medicaid. Thus, changes in government reimbursement policies, government negotiation of the price of any of products, reductions in payments and/or our suspension or exclusion from participation in federal healthcare programs could have a material adverse effect on our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, during the COVID-19 pandemic, the use of physician telehealth services rapidly increased, fueled by an unprecedented expansion of coverage and reimbursement for telehealth services across public and private insurers. The limitations that telehealth places on the ability to conduct a thorough physical examination may impact the ability of providers to screen for movement disorders, leading to fewer patients being diagnosed and/or treated.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. The EU provides options for EU Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. An EU Member State may approve a specific price for the medicinal product, it may refuse to reimburse a product at the price set by the manufacturer or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain reimbursement for our products in some European countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. The Health Technology Assessment (HTA) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States. In December 2021, Regulation No 2021/2282 on HTA, amending Directive 2011/24/EU, was adopted in the EU. This regulation, which entered into force in January 2022 will apply as of January 2025. The regulation will permit EU Member States to use common HTA tools, methodologies, and procedures across the EU to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. If we are unable to maintain favorable pricing and reimbursement status in EU Member States for product candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated revenue from and growth prospects for those products in the EU could be negatively affected.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of the fact that the UK has left the EU, Regulation No 2021/2282 on HTA will not apply in the UK. However, the MHRA is working with UK HTA bodies and other national organizations, such as the Scottish Medicines Consortium, the National Institute for Health and Care Excellence, and the All-Wales Medicines Strategy Group, to introduce new pathways supporting innovative approaches to the safe, timely and efficient development of medicinal products. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislators, policymakers and healthcare insurance funds in the EU and the UK may continue to propose and implement cost-containing measures to keep healthcare costs down, particularly due to the financial strain that the COVID-19 pandemic has placed on national healthcare systems of European countries. These measures could include limitations on the prices we would be able to charge for product candidates that we may successfully develop and for which we may obtain regulatory approval or the level of reimbursement available for these products from governmental authorities or third-party payors. Further, an increasing number of EU and other foreign countries use prices for medicinal products established in other countries as &#8220;reference prices&#8221; to help determine the price of the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may also arise from, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other drug development technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods of preventing or reducing the incidence of disease, including vaccines; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new small molecule or other classes of therapeutic agents.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments by others (including the development of generic equivalents) may render our product candidates or technologies obsolete or noncompetitive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are commercializing and performing research on or developing products for the treatment of several disorders including endometriosis, tardive dyskinesia, chorea associated with Huntington's disease, uterine fibroids, classic congenital adrenal hyperplasia, pain, Parkinson&#8217;s disease and other neurology, neuroendocrinology and neuropsychiatry-related diseases and disorders, and there are a number of competitors to our products and product candidates. If one or more of our competitors&#8217; products or programs are successful (including the development of generic equivalents), the market for our products may be reduced or eliminated.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INGREZZA competes with AUSTEDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (deutetrabenazine), marketed by Teva Pharmaceuticals Industries, for the treatment of tardive dyskinesia in adults and chorea associated with Huntington's disease. A once-daily dosing of AUSTEDO (AUSTEDO XR) was introduced in February 2023. Additionally, there are a number of commercially available medicines used to treat tardive dyskinesia off-label, such as XENAZINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tetrabenazine) and generic equivalents, and various antipsychotic medications (e.g., clozapine), anticholinergics, benzodiazepines (off-label), and botulinum toxin. In addition, there are several programs in clinical development by other companies targeting Huntington's disease.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORILISSA and ORIAHNN each compete with several FDA-approved products for the treatment of endometriosis, uterine fibroids, infertility and central precocious puberty. Additionally, there is also competition from surgical intervention, including hysterectomies and ablations. Separate from these options, there are many programs in clinical development which serve as potential future competition. Lastly, there are numerous medicines used to treat the symptoms of disease (vs. endometriosis or uterine fibroids directly) which may also serve as competition: oral contraceptives, NSAIDs and other pain medications, including opioids.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For CAH, high doses of corticosteroids are the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive ACTH levels. In the U.S. alone, there are more than two dozen companies manufacturing steroid-based products. In addition, there are several programs in clinical development by other companies targeting CAH.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in epilepsy may in the future compete with numerous approved anti-seizure medications and development-stage programs being pursued by several other companies. Commonly used anti-seizure medications include phenytoin, levetiracetam, brivaracetam, cenobamate, carbamazepine, clobazam, lamotrigine, valproate, oxcarbazepine, topiramate, lacosamide, perampanel and cannabidiol, among others. There are currently no FDA-approved treatments specifically indicated for the early infantile epileptic encephalopathy SCN8A-DEE; however, a number of different anti-seizure medications are currently used in these patient populations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in schizophrenia, anhedonia and depression may in the future compete with several development-stage programs being pursued by other companies. Currently, there are no FDA-approved treatments specifically indicated for anhedonia or CIAS; however, there are a number of different anti-psychotic medications currently used in these patient populations.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in neurology, neuroendocrinology and neuropsychiatry may in the future compete with numerous approved products and development-stage programs being pursued by several other companies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to us, many of our competitors and potential competitors have substantially greater:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital resources;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales and marketing experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">research and development resources, including personnel and technology;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical study and clinical testing experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing, marketing and distribution experience; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production facilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increased competition in certain disorders or therapies may make it more difficult for us to recruit or enroll patients in our clinical trials for similar disorders or therapies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only a small number of research and development programs ultimately result in commercially successful drugs. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential products that appear to be promising at early stages of development may not reach the market for a number of reasons. These reasons include the possibilities that the potential products may:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be found ineffective or cause harmful side effects during preclinical studies or clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fail to receive necessary regulatory approvals on a timely basis or at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be precluded from commercialization by proprietary rights of third parties;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be difficult to manufacture on a large scale; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be uneconomical to commercialize or fail to achieve market acceptance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates encounters any of these potential problems, we may never successfully market that product candidate.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may be delayed for safety or other reasons or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval for the sale of any of our potential products, we must subject these product candidates to extensive preclinical and clinical testing to demonstrate their safety and efficacy for humans. Clinical trials are expensive, time-consuming and may take years to complete and the outcomes are uncertain.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the clinical trials of our product candidates, we face the risks that:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authority may not allow an IND or foreign equivalent filings required to initiate human clinical studies for our drug candidates or the FDA or similar foreign regulatory authorities may require additional preclinical studies as a condition of the initiation of Phase 1 clinical studies, or additional clinical studies for progression from Phase&#160;1 to Phase&#160;2, or Phase&#160;2 to Phase&#160;3, or for NDA approval;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate may not prove to be effective or as effective as other competing product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may discover that a product candidate may cause harmful side effects or results of required toxicology or other studies may not be acceptable to the FDA or similar foreign regulatory authorities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial results may not replicate the results of previous trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authorities may require use of new or experimental endpoints that may prove insensitive to treatment effects;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the FDA or similar foreign regulatory authorities may suspend or vary the trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not be statistically significant;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical site initiation or patient recruitment and enrollment may be slower or more difficult than expected;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authorities may not accept the data from any trial or trial site outside of the U.S.;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients may drop out of the trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen disruptions or delays may occur, caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the conflict between Russia and Ukraine and the conflict in the Middle East; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory requirements may change.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks and uncertainties impact all of our clinical programs and any of the clinical, regulatory or operational events described above could change our planned clinical and regulatory activities. For example, the conflict between Russia and Ukraine, together with sanctions imposed on Russia, caused us to suspend all planned clinical trial activities in Russia and Ukraine. As a result, our planned clinical development timelines for valbenazine and luvadaxistat were significantly delayed while we identified and operationalized alternative clinical trial sites, which we have now done. Additionally, any of these events described above could result in suspension of a program and/or obviate any filings for necessary regulatory approvals.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, late-stage clinical trials are often conducted with patients having the most advanced stages of disease. During the course of treatment, these patients can die or suffer other adverse medical effects for reasons that may not be related to the pharmaceutical agent being tested but which can nevertheless adversely affect clinical trial conduct, completion and results. Any failure or substantial delay in completing clinical trials for our product candidates may severely harm our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates. For example, we depend on AbbVie for the manufacture and commercialization of ORILISSA and ORIAHNN and for the continued development of elagolix. We collaborate with MTPC for the commercialization of DYSVAL in Japan and for the continued development and commercialization of valbenazine for movement disorders in other select Asian markets. Our additional collaborators include Xenon Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd., Takeda Pharmaceutical Company Limited, Heptares Therapeutics Limited and Voyager Therapeutics, Inc.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future collaborations and licenses could subject us to a number of risks, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may sell, transfer or divest assets or programs related to our partnered product or product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to undertake the expenditure of substantial operational, financial and management resources; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to assume substantial actual or contingent liabilities; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our products or product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to influence our strategic collaborator&#8217;s decisions regarding the development and collaboration of our partnered product and product candidates, and as a result, our collaboration partners may not pursue or prioritize the development and commercialization of those partnered products and product candidates in a manner that is in our best interest;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may select indications or design clinical trials in a way that may be less successful than if we were doing so; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not conduct collaborative activities in a timely manner, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements or disputes may arise between us and our strategic collaborators that result in delays or in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may experience financial difficulties; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or strategic collaborators could terminate the arrangement (in whole or in part) or allow it to expire, which would delay the development and commercialization, result in disagreements or disputes or may increase the cost of developing and commercializing our products or product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators could develop, either alone or with others, products or product candidates that may compete with ours. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these issues arise, it may delay and/or negatively impact the development and commercialization of drug candidates and, ultimately, our generation of product revenues.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of our approved products or those of our collaborators could be associated with side effects or adverse events.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most pharmaceutical products, use of our approved products or those of our collaborators could be associated with side effects or adverse events which can vary in severity (from minor adverse reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our products or those of our collaborators may be observed at any time, including after a product is commercialized, and reports of any such side effects or adverse events may negatively impact demand for our or our collaborators&#8217; products or affect our or our collaborators&#8217; ability to maintain regulatory approval for such products. Side effects or other safety issues associated with the use of our approved products or those of our collaborators could require us or our collaborators to modify or halt commercialization of these products or expose us to product liability lawsuits which will harm our business. We or our collaborators may be required by regulatory agencies to conduct additional studies regarding the safety and efficacy of our products which we have not planned or anticipated. Furthermore, there can be no assurance that we or our collaborators will resolve any issues related to any product related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on licenses from third parties for some of our key technologies. These licenses typically subject us to various commercialization, reporting and other obligations. If we fail to comply with these obligations, we could lose important rights. If we were to default on our obligations under any of our licenses, we could lose some or all of our rights to develop, market and sell products covered by these licenses. In addition, several of our collaboration and license agreements allow our licensors to terminate such agreements if we challenge the validity or enforceability of certain intellectual property rights or if we commit a material breach in whole or in part of the agreement and do not cure such breach within the agreed upon cure period. In addition, if we were to violate any of the terms of our licenses, we could become subject to damages. Likewise, if we were to lose our rights under a license to use proprietary research tools, it could adversely affect our existing collaborations or adversely affect our ability to form new collaborations. We also face the risk that our licensors could, for a number of reasons, lose patent protection or lose their rights to the technologies we have licensed, thereby impairing or extinguishing our rights under our licenses with them.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had approximately 1,400 full-time employees. Although we have substantially increased the size of our organization, we may need to add additional qualified personnel and resources, especially with the recent increase in the size of our sales force. Our current infrastructure may be inadequate to support our development and commercialization efforts and expected growth. Future growth will impose significant added responsibilities on our organization, including the need to identify, recruit, maintain and integrate additional employees and implement and expand managerial, operational and financial systems and may be costly and take time away from running other aspects of our business, including development and commercialization of our product candidates. For example, we are in the process of implementing a new company-wide enterprise resource planning (ERP) system to streamline certain existing business, operational, and financial processes. This project has required and may continue to require investment of capital and human resources, the re-engineering of processes of our business, and the attention of many employees who would otherwise be focused on other aspects of our business. Any disruptions, delays, or deficiencies in the implementation or design of the ERP system could adversely affect the effectiveness of our internal control over financial reporting or our ability to accurately maintain our books and records, provide accurate, timely and reliable reports on our financial and operating results, or otherwise operate our business. Any of these consequences could have an adverse effect on our results of operations and financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize INGREZZA and any of our other products, or any of our product candidates that receive regulatory approval in the future, will partially depend on our ability to manage any future growth effectively. In particular, as we commercialize INGREZZA, we will need to support the training and ongoing activities of our sales force and will likely need to continue to expand the size of our employee base for managerial, operational, financial and other resources. To that end, we must be able to successfully:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our development efforts effectively;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrate additional management, administrative and manufacturing personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop our marketing and sales organization; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compensate our employees on adequate terms in an increasingly competitive, inflationary market;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain personnel; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain sufficient administrative, accounting and management information systems and controls.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to accomplish these tasks or successfully manage our operations and, accordingly, may not achieve our research, development and commercialization goals. Our failure to accomplish any of these goals could harm our financial results and prospects.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to retain and recruit qualified scientists and other employees or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA or any of our other products, or any product candidate approved by the FDA in the future.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our management, commercial and scientific staff. The loss of any of these people could impede the achievement of our objectives, including the successful commercialization of INGREZZA or any of our other products, or any product candidate approved by the FDA in the future. Furthermore, recruiting and retaining qualified scientific personnel to perform research and development work in the future, along with personnel with experience marketing and selling pharmaceutical products, is critical to our success. We may be unable to attract and retain personnel on acceptable terms given the competition among biotechnology, pharmaceutical and healthcare companies, universities and non-profit research institutions for experienced scientists and individuals with experience marketing and selling pharmaceutical products. We may face particular retention challenges in light of the recent rapid growth in our personnel and infrastructure and the perceived impact of those changes upon our corporate culture. In addition, we rely on a significant number of consultants to assist us in formulating our research and development strategy and our commercialization strategy. Our consultants may have commitments to, or advisory or consulting agreements with, other entities that may limit their availability to us.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA or any of our other products, or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past utilized, and intend to continue to utilize, third-party manufacturers to produce the drug compounds we use in our clinical trials and for the commercialization of our products. We have limited experience in manufacturing products for commercial purposes and do not currently have any manufacturing facilities. Establishing internal commercial manufacturing capabilities would require significant time and resources, and we may not be able to timely or successfully establish such capabilities. Consequently, we depend on, and will continue to depend on, several contract manufacturers for all production of products for development and commercial purposes, including INGREZZA. If we are unable to obtain or retain third-party manufacturers, we will not be able to develop or commercialize our products, including INGREZZA. The manufacture of our products for clinical trials and commercial purposes is subject to specific FDA and equivalent foreign regulations, including current Good Manufacturing Practice regulations. Our third-party manufacturers might not comply with FDA or equivalent foreign regulations relating to manufacturing our products for clinical trials and commercial purposes or other regulatory requirements now or in the future. Our reliance on contract manufacturers also exposes us to the following risks:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturers may encounter difficulties in achieving volume production, quality control or quality assurance, and also may experience shortages in qualified personnel or materials and ingredients necessary to conduct their operations. As a result, our contract manufacturers might not be able to meet our clinical schedules or adequately manufacture our products in commercial quantities when required;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly on acceptable terms, or at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store or distribute our products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the U.S. Drug Enforcement Administration, equivalent foreign regulatory authorities, and other agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current dependence upon third parties for the manufacture of our products may reduce our profit margin, if any, on the sale of INGREZZA or any of our other products, or our future products and our ability to develop and deliver products on a timely and competitive basis.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or any of our other products, could materially and adversely affect our ability to successfully commercialize INGREZZA or any of our other products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of process controls required to consistently produce the active pharmaceutical ingredients (API), the finished drug product and packaging in sufficient quantities while meeting detailed product specifications on a repeated basis. Manufacturers of pharmaceutical products may encounter difficulties in production, such as difficulties with production costs and yields, process controls, quality control and quality assurance, including testing of stability, impurities and impurity levels and other product specifications by validated test methods, compliance with strictly enforced U.S., state and non-U.S. regulations, and disruptions or delays caused by man-made or natural disasters, pandemics or epidemics, or other business interruptions. We depend on a limited number of suppliers for the production and packaging of INGREZZA and its API. If our third-party suppliers for INGREZZA encounter these or any other manufacturing, quality or compliance difficulties, we may be unable to meet commercial demand for INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our suppliers fail or refuse to supply us with INGREZZA or its API for any reason, it would take a significant amount of time and expense to qualify a new supplier. The FDA and similar foreign regulatory authorities must approve manufacturers of the active and inactive pharmaceutical ingredients and certain packaging materials used in pharmaceutical products. The loss of a supplier could require us to obtain regulatory clearance and to incur validation and other costs associated with the transfer of the API or product manufacturing processes. If there are delays in qualifying new suppliers or facilities or if a new supplier is unable to meet FDA or a similar foreign regulatory authority&#8217;s requirements for approval, there could be a shortage of INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The independent clinical investigators and contract research organizations that we rely upon to conduct our clinical trials may not be diligent, careful or timely, or may make mistakes in the conduct of our trials.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators and CROs to conduct our clinical trials under their agreements with us. The investigators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. If our independent investigators fail to devote sufficient time and resources to our drug development programs, or if their performance is substandard, or not in compliance with GCPs, it may delay or prevent the approval of our regulatory applications and our introduction of new treatments. The CROs we contract with for execution of our clinical trials play a significant role in the conduct of the trials and the subsequent collection and analysis of data. Failure of the CROs to meet their obligations could adversely affect clinical development of our products. Moreover, these independent investigators and CROs may also have relationships with other commercial entities, some of which may compete with us. If independent investigators and CROs assist our competitors at our expense, it could harm our competitive position.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing obligations and continued regulatory review for INGREZZA. Additionally, our other product candidates, if approved, could be subject to labeling and other post-marketing requirements and restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approvals for any of our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. In addition, with respect to INGREZZA, and any product candidate that the FDA or a comparable foreign regulatory authority approves, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with GCPs for any clinical trials that we conduct post-approval. Failure to comply with these ongoing regulatory requirements, or later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, may result in, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, changes in the product&#8217;s label, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning or untitled letters or holds on clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA or similar foreign regulatory authorities to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse inspection findings or other activities that temporarily delay manufacture and distribution of our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events may adversely affect our business, prospects and ability to achieve or sustain profitability on a sustained basis.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our products and product candidates are smaller than we believe they are, our expected revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the diseases that INGREZZA, crinecerfont, and our other product candidates are being developed to address are in underserved and underdiagnosed populations. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who will seek treatment utilizing our products or product candidates, may not be accurate. If our estimates of the prevalence or number of patients potentially on therapy prove to be inaccurate, the market opportunities for INGREZZA, crinecerfont, and our other product candidates may be smaller than we believe they are, our prospects for generating expected revenue may be adversely affected and our business may suffer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because our operating results may vary significantly in future periods, our stock price may decline.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenues, expenses and operating results have fluctuated in the past and are likely to fluctuate significantly in the future. Our financial results are unpredictable and may fluctuate, for among other reasons, due to seasonality and timing of customer purchases and commercial sales of INGREZZA, royalties from out-licensed products, the impact of Medicare Part D coverage, including redesign of the Part D benefit enacted as part of the Inflation Reduction Act, our achievement of product development objectives and milestones, clinical trial enrollment and expenses, research and development expenses and the timing and nature of contract manufacturing, contract research payments, fluctuations in our effective tax rate, and disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the conflict between Russia and Ukraine, or in the Middle East. Because a majority of our costs are predetermined on an annual basis, due in part to our significant research and development costs, small declines in revenue could disproportionately affect financial results in a quarter. Thus, our future operating results and profitability may fluctuate from period to period, and even if we become profitable on a quarterly or annual basis, we may not be able to sustain or increase our profitability. Moreover, as our company and our market capitalization have grown, our financial performance has become increasingly subject to quarterly and annual comparisons with the expectations of securities analysts or investors. The failure of our financial results to meet these expectations, either in a single quarterly or annual period over a sustained period time, could cause our stock price to decline.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we sold $517.5&#160;million aggregate principal amount of the 2024 Notes. In 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. In 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. As of December&#160;31, 2023, $170.4 million aggregate principal amount of the 2024 Notes remained outstanding. We may also incur additional indebtedness to meet future financing needs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under the 2024 Notes and any additional indebtedness that we may incur. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant net losses and negative cash flow from operations. As of December&#160;31, 2023, we had an accumulated deficit of $157.1 million as a result of historical operating losses.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received FDA approval for INGREZZA for tardive dyskinesia in April 2017 and for chorea associated with Huntington's disease in August 2023. Our partner AbbVie received FDA approval for ORILISSA for endometriosis in July 2018 and for ORIAHNN for uterine fibroids in May 2020. Additionally, our partner MTPC received Japanese Ministry of Health, Labour and Welfare approval for DYSVAL for the treatment of tardive dyskinesia in March 2022. However, we have not yet obtained regulatory approvals for any other product candidates. Even if we continue to succeed in commercializing INGREZZA, or are successful in developing and commercializing any of our other product candidates, we may not be able to sustain profitability. We also expect to continue to incur significant operating and capital expenditures as we:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for our product candidates or for additional indications for our current products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop, formulate, manufacture and commercialize our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire new product development opportunities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implement additional internal systems and infrastructure; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, scientific, sales and marketing personnel.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to increase our expenses and other investments in the coming years as we fund our operations and capital expenditures. Thus, our future operating results and profitability may fluctuate from period to period due to the factors described above, and we will need to generate significant revenues to achieve and maintain profitability and positive cash flow on a sustained basis. We may not be able to generate these revenues, and we may never achieve profitability on a sustained basis in the future. Our failure to maintain or increase profitability on a sustained basis could negatively impact the market price of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenses for tax purposes in the year incurred and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the U.S. and over 15 years for research activities conducted outside the U.S. Unless the U.S. Department of the Treasury issues regulations that narrow the application of this provision to a smaller subset of our research and development expenses or the provision is deferred, modified, or repealed by Congress, we expect a material decrease in our cash flows from operations and an offsetting similarly sized increase in our net deferred tax assets over these amortization periods. The actual impact of this provision will depend on multiple factors, including the amount of research and development expenses we will incur and whether we conduct our research and development activities inside or outside the U.S.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, new income, sales, use, excise or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act of 2017, the Coronavirus Aid, Relief, and Economic Security Act and the Inflation Reduction Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation. Furthermore, it is uncertain if and to what extent various states will conform to federal tax laws. Future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use tax attributes may be limited.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use certain pre-change federal tax attributes such as research and development tax credits to offset its post-change income or taxes may be limited. Based on completed Section 382 analysis done annually, we do not believe we have experienced any previous ownership changes, but the determination is complex and there can be no assurance we are correct. Furthermore, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes, including net operating loss (NOL) carryforwards. In addition, at the state level, there may be periods during which the use of NOLs or credits is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our NOLs, research and development credits, and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each such place. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including the impact of stock-based compensation, changes in the mix of our profitability from jurisdiction to jurisdiction, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock is volatile.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology and pharmaceutical companies historically have been highly volatile, and the market for these securities has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. The COVID-19 pandemic, for example, negatively affected the stock market and investor sentiment and resulted in significant volatility, as has the applicability of the Medicare drug price negotiation provisions in the Inflation Reduction Act. Furthermore, especially as we and our market capitalization have grown, the price of our common stock has been increasingly affected by quarterly and annual comparisons with the valuations and recommendations of the analysts who cover our business. If our results do not meet these analysts&#8217; forecasts, the expectations of our investors or the financial guidance we provide to investors in any period, which is based on assumptions that may be incorrect or that may change from quarter to quarter, the market price of our common stock could decline. Over the course of the last 12 months, the price of our common stock has ranged from approximately $89 per share to approximately $143 per share.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may fluctuate in response to many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of INGREZZA and our other products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports of safety issues related to INGREZZA, ORILISSA, ORIAHNN, DYSVAL, or any of our other products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning new and existing collaboration agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products by us or others, including our competitors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and market conditions, including economic and market conditions affecting the biotechnology industry;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to the FDA, CMS and foreign regulatory agencies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government regulation, including the Inflation Reduction Act;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future sales of our common stock by us or our stockholders;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comments by securities analysts;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential litigation matters;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government and third-party payor coverage and reimbursement;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our product candidates, if approved, to achieve commercial success;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions caused by man-made or natural disasters, pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of our drugs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are a member of the S&amp;P MidCap 400 index. If we cease to be represented in the S&amp;P MidCap 400 index, or other indexes or indexed products, as a result of our market capitalization falling below the threshold for inclusion in the index, certain institutional shareholders may, due to their internal policies and investment guidelines, be required to sell their shareholdings. Such sales may result in further negative pressure on our stock price and, when combined with reduced trading volume and liquidity, could adversely affect the value of your investment and your ability to sell your shares.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors, and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 91% of our total product sales for 2023 and approximately 98% of our accounts receivable balance as of December&#160;31, 2023. If any of these significant customers becomes subject to bankruptcy, is unable to pay us for our products or is acquired by a company that wants to terminate the relationship with us, or if we otherwise lose any of these significant customers, our revenue, results of operations and cash flows would be adversely affected. Even if we replace the loss of a significant customer, we cannot predict with certainty that such transition would not result in a decline in our revenue, results of operations and cash flows.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional capital in the future. If we cannot raise additional funding, we may be unable to fund our business plan and our future research, development, commercial and manufacturing efforts.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors and we may need to raise additional capital to fund our business plan and our future research, development, commercial and manufacturing efforts.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of INGREZZA, ORILISSA, ORIAHNN, DYSVAL, and/or any of our other products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt services obligations on the 2024 Notes;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued scientific progress in our R&amp;D and clinical development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude and complexity of our research and development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical testing and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with securing adequate coverage and reimbursement for our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities and arrangements, including advertising campaigns;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic or a future pandemic or epidemic on our business; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of any strategic alliances, collaborations, product in-licensing, or acquisitions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek additional funding through strategic alliances and may seek additional funding through public or private sales of our securities, including equity securities. In addition, during the second quarter of 2017, we issued the 2024 Notes and we have previously financed capital purchases and may continue to pursue opportunities to obtain additional debt financing in the future. In 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. In 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 Notes for an aggregate repurchase price of $279.0 million in cash. As of December&#160;31, 2023, $170.4 million aggregate principal amount of the 2024 Notes remained outstanding. Additional equity or debt financing might not be available on reasonable terms, if at all. Any additional equity financings will be dilutive to our stockholders and any additional debt financings may involve operating covenants that restrict our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, new SEC regulations and Nasdaq rules, are creating uncertainty for companies such as ours. These laws, regulations and standards are subject to varying interpretations in some cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, our efforts to comply with evolving laws, regulations and standards have resulted in, and are likely to continue to result in, increased selling, general and administrative expenses and management time related to compliance activities. If we fail to comply with these laws, regulations and standards, our reputation may be harmed and we might be subject to sanctions or investigation by regulatory authorities, such as the SEC. Any such action could adversely affect our financial results and the market price of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability and result in harm to our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees are increasingly utilizing social media tools and our website as a means of communication. Despite our efforts to monitor social media communications, there is risk that the unauthorized use of social media by our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may result in violations of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a material adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is commonplace in the biotechnology industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics, which could also cause significant disruption in the operations of third-party manufacturers, CROs, or other third parties upon whom we rely.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics, which could also cause significant disruption in the operations of third-party manufacturers, CROs and other third parties upon whom we rely. As a result, we may experience disruptions that could severely impact our supply chain, ongoing and future clinical trials and commercialization of INGREZZA or any of our other products. In response to the COVID-19 pandemic, we implemented a remote work model for all employees except certain key essential members involved in business-critical activities.&#160;Our employees have resumed in-person interactions and have returned to the office under flexible work guidelines. However, a remote work model may nevertheless need to be reinstated at some point in the future. The effects of a remote and flexible work model may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend on our ability to conduct our business in the ordinary course. Remote work may also create increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations. In addition, we may face several challenges or disruptions upon a return back to the workplace, including re-integration challenges by our employees and distractions to management related to such transition. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, clinical site initiation and patient enrollment may be delayed due to concerns for patient safety. Some patients may not be able to comply with clinical trial protocols and our ability to recruit and retain patients, principal investigators and site staff may be hindered, which would adversely impact our clinical trial operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate effects of health pandemics or epidemics is highly uncertain and subject to change and these effects could have a material impact on our operations, or the operations of third parties on whom we rely.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patent protection for our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve our trade secrets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent third parties from infringing upon our proprietary rights; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing upon the proprietary rights of others, both in the U.S. and internationally.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the substantial length of time and expense associated with bringing new products through the development and regulatory approval processes in order to reach the marketplace, the pharmaceutical industry places considerable importance on obtaining patent and trade secret protection for new technologies, products and processes. Accordingly, we intend to seek patent protection for our proprietary technology and compounds. However, we face the risk that we may not obtain any of these patents and that the breadth of claims we obtain, if any, may not provide adequate protection of our proprietary technology or compounds. Additionally, if our employees, commercial collaborators or consultants use generative artificial intelligence (AI) technologies to develop our proprietary technology and compounds, it may impact our ability to obtain or successfully defend certain intellectual property rights.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, through confidentiality agreements with our commercial collaborators, employees and consultants. We also have invention or patent assignment agreements with our employees and some, but not all, of our commercial collaborators and consultants. However, if our employees, commercial collaborators or consultants breach these agreements, we may not have adequate remedies for any such breach, and our trade secrets may otherwise become known or independently discovered by our competitors.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we own a number of patents, the issuance of a patent is not conclusive as to its validity or enforceability, and third parties may challenge the validity or enforceability of our patents. We cannot assure you how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court or in other proceedings. It is possible that a competitor may successfully challenge our patents or that challenges will result in limitations of their coverage. Moreover, competitors may infringe our patents or successfully avoid them through design innovation. In addition, potential competitors have in the past and may in the future file an abbreviated new drug application (ANDA) with the FDA seeking approval to market a generic version of our products, or our competitors&#8217; products, before the expiration of the patents covering our products or our competitors&#8217; products, as applicable. To prevent infringement or unauthorized use, we have in the past and may in the future need to file infringement claims, which are expensive and time-consuming. Refer to Note 13 to the consolidated financial statements f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a description of our legal proceedings related to intellectual property matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, in an infringement proceeding a court may decide that a patent of ours or a patent of a competitor is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. Derivation proceedings declared by the U.S. Patent and Trademark Office may be necessary to determine the priority of inventions with respect to our patent applications (or those of our licensors) or a patent of a competitor. Litigation or derivation proceedings may fail and, even if successful, may result in substantial costs and be a distraction to management. Litigation or derivation proceedings, including proceedings of a competitor, may also result in a competitor entering the marketplace faster than expected. We cannot assure you that we will be able to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the U.S.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enacted healthcare reform, drug pricing measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of government and third-party payors to contain or reduce the costs of healthcare and to lower drug prices. In the U.S., comprehensive drug pricing legislation enacted by the Federal government implements, for the first time, government control over the pricing of certain prescription pharmaceuticals. Moreover, in some foreign jurisdictions, pricing of prescription pharmaceuticals is also subject to government control. Additionally, other federal and state laws impose obligations on manufacturers of pharmaceutical products, among others, related to disclosure of new drug products introduced to the market and increases in drug prices above a specified threshold.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in August 2022, President Biden signed into law the Inflation Reduction Act of 2022, or the IRA, which, among other things: (1) directs the Secretary of the HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare; (2) redesigns the Medicare Part D prescription drug benefit to lower patient out-of-pocket costs and increase manufacturer liability; and (3) requires drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in the ACA marketplaces through plan year 2025 and beginning in 2025, eliminates the &#8220;donut hole&#8221; under the Medicare Part D program and creates a new, permanent cap on beneficiary out-of-pocket spending, in addition to a newly established manufacturer discount program. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has issued and updated and will continue to issue and update guidance as these programs are implemented. These provisions take effect progressively starting in 2023. On August 29, 2023, HHS announced the list of the first 10 drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently uncertain how the IRA will be implemented over time; however, it is likely to have a significant impact on the pharmaceutical industry and prescription drug pricing. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the IRA drug price negotiation program targets high-expenditure drugs that have been on the market for several years without generic or biosimilar competition, we believe we will qualify for the small biotech exception from negotiation that is set to expire in 2029. However, the qualification for this exception is subject to various requirements and there is no assurance that we will continue to qualify for this exemption in the future. Further, the loss of this exception or the potential loss of this exception, including as a result of a potential acquisition or strategic transaction, could have an adverse impact on our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IRA&#8217;s enactment, the most significant recent federal legislation impacting the pharmaceutical industry occurred in March 2010, when the ACA was signed into law. The ACA was intended to broaden access to health insurance and reduce the number of uninsured individuals, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry and impose additional health policy reforms.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments to the statute, including the Infrastructure Investment and Jobs Act and Consolidated Appropriations Act of 2023, will remain in effect until 2032. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s SIP proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. Further, certain states through legislation have created a state PDAB to help control costs of drugs for that state. The functions of the PDABs vary by state, and may include among other things, recommending or setting upper limits on the price the state pays for certain drugs, performing drug affordability reviews, and advising state lawmakers on additional ways to reduce the state&#8217;s drug spending. It is possible that the actions taken by the PDABs may result in lower prices for certain drug products sold in their in states. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implementation of these cost containment measures may prevent us from being able to generate revenue, attain sustained profitability or commercialize our drugs, particularly since the majority of our current revenue is derived from federal healthcare programs, including Medicare and Medicaid.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proposed healthcare reform, drug pricing measures and other prospective legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that there will continue to be a number of federal and state proposals to implement additional government controls over the pricing of prescription pharmaceuticals. In addition, increasing emphasis on reducing the cost of healthcare in the U.S. will continue to put pressure on the pricing and reimbursement of prescription pharmaceuticals. For example, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain jurisdictions outside of the U.S., including the EU, have instituted price ceilings on specific products and therapies, as described further in the risk factor titled &#8220;Government and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products or impose policies and/or make decisions regarding the status of our products that could limit our product revenues and delay sustained profitability.&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently unable to predict what other additional legislation or regulation, if any, relating to the healthcare industry may be enacted in the future or what effect recently enacted federal or equivalent foreign legislation or any such additional legislation or regulation would have on our business. The pendency or approval of such proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to enter into collaboration agreements for the further development and commercialization of our programs and products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could&#160;face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and activities may be directly, or indirectly, subject to various federal and state healthcare laws, including without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as current and future sales, marketing, patient co-payment assistance and education programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such laws include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the federal civil False Claims Act, and Civil Monetary Penalties Laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by HITECH and its implementing regulations, which also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans and healthcare clearinghouses, as well as their business associates and their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state, local and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing; state laws that require disclosure of price increases above certain identified thresholds as well as of new commercial launches in the state; state laws that create Prescription Drug Price Affordability Boards to review or attempt to cap drug spending; state and local laws that require the registration of pharmaceutical sales representatives; state and local &#8220;drug take back&#8221; laws and regulations; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While our interactions with healthcare professionals, including our speaker programs and other arrangements have been structured to comply with these laws and related guidance, it is possible that governmental and enforcement authorities will conclude that our business practices, or a rogue employee&#8217;s activities, may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. For example, we maintain a patient assistance program to help eligible patients afford our products. These and other types of programs have become the subject of governmental scrutiny, and numerous organizations, including pharmaceutical manufacturers, have been subject to litigation, enforcement actions and settlements related to their patient assistance programs. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any sales of our product once commercialized outside the U.S. will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could face liability if a regulatory authority determines that we are promoting INGREZZA or any of our product candidates that receives regulatory approval, for &#8220;off-label&#8221; uses.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company may not promote &#8220;off-label&#8221; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#8217;s FDA-approved label in the U.S. or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. A company that is found to have promoted off-label use of its product may be subject to significant liability, including civil and criminal sanctions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or any other governmental agency, including equivalent foreign authorities, initiates an enforcement action against us, or if we are the subject of a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit brought by a private plaintiff on behalf of the government, and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems, those third parties upon which we rely, or our data is or were compromised, we could experience adverse impacts resulting from such compromise, including, but not limited to, interruptions to our operations such as our clinical trials, claims that we breached our data protection obligations, harm to our reputation, regulatory investigations or actions, litigation, fines and penalties, and a loss of customers or sales.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we and the third parties upon which we rely, collect, receive, store, process, generate, disclose, make accessible, protect, dispose of, transmit, use, safeguard, share and transfer, or collectively, process, confidential and sensitive electronic information on our networks and in our data centers. This information includes, among other things, de-identified or pseudonymous sensitive personal data (including health data), our intellectual property and proprietary information, the confidential information of our collaborators and licensees, and the personal data of our employees. It is important to our operations and business strategy that this electronic information remains secure and is perceived to be secure. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, and the volume of data we retain, make such systems potentially vulnerable to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code, malware (such as malicious code, adware, and command and control (C2)), denial-of-service attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, attacks enhanced or facilitated by AI, telecommunications failures, and other similar threats. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties upon which we rely. Such threats continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors (also referred to as APTs). Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, which could materially disrupt our systems and operations, as well as our ability to conduct clinical trials. Ransomware attacks are also becoming increasingly prevalent and severe, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and can lead to significant interruptions in our operations (including our ability to conduct clinical trials), loss of sensitive data (including related to our clinical trials) and income, reputational harm, and diversion of funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To alleviate the financial, operational and reputational impact of a ransomware attack, it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including, for example, if applicable laws or regulations prohibit such payments). Similarly, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties in our supply chain have not been compromised or that they do not contain exploitable defects, vulnerabilities, or bugs that could result in a breach of or disruption to our information technology systems and infrastructure or the information technology systems and infrastructure of third parties that support our operations. Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections, computers and devices outside our premises, including at home, while in transit or in public locations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, natural disasters, public health pandemics or epidemics, terrorism, war and geopolitical conflicts, and telecommunication and electrical failures may result in damage to or the interruption or impairment of key business processes, or the loss or corruption of confidential information, including intellectual property, proprietary business information and personal data. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities or modify our business activities (including our clinical trial activities) to try to protect against security incidents. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We take steps designed to detect, mitigate, and remediate vulnerabilities in our information security systems (such as our hardware and/or software, including that of third parties upon which we rely). We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vulnerabilities could be exploited and result in a security incident.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email and other functions. We also rely on third-party service providers to provide other products, services, parts, or otherwise to operate our business, including clinical trial sites and investigators, contractors, manufacturers, suppliers and consultants. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers or CROs experience a security incident or other interruption, we could experience adverse consequences. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised or otherwise subject to a security incident. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although to our knowledge we, or the third parties upon who we rely, have not experienced a security incident or disruption to date that is material to us, we and our vendors have been, either directly or indirectly, the target of cybersecurity incidents and expect them to continue. While we have implemented security measures designed to protect our data security and information technology systems, such measures may not prevent such events. Furthermore, while we have implemented and are planning to implement redundancies designed to avoid interruptions to our operations, not all potential events can be anticipated and interruptions to our operations could lead to decreased productivity. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we (or a third party upon whom we rely) experience a security incident, ransomware attack or are perceived to have experienced a security incident, we may experience adverse consequences. Such consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm (including but not limited to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">damage to our patient, partner, or employee relationships)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; monetary fund diversions; diversion of management&#8217;s attention; interruptions in our operations (including availability of data, loss of connectivity to our network or internet); financial loss (including decreased productivity resulting from interruptions in our operations); and other similar harms. Similarly, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy. Applicable data privacy and security obligations may also require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts, with for example third parties or CROs, may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We also cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, our sensitive information could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; potential use of generative AI technologies.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to any patent protection, we rely on forms of regulatory exclusivity to protect our products such as orphan drug designation. A product candidate that receives orphan drug designation can benefit from a streamlined regulatory process as well as potential commercial benefits following approval. Currently, this designation provides market exclusivity in the U.S. for seven years and EU for 10 years if a product is the first such product approved for such orphan indication. This market exclusivity does not, however, pertain to indications other than those for which the drug was specifically designated in the approval, nor does it prevent other types of drugs from receiving orphan designations or approvals in these same indications. Further, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the new drug is clinically superior to the orphan product or a market shortage occurs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, orphan exclusivity may be reduced to six years if the drug no longer satisfies the original designation criteria or can be lost altogether if the marketing authorization holder consents to a second orphan drug application or cannot supply enough drug, or when a second applicant demonstrates its drug is &#8220;clinically superior&#8221; to the original orphan drug. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not have adequate patent protection for our products, then the relative importance of obtaining regulatory exclusivity is even greater. We may not be successful obtaining orphan drug designations for any indications and, even if we succeed, such product candidates with such orphan drug designations may fail to achieve FDA approval. Even if a product candidate with orphan drug designation may receive marketing approval from the FDA, it may fail to result in or maintain orphan drug exclusivity upon approval, which would harm our competitive position.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The technologies we use in our research as well as the drug targets we select may infringe the patents or violate the proprietary rights of third&#160;parties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that third parties will not assert patent or other intellectual property infringement claims against us or our collaborators with respect to technologies used in potential products. If a patent infringement suit were brought against us or our collaborators, we or our collaborators could be forced to stop or delay developing, manufacturing or selling potential products that are claimed to infringe a third party&#8217;s intellectual property unless that party grants us or our collaborators rights to use its intellectual property. In such cases, we could be required to obtain licenses to patents or proprietary rights of others in order to continue to commercialize our products. However, we may not be able to obtain any licenses required under any patents or proprietary rights of third parties on acceptable terms, or at all. Even if our collaborators or we were able to obtain rights to the third party&#8217;s intellectual property, these rights may be non-exclusive, thereby giving our competitors access to the same intellectual property. Ultimately, we may be unable to commercialize some of our potential products or may have to cease some of our business operations as a result of patent infringement claims, which could severely harm our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations may subject us to disputes, claims and lawsuits, which may be costly and time-consuming and could materially and adversely impact our financial position and results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in disputes, claims and lawsuits relating to our business operations. In particular, we may face claims related to the safety of our products, intellectual property matters, employment matters, tax matters, commercial disputes, competition, sales and marketing practices, environmental matters, personal injury, insurance coverage and acquisition or divestiture-related matters. Any dispute, claim or lawsuit may divert management&#8217;s attention away from our business, we may incur significant expenses in addressing or defending any dispute, claim or lawsuit, and we may be required to pay damage awards or settlements or become subject to equitable remedies that could adversely affect our operations and financial results. For example, we recently settled various intellectual property litigation matters against potential competitors related to INGREZZA. Refer to Note 13 to the consolidated financial statements f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a more detailed description of these matters.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation related to these disputes may be costly and time-consuming and could materially and adversely impact our financial position and results of operations if resolved against us. In addition, the uncertainty associated with litigation could lead to increased volatility in our stock price.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees and independent contractors, such as principal investigators, consultants, commercial partners and vendors, or by employees of our commercial partners could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws, to report financial information or data accurately, to maintain the confidentiality of our trade secrets or the trade secrets of our commercial partners, or to disclose unauthorized activities to us. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. Employee and independent contractor misconduct could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any action against our employees, independent contractors, principal investigators, consultants, commercial partners or vendors for violations of these laws could result in significant civil, criminal and administrative penalties, fines and imprisonment.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our insurance coverage.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of any of our potential products in clinical trials, and the sale of any approved products, including INGREZZA, may expose us to liability claims. These claims might be made directly by consumers, healthcare providers, pharmaceutical companies or others selling our products. We have product liability insurance coverage for both our clinical trials as well as related to the sale of INGREZZA in amounts consistent with customary industry practices. However, our insurance may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability from any current or future clinical trials or approved products. A successful product liability claim, or series of claims, brought against us would decrease our cash reserves and could cause our stock price to fall. Furthermore, regardless of the eventual outcome of a product liability claim, any product liability claim against us may decrease demand for our approved products, including INGREZZA, damage our reputation, result in regulatory investigations that could require costly recalls or product modifications, cause clinical trial participants to withdrawal, result in costs to defend the related litigation, decrease our revenue, and divert management&#8217;s attention from managing our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our activities involve hazardous materials, and we may be liable for any resulting contamination or injuries.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research activities involve the controlled use of hazardous materials. We cannot eliminate the risk of accidental contamination or injury from these materials. If an accident occurs, a court may hold us liable for any resulting damages, which may harm our results of operations and cause us to use a substantial portion of our cash reserves, which would force us to seek additional financing.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing obligations related to data privacy and information security. Our actual or perceived failure to comply with such obligations could have a material adverse effect on our reputation, business, financial condition or results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we process confidential and sensitive information, including personal data, proprietary and confidential business data, trade secrets, intellectual property, data we collect about clinical trial participants in connection with clinical trials, and sensitive third-party data, on our networks and in our data centers. We are subject to numerous federal, state, local and foreign laws, orders, codes, regulations and regulatory guidance regarding privacy, data protection, information security and the processing of personal information (including clinical trial data), the number and scope of which are expanding, changing, subject to differing applications and interpretations, and may be inconsistent among jurisdictions. Our data processing activities may also subject us to other data privacy and security obligations, such as industry standards, external and internal privacy and security policies, contracts and other obligations that govern the processing of data by us and by third parties on our behalf.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws regarding privacy, data protection, information security and the processing of personal data are becoming increasingly common in the U.S. at both the federal and state level. Additionally, in the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut, and Utah&#8212;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act of 2020 (CPRA) (collectively, CCPA), requires businesses to provide specific disclosures in privacy notices, and honor requests of California residents to exercise certain privacy rights. The CCPA allows for fines for noncompliance (up to $7,500 per intentional violation). Although some U.S. comprehensive privacy laws and the CCPA exempt some data processed in the context of clinical trials, these laws may increase compliance costs and potential liability with respect to other personal data we may maintain about California residents. Other states have also enacted data privacy laws and we expect more jurisdictions to pass similar laws in the future. These developments may further complicate compliance efforts, and may increase legal risk and compliance costs for us and the third parties upon whom we rely.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws in Europe regarding privacy, data protection, information security and the processing of personal data have also been significantly reformed and continue to undergo reform. For example, the EU&#8217;s General Data Protection Regulation (EU GDPR) and the UK&#8217;s GDPR (UK GDPR) (collectively, GDPR) impose strict requirements for processing the personal data of individuals located, respectively, within the European Economic Area (EEA) and the UK. The GDPR provides for enhanced data protection obligations for processors and controllers of personal data, including, for example, obligations relating to: processing health and other sensitive data; obtaining consent of individuals; providing notice to individuals regarding data processing activities; responding to data subject requests; taking certain measures when engaging third-party processors; notifying data subjects and regulators of data breaches; and implementing safeguards to protect the security and confidentiality of personal data. The GDPR impose substantial fines for breaches of data protection requirements. For example, under the GDPR, such fines can be up to four percent of global revenue or 20 million euros under the EU GDPR / 17.5 million pounds sterling under the UK GDPR, whichever is greater in either case, and also allow for private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as EU regulations governing clinical trial data and other healthcare data, could require us to change our business practices or lead to government enforcement actions, private litigation or significant penalties against us and could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to additional foreign data laws. For example, in Canada, the Personal Information Protection and Electronic Documents Act (PIPEDA) and various related provincial laws, as well as Canada&#8217;s Anti-Spam Legislation (CASL), may apply to our operations. As another example, the General Data Protection Law, Lei Geral de Prote&#231;&#227;o de Dados Pessoais (LGPD) (Law No. 13,709/2018), may apply to our operations. The LGPD broadly regulates processing personal data of individuals in Brazil and imposes compliance obligations and penalties comparable to those of the EU GDPR. We also target customers in Asia and may be subject to new and emerging data privacy regimes in Asia, including Japan&#8217;s Act on the Protection of Personal Information and Singapore&#8217;s Personal Data Protection Act.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the U.S. or other countries. Certain jurisdictions have enacted data localization laws and cross-border personal data transfers laws. For example, countries in the EEA and the UK have significantly restricted the transfer of personal data to the U.S. and other countries, whose privacy laws it generally believes are inadequate. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the U.S. in compliance with law, such as the EEA standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers for to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S. If we cannot implement a valid compliance mechanism for cross-border personal data transfers or if the requirements for a legally-compliant transfer are too onerous, we may face increased exposure to regulatory actions, substantial fines and injunctions against processing or transferring personal data from Europe or elsewhere. The inability to import personal data to the U.S. may significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with parties subject to European and other data protection laws or requiring us to increase our personal data processing capabilities in Europe and/or elsewhere at significant expense. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees and personnel may use generative AI technologies to perform some of their work, and the disclosure and use of personal information data in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and consumer lawsuits. Furthermore, any use of generative AI to develop our proprietary technology and compounds may also impact our ability to obtain or successfully defend certain intellectual property rights. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to data privacy and security laws, we may contractually be subject to industry standards adopted by industry groups and, we are, or may become subject to such obligations in the future. We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We publish privacy policies, marketing materials and other statements regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing in an increasingly stringent fashion and creating uncertainty. These obligations may be subject to differing applications and interpretations, which may be inconsistent among jurisdictions or in conflict. Preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources). These obligations may necessitate changes to our information technologies, systems and practices and those of any third parties that process personal data on our behalf. In addition, these obligations may even require us to change our business model.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third-parties upon whom we rely may fail to comply such obligations that impacts our compliance posture. If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions, litigation(including class claims), additional reporting requirements and/or oversight, bans on processing personal data, imprisonment of company officials, and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, financial condition or results of operations.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_64"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 1B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Unresolved Staff Comments</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_1809"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 1C. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Management and Strategy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology and data to operate our business and develop, market, and deliver our therapies to our customers. We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to critical computer networks, third party hosted services, communications systems, hardware, lab equipment, software, and our critical data includes confidential, personal, proprietary, and sensitive data (collectively &#8220;Information Assets&#8221;). Accordingly, we maintain certain risk assessment processes intended to identify cybersecurity threats, determine their likelihood of occurring, and assess potential material impact to our business. Based on our assessment, we implement and maintain risk management processes designed to protect the confidentiality, integrity, and availability of our Information Assets and mitigate harm to our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s general risk management program is designed to manage identified material risks, which would include material cybersecurity risks.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in processes designed to identify such threats by, among other things, monitoring the threat environment using manual and automated tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats and actors, conducting scans of the threat environment, evaluating our and our industry&#8217;s risk profile, evaluating threats reported to us, coordinating with law enforcement concerning threats, conducting threat assessments for internal and external threats, and conducting vulnerability assessments to identify vulnerabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a multidisciplinary team (including from our information security function, management, and third party service providers, as described further below) to assess how identified cybersecurity threats could impact our business. These assessments may leverage, among other processes, industry tools and metrics designed to assist in the assessment of risks from such cybersecurity threats.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the environment, we implement and maintain various technical, physical and organizational measures designed to manage and mitigate material risks from cybersecurity threats to our Information Assets. The cybersecurity risk management and mitigation measures we implement for certain of our Information Assets include: policies and procedures designed to address cybersecurity threats, including an incident response plan, vulnerability management policy, and disaster recovery/business continuity plans; incident detection and response tools; internal and/or external audits to assess our exposure to cybersecurity threats, environment, compliance with risk mitigation procedures, and effectiveness of relevant controls; documented risk assessments; implementation of security standards/certifications; credit and background checks on our and/or third parties&#8217; personnel; encryption of data; network security controls; threat modeling; data segregation; physical and electronic access controls; physical security; asset management, tracking and disposal; systems monitoring; vendor risk management program; employee security training; penetration testing; red/blue team exercises; cyber insurance; dedicated cybersecurity staff/officer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with third parties from time to time that assist us from time to time to identify, assess, and manage cybersecurity risks, including professional services firms, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, and penetration testing.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To operate our business, we utilize certain third-party service providers to perform a variety of functions, such as outsourced business critical functions, clinical research, professional services, SaaS platforms, managed services, property management, cloud-based infrastructure, data center facilities, content delivery, encryption and authentication technology, corporate productivity services, and other functions. We have certain vendor management processes designed to help to manage cybersecurity risks associated with our use of certain of these providers. Depending on the nature of the services provided, the sensitivity and quantity of information processed, and the identity of the service provider, our vendor management process may include reviewing the cybersecurity practices of such provider, contractually imposing obligations on the provider related to the services they provide and/or the information they process, conducting security assessments, conducting on-site inspections, requiring their completion of written questionnaires regarding their services and data handling practices, and conducting periodic re-assessments during their engagement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, refer to Part I, Item 1A. Risk Factors for additional information about cybersecurity-related risks.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including a Chief Information Officer, who reports to the CFO. Management is also responsible for hiring appropriate personnel, integrating cybersecurity considerations into the company&#8217;s overall risk management strategy, and for communicating key priorities to employees, as well as for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. Our cybersecurity incident response and vulnerability management processes involve management, who participates in our disclosure controls and procedures.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents and vulnerabilities to members of management depending on the circumstances, including work with the company&#8217;s incident response team to help the company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the company&#8217;s incident response processes include reporting to the Audit committee of the board of directors for certain cybersecurity incidents.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is involved with the Company&#8217;s efforts to prevent, detect, and mitigate cybersecurity incidents by overseeing preparation of cybersecurity policies and procedures, testing of incident response plans, engagement of vendors to conduct penetration tests. Management participates in cybersecurity incident response efforts by being a member of the incident response team and helping direct the company&#8217;s response to cybersecurity incidents.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing the company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats. The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk, and mitigation.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_67"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Properties</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in San Diego, California. We believe that our property and equipment are generally well maintained, in good operating condition and suitable for the conduct of our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our leased facilities, which include our corporate headquarters and consist of office space and research and development laboratories, follow. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Address</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square Feet</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12780 El Camino Real, San Diego, California</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Space, Research and Development Laboratories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6027 Edgewood Bend Court, San Diego, California</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Space</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6029 Edgewood Bend Court, San Diego, California</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Space</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, San Diego, California</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Space</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10420 Wateridge Circle, San Diego, California</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and Development Laboratories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12777 High Bluff Drive, San Diego, California</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Space</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12770 El Camino Real, San Diego, California</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Space</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, including a six-year option for the construction of a fifth building. This campus facility, comprised of office space and research and development laboratories, will serve as our new corporate headquarters.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The construction of the campus facility is phased. The first phase of construction relating to office space was completed in December 2023. As we begin to occupy our new campus facility, we will sublease certain of our existing leased premises when we determine there is excess leased capacity.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_70"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Legal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Proceedings</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our legal proceedings, refer to Note 13 to the consolidated financial statements, which is incorporated herein by reference.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_73"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_79"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;NBIX&#8221;.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February&#160;5, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were approximately 43 stockholders of record of our common stock. We have not paid any cash dividends on our common stock since inception and do not anticipate paying cash dividends in the foreseeable future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no unregistered sales of our equity securities and we did not repurchase any of our equity securities during 2023.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph and Cumulative Total Return*</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph presents the cumulative total stockholder return assuming the investment of $100 on December&#160;31, 2018 (and the reinvestment of dividends thereafter) in each of (i)&#160;Neurocrine Biosciences, Inc.&#8217;s common stock, (ii)&#160;the Nasdaq Composite Index and (iii)&#160;the Nasdaq Biotechnology Index. The comparisons in the graph below are based upon historical data and are not indicative of, or intended to forecast, future performance of our common stock or Indexes.</span></div><div style="text-align:center"><img src="nbix-20231231_g7.jpg" alt="1309" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The material in this section is not &#8220;soliciting material&#8221;, is not deemed &#8220;filed&#8221; with the Securities and Exchange Commission and is not to be incorporated by reference into any of our SEC filings whether made before or after the date hereof and irrespective of any general incorporation language in any such SEC filing except to the extent we specifically incorporate this section by reference.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section contains forward-looking statements pertaining to, among other things, the commercialization of our product and product candidates, the expected continuation of our collaborative agreements, the progress, timing, results or implications of clinical trials and other development activities, our plans and timing with respect to seeking regulatory approvals, the period of time that our existing capital resources will meet our funding requirements, and our financial results of operations. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various risks and uncertainties, including those set forth in this Annual Report on Form 10-K under the heading &#8220;Item 1A. Risk Factors.&#8221; See &#8220;Forward-Looking Statements&#8221; in Part I of this Annual Report on Form 10-K.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_85"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The Company&#8217;s diverse portfolio includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, adrenal insufficiency, and endometriosis and uterine fibroids in collaboration with AbbVie Inc. (AbbVie), a European Medicines Agency (EMA) approved treatment for classic congenital adrenal hyperplasia (CAH) and a diversified portfolio of advanced clinical-stage programs in multiple therapeutic areas.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in the U.S. as the first FDA-approved drug for the treatment of tardive dyskinesia in May 2017 and for the treatment of adults with chorea associated with Huntington's disease in August 2023. INGREZZA net product sales totaled $1.8 billion for 2023 and accounted for approximately 99% of our total net product sales for 2023.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner Mitsubishi Tanabe Pharma Corporation (MTPC) launched DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan for the treatment of tardive dyskinesia in June 2022 and subsequently in other select Asian markets, where it is marketed as REMLEAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine). We receive royalties at tiered percentage rates on MTPC net sales of valbenazine.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (elagolix tablets) in the U.S. for the treatment of moderate to severe pain associated with endometriosis in August 2018 and ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Highlights</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">INGREZZA net product sales for 2023 increased $0.4 billion, or 28.6%, to $1.8 billion, reflecting higher prescription demand and increased commercial activities, including continued investment in our branded direct-to-consumer INGREZZA advertising campaign and benefit from the expansion of our sales force completed in April 2022.</span></div><div style="margin-bottom:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In the fourth quarter of 2023, we announced that all patent litigation brought by Neurocrine Biosciences against the companies that filed an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market generic versions of INGREZZA prior to the expiration of the Orange Book listed patents have been resolved. Pursuant to the terms of the respective settlement agreements, such companies have the right to sell generic versions of INGREZZA in the U.S. beginning March 1, 2038, or earlier under certain circumstances.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pipeline Highlights</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Announced positive top-line data from the Phase 3 clinical studies of crinecerfont in adults and pediatrics with CAH. Crinecerfont subsequently received Breakthrough Therapy designation from the FDA for the treatment of CAH. Data from the Phase 3 studies will support a New Drug Application (NDA) submission to the FDA in the second quarter of 2024.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Expanded strategic partnership with Voyager Therapeutics Inc. (Voyager) to advance multiple gene therapy programs, each enabled by Voyager's next-generation TRACER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsids, for the treatment of neurological diseases. Upfront fee associated with the agreement totaled $175.0 million, including an equity investment valued at $31.3 million on the transaction date, with the remaining $143.9 million of the purchase price, which includes the applicable transaction costs, expensed as in-process research and development in 2023.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In the third quarter of 2023, we announced the FDA accepted the NDA for INGREZZA oral granules, a new sprinkle formulation of INGREZZA capsules for oral administration. The agency set a Prescription Drug User Fee Act target action date of April 30, 2024.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In the third quarter of 2023, the FDA approved INGREZZA for the treatment of adults with chorea associated with Huntington's disease.</span></div><div style="margin-bottom:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In the fourth quarter of 2023, we announced the Phase 2 clinical studies of NBI-921352 in focal onset seizures and NBI-1065846 for anhedonia in major depressive disorder (MDD) did not meet their primary endpoints. No further development of NBI-921352 in focal onset seizures or NBI-1065846 for anhedonia in MDD is planned at this time.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_88"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales by Sales Product.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INGREZZA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in total net product sales from 2021 to 2022 and from 2022 to 2023 were primarily driven by increased INGREZZA net product sales on higher prescription demand and increased commercial activities, including continued investment in our branded direct-to-consumer INGREZZA advertising campaign and benefit from the expansion of our sales force completed in April 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues by Category.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties reflect revenue earned on AbbVie net sales of elagolix for all periods presented and MTPC net sales of valbenazine beginning in June 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022, total collaboration revenue also reflected the achievement of a $20.0 million milestone in connection with MTPC's first commercial sale of DYSVAL in Japan.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021, total collaboration revenue also reflected the achievement of a $15.0 million milestone in connection with MTPC's marketing authorization application submission for valbenazine for the treatment of tardive dyskinesia in Japan.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenues. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023 compared to 2022, the increase in cost of revenues was primarily driven by increased INGREZZA and other net product sales, increased amortization costs related to intangible assets, increased reserves for ONGENTYS inventory obsolescence in connection with the termination of our license agreement with BIAL, and increased manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with MTPC. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the increase in cost of revenues was primarily driven by increased INGREZZA net product sales.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development by Category. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs, and business development opportunities. Costs are reflected in the applicable development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same reporting period. For several of our programs, the research and development activities are part of our collaborative arrangements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Late stage </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early stage </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and discovery </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Late Stage.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of costs incurred for product candidates in Phase 2 registrational studies and all subsequent activities.</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in late stage expenses from 2021 to 2022 and from 2022 to 2023 primarily reflected increased investment in the Phase 3 programs for crinecerfont in CAH and valbenazine in schizophrenia and Phase 2 program for EFMODY in CAH.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Stage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of costs incurred for product candidates after the approval of an investigational new drug application by the applicable regulatory agency through Phase 2 non-registrational studies. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023 compared to 2022, the increase in early stage expenses primarily reflected increased investment in the Phase 2 program for NBI-1117568 in schizophrenia and other advancing Phase 2 programs in psychiatry, partially offset by decreased spend on early stage programs in epilepsy.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the increase in early stage expenses primarily reflected increased investment in advancing Phase 2 programs in epilepsy and psychiatry.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Discovery.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of expenses incurred prior to the approval of an investigational new drug application by the applicable regulatory agency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023 compared to 2022, the increase in research and discovery expenses primarily reflected increased investment in preclinical development programs including muscarinic agonists, gene therapies, and second generation VMAT2 inhibitors.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the increase in research and discovery expenses reflected increased investment in preclinical development programs including psychiatry, epilepsy, and gene therapies .</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consist of development and regulatory milestone expenses incurred in connection with our collaborative arrangements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we recognized milestone expenses of $30.0 million in connection with the FDA's acceptance of the investigational new drug application for NBI-1117568 in schizophrenia, $7.3 million in connection with the FDA's acceptance of the amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol, and $5.0 million in connection with the approval of the clinical trial application for NBI-1070770 in major depressive disorder.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recognized milestone expense of $5.4 million in connection with the regulatory approval of the clinical trial application in Europe for NBI-921352 in epilepsy.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payroll and Benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consists of costs incurred for salaries and wages, payroll taxes, benefits and stock-based compensation associated with employees involved in research and development activities. Stock-based compensation may fluctuate from period to period based on factors that are not within our control, such as our stock price on the dates stock-based grants are issued.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023 compared to 2022, the increase in payroll and benefits expenses primarily reflected higher headcount and an increase of $10.3 million in non-cash stock-based compensation expense primarily driven by an incremental charge related to a change in equity grant agreement terms.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the increase in payroll and benefits expenses primarily reflected higher headcount, including an increase of $9.3 million in non-cash stock-based compensation expense driven by an August 2021 equity grant of approximately 0.5 million restricted stock units to our full-time employees other than our executive officers and performance-based restricted stock units to our executive officers for which attainment of the performance-based criteria was achieved in 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Facilities and Other.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of indirect costs incurred for the benefit of multiple programs, including depreciation, information technology, and other facility-based expenses, such as rent expense.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-Process Research and Development, or IPR&amp;D.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we recognized $143.9 million of IPR&amp;D expense in connection with our payment of the upfront fee pursuant to our expanded strategic partnership with Voyager.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recognized $105.3 million of IPR&amp;D expense, of which $100.3 million was in connection with our payment of the upfront fee pursuant to our collaboration with Heptares Therapeutics Limited.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative, or SG&amp;A. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023 compared to 2022, the increase in SG&amp;A expenses was primarily driven by increased investment in our commercial initiatives, including our branded direct-to-consumer INGREZZA advertising campaign and deployment of our expanded salesforce completed in April 2022, and increased payroll and benefits expenses on higher headcount and an increase of $10.9 million in non-cash stock-based compensation expense primarily driven by an incremental charge related to a change in equity grant agreement terms.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the increase in SG&amp;A expenses was primarily driven by increased investment in our commercial initiatives and increased payroll and benefits expenses on higher headcount and an increase of $29.6 million in non-cash stock-based compensation expense driven by an August 2021 equity grant of approximately 0.5 million restricted stock units to our full-time employees other than our executive officers and performance-based restricted stock units to our executive officers for which attainment of the performance-based criteria was achieved in 2022.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in other income (expense), net from 2021 to 2022 and from 2022 to 2023 primarily reflected debt extinguishment charges in connection with the repurchase of our convertible senior notes in 2022, periodic fluctuations in the fair values of our equity security investments, increased interest income on our debt security investments and decreased interest expense on lower total debt outstanding. The change in other expense, net from 2021 to 2022 also reflected decreased interest expense due to the adoption of ASU 2020-06 on January 1, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023, the effective tax rate varied from the federal and state statutory rates primarily due to credits generated for research activities, certain nondeductible expenses, the impact of changes in the state effective rate, and losses incurred in foreign jurisdictions for which no tax benefit was recorded as management cannot conclude that it is more likely than not that the tax benefit of such losses will be realized in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022, the effective tax rate varied from the federal and state statutory rates primarily due to credits generated for research activities and certain nondeductible expenses, including the premium paid on the repurchase of our convertible senior notes in 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021, the effective tax rate varied from the federal and state statutory rates primarily due to excess tax benefits associated with stock-based compensation and credits generated for research activities. In the first quarter of 2021, we began recording a provision for income taxes using an effective tax rate that approximated federal and state statutory rates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net Income.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023 compared to 2022, the increase in net income primarily reflected increased INGREZZA net product sales, decreased debt extinguishment charges in connection with the repurchase of our convertible senior notes in 2022, and decreased milestone expenses in connection with our collaborations, partially offset by increased upfront payments in connection with our expanded strategic partnership with Voyager and increased investment in our commercial initiatives and expanded clinical portfolio.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the increase in net income primarily reflected increased INGREZZA net product sales and lower upfront payments for asset acquisitions, partially offset by increased debt extinguishment charges in connection with the repurchase of our convertible senior notes in 2022 and increased investment in our commercial initiatives and expanded clinical portfolio.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources, funds generated by anticipated INGREZZA net product sales and investment income will be sufficient to satisfy our current and projected funding requirements for at least the next 12 months. However, we cannot guarantee that our existing capital resources and anticipated revenues will be sufficient to conduct and complete all of our research and development programs or commercialization activities as planned. We may seek to access the public or private equity markets whenever conditions are favorable or pursue opportunities to obtain additional debt financing in the future. We may also seek additional funding through strategic alliances or other financing mechanisms. However, we cannot provide assurance that adequate funding will be available on terms acceptable to us, if at all.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Information Regarding Our Financial Condition.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working Capital:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total working capital</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Information Regarding Our Cash Flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(467.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023 compared to 2022, the change in cash flows from operating activities primarily reflected increased INGREZZA net product sales and lower milestone payments in connection with our collaborations, partially offset by higher upfront payments in connection with our expanded strategic partnership with Voyager and increased investment in our commercial initiatives and expanded clinical portfolio.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the change in cash flows from operating activities primarily reflected increased INGREZZA net product sales and lower upfront payments for asset acquisitions, partially offset by increased investment in our commercial initiatives and expanded clinical portfolio. In addition, we experienced an increase in accounts receivable driven by increased INGREZZA net product sales on extended customer payment terms attributed to the expansion of our distribution network at the end of 2021 and an increase in accrued liabilities driven by increased revenue-related reserves for discounts and allowances on higher INGREZZA net product sales and the timing of payments.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic fluctuations in cash flows from investing activities for all periods presented reflected timing differences related to our purchases, sales, and maturities of debt security investments and changes in our portfolio-mix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023, cash flows from investing activities also reflected a $31.3 million equity investment in Voyager.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022, cash flows from investing activities also reflected the acquisition of Diurnal Group plc for $42.7 million in cash, which is net of cash acquired, and a $7.7 million equity investment in Xenon Pharmaceuticals Inc.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from financing activities for all periods presented reflected proceeds from issuances of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022, cash flows from financing activities also reflected the repurchase of $210.8 million aggregate principal amount of our convertible senior notes for an aggregate repurchase price of $279.0 million in cash.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_94"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pharmaceutical industry, it can take a significant amount of time and capital resources to successfully complete all stages of research and development and commercialize a product candidate, which ultimate length of time and spend required cannot be accurately estimated as it varies substantially according to the type, complexity, novelty and intended use of a product candidate. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The funding necessary to execute our business strategies is subject to numerous uncertainties and we may be required to make substantial expenditures if unforeseen difficulties arise in certain areas of our business. In particular, our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of INGREZZA, ORILISSA, ORIAHNN and/or DYSVAL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued scientific progress in our research and clinical development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude and complexity of our research and development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical testing and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities and arrangements, including our advertising campaigns;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing of our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future litigation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing factors, we have significant future capital requirements, including:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">External Business Developments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our independent efforts to develop and market products, we may enter into collaboration and license agreements or acquire businesses from time-to-time to enhance our drug development and commercial capabilities. With respect to our existing collaboration and license agreements, we may be required to make potential future payments of up to $17.0 billion upon the achievement of certain event-based milestones. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2 to the consolidated financial statements for more information on our significant collaboration and license agreements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases that have commenced have terms that expire beginning 2025 through 2036 and consist of office space and research and development laboratories, including our corporate headquarters. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, including a six-year option for the construction of a fifth building. This campus facility, comprised of office space and research and development laboratories, will serve as our new corporate headquarters.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The construction of the campus facility is phased. The first phase of construction relating to office space was completed in December 2023. As we begin to occupy our new campus facility, we will sublease certain of our existing leased premises when we determine there is excess leased capacity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 11 to the consolidated financial statements for more information on our leases, including a presentation of our approximate future minimum lease payments under non-cancelable operating leases.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% fixed-rated convertible senior notes due May&#160;15, 2024 (the 2024 Notes). In 2020, we repurchased $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. In 2022, we repurchased $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. As of December&#160;31, 2023, $170.4 million aggregate principal amount of the 2024 Notes remained outstanding.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At our election, we may redeem all or any portion of the 2024 Notes under certain circumstances. In addition, holders of the 2024 Notes may convert the 2024 Notes at any time until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024. Upon conversion, holders will receive the principal amount of their 2024 Notes and any conversion premium, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in cash. Unless earlier converted, redeemed, or repurchased, we would be required to pay interest of $1.9 million in 2024 and pay the aggregate principal amount outstanding of $170.4 million upon maturity of the 2024 Notes.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. There are customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes would become due and payable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5 to the consolidated financial statements for more information on the 2024 Notes.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_97"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations is based upon financial statements that we have prepared in accordance with accounting principles generally accepted in the United&#160;States of America (GAAP). The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and related disclosures. On an on-going basis, we evaluate these estimates, including those related to revenue recognition. Estimates are based on historical experience, information received from third parties and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Historically, revisions to our estimates have not resulted in a material change to the financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The items in our financial statements requiring significant estimates and judgments are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenues from product sales of INGREZZA net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors, and other third parties. Such reserves include estimates for government rebates that we are obligated to pay for discounts including under the Medicaid Drug Rebate Program and Medicare Part D. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates require us to project the magnitude of our sales that will be subject to such rebates and are based on actual historical rebates by state, estimated payor mix, state and federal regulations, and relevant contractual terms, as supplemented by management&#8217;s judgement. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). To date, actual government rebates have not differed materially from our estimates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision is computed under the asset and liability method. Significant estimates are required in determining our income tax provision. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_100"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Information</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 to the consolidated financial statements for information on accounting pronouncements that have impacted or are expected to materially impact our consolidated financial condition, results of operations, or cash flows.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_103"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 7A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a diversified investment portfolio consisting of low-risk, investment-grade debt securities with maturities of up to three years, including investments in commercial paper, securities of government-sponsored entities and corporate bonds that are subject to interest rate risk. The primary objective of our investment activities is to preserve principal and maintain liquidity. If a 1% unfavorable change in interest rates were to have occurred on December&#160;31, 2023, it would not have had a material effect on the fair value of our investment portfolio as of that date.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements and Supplementary Data</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_109"></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:93.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.509%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_112">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-36">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_112">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_115">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_115">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_118">Consolidated Statements of Income and Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_118">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_121">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_121">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_124">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_124">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_127">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iceaa8dd12d3e4afdac5da09d72a8e8c8_127">69</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_112"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Neurocrine Biosciences, Inc.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, the related consolidated statements of income and comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February&#160;9, 2024 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.394%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Reserves for government rebates related to product sales</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells product to specialty pharmacies and specialty distributors in the US (collectively, &#8220;customers&#8221;).  As described in Note 1 to the consolidated financial statements, the Company recognizes revenues for sales of INGREZZA to its customers after deducting management&#8217;s estimates of reserves, including drug coverage gap rebates, it will provide under government rebate programs (&#8220;government rebates&#8221;). Estimated government rebates are presented within accounts payable and accrued liabilities on the consolidated balance sheet.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the estimates of government rebates was complex and judgmental due to the level of uncertainty involved in management&#8217;s assumptions used in the measurement process. In particular, management was required to estimate at December 31, 2023, the portion of product that is expected to be subject to a government rebate, the applicable contractual government rebate percentage by payor type underlying the revenue and the applicable rebate amount applicable for the payor type.</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.394%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We tested the Company&#8217;s internal controls over management&#8217;s process for estimating the portion of product that is expected to be subject to a government rebate at December 31, 2023. This included controls over management&#8217;s review of significant assumptions and other inputs into the estimation of government rebates including the accuracy of data used in the calculation.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test management&#8217;s estimate of government rebate reserves our audit procedures included, among others, evaluating the methodologies used, testing the significant assumptions discussed above and testing the completeness and accuracy of the underlying data used by the Company in its analyses. Specifically, we compared the significant assumptions to third-party reports used by the Company to estimate government rebate reserves at December 31, 2023. In addition, we compared the underlying government rebate percentages used in the Company&#8217;s analyses to those published by the applicable government entity. We assessed the historical accuracy of management&#8217;s rebate estimates, tested payments of rebates and performed a sensitivity analysis of significant assumptions to evaluate the changes in the rebate allowance that would result from changes in the assumptions.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-37">Ernst&#160;&amp; Young LLP</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1992.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-38">San Diego, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;9, 2024</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-39">251.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-40">262.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="f-41">780.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="f-42">726.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="f-43">439.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="f-44">350.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-45">38.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-46">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-47">97.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-48">79.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-49">1,607.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-50">1,453.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-51">362.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-52">305.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-53">687.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-54">299.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-55">276.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-56">87.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-57">161.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-58">102.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-59">70.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-60">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="f-61">35.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="f-62">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-63">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-64">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-65">3,251.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-66">2,368.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-67">448.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-68">347.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" scale="6" id="f-69">170.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" scale="6" id="f-70">169.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-71">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-72">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-73">654.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-74">537.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-75">258.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-76">93.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-77">106.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-78">29.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-79">1,019.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Liabilities" scale="6" id="f-80">660.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:14.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-81"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-82">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-83"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-84">5.0</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="f-85"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-87"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="f-88">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:14.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-91"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-92">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-93"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-94">220.0</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-95"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-96">98.7</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-97"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-98">96.5</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-99">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-100">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-101">2,382.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-102">2,122.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-103">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-104">7.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-105">157.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-106">406.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-107">2,232.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-108">1,707.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-109">3,251.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-110">2,368.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND COMPREHENSIVE INCOME</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product sales</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-111">1,860.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-112">1,440.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-113">1,090.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-114">26.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-115">47.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-116">43.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-117">1,887.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-118">1,488.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-119">1,133.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-120">39.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-121">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-122">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-123">565.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-124">463.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-125">328.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="f-126">143.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="f-127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="f-128">105.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-129">887.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-130">752.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-131">583.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-132">1,636.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-133">1,239.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-134">1,031.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-135">250.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-136">249.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-137">102.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense): </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-138">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-139">7.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-140">25.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-141">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-142">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-143">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-145">70.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="f-147">57.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="f-148">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="f-149">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-150">81.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-151">35.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-152">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-153">332.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-154">213.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-155">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-156">82.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-157">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-158">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-159">249.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-160">154.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-161">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net of tax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="6" id="f-162">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="6" id="f-163">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) on debt securities available-for-sale, net of tax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-165">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-166">9.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-167">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-168">264.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-169">148.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-170">86.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share, basic</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-171">2.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-172">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-173">0.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-174">2.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-175">1.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-176">0.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-177">97.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-178">95.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-179">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-180">101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-181">98.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-182">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.281%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:SharesOutstanding" scale="6" id="f-183">93.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-184">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-185">1,849.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-186">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-187">725.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-188">1,126.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-189">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-190">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-191">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-192">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-193">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-194">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-195">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-196">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-197">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:SharesOutstanding" scale="6" id="f-198">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-199">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-200">2,011.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-201">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-202">635.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-203">1,374.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-204">154.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-205">154.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-206">6.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-207">6.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-208">Cumulative-effect adjustment due to adoption of ASU 2020-06</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-209">106.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-210">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-211">32.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-212">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-213">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-214">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-215">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-216">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:SharesOutstanding" scale="6" id="f-217">96.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-218">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-219">2,122.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-220">7.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-221">406.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-222">1,707.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-223">249.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-224">249.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-225">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-226">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-227">194.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-228">194.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-229">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-230">65.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-231">65.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:SharesOutstanding" scale="6" id="f-232">98.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-233">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-234">2,382.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-235">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-236">157.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-237">2,232.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-238">249.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-239">154.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-240">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-241">194.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-242">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-243">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-244">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-245">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-246">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Accretion) amortization of (discount) premium on investments, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="f-247">18.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="f-248">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="f-249">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="6" id="f-250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="6" id="f-251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="f-252">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-253">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-254">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-255">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-256">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-257">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-259">28.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-260">30.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-261">20.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-262">56.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-263">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-264">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-266">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="f-268">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="f-269">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="f-270">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-271">89.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-272">162.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-273">28.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-274">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-275">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-276">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-277">64.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-278">114.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-279">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-280">47.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-281">17.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-282">9.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-283">389.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-284">339.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-285">256.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-286">1,379.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="f-287">621.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="f-288">800.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and maturities of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="f-289">972.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="f-290">511.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="f-291">697.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of business, net of cash acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-293">42.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="f-294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="6" id="f-295">31.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="6" id="f-296">7.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="6" id="f-297">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-298">28.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-299">16.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-300">23.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-301">467.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-302">177.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-303">130.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-304">65.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-305">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-306">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="6" id="f-307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="f-308">279.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="f-309">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-310">65.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-311">234.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-312">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-313">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-314">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-316">11.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-317">73.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-318">153.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-319">270.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-320">344.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-321">190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-322">259.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-323">270.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-324">344.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Disclosure:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash capital expenditures</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-325">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-326">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-327">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-328">200.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="f-329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-330">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-331">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-332">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-333">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-334">51.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-335">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-336">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_130"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="f-337" continuedAt="f-337-1" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-337-1" continuedAt="f-337-2"><ix:nonNumeric contextRef="c-1" name="nbix:OrganizationAndBusinessDescriptionPolicyPolicyTextBlock" id="f-338" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc. and its subsidiaries (Neurocrine Biosciences, the Company, we, our or us) is a neuroscience-focused biopharmaceutical company focused on discovering, developing and delivering innovative therapies to help ease the burden of debilitating disorders and diseases.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single business segment, which includes all activities related to the research, development and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine and neuropsychiatric disorders and reflects the way in which internally-reported financial information is regularly reviewed by our chief operating decision maker to analyze performance, make decisions and allocate resources.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-339" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Neurocrine Biosciences as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-340" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-341" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments that are readily convertible into cash without penalty and have an original maturity of three months or less at the time of purchase to be cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ReceivablesPolicyTextBlock" id="f-342" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks, and any allowance for credit losses. Our estimate for the allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, actual payment patterns of our customers, and individual customer circumstances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-343" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We perform an assessment of the recoverability of our inventory on a quarterly basis and write down any excess and obsolete inventory to its net realizable value in the period in which the impairment is first identified. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-344" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become <ix:nonNumeric contextRef="c-4" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" format="ixt-sec:durday" id="f-345">90</ix:nonNumeric> days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-337-2" continuedAt="f-337-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="f-346" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-347">11.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-348">4.7</ix:nonFraction> million, respectively, as of December&#160;31, 2023 and 2022. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" format="ixt:fixed-zero" scale="6" id="f-349"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" format="ixt:fixed-zero" scale="6" id="f-350"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" format="ixt:fixed-zero" scale="6" id="f-351">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> accrued interest receivables were written off during 2023, 2022 or 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-352" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity security investments at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deem transfers between levels of the fair value hierarchy to have occurred at the end of the reporting period during which the event or change in circumstances that caused the transfer occurred.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We account for certain equity investments subject to the equity method of accounting, or through which we have the ability to exercise significant influence (but not control) over the operating and financial policies of an investee, under the fair value option. In assessing whether we exercise significant influence, we consider the nature and magnitude of such an investment, the voting and protective rights we hold, any participation in the governance of the investee and other relevant factors, such as the presence of a collaborative or other business relationship. Such investments in publicly traded companies are currently classified within Level 1 of the fair value hierarchy and carried at fair value, with any changes in the fair value of such investments recognized in earnings.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-353" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of <ix:nonNumeric contextRef="c-48" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-354">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-49" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-355">7</ix:nonNumeric> years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-356">17.8</ix:nonFraction> million for 2023, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-357">15.1</ix:nonFraction> million for 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-358">10.9</ix:nonFraction> million for 2021.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-337-3" continuedAt="f-337-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-359" continuedAt="f-359-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. In addition, costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as selling, general and administrative when incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-360" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (IPR&amp;D) and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually, as of October 1, and more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceed the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with a finite life are typically comprised of acquired product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-361" continuedAt="f-361-1" escape="true"><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We determine if an arrangement is a lease at contract inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that such options will be exercised. </span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As none of our operating leases provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease payments used to determine our ROU assets may include prepaid or accrued lease payments and any lease incentives received and are recognized in ROU assets in our consolidated balance sheets.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-337-4" continuedAt="f-337-5"><ix:continuation id="f-361-1"><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in lease agreements are expensed as incurred.</span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases are reflected in ROU assets, noncurrent operating lease liabilities, and other current liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-362" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in retained earnings during the period, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income (loss) in the accompanying consolidated statements of stockholders&#8217; equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-363" continuedAt="f-363-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for such goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the U.S., we sell INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) primarily to specialty pharmacy providers and distributors. We recognize net product sales when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors, and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#8217;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant categories of sales discounts and allowances are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Discounts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates for discounts including under the Medicaid Drug Rebate Program and Medicare Part D. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations, and relevant contractual terms, as supplemented by management&#8217;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-363-1"><ix:continuation id="f-337-5" continuedAt="f-337-6"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor and Pharmacy Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel, and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Financial Assistance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To help patients afford our products, we offer financial assistance to qualified patients with prescription drug copay requirements. We accrue for patient financial assistance based on estimated claims and the cost per claim we expect to receive in connection with inventory that remains in the distribution channel at period end. To date, actual patient financial assistance has not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor and Other Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the sales of our products, we pay distributor and other fees, which are generally recorded as a reduction of revenue, to certain customers that provide us with inventory management, data, and/or distribution services. Costs associated with such services are expensed as selling, general and administrative to the extent we can demonstrate a separable benefit and fair value for such services. To date, actual distributor and other fees have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring product, provided it is within a specified period of the product expiration date, as set forth in the associated distribution agreement. Where actual returns history is not available, we estimate a returns allowance based on benchmarking data for similar products and industry experience. Such estimates are recorded as a reduction of revenue in the period the related sale is recognized. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration and license agreements under which we out-license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of the out-licensed products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use, and benefit from, the license. For licenses that are bundled with other promises, we assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development, regulatory, and/or commercial milestones, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Amounts for milestones that are not within our control, such as when achievement of a specified event is dependent on the development activities of a third party or approvals from regulators, are not considered probable of being achieved until such specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, and under which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-337-6" continuedAt="f-337-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-364" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, accounts receivable and debt securities available-for-sale. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio with low-risk investment-grade debt securities with maturities of up to three years and by placing our investments with high-credit-quality financial institutions to maintain liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in connection with these financial instruments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately <ix:nonFraction unitRef="number" contextRef="c-50" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-365">91</ix:nonFraction>% of our total product sales for 2023 and approximately <ix:nonFraction unitRef="number" contextRef="c-51" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-366">98</ix:nonFraction>% of our accounts receivable balance as of December&#160;31, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-367" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues includes third-party manufacturing, transportation, freight, and indirect overhead costs primarily for the manufacture and distribution of INGREZZA drug product sold, manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with Mitsubishi Tanabe Pharma Corporation, royalty fees on net sales of elagolix, amortization of intangible assets, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-368" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development, or R&amp;D. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses primarily consist of preclinical and clinical trial costs, payroll and benefits costs, including stock-based compensation associated with employees involved in R&amp;D activities, certain facility-based costs, and costs associated with our collaborative arrangements, including event-based milestones. All such costs are expensed as R&amp;D when incurred.</span></div></ix:nonNumeric><ix:continuation id="f-359-1"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions of assets (or groups of assets) that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets (or group of assets) acquired on the basis of their relative fair value(s) on the measurement date. No goodwill is recognized in an asset acquisition. Intangible assets acquired in an asset acquisition for use in R&amp;D activities which have no alternative future use are expensed as IPR&amp;D on the acquisition date. Future costs to develop these assets are expensed as R&amp;D when incurred.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-369" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-370">159.9</ix:nonFraction> million for 2023, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-371">149.7</ix:nonFraction> million for 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-372">139.8</ix:nonFraction> million for 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-373" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units (RSUs) and performance-based restricted stock units (PRSUs). Additionally, we allow employees to participate in an employee stock purchase plan (ESPP).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. RSUs are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest is recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally <span style="-sec-ix-hidden:f-374">three</span> to <ix:nonNumeric contextRef="c-53" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-375">four years</ix:nonNumeric>; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP is recognized and amortized on a straight-line basis over the purchase period, which is generally <ix:nonNumeric contextRef="c-54" name="nbix:ESPPPurchasePeriod" format="ixt-sec:durwordsen" id="f-376">six months</ix:nonNumeric>. PRSUs vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-337-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-377" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax provision is computed under the asset and liability method. Significant estimates are required in determining our income tax provision. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-378" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share are computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed using the treasury stock and if-converted methods and reflect the weighted average number of common and potentially dilutive shares outstanding during the period, excluding those which effect would be anti-dilutive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the <ix:nonFraction unitRef="number" contextRef="c-55" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-379">2.25</ix:nonFraction>% fixed-rate convertible senior notes due May&#160;15, 2024 in cash upon conversion and to settle any conversion premium in either cash or shares of our common stock. As a result, only the shares required to settle any conversion premium are considered dilutive under the if-converted method. Further, PRSUs for which the performance condition has not been achieved are excluded from the calculation of diluted earnings per share.</span></div></ix:nonNumeric></ix:continuation><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_136"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-382" continuedAt="f-382-1" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><ix:continuation id="f-382-1" continuedAt="f-382-2"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heptares Therapeutics Limited, or Heptares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We entered into a collaboration and license agreement with Heptares, which became effective in December 2021, to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, for which we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Heptares retains the rights to develop, manufacture, and commercialize all compounds comprised of M1 receptor agonists, subject to certain exceptions. With respect to such rights retained by Heptares, we retain the rights to opt in to profit sharing arrangements, pursuant to which we and Heptares will equally share in the operating profits and losses for such compounds in Japan. Subject to specified conditions, we may elect to exercise such opt-in rights with respect to each such compound either before initiation of the first proof of concept Phase 2 clinical trial for such compound or following our receipt from Heptares of the top-line data from such clinical trial for such compound. We are responsible for all development, manufacturing, and commercialization costs of any collaboration product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Heptares $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="f-383">100.0</ix:nonFraction> million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;D in 2021 as the license had no foreseeable alternative future use. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA's acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in June 2022, we paid Heptares a milestone of $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-384">30.0</ix:nonFraction> million, which was expensed as R&amp;D in 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Heptares may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="f-385">2.6</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-382-2" continuedAt="f-382-3"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which the royalty term for such licensed product has expired in such country. On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a licensed product and terminate on the later of (i) the expiration of the last patent covering such licensed product in such country, (ii) a number of years from the first commercial sale of such licensed product in such country and (iii) the expiration of regulatory exclusivity for such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or with respect to one or more targets upon <ix:nonNumeric contextRef="c-56" name="nbix:AgreementTerminationMinimalContractualTime" format="ixt-sec:durday" id="f-386">180</ix:nonNumeric> days&#8217; written notice to Heptares during the research collaboration term and upon <ix:nonNumeric contextRef="c-56" name="nbix:AgreementTerminationContractualTimeThreshold" format="ixt-sec:durday" id="f-387">90</ix:nonNumeric> days&#8217; written notice to Heptares following the expiration of the research collaboration term. Following the expiration of the research collaboration term, Heptares may terminate the agreement on a target-by-target basis in the event that we do not conduct any material development activities outside of Japan with respect to a certain compound or licensed product within the applicable target class for a continuous period of not less than <ix:nonNumeric contextRef="c-56" name="nbix:AgreementTerminationByCounterpartyContractualTimeThreshold" format="ixt-sec:durday" id="f-388">365</ix:nonNumeric> days and do not commence any such activities within <ix:nonNumeric contextRef="c-56" name="nbix:AgreementTerminationByCounterpartyMinimalContractualTime" format="ixt-sec:durday" id="f-389">120</ix:nonNumeric> days of receiving written notice. Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited, or Takeda.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into an exclusive license agreement with Takeda, pursuant to which we acquired the exclusive rights to develop and commercialize certain early-to-mid stage psychiatry compounds, including luvadaxistat, NBI-1065845, NBI-1065846 and <ix:nonFraction unitRef="non-clinicalstagecompound" contextRef="c-59" decimals="INF" name="nbix:NumberOfNonClinicalStageCompound" format="ixt-sec:numwordsen" scale="0" id="f-390">four</ix:nonFraction> non-clinical stage compounds. Luvadaxistat and the <ix:nonFraction unitRef="non-clinicalstagecompound" contextRef="c-59" decimals="INF" name="nbix:NumberOfNonClinicalStageCompound" format="ixt-sec:numwordsen" scale="0" id="f-391">four</ix:nonFraction> non-clinical stage compounds have each been designated as a royalty-bearing product. NBI-1065845 and NBI-1065846 are currently each designated as a profit-share product. We are responsible for all manufacturing, development, and commercialization costs of any royalty-bearing product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to NBI-1065845 and NBI-1065846, we and Takeda will equally share in the operating profits and losses. Takeda retains the rights to opt-out of the profit-sharing arrangements, pursuant to which Takeda would be entitled to receive potential future payments upon the achievement of certain event-based milestones with respect to such compounds and receive royalties on the future net sales of such compounds (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out right for such compound immediately following the completion of a second Phase 2 clinical trial for such compound, or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase 3 clinical trial for such compound.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in 2022, we paid Takeda a milestone of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-392">5.0</ix:nonFraction> million, which was expensed as R&amp;D in 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="f-393">1.9</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any royalty-bearing product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any royalty-bearing product, the royalty term has expired in such country; and (ii) for any profit-share product, for so long as we continue to develop, manufacture, or commercialize such licensed product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a royalty-bearing product and terminate on the later of (i) the expiration of the last patent covering such royalty-bearing product in such country, (ii) a number of years from the first commercial sale of such royalty-bearing product in such country and (iii) the expiration of regulatory exclusivity for such royalty-bearing product in such country.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-382-3" continuedAt="f-382-4"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or in one or more (but not all) of the U.S., Japan, the European Union (EU) and the United Kingdom (UK) (collectively, the major markets) upon <ix:nonNumeric contextRef="c-59" name="nbix:AgreementTerminationMinimalContractualTime" format="ixt-sec:durwordsen" id="f-394">six months</ix:nonNumeric>&#8217; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. We may terminate the agreement in its entirety or in one or more (but not all) of the major markets upon <ix:nonNumeric contextRef="c-59" name="nbix:AgreementTerminationContractualTimeThreshold" format="ixt-sec:durmonth" id="f-395">12</ix:nonNumeric> months&#8217; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. Takeda may terminate the agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd., or Idorsia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into a collaboration and license agreement with Idorsia, pursuant to which we acquired the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker in clinical development for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. We are responsible for all manufacturing, development, and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="f-396">1.7</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement, in its entirety or with respect to a particular compound or development candidate, upon <ix:nonNumeric contextRef="c-63" name="nbix:AgreementTerminationMinimalContractualTime" format="ixt-sec:durday" id="f-397">90</ix:nonNumeric> days&#8217; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within <ix:nonNumeric contextRef="c-63" name="nbix:AgreementTerminationDueToMaterialBreach" format="ixt-sec:durday" id="f-398">90</ix:nonNumeric> days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals Inc., or Xenon. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Xenon to identify, research and develop sodium channel inhibitors, including NBI-921352 and <ix:nonFraction unitRef="preclinicalcandidate" contextRef="c-64" decimals="INF" name="nbix:NumberOfPreclinicalCandidates" format="ixt-sec:numwordsen" scale="0" id="f-399">three</ix:nonFraction> preclinical candidates, which compounds we have the exclusive rights to develop and commercialize. We are responsible for all development and manufacturing costs of any collaboration product, subject to certain exceptions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we purchased approximately <ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-400">1.4</ix:nonFraction> million shares (at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-66" decimals="3" name="us-gaap:SharePrice" scale="0" id="f-401">14.196</ix:nonFraction> per share) of Xenon common stock in 2019. The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="6" id="f-402">14.1</ix:nonFraction> million after considering Xenon&#8217;s stock price and certain transfer restrictions that were applicable to the shares on the measurement date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approval of our clinical trial application in Europe for NBI-921352 for the treatment of focal onset seizures in adults in 2021, we paid Xenon a regulatory milestone of $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="nbix:MilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-403">10.0</ix:nonFraction> million, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="c-68" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-404">0.3</ix:nonFraction> million shares (at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-67" decimals="4" name="us-gaap:SharePrice" scale="0" id="f-405">19.9755</ix:nonFraction> per share) of Xenon common stock. The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="6" id="f-406">4.6</ix:nonFraction> million after considering Xenon&#8217;s stock price and certain transfer restrictions that were applicable to the shares on the measurement date. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-407">5.4</ix:nonFraction> million of the milestone payment was expensed as R&amp;D in 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA's acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol in 2022, we paid Xenon a regulatory milestone of $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="nbix:MilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-408">15.0</ix:nonFraction> million, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-409">0.3</ix:nonFraction> million shares (at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-70" decimals="3" name="us-gaap:SharePrice" scale="0" id="f-410">31.855</ix:nonFraction> per share) of Xenon common stock. The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="f-411">7.7</ix:nonFraction> million after considering Xenon&#8217;s stock price on the measurement date. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-412">7.3</ix:nonFraction> million of the milestone payment was expensed as R&amp;D in 2022.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-382-4" continuedAt="f-382-5"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="f-413">1.7</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product. Xenon retains the right to elect to co-develop one product in a major indication, pursuant to which Xenon would receive a mid-single digit percentage increase in royalties earned on the future net sales of such product in the U.S. and we and Xenon would equally share in the development costs of such product in the applicable indication, except where such development costs relate solely to the regulatory approval of such product outside the U.S.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular licensed product and country, the license obtained by us with respect to such product and country will become fully paid, royalty free, perpetual and irrevocable. We may terminate the agreement upon <ix:nonNumeric contextRef="c-64" name="nbix:AgreementTerminationContractualTimeThreshold" format="ixt-sec:durday" id="f-414">90</ix:nonNumeric> days&#8217; written notice to Xenon, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc., or Voyager.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Voyager Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2019, we entered into a collaboration and license agreement with Voyager (the 2019 Voyager Agreement), pursuant to which we retain certain rights to develop and commercialize the Friedreich&#8217;s ataxia program and <ix:nonFraction unitRef="undisclosedprogram" contextRef="c-74" decimals="INF" name="nbix:NumberOfUndisclosedPrograms" format="ixt-sec:numwordsen" scale="0" id="f-415">two</ix:nonFraction> undisclosed programs. We are responsible for all development and commercialization costs of any collaboration product under the 2019 Voyager Agreement, subject to certain co-development and co-commercialization rights retained by Voyager.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2019 Voyager Agreement, we purchased approximately <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-416">4.2</ix:nonFraction> million shares (at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-76" decimals="4" name="us-gaap:SharePrice" scale="0" id="f-417">11.9625</ix:nonFraction> per share) of Voyager common stock (the 2019 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to <ix:nonNumeric contextRef="c-77" name="nbix:VotingRestrictionPeriod" format="ixt-sec:durwordsen" id="f-418">three years</ix:nonNumeric> from the effective date of the 2023 Voyager Agreement (defined below). The 2019 Purchased Shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="6" id="f-419">54.7</ix:nonFraction> million after considering Voyager&#8217;s stock price and certain transfer restrictions that were applicable to the shares on the measurement date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2019 Voyager Agreement, Voyager may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="f-420">1.3</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the 2019 Voyager Agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product under the agreement or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the 2019 Voyager Agreement. We may terminate the 2019 Voyager Agreement upon <ix:nonNumeric contextRef="c-74" name="nbix:AgreementTerminationMinimalContractualTime" format="ixt-sec:durday" id="f-421">180</ix:nonNumeric> days&#8217; written notice to Voyager prior to the first commercial sale of any collaboration product under the 2019 Voyager Agreement or upon <ix:nonNumeric contextRef="c-74" name="nbix:AgreementTerminationContractualTimeThreshold" format="ixt-sec:durwordsen" id="f-422">one year</ix:nonNumeric> after the date of notice if such notice is provided after the first commercial sale of any collaboration product under the 2019 Voyager Agreement.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-382-5" continuedAt="f-382-6"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Voyager Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2023, we entered into a collaboration and license agreement with Voyager (the 2023 Voyager Agreement), pursuant to which we acquired the global rights to the gene therapy products directed to the gene that encodes glucosylceramidase beta 1 (GBA1) for the treatment of Parkinson's disease and other diseases associated with GBA1 (the GBA1 Program), and <ix:nonFraction unitRef="genetherapyprogram" contextRef="c-79" decimals="INF" name="nbix:NumberOfGeneTherapyPrograms" format="ixt-sec:numwordsen" scale="0" id="f-423">three</ix:nonFraction> gene therapy programs directed to rare central nervous system (CNS) targets, each enabled by Voyager's next-generation TRACER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsids. With respect to collaboration products subject to the GBA1 Program, we are responsible for all development and commercialization costs of any such products, including in the U.S., where Voyager retains certain co-development and co-commercialization rights. Voyager may elect to exercise such rights, pursuant to which we and Voyager would equally share in the operating profits and losses of such products in the U.S. (in lieu of Voyager being entitled to receive potential future payments of certain event-based milestones upon their achievement in the U.S. and receive royalties on the future net sales of such products in the U.S.), following Voyager&#8217;s receipt of the top-line data from a first Phase 1 clinical trial for each such product. Irrespective of Voyager&#8217;s election to exercise such rights, Voyager may be entitled to receive potential future payments upon the achievement of certain event-based milestones outside the U.S. and would be entitled to receive royalties on the future net sales of any such product outside the U.S. With respect to collaboration products subject to the <ix:nonFraction unitRef="genetherapyprogram" contextRef="c-79" decimals="INF" name="nbix:NumberOfGeneTherapyPrograms" format="ixt-sec:numwordsen" scale="0" id="f-424">three</ix:nonFraction> gene therapy programs directed to rare CNS targets, we are responsible for all development and commercialization costs for any such products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2023 Voyager Agreement, we paid Voyager $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="nbix:UpfrontPaymentsMade" format="ixt:num-dot-decimal" scale="6" id="f-425">175.0</ix:nonFraction> million upfront, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-426">4.4</ix:nonFraction> million shares (at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-80" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-427">8.88</ix:nonFraction> per share) of Voyager common stock (the 2023 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to <ix:nonNumeric contextRef="c-79" name="nbix:VotingRestrictionPeriod" format="ixt-sec:durwordsen" id="f-428">three years</ix:nonNumeric> from the effective date of the 2023 Voyager Agreement. In addition, as part of the collaboration, Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine, was appointed to Voyager's board of directors with an initial term expiring in 2024. Mr. Onyia (or another individual designated by us) will be nominated for election to Voyager's board of directors annually for a maximum duration of <ix:nonNumeric contextRef="c-79" name="nbix:BoardOfDirectorsMaximumDurationTerm" format="ixt-sec:duryear" id="f-429">10</ix:nonNumeric> years from the effective date of the 2023 Voyager Agreement. As a result, our strategic investment in Voyager became subject to the equity method of accounting, and Voyager became a related party under ASC 850, following our purchase of the 2023 Purchased Shares, after which, together with the 2019 Purchased Shares, we owned approximately <ix:nonFraction unitRef="number" contextRef="c-82" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-430">19.9</ix:nonFraction>% of the voting stock of Voyager. We elected the fair value option to account for our strategic investment in Voyager as we believe it creates greater transparency regarding the investment's fair value at future reporting dates. The 2023 Purchased Shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="f-431">31.3</ix:nonFraction> million after considering Voyager&#8217;s stock price on the measurement date. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="f-432">143.9</ix:nonFraction> million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2023 as the license had no foreseeable alternative future use. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. We recognized unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-433">15.5</ix:nonFraction> million for 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-434">14.5</ix:nonFraction> million for 2022 and an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-435">8.7</ix:nonFraction> million for 2021 on our strategic investment in Voyager. As of December&#160;31, 2023, the fair value (Level 1) of our strategic investment in Voyager was $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-436">72.4</ix:nonFraction> million.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2023 Voyager Agreement, Voyager may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="f-437">6.1</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the 2023 Voyager Agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product under the 2023 Voyager Agreement or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the 2023 Voyager Agreement. We may terminate the 2023 Voyager Agreement upon <ix:nonNumeric contextRef="c-79" name="nbix:AgreementTerminationMinimalContractualTime" format="ixt-sec:durday" id="f-438">180</ix:nonNumeric> days&#8217; written notice to Voyager prior to the first commercial sale of any collaboration product under the 2023 Voyager Agreement or upon <ix:nonNumeric contextRef="c-79" name="nbix:AgreementTerminationContractualTimeThreshold" format="ixt-sec:durwordsen" id="f-439">one year</ix:nonNumeric> after the date of notice if such notice is provided after the first commercial sale of any collaboration product under the 2023 Voyager Agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A., or BIAL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2017, we received from BIAL a license to commercialize and market ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone) in the U.S. and Canada. We launched ONGENTYS in the U.S. as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations in 2020. In 2023, we provided BIAL with written notice of termination of the license agreement to commercialize and market ONGENTYS in the U.S. and Canada, and recognized reserves for ONGENTYS inventory obsolescence totaling $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="f-440">5.2</ix:nonFraction> million in cost of revenues in connection with the termination, which became effective in December 2023, as management determined the cost cannot be recovered.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-382-6"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation, or MTPC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015. In 2020, we entered into a commercial supply agreement with MTPC, pursuant to which we supply MTPC with valbenazine drug product for commercial use in such markets. MTPC is responsible for all development, manufacturing, and commercialization costs of valbenazine in such markets.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MTPC launched DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan for the treatment of tardive dyskinesia in June 2022 and subsequently in other select Asian markets, where it is marketed as REMLEAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine). We receive royalties at tiered percentage rates on MTPC net sales of valbenazine. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-441">20.0</ix:nonFraction> million in 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC&#8217;s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with MTPC, we may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="nbix:PotentialMilestonePaymentReceipts" format="ixt:num-dot-decimal" scale="6" id="f-442">30.0</ix:nonFraction> million upon the achievement of certain sales-based milestones and are entitled to receive royalties at tiered percentage rates on future MTPC net sales of valbenazine for the longer of <ix:nonNumeric contextRef="c-90" name="nbix:PatentTerm" format="ixt-sec:duryear" id="f-443">10</ix:nonNumeric> years or the life of the related patent rights. MTPC may terminate the agreement upon <ix:nonNumeric contextRef="c-91" name="nbix:AgreementTerminationContractualTimeThreshold" format="ixt-sec:durday" id="f-444">180</ix:nonNumeric> days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc., or AbbVie. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (elagolix tablets) in the U.S. for the treatment of moderate to severe pain associated with endometriosis in August 2018 and ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-445">16.7</ix:nonFraction>&#160;million for 2023, $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-446">21.2</ix:nonFraction>&#160;million for 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-447">22.3</ix:nonFraction>&#160;million for 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with AbbVie, we may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="nbix:PotentialMilestonePaymentReceipts" format="ixt:num-dot-decimal" scale="6" id="f-448">366.0</ix:nonFraction> million upon the achievement of certain event-based milestones and are entitled to receive royalties at tiered percentage rates on future AbbVie net sales of elagolix for the longer of <ix:nonNumeric contextRef="c-96" name="nbix:PatentTerm" format="ixt-sec:duryear" id="f-449">10</ix:nonNumeric> years or the life of the related patent rights. AbbVie may terminate the agreement upon <ix:nonNumeric contextRef="c-97" name="nbix:AgreementTerminationContractualTimeThreshold" format="ixt-sec:durday" id="f-450">180</ix:nonNumeric> days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div></ix:continuation><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_139"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-451" continuedAt="f-451-1" escape="true">Debt Securities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-452" escape="true"><ix:continuation id="f-451-1" continuedAt="f-451-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.075%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="f-453">53.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="f-454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="f-455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="f-456">53.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="f-457">156.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="f-458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="f-459">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="f-460">156.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="f-461">382.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="6" id="f-462">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="f-463">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="f-464">381.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="f-465">296.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="f-467">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="f-468">293.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="f-469">346.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="6" id="f-470">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="f-471">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="f-472">345.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="f-473">283.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="f-475">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="f-476">277.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="f-477">781.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="6" id="f-478">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="f-479">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="f-480">780.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="f-481">735.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="f-482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="f-483">9.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="f-484">726.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="f-485">483.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="6" id="f-486">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="f-487">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="f-488">486.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="f-489">259.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="6" id="f-490">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="f-491">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="f-492">255.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="f-493">201.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="6" id="f-494">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="f-495">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="f-496">201.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="f-497">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="6" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="f-499">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="f-500">44.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="f-501">684.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="6" id="f-502">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="f-503">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="f-504">687.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="f-505">304.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="6" id="f-506">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="f-507">5.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="f-508">299.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-451-2"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses on our available-for-sale debt security investments were primarily due to changes in interest rates. These investments are of high credit quality, and we do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recognized as of December&#160;31, 2023 or 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-509" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2023, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-510">265.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-511">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-512">183.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-513">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-514">448.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-515">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-516">214.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-517">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-518">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-519">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-520">231.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-521">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2022, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-522">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-523">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="f-524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-526">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-527">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-528">199.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-529">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-530">299.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-531">5.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-532">498.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-533">7.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-534">107.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-535">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-536">198.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-537">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-538">306.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-539">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_148"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-540" continuedAt="f-540-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-541" escape="true"><ix:continuation id="f-540-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of financial assets, which were measured at fair value on a recurring basis.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.271%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:Investments" scale="6" id="f-542">251.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-543">251.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:Investments" scale="6" id="f-545">262.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-546">262.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:Investments" scale="6" id="f-548">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-549">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:Investments" scale="6" id="f-551">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-552">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:Investments" scale="6" id="f-554">53.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-556">53.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:Investments" scale="6" id="f-557">156.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-559">156.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:Investments" scale="6" id="f-560">867.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-562">867.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:Investments" scale="6" id="f-563">548.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-565">548.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:Investments" scale="6" id="f-566">547.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-568">547.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:Investments" scale="6" id="f-569">321.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-571">321.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:Investments" scale="6" id="f-572">161.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-573">161.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:Investments" scale="6" id="f-575">102.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-576">102.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-578">1,889.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-579">421.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-580">1,468.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-581">1,398.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-582">372.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-583">1,025.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_160"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-584" continuedAt="f-584-1" escape="true">Convertible Senior Notes</ix:nonNumeric></span></div><ix:continuation id="f-584-1" continuedAt="f-584-2"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-585">517.5</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-55" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-586">2.25</ix:nonFraction>% fixed-rate convertible senior notes due May&#160;15, 2024 (the 2024 Notes) and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we repurchased $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-587">136.2</ix:nonFraction> million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-588">186.9</ix:nonFraction> million in cash. In 2022, we repurchased $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-589">210.8</ix:nonFraction> million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-590">279.0</ix:nonFraction> million in cash, which resulted in the recognition of a $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-591">70.0</ix:nonFraction> million loss on extinguishment.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-592" continuedAt="f-592-1" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-593">170.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-594">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" scale="6" id="f-595">170.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:DebtInstrumentFairValue" scale="6" id="f-596">295.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-584-2" continuedAt="f-584-3"><ix:continuation id="f-592-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-597">170.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-598">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" scale="6" id="f-599">169.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:DebtInstrumentFairValue" scale="6" id="f-600">268.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the interest expense of the 2024 Notes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="f-601">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="f-602">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="f-603">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="f-604">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="f-605">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="f-606">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-607">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-608">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-609">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="INF" name="nbix:PrincipalAmountOnConversionRate" format="ixt:num-dot-decimal" scale="0" id="f-610">1,000</ix:nonFraction> principal amount and equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-55" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-611">75.92</ix:nonFraction> per share, reflecting a conversion premium of approximately <ix:nonFraction unitRef="number" contextRef="c-55" decimals="3" name="nbix:DebtInstrumentConvertibleConversionPremium" scale="-2" id="f-612">42.5</ix:nonFraction>% above the closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-55" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-613">53.28</ix:nonFraction> per share of our common stock on April&#160;26, 2017.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="c-152" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-614">130</ix:nonFraction>% of the conversion price then in effect (equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-153" decimals="2" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" id="f-615">98.70</ix:nonFraction> as of December&#160;31, 2023) for at least <ix:nonFraction unitRef="d" contextRef="c-152" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-616">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="d" contextRef="c-152" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-617">30</ix:nonFraction> consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;<ix:nonFraction unitRef="d" contextRef="c-152" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-618">20</ix:nonFraction>&#160;trading days (whether or not consecutive) during a period of&#160;<ix:nonFraction unitRef="d" contextRef="c-152" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-619">30</ix:nonFraction>&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;<ix:nonFraction unitRef="number" contextRef="c-152" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-620">130</ix:nonFraction>%&#160;of the conversion price (equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-153" decimals="2" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" id="f-621">98.70</ix:nonFraction> as of December&#160;31, 2023) on each applicable trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the&#160;five business-day period immediately after any&#160;five&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2017 Indenture) per&#160;$<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="INF" name="nbix:PrincipalAmountOnConversionRate" format="ixt:num-dot-decimal" scale="0" id="f-622">1,000</ix:nonFraction>&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;<ix:nonFraction unitRef="number" contextRef="c-154" decimals="INF" name="nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice" scale="-2" id="f-623">98</ix:nonFraction>% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time. On January 4, 2024, we provided notice to the holders of the 2024 Notes electing to settle all conversions of the 2024 Notes in cash. As such, upon conversion, holders will receive the principal amount of their 2024 Notes and any conversion premium, calculated based on the per share volume-weighted average price for each of the <ix:nonFraction unitRef="d" contextRef="c-152" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-624">30</ix:nonFraction> consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in cash.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="c-155" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="f-625">100</ix:nonFraction>% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the 2017 Indenture) occurs prior to January&#160;15, 2024, we would, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-584-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2017 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, <ix:nonFraction unitRef="number" contextRef="c-155" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="f-626">100</ix:nonFraction>% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div></ix:continuation><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_151"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-628" continuedAt="f-628-1" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="f-628-1"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of goodwill. Goodwill is included in other assets in our consolidated balance sheets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-629" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill recognized in connection with business combination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-631">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-632">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-633">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-634">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-635">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-637" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="f-636" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information relating to our recognized intangible assets as of December&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed product rights</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-156" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-638">10</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-639">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-640">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-641">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-642">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-643">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="f-644">35.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate future annual amortization expense for our finite-lived intangible assets as of December&#160;31, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-645" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-646">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-647">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2026</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-648">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="f-649">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="f-650">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="f-651">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_154"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-652" continuedAt="f-652-1" escape="true">Other Balance Sheet Details</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-653" escape="true"><ix:continuation id="f-652-1" continuedAt="f-652-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryRawMaterials" scale="6" id="f-654">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryRawMaterials" scale="6" id="f-655">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryWorkInProcess" scale="6" id="f-656">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryWorkInProcess" scale="6" id="f-657">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryFinishedGoods" scale="6" id="f-658">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryFinishedGoods" scale="6" id="f-659">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryGross" scale="6" id="f-660">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryGross" scale="6" id="f-661">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less inventory reserves</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryValuationReserves" scale="6" id="f-662">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:fixed-zero" scale="6" id="f-663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-664">38.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-665">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-652-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-666" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-667">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-668">37.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-669">79.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-670">58.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-671">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-672">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-673">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-674">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-675">153.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-676">124.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-677">83.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-678">66.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-679">70.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-680">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-681" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales rebates and reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccruedMarketingCostsCurrent" scale="6" id="f-682">139.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccruedMarketingCostsCurrent" scale="6" id="f-683">131.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-684">86.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-685">72.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:AccruedBrandedPrescriptionDrugFee" scale="6" id="f-686">45.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:AccruedBrandedPrescriptionDrugFee" scale="6" id="f-687">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="f-688">44.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="f-689">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current income taxes payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="f-690">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="f-691">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="6" id="f-692">108.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="6" id="f-693">67.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-694">448.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-695">347.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherLiabilitiesTableTextBlock" id="f-696" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent income taxes payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="f-697">96.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="f-698">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent branded prescription drug fee</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:PrescriptionDrugFeeNoncurrent" scale="6" id="f-699">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:PrescriptionDrugFeeNoncurrent" scale="6" id="f-700">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-701">106.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-702">29.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" id="f-703" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-704">251.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-705">262.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-706">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-707">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-708">259.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-709">270.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_145"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-710" continuedAt="f-710-1" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="f-710-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-711" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share were calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="f-712"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="f-713">249.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="f-714"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="f-715">154.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="f-716"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="f-717">89.6</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-718">97.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-719">95.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-720">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-721">3.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-722">3.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-723">3.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-724">101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-725">98.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-726">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-727">2.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-728">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-729">0.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-730">2.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-731">1.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-732">0.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were <ix:nonFraction unitRef="shares" contextRef="c-166" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-733">4.7</ix:nonFraction> million for 2023, <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-734">4.6</ix:nonFraction> million for 2022 and <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-735">4.1</ix:nonFraction> million for 2021.</span></div></ix:continuation><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_142"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-736" continuedAt="f-736-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-736-1" continuedAt="f-736-2"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, our stockholders approved an amendment of the 2020 Equity Incentive Plan (as so amended, the Amended 2020 Plan). The Amended 2020 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other awards. As of December 31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-737">10.5</ix:nonFraction>&#160;million shares of common stock remain available for future grant under the Amended 2020 Plan.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Amended 2020 Plan, the number of shares of common stock available for issuance will be: (i) reduced by (a) <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="0" name="nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" format="ixt-sec:numwordsen" scale="0" id="f-738">one</ix:nonFraction> share for each share issued pursuant to an appreciation award (as defined in the Amended 2020 Plan) granted under the Amended 2020 Plan and (b) <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="2" name="nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" scale="0" id="f-739">2.13</ix:nonFraction> shares for each share issued pursuant to a full value award (as defined in the Amended 2020 Plan) granted under the Amended 2020 Plan on or after May 18, 2022; and (ii) increased by (a) <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="0" name="nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" format="ixt-sec:numwordsen" scale="0" id="f-740">one</ix:nonFraction> share for each share subject to an appreciation award that becomes available again for issuance under the terms of the Amended 2020 Plan and (b) <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="2" name="nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" scale="0" id="f-741">2.13</ix:nonFraction> shares for each share subject to a full value award that becomes available again for issuance under the terms of the Amended 2020 Plan on or after May 18, 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2011 Equity Incentive Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2011, we adopted the 2011 Equity Incentive Plan (the 2011 Plan). The 2011 Plan was a stockholder-approved plan pursuant to which outstanding awards have been made, but from which <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:fixed-zero" scale="0" id="f-742">no</ix:nonFraction> further awards can or will be made.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, our stockholders approved an amendment and restatement of the 2018 Employee Stock Purchase Plan (as so amended and restated, the Amended 2018 ESPP). As of December 31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-172" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-743">0.5</ix:nonFraction>&#160;million shares of common stock remain available for future issuance under the Amended 2018 ESPP.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense. </span><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-744" continuedAt="f-744-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of stock-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:</span></ix:nonNumeric></div><ix:continuation id="f-744-1" continuedAt="f-744-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-745">126.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-746">115.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-747">85.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-748">68.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-749">57.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-750">48.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-751">194.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-752">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-753">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-736-2" continuedAt="f-736-3"><ix:continuation id="f-744-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by award-type <span id="iae12b1f8f345443688fcf6efba5f4f06_8127"></span>follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-754">91.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-755">62.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-756">60.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-757">93.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-758">86.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-759">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-760">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-761">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-762">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-763">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-764">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-765">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-766">194.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-767">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-768">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, unrecognized stock-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.729%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-769">94.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-179" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-770">2.3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-771">162.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-182" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-772">2.3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-773">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:continuation><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, stock options have a <ix:nonNumeric contextRef="c-179" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-774">10-year</ix:nonNumeric> term and vest over a <span style="-sec-ix-hidden:f-775">three</span> to <ix:nonNumeric contextRef="c-195" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-776">four-year</ix:nonNumeric> period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, term and interest rates. The weighted-average grant-date fair values of stock options granted were $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-777">45.19</ix:nonFraction> for 2023, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-778">32.05</ix:nonFraction> for 2022 and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-779">45.02</ix:nonFraction> for 2021.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-780" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-179" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-781">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-180" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-782">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-181" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-783">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-179" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-784">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-180" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-785">42.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-181" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-786">45.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-179" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-787">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-180" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-788">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-181" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-789">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected option term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-179" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-790">5.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-180" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-791">5.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-181" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-792">5.2</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average valuation assumptions were determined as follows:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected volatility of common stock is estimated based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risk-free interest rate for periods within the contractual life of a stock option is based upon observed interest rates appropriate for the expected term of our employee stock options. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have not historically declared or paid dividends and do not intend to do so in the foreseeable future. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-793" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summary of activity related to stock options.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="f-794">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-795">79.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="f-796">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-797">103.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-798">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-799">66.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" id="f-800">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-801">98.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="f-802">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-803">84.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-804">6.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="f-805">467.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="6" id="f-806">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-807">78.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-808">5.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="f-809">361.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-736-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-810">39.9</ix:nonFraction> million for 2023, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-811">39.7</ix:nonFraction> million for 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-812">58.0</ix:nonFraction> million for 2021. Cash received from stock option exercises was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-813">55.5</ix:nonFraction> million for 2023, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-814">37.0</ix:nonFraction> million for 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-815">20.7</ix:nonFraction> million for 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs typically vest over a <ix:nonNumeric contextRef="c-182" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-816">four-year</ix:nonNumeric> period and may be subject to a deferred delivery arrangement at the election of eligible employees. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. The total fair value of RSUs that vested was $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="f-817">101.0</ix:nonFraction> million for 2023, $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="f-818">72.4</ix:nonFraction> million for 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="f-819">64.3</ix:nonFraction> million for 2021.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-820" continuedAt="f-820-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to RSUs.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-196" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-821">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-196" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-822">92.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-182" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="f-823">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-182" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-824">103.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-182" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="f-825">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-182" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-826">93.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-182" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="f-827">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-182" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-828">95.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-829">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-192" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-830">97.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-182" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-831">1.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="f-832">312.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRSUs vest based on the achievement of certain predefined Company-specific performance criteria. Any unvested PRSUs will expire if it is determined the related performance criteria has not been met during the applicable <span style="-sec-ix-hidden:f-833">three</span> to <ix:nonNumeric contextRef="c-198" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-834">four-year</ix:nonNumeric> performance period. The fair value of PRSUs is estimated based on the closing sale price of our common stock on the date of grant. The fair value of PRSUs that vested during 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-835">34.4</ix:nonFraction> million. <ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:fixed-zero" scale="0" id="f-836"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:fixed-zero" scale="0" id="f-837">No</ix:nonFraction></ix:nonFraction> PRSUs vested during 2022 or 2021.</span></div><ix:continuation id="f-820-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to PRSUs.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-199" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-838">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-199" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-839">101.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-185" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="f-840">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-841">97.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-185" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="f-842">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-843">98.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-185" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="f-844">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-845">115.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-193" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-846">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-847">89.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-185" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-848">1.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="f-849">33.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended 2018 ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of <ix:nonFraction unitRef="number" contextRef="c-200" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-850">85</ix:nonFraction>% of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of common stock on the purchase date.</span></div></ix:continuation><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_166"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-851" continuedAt="f-851-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-852" escape="true"><ix:continuation id="f-851-1" continuedAt="f-851-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents income from continuing operations before provision for income taxes for domestic and international operations.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-853">409.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-854">218.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-855">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-856">77.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-857">4.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:fixed-zero" scale="6" id="f-858">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-859">332.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-860">213.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-861">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-851-2" continuedAt="f-851-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-862" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of income tax expense (benefit) for continuing operations.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-863">115.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-864">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-866">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-867">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-868">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-869">143.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-870">37.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-871">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-872">45.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-873">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-874">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-875">15.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-876">5.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-877">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-878">60.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-879">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-880">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-881">82.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-882">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-883">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-884" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal income taxes at <ix:nonFraction unitRef="number" contextRef="c-13" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-885"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-886"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-887">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-888">69.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-889">44.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-890">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-891">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-892">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-893">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" scale="6" id="f-894">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" scale="6" id="f-895">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" scale="6" id="f-896">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" format="ixt:fixed-zero" scale="6" id="f-897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" scale="6" id="f-898">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" format="ixt:fixed-zero" scale="6" id="f-899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-900">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-901">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-902">11.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" scale="6" id="f-903">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" scale="6" id="f-904">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" scale="6" id="f-905">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="f-906">2.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="f-907">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="f-908">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="nbix:IncomeTaxReconciliationExpirationOfTaxCredits" format="ixt:fixed-zero" scale="6" id="f-909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="nbix:IncomeTaxReconciliationExpirationOfTaxCredits" format="ixt:fixed-zero" scale="6" id="f-910">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="nbix:IncomeTaxReconciliationExpirationOfTaxCredits" scale="6" id="f-911">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="f-912">42.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="f-913">29.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="f-914">22.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-915">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-916">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-917">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="f-918">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="f-919">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="6" id="f-920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-921">82.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-922">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-923">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-924" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of our deferred tax assets. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="f-925">36.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="f-926">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="f-927">55.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="f-928">108.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="6" id="f-929">178.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="6" id="f-930">91.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="f-931">52.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="f-932">45.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:DeferredTaxAssetsOperatingLeasesAssets" scale="6" id="f-933">72.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:DeferredTaxAssetsOperatingLeasesAssets" scale="6" id="f-934">26.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="f-935">110.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="f-936">80.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-937">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-938">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="f-939">530.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="f-940">405.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities" scale="6" id="f-941">66.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities" scale="6" id="f-942">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-943">12.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-944">11.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="f-945">78.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="f-946">32.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of deferred tax assets and liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:DeferredTaxAssetsLiabilitiesGross" scale="6" id="f-947">451.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="nbix:DeferredTaxAssetsLiabilitiesGross" scale="6" id="f-948">372.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-949">88.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-950">67.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="f-951">362.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="f-952">305.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-851-3" continuedAt="f-851-4"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, our deferred tax assets were primarily the result of net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. As of December 31, 2023 and 2022, we recorded a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-953">88.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-954">67.0</ix:nonFraction> million, respectively, against our gross deferred tax asset balance.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. As of December&#160;31, 2023, management determined there was sufficient positive evidence to conclude that it is more likely than not deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-955">362.6</ix:nonFraction> million are realizable. The recorded valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-956">88.9</ix:nonFraction> million consisted primarily of state and foreign net operating loss carryforwards and state credit carryforwards for which management cannot conclude it is more likely than not to be realized.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had state and foreign income tax net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-957">286.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-958">134.3</ix:nonFraction> million, respectively. We had <ix:nonFraction unitRef="usd" contextRef="c-203" decimals="INF" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="6" id="f-959">no</ix:nonFraction> federal income tax operating loss carryforwards as of December&#160;31, 2023. California net operating losses will begin to expire in 2029 unless previously utilized and the net operating losses related to other states will begin to expire in 2026. Swiss net operating losses will begin to expire in 2030 unless previously utilized. UK net operating losses will carry forward indefinitely.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had state R&amp;D tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="f-960">85.6</ix:nonFraction> million. California R&amp;D tax credits carry forward indefinitely, while R&amp;D tax credits related to other states will begin to expire in 2033 unless previously utilized.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the future utilization of our net operating loss and R&amp;D tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. No ownership changes have occurred through December&#160;31, 2023.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to income tax matters in income tax expense. We had accruals for interest related to income tax matters of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:IncomeTaxExaminationInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="f-961">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IncomeTaxExaminationInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="f-962">1.2</ix:nonFraction> million, respectively, as of December 31, 2023 and 2022. We had accruals for penalties relates to income tax matters of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:IncomeTaxExaminationPenaltiesAccrued" format="ixt:num-dot-decimal" scale="6" id="f-963">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IncomeTaxExaminationPenaltiesAccrued" format="ixt:num-dot-decimal" scale="6" id="f-964">0.4</ix:nonFraction> million, respectively, as of December 31, 2023 and 2022. Accruals for interest and penalties related to income tax matters were not material as of December 31, 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the U.S. and various state and foreign jurisdictions. Tax years for 2020 for federal, inception for California, 2016 to 2020 for other significant state jurisdictions, and 2021 and forward for foreign are subject to examination by tax authorities due to the carryforward of unutilized net operating losses and R&amp;D tax credits.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-965" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to unrecognized tax benefits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-966">84.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-967">64.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-968">60.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-969">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-970">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-971">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-972">36.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-973">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-974">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease related to prior year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-975">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="f-976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="f-977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of the statute of limitations for the assessment of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="f-978">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="f-979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-980">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-981">121.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-982">84.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-983">64.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-984">105.3</ix:nonFraction> million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate, subject to changes in the valuation allowance. We do not expect a significant change in our unrecognized tax benefits in the next 12 months.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-851-4"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the OECD announced an Inclusive Framework on Base Erosion and Profit Shifting including Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15%. Subsequently, multiple sets of administrative guidance have been issued. Many non-U.S. tax jurisdictions have either recently enacted legislation to adopt certain components of the Pillar Two Model Rules beginning in 2024 (including EU Member States) with the adoption of additional components in later years or announced their plans to enact legislation in future years. We are continuing to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in the non-U.S. tax jurisdictions we operate in.</span></div></ix:continuation><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_157"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-985" continuedAt="f-985-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-985-1" continuedAt="f-985-2"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases that have commenced have terms that expire beginning 2025 through 2036 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our ROU assets or operating lease liabilities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-986" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental operating lease information for operating leases that have commenced.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-987">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-988">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-989">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="f-990">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="6" id="f-991">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="6" id="f-992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="nbix:OperatingLeaseCostNet" scale="6" id="f-993">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="nbix:OperatingLeaseCostNet" scale="6" id="f-994">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="nbix:OperatingLeaseCostNet" scale="6" id="f-995">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-996">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-997">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-998">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-999">10.8</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1000">7.9</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1001">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1002">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash related to letters of credit issued in lieu of cash security deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-1003">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-1004">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1005" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate future non-cancelable minimum lease payments under operating leases and sublease income as of December&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease<br/>Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="f-1006">33.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" scale="6" id="f-1007">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="f-1008">34.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" scale="6" id="f-1009">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="f-1010">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" scale="6" id="f-1011">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="f-1012">34.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" scale="6" id="f-1013">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="f-1014">35.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears" scale="6" id="f-1015">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="f-1016">211.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter" scale="6" id="f-1017">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments (sublease income)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="f-1018">383.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="6" id="f-1019">12.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-1020">93.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-1021">290.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1022">Less current operating lease liabilities included in other current liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-1023">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-1024">258.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts presented in the table above exclude $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-1025">15.4</ix:nonFraction> million for 2025, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" format="ixt:num-dot-decimal" scale="6" id="f-1026">23.6</ix:nonFraction> million for 2026, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" format="ixt:num-dot-decimal" scale="6" id="f-1027">24.3</ix:nonFraction> million for 2027, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" format="ixt:num-dot-decimal" scale="6" id="f-1028">25.1</ix:nonFraction> million for 2028 and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour" format="ixt:num-dot-decimal" scale="6" id="f-1029">223.5</ix:nonFraction> million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Campus Facility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, including a <ix:nonNumeric contextRef="c-206" name="nbix:LesseeOperatingLeaseOptionTermToConstructBuilding" format="ixt-sec:durwordsen" id="f-1030">six-year</ix:nonNumeric> option for the construction of a fifth building. This campus facility, comprised of office space and research and development laboratories, will serve as our new corporate headquarters.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-985-2"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The construction of the campus facility is phased. We recognized ROU assets of $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-1031">199.0</ix:nonFraction> million and operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-1032">189.8</ix:nonFraction> million in association with the commencement of operating leases following the completion of the first phase of construction relating to office space in December 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we begin to occupy our new campus facility, we will sublease certain of our existing leased premises when we determine there is excess leased capacity. Certain of these subleases contain both lease and non-lease components. Sublease income is recognized as an offset to operating expense on a straight-line basis over the lease term. Income related to non-lease components is recognized in operating expenses as a reduction to costs we incur in relation to the primary lease.</span></div></ix:continuation><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_169"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1033" continuedAt="f-1033-1" escape="true">Retirement Plan</ix:nonNumeric></span></div><ix:continuation id="f-1033-1"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a 401(k) defined contribution savings plan for the benefit of all qualifying employees and permits voluntary contributions by employees up to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-1034">60</ix:nonFraction>% of base salary limited by the IRS-imposed maximum. Employer contributions were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1035">12.5</ix:nonFraction> million for 2023, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1036">10.3</ix:nonFraction> million for 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1037">8.1</ix:nonFraction> million for 2021.</span></div></ix:continuation><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_172"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1038" continuedAt="f-1038-1" escape="true">Legal Proceedings</ix:nonNumeric></span></div><ix:continuation id="f-1038-1"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, 2022, and 2023, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., (iv) Sandoz Inc. and (v) Zydus Pharmaceuticals (USA) Inc. that each company had filed an abbreviated new drug application (ANDA) with the FDA seeking approval of a generic version of INGREZZA. These companies represented that their respective ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by the manufacture, use or sale of the medicine for which the ANDA was submitted.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed suit in the U.S. District Court for the District of Delaware during 2021, 2022 and 2023, against (i) Teva Pharmaceuticals, Inc., Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (entity dismissed), collectively, "Teva", (ii) Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc. and Lupin Atlantis Holdings S.A., collectively, &#8220;Lupin&#8221;, (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., collectively, &#8220;Crystal&#8221;, (iv) Sandoz Inc., Sandoz International GmbH (entity dismissed) and Sandoz AG (entity dismissed), collectively, &#8220;Sandoz&#8221; and (v) Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC (entity dismissed), collectively, &#8220;Zydus&#8221;. We also filed suit in the U.S. District Court for the District of New Jersey during 2021, 2022 and 2023 against Zydus.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023 we entered into settlement agreements resolving the foregoing litigation with each of (i) Sandoz and Crystal, collectively, the &#8220;Sandoz Parties&#8221;, (ii) Teva, (iii) Lupin and (iv) Zydus. Pursuant to the terms of the respective agreements with the Sandoz Parties, Teva, Lupin, and Zydus, each of Teva, the Sandoz Parties, Lupin, and Zydus has the right to sell generic versions of INGREZZA in the United States beginning March 1, 2038, or earlier under certain circumstances. The settlements with Teva, the Sandoz Parties, Lupin and Zydus resolve all patent litigation brought by us against the companies that filed ANDAs seeking approval to market generic INGREZZA, and all cases have been dismissed.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_175"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Changes and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_178"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by SEC Rule&#160;13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the year covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_181"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">&#160;&#160;&#160;&#160;Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">&#160;&#160;&#160;&#160;Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorization of our management and directors;&#160;and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">&#160;&#160;&#160;&#160;Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Management is responsible for establishing and maintaining adequate internal control over financial reporting for the company.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has used the framework set forth in the report entitled Internal Control-Integrated Framework (2013&#160;framework)&#160;published by the Committee of Sponsoring Organizations of the Treadway Commission (2013&#160;framework), known as COSO, to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December&#160;31, 2023. Ernst&#160;&amp; Young, LLP, our independent registered public accounting firm, has issued an attestation report on our internal control over financial reporting as of December&#160;31, 2023, which is included herein.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_184"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Neurocrine Biosciences, Inc.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Neurocrine Biosciences, Inc.&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Neurocrine Biosciences, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of income and comprehensive income, stockholders&#8216; equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes and our report dated February&#160;9, 2024 expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.051%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ernst &amp; Young LLP</span></div></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;9, 2024</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_187"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Information </span></div><ix:nonNumeric contextRef="c-1" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1039" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from October&#160;1, 2023, to December&#160;31, 2023, our executive officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Action</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Arrangement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shares Authorized <br/>to be Sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration <br/>Date</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rule 10b5-1*</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Rule 10b5-1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-208" name="ecd:TrdArrIndName" id="f-1040">George Morrow</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-208" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1041">Adopt</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-208" name="ecd:TrdArrAdoptionDate" id="f-1042">12/14/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-209" decimals="0" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1043">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/15/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-208" name="ecd:TrdArrIndTitle" id="f-1044">(Director)</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-210" name="ecd:TrdArrIndName" id="f-1045">Eric Benevich</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><ix:nonNumeric contextRef="c-211" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true" id="f-1046"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Terminate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></ix:nonNumeric></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-211" name="ecd:TrdArrTerminationDate" id="f-1047">11/30/2023</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-212" decimals="0" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1048">131,341</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-210" name="ecd:TrdArrIndTitle" id="f-1049">(Chief Commercial Officer)</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-213" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1050">Adopt</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-213" name="ecd:TrdArrAdoptionDate" id="f-1051">11/29/2023</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-214" decimals="0" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1052">169,818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/27/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-215" name="ecd:TrdArrIndName" id="f-1053">Ingrid Delaet</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-215" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1054">Adopt</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-215" name="ecd:TrdArrAdoptionDate" id="f-1055">11/29/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-216" decimals="0" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1056">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/7/2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-215" name="ecd:TrdArrIndTitle" id="f-1057">(Chief Regulatory Officer)</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-217" name="ecd:TrdArrIndName" id="f-1058">Leslie Norwalk</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-217" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1059">Adopt</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-217" name="ecd:TrdArrAdoptionDate" id="f-1060">11/28/2023</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-218" decimals="0" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1061">9,106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/28/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-217" name="ecd:TrdArrIndTitle" id="f-1062">(Director)</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-219" name="ecd:TrdArrIndName" id="f-1063">Shalini Sharp</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-219" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1064">Adopt</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-219" name="ecd:TrdArrAdoptionDate" id="f-1065">11/27/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-220" decimals="0" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1066">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/31/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-219" name="ecd:TrdArrIndTitle" id="f-1067">(Director)</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-221" name="ecd:TrdArrIndName" id="f-1068">Richard Pops</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-221" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1069">Adopt</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-221" name="ecd:TrdArrAdoptionDate" id="f-1070">11/21/2023</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-222" decimals="0" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1071">42,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/30/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-221" name="ecd:TrdArrIndTitle" id="f-1072">(Director)</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* Intended to satisfy the affirmative defense of Rule 10b5-1(c)</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">** <ix:nonNumeric contextRef="c-223" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1073"><ix:nonNumeric contextRef="c-223" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1074">Not intended to satisfy the affirmative defense of Rule 10b5-1(c)</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) On November 30, 2023, Eric Benevich, Chief Commercial Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1 (the &#8220;Benevich 10b5-1 Plan&#8221;). The Benevich 10b5-1 Plan was entered into on <ix:nonNumeric contextRef="c-224" name="ecd:TrdArrAdoptionDate" id="f-1075">February 23, 2022</ix:nonNumeric>, with an expiration date of December 31, 2023.</span></div></ix:nonNumeric><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_190"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9C. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_193"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_196"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;10. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the SEC within 120&#160;days of December&#160;31, 2023. Such information is incorporated herein by reference.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of ethics that applies to our Chief Executive Officer, Chief Financial Officer, and to all of our other officers, directors, employees and agents. The code of ethics is available at the Corporate Governance section of the Investors page on our website at www.neurocrine.com. We intend to disclose future amendments to, or waivers from, certain provisions of our code of ethics on the above website within four business days following the date of such amendment or waiver. Information found on, or accessible through, our website is not part of, and is not incorporated into, this Annual Report on Form 10-K.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_199"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the SEC within 120&#160;days of December&#160;31, 2023. Such information is incorporated herein by reference.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_202"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the SEC within 120&#160;days of December&#160;31, 2023. Such information is incorporated herein by reference.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_205"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;13. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the SEC within 120&#160;days of December&#160;31, 2023. Such information is incorporated herein by reference.</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_208"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;14. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Principal Accounting Fees and Services</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2024 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the SEC within 120&#160;days of December&#160;31, 2023. Such information is incorporated herein by reference.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_211"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART IV</span></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_214"></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 15. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Exhibits, Financial Statement Schedules</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;Documents filed as part of this report.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. List of Financial Statements. The following are included in Item&#160;8 of this report:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets as of December&#160;31, 2023 and 2022</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Income and Comprehensive Income for the years ended December&#160;31, 2023, 2022 and 2021</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2023, 2022 and 2021</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2023, 2022 and 2021</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. List of all Financial Statement schedules. All schedules are omitted because they are not applicable, or the required information is shown in the Financial Statements or notes thereto.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. List of Exhibits required by Item&#160;601 of Regulation&#160;S-K. See part (b)&#160;below.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Exhibits. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of, or incorporated by reference into, this report:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459018026844/nbix-ex31_91.htm">Certificate of Incorporation, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 5, 2018</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447523000057/q2-2023xexhibit3_2.htm">Bylaws, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.2 of the Company's Quarterly Report on Form 10-Q filed on August 1, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/0000898430-96-002108.txt">Form of Common Stock Certificate</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-03172)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex41.htm">Indenture, dated as of May&#160;2, 2017, by and between the Company and U.S. Bank National Association, as Trustee</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000013/nbix-20211231exhibit43.htm">First Supplemental Indenture, dated as of December 22, 2021, by and between the Company and U.S. Bank National Association, as Trustee</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Incorporated by reference to Exhibit 4.3 of the Company&#8217;s Annual Report on Form 10-K filed on February 11, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex991.htm">Form of Note representing the Company&#8217;s 2.25% Convertible Notes due 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459020003773/nbix-ex44_74.htm">Description of Common Stock of the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.4 of the Company&#8217;s Annual Report on Form 10-K filed on February 7, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q4-2023xexhibit211.htm">Subsidiaries of the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q4-2023xexhibit231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q4-2023xexhibit311.htm">Certification of Chief Executive Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q4-2023xexhibit312.htm">Certification of Chief Financial Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32***</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q4-2023xexhibit32.htm">Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q4-2023xexhibit97.htm">Neurocrine Biosciences</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q4-2023xexhibit97.htm">, Inc. Clawback Policy</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document. &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101)</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Collaboration and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447521000036/nbix-20210331exhibit101.htm">Collaboration Agreement dated June 15, 2010, by and between Abbott International Luxembourg S.a.r.l. and the Company as amended on August&#160;31, 2011</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company's Quarterly Report on Form 10-Q filed on May 5, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447521000036/nbix-20210331exhibit102.htm">First Amendment to Collaboration and License Agreement Dated August 31, 2011 between the Company and Abbott International Luxemburg S.a.r.l.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.2 of the Company's Quarterly Report on Form 10-Q filed on May 5, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447521000036/nbix-20210331exhibit103.htm">Collaboration and License Agreement dated March&#160;31, 2015 between Mitsubishi Tanabe Pharma Corporation and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company's Quarterly Report on Form 10-Q filed on May 5, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019002328/nbix-ex105_822.htm">Collaboration and License Agreement dated January 28, 2019 between Voyager Therapeutics, Inc. and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.5 of the Company&#8217;s Annual Report on Form 10-K filed on February 7, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019002328/nbix-ex106_401.htm">Stock Purchase Agreement dated January 28, 2019 between Voyager Therapeutics, Inc. and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.6 of the Company&#8217;s Annual Report on Form 10-K filed on February 7, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019026602/nbix-ex101_71.htm">Amendment No. 1 to Collaboration and License Agreement dated June 14, 2019 between Voyager Therapeutics, Inc. and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on July 29, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447520000018/nbix-20200630exhibit103.htm">Exclusive License Agreement dated June 12, 2020 between Takeda Pharmaceutical Company Limited and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 3, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000013/nbix-20211231exhibit1010.htm">Collaboration and License Agreement dated November 22, 2021 between Heptares Therapeutics Limited and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.10 of the Company&#8217;s Annual Report on Form 10-K filed on February 11, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447523000044/q1-2023x10qxexhibit102.htm">Collaboration and License Agreement dated January 8, 2023 between Voyager Therapeutics, Inc. and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Quarterly Report on Form 10-Q filed on May 3, 2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447523000044/q1-2023x10qxexhibit103.htm">Stock Purchase Agreement dated January 8, 2023 between Voyager Therapeutics, Inc. and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q filed on May 3, 2023</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447523000044/q1-2023x10qxexhibit104.htm">Amended and Restated Investor Agreement dated January 8, 2023 between Voyager Therapeutics, Inc. and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.4 of the Company&#8217;s Quarterly Report on Form 10-Q filed on May 3, 2023</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Equity Plans and Related Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517181670/d363882dex991.htm">Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on May 30, 2018</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312515209053/d934906dex991.htm">Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan, and Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for use under the Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on June 1, 2015</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312518042794/d520757dex1017.htm">Neurocrine Biosciences, Inc. Inducement Plan, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.17 of the Company&#8217;s Annual Report on Form 10-K filed on February 13, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312515268390/d938011dex101.htm">Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. Inducement Plan, and Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for use under the Neurocrine Biosciences, Inc. Inducement Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on July 29, 2015</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000044/q2-2022xexhibit103.htm">Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan, as amended and restated</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 4, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000914475/000091447522000013/nbix-20211231exhibit1017.htm">Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, and Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.17 of the Company&#8217;s Annual Report on Form 10-K filed on February 11, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447523000057/q2-2023xexhibit101.htm">Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended and restated</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 1, 2023</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Agreements with Officers and Directors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000093639207000628/a32155exv10w3.htm">Amended and Restated Employment Agreement effective August&#160;1, 2007 between the Company and Kevin C. Gorman,&#160;Ph.D.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 3, 2007</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312511030707/dex1032.htm">Form of Amendment to Employment Agreement for executive officers, effective as of December 15, 2010</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.32 of the Company&#8217;s Annual Report on Form 10-K filed on February 11, 2008</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447523000044/q1-2023x10qxexhibit101.htm">Employment Agreement dated October 28, 2014 between the Company and Darin Lippoldt</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on May 3, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517043838/d324435dex103.htm">Employment Agreement dated May 26, 2015 between the Company and Eric Benevich</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Annual Report on Form 10-K filed on February 14, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312518042794/d520757dex1026.htm">Employment Agreement effective November&#160;29, 2017 between the Company and Matthew C. Abernethy</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.26 of the Company&#8217;s Annual Report on Form 10-K filed on February 13, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517329460/d466738dex101.htm">Form of Indemnity Agreement entered into between the Company and its officers and directors</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 1, 2017</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019026602/nbix-ex102_72.htm">Employment Agreement dated January 8, 2018 between the Company and Eiry W. Roberts, M.D.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Quarterly Report on Form 10-Q filed on July 29, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000044/q2-2022xexhibit101.htm">Employment Agreement dated November 29, 2021 between the Company and Jude Onyia</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 4, 2022</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Agreements Related to Real Property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312512015472/d284170dex992.htm">Amended and Restated Lease dated November 1, 2011 between the Company and Kilroy Realty, L.P.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on January 18, 2012</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517247437/d253292dex101.htm">First Amendment to Amended and Restated Lease between the Company and Kilroy Realty, L.P., dated June&#160;5, 2017</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 3, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517329460/d466738dex103.htm">Second Amendment to Amended and Restated Lease between the Company and Kilroy Realty, L.P., dated October&#160;12, 2017</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 1, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019039803/nbix-ex101_32.htm">Third Amendment to Amended and Restated Lease between the Company and Kilroy Realty, L.P. dated August 7, 2019</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 4, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000022/gemdale-neurocrinexcomme.htm">Commercial Lease dated February 8, 2022, by and between the Company and Gemdale Aperture Phase I, LLC</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on May 4, 2022</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted with respect to certain portions of the exhibit.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain information in this exhibit has been omitted pursuant to Item 601 of Regulation S-K.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These certifications are being furnished solely to accompany this annual report pursuant to 18&#160;U.S.C. Section&#160;1350 and are not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Neurocrine Biosciences, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except as specifically noted above, the Company&#8217;s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K have a Commission File Number of 000-22705.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;Financial Statement Schedules. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;15(a)(2) above.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_217"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.971%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Kevin C. Gorman</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 9, 2024</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Matthew C. Abernethy</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 9, 2024</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="iceaa8dd12d3e4afdac5da09d72a8e8c8_220"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin C. Gorman and Matthew C. Abernethy, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power of authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities indicated as of February&#160;9, 2024:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:57.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Kevin C. Gorman</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kevin C. Gorman, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">/ Matthew C. Abernethy</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">William H. Rastetter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">William H. Rastetter, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Gary A. Lyons</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gary A. Lyons</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Johanna Mercier</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johanna Mercier</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">George J. Morrow</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">George J. Morrow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Leslie V. Norwalk</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leslie V. Norwalk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Christine A. Poon</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Christine A. Poon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Richard F. Pops</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard F. Pops</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Shalini Sharp</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shalini Sharp</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Stephen A. Sherwin</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stephen A. Sherwin, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>q4-2023xexhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4cc0588bc7654488b693782f527afaf5_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.102%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Jurisdiction</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine Continental, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, USA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine International, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, USA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine Europe, Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine Therapeutics, Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine UK Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine Switzerland GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diurnal Group Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diurnal Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diurnal Europe B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Netherlands</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>q4-2023xexhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i01816efac70b46c4a48249b2ea2633dc_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Registration Statements (Form S-8 Nos. 333-175889, 333-190178, 333-197916, and 333-212871) pertaining to the 2011 Equity Incentive Plan of Neurocrine Biosciences, Inc.,</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Registration Statements (Form S-8 Nos. 333-199837 and 333-216067) pertaining to the Inducement Plan of Neurocrine Biosciences, Inc.,  </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Registration Statements (Form S-8 Nos. 333-205933 and 333-223020) pertaining to the 2011 Equity Incentive Plan and Inducement Plan of Neurocrine Biosciences, Inc.,</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Registration Statements (Form S-8 No. 333-226971) pertaining to the 2011 Equity Incentive Plan and 2018 Employee Stock Purchase Plan of Neurocrine Biosciences, Inc.,</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Registration Statements (Form S-8 No. 333-234501) pertaining to the 2011 Equity Incentive Plan of Neurocrine Biosciences, Inc.,</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Registration Statements (Form S-8 No. 333-240301) pertaining to the 2020 Equity Incentive Plan of Neurocrine Biosciences, Inc.,</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)  Registration Statements (Form S-8 No. 333-266530) pertaining to the 2020 Equity Incentive Plan and 2018 Employee Stock Purchase Plan of Neurocrine Biosciences, Inc., and</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)  Registration Statements (Form S-8 No. 333-273554) pertaining to the 2020 Equity Incentive Plan of Neurocrine Biosciences, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;9, 2024 with respect to the consolidated financial statements of Neurocrine Biosciences, Inc., and the effectiveness of internal control over financial reporting of Neurocrine Biosciences, Inc., included in this Annual Report (Form 10-K) of Neurocrine Biosciences, Inc. for the year ended December&#160;31, 2023.</font></div><div style="margin-top:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.051%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Ernst &#38; Young LLP</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;9, 2024</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>q4-2023xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8a06bec5de5e4b87927afe1f6ddaafac_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this annual report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;9, 2024</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:147.75pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Kevin C. Gorman</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>q4-2023xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ide42d473407048c7a7b2ef994bad63d5_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Matthew C. Abernethy, Chief Financial Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;9, 2024</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:147.75pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Matthew C. Abernethy</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>q4-2023xexhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id1b942181a574acea27abcb7e72f7df4_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATIONS OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kevin C. Gorman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;9, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Kevin C. Gorman</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Matthew C. Abernethy, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;9, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Matthew C. Abernethy</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>7
<FILENAME>q4-2023xexhibit97.htm
<DESCRIPTION>EX-97
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id3bd22cfde6b452b81ff23c383a9efa7_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 97</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Neurocrine Biosciences, Inc.</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Incentive Compensation Recoupment Policy</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">October 2023</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Introduction</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Compensation Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of Neurocrine Biosciences, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) providing for the Company&#8217;s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Rule 10D-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Nasdaq Listing Rule 5608 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Listing Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Effective Date</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). This Policy shall replace and supersede the Company&#8217;s Policy for Recoupment of Incentive Compensation that was adopted February 6, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Prior Clawback Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with respect to all Incentive Compensation that is received by a Covered Officer on or after the Effective Date&#59; for clarity, the Prior Clawback Policy shall continue to apply to any Incentive Compensation that is received by a Covered Officer prior to the Effective Date. Incentive Compensation is deemed &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; in the Company&#8217;s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Definitions</font></div><div style="margin-bottom:6pt;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Accounting Restatement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Compensation Committee or, in the absence of such committee, the Board.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Covered Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each current and former Executive Officer.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Nasdaq Stock Market.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Company&#8217;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#8217;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). A measure need not be presented in the Company&#8217;s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Lookback Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#8217;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date. </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recoverable Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, on a gross basis without regarding to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Recoupment</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.18pt">Applicability of Policy. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv)&#160;during the Lookback Period. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.57pt">Recoupment Generally. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#8217;s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed. </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.8pt">Impracticability of Recovery.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Recoupment may be determined to be impracticable if, and only if&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation&#59; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards&#59; or</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.57pt">Sources of Recoupment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date&#58; (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer&#59; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid)&#59; (iii) cancelling or offsetting against any planned future cash or equity-based awards&#59; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A&#59; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.8pt">No Indemnification of Covered Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#8217;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:25.02pt">Indemnification of Administrator.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.18pt">No &#8220;Good Reason&#8221; for Covered Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i)&#160;&#8220;good reason&#8221; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii)&#160;to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Administration</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy. Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#8217;s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Severability</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">No Impairment of Other Remedies</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#8217;s obligations to the Company, including, without limitation, termination of employment and&#47;or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">SOX 304</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that are applicable to the Company&#8217;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and&#47;or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time&#59; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and&#47;or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Amendment&#59; Termination</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Successors</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and&#47;or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;Required Filings</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><div id="id3bd22cfde6b452b81ff23c383a9efa7_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Neurocrine Biosciences, Inc.</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Incentive Compensation Recoupment Policy</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Form of Executive Acknowledgment</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, the undersigned, agree and acknowledge that I am bound by, and subject to, the Neurocrine Biosciences, Inc. Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with Neurocrine Biosciences, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and&#47;or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Agreed and Acknowledged&#58;</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>nbix-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a3353234-f254-4413-b1f0-e8e01a8cce8f,g:81591885-31e3-4e25-a8db-e5a73f7fd8a5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.neurocrine.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.neurocrine.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsIncomeandComprehensiveIncome" roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome">
        <link:definition>0000005 - Statement - Consolidated Statements Income and Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreements">
        <link:definition>0000009 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecurities" roleURI="http://www.neurocrine.com/role/DebtSecurities">
        <link:definition>0000010 - Disclosure - Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.neurocrine.com/role/FairValueMeasurements">
        <link:definition>0000011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes">
        <link:definition>0000012 - Disclosure - Convertible Senior Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000013 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetails">
        <link:definition>0000014 - Disclosure - Other Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.neurocrine.com/role/EarningsPerShare">
        <link:definition>0000015 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.neurocrine.com/role/ShareBasedCompensation">
        <link:definition>0000016 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.neurocrine.com/role/IncomeTaxes">
        <link:definition>0000017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.neurocrine.com/role/Leases">
        <link:definition>0000018 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlan" roleURI="http://www.neurocrine.com/role/RetirementPlan">
        <link:definition>0000019 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.neurocrine.com/role/LegalProceedings">
        <link:definition>0000020 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesTables" roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables">
        <link:definition>9954472 - Disclosure - Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables">
        <link:definition>9954473 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables">
        <link:definition>9954474 - Disclosure - Convertible Senior Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>9954475 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsTables" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables">
        <link:definition>9954476 - Disclosure - Other Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.neurocrine.com/role/EarningsPerShareTables">
        <link:definition>9954477 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationTables">
        <link:definition>9954478 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.neurocrine.com/role/IncomeTaxesTables">
        <link:definition>9954479 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.neurocrine.com/role/LeasesTables">
        <link:definition>9954480 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9954481 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails">
        <link:definition>9954482 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails">
        <link:definition>9954483 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails">
        <link:definition>9954484 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954485 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails">
        <link:definition>9954486 - Disclosure - Convertible Senior Notes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes2024NotesDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails">
        <link:definition>9954487 - Disclosure - Convertible Senior Notes - 2024 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesInterestExpenseDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails">
        <link:definition>9954488 - Disclosure - Convertible Senior Notes - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails">
        <link:definition>9954489 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails">
        <link:definition>9954490 - Disclosure - Goodwill and Intangible Assets - Intangible Assets Amortized Over Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails" roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails">
        <link:definition>9954491 - Disclosure - Goodwill and Intangible Assets - Estimated Annual Amortization Expense for Finite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsInventoryDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails">
        <link:definition>9954492 - Disclosure - Other Balance Sheet Details - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsPropertyandEquipmentDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails">
        <link:definition>9954493 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>9954494 - Disclosure - Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails">
        <link:definition>9954495 - Disclosure - Other Balance Sheet Details - Other Long-term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>9954496 - Disclosure - Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareScheduleofNetIncomeLossPerShareDetails" roleURI="http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails">
        <link:definition>9954497 - Disclosure - Earnings Per Share - Schedule of Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" roleURI="http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails">
        <link:definition>9954498 - Disclosure - Earnings Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails">
        <link:definition>9954499 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails">
        <link:definition>9954500 - Disclosure - Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails">
        <link:definition>9954501 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails">
        <link:definition>9954502 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails">
        <link:definition>9954503 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails">
        <link:definition>9954504 - Disclosure - Share-Based Compensation - Summary of Activity Related to Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails">
        <link:definition>9954505 - Disclosure - Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails">
        <link:definition>9954506 - Disclosure - Income Taxes - Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails">
        <link:definition>9954507 - Disclosure - Income Taxes - Components of the Provision for Income Taxes for Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails">
        <link:definition>9954508 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredTaxAssetsDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails">
        <link:definition>9954509 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9954510 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails">
        <link:definition>9954511 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalInformationDetails" roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails">
        <link:definition>9954512 - Disclosure - Leases - Supplemental Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" roleURI="http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails">
        <link:definition>9954513 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1">
        <link:definition>9954513 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeInformationDetails" roleURI="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails">
        <link:definition>9954514 - Disclosure - Leases - Narrative Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlanAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails">
        <link:definition>9954515 - Disclosure - Retirement Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nbix_ConversionPeriodTwoMember" abstract="true" name="ConversionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" abstract="false" name="SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbix_VotingRestrictionPeriod" abstract="false" name="VotingRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_HeptaresTherapeuticsLimitedMember" abstract="true" name="HeptaresTherapeuticsLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_PrincipalAmountOnConversionRate" abstract="false" name="PrincipalAmountOnConversionRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_BIALPortelaCaSAMember" abstract="true" name="BIALPortelaCaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" abstract="false" name="MinimumPercentageOfTradingPriceToLastReportedSalePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock" abstract="false" name="OrganizationAndBusinessDescriptionPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nbix_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_PotentialMilestonePayments" abstract="false" name="PotentialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_DeferredTaxAssetsOperatingLeasesAssets" abstract="false" name="DeferredTaxAssetsOperatingLeasesAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtInstrumentConvertibleConversionPremium" abstract="false" name="DebtInstrumentConvertibleConversionPremium" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nbix_EricBenevichMember" abstract="true" name="EricBenevichMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PrescriptionDrugFeeNoncurrent" abstract="false" name="PrescriptionDrugFeeNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_EricBenevich2023PlanMember" abstract="true" name="EricBenevich2023PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AbbVieIncMember" abstract="true" name="AbbVieIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_TwoThousandAndElevenEquityIncentivePlanMember" abstract="true" name="TwoThousandAndElevenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" abstract="false" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_EricBenevich2024PlanMember" abstract="true" name="EricBenevich2024PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_PotentialMilestonePaymentReceipts" abstract="false" name="PotentialMilestonePaymentReceipts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_SaleOfStockNumberOfSharesSoldInTransaction" abstract="false" name="SaleOfStockNumberOfSharesSoldInTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_DebtInstrumentCouponInterest" abstract="false" name="DebtInstrumentCouponInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbix_DeferredTaxAssetsLiabilitiesGross" abstract="false" name="DeferredTaxAssetsLiabilitiesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_Amended2018EmployeeStockPurchasePlanMember" abstract="true" name="Amended2018EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" abstract="false" name="IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AccruedBrandedPrescriptionDrugFee" abstract="false" name="AccruedBrandedPrescriptionDrugFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_CashAndMoneyMarketFundMember" abstract="true" name="CashAndMoneyMarketFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_UpfrontPaymentsMade" abstract="false" name="UpfrontPaymentsMade" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_LesseeOperatingLeaseOptionTermToConstructBuilding" abstract="false" name="LesseeOperatingLeaseOptionTermToConstructBuilding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_AgreementTerminationByCounterpartyMinimalContractualTime" abstract="false" name="AgreementTerminationByCounterpartyMinimalContractualTime" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_PatentTerm" abstract="false" name="PatentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_IdorsiaPharmaceuticalsLtdMember" abstract="true" name="IdorsiaPharmaceuticalsLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbix_RichardPopsMember" abstract="true" name="RichardPopsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_PerformanceBasedRestrictedStockUnitMember" abstract="true" name="PerformanceBasedRestrictedStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" abstract="false" name="IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_OperatingLeaseCostNet" abstract="false" name="OperatingLeaseCostNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_A2023VoyagerAgreementMember" abstract="true" name="A2023VoyagerAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_LargestFourCustomersMember" abstract="true" name="LargestFourCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_Amended2020EquityIncentivePlanMember" abstract="true" name="Amended2020EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_LeslieNorwalkMember" abstract="true" name="LeslieNorwalkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_BoardOfDirectorsMaximumDurationTerm" abstract="false" name="BoardOfDirectorsMaximumDurationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" abstract="false" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_OtherBalanceSheetDetailsAbstract" abstract="true" name="OtherBalanceSheetDetailsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_ESPPPurchasePeriod" abstract="false" name="ESPPPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_InvestmentIncomeAndOtherNet" abstract="false" name="InvestmentIncomeAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" abstract="true" name="SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_ShaliniSharpMember" abstract="true" name="ShaliniSharpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_A2019VoyagerAgreementMember" abstract="true" name="A2019VoyagerAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_TakedaPharmaceuticalCompanyLimitedMember" abstract="true" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_ConversionPeriodOneMember" abstract="true" name="ConversionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_AgreementTerminationMinimalContractualTime" abstract="false" name="AgreementTerminationMinimalContractualTime" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_AgreementTerminationDueToMaterialBreach" abstract="false" name="AgreementTerminationDueToMaterialBreach" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_DebtInstrumentConversionAxis" abstract="true" name="DebtInstrumentConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbix_NumberOfNonClinicalStageCompound" abstract="false" name="NumberOfNonClinicalStageCompound" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" abstract="false" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_MilestonePayment" abstract="false" name="MilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" abstract="true" name="StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_DebtInstrumentConversionDomain" abstract="true" name="DebtInstrumentConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_ScientificEquipmentMember" abstract="true" name="ScientificEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_NumberOfUndisclosedPrograms" abstract="false" name="NumberOfUndisclosedPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" abstract="false" name="DeferredTaxLiabilitiesOperatingLeasesLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_IngridDelaetMember" abstract="true" name="IngridDelaetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_NumberOfPreclinicalCandidates" abstract="false" name="NumberOfPreclinicalCandidates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_VoyagerTherapeuticsMember" abstract="true" name="VoyagerTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_GeorgeMorrowMember" abstract="true" name="GeorgeMorrowMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_AgreementTerminationContractualTimeThreshold" abstract="false" name="AgreementTerminationContractualTimeThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_NumberOfGeneTherapyPrograms" abstract="false" name="NumberOfGeneTherapyPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_AgreementTerminationByCounterpartyContractualTimeThreshold" abstract="false" name="AgreementTerminationByCounterpartyContractualTimeThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_IncomeTaxReconciliationExpirationOfTaxCredits" abstract="false" name="IncomeTaxReconciliationExpirationOfTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" abstract="false" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_MitsubishiTanabePharmaCorporationMember" abstract="true" name="MitsubishiTanabePharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nbix_XenonPharmaceuticalsIncMember" abstract="true" name="XenonPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>nbix-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a3353234-f254-4413-b1f0-e8e01a8cce8f,g:81591885-31e3-4e25-a8db-e5a73f7fd8a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3f8a1aec-b842-4030-9e2b-923ae992d7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fccfce40-0953-4fc6-a43d-ea21f4a148bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3f8a1aec-b842-4030-9e2b-923ae992d7cb" xlink:to="loc_us-gaap_LiabilitiesCurrent_fccfce40-0953-4fc6-a43d-ea21f4a148bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c317bb64-8d71-4a46-81dc-40f51fbe0647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3f8a1aec-b842-4030-9e2b-923ae992d7cb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c317bb64-8d71-4a46-81dc-40f51fbe0647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_23687ad2-635b-4eff-9962-5a88f7aeee84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3f8a1aec-b842-4030-9e2b-923ae992d7cb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_23687ad2-635b-4eff-9962-5a88f7aeee84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_897837e7-eb5c-4181-854f-01670a398df8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c0d0bae-67ba-4114-9a52-be724bb5c31e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_897837e7-eb5c-4181-854f-01670a398df8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c0d0bae-67ba-4114-9a52-be724bb5c31e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d44ab9e0-f752-42bf-b2b0-fed53d61d044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_897837e7-eb5c-4181-854f-01670a398df8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d44ab9e0-f752-42bf-b2b0-fed53d61d044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_23ff03bc-240a-48e5-804b-eace658a1b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_897837e7-eb5c-4181-854f-01670a398df8" xlink:to="loc_us-gaap_ReceivablesNetCurrent_23ff03bc-240a-48e5-804b-eace658a1b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_80081aea-adca-47de-a92e-c60025422c72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_897837e7-eb5c-4181-854f-01670a398df8" xlink:to="loc_us-gaap_InventoryNet_80081aea-adca-47de-a92e-c60025422c72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b32e2026-60ba-4ca6-a747-791747d475da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_897837e7-eb5c-4181-854f-01670a398df8" xlink:to="loc_us-gaap_OtherAssetsCurrent_b32e2026-60ba-4ca6-a747-791747d475da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8027029b-b19f-458f-b99c-e911d050e057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_109218a2-6ba8-4755-8c57-bb4d2d52c521" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8027029b-b19f-458f-b99c-e911d050e057" xlink:to="loc_us-gaap_AssetsCurrent_109218a2-6ba8-4755-8c57-bb4d2d52c521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_308b9736-896c-468e-a096-508cba7036a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8027029b-b19f-458f-b99c-e911d050e057" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_308b9736-896c-468e-a096-508cba7036a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f60f412d-b42c-4b10-a4f5-b75599ea8c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8027029b-b19f-458f-b99c-e911d050e057" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f60f412d-b42c-4b10-a4f5-b75599ea8c7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4f308fa4-2966-40d2-a701-33b2a5e62c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8027029b-b19f-458f-b99c-e911d050e057" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4f308fa4-2966-40d2-a701-33b2a5e62c7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_7db22021-2f91-4729-8d42-dea4db63fe24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8027029b-b19f-458f-b99c-e911d050e057" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_7db22021-2f91-4729-8d42-dea4db63fe24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3a82ed1c-59ce-46cf-b9fb-c22c737adcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8027029b-b19f-458f-b99c-e911d050e057" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3a82ed1c-59ce-46cf-b9fb-c22c737adcf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_85781af6-c73a-4c98-bfc3-94b7495dcd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8027029b-b19f-458f-b99c-e911d050e057" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_85781af6-c73a-4c98-bfc3-94b7495dcd0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_075bf8fb-f70f-4233-8505-399d7b60c6da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8027029b-b19f-458f-b99c-e911d050e057" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_075bf8fb-f70f-4233-8505-399d7b60c6da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2f0a0e26-02d0-4671-bf0d-70523b22d1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cbdb982b-4bff-4417-ba00-511a3bc94d10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f0a0e26-02d0-4671-bf0d-70523b22d1a8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cbdb982b-4bff-4417-ba00-511a3bc94d10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_efe3bb9c-ee6f-4ed0-888f-ab1fa6ecf2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f0a0e26-02d0-4671-bf0d-70523b22d1a8" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_efe3bb9c-ee6f-4ed0-888f-ab1fa6ecf2f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8375b8dd-291a-4d78-a8b6-9c6a1b75865b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2f0a0e26-02d0-4671-bf0d-70523b22d1a8" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8375b8dd-291a-4d78-a8b6-9c6a1b75865b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04fde671-6911-4fea-ab99-74df9db2e40a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e9161a7a-1e37-4bbb-9227-689713a4078e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04fde671-6911-4fea-ab99-74df9db2e40a" xlink:to="loc_us-gaap_PreferredStockValue_e9161a7a-1e37-4bbb-9227-689713a4078e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f20a256d-aede-4130-b09a-671a576b05df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04fde671-6911-4fea-ab99-74df9db2e40a" xlink:to="loc_us-gaap_CommonStockValue_f20a256d-aede-4130-b09a-671a576b05df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a0efa88d-6de3-4b80-8858-d437213b8377" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04fde671-6911-4fea-ab99-74df9db2e40a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a0efa88d-6de3-4b80-8858-d437213b8377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f9215449-a1eb-451f-85ae-8def8fb21879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04fde671-6911-4fea-ab99-74df9db2e40a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f9215449-a1eb-451f-85ae-8def8fb21879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9793d942-b246-4b5b-9cec-80e9bcc4d84d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04fde671-6911-4fea-ab99-74df9db2e40a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9793d942-b246-4b5b-9cec-80e9bcc4d84d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4f528b4c-003f-4bc3-8d0e-d32d02de9036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9c5c467d-8f53-4376-8989-06286d07e2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4f528b4c-003f-4bc3-8d0e-d32d02de9036" xlink:to="loc_us-gaap_Liabilities_9c5c467d-8f53-4376-8989-06286d07e2b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1880900a-7e58-4718-a69a-5e16f75c62d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4f528b4c-003f-4bc3-8d0e-d32d02de9036" xlink:to="loc_us-gaap_StockholdersEquity_1880900a-7e58-4718-a69a-5e16f75c62d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConsolidatedStatementsIncomeandComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_68c3fa1b-7f5d-4d94-a7fa-dfcfa6b9ca81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_10285d8d-d679-4246-b6c9-f96437df37df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68c3fa1b-7f5d-4d94-a7fa-dfcfa6b9ca81" xlink:to="loc_us-gaap_InterestExpense_10285d8d-d679-4246-b6c9-f96437df37df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_02ca9fcc-b2c2-4b91-97b9-2e0f9af2420e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68c3fa1b-7f5d-4d94-a7fa-dfcfa6b9ca81" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_02ca9fcc-b2c2-4b91-97b9-2e0f9af2420e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b3d9df84-7267-4d39-be95-97eb474193af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68c3fa1b-7f5d-4d94-a7fa-dfcfa6b9ca81" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b3d9df84-7267-4d39-be95-97eb474193af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_7b71a370-e5e7-44d1-8961-ff5043f9b1b0" xlink:href="nbix-20231231.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68c3fa1b-7f5d-4d94-a7fa-dfcfa6b9ca81" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_7b71a370-e5e7-44d1-8961-ff5043f9b1b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c33df194-ca85-406e-a83d-586f87e729db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76699b0c-810d-4da2-8931-2067d8de7554" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c33df194-ca85-406e-a83d-586f87e729db" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76699b0c-810d-4da2-8931-2067d8de7554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d5ba4aef-c753-4a4f-9c02-2976b9e502d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c33df194-ca85-406e-a83d-586f87e729db" xlink:to="loc_us-gaap_CostsAndExpenses_d5ba4aef-c753-4a4f-9c02-2976b9e502d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_882f2a2d-b07d-43e8-b10a-8ae5925e8c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_636180d4-2f61-4223-bca0-3ef954bba372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_882f2a2d-b07d-43e8-b10a-8ae5925e8c8c" xlink:to="loc_us-gaap_NetIncomeLoss_636180d4-2f61-4223-bca0-3ef954bba372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_25463916-34e6-44f7-b01c-bd738f39d90d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_882f2a2d-b07d-43e8-b10a-8ae5925e8c8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_25463916-34e6-44f7-b01c-bd738f39d90d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_22bc5651-66a3-49bb-ada8-87b5c57c5321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_882f2a2d-b07d-43e8-b10a-8ae5925e8c8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_22bc5651-66a3-49bb-ada8-87b5c57c5321" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3041c0b3-6fc0-4832-9a2a-5f59d6777c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1decb488-9876-46b1-85c8-8ba527743920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3041c0b3-6fc0-4832-9a2a-5f59d6777c8a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1decb488-9876-46b1-85c8-8ba527743920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3681cb75-559d-4c65-9ab9-3587d561e1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3041c0b3-6fc0-4832-9a2a-5f59d6777c8a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3681cb75-559d-4c65-9ab9-3587d561e1c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_767aa563-228c-49d6-9550-b902fcee85b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_16e4a58e-d6c4-4537-b6f7-95b6ab909ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_767aa563-228c-49d6-9550-b902fcee85b8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_16e4a58e-d6c4-4537-b6f7-95b6ab909ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_14b3a1f6-f18b-4efb-aaba-e21f9cbdfa49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_767aa563-228c-49d6-9550-b902fcee85b8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_14b3a1f6-f18b-4efb-aaba-e21f9cbdfa49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_fe178776-419a-4a56-b453-40d70ff9144c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_767aa563-228c-49d6-9550-b902fcee85b8" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_fe178776-419a-4a56-b453-40d70ff9144c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f2432b98-d63e-49c7-b001-d8df447ef863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_767aa563-228c-49d6-9550-b902fcee85b8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f2432b98-d63e-49c7-b001-d8df447ef863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a180410-21c1-4693-8697-8ce7e942229f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_45cd3174-0e6d-4a4d-8436-c523b8a58cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a180410-21c1-4693-8697-8ce7e942229f" xlink:to="loc_us-gaap_OperatingIncomeLoss_45cd3174-0e6d-4a4d-8436-c523b8a58cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fe650511-e0b6-4b9c-aabf-545bf79ef103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a180410-21c1-4693-8697-8ce7e942229f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fe650511-e0b6-4b9c-aabf-545bf79ef103" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08321880-2a09-4e17-b954-431cd51d8598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e8459f1-46db-4004-88c9-4c97c26fdbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08321880-2a09-4e17-b954-431cd51d8598" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e8459f1-46db-4004-88c9-4c97c26fdbc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0a82d1c5-f86b-47ad-85fb-bdae825608bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08321880-2a09-4e17-b954-431cd51d8598" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0a82d1c5-f86b-47ad-85fb-bdae825608bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_396a0087-676c-411a-ab5d-c281e9fdfde4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08321880-2a09-4e17-b954-431cd51d8598" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_396a0087-676c-411a-ab5d-c281e9fdfde4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f63de51f-10c4-4bcb-a515-6de62f677322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08321880-2a09-4e17-b954-431cd51d8598" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f63de51f-10c4-4bcb-a515-6de62f677322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0846557-d834-4ec7-be1f-102210bf5e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e7a8cf47-76b8-462f-9f9f-1b9ea03aa5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0846557-d834-4ec7-be1f-102210bf5e2b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e7a8cf47-76b8-462f-9f9f-1b9ea03aa5a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_649f293f-df6c-4433-832a-9bb2c6369f24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0846557-d834-4ec7-be1f-102210bf5e2b" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_649f293f-df6c-4433-832a-9bb2c6369f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_05fa5427-6e9d-4560-b998-bc520125d600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_NetIncomeLoss_05fa5427-6e9d-4560-b998-bc520125d600" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_85684e9d-c5a9-4c9b-830b-a74edf4be4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_ShareBasedCompensation_85684e9d-c5a9-4c9b-830b-a74edf4be4ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_02729e04-3f2d-47ef-8816-40e62414ce39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_Depreciation_02729e04-3f2d-47ef-8816-40e62414ce39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_cb7b7874-877f-4e80-953d-6497619cbcea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_cb7b7874-877f-4e80-953d-6497619cbcea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8021e115-3e44-43cc-be4a-cf6e21a8aea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8021e115-3e44-43cc-be4a-cf6e21a8aea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c24cc565-6db6-4d79-846d-af4d9a170628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c24cc565-6db6-4d79-846d-af4d9a170628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d0b0f5b4-1af4-4a22-b25d-5ae75966546d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d0b0f5b4-1af4-4a22-b25d-5ae75966546d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_64a65846-22ce-4d73-b06f-e7bc42525489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_64a65846-22ce-4d73-b06f-e7bc42525489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_836a76f4-d61a-4aff-b1ab-d425e7f623df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_836a76f4-d61a-4aff-b1ab-d425e7f623df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_4e0b05cc-de20-460d-8b8d-e82154dd99ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_4e0b05cc-de20-460d-8b8d-e82154dd99ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1a04b319-7b24-4e49-8af8-f79d8932c3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1a04b319-7b24-4e49-8af8-f79d8932c3bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_080eb842-783f-408d-b261-5122e2e44f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_080eb842-783f-408d-b261-5122e2e44f2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_23cc8d56-d48d-43d1-b980-bb4bd1530ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_23cc8d56-d48d-43d1-b980-bb4bd1530ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_e2498e89-d3b4-4916-86e9-b775791fdff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_e2498e89-d3b4-4916-86e9-b775791fdff7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_05d3abc2-bd70-4de3-ae7e-0f4b7df24818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5adf1e0b-9570-4a1c-a185-e0c26e3a5c9e" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_05d3abc2-bd70-4de3-ae7e-0f4b7df24818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ef50f497-8f25-4ab7-a3b5-25c0d74eb07a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_412ff421-208f-497c-9f78-c5a1aa4c48b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ef50f497-8f25-4ab7-a3b5-25c0d74eb07a" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_412ff421-208f-497c-9f78-c5a1aa4c48b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_86e03a2e-61d1-4795-9402-f29485e10c80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ef50f497-8f25-4ab7-a3b5-25c0d74eb07a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_86e03a2e-61d1-4795-9402-f29485e10c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0530cbc1-5cdb-43a3-86ea-6f66207a5842" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ef50f497-8f25-4ab7-a3b5-25c0d74eb07a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0530cbc1-5cdb-43a3-86ea-6f66207a5842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_cae11389-cd22-483b-b4ff-7ea1ca3b1964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ef50f497-8f25-4ab7-a3b5-25c0d74eb07a" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_cae11389-cd22-483b-b4ff-7ea1ca3b1964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e5843010-b5d2-467e-966d-021aa801ee1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ef50f497-8f25-4ab7-a3b5-25c0d74eb07a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e5843010-b5d2-467e-966d-021aa801ee1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d0cefe80-6e12-42a9-8f00-cf0634b739d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_44fbdf4b-7df6-43d5-a024-e87b4b4cad05" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d0cefe80-6e12-42a9-8f00-cf0634b739d3" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_44fbdf4b-7df6-43d5-a024-e87b4b4cad05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_56945221-a1e4-4177-9452-e036da428cb5" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d0cefe80-6e12-42a9-8f00-cf0634b739d3" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_56945221-a1e4-4177-9452-e036da428cb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_56992dc2-a963-4a29-b7c2-832564c5a347" xlink:href="nbix-20231231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d0cefe80-6e12-42a9-8f00-cf0634b739d3" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_56992dc2-a963-4a29-b7c2-832564c5a347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_86f754a5-e03f-41fa-9bc3-0479b651176e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_8cb21f21-2912-4e88-9246-b55b1f938c35" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_86f754a5-e03f-41fa-9bc3-0479b651176e" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_8cb21f21-2912-4e88-9246-b55b1f938c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_72bed78d-26bf-4453-bd61-9f3e4728c488" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_86f754a5-e03f-41fa-9bc3-0479b651176e" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_72bed78d-26bf-4453-bd61-9f3e4728c488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_f4f506f8-91ea-4eea-bd2a-44f42ea109ab" xlink:href="nbix-20231231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_86f754a5-e03f-41fa-9bc3-0479b651176e" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_f4f506f8-91ea-4eea-bd2a-44f42ea109ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_d6939c0f-777f-4916-b515-e3d4497d5f92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a9d55568-5987-41a8-a4c5-4782c19355b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_d6939c0f-777f-4916-b515-e3d4497d5f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a9d55568-5987-41a8-a4c5-4782c19355b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_9339963f-fb30-43ec-b348-e7a909304e62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_d6939c0f-777f-4916-b515-e3d4497d5f92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_9339963f-fb30-43ec-b348-e7a909304e62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_d23a5a24-4999-461d-8883-38335c3518aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_8c67cf03-a1f1-465a-b49f-29f067e44128" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_d23a5a24-4999-461d-8883-38335c3518aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_8c67cf03-a1f1-465a-b49f-29f067e44128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_8a00735e-b5f1-49fa-be59-f528c85ab32e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_d23a5a24-4999-461d-8883-38335c3518aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_8a00735e-b5f1-49fa-be59-f528c85ab32e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConvertibleSeniorNotesInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e8d4a4d1-6d52-445c-9f7c-ed6910292158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentCouponInterest_f69f56a7-ca69-4c43-bfa8-c25f8a14fade" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentCouponInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_e8d4a4d1-6d52-445c-9f7c-ed6910292158" xlink:to="loc_nbix_DebtInstrumentCouponInterest_f69f56a7-ca69-4c43-bfa8-c25f8a14fade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8bc96520-8c71-49b6-a2d7-8822f7d6bb98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_e8d4a4d1-6d52-445c-9f7c-ed6910292158" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8bc96520-8c71-49b6-a2d7-8822f7d6bb98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_64b37d29-e388-47b6-975d-3519983c61bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b60c3ca1-bbee-4072-ab0f-0ebcfcf738f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_64b37d29-e388-47b6-975d-3519983c61bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b60c3ca1-bbee-4072-ab0f-0ebcfcf738f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_69dd15f9-0bb4-4cc3-96f2-0b166e806174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_64b37d29-e388-47b6-975d-3519983c61bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_69dd15f9-0bb4-4cc3-96f2-0b166e806174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_edad3b93-743b-4f66-8b90-7c248069adaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f5a75f03-abd7-44cf-b06e-366dfaf0cd80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_edad3b93-743b-4f66-8b90-7c248069adaa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f5a75f03-abd7-44cf-b06e-366dfaf0cd80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4bf6829a-618f-4687-893d-4ab262d5cb28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_edad3b93-743b-4f66-8b90-7c248069adaa" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4bf6829a-618f-4687-893d-4ab262d5cb28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetailsInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_ece27b0f-9ca6-4a7e-80b8-145e8652ac4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_5beeca44-6c8f-4da5-a302-aa0a79c3201a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_ece27b0f-9ca6-4a7e-80b8-145e8652ac4c" xlink:to="loc_us-gaap_InventoryWorkInProcess_5beeca44-6c8f-4da5-a302-aa0a79c3201a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_d6dfb0c3-f97f-4dc3-9527-5c8dabe0578a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_ece27b0f-9ca6-4a7e-80b8-145e8652ac4c" xlink:to="loc_us-gaap_InventoryFinishedGoods_d6dfb0c3-f97f-4dc3-9527-5c8dabe0578a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_0c50601e-0449-47d0-bad5-955465cdc1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_ece27b0f-9ca6-4a7e-80b8-145e8652ac4c" xlink:to="loc_us-gaap_InventoryRawMaterials_0c50601e-0449-47d0-bad5-955465cdc1ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_587a2d98-71b0-4379-9242-8736fab180bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_842a0cb1-335f-4ec7-8a6b-d2dcab8424b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_587a2d98-71b0-4379-9242-8736fab180bf" xlink:to="loc_us-gaap_InventoryValuationReserves_842a0cb1-335f-4ec7-8a6b-d2dcab8424b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_69b54f3d-e94b-4f5c-b6d8-a184d0272a86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_587a2d98-71b0-4379-9242-8736fab180bf" xlink:to="loc_us-gaap_InventoryGross_69b54f3d-e94b-4f5c-b6d8-a184d0272a86" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetailsPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_457ed195-b480-453c-b9a2-37194a31792e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b07ba1ad-9dd0-4203-9651-0a7f814dd446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_457ed195-b480-453c-b9a2-37194a31792e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b07ba1ad-9dd0-4203-9651-0a7f814dd446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6c5ffd9a-fa3b-4f37-8bc7-4e0cc134947e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_457ed195-b480-453c-b9a2-37194a31792e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6c5ffd9a-fa3b-4f37-8bc7-4e0cc134947e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_05f09e54-d785-4aee-bb85-cc32a936e64a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_dbb2aeaa-ce40-4340-8947-d5d334dc78c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_05f09e54-d785-4aee-bb85-cc32a936e64a" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_dbb2aeaa-ce40-4340-8947-d5d334dc78c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_c6bb6c89-cc15-4d37-a80b-0ff059cc27ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_05f09e54-d785-4aee-bb85-cc32a936e64a" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_c6bb6c89-cc15-4d37-a80b-0ff059cc27ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_e2ab2582-8ddd-461a-8bec-f0b058d46d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_05f09e54-d785-4aee-bb85-cc32a936e64a" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_e2ab2582-8ddd-461a-8bec-f0b058d46d6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ad67cf9c-bc26-4ef9-92d3-e6fee3abe913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_05f09e54-d785-4aee-bb85-cc32a936e64a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ad67cf9c-bc26-4ef9-92d3-e6fee3abe913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedBrandedPrescriptionDrugFee_bf321aba-91b5-4397-8ab3-4bb37d01292b" xlink:href="nbix-20231231.xsd#nbix_AccruedBrandedPrescriptionDrugFee"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_05f09e54-d785-4aee-bb85-cc32a936e64a" xlink:to="loc_nbix_AccruedBrandedPrescriptionDrugFee_bf321aba-91b5-4397-8ab3-4bb37d01292b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent_6f047c10-5dfd-41d5-a715-87cca7253e26" xlink:href="nbix-20231231.xsd#nbix_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_05f09e54-d785-4aee-bb85-cc32a936e64a" xlink:to="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent_6f047c10-5dfd-41d5-a715-87cca7253e26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_05f9fd20-eab4-4b1d-a966-33e7248d82cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f87a760c-ad6d-45e5-b72f-261214c9f80b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_05f9fd20-eab4-4b1d-a966-33e7248d82cc" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f87a760c-ad6d-45e5-b72f-261214c9f80b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrescriptionDrugFeeNoncurrent_9184730a-1827-4545-9e40-76b706d6b319" xlink:href="nbix-20231231.xsd#nbix_PrescriptionDrugFeeNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_05f9fd20-eab4-4b1d-a966-33e7248d82cc" xlink:to="loc_nbix_PrescriptionDrugFeeNoncurrent_9184730a-1827-4545-9e40-76b706d6b319" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5738c0fe-f85b-4a62-862f-c3f1a0c61973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5ea9f31-d2b2-4081-bf82-1735811a189d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5738c0fe-f85b-4a62-862f-c3f1a0c61973" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5ea9f31-d2b2-4081-bf82-1735811a189d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_593023ca-ea7b-4e0b-ae87-103bf1349267" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5738c0fe-f85b-4a62-862f-c3f1a0c61973" xlink:to="loc_us-gaap_RestrictedCash_593023ca-ea7b-4e0b-ae87-103bf1349267" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#EarningsPerShareScheduleofNetIncomeLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_597c6e53-e699-4abe-b3bc-410a9dcd8031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1caa3b26-9913-436b-adfb-82c8d60165ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_597c6e53-e699-4abe-b3bc-410a9dcd8031" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1caa3b26-9913-436b-adfb-82c8d60165ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5a611da8-1070-4c57-a28d-21d089df8831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_597c6e53-e699-4abe-b3bc-410a9dcd8031" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5a611da8-1070-4c57-a28d-21d089df8831" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d141bc96-263c-4499-a230-3884141df704" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bb69dfe8-4cd2-4d26-82de-291c1bb23b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d141bc96-263c-4499-a230-3884141df704" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bb69dfe8-4cd2-4d26-82de-291c1bb23b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_f56519af-bc30-4411-bd4a-efa759e2a23f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d141bc96-263c-4499-a230-3884141df704" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_f56519af-bc30-4411-bd4a-efa759e2a23f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bb7eafc1-b412-4cca-9dcb-acffc922ed83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4e10b2ee-f634-4377-a4a6-2c4e9f06e0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb7eafc1-b412-4cca-9dcb-acffc922ed83" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4e10b2ee-f634-4377-a4a6-2c4e9f06e0c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a8da65e9-188b-44a7-a91c-578232c076b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bb7eafc1-b412-4cca-9dcb-acffc922ed83" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a8da65e9-188b-44a7-a91c-578232c076b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2116687d-1d11-4861-a935-15eab1f3144d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3c1f9115-f527-467a-ba71-1c63ca71d34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2116687d-1d11-4861-a935-15eab1f3144d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3c1f9115-f527-467a-ba71-1c63ca71d34c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_64998ee9-c95e-4d4f-88f3-18560e664db4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2116687d-1d11-4861-a935-15eab1f3144d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_64998ee9-c95e-4d4f-88f3-18560e664db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_dc8d9ac5-3935-4994-ac2f-9af98823f8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_14b59f76-3242-4c3e-87f3-69c3cd31beaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_dc8d9ac5-3935-4994-ac2f-9af98823f8b0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_14b59f76-3242-4c3e-87f3-69c3cd31beaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_005751c8-f487-4708-87ca-1fc7df0ed036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_dc8d9ac5-3935-4994-ac2f-9af98823f8b0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_005751c8-f487-4708-87ca-1fc7df0ed036" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_784a1b99-b9fb-41d9-bec0-3887044c612f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a4beb912-569e-4213-90b0-5b9d68c8cf58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_784a1b99-b9fb-41d9-bec0-3887044c612f" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a4beb912-569e-4213-90b0-5b9d68c8cf58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5c1a4bac-42d4-4e0a-b3f7-198fb4651f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_784a1b99-b9fb-41d9-bec0-3887044c612f" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5c1a4bac-42d4-4e0a-b3f7-198fb4651f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_843524f5-afad-4994-b91d-4915afdabd1c" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_784a1b99-b9fb-41d9-bec0-3887044c612f" xlink:to="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_843524f5-afad-4994-b91d-4915afdabd1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_a12ed988-89dd-417d-8e1d-97e2706408e4" xlink:href="nbix-20231231.xsd#nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_784a1b99-b9fb-41d9-bec0-3887044c612f" xlink:to="loc_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_a12ed988-89dd-417d-8e1d-97e2706408e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_bbdfbdac-a35c-43fd-8c7e-302c1b20aea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_784a1b99-b9fb-41d9-bec0-3887044c612f" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_bbdfbdac-a35c-43fd-8c7e-302c1b20aea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_b90a190a-b6be-43be-a1e0-5fc571c58f9a" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_784a1b99-b9fb-41d9-bec0-3887044c612f" xlink:to="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_b90a190a-b6be-43be-a1e0-5fc571c58f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_d150abee-2ad9-454e-a15a-238067259a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_784a1b99-b9fb-41d9-bec0-3887044c612f" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_d150abee-2ad9-454e-a15a-238067259a4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_eac94ab3-119d-4cf4-90ba-6572e0491c81" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxReconciliationExpirationOfTaxCredits"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_784a1b99-b9fb-41d9-bec0-3887044c612f" xlink:to="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_eac94ab3-119d-4cf4-90ba-6572e0491c81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_239c0cd4-cfbc-436c-8b5e-b9ba09e31205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_784a1b99-b9fb-41d9-bec0-3887044c612f" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_239c0cd4-cfbc-436c-8b5e-b9ba09e31205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_8de3de56-c07f-4986-ba80-5a49ecdb1a32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_784a1b99-b9fb-41d9-bec0-3887044c612f" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_8de3de56-c07f-4986-ba80-5a49ecdb1a32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8b09073e-3f1c-4dfa-856c-ab61face8e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_784a1b99-b9fb-41d9-bec0-3887044c612f" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8b09073e-3f1c-4dfa-856c-ab61face8e6e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_875cc112-6d8b-46be-8491-f75ff5b1546f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_29cc7657-440b-43b6-9f18-f81449814390" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_875cc112-6d8b-46be-8491-f75ff5b1546f" xlink:to="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_29cc7657-440b-43b6-9f18-f81449814390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_696449d5-6bf3-4064-9e64-1ef3074d4695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_875cc112-6d8b-46be-8491-f75ff5b1546f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_696449d5-6bf3-4064-9e64-1ef3074d4695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsLiabilitiesGross_14d8e125-022b-49a2-9f0f-6aac2568984e" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxAssetsLiabilitiesGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_04e3e0d8-7b84-4a1c-87ff-4df31a9b11a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbix_DeferredTaxAssetsLiabilitiesGross_14d8e125-022b-49a2-9f0f-6aac2568984e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_04e3e0d8-7b84-4a1c-87ff-4df31a9b11a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f4b2e360-01f0-40f4-8ad2-237cbe99a602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbix_DeferredTaxAssetsLiabilitiesGross_14d8e125-022b-49a2-9f0f-6aac2568984e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_f4b2e360-01f0-40f4-8ad2-237cbe99a602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3ea9f757-9a52-4a8c-829d-1eb9d8217c39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d6d5bd41-374d-4560-b6e6-1c7e017bd833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ea9f757-9a52-4a8c-829d-1eb9d8217c39" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d6d5bd41-374d-4560-b6e6-1c7e017bd833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b23b0301-9b95-4a23-a6ee-79429552cc46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ea9f757-9a52-4a8c-829d-1eb9d8217c39" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b23b0301-9b95-4a23-a6ee-79429552cc46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_bd231675-08f9-4c65-ad40-f27e2a231756" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ea9f757-9a52-4a8c-829d-1eb9d8217c39" xlink:to="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_bd231675-08f9-4c65-ad40-f27e2a231756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_40d331da-eff0-4746-b3b0-3d2ed174ff2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ea9f757-9a52-4a8c-829d-1eb9d8217c39" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_40d331da-eff0-4746-b3b0-3d2ed174ff2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets_6b582913-5f2f-4c99-bfa0-84f8da796a03" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxAssetsOperatingLeasesAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ea9f757-9a52-4a8c-829d-1eb9d8217c39" xlink:to="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets_6b582913-5f2f-4c99-bfa0-84f8da796a03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_803e1aca-d23d-41aa-a3d9-f04650ded22c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ea9f757-9a52-4a8c-829d-1eb9d8217c39" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_803e1aca-d23d-41aa-a3d9-f04650ded22c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a9dd99a0-3a58-481e-88f7-959142ff4b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ea9f757-9a52-4a8c-829d-1eb9d8217c39" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a9dd99a0-3a58-481e-88f7-959142ff4b20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0abd3c38-05d6-4d1b-b67e-0a47d34762a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsLiabilitiesGross_8fdb5061-b464-460c-a6d6-85641b9c7289" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxAssetsLiabilitiesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0abd3c38-05d6-4d1b-b67e-0a47d34762a9" xlink:to="loc_nbix_DeferredTaxAssetsLiabilitiesGross_8fdb5061-b464-460c-a6d6-85641b9c7289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_27c17899-3e0a-4508-8aa3-97d94894625a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0abd3c38-05d6-4d1b-b67e-0a47d34762a9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_27c17899-3e0a-4508-8aa3-97d94894625a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#LeasesSupplementalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OperatingLeaseCostNet_3fecd9f3-b0a6-40d1-8f32-dd99b9507393" xlink:href="nbix-20231231.xsd#nbix_OperatingLeaseCostNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_cd7ab1e0-8986-47d3-9088-caabe79807fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbix_OperatingLeaseCostNet_3fecd9f3-b0a6-40d1-8f32-dd99b9507393" xlink:to="loc_us-gaap_OperatingLeaseCost_cd7ab1e0-8986-47d3-9088-caabe79807fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_c867cc7a-76fd-49cd-995b-1a41e16d9d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbix_OperatingLeaseCostNet_3fecd9f3-b0a6-40d1-8f32-dd99b9507393" xlink:to="loc_us-gaap_SubleaseIncome_c867cc7a-76fd-49cd-995b-1a41e16d9d3a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5486f44-2047-47ba-842f-683db70ec601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7d11186c-201b-40e7-a6ac-329da65df53e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5486f44-2047-47ba-842f-683db70ec601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7d11186c-201b-40e7-a6ac-329da65df53e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b5bb58f4-ca98-4b89-81b1-00e4182e2597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5486f44-2047-47ba-842f-683db70ec601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b5bb58f4-ca98-4b89-81b1-00e4182e2597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_be3daf9a-77e9-4076-9cef-e20faf214cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5486f44-2047-47ba-842f-683db70ec601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_be3daf9a-77e9-4076-9cef-e20faf214cb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_adc88685-4b8c-4657-a4ba-eda0e3abf59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5486f44-2047-47ba-842f-683db70ec601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_adc88685-4b8c-4657-a4ba-eda0e3abf59e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9f81d709-b55d-4e59-b301-723afcecc705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5486f44-2047-47ba-842f-683db70ec601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9f81d709-b55d-4e59-b301-723afcecc705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2b6aaa42-d150-459a-80a5-96502aa757df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5486f44-2047-47ba-842f-683db70ec601" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2b6aaa42-d150-459a-80a5-96502aa757df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7b0ffcb5-6ca0-426f-a1fa-f13281a2807c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bff74c71-5879-424e-9c1b-7b9cf6e7ec49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_7b0ffcb5-6ca0-426f-a1fa-f13281a2807c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bff74c71-5879-424e-9c1b-7b9cf6e7ec49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_769e13c2-dc4f-4bc8-9340-9af888899ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_7b0ffcb5-6ca0-426f-a1fa-f13281a2807c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_769e13c2-dc4f-4bc8-9340-9af888899ba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_cd36d30c-d521-42a2-b22f-fc544a18bb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_1302ef7f-7f83-47ba-ae19-54f7fc34330a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_cd36d30c-d521-42a2-b22f-fc544a18bb1f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_1302ef7f-7f83-47ba-ae19-54f7fc34330a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_356a9121-a276-4831-8b7b-50f05d0bcd96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_cd36d30c-d521-42a2-b22f-fc544a18bb1f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_356a9121-a276-4831-8b7b-50f05d0bcd96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_9dcc379f-7d6f-43f0-929e-107a62b41c78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_cd36d30c-d521-42a2-b22f-fc544a18bb1f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_9dcc379f-7d6f-43f0-929e-107a62b41c78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_29a01d0b-09a6-4f60-b859-b2dcd6e3781c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_cd36d30c-d521-42a2-b22f-fc544a18bb1f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_29a01d0b-09a6-4f60-b859-b2dcd6e3781c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_2f7d2d55-6b03-4a11-8778-efbab5cc05c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_cd36d30c-d521-42a2-b22f-fc544a18bb1f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_2f7d2d55-6b03-4a11-8778-efbab5cc05c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_92c470cd-64d0-4f67-893c-b7147ae8812d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_cd36d30c-d521-42a2-b22f-fc544a18bb1f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_92c470cd-64d0-4f67-893c-b7147ae8812d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="nbix-20231231.xsd#LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ccae914-e8ca-4a1f-968c-ee1efe9dc937" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_828aab2e-93ea-428c-bd32-0ccfd1d8bdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ccae914-e8ca-4a1f-968c-ee1efe9dc937" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_828aab2e-93ea-428c-bd32-0ccfd1d8bdc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e494c5fc-8df8-4a52-8b00-07e11eb799b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4ccae914-e8ca-4a1f-968c-ee1efe9dc937" xlink:to="loc_us-gaap_OperatingLeaseLiability_e494c5fc-8df8-4a52-8b00-07e11eb799b3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>nbix-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a3353234-f254-4413-b1f0-e8e01a8cce8f,g:81591885-31e3-4e25-a8db-e5a73f7fd8a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConsolidatedStatementsIncomeandComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5d0c2dd2-33c0-4cd2-bbb4-fe7f868a40fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_StatementTable_5d0c2dd2-33c0-4cd2-bbb4-fe7f868a40fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6a3bce82-156f-4c37-96c4-e013e8ba51c1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5d0c2dd2-33c0-4cd2-bbb4-fe7f868a40fe" xlink:to="loc_srt_ProductOrServiceAxis_6a3bce82-156f-4c37-96c4-e013e8ba51c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6a3bce82-156f-4c37-96c4-e013e8ba51c1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6a3bce82-156f-4c37-96c4-e013e8ba51c1" xlink:to="loc_srt_ProductsAndServicesDomain_6a3bce82-156f-4c37-96c4-e013e8ba51c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_19c87576-40cb-4108-83f9-bee601f7c96e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6a3bce82-156f-4c37-96c4-e013e8ba51c1" xlink:to="loc_srt_ProductsAndServicesDomain_19c87576-40cb-4108-83f9-bee601f7c96e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b8af9f38-52cb-450f-aaef-dd1bb54de03d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_19c87576-40cb-4108-83f9-bee601f7c96e" xlink:to="loc_us-gaap_ProductMember_b8af9f38-52cb-450f-aaef-dd1bb54de03d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_0e44d826-9adf-4760-89ee-98f937d7a832" xlink:href="nbix-20231231.xsd#nbix_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_19c87576-40cb-4108-83f9-bee601f7c96e" xlink:to="loc_nbix_CollaborationRevenueMember_0e44d826-9adf-4760-89ee-98f937d7a832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_fa4cf05c-4e27-4a34-9a6d-7478f73301c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_RevenuesAbstract_fa4cf05c-4e27-4a34-9a6d-7478f73301c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8027554-c23f-4945-8502-2afe0c8dd255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_fa4cf05c-4e27-4a34-9a6d-7478f73301c8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8027554-c23f-4945-8502-2afe0c8dd255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_525f90e0-454d-4c85-8e8d-f8eeab3fe639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_525f90e0-454d-4c85-8e8d-f8eeab3fe639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_eeec82f2-d6a1-410b-ba2c-a7bc9760628b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_eeec82f2-d6a1-410b-ba2c-a7bc9760628b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_bd0bffac-adb2-45b3-8fd2-11808306f121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_bd0bffac-adb2-45b3-8fd2-11808306f121" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e03b3e46-7a2c-4f9a-94fe-c9aac76478be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e03b3e46-7a2c-4f9a-94fe-c9aac76478be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cd95134c-9531-450c-b95c-c597c31c1703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:to="loc_us-gaap_CostsAndExpenses_cd95134c-9531-450c-b95c-c597c31c1703" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b3bc0521-0142-45ce-81bf-89b8498f7275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_OperatingIncomeLoss_b3bc0521-0142-45ce-81bf-89b8498f7275" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f1ae5b34-b3e2-4abb-ae68-c45a911efa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:to="loc_us-gaap_InterestExpense_f1ae5b34-b3e2-4abb-ae68-c45a911efa5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3c400494-0ca7-49a8-af23-f531b10a1a65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3c400494-0ca7-49a8-af23-f531b10a1a65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5ae8c987-d6e5-42d0-be58-38463623360f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5ae8c987-d6e5-42d0-be58-38463623360f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_057aa6a8-4823-4e95-87f2-1fbcf990d883" xlink:href="nbix-20231231.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_057aa6a8-4823-4e95-87f2-1fbcf990d883" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3fd41ab8-ac8e-443f-8a17-3d8840ba17da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3fd41ab8-ac8e-443f-8a17-3d8840ba17da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4538bd94-d41c-4e9b-b1a5-6c30fef39fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4538bd94-d41c-4e9b-b1a5-6c30fef39fbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4dc33444-96f3-4f9d-97a7-3671e86ed6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4dc33444-96f3-4f9d-97a7-3671e86ed6b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e14d0caf-0ba8-4efa-b912-bb5afa155b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_NetIncomeLoss_e14d0caf-0ba8-4efa-b912-bb5afa155b57" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_de178cde-4a22-4148-b778-5030012152cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_de178cde-4a22-4148-b778-5030012152cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6b9e248e-a463-4d57-9be7-0000066223f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6b9e248e-a463-4d57-9be7-0000066223f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ccb35277-3b83-45fe-8583-0708393c90c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ccb35277-3b83-45fe-8583-0708393c90c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_126af9ed-8900-4fdf-b62d-480ceeb4e142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_EarningsPerShareBasic_126af9ed-8900-4fdf-b62d-480ceeb4e142" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_32511626-9f7f-4aff-94d0-3d94647705ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_EarningsPerShareDiluted_32511626-9f7f-4aff-94d0-3d94647705ac" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6be25821-5682-4afa-adef-8e7bf6eec529" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6be25821-5682-4afa-adef-8e7bf6eec529" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_10e2d311-23e7-4fad-9754-b8bf804d138b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_10e2d311-23e7-4fad-9754-b8bf804d138b" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4508530b-7b3b-4897-a547-31a5438596a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_73d9b714-5d82-4f2d-bb2c-799d47e06424" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4508530b-7b3b-4897-a547-31a5438596a2" xlink:to="loc_us-gaap_StatementTable_73d9b714-5d82-4f2d-bb2c-799d47e06424" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b3a0a7fa-8c25-4de7-b316-210dc89db86e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_73d9b714-5d82-4f2d-bb2c-799d47e06424" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b3a0a7fa-8c25-4de7-b316-210dc89db86e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3a0a7fa-8c25-4de7-b316-210dc89db86e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b3a0a7fa-8c25-4de7-b316-210dc89db86e" xlink:to="loc_us-gaap_EquityComponentDomain_b3a0a7fa-8c25-4de7-b316-210dc89db86e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_15882ed5-67f3-49c3-9951-70f5549cd404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b3a0a7fa-8c25-4de7-b316-210dc89db86e" xlink:to="loc_us-gaap_EquityComponentDomain_15882ed5-67f3-49c3-9951-70f5549cd404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_29fc5c0d-994c-41a3-b0a7-d8ffb87c36c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_15882ed5-67f3-49c3-9951-70f5549cd404" xlink:to="loc_us-gaap_CommonStockMember_29fc5c0d-994c-41a3-b0a7-d8ffb87c36c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9f68ed66-9972-49d8-b6c6-ee8ca00bdfec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_15882ed5-67f3-49c3-9951-70f5549cd404" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9f68ed66-9972-49d8-b6c6-ee8ca00bdfec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9970c0fc-473e-49f2-ba64-3734337adad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_15882ed5-67f3-49c3-9951-70f5549cd404" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9970c0fc-473e-49f2-ba64-3734337adad9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6d4cb9af-dc1a-4afa-b30f-e2cf386b916f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_15882ed5-67f3-49c3-9951-70f5549cd404" xlink:to="loc_us-gaap_RetainedEarningsMember_6d4cb9af-dc1a-4afa-b30f-e2cf386b916f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0adb1c63-5102-4768-af35-eee96e6714a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_73d9b714-5d82-4f2d-bb2c-799d47e06424" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0adb1c63-5102-4768-af35-eee96e6714a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_0adb1c63-5102-4768-af35-eee96e6714a8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0adb1c63-5102-4768-af35-eee96e6714a8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_0adb1c63-5102-4768-af35-eee96e6714a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8aaaba4d-60d2-462d-b991-8d15fcd38d93" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0adb1c63-5102-4768-af35-eee96e6714a8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8aaaba4d-60d2-462d-b991-8d15fcd38d93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_21007123-fcb4-4b79-95ee-44cc12b1b271" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8aaaba4d-60d2-462d-b991-8d15fcd38d93" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_21007123-fcb4-4b79-95ee-44cc12b1b271" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_3d294b68-9cc8-4b1f-bdaf-df02ebcf8803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4508530b-7b3b-4897-a547-31a5438596a2" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_3d294b68-9cc8-4b1f-bdaf-df02ebcf8803" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4508530b-7b3b-4897-a547-31a5438596a2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f0d9fa09-903b-436a-ad22-76ece8035bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_SharesOutstanding_f0d9fa09-903b-436a-ad22-76ece8035bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_77cf0416-0eea-435f-a19f-4acf32b65f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_StockholdersEquity_77cf0416-0eea-435f-a19f-4acf32b65f7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4c2bb2c2-f197-4cb1-8f05-8f3ec38d9637" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_NetIncomeLoss_4c2bb2c2-f197-4cb1-8f05-8f3ec38d9637" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27cd9f93-f14a-4d00-9132-9f5a7170134a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27cd9f93-f14a-4d00-9132-9f5a7170134a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dd91621f-aa6a-4e28-bba9-bb1f37019ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dd91621f-aa6a-4e28-bba9-bb1f37019ba9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_39bad6c3-8913-4299-8ef9-c109600b1310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_39bad6c3-8913-4299-8ef9-c109600b1310" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8b1d89d8-45af-4d87-aadd-fd42a8acee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8b1d89d8-45af-4d87-aadd-fd42a8acee0d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_61b36183-144a-46b1-af74-59739c8333cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_212c5b04-3c11-460f-80cb-15faa09f31a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:href="nbix-20231231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:href="nbix-20231231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd181c39-c08a-48c7-85c4-37f855a860cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd181c39-c08a-48c7-85c4-37f855a860cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bd181c39-c08a-48c7-85c4-37f855a860cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd181c39-c08a-48c7-85c4-37f855a860cc" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bd181c39-c08a-48c7-85c4-37f855a860cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36fbfaa1-0eaf-40fc-ba00-2502aaee3f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd181c39-c08a-48c7-85c4-37f855a860cc" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36fbfaa1-0eaf-40fc-ba00-2502aaee3f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_3af83b65-23b2-405c-a3da-f9d109f07963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36fbfaa1-0eaf-40fc-ba00-2502aaee3f75" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_3af83b65-23b2-405c-a3da-f9d109f07963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e32969e3-2dbe-441f-a4e6-0a6aae6d1e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36fbfaa1-0eaf-40fc-ba00-2502aaee3f75" xlink:to="loc_us-gaap_AccountsReceivableMember_e32969e3-2dbe-441f-a4e6-0a6aae6d1e6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_382425ef-8bc4-4bb3-94fc-a74023d03152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_382425ef-8bc4-4bb3-94fc-a74023d03152" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_382425ef-8bc4-4bb3-94fc-a74023d03152_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_382425ef-8bc4-4bb3-94fc-a74023d03152" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_382425ef-8bc4-4bb3-94fc-a74023d03152_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2f872314-a88e-474b-a0c2-90741a4ead90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_382425ef-8bc4-4bb3-94fc-a74023d03152" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2f872314-a88e-474b-a0c2-90741a4ead90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a2589897-5d4f-4904-9cf9-f1ee919325a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2f872314-a88e-474b-a0c2-90741a4ead90" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a2589897-5d4f-4904-9cf9-f1ee919325a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a3596232-0764-4587-9a4f-113031baa2b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_srt_MajorCustomersAxis_a3596232-0764-4587-9a4f-113031baa2b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a3596232-0764-4587-9a4f-113031baa2b1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a3596232-0764-4587-9a4f-113031baa2b1" xlink:to="loc_srt_NameOfMajorCustomerDomain_a3596232-0764-4587-9a4f-113031baa2b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5779befc-9c11-4a81-a55a-d8f3e9b4cfb7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a3596232-0764-4587-9a4f-113031baa2b1" xlink:to="loc_srt_NameOfMajorCustomerDomain_5779befc-9c11-4a81-a55a-d8f3e9b4cfb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LargestFourCustomersMember_32a2928c-b2b5-4d2f-9a72-bdaceb02ecc5" xlink:href="nbix-20231231.xsd#nbix_LargestFourCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5779befc-9c11-4a81-a55a-d8f3e9b4cfb7" xlink:to="loc_nbix_LargestFourCustomersMember_32a2928c-b2b5-4d2f-9a72-bdaceb02ecc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f9cea44d-e823-44da-bef4-5fbc579be137" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_srt_RangeAxis_f9cea44d-e823-44da-bef4-5fbc579be137" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9cea44d-e823-44da-bef4-5fbc579be137_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f9cea44d-e823-44da-bef4-5fbc579be137" xlink:to="loc_srt_RangeMember_f9cea44d-e823-44da-bef4-5fbc579be137_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3632bbb3-93cc-4129-a9ce-7a55fb0f8d8d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f9cea44d-e823-44da-bef4-5fbc579be137" xlink:to="loc_srt_RangeMember_3632bbb3-93cc-4129-a9ce-7a55fb0f8d8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7514593a-bfae-4106-b052-ad0cce6619f3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3632bbb3-93cc-4129-a9ce-7a55fb0f8d8d" xlink:to="loc_srt_MinimumMember_7514593a-bfae-4106-b052-ad0cce6619f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_44429323-b8fe-4972-b518-721e4ee3e28d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3632bbb3-93cc-4129-a9ce-7a55fb0f8d8d" xlink:to="loc_srt_MaximumMember_44429323-b8fe-4972-b518-721e4ee3e28d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_475d49fe-9cf0-4959-8de0-cb44add744a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_475d49fe-9cf0-4959-8de0-cb44add744a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_475d49fe-9cf0-4959-8de0-cb44add744a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_475d49fe-9cf0-4959-8de0-cb44add744a1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_475d49fe-9cf0-4959-8de0-cb44add744a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ce8800d-6dcf-408d-81df-fff1e76523ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_475d49fe-9cf0-4959-8de0-cb44add744a1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ce8800d-6dcf-408d-81df-fff1e76523ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8c3c50d7-94ec-4e39-aa47-63a558b44ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ce8800d-6dcf-408d-81df-fff1e76523ca" xlink:to="loc_us-gaap_EmployeeStockMember_8c3c50d7-94ec-4e39-aa47-63a558b44ab0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9432cda8-294a-4024-9c6a-84275086d8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_us-gaap_DebtInstrumentAxis_9432cda8-294a-4024-9c6a-84275086d8a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9432cda8-294a-4024-9c6a-84275086d8a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9432cda8-294a-4024-9c6a-84275086d8a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9432cda8-294a-4024-9c6a-84275086d8a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bdc1ccfe-e03e-4625-a180-ce0265a788f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9432cda8-294a-4024-9c6a-84275086d8a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bdc1ccfe-e03e-4625-a180-ce0265a788f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_21db5337-9643-4033-987a-e2ce103a090a" xlink:href="nbix-20231231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bdc1ccfe-e03e-4625-a180-ce0265a788f7" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_21db5337-9643-4033-987a-e2ce103a090a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_47f4cae4-1a96-4a31-857b-17ef01356a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_NumberOfOperatingSegments_47f4cae4-1a96-4a31-857b-17ef01356a8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_010805d2-791b-4765-9efb-9ef8b1d8173f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_NumberOfReportableSegments_010805d2-791b-4765-9efb-9ef8b1d8173f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_c2e85b9b-77b2-46cf-ac03-acb21c5b024d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_c2e85b9b-77b2-46cf-ac03-acb21c5b024d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_c72666ba-8ec2-41d2-8155-6b2c90357299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_InterestReceivableCurrent_c72666ba-8ec2-41d2-8155-6b2c90357299" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_724b39af-b92b-4d1f-8e2b-b37cd5ef998a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_724b39af-b92b-4d1f-8e2b-b37cd5ef998a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7d66eb64-87ff-47fd-b88c-2386291b7256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7d66eb64-87ff-47fd-b88c-2386291b7256" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3289a184-cdfd-4bbd-8058-25da3bc564e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_Depreciation_3289a184-cdfd-4bbd-8058-25da3bc564e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fcd0811c-aebf-4e3f-ac5b-33530c4f8740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fcd0811c-aebf-4e3f-ac5b-33530c4f8740" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_45a1aded-0f23-4f3a-9ba0-6a6ebfa04714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_AdvertisingExpense_45a1aded-0f23-4f3a-9ba0-6a6ebfa04714" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_796f680a-3537-4d2e-8c02-78c8a6e4fffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_796f680a-3537-4d2e-8c02-78c8a6e4fffb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ESPPPurchasePeriod_f185d59d-057a-4e13-9161-b29f2e881dc7" xlink:href="nbix-20231231.xsd#nbix_ESPPPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_nbix_ESPPPurchasePeriod_f185d59d-057a-4e13-9161-b29f2e881dc7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1c54d765-38ec-4879-900d-fd70ab061620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1c54d765-38ec-4879-900d-fd70ab061620" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_45b64f84-893f-41af-8dbd-ec677b70f5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_45b64f84-893f-41af-8dbd-ec677b70f5ac" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d1a0583a-4f58-496e-81f6-a3e7c7180dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d1a0583a-4f58-496e-81f6-a3e7c7180dbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1a0583a-4f58-496e-81f6-a3e7c7180dbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d1a0583a-4f58-496e-81f6-a3e7c7180dbe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1a0583a-4f58-496e-81f6-a3e7c7180dbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc522c99-b0ef-47a8-aad0-30d210b91274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d1a0583a-4f58-496e-81f6-a3e7c7180dbe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc522c99-b0ef-47a8-aad0-30d210b91274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_141ee9ac-602d-446e-aab7-039859c5aab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc522c99-b0ef-47a8-aad0-30d210b91274" xlink:to="loc_us-gaap_CollaborativeArrangementMember_141ee9ac-602d-446e-aab7-039859c5aab5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_250d3d01-4273-4f28-929a-057a79e5aa71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_srt_CounterpartyNameAxis_250d3d01-4273-4f28-929a-057a79e5aa71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_250d3d01-4273-4f28-929a-057a79e5aa71_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_250d3d01-4273-4f28-929a-057a79e5aa71" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_250d3d01-4273-4f28-929a-057a79e5aa71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_250d3d01-4273-4f28-929a-057a79e5aa71" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_HeptaresTherapeuticsLimitedMember_cf3939bc-30cc-4e97-bd16-a79c9b342570" xlink:href="nbix-20231231.xsd#nbix_HeptaresTherapeuticsLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_HeptaresTherapeuticsLimitedMember_cf3939bc-30cc-4e97-bd16-a79c9b342570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_aed11e36-4b91-406a-b645-858b8d99eb6b" xlink:href="nbix-20231231.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_aed11e36-4b91-406a-b645-858b8d99eb6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_8a829b97-6033-469d-b144-cdd77d89501f" xlink:href="nbix-20231231.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_8a829b97-6033-469d-b144-cdd77d89501f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_e8f727b8-7e45-4359-b46b-4acfd5dff7ce" xlink:href="nbix-20231231.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_e8f727b8-7e45-4359-b46b-4acfd5dff7ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_00297e07-5292-440b-9f20-98676cee00b4" xlink:href="nbix-20231231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_VoyagerTherapeuticsMember_00297e07-5292-440b-9f20-98676cee00b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A2019VoyagerAgreementMember_7d2eddae-75b8-43e9-a6da-ba55d97a92ec" xlink:href="nbix-20231231.xsd#nbix_A2019VoyagerAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_VoyagerTherapeuticsMember_00297e07-5292-440b-9f20-98676cee00b4" xlink:to="loc_nbix_A2019VoyagerAgreementMember_7d2eddae-75b8-43e9-a6da-ba55d97a92ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A2023VoyagerAgreementMember_4a996b35-9360-4497-bd84-b185a9e3d849" xlink:href="nbix-20231231.xsd#nbix_A2023VoyagerAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_VoyagerTherapeuticsMember_00297e07-5292-440b-9f20-98676cee00b4" xlink:to="loc_nbix_A2023VoyagerAgreementMember_4a996b35-9360-4497-bd84-b185a9e3d849" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember_6fb504aa-fcae-42ef-99a3-92e7635133d0" xlink:href="nbix-20231231.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_BIALPortelaCaSAMember_6fb504aa-fcae-42ef-99a3-92e7635133d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_ab1fdff2-ae42-4538-ba5e-f99598a38f25" xlink:href="nbix-20231231.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_ab1fdff2-ae42-4538-ba5e-f99598a38f25" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember_833b6324-050f-43da-8de5-3f72c9947cbe" xlink:href="nbix-20231231.xsd#nbix_AbbVieIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_AbbVieIncMember_833b6324-050f-43da-8de5-3f72c9947cbe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7d9a46bc-8c97-445e-a7b0-9bd0d7a8f7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7d9a46bc-8c97-445e-a7b0-9bd0d7a8f7ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7d9a46bc-8c97-445e-a7b0-9bd0d7a8f7ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7d9a46bc-8c97-445e-a7b0-9bd0d7a8f7ca" xlink:to="loc_us-gaap_EquityComponentDomain_7d9a46bc-8c97-445e-a7b0-9bd0d7a8f7ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_69ac7de0-3306-40b0-a4a0-1e7d7429115d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7d9a46bc-8c97-445e-a7b0-9bd0d7a8f7ca" xlink:to="loc_us-gaap_EquityComponentDomain_69ac7de0-3306-40b0-a4a0-1e7d7429115d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7cb0e6b0-0079-4bdb-8712-e5baa6a8bffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_69ac7de0-3306-40b0-a4a0-1e7d7429115d" xlink:to="loc_us-gaap_CommonStockMember_7cb0e6b0-0079-4bdb-8712-e5baa6a8bffc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c9b54842-7089-470a-bbf2-1f075757db62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c9b54842-7089-470a-bbf2-1f075757db62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c9b54842-7089-470a-bbf2-1f075757db62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c9b54842-7089-470a-bbf2-1f075757db62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c9b54842-7089-470a-bbf2-1f075757db62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8dea2092-5f1b-4ff5-bc2c-3495c88f450c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c9b54842-7089-470a-bbf2-1f075757db62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8dea2092-5f1b-4ff5-bc2c-3495c88f450c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_c796b890-a783-499e-b561-81ab27fa8ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8dea2092-5f1b-4ff5-bc2c-3495c88f450c" xlink:to="loc_us-gaap_PatentsMember_c796b890-a783-499e-b561-81ab27fa8ec2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e5f03846-9d9b-4a07-affe-5d92ad6a9175" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_srt_ProductOrServiceAxis_e5f03846-9d9b-4a07-affe-5d92ad6a9175" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5f03846-9d9b-4a07-affe-5d92ad6a9175_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e5f03846-9d9b-4a07-affe-5d92ad6a9175" xlink:to="loc_srt_ProductsAndServicesDomain_e5f03846-9d9b-4a07-affe-5d92ad6a9175_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f83a37b3-b4fa-42b8-ad24-359ea7e296af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e5f03846-9d9b-4a07-affe-5d92ad6a9175" xlink:to="loc_srt_ProductsAndServicesDomain_f83a37b3-b4fa-42b8-ad24-359ea7e296af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_8de1a682-cdea-47f0-b179-7195b0b1cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f83a37b3-b4fa-42b8-ad24-359ea7e296af" xlink:to="loc_us-gaap_RoyaltyMember_8de1a682-cdea-47f0-b179-7195b0b1cd4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f704967d-9b02-4d57-8bab-160eeff629d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_srt_RangeAxis_f704967d-9b02-4d57-8bab-160eeff629d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f704967d-9b02-4d57-8bab-160eeff629d3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f704967d-9b02-4d57-8bab-160eeff629d3" xlink:to="loc_srt_RangeMember_f704967d-9b02-4d57-8bab-160eeff629d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_67252507-3c16-44ec-bdd9-ebb000be366d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f704967d-9b02-4d57-8bab-160eeff629d3" xlink:to="loc_srt_RangeMember_67252507-3c16-44ec-bdd9-ebb000be366d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c5d55f2-7820-4719-b0ee-778bb57e5fca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_67252507-3c16-44ec-bdd9-ebb000be366d" xlink:to="loc_srt_MinimumMember_5c5d55f2-7820-4719-b0ee-778bb57e5fca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e1752ee-766f-4791-9b51-ba282f262a98" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e1752ee-766f-4791-9b51-ba282f262a98" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5e1752ee-766f-4791-9b51-ba282f262a98_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e1752ee-766f-4791-9b51-ba282f262a98" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5e1752ee-766f-4791-9b51-ba282f262a98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_071cf25e-c52c-44a8-a9a9-0d13a7a93dc1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e1752ee-766f-4791-9b51-ba282f262a98" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_071cf25e-c52c-44a8-a9a9-0d13a7a93dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_84563773-b1af-479a-baf0-5d0c176e6c63" xlink:href="nbix-20231231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_071cf25e-c52c-44a8-a9a9-0d13a7a93dc1" xlink:to="loc_nbix_VoyagerTherapeuticsMember_84563773-b1af-479a-baf0-5d0c176e6c63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_207b9484-da7d-4709-a882-2ea00aa1306f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_207b9484-da7d-4709-a882-2ea00aa1306f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a8900b4e-9634-4000-a401-4558ba2d2696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a8900b4e-9634-4000-a401-4558ba2d2696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_4b62ec21-6a03-4f5e-b831-122bf874a2c5" xlink:href="nbix-20231231.xsd#nbix_PotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_PotentialMilestonePayments_4b62ec21-6a03-4f5e-b831-122bf874a2c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationMinimalContractualTime_57ce055a-07f3-4c7c-8c0b-fde648c9b8a0" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationMinimalContractualTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_AgreementTerminationMinimalContractualTime_57ce055a-07f3-4c7c-8c0b-fde648c9b8a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationContractualTimeThreshold_30aac5ba-373e-417d-b071-e1e4830734fd" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationContractualTimeThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_AgreementTerminationContractualTimeThreshold_30aac5ba-373e-417d-b071-e1e4830734fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold_d42dd9cc-9dc9-46f9-bccf-c82120deb1a9" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationByCounterpartyContractualTimeThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold_d42dd9cc-9dc9-46f9-bccf-c82120deb1a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationByCounterpartyMinimalContractualTime_8ca23f5b-3406-4bd2-8069-443193d14308" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationByCounterpartyMinimalContractualTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_AgreementTerminationByCounterpartyMinimalContractualTime_8ca23f5b-3406-4bd2-8069-443193d14308" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfNonClinicalStageCompound_3bdffc7f-37c5-4893-a58a-004847e03730" xlink:href="nbix-20231231.xsd#nbix_NumberOfNonClinicalStageCompound"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_NumberOfNonClinicalStageCompound_3bdffc7f-37c5-4893-a58a-004847e03730" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationDueToMaterialBreach_4efdaafd-6d6c-47d9-9b8f-5bc95fe86597" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationDueToMaterialBreach"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_AgreementTerminationDueToMaterialBreach_4efdaafd-6d6c-47d9-9b8f-5bc95fe86597" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfPreclinicalCandidates_eb08e93b-72e1-433a-b9b3-6098fafa0c6f" xlink:href="nbix-20231231.xsd#nbix_NumberOfPreclinicalCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_NumberOfPreclinicalCandidates_eb08e93b-72e1-433a-b9b3-6098fafa0c6f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_780ef89f-5934-475e-a69a-7f54a244ef65" xlink:href="nbix-20231231.xsd#nbix_SaleOfStockNumberOfSharesSoldInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_780ef89f-5934-475e-a69a-7f54a244ef65" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_e9be2fed-b56a-4e07-a88c-5d745fb0e0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_SharePrice_e9be2fed-b56a-4e07-a88c-5d745fb0e0f3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_59bb4fa5-2d99-4222-a7ed-824dcc10561b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_59bb4fa5-2d99-4222-a7ed-824dcc10561b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_87bc681c-89ed-4032-ac6a-70912c3e04e1" xlink:href="nbix-20231231.xsd#nbix_MilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_MilestonePayment_87bc681c-89ed-4032-ac6a-70912c3e04e1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_ef7af634-b1ee-4cfc-a029-098c77a21076" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_ef7af634-b1ee-4cfc-a029-098c77a21076" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfUndisclosedPrograms_43861e9b-d376-4f18-a540-4c64ab7014b6" xlink:href="nbix-20231231.xsd#nbix_NumberOfUndisclosedPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_NumberOfUndisclosedPrograms_43861e9b-d376-4f18-a540-4c64ab7014b6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VotingRestrictionPeriod_1f7582d4-9789-445c-94b4-e43f569a0908" xlink:href="nbix-20231231.xsd#nbix_VotingRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_VotingRestrictionPeriod_1f7582d4-9789-445c-94b4-e43f569a0908" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfGeneTherapyPrograms_b455a82a-3f17-4121-b24b-f4dddd4e407b" xlink:href="nbix-20231231.xsd#nbix_NumberOfGeneTherapyPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_NumberOfGeneTherapyPrograms_b455a82a-3f17-4121-b24b-f4dddd4e407b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_bc458ae7-cfab-4f7c-8485-dcfa72769e0c" xlink:href="nbix-20231231.xsd#nbix_UpfrontPaymentsMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_UpfrontPaymentsMade_bc458ae7-cfab-4f7c-8485-dcfa72769e0c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BoardOfDirectorsMaximumDurationTerm_0b498d56-12fc-4cc8-8275-f81c981bd16f" xlink:href="nbix-20231231.xsd#nbix_BoardOfDirectorsMaximumDurationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_BoardOfDirectorsMaximumDurationTerm_0b498d56-12fc-4cc8-8275-f81c981bd16f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_affe9cb0-18fe-4527-9ea6-e9343ff9ceaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_affe9cb0-18fe-4527-9ea6-e9343ff9ceaa" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_12da6dfe-3825-4fd3-8003-85bfa1e18454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_12da6dfe-3825-4fd3-8003-85bfa1e18454" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6ea46239-75b6-4048-9905-573eb0edf3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6ea46239-75b6-4048-9905-573eb0edf3d5" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_75571bbe-fc63-494d-a2e7-a2123bc2f9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_InventoryValuationReserves_75571bbe-fc63-494d-a2e7-a2123bc2f9e4" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3aacba76-a66d-422b-b4e7-72dc45e50017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3aacba76-a66d-422b-b4e7-72dc45e50017" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_927ad5f4-74b9-49bf-82fa-e56227853083" xlink:href="nbix-20231231.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_927ad5f4-74b9-49bf-82fa-e56227853083" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm_8853cdb6-9d59-415a-b3f3-1c71129be1e9" xlink:href="nbix-20231231.xsd#nbix_PatentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_PatentTerm_8853cdb6-9d59-415a-b3f3-1c71129be1e9" xlink:type="arc" order="26"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a3f49e47-6dee-4fe6-94fd-bed69da9c310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a3f49e47-6dee-4fe6-94fd-bed69da9c310" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b47710de-a9cf-491c-b65c-4e38c13bef24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a3f49e47-6dee-4fe6-94fd-bed69da9c310" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b47710de-a9cf-491c-b65c-4e38c13bef24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b47710de-a9cf-491c-b65c-4e38c13bef24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b47710de-a9cf-491c-b65c-4e38c13bef24" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b47710de-a9cf-491c-b65c-4e38c13bef24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffca9d80-3c9f-47d2-99a3-e6c5906d6fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b47710de-a9cf-491c-b65c-4e38c13bef24" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffca9d80-3c9f-47d2-99a3-e6c5906d6fbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a1b0f80d-f2ff-4125-be57-f2fad3c39ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffca9d80-3c9f-47d2-99a3-e6c5906d6fbe" xlink:to="loc_us-gaap_CommercialPaperMember_a1b0f80d-f2ff-4125-be57-f2fad3c39ba1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_65d177bd-cd86-45c8-a8af-8703afa8c78e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffca9d80-3c9f-47d2-99a3-e6c5906d6fbe" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_65d177bd-cd86-45c8-a8af-8703afa8c78e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0294c337-cb9e-427c-86c9-eac041d1231f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffca9d80-3c9f-47d2-99a3-e6c5906d6fbe" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0294c337-cb9e-427c-86c9-eac041d1231f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_02f1e824-7a0e-45de-a56d-18a62ef93546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_02f1e824-7a0e-45de-a56d-18a62ef93546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_1c4dabf6-9a5b-4222-a51c-c369e64873cd" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_1c4dabf6-9a5b-4222-a51c-c369e64873cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_c19317a5-01c6-4196-b527-10e8bcd46fea" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_c19317a5-01c6-4196-b527-10e8bcd46fea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_7d3a2603-edf4-48d6-af18-f6e90e864127" xlink:href="nbix-20231231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_7d3a2603-edf4-48d6-af18-f6e90e864127" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_a387e467-92c8-4435-8ca6-d0a7481c772d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_a387e467-92c8-4435-8ca6-d0a7481c772d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_c5f6bd18-3d50-4b9b-b3ec-b5ba9ebb819b" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_c5f6bd18-3d50-4b9b-b3ec-b5ba9ebb819b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_9d718078-f28d-4551-ae69-ef6c8e443945" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_9d718078-f28d-4551-ae69-ef6c8e443945" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_9b87a64c-7f31-4cac-8ae3-32c7cb17be48" xlink:href="nbix-20231231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_9b87a64c-7f31-4cac-8ae3-32c7cb17be48" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d002fb1-84d6-4eec-b5e6-3864dcde0fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d002fb1-84d6-4eec-b5e6-3864dcde0fc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7a55b677-aa65-4c3e-9380-fae50d5cc619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d002fb1-84d6-4eec-b5e6-3864dcde0fc8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7a55b677-aa65-4c3e-9380-fae50d5cc619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7a55b677-aa65-4c3e-9380-fae50d5cc619_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7a55b677-aa65-4c3e-9380-fae50d5cc619" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7a55b677-aa65-4c3e-9380-fae50d5cc619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63afdd25-ae96-47a3-b4dc-6eb33e7deddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7a55b677-aa65-4c3e-9380-fae50d5cc619" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63afdd25-ae96-47a3-b4dc-6eb33e7deddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3355d07c-732c-4e75-8ef3-be7b2b01d702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63afdd25-ae96-47a3-b4dc-6eb33e7deddf" xlink:to="loc_us-gaap_CommercialPaperMember_3355d07c-732c-4e75-8ef3-be7b2b01d702" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c048cbbe-f5d9-4af6-834f-9e4fb30aaa96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63afdd25-ae96-47a3-b4dc-6eb33e7deddf" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c048cbbe-f5d9-4af6-834f-9e4fb30aaa96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_23b7796d-9cdc-49bf-907d-30dccdcf6bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63afdd25-ae96-47a3-b4dc-6eb33e7deddf" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_23b7796d-9cdc-49bf-907d-30dccdcf6bd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_86baca8d-938e-4c15-bfd6-b889b2ad43e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_86baca8d-938e-4c15-bfd6-b889b2ad43e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_19c95a1f-8ef9-426d-9a60-1bbb313e4cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_19c95a1f-8ef9-426d-9a60-1bbb313e4cc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_13da3300-308d-4e3f-a1f3-03c51ca4ec92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_13da3300-308d-4e3f-a1f3-03c51ca4ec92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_82aa770e-4c69-4ce9-a938-5002070baaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_82aa770e-4c69-4ce9-a938-5002070baaa0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b1166eb8-9d3e-4d72-98d1-69feeae0b5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b1166eb8-9d3e-4d72-98d1-69feeae0b5b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_ded2e7dd-9198-4604-a990-d9c3ffc246fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_ded2e7dd-9198-4604-a990-d9c3ffc246fb" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea34854f-d54e-4d1b-a708-3d0903b81e51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea34854f-d54e-4d1b-a708-3d0903b81e51" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0947a21e-2553-4504-8fe2-4216dd033abd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0947a21e-2553-4504-8fe2-4216dd033abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0947a21e-2553-4504-8fe2-4216dd033abd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0947a21e-2553-4504-8fe2-4216dd033abd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0947a21e-2553-4504-8fe2-4216dd033abd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_088645a4-1e41-4f3c-b351-b3d33e76b728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0947a21e-2553-4504-8fe2-4216dd033abd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_088645a4-1e41-4f3c-b351-b3d33e76b728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_aca48c18-e10c-44b5-bc34-75d8d72340b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_088645a4-1e41-4f3c-b351-b3d33e76b728" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_aca48c18-e10c-44b5-bc34-75d8d72340b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_005b0b00-b32c-45e6-a9d5-85bd1f704d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_088645a4-1e41-4f3c-b351-b3d33e76b728" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_005b0b00-b32c-45e6-a9d5-85bd1f704d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3fd12cda-0571-4623-ac8b-7482c476593a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3fd12cda-0571-4623-ac8b-7482c476593a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3fd12cda-0571-4623-ac8b-7482c476593a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3fd12cda-0571-4623-ac8b-7482c476593a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3fd12cda-0571-4623-ac8b-7482c476593a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3aa4d5a9-b229-459c-ab9e-2d5d978984ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3fd12cda-0571-4623-ac8b-7482c476593a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3aa4d5a9-b229-459c-ab9e-2d5d978984ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_16ddca48-028f-4a86-ac52-98fb7e482d97" xlink:href="nbix-20231231.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3aa4d5a9-b229-459c-ab9e-2d5d978984ee" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_16ddca48-028f-4a86-ac52-98fb7e482d97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_9fd350d0-6725-43ff-9b4f-6387723a8ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3aa4d5a9-b229-459c-ab9e-2d5d978984ee" xlink:to="loc_us-gaap_CertificatesOfDepositMember_9fd350d0-6725-43ff-9b4f-6387723a8ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_29f470d0-7811-4281-a6e9-abcf59af3689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3aa4d5a9-b229-459c-ab9e-2d5d978984ee" xlink:to="loc_us-gaap_CommercialPaperMember_29f470d0-7811-4281-a6e9-abcf59af3689" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_561eb429-ffcf-4b0b-be4f-fec44c8cc035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:to="loc_us-gaap_FinancialInstrumentAxis_561eb429-ffcf-4b0b-be4f-fec44c8cc035" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_561eb429-ffcf-4b0b-be4f-fec44c8cc035_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_561eb429-ffcf-4b0b-be4f-fec44c8cc035" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_561eb429-ffcf-4b0b-be4f-fec44c8cc035_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd6dc94f-6041-423a-b3d6-cbfe7c11e109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_561eb429-ffcf-4b0b-be4f-fec44c8cc035" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd6dc94f-6041-423a-b3d6-cbfe7c11e109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f5563dda-3e7a-42a7-b7a5-f7cc560cd89f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd6dc94f-6041-423a-b3d6-cbfe7c11e109" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f5563dda-3e7a-42a7-b7a5-f7cc560cd89f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7fb6d78e-de42-4ca1-81bc-d0a4473eadae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd6dc94f-6041-423a-b3d6-cbfe7c11e109" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7fb6d78e-de42-4ca1-81bc-d0a4473eadae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_95d9ebb2-ac05-49b9-aef0-f8c699a1e008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd6dc94f-6041-423a-b3d6-cbfe7c11e109" xlink:to="loc_us-gaap_EquitySecuritiesMember_95d9ebb2-ac05-49b9-aef0-f8c699a1e008" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2a341ebe-136c-4b89-bbb4-f50779698e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2a341ebe-136c-4b89-bbb4-f50779698e53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2a341ebe-136c-4b89-bbb4-f50779698e53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2a341ebe-136c-4b89-bbb4-f50779698e53" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2a341ebe-136c-4b89-bbb4-f50779698e53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_570c698c-ee09-4ab0-a27e-98c3e8f975ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2a341ebe-136c-4b89-bbb4-f50779698e53" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_570c698c-ee09-4ab0-a27e-98c3e8f975ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fd99101b-f3e3-430a-b309-b1cbf5a1b164" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_570c698c-ee09-4ab0-a27e-98c3e8f975ec" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fd99101b-f3e3-430a-b309-b1cbf5a1b164" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_0cc8d8a1-028d-4800-8921-1b74e61cd83c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea34854f-d54e-4d1b-a708-3d0903b81e51" xlink:to="loc_us-gaap_Investments_0cc8d8a1-028d-4800-8921-1b74e61cd83c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6aa3bae6-7b2d-41ae-9420-4834c5fe7699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea34854f-d54e-4d1b-a708-3d0903b81e51" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6aa3bae6-7b2d-41ae-9420-4834c5fe7699" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConvertibleSeniorNotesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_101c07e1-27b3-4700-bbc1-a5e9ec99b17d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentTable_101c07e1-27b3-4700-bbc1-a5e9ec99b17d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_55ab7631-e396-4fd0-a907-caa5118b09c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_101c07e1-27b3-4700-bbc1-a5e9ec99b17d" xlink:to="loc_us-gaap_DebtInstrumentAxis_55ab7631-e396-4fd0-a907-caa5118b09c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_55ab7631-e396-4fd0-a907-caa5118b09c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_55ab7631-e396-4fd0-a907-caa5118b09c8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_55ab7631-e396-4fd0-a907-caa5118b09c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3be48499-8bc0-4752-b836-77aeb99ceb62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_55ab7631-e396-4fd0-a907-caa5118b09c8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3be48499-8bc0-4752-b836-77aeb99ceb62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_abf1c564-f174-4607-bd27-45e5a776c544" xlink:href="nbix-20231231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3be48499-8bc0-4752-b836-77aeb99ceb62" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_abf1c564-f174-4607-bd27-45e5a776c544" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis_6b3c9282-fd63-4111-b8a1-8207b7514932" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_101c07e1-27b3-4700-bbc1-a5e9ec99b17d" xlink:to="loc_nbix_DebtInstrumentConversionAxis_6b3c9282-fd63-4111-b8a1-8207b7514932" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_6b3c9282-fd63-4111-b8a1-8207b7514932_default" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbix_DebtInstrumentConversionAxis_6b3c9282-fd63-4111-b8a1-8207b7514932" xlink:to="loc_nbix_DebtInstrumentConversionDomain_6b3c9282-fd63-4111-b8a1-8207b7514932_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_71cc9213-f91b-4aa3-b7a8-cb71f7da20e4" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbix_DebtInstrumentConversionAxis_6b3c9282-fd63-4111-b8a1-8207b7514932" xlink:to="loc_nbix_DebtInstrumentConversionDomain_71cc9213-f91b-4aa3-b7a8-cb71f7da20e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember_69dd9364-c440-41e2-b51f-85fbdb1995a0" xlink:href="nbix-20231231.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_DebtInstrumentConversionDomain_71cc9213-f91b-4aa3-b7a8-cb71f7da20e4" xlink:to="loc_nbix_ConversionPeriodTwoMember_69dd9364-c440-41e2-b51f-85fbdb1995a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember_e824cf23-9fa4-45f4-b5de-578c4e8122ef" xlink:href="nbix-20231231.xsd#nbix_ConversionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_DebtInstrumentConversionDomain_71cc9213-f91b-4aa3-b7a8-cb71f7da20e4" xlink:to="loc_nbix_ConversionPeriodOneMember_e824cf23-9fa4-45f4-b5de-578c4e8122ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_835c7106-1105-4c41-be75-409101284ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_835c7106-1105-4c41-be75-409101284ed0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_271ccc8c-6405-48e4-b8d8-7410b9b487e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_271ccc8c-6405-48e4-b8d8-7410b9b487e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_810c37ca-a3a4-4c7f-9a5e-252d53fb4f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_810c37ca-a3a4-4c7f-9a5e-252d53fb4f6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_d50de18d-47b4-4a9e-b04c-022530284750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_RepaymentsOfDebt_d50de18d-47b4-4a9e-b04c-022530284750" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8c927736-7cfb-45da-a913-9022e320041d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8c927736-7cfb-45da-a913-9022e320041d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_adb6ba87-6b37-45c4-9bba-355489b43b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_adb6ba87-6b37-45c4-9bba-355489b43b3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_ce437ba7-42f7-4465-a329-863b6624d1bc" xlink:href="nbix-20231231.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_ce437ba7-42f7-4465-a329-863b6624d1bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5da03276-88c5-4724-b09c-97d238518a72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5da03276-88c5-4724-b09c-97d238518a72" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_253cdefe-b20d-4b58-b6bd-2dce5f67ea01" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_253cdefe-b20d-4b58-b6bd-2dce5f67ea01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_e3c329c7-09d5-44f5-85fd-cbcda0008b08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_SharePrice_e3c329c7-09d5-44f5-85fd-cbcda0008b08" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4ce727c3-e707-4f84-ad5c-fa70d30efd19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4ce727c3-e707-4f84-ad5c-fa70d30efd19" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_dd14b7ef-05e9-48ef-a67a-b741fd69e715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_dd14b7ef-05e9-48ef-a67a-b741fd69e715" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5143d309-1f1a-438d-af17-77680023ee25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5143d309-1f1a-438d-af17-77680023ee25" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_a2f829b3-c41c-4b43-b63c-573fa6665509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_a2f829b3-c41c-4b43-b63c-573fa6665509" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_c215747a-eaf6-4c10-9e0d-46a92fb94bbf" xlink:href="nbix-20231231.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_c215747a-eaf6-4c10-9e0d-46a92fb94bbf" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_fe7b8128-94e6-449c-925a-e36f7e9f3e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_fe7b8128-94e6-449c-925a-e36f7e9f3e04" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConvertibleSeniorNotes2024NotesDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e4cf98a6-9458-44f3-9279-03f7bcbeae99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_74f9911d-4cf6-4173-b5ce-4eb85a8376fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4cf98a6-9458-44f3-9279-03f7bcbeae99" xlink:to="loc_us-gaap_DebtInstrumentTable_74f9911d-4cf6-4173-b5ce-4eb85a8376fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2893f76d-7643-48ab-aabf-c6d366266006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_74f9911d-4cf6-4173-b5ce-4eb85a8376fc" xlink:to="loc_us-gaap_DebtInstrumentAxis_2893f76d-7643-48ab-aabf-c6d366266006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2893f76d-7643-48ab-aabf-c6d366266006_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2893f76d-7643-48ab-aabf-c6d366266006" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2893f76d-7643-48ab-aabf-c6d366266006_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d8b997f5-498e-47bd-9a47-83d2772e6349" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2893f76d-7643-48ab-aabf-c6d366266006" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d8b997f5-498e-47bd-9a47-83d2772e6349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_f8352ddb-92c6-43d5-b5d3-723e990e8377" xlink:href="nbix-20231231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8b997f5-498e-47bd-9a47-83d2772e6349" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_f8352ddb-92c6-43d5-b5d3-723e990e8377" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_798c6939-a22f-4888-a136-b33107a14478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4cf98a6-9458-44f3-9279-03f7bcbeae99" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_798c6939-a22f-4888-a136-b33107a14478" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a5cf445d-857b-42da-9bcb-c21cd0c075b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4cf98a6-9458-44f3-9279-03f7bcbeae99" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a5cf445d-857b-42da-9bcb-c21cd0c075b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_74d4c13d-f308-4089-8f1d-205932ddf28a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4cf98a6-9458-44f3-9279-03f7bcbeae99" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_74d4c13d-f308-4089-8f1d-205932ddf28a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_0899ef52-d34c-4391-a7f2-e14c593f0f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4cf98a6-9458-44f3-9279-03f7bcbeae99" xlink:to="loc_us-gaap_DebtInstrumentFairValue_0899ef52-d34c-4391-a7f2-e14c593f0f35" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_9fc74be3-6eac-4b60-b4b2-28889e12f8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_9fc74be3-6eac-4b60-b4b2-28889e12f8b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff023bc8-3678-42f3-9aae-7639a0a3716a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9fc74be3-6eac-4b60-b4b2-28889e12f8b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff023bc8-3678-42f3-9aae-7639a0a3716a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff023bc8-3678-42f3-9aae-7639a0a3716a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff023bc8-3678-42f3-9aae-7639a0a3716a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff023bc8-3678-42f3-9aae-7639a0a3716a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04e8f961-9257-431e-ad68-0dce6b92c727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff023bc8-3678-42f3-9aae-7639a0a3716a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04e8f961-9257-431e-ad68-0dce6b92c727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_ad348835-1d15-4e9a-985a-e4681b66672c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04e8f961-9257-431e-ad68-0dce6b92c727" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_ad348835-1d15-4e9a-985a-e4681b66672c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3e230cc-f5da-4d04-a655-a689f1588818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9fc74be3-6eac-4b60-b4b2-28889e12f8b7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3e230cc-f5da-4d04-a655-a689f1588818" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a3e230cc-f5da-4d04-a655-a689f1588818_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3e230cc-f5da-4d04-a655-a689f1588818" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a3e230cc-f5da-4d04-a655-a689f1588818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68eea50f-7ba3-4969-bd11-071ddef6bce2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3e230cc-f5da-4d04-a655-a689f1588818" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68eea50f-7ba3-4969-bd11-071ddef6bce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_887c5af7-8625-4273-83f2-7bdcbe698ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68eea50f-7ba3-4969-bd11-071ddef6bce2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_887c5af7-8625-4273-83f2-7bdcbe698ee4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78f715a1-1c25-43b4-a8e8-dbad643c4bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78f715a1-1c25-43b4-a8e8-dbad643c4bc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9c7401fb-abd3-4945-85d4-5c2042371ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9c7401fb-abd3-4945-85d4-5c2042371ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_63aaa622-ab1e-423f-ad84-32ec2d07d983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_63aaa622-ab1e-423f-ad84-32ec2d07d983" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_abf69605-e9f7-4b41-aac0-9add7e4f6d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_abf69605-e9f7-4b41-aac0-9add7e4f6d43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_31f9874e-a431-4498-9ece-7bb976512604" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_31f9874e-a431-4498-9ece-7bb976512604" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09226ec9-5f00-4165-808d-cee18d81867e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09226ec9-5f00-4165-808d-cee18d81867e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetailsPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3229c9fc-ea78-4973-b7a0-ff32d6966cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_815d670f-ab50-4199-a726-6423aaac99b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3229c9fc-ea78-4973-b7a0-ff32d6966cd3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_815d670f-ab50-4199-a726-6423aaac99b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bbd9f6f-75ae-489d-aee9-7910c9f590a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_815d670f-ab50-4199-a726-6423aaac99b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bbd9f6f-75ae-489d-aee9-7910c9f590a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6bbd9f6f-75ae-489d-aee9-7910c9f590a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bbd9f6f-75ae-489d-aee9-7910c9f590a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6bbd9f6f-75ae-489d-aee9-7910c9f590a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7ac4e1-e384-4262-9ac9-e7d6c5ffd800" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bbd9f6f-75ae-489d-aee9-7910c9f590a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7ac4e1-e384-4262-9ac9-e7d6c5ffd800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_aadf96a4-2557-4975-ae60-dee0c85f6a64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7ac4e1-e384-4262-9ac9-e7d6c5ffd800" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_aadf96a4-2557-4975-ae60-dee0c85f6a64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ScientificEquipmentMember_b789e73e-8d0d-4863-bab1-72a36c5e4858" xlink:href="nbix-20231231.xsd#nbix_ScientificEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7ac4e1-e384-4262-9ac9-e7d6c5ffd800" xlink:to="loc_nbix_ScientificEquipmentMember_b789e73e-8d0d-4863-bab1-72a36c5e4858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_898d5300-a939-4161-94e3-329d7a54735d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7ac4e1-e384-4262-9ac9-e7d6c5ffd800" xlink:to="loc_us-gaap_ComputerEquipmentMember_898d5300-a939-4161-94e3-329d7a54735d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d7b00554-bd81-4ddb-81c5-875ec5c1ff58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7ac4e1-e384-4262-9ac9-e7d6c5ffd800" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d7b00554-bd81-4ddb-81c5-875ec5c1ff58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d768dd87-3f67-4cef-ae47-688155d0210f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3229c9fc-ea78-4973-b7a0-ff32d6966cd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d768dd87-3f67-4cef-ae47-688155d0210f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_592c300a-1079-4d44-bcda-8596541a71d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3229c9fc-ea78-4973-b7a0-ff32d6966cd3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_592c300a-1079-4d44-bcda-8596541a71d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ef44e638-fec7-4f8d-bd36-68a358f4ebf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3229c9fc-ea78-4973-b7a0-ff32d6966cd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ef44e638-fec7-4f8d-bd36-68a358f4ebf8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_18e3f1d4-e5fd-4cd9-ae27-9dce4b6869f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fce817f3-5058-46c8-9311-bd1a4feb21bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_18e3f1d4-e5fd-4cd9-ae27-9dce4b6869f0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fce817f3-5058-46c8-9311-bd1a4feb21bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d55863d0-49b4-4817-a3f7-fa193d603b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fce817f3-5058-46c8-9311-bd1a4feb21bd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d55863d0-49b4-4817-a3f7-fa193d603b62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d55863d0-49b4-4817-a3f7-fa193d603b62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d55863d0-49b4-4817-a3f7-fa193d603b62" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d55863d0-49b4-4817-a3f7-fa193d603b62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa9a3cc7-828f-42fb-8e25-960614e44763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d55863d0-49b4-4817-a3f7-fa193d603b62" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa9a3cc7-828f-42fb-8e25-960614e44763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_61edc6de-0c94-4abc-8edd-40f356b79a11" xlink:href="nbix-20231231.xsd#nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa9a3cc7-828f-42fb-8e25-960614e44763" xlink:to="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_61edc6de-0c94-4abc-8edd-40f356b79a11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8c7fc8c3-0eae-4987-beaa-5b61feb5843c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_18e3f1d4-e5fd-4cd9-ae27-9dce4b6869f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8c7fc8c3-0eae-4987-beaa-5b61feb5843c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdcb73e-2b1b-4822-8723-6387958eb086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdcb73e-2b1b-4822-8723-6387958eb086" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_005d086c-e0e8-4c09-a1d1-f1f34f79dae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdcb73e-2b1b-4822-8723-6387958eb086" xlink:to="loc_us-gaap_PlanNameAxis_005d086c-e0e8-4c09-a1d1-f1f34f79dae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_005d086c-e0e8-4c09-a1d1-f1f34f79dae7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_005d086c-e0e8-4c09-a1d1-f1f34f79dae7" xlink:to="loc_us-gaap_PlanNameDomain_005d086c-e0e8-4c09-a1d1-f1f34f79dae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a0dd43c8-a7a2-4ff6-9575-5ba967d758ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_005d086c-e0e8-4c09-a1d1-f1f34f79dae7" xlink:to="loc_us-gaap_PlanNameDomain_a0dd43c8-a7a2-4ff6-9575-5ba967d758ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_Amended2020EquityIncentivePlanMember_07427fd0-4416-459f-aa50-5789f4fde7dd" xlink:href="nbix-20231231.xsd#nbix_Amended2020EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a0dd43c8-a7a2-4ff6-9575-5ba967d758ed" xlink:to="loc_nbix_Amended2020EquityIncentivePlanMember_07427fd0-4416-459f-aa50-5789f4fde7dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TwoThousandAndElevenEquityIncentivePlanMember_c61c0340-ac25-488c-b2cc-554574cf382e" xlink:href="nbix-20231231.xsd#nbix_TwoThousandAndElevenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a0dd43c8-a7a2-4ff6-9575-5ba967d758ed" xlink:to="loc_nbix_TwoThousandAndElevenEquityIncentivePlanMember_c61c0340-ac25-488c-b2cc-554574cf382e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_Amended2018EmployeeStockPurchasePlanMember_69183a90-1cb2-4b09-b760-15ab5f6b1c40" xlink:href="nbix-20231231.xsd#nbix_Amended2018EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a0dd43c8-a7a2-4ff6-9575-5ba967d758ed" xlink:to="loc_nbix_Amended2018EmployeeStockPurchasePlanMember_69183a90-1cb2-4b09-b760-15ab5f6b1c40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_da52123a-0b23-427e-892e-d8466d9a314b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdcb73e-2b1b-4822-8723-6387958eb086" xlink:to="loc_us-gaap_AwardTypeAxis_da52123a-0b23-427e-892e-d8466d9a314b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da52123a-0b23-427e-892e-d8466d9a314b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_da52123a-0b23-427e-892e-d8466d9a314b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da52123a-0b23-427e-892e-d8466d9a314b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94fa65e2-f2c1-4c76-87e8-5835c013e4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_da52123a-0b23-427e-892e-d8466d9a314b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94fa65e2-f2c1-4c76-87e8-5835c013e4a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7a872726-26df-4299-9900-d2697d647fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94fa65e2-f2c1-4c76-87e8-5835c013e4a7" xlink:to="loc_us-gaap_EmployeeStockMember_7a872726-26df-4299-9900-d2697d647fbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b974820f-c76f-4edd-8e23-454a7d88b2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94fa65e2-f2c1-4c76-87e8-5835c013e4a7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b974820f-c76f-4edd-8e23-454a7d88b2a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_74fda9a4-942c-4fb2-9839-483208a479e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94fa65e2-f2c1-4c76-87e8-5835c013e4a7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_74fda9a4-942c-4fb2-9839-483208a479e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_093bb4e3-9030-4446-bfc2-26d8f6eee0b8" xlink:href="nbix-20231231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94fa65e2-f2c1-4c76-87e8-5835c013e4a7" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_093bb4e3-9030-4446-bfc2-26d8f6eee0b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dbfdfda4-621a-4bee-bd11-ea978875d2ab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdcb73e-2b1b-4822-8723-6387958eb086" xlink:to="loc_srt_RangeAxis_dbfdfda4-621a-4bee-bd11-ea978875d2ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dbfdfda4-621a-4bee-bd11-ea978875d2ab_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dbfdfda4-621a-4bee-bd11-ea978875d2ab" xlink:to="loc_srt_RangeMember_dbfdfda4-621a-4bee-bd11-ea978875d2ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a859426-886b-481d-bf55-c5ffec51fdb2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dbfdfda4-621a-4bee-bd11-ea978875d2ab" xlink:to="loc_srt_RangeMember_2a859426-886b-481d-bf55-c5ffec51fdb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_80f7f2d8-70c1-460f-a3d9-21d484603c02" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2a859426-886b-481d-bf55-c5ffec51fdb2" xlink:to="loc_srt_MinimumMember_80f7f2d8-70c1-460f-a3d9-21d484603c02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_086ca74f-3e43-4503-8f86-a3fd1ec66aa8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2a859426-886b-481d-bf55-c5ffec51fdb2" xlink:to="loc_srt_MaximumMember_086ca74f-3e43-4503-8f86-a3fd1ec66aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b7089b2c-ea48-4e98-b578-41aa888ce1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b7089b2c-ea48-4e98-b578-41aa888ce1d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_8b921408-e307-4c70-b02d-69d255c90065" xlink:href="nbix-20231231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_8b921408-e307-4c70-b02d-69d255c90065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_7e29a883-ca7e-4b53-b7c8-285b15198a38" xlink:href="nbix-20231231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_7e29a883-ca7e-4b53-b7c8-285b15198a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_c072b7da-0248-4e65-9b99-217ff160fa59" xlink:href="nbix-20231231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_c072b7da-0248-4e65-9b99-217ff160fa59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_52dd51f1-e9da-4e7f-8a15-a12e804ff799" xlink:href="nbix-20231231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_52dd51f1-e9da-4e7f-8a15-a12e804ff799" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_398abc81-f1fd-425a-9e4a-97704f978361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_398abc81-f1fd-425a-9e4a-97704f978361" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5e5759b1-f994-44d0-af88-93f6ec7a948a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5e5759b1-f994-44d0-af88-93f6ec7a948a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_57b3f3cf-5c75-4691-a4a9-70808bacc140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_57b3f3cf-5c75-4691-a4a9-70808bacc140" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cded89df-4ab1-4254-afef-c8812ca2c3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cded89df-4ab1-4254-afef-c8812ca2c3ef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03aa832b-60ac-4e7b-97a2-0d0b1c547e74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03aa832b-60ac-4e7b-97a2-0d0b1c547e74" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f287bd22-3f61-4203-b0b4-34792da93c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f287bd22-3f61-4203-b0b4-34792da93c79" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_28a2a607-4948-49cd-b8df-d25c8db3f7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_28a2a607-4948-49cd-b8df-d25c8db3f7c1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_14b00507-6dcb-4b82-9870-9150056ad8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_14b00507-6dcb-4b82-9870-9150056ad8e3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_80dea01b-1c67-459f-9a2a-79948756d8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_80dea01b-1c67-459f-9a2a-79948756d8f3" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_219c8037-5ebf-488a-b5e6-8c5d5717399b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c2e9b6eb-9d87-46b4-8bca-268daf44937d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_219c8037-5ebf-488a-b5e6-8c5d5717399b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c2e9b6eb-9d87-46b4-8bca-268daf44937d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_230e7c3b-8b8a-4ab2-9df8-4f1531f136ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c2e9b6eb-9d87-46b4-8bca-268daf44937d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_230e7c3b-8b8a-4ab2-9df8-4f1531f136ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_230e7c3b-8b8a-4ab2-9df8-4f1531f136ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_230e7c3b-8b8a-4ab2-9df8-4f1531f136ea" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_230e7c3b-8b8a-4ab2-9df8-4f1531f136ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_07cdb56b-9af2-4ba3-9d17-42576f761d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_230e7c3b-8b8a-4ab2-9df8-4f1531f136ea" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_07cdb56b-9af2-4ba3-9d17-42576f761d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8b74d972-e206-424a-b916-89ec74fad792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07cdb56b-9af2-4ba3-9d17-42576f761d82" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8b74d972-e206-424a-b916-89ec74fad792" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_71254528-788d-4629-a3c4-ffb10e9658fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07cdb56b-9af2-4ba3-9d17-42576f761d82" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_71254528-788d-4629-a3c4-ffb10e9658fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f14f531c-f3ed-4972-adfb-765c33b960a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_219c8037-5ebf-488a-b5e6-8c5d5717399b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f14f531c-f3ed-4972-adfb-765c33b960a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1a461bd1-6283-49fd-83ae-486e4cfb7512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837246fb-e598-4d19-873b-94710327cc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1a461bd1-6283-49fd-83ae-486e4cfb7512" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837246fb-e598-4d19-873b-94710327cc0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2b01947b-fc9d-452b-b38a-5382e6747c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837246fb-e598-4d19-873b-94710327cc0e" xlink:to="loc_us-gaap_AwardTypeAxis_2b01947b-fc9d-452b-b38a-5382e6747c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b01947b-fc9d-452b-b38a-5382e6747c4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2b01947b-fc9d-452b-b38a-5382e6747c4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b01947b-fc9d-452b-b38a-5382e6747c4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a58c6afb-2d69-41a5-8f8a-5d4e3769e6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2b01947b-fc9d-452b-b38a-5382e6747c4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a58c6afb-2d69-41a5-8f8a-5d4e3769e6dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ccf95b76-de13-49fa-aec6-d77b4655799e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a58c6afb-2d69-41a5-8f8a-5d4e3769e6dc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ccf95b76-de13-49fa-aec6-d77b4655799e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f48e6c83-e9a8-404c-9a8e-3ce0e867f53b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a58c6afb-2d69-41a5-8f8a-5d4e3769e6dc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f48e6c83-e9a8-404c-9a8e-3ce0e867f53b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_86996379-9670-4dea-ad5e-3989b3a229ba" xlink:href="nbix-20231231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a58c6afb-2d69-41a5-8f8a-5d4e3769e6dc" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_86996379-9670-4dea-ad5e-3989b3a229ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_06e60d04-e88a-42d7-bc3a-059d261622e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a58c6afb-2d69-41a5-8f8a-5d4e3769e6dc" xlink:to="loc_us-gaap_EmployeeStockMember_06e60d04-e88a-42d7-bc3a-059d261622e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a6ec44bb-0bcd-4a1c-bd6d-d115d67daad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1a461bd1-6283-49fd-83ae-486e4cfb7512" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a6ec44bb-0bcd-4a1c-bd6d-d115d67daad0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9bd7e15b-0bc7-4ea2-9d54-3710413ca6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a41afc9a-c508-40a8-99aa-34d0cd77f790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9bd7e15b-0bc7-4ea2-9d54-3710413ca6dc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a41afc9a-c508-40a8-99aa-34d0cd77f790" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d2c236d7-eec6-4c19-8c1b-3d0939f71f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a41afc9a-c508-40a8-99aa-34d0cd77f790" xlink:to="loc_us-gaap_AwardTypeAxis_d2c236d7-eec6-4c19-8c1b-3d0939f71f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2c236d7-eec6-4c19-8c1b-3d0939f71f87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d2c236d7-eec6-4c19-8c1b-3d0939f71f87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2c236d7-eec6-4c19-8c1b-3d0939f71f87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd56ee7a-fa60-4ca4-bb43-cbe9b37507fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d2c236d7-eec6-4c19-8c1b-3d0939f71f87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd56ee7a-fa60-4ca4-bb43-cbe9b37507fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4392968c-e6e3-4d31-8aed-174226c40c44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd56ee7a-fa60-4ca4-bb43-cbe9b37507fb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4392968c-e6e3-4d31-8aed-174226c40c44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6d9991d2-8195-414a-81f6-14a47ec9b385" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd56ee7a-fa60-4ca4-bb43-cbe9b37507fb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6d9991d2-8195-414a-81f6-14a47ec9b385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_05519619-0f10-4323-87da-80a220eb0119" xlink:href="nbix-20231231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd56ee7a-fa60-4ca4-bb43-cbe9b37507fb" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_05519619-0f10-4323-87da-80a220eb0119" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e61dc0da-7a15-4017-a666-514498c05c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9bd7e15b-0bc7-4ea2-9d54-3710413ca6dc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e61dc0da-7a15-4017-a666-514498c05c92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c7d99835-d569-446a-8dc8-368f7e1bf559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9bd7e15b-0bc7-4ea2-9d54-3710413ca6dc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c7d99835-d569-446a-8dc8-368f7e1bf559" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cce782fe-2b52-4839-b010-938e594858ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ce95f69-daf4-43c6-97dd-ecf2ef039039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cce782fe-2b52-4839-b010-938e594858ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ce95f69-daf4-43c6-97dd-ecf2ef039039" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_336360ec-1e38-474f-b403-dc9f4fd5d55d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ce95f69-daf4-43c6-97dd-ecf2ef039039" xlink:to="loc_us-gaap_AwardTypeAxis_336360ec-1e38-474f-b403-dc9f4fd5d55d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_336360ec-1e38-474f-b403-dc9f4fd5d55d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_336360ec-1e38-474f-b403-dc9f4fd5d55d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_336360ec-1e38-474f-b403-dc9f4fd5d55d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339c369f-5a68-4400-a066-817c6857886c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_336360ec-1e38-474f-b403-dc9f4fd5d55d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339c369f-5a68-4400-a066-817c6857886c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_adfc8f54-3119-47a7-a3f4-d37b2e8b8281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339c369f-5a68-4400-a066-817c6857886c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_adfc8f54-3119-47a7-a3f4-d37b2e8b8281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_81a8b583-5307-417f-9ce6-5d8f3401bfef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cce782fe-2b52-4839-b010-938e594858ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_81a8b583-5307-417f-9ce6-5d8f3401bfef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_804170d9-b764-4ec3-bcdc-357469a23f93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cce782fe-2b52-4839-b010-938e594858ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_804170d9-b764-4ec3-bcdc-357469a23f93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6842e541-e46d-4749-87ac-4206ebae5092" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cce782fe-2b52-4839-b010-938e594858ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6842e541-e46d-4749-87ac-4206ebae5092" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_65a047b2-76c6-4ac8-82ad-d4868ff402cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cce782fe-2b52-4839-b010-938e594858ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_65a047b2-76c6-4ac8-82ad-d4868ff402cd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68412f0f-449a-4edb-ae4d-94c8956b47da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4688d840-494b-48d9-83b8-2f195c3798fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68412f0f-449a-4edb-ae4d-94c8956b47da" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4688d840-494b-48d9-83b8-2f195c3798fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_78b0c669-fca8-4c89-9ee9-950927e2f4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4688d840-494b-48d9-83b8-2f195c3798fc" xlink:to="loc_us-gaap_AwardTypeAxis_78b0c669-fca8-4c89-9ee9-950927e2f4e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78b0c669-fca8-4c89-9ee9-950927e2f4e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_78b0c669-fca8-4c89-9ee9-950927e2f4e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78b0c669-fca8-4c89-9ee9-950927e2f4e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7951edb-1fcf-4ebc-a317-da38e8953884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_78b0c669-fca8-4c89-9ee9-950927e2f4e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7951edb-1fcf-4ebc-a317-da38e8953884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7deeb5c6-2ae0-4118-9318-a9d8842248d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7951edb-1fcf-4ebc-a317-da38e8953884" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7deeb5c6-2ae0-4118-9318-a9d8842248d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_f2000d0b-0b74-4412-9c47-3814af616e99" xlink:href="nbix-20231231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7951edb-1fcf-4ebc-a317-da38e8953884" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_f2000d0b-0b74-4412-9c47-3814af616e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68412f0f-449a-4edb-ae4d-94c8956b47da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_317410f5-1fb5-456d-b289-ada6290137ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_317410f5-1fb5-456d-b289-ada6290137ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21f82125-422b-45e8-912f-41ff80af788b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21f82125-422b-45e8-912f-41ff80af788b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_024b694a-f1bc-4b23-9416-0701c4f9170b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_024b694a-f1bc-4b23-9416-0701c4f9170b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d519f219-f583-4ee3-a1f6-a66b5f4929d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d519f219-f583-4ee3-a1f6-a66b5f4929d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d2762317-0824-4bf5-bcd4-a1ce7ca7f8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68412f0f-449a-4edb-ae4d-94c8956b47da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e3069428-9aad-422b-b132-7e19069f7420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e3069428-9aad-422b-b132-7e19069f7420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_daa82137-c673-464e-b2e1-674c18675593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_daa82137-c673-464e-b2e1-674c18675593" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35c72edb-19be-496e-965c-35a42bea3cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35c72edb-19be-496e-965c-35a42bea3cc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02194346-7823-41eb-b9b4-90cb1a7cb5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02194346-7823-41eb-b9b4-90cb1a7cb5ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5af94038-2d45-4313-9499-127068eb4d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e20ac2a9-8e12-44fb-b8dc-0e86e899c924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68412f0f-449a-4edb-ae4d-94c8956b47da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e20ac2a9-8e12-44fb-b8dc-0e86e899c924" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c0e5a71d-1c1d-42f1-946f-754438a885c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e20ac2a9-8e12-44fb-b8dc-0e86e899c924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c0e5a71d-1c1d-42f1-946f-754438a885c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f82850dd-1e6c-4070-9e40-b7890eb4d548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e20ac2a9-8e12-44fb-b8dc-0e86e899c924" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f82850dd-1e6c-4070-9e40-b7890eb4d548" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesTable_3af2ae7e-495f-4bd7-81ba-0169cccff4be" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_nbix_IncomeTaxesTable_3af2ae7e-495f-4bd7-81ba-0169cccff4be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f4ee6596-d901-43e8-81f7-a49229eb62fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_IncomeTaxesTable_3af2ae7e-495f-4bd7-81ba-0169cccff4be" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f4ee6596-d901-43e8-81f7-a49229eb62fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f4ee6596-d901-43e8-81f7-a49229eb62fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f4ee6596-d901-43e8-81f7-a49229eb62fb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f4ee6596-d901-43e8-81f7-a49229eb62fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2bba3332-087c-4695-9376-0102c44b3feb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f4ee6596-d901-43e8-81f7-a49229eb62fb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2bba3332-087c-4695-9376-0102c44b3feb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_c77d483a-ba07-45a1-879f-b072786e23c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2bba3332-087c-4695-9376-0102c44b3feb" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_c77d483a-ba07-45a1-879f-b072786e23c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_4d7fa6fd-4287-4ea6-bc83-a6853fa127e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2bba3332-087c-4695-9376-0102c44b3feb" xlink:to="loc_us-gaap_ForeignCountryMember_4d7fa6fd-4287-4ea6-bc83-a6853fa127e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_e9df3cce-4542-4044-833b-eae232e6957a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2bba3332-087c-4695-9376-0102c44b3feb" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_e9df3cce-4542-4044-833b-eae232e6957a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c1f2859a-942c-4b60-85fb-9094dec4ec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c1f2859a-942c-4b60-85fb-9094dec4ec9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5b0f3a9e-77ec-4f1b-8873-3f81e0e1a185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5b0f3a9e-77ec-4f1b-8873-3f81e0e1a185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d5a1154b-c448-49ee-9dfd-7d408dc0eaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d5a1154b-c448-49ee-9dfd-7d408dc0eaf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c17d6875-8c16-48d6-b83c-16c192f4b9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c17d6875-8c16-48d6-b83c-16c192f4b9e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationInterestAccrued_6f2bfcf7-08d2-4690-a6e3-e541b9537c95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_IncomeTaxExaminationInterestAccrued_6f2bfcf7-08d2-4690-a6e3-e541b9537c95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued_4b4631a2-84da-4e39-a362-00d116d7cabe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued_4b4631a2-84da-4e39-a362-00d116d7cabe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95a6035e-4da0-4684-9850-98081b1057db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95a6035e-4da0-4684-9850-98081b1057db" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#LeasesSupplementalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a7ea6817-151c-410a-a470-a16fb803119c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a7ea6817-151c-410a-a470-a16fb803119c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c30fc153-ac54-40c2-9b10-b4f2eb52f22c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a7ea6817-151c-410a-a470-a16fb803119c" xlink:to="loc_us-gaap_CreditFacilityAxis_c30fc153-ac54-40c2-9b10-b4f2eb52f22c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c30fc153-ac54-40c2-9b10-b4f2eb52f22c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_c30fc153-ac54-40c2-9b10-b4f2eb52f22c" xlink:to="loc_us-gaap_CreditFacilityDomain_c30fc153-ac54-40c2-9b10-b4f2eb52f22c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_780f4af5-fdec-40c9-935f-119459f739c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_c30fc153-ac54-40c2-9b10-b4f2eb52f22c" xlink:to="loc_us-gaap_CreditFacilityDomain_780f4af5-fdec-40c9-935f-119459f739c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_33d4a3e2-3696-46a9-b46b-6475db1c036a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_780f4af5-fdec-40c9-935f-119459f739c0" xlink:to="loc_us-gaap_LetterOfCreditMember_33d4a3e2-3696-46a9-b46b-6475db1c036a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c7346dae-28a2-4477-9bce-51959ac9f1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_OperatingLeaseCost_c7346dae-28a2-4477-9bce-51959ac9f1b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_3655e1c5-38ef-424c-85c5-8035ca4c0823" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_SubleaseIncome_3655e1c5-38ef-424c-85c5-8035ca4c0823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OperatingLeaseCostNet_331ca52c-cd7d-4ea8-b362-ced4643bdf72" xlink:href="nbix-20231231.xsd#nbix_OperatingLeaseCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_nbix_OperatingLeaseCostNet_331ca52c-cd7d-4ea8-b362-ced4643bdf72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a91baec9-acbb-453a-a955-a881b08ca51f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_OperatingLeasePayments_a91baec9-acbb-453a-a955-a881b08ca51f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7c20053c-69f7-4339-b9b3-0644ee74d277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7c20053c-69f7-4339-b9b3-0644ee74d277" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f9f4f6bc-e74f-4457-877f-ccec9a4970fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f9f4f6bc-e74f-4457-877f-ccec9a4970fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bd259cfa-572e-4954-bc88-8031c19a463e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_RestrictedCash_bd259cfa-572e-4954-bc88-8031c19a463e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#LeasesNarrativeInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f5a0f51a-3532-40b2-8c1b-71fd59a14525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6ea03738-355a-4aac-81c5-2b453a2a8ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f5a0f51a-3532-40b2-8c1b-71fd59a14525" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6ea03738-355a-4aac-81c5-2b453a2a8ebc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae8fc868-fb6d-4701-9829-5e5749c9d8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6ea03738-355a-4aac-81c5-2b453a2a8ebc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae8fc868-fb6d-4701-9829-5e5749c9d8ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae8fc868-fb6d-4701-9829-5e5749c9d8ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae8fc868-fb6d-4701-9829-5e5749c9d8ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae8fc868-fb6d-4701-9829-5e5749c9d8ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e81f7cfc-f75e-482c-93be-f48125f90869" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae8fc868-fb6d-4701-9829-5e5749c9d8ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e81f7cfc-f75e-482c-93be-f48125f90869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_bcf5d383-78bc-4ffa-9676-194ef1991b65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e81f7cfc-f75e-482c-93be-f48125f90869" xlink:to="loc_us-gaap_BuildingMember_bcf5d383-78bc-4ffa-9676-194ef1991b65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding_5b989cdf-0da7-47c9-afde-5a06b6f0593c" xlink:href="nbix-20231231.xsd#nbix_LesseeOperatingLeaseOptionTermToConstructBuilding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f5a0f51a-3532-40b2-8c1b-71fd59a14525" xlink:to="loc_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding_5b989cdf-0da7-47c9-afde-5a06b6f0593c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ef0b3d0a-1001-440a-af9f-1f4e245a0b89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f5a0f51a-3532-40b2-8c1b-71fd59a14525" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ef0b3d0a-1001-440a-af9f-1f4e245a0b89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4e7dd397-9199-4520-9f19-0123c657e65f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f5a0f51a-3532-40b2-8c1b-71fd59a14525" xlink:to="loc_us-gaap_OperatingLeaseLiability_4e7dd397-9199-4520-9f19-0123c657e65f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TradingArrangmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EricBenevich2023PlanMember_33c5d85d-cdd1-4147-81ab-1a0e6558a2ee" xlink:href="nbix-20231231.xsd#nbix_EricBenevich2023PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_nbix_EricBenevich2023PlanMember_33c5d85d-cdd1-4147-81ab-1a0e6558a2ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EricBenevich2024PlanMember_7efdc56e-a7c2-465a-9fdf-73b481c66527" xlink:href="nbix-20231231.xsd#nbix_EricBenevich2024PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_nbix_EricBenevich2024PlanMember_7efdc56e-a7c2-465a-9fdf-73b481c66527" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_50bd9123-d5f5-49a2-b2b9-265b592577a6" xlink:href="nbix-20231231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_50bd9123-d5f5-49a2-b2b9-265b592577a6" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_GeorgeMorrowMember_26d12d83-bd9b-4821-bd95-4fee6fda9579" xlink:href="nbix-20231231.xsd#nbix_GeorgeMorrowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nbix_GeorgeMorrowMember_26d12d83-bd9b-4821-bd95-4fee6fda9579" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EricBenevichMember_535ee5ac-c93d-400e-925b-b7755788860c" xlink:href="nbix-20231231.xsd#nbix_EricBenevichMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nbix_EricBenevichMember_535ee5ac-c93d-400e-925b-b7755788860c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IngridDelaetMember_9c3e4726-da35-4fbc-82e8-516df1d5eede" xlink:href="nbix-20231231.xsd#nbix_IngridDelaetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nbix_IngridDelaetMember_9c3e4726-da35-4fbc-82e8-516df1d5eede" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LeslieNorwalkMember_7f9c1603-2f04-409d-a22a-62cd921d3862" xlink:href="nbix-20231231.xsd#nbix_LeslieNorwalkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nbix_LeslieNorwalkMember_7f9c1603-2f04-409d-a22a-62cd921d3862" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShaliniSharpMember_0eaae9e4-ffde-4d61-a6bc-b6328c1b8cbf" xlink:href="nbix-20231231.xsd#nbix_ShaliniSharpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nbix_ShaliniSharpMember_0eaae9e4-ffde-4d61-a6bc-b6328c1b8cbf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RichardPopsMember_817c925e-cac8-4fbf-ae79-f48043a76a29" xlink:href="nbix-20231231.xsd#nbix_RichardPopsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nbix_RichardPopsMember_817c925e-cac8-4fbf-ae79-f48043a76a29" xlink:type="arc" order="7"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>nbix-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a3353234-f254-4413-b1f0-e8e01a8cce8f,g:81591885-31e3-4e25-a8db-e5a73f7fd8a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_6b599574-484f-4f31-b519-c46ca8e0abb7_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_label_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConversionDomain" xlink:to="lab_nbix_DebtInstrumentConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_99e0e2ee-bc7f-483e-aeff-0e1043ca587d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_a56590ec-1b2e-4171-94f4-5d594ef9f55d_terseLabel_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_label_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_documentation_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of reconciliation of cash cash equivalents and restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:href="nbix-20231231.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_0996616d-845c-464e-9c0a-2bbbf6b2e423_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6b3a24bb-eded-48a0-8767-f7aa4c8479bc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_6738f7e4-23fe-4a2c-93c4-a367e1799519_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_6830c74a-5718-4506-9611-600e21a12b98_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less inventory reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_c09b2b1f-f1ba-42c2-a2d2-6d470fcd607a_terseLabel_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reduced pursuant to any full value award granted (in shares)</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_label_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Award Granted</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_documentation_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Award Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" xlink:href="nbix-20231231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" xlink:to="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9b28751e-0e53-42b1-8008-d3269a3fd44e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfNonClinicalStageCompound_0889e3d1-d3a5-4add-8e6a-ae0516bc836d_terseLabel_en-US" xlink:label="lab_nbix_NumberOfNonClinicalStageCompound" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of non-clinical stage compounds</link:label>
    <link:label id="lab_nbix_NumberOfNonClinicalStageCompound_label_en-US" xlink:label="lab_nbix_NumberOfNonClinicalStageCompound" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Non-clinical Stage Compound</link:label>
    <link:label id="lab_nbix_NumberOfNonClinicalStageCompound_documentation_en-US" xlink:label="lab_nbix_NumberOfNonClinicalStageCompound" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Non-clinical Stage Compound</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfNonClinicalStageCompound" xlink:href="nbix-20231231.xsd#nbix_NumberOfNonClinicalStageCompound"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfNonClinicalStageCompound" xlink:to="lab_nbix_NumberOfNonClinicalStageCompound" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3d4c008d-d497-4764-9a74-2b07398d78ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_79017637-5623-4ac3-98d9-582a7c9ec7f5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term of stock options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_83aa6da3-5860-4715-8f48-8a456db25a79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_351a4721-b5fb-4bba-92bb-3a480a73dee8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour_abc2315b-74e8-44a1-a4ac-fd7c06fa9688_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for thereafter</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, After Year Four</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour" xlink:href="nbix-20231231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_bb9693c5-851f-429c-95b6-acf658a8abb8_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_6db85bc0-008f-4245-aa9a-7151c5856d49_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b8397d0e-a8ad-47c0-b3e2-560796713ce1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Unvested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8e83217c-210c-4003-b396-f3a13923f83c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Unvested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a2180296-bdef-4f0d-9075-4d6033869a24_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_197d262e-44b3-4008-aaa6-71880c2f577f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_601718a4-d991-498b-bf23-37f6cf367a41_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development, or R&amp;D</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_9d2d1d03-cc20-4c55-b09a-634fa15c75b0_terseLabel_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of common stock price trigger</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_label_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percentage Of Trading Price To Last Reported Sale Price</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_documentation_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:href="nbix-20231231.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:to="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8d7e8291-ce17-49ec-aecb-0c5e56f0eb55_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_d9723ed1-2521-44da-bd6c-c4deae99c34b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d5119e89-c478-4013-80f0-ffefb616d59d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_UpfrontPaymentsMade_508e2a3b-a25f-4421-ab0e-6212cb89ca52_terseLabel_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments made</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsMade_label_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments Made</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsMade_documentation_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments made under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade" xlink:href="nbix-20231231.xsd#nbix_UpfrontPaymentsMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_UpfrontPaymentsMade" xlink:to="lab_nbix_UpfrontPaymentsMade" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued_14e0b480-25ee-4be6-8453-abe8e75c7401_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalties accrued</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_6e7c419d-0e4d-403e-b59c-33bc1f254a56_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AgreementTerminationContractualTimeThreshold_9ce5f1d9-1a49-4450-9b25-60fab04e0ad9_terseLabel_en-US" xlink:label="lab_nbix_AgreementTerminationContractualTimeThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination, contractual time threshold (in days)</link:label>
    <link:label id="lab_nbix_AgreementTerminationContractualTimeThreshold_label_en-US" xlink:label="lab_nbix_AgreementTerminationContractualTimeThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Contractual Time Threshold</link:label>
    <link:label id="lab_nbix_AgreementTerminationContractualTimeThreshold_documentation_en-US" xlink:label="lab_nbix_AgreementTerminationContractualTimeThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Contractual Time Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationContractualTimeThreshold" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationContractualTimeThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AgreementTerminationContractualTimeThreshold" xlink:to="lab_nbix_AgreementTerminationContractualTimeThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efed2de9-43a8-4893-aab2-a10abf1e7c68_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_e45c8e53-84a7-4f66-9d57-faeb4caa0e0c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_05849a3b-3dfb-4774-af7d-27b2402b0a7a_terseLabel_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other, net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_label_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income And Other Net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_documentation_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet" xlink:href="nbix-20231231.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_InvestmentIncomeAndOtherNet" xlink:to="lab_nbix_InvestmentIncomeAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5d1606f6-a0b3-47d0-846f-982d38793ca6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4b3d7e22-80e5-4d0f-995c-6dd6e37bb6d8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income taxes, rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5837d9d5-1eb2-4cf9-96e0-53681a61cc15_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f5eac29d-78c5-4bb3-ac57-fbb11bc61143_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_ed71b6e8-26cc-449d-a906-210962c819b0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under benefit plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_f6737bb4-427b-4297-a9fd-93bbe7b81d84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_4fe7f2da-a84f-4cec-a192-30fb57015bc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b0f3082b-301e-4ef8-a07d-9bbcb84119b8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c173c36d-b649-4142-b451-3b9a46c0b4e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_72c13a7c-ea0f-4278-aaf7-e2070249ab60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_d7694b29-a785-4455-b3d0-7627855c382f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_44968b54-fe5c-4b56-bb97-6ba552cd80ad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_8ef82a41-4bdd-4c57-8be8-8cfef767ab9a_negatedTerseLabel_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss, current</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_label_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_documentation_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_b32686d7-1075-42d1-bd27-6dccbb89b46f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c6a2465d-6636-420f-857a-1e28d9233c36_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_9f0cd858-a5fc-4e30-bdc4-6c644a3758a0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ef6fa58b-ceef-4fae-b0d9-3e6ed8b319a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_cefa1b73-50b6-49a5-a146-fac2ab12dfc1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_38f20521-453a-4ac1-8cb1-f8663db57ea0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_a335d616-65dd-4b92-ad17-a8912041ec61_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_290942ce-512f-4e37-9fd0-4eb1cc127388_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29db8f93-d7f9-4616-9ae2-7cce0540ed38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_58ccb1f3-bef0-4073-9dfa-a01ecf95ec11_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_998bb117-baf6-47c4-b809-05d77479394c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d0b62cd-3d69-496c-ade9-430717cd50a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_9ddb4329-f7bc-4b44-ac49-d5ff088598de_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_3bdc1835-d566-406d-ae3f-8124e9d2f89f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_67a2a556-531c-4d25-a81b-dcbd540bb43c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_d071cce5-2f12-4888-a15c-eb32fd9011d3_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_41806a85-c1b4-4bb6-a3f5-7a7cb447de02_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dc295a58-c260-4455-aefa-c29fcd573e53_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b9d98380-3031-4660-b3eb-731c4ed7c424_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c387567b-e0f7-4dac-9e05-8797eadc3df2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_294ae2f1-949b-41be-96eb-36bb38c94ea0_terseLabel_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and money market funds</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_label_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Money Market Fund [Member]</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_documentation_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember" xlink:href="nbix-20231231.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CashAndMoneyMarketFundMember" xlink:to="lab_nbix_CashAndMoneyMarketFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8cc35ed1-23e1-4f97-8c70-2d938edfdf44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_984b1dce-36f4-4e7e-b33d-a95ab53715fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair values of stock options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec1d2318-44ce-405e-abc1-f2c39ae171fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a2b6ce9f-5735-40bc-8824-523ad15f6533_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ee81d52a-8a41-4f20-b178-0826288d78bc_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a181b1b2-4e33-43b5-80b5-258b661051f1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_3ca1ac91-b547-4617-888c-0827e41acf61_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6246d975-ea6c-49da-a278-5e91d3c78041_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9e2b1dd7-0e70-46d4-86b2-1da536ad80d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5b6b17bc-2295-4212-aecc-92a8bfc20a97_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AgreementTerminationMinimalContractualTime_942f2030-0c38-41e0-8253-af1a9f8a4039_terseLabel_en-US" xlink:label="lab_nbix_AgreementTerminationMinimalContractualTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination, minimal contractual time (in days)</link:label>
    <link:label id="lab_nbix_AgreementTerminationMinimalContractualTime_label_en-US" xlink:label="lab_nbix_AgreementTerminationMinimalContractualTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Minimal Contractual Time</link:label>
    <link:label id="lab_nbix_AgreementTerminationMinimalContractualTime_documentation_en-US" xlink:label="lab_nbix_AgreementTerminationMinimalContractualTime" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Minimal Contractual Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationMinimalContractualTime" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationMinimalContractualTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AgreementTerminationMinimalContractualTime" xlink:to="lab_nbix_AgreementTerminationMinimalContractualTime" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01bd5c54-089d-4d38-891a-5c53b024ca5c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_4ca53caa-35f6-42c3-b1d5-e2810560eab1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_91a59ca8-e7c8-4341-9e72-f939fb511ddb_terseLabel_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_label_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount On Conversion Rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_documentation_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate" xlink:href="nbix-20231231.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PrincipalAmountOnConversionRate" xlink:to="lab_nbix_PrincipalAmountOnConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d85c7d2c-e870-44d3-9d28-761025db011d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_13765ce7-6fbb-4200-8295-39740e93ec4d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments (sublease income)</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_55947b06-c04b-4b31-984e-32cbe7b578b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_bf76e9ea-8cd6-44d4-a97f-3f9d979aab41_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_6b2f93b7-c5d2-4015-9f43-ed3d3625afb5_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, current</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_15f8ab98-1ac0-48eb-a181-5109c3c2f8ec_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0281e31f-da56-4299-a690-da123022d3f7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6be2851f-3120-42d2-b9e0-9a40be17f06e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_00401aa5-95b6-42e1-8b0f-1865788070ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_57e981a3-8bfa-4193-965e-3ada2ea0dcbd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_6183ee90-91e7-45ec-af8b-33ab3decda4e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity Related to Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_RichardPopsMember_label_en-US" xlink:label="lab_nbix_RichardPopsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richard Pops [Member]</link:label>
    <link:label id="lab_nbix_RichardPopsMember_documentation_en-US" xlink:label="lab_nbix_RichardPopsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richard Pops</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RichardPopsMember" xlink:href="nbix-20231231.xsd#nbix_RichardPopsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_RichardPopsMember" xlink:to="lab_nbix_RichardPopsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_510eeca4-eff0-44d9-909f-913a8d5dbeec_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_9362c78f-697e-41e8-b0b1-23eeb409ae9b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_d89b67d7-fc67-4ba4-8f7c-f868d90063c4_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, gross</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f9453251-5ce2-4f9c-aab6-f75f6f41c2b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_83a7846c-a26a-40e4-9f72-9cea7044988b_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_a47a0777-18a9-4b49-bc04-20a7a66f5f47_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_9298e64a-8aae-4cc4-8cd3-1c7d87e8d754_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Tax Authority</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc7a58ef-736c-412c-8cb0-d391bb3db2ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_f929f328-45ec-4698-98b5-1f783f2cb5b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Information Relating to our Recognized Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_b0600ca2-bc7c-4bdc-ac1e-d3c2feba0d14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2027</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09f95379-bcc5-44b0-bc3e-3cd9e142210f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_OtherBalanceSheetDetailsAbstract_1ce4105e-c063-4135-a933-54a72789accc_terseLabel_en-US" xlink:label="lab_nbix_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:label id="lab_nbix_OtherBalanceSheetDetailsAbstract_label_en-US" xlink:label="lab_nbix_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:label id="lab_nbix_OtherBalanceSheetDetailsAbstract_documentation_en-US" xlink:label="lab_nbix_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other balance sheet details.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract" xlink:href="nbix-20231231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract" xlink:to="lab_nbix_OtherBalanceSheetDetailsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5fd26971-1e8e-4c0b-8b52-2c3162ae660b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_cc4851e1-aa89-4d7b-bbba-90bedebcc040_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_d80dfbeb-1aab-4c44-b205-7b40be794eec_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4c7da071-1260-4685-a7e4-80b8cc877fe0_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, at beginning period</link:label>
    <link:label id="lab_us-gaap_Goodwill_cb636d97-9277-4ba7-b938-7675cf2686fe_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, at ending period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_85ab4f54-e4eb-402e-bf2d-3dc517784d31_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ca1a33e8-5465-4b57-8c6d-cd6342091904_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5cb06159-9e44-478a-89b5-852450264d61_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39f2a928-b482-4325-be72-5b8ad6ae34fe_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_5b979574-e8fa-4dab-a32e-454e4db8285c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_227b7565-f7c0-4d9c-920f-e92d5f8cb9b5_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_73152f17-0015-430b-b1d8-d6a485a3b063_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_9ed00c9a-2052-462e-bad6-ec7afe27427a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4be82e72-a3cc-4813-87ce-cb51ea9bbd40_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6b530de4-994e-4f61-814b-dad867a3b813_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c6a975fa-990d-49c3-bd3b-a9128433c140_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_13075a55-ab80-43a6-a431-c7cf3b8cb471_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8f7af041-52c3-4a23-a273-99816c8de383_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_bd663a00-8e3b-4aeb-a61a-b16b230de831_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent_1cc9399a-2173-4db2-a52c-2a8f54d15e9d_terseLabel_en-US" xlink:label="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued development costs</link:label>
    <link:label id="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense Current</link:label>
    <link:label id="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="nbix-20231231.xsd#nbix_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_76eb6b2d-ad2b-4a48-9a92-a7f2043ade30_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables write-off threshold period</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, Threshold Period, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_80b06efb-ae8a-4054-8c2a-cdeac6aa627a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_81278b31-8a41-46d5-8a70-f33e96fd0bd4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9cc977cd-4228-48bf-8b8e-014aeaaf7f49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b460b47a-10f3-47bf-9121-ebfbe5e64320_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ae5be351-82d3-44fe-97b2-fbd246cfa3bc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesOperatingAbstract_1012c814-27f3-4dfb-a3fc-67dd03a3adfd_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesOperatingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LeasesOperatingAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesOperatingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Operating [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOperatingAbstract" xlink:to="lab_us-gaap_LeasesOperatingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_888c2309-f413-471e-aa92-bc57961bc3fa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_709b0646-abfa-44fb-acea-2a4bca1d17b4_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_984dbcb1-f711-4aaf-a301-8badd2a5b220_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_79c21f30-062b-4160-9534-7660490d1915_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f3154aa6-675f-4a62-aade-47a24211a477_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_992641c4-0cb8-4e85-a92a-e1f69c8ef6af_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_23d0e94c-a016-490d-8e09-62bcebf686d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notes Net of Discount and Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db032ff8-cb86-4879-97d2-2ed79ecc7df7_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c017af5e-25f1-40fb-a72f-4c0aced1eae2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MilestonePayment_a99c1226-86db-48fa-aa41-9c3e12db1e01_terseLabel_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_label_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_documentation_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made for milestones under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment" xlink:href="nbix-20231231.xsd#nbix_MilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MilestonePayment" xlink:to="lab_nbix_MilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c984aa84-21fa-4191-8fe5-808081e06d22_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liability Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4043376e-e042-4eba-8002-4b70981057d5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_362b426f-6546-4575-b125-db7b7748cbda_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_e5f52732-780d-4081-995b-a87b47e94a09_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenues</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_EricBenevich2024PlanMember_label_en-US" xlink:label="lab_nbix_EricBenevich2024PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eric Benevich 2024 Plan [Member]</link:label>
    <link:label id="lab_nbix_EricBenevich2024PlanMember_documentation_en-US" xlink:label="lab_nbix_EricBenevich2024PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eric Benevich 2024 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EricBenevich2024PlanMember" xlink:href="nbix-20231231.xsd#nbix_EricBenevich2024PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_EricBenevich2024PlanMember" xlink:to="lab_nbix_EricBenevich2024PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f7124db2-edfa-461f-82c9-cabc1622154a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_210bd4db-3549-4f0c-a690-2605bbc52aa1_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_5ca50672-c17e-4575-abeb-38da02eca330_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Description of Operating Lease</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_fc01b6f3-0f17-424d-b868-4a4df63a75b6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_94d1d5d6-c341-4f55-b943-14aa88e3f533_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe897b64-662e-4f9b-b082-0abf30141776_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PatentTerm_8860e67d-7beb-4d08-8ac8-66b7f5f2d1ef_terseLabel_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent term (in years)</link:label>
    <link:label id="lab_nbix_PatentTerm_label_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent term</link:label>
    <link:label id="lab_nbix_PatentTerm_documentation_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm" xlink:href="nbix-20231231.xsd#nbix_PatentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PatentTerm" xlink:to="lab_nbix_PatentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6e60d948-33cd-4974-8a7b-6079e00c770e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_661a55f9-cf26-49e0-89f6-cdac7c91b275_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares excluded from diluted per share amounts (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dd372edb-f61d-43af-9200-627b3df29785_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b822cccf-a426-4628-8f23-8d648e705c60_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_25a6008f-75ec-4f53-b97c-269511a03526_negatedTerseLabel_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_label_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Operating Leases Liabilities</link:label>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_documentation_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities operating leases liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:to="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d8b44ee5-b3dc-4656-899d-16283bd51c2b_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a2a394e9-2465-42d1-b55c-28cf5aaa4bc1_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_f93dc85d-4c10-4c98-b985-69f0729d99dc_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Total</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_01130510-9fbf-4e0b-be84-2164b1e2fb0f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_075f5a96-d3c3-41f0-b444-fb731a1e0e1e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f15f4afa-71ea-42e5-96b3-55984ad1916b_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4e0d2272-44d6-4561-829e-5a4ea99378dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_0d1094aa-fb30-4eb4-aa3a-c5093f80f60e_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67031001-0a0c-4eed-9937-b6ac648b2838_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4ca6f956-849d-4451-968a-624b1d696e0f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_1ddfca73-83dc-46b2-87f2-4840856f9983_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_72a16e3b-ac37-4260-a3ba-50c111168545_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c5ae79ee-5ccd-4b77-9aa3-f40f846ca80e_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accreted interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_90ac6bce-7712-49eb-9798-3a7257a6b339_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9461126d-52a3-4c22-9df8-02310e187b38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the Provision for Income Tax Expense (Benefit) for Continuing Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding_2f52d4bf-4b6f-45fb-b3ab-7e09ef1c7a50_terseLabel_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee option term for construction of fifth building</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding_label_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option Term To Construct Building</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding_documentation_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of term of lessee's option for the construction of a fifth building under operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding" xlink:href="nbix-20231231.xsd#nbix_LesseeOperatingLeaseOptionTermToConstructBuilding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding" xlink:to="lab_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_04828e3e-b6ac-49a8-8b02-5812c8fdb092_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e6a78b93-722e-4e90-96ba-495b08cfed57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5ffd1f1b-f5d9-4e18-b902-478a501332eb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current operating lease liabilities included in other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a2b9633c-bff6-4515-884d-34b928f84018_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3ada2f94-1700-40b0-aa76-9fe565009bfe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary and Changes in Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_5a929ffd-8a37-47e7-86fa-9c74ca22428f_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AccruedBrandedPrescriptionDrugFee_a089d409-6128-4f39-b011-3b146d5a3208_terseLabel_en-US" xlink:label="lab_nbix_AccruedBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current branded prescription drug fee</link:label>
    <link:label id="lab_nbix_AccruedBrandedPrescriptionDrugFee_label_en-US" xlink:label="lab_nbix_AccruedBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Branded Prescription Drug Fee</link:label>
    <link:label id="lab_nbix_AccruedBrandedPrescriptionDrugFee_documentation_en-US" xlink:label="lab_nbix_AccruedBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Branded Prescription Drug Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedBrandedPrescriptionDrugFee" xlink:href="nbix-20231231.xsd#nbix_AccruedBrandedPrescriptionDrugFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AccruedBrandedPrescriptionDrugFee" xlink:to="lab_nbix_AccruedBrandedPrescriptionDrugFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6da3511e-4a5d-4991-88bb-63957335b08c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_cdc8159d-67fc-4abe-b34b-99f873170c5b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_00749a94-7038-435e-9690-d515df3a4957_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fab01d30-572c-4fa2-bf75-22f53ff00f45_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_97c584ad-1540-44fb-9cc1-4eb17063fbc9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_78083cb8-b76b-426e-b880-e4bc8c08ae52_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_7b85a7fc-ff77-466f-8e58-135f3f338d86_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_bd15e4d0-4ac6-44b9-8b80-c20eadde39b9_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer compensation</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_label_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_documentation_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation nondeductible expense officer compensation cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:to="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_83603a95-db26-4967-ba33-ec4b1ce4c26d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1f0cec57-2c9a-4c3c-bc32-a94164909f5e_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb3e2ef1-ae9b-4ae3-9719-d6f4e9634ac8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cfb2c457-9e01-422b-a260-fa1c84c5b172_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f993fb1-e742-4b35-b812-051f5660d064_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2dfa3c77-dddb-4c9c-a919-590a2e54c5d7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6c7e9ad0-a037-41f4-a858-df5537c0963b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_4e0fd963-55d9-43ee-b73a-5f3ae3687ade_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d7ccfc30-a5e0-4731-b7cb-067e729f1930_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_fa063a4b-1b00-41a1-8794-d3849f1d5bb9_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities of government-sponsored entities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_01164529-72e7-48ec-9a9a-fcbd2025a939_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_15fea86f-e25e-4c0b-a218-313144544dbf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6ee48079-0760-4838-86ef-1be0b2a867a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5e4b9e8f-3826-4ad5-9837-7aff829edb17_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_95bb4c44-bdfe-4f23-a8e3-4f8005686df0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9c0148b2-2c3a-4f1d-996c-e19bf782c761_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c23f4c09-a0f9-43ba-8ae9-07f2e4b2c925_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0484aad5-b94d-4df8-974e-5ead6c581cfa_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e5f67515-a8d1-4bd1-8aea-6b639ee129fe_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets on recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_738ffba8-42eb-4780-b8d1-c250a10faf80_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a6cabc3c-f721-4164-b431-f19bcc4167a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_608e6d69-1206-4f36-bb35-6eb146c2a821_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2430919c-95e1-46cb-aa80-3392c967ce43_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d3a17d21-bb5f-4043-a6b2-73a913d12913_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ec5d057f-ba11-441f-a9ff-96d75ae6cac8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_a0596237-cc3e-40a0-a15d-1e711d2de462_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_c946505a-bdfd-46aa-a4dc-75ebf31ccf6b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0b8814f7-ba40-4d2e-bf98-c8725ae60b4e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Recognition Period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_dbe9b301-f283-433c-821d-f6777dc668a4_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_56e3da9b-d87d-44ab-aada-98d404ece61c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount repurchased</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8a691057-455c-428d-904f-9f43cb1d998d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_d8eb44da-d911-4d23-a6c3-a870dcab4302_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e07f8f1f-66dc-4f3b-99a6-ae628b6a2c08_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_063825ed-6b00-41d1-8aa6-b485138f3332_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_0aeb1ef3-7899-49bd-921b-515783f5c3f3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill recognized in connection with business combination</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_OperatingLeaseCostNet_25d4724e-25f7-4018-9d47-1b3145198b1b_totalLabel_en-US" xlink:label="lab_nbix_OperatingLeaseCostNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating lease cost</link:label>
    <link:label id="lab_nbix_OperatingLeaseCostNet_label_en-US" xlink:label="lab_nbix_OperatingLeaseCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost, Net</link:label>
    <link:label id="lab_nbix_OperatingLeaseCostNet_documentation_en-US" xlink:label="lab_nbix_OperatingLeaseCostNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OperatingLeaseCostNet" xlink:href="nbix-20231231.xsd#nbix_OperatingLeaseCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_OperatingLeaseCostNet" xlink:to="lab_nbix_OperatingLeaseCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_8d070186-632f-455f-894b-79e71d1586cf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value vested in period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_996c885d-96e7-4639-a494-f926e0b3a51f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_da2345d0-e112-43dc-babe-104552988675_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_1d5bd9c5-c816-4dac-8d76-835492fa6151_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_75bd53cc-5876-42c6-999c-45e175307ebf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_98d1ff5c-2088-4854-9d9d-7ea3c7889b6a_terseLabel_en-US" xlink:label="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS [Abstract]</link:label>
    <link:label id="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="nbix-20231231.xsd#nbix_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e4ab67b7-0b55-4d97-bfde-17434016f2e3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_15a1bd17-0ee3-4bc4-b45f-7025106b0341_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_49d91c63-408c-4f18-b8e8-d39397b0c7b8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c6085416-f45d-4c4d-ab09-dacf58726a92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_3dadb349-f728-4e91-bbc5-e6868dcdc851_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2026</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:href="nbix-20231231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_d3500e3e-0dbb-4d16-9fc2-cc0d8bdda5fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IngridDelaetMember_label_en-US" xlink:label="lab_nbix_IngridDelaetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ingrid Delaet [Member]</link:label>
    <link:label id="lab_nbix_IngridDelaetMember_documentation_en-US" xlink:label="lab_nbix_IngridDelaetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ingrid Delaet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IngridDelaetMember" xlink:href="nbix-20231231.xsd#nbix_IngridDelaetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IngridDelaetMember" xlink:to="lab_nbix_IngridDelaetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_82af028b-17f4-4e2f-bc89-995b44980dae_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_dfe95214-4510-40f3-8ef3-86f06edb17f9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_47704284-1a26-48e4-8c3e-ab088843c711_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Information Relating to our Recognized Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_07d0d3cc-7121-40ea-b5db-72db2549503c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c20eed11-aa4a-4b45-933f-9fde9d06ab25_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f4e47b93-dd61-40ec-8fb2-e1d9a79774ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_75dad50a-a884-49e7-9b65-0899eb9d89d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_fd9aa928-cb11-464b-93fb-6e8c3e434b43_terseLabel_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Two Point Two Five Percent Due In May Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the 2.25% Convertible Senior Notes Due in May 2024.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:href="nbix-20231231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:to="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20a4370-8daa-42c1-b09a-91a926ce57d4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_a4859d2c-3127-4b74-9ee6-adb82454cd90_terseLabel_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain, current</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_label_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_documentation_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_be1f6274-af90-4a30-836b-9676eb46617a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_b89ebfae-a91c-477e-85bf-5ae7a772d775_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3a3f813f-a324-427b-90d9-0f6614f813f8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_19e6fcd5-29c5-4481-af26-9a6b37afa31f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Unvested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b0b11653-542d-4a85-b5ec-93ad5e69c152_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Unvested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_d7f521a6-02b4-4673-a4eb-9a94428d3f1e_terseLabel_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:href="nbix-20231231.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0fc404aa-3a5f-4405-aa82-3d149d84d757_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under stock plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_1eaa8e45-605d-4574-a4a5-3d4b0fe870dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1125c131-ec5d-4d95-a1e3-5d71503be1c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_EricBenevich2023PlanMember_label_en-US" xlink:label="lab_nbix_EricBenevich2023PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eric Benevich 2023 Plan [Member]</link:label>
    <link:label id="lab_nbix_EricBenevich2023PlanMember_documentation_en-US" xlink:label="lab_nbix_EricBenevich2023PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eric Benevich 2023 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EricBenevich2023PlanMember" xlink:href="nbix-20231231.xsd#nbix_EricBenevich2023PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_EricBenevich2023PlanMember" xlink:to="lab_nbix_EricBenevich2023PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e6ccb53d-755a-4124-92fa-5bf4f04e44e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income taxes at 21%</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09dbf950-a1b1-4aba-a546-db12076de93c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction_c3370aaa-daa6-4747-a701-4cf97fe6fae3_terseLabel_en-US" xlink:label="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction_label_en-US" xlink:label="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Sold in Transaction</link:label>
    <link:label id="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction_documentation_en-US" xlink:label="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares sold by the collaboration partner per stock transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:href="nbix-20231231.xsd#nbix_SaleOfStockNumberOfSharesSoldInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:to="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f455caad-73f2-4274-a5fc-6f09adb2a885_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_9b8f7832-de9e-4faa-b3d3-8fe4ccc95eeb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_50226a3e-ed51-4612-93e2-70c81c98cecb_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_86b9d44b-0393-4825-92d1-df29d58b6d7d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_50abc544-f52b-40d6-8626-23f39682074f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5ba4f32f-374e-487a-bd7c-b695b78cff1d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_fa950ada-0eea-47ce-9469-6c13d53e299c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_be6a2a35-456f-427b-bf82-43cb6dbedc1c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f9745c27-b105-46fb-a304-a45180038e10_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_82b38d85-84ad-428a-812d-a760a2991a53_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_4ce8a9df-99e3-440c-a54c-4c0249cf92a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_19854ac9-874f-49fa-810d-f3e1c9fb5cdd_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_479903d3-cece-4a5e-9132-c2d4421e7a6f_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_6ddfb8ad-b3d4-456a-a8b9-2fdde5b012ed_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_57068c80-1b21-4323-85dc-078db841150d_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentCouponInterest_54e04021-482e-4226-93ef-ce2a925c385e_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentCouponInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon interest</link:label>
    <link:label id="lab_nbix_DebtInstrumentCouponInterest_label_en-US" xlink:label="lab_nbix_DebtInstrumentCouponInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Coupon Interest</link:label>
    <link:label id="lab_nbix_DebtInstrumentCouponInterest_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentCouponInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Coupon Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentCouponInterest" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentCouponInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentCouponInterest" xlink:to="lab_nbix_DebtInstrumentCouponInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79266ba2-c7f2-4e19-a083-90e31f1530ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_df6dd1b1-794a-4e10-a319-2d3b80c93d9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_EricBenevichMember_label_en-US" xlink:label="lab_nbix_EricBenevichMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eric Benevich [Member]</link:label>
    <link:label id="lab_nbix_EricBenevichMember_documentation_en-US" xlink:label="lab_nbix_EricBenevichMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eric Benevich</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EricBenevichMember" xlink:href="nbix-20231231.xsd#nbix_EricBenevichMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_EricBenevichMember" xlink:to="lab_nbix_EricBenevichMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e899f6fb-82ad-4b0f-a620-6cbce89b50a9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50df1221-4db4-4ab2-86fa-976e7c0bb1e0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_919524d3-46a8-432a-8223-4d1d0e835326_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A2023VoyagerAgreementMember_481a92b2-eaa0-4d53-bfcf-f2c087f37963_terseLabel_en-US" xlink:label="lab_nbix_A2023VoyagerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Voyager Agreement</link:label>
    <link:label id="lab_nbix_A2023VoyagerAgreementMember_label_en-US" xlink:label="lab_nbix_A2023VoyagerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Voyager Agreement [Member]</link:label>
    <link:label id="lab_nbix_A2023VoyagerAgreementMember_documentation_en-US" xlink:label="lab_nbix_A2023VoyagerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Voyager Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A2023VoyagerAgreementMember" xlink:href="nbix-20231231.xsd#nbix_A2023VoyagerAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A2023VoyagerAgreementMember" xlink:to="lab_nbix_A2023VoyagerAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_c220401f-f5bd-41a1-af03-49c40908e500_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_15743704-4627-4fd0-b204-8638ba0b499e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_14cc1525-a09d-4135-8ccf-cb18cd51200a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_bb9d67af-e112-4694-87b2-37b2616e3fb7_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_c946b7da-b220-4b28-b9e7-bc78c3c5f9fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_1fc15bcd-df19-4291-8840-63250152f4cc_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_5a8e1e0d-3344-4b3f-922a-2cdbd5805997_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1f3228d4-bc51-40ae-9f40-ffbb02975e2f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_09e5dd08-7c83-4015-ab5d-f909097f4de6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_bbd80572-0923-411f-94cb-4ce78a7ce07e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_14db2963-fb68-425c-aab9-7f61d2f26335_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_51d2e2e4-6d54-476b-adb1-f0f89162da7d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_397af7c9-c684-4f0f-9872-61c4009c0c37_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_36764809-736b-407a-89f4-f34043eb57f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_61168c28-1ecb-4fa9-b961-5e8224d295a9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on debt securities available-for-sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_41e5fbd1-b9b7-4ec7-8597-ae304ccbe3bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_f9ec6e02-2e7a-4e32-906f-6d48e5214599_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_50c4905b-5c9a-4e9e-a86d-2c41398d9642_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_cfee3765-598c-45e2-b89a-3a5fc76fde98_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock price trigger (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_c128c67c-1cd6-406a-9055-fcc941232148_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_861987bf-b729-4397-922b-81229207a563_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_7a9c7736-3c19-4882-81da-51025fd0cf7b_terseLabel_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reduced pursuant to appreciation award (in shares)</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_label_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Appreciation Award</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_documentation_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" xlink:href="nbix-20231231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" xlink:to="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_496f27db-fdcb-4843-b199-f35414aeb7ea_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_2e93105a-e955-4409-8944-776f6cd83639_terseLabel_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="nbix-20231231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_ff56dfc8-943b-4905-9b96-a53370f251a2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_e1fd7ffc-c191-4e2a-922b-bb2fb0391801_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_199e6573-93ac-4f4c-93ac-8f28f1ca0722_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2a439364-89ea-46a7-993d-37e23d1970c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of common stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_0a42ab4a-05c4-4c65-acf4-87851ebb5bce_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_label_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment Receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential later stage milestone payments and royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts" xlink:href="nbix-20231231.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePaymentReceipts" xlink:to="lab_nbix_PotentialMilestonePaymentReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_d1ddfcc9-61bc-4b98-a42f-1c88613cd881_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2027</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:href="nbix-20231231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_45cce6cd-e64c-4106-ade4-c82befb4db9a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_886a87fd-c07c-4326-a561-a124408445a9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a6247759-496a-45c7-b90a-483113811400_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, maximum employee contribution percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_b23e590e-54c7-4c40-bcf9-21331f3ec52c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e46114cb-3bdd-464e-8438-fcd11ad716fa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_81419215-8155-452a-935c-f735f50ed65f_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_22fdb535-0cf4-487c-bf98-ac2c61f74d1f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1e5850c7-1fa0-4c26-813d-ef7dbc4952f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_58e69992-771a-4f51-8e43-37f66ce4e8a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_cc763ba9-2d1c-4c27-adc4-83167987badd_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b9773d92-f7ce-4bbc-8605-d317ef939ff1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_c41dbdbc-d388-4705-b7eb-1f017f79da1f_terseLabel_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, current</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_label_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Current</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_documentation_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:href="nbix-20231231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:to="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_21d203c8-a0bb-4cc7-96d6-38ee952ad767_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate repurchase price paid in cash</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LargestFourCustomersMember_b2773ee9-7068-41fc-9898-f1f128727a77_terseLabel_en-US" xlink:label="lab_nbix_LargestFourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Four Customers</link:label>
    <link:label id="lab_nbix_LargestFourCustomersMember_label_en-US" xlink:label="lab_nbix_LargestFourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Four Customers [Member]</link:label>
    <link:label id="lab_nbix_LargestFourCustomersMember_documentation_en-US" xlink:label="lab_nbix_LargestFourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Four Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LargestFourCustomersMember" xlink:href="nbix-20231231.xsd#nbix_LargestFourCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LargestFourCustomersMember" xlink:to="lab_nbix_LargestFourCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d2604d3e-3c09-48af-a6ad-b72ec4d59d1f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b32f4c24-0dda-4069-90e8-0e8df7911023_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_fc62b439-f132-493e-9f51-47cfdef1c38c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_572873ce-3472-4aad-ab75-db5ab0025a5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_96c2a1fc-16f0-4180-bd13-f2a1b1850b10_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_82f6d3c9-2525-4131-9775-07a80500a210_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_30492273-5a1f-440e-b3e2-09796429666e_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_051778c4-b8b8-46ed-961d-2de79c84d4b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fc699a2a-e862-4ac7-a1c1-28ff242785e3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AbbVieIncMember_4b73c7e7-7ebe-4dbf-8f42-2c26457effee_terseLabel_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Inc.</link:label>
    <link:label id="lab_nbix_AbbVieIncMember_label_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Inc. [Member]</link:label>
    <link:label id="lab_nbix_AbbVieIncMember_documentation_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember" xlink:href="nbix-20231231.xsd#nbix_AbbVieIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AbbVieIncMember" xlink:to="lab_nbix_AbbVieIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_56cf0ca3-4cdb-4a62-990f-59f9c725bd77_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c8eefe69-3eb2-40b9-befe-98482b052970_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_c02c26d3-71ef-4859-b836-8919e6a485bf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b2f2abae-8ef2-4007-979e-2159449a6e53_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_17900a8e-e3d4-447b-8005-6526bf428036_verboseLabel_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, noncurrent</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_label_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Noncurrent</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_documentation_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:href="nbix-20231231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:to="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_ad6d789a-c1ac-4643-af58-99941a35eb51_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_label_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Conversion Premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:to="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_5fb6538a-0f06-40d2-916f-9a8dea3cb0a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2026</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_2f6f5a9e-25d6-4176-a84c-ffad456e5e60_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PrescriptionDrugFeeNoncurrent_b6e5707e-2d39-4971-bc23-88e6a4f4f841_terseLabel_en-US" xlink:label="lab_nbix_PrescriptionDrugFeeNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent branded prescription drug fee</link:label>
    <link:label id="lab_nbix_PrescriptionDrugFeeNoncurrent_label_en-US" xlink:label="lab_nbix_PrescriptionDrugFeeNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription Drug Fee, Noncurrent</link:label>
    <link:label id="lab_nbix_PrescriptionDrugFeeNoncurrent_documentation_en-US" xlink:label="lab_nbix_PrescriptionDrugFeeNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription Drug Fee, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrescriptionDrugFeeNoncurrent" xlink:href="nbix-20231231.xsd#nbix_PrescriptionDrugFeeNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PrescriptionDrugFeeNoncurrent" xlink:to="lab_nbix_PrescriptionDrugFeeNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_34aeb2cb-4c37-47fb-95c0-3cb91bb2596d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_be0c3bf1-894e-4a26-984d-9db50ccb3dec_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, noncurrent</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4f8bf23f-140f-4dd8-9b56-54a1ffd1932e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_70727ade-0513-48f0-9ddb-9760ea4d3d51_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_158c2547-8008-427c-8ed0-1d1948e2e179_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_95214e17-11b0-4de2-a4c6-8512499428c9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_cfe30293-ca11-46a4-9849-652e1cae7e8a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_9f67a6c3-203d-433b-aa52-1628eec0ffb9_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_label_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConversionAxis" xlink:to="lab_nbix_DebtInstrumentConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a4798766-993c-463a-80e2-6c84617900d9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 220.0 shares authorized; 98.7 and 96.5 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d15ef6ea-7d95-453b-be41-1ef6c8a9f859_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember_5dfb15e7-50e9-46b7-ba7a-186283d031f9_terseLabel_en-US" xlink:label="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Equity Incentive Plan</link:label>
    <link:label id="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember_label_en-US" xlink:label="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Eleven Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Eleven Equity Incentive Plan [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TwoThousandAndElevenEquityIncentivePlanMember" xlink:href="nbix-20231231.xsd#nbix_TwoThousandAndElevenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TwoThousandAndElevenEquityIncentivePlanMember" xlink:to="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_VotingRestrictionPeriod_bd493ded-d973-43a3-af13-19b8278d274a_terseLabel_en-US" xlink:label="lab_nbix_VotingRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting restriction period (in years)</link:label>
    <link:label id="lab_nbix_VotingRestrictionPeriod_label_en-US" xlink:label="lab_nbix_VotingRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Restriction Period</link:label>
    <link:label id="lab_nbix_VotingRestrictionPeriod_documentation_en-US" xlink:label="lab_nbix_VotingRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VotingRestrictionPeriod" xlink:href="nbix-20231231.xsd#nbix_VotingRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_VotingRestrictionPeriod" xlink:to="lab_nbix_VotingRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_620fbc5e-76fc-4190-a798-87707d99c432_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c8007737-d8fe-4944-9e2c-bf004bcd8d68_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_013dd127-766c-4bb2-ad2c-69deb085956f_negatedLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2028</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_727141e0-54d6-492e-b84f-16d614a8d0ed_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_621a701c-1515-475b-8782-e6b1c17f4b39_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d9d9e943-ebf4-4f43-a79e-cd409187a48b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_273c762c-5a25-4e1e-b5db-8359565e4fa6_negatedLabel_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss, noncurrent</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_label_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_documentation_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:to="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6c8beb27-bebe-425a-a6c7-653b65b511a4_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d87d9ded-a5f7-4bd6-90df-df748daabc89_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_aea86a6a-0a8e-4b51-9422-c4dd869d0e24_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8fa69654-7e09-477e-b700-b174b1e61317_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_HeptaresTherapeuticsLimitedMember_de0b41a0-702f-464f-96e4-3b2dcad2dd0b_terseLabel_en-US" xlink:label="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heptares</link:label>
    <link:label id="lab_nbix_HeptaresTherapeuticsLimitedMember_label_en-US" xlink:label="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heptares Therapeutics Limited [Member]</link:label>
    <link:label id="lab_nbix_HeptaresTherapeuticsLimitedMember_documentation_en-US" xlink:label="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heptares Therapeutics Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_HeptaresTherapeuticsLimitedMember" xlink:href="nbix-20231231.xsd#nbix_HeptaresTherapeuticsLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_HeptaresTherapeuticsLimitedMember" xlink:to="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_652d9913-47ba-46ae-877d-7f2056eced84_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d0796a20-0de2-4e20-8478-8734cae13dd3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Provision For Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a0837d1a-0a88-422e-a1d7-924d6a53fd0a_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c59950f3-117f-484f-b784-aea2893e2644_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_02b478bd-4c94-4cd5-824d-4b6c846e3f1c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold_04443c81-4c06-4aa1-97a9-a3966921922d_terseLabel_en-US" xlink:label="lab_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination by counterparty, contractual time threshold (in days)</link:label>
    <link:label id="lab_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold_label_en-US" xlink:label="lab_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination By Counterparty, Contractual Time Threshold</link:label>
    <link:label id="lab_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold_documentation_en-US" xlink:label="lab_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination By Counterparty, Contractual Time Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationByCounterpartyContractualTimeThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold" xlink:to="lab_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_bf50d410-57e0-471e-a01d-4314b3361058_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b369cf1a-42bc-4482-b33c-24d6d27be0b7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_500fc584-60ae-45a6-8dc3-9c74943d7b53_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ba5903e-06a3-4ecb-8b52-4d08b815ef3e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_87f17852-1723-417c-8c70-cc4a5ea626bf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_84e51c96-f26c-41ea-89f6-a458a0a835c0_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_76ed2f5d-4d0b-42b8-84eb-4fad8e42693e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_b95f55c4-d1cc-4b37-9dd5-60d744714610_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6efe0a22-4fef-43fe-8bf9-fd51d2eda5b9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8d055122-c988-4535-8667-2301e6921178_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Annual Amortization Expense for our Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2f0c08d3-35c3-419d-bbdd-b969272580d4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_ddd2e0db-132f-4ec1-b35f-917a9218b465_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_0bfa6bce-1d2f-4091-b12a-da0165a70f6c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_b1935684-749d-4e82-bed4-f41f852ce056_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_22a35eb8-f6a8-4c51-9cd4-c9f18b88894e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CollaborationRevenueMember_0ff0add7-2c58-40d2-8a7a-ba0938722b2f_terseLabel_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_label_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember" xlink:href="nbix-20231231.xsd#nbix_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CollaborationRevenueMember" xlink:to="lab_nbix_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7db202c8-b572-4249-a515-3b181f4fb3f8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9122a586-0ef6-4ea4-a7a3-d1b79917d313_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e311f88b-3692-4fe0-94b8-b2591daa73ae_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2f6e720f-4c6e-4031-bc26-f44a199712b3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_93f7721a-b997-4e0f-911f-33cfc726139e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8c43853e-dd3a-4e0c-8104-9b0f94dc5cb0_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_0a040244-2572-49a9-a88a-6835856d15b5_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a7a4a656-0a1b-41f7-b4e4-742ce42d4430_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would affect effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_44920dd8-ab09-4af0-af0a-ba6a0bb8a279_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_07677a5e-d3fc-41f2-88a4-4e0ca03c781c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c3db036-d955-464e-adb2-ea3fb1817355_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_722f2b5e-08d9-4dfe-b5d5-d22db29ac703_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_c305d0ed-aa0a-4f45-bf76-47a8d7baba4a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_25ee75bd-e633-4303-94f8-a92404d28102_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected option term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfPreclinicalCandidates_e6f0fee6-3edb-4768-ba47-a3c799347312_terseLabel_en-US" xlink:label="lab_nbix_NumberOfPreclinicalCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of preclinical candidates</link:label>
    <link:label id="lab_nbix_NumberOfPreclinicalCandidates_label_en-US" xlink:label="lab_nbix_NumberOfPreclinicalCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Preclinical Candidates</link:label>
    <link:label id="lab_nbix_NumberOfPreclinicalCandidates_documentation_en-US" xlink:label="lab_nbix_NumberOfPreclinicalCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Preclinical Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfPreclinicalCandidates" xlink:href="nbix-20231231.xsd#nbix_NumberOfPreclinicalCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfPreclinicalCandidates" xlink:to="lab_nbix_NumberOfPreclinicalCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8671ca1b-349f-4e22-b0f7-84563fe03565_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A2019VoyagerAgreementMember_6f74964e-e36c-488c-ab85-afaafd0f1c06_terseLabel_en-US" xlink:label="lab_nbix_A2019VoyagerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Voyager Agreement</link:label>
    <link:label id="lab_nbix_A2019VoyagerAgreementMember_label_en-US" xlink:label="lab_nbix_A2019VoyagerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Voyager Agreement [Member]</link:label>
    <link:label id="lab_nbix_A2019VoyagerAgreementMember_documentation_en-US" xlink:label="lab_nbix_A2019VoyagerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Voyager Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A2019VoyagerAgreementMember" xlink:href="nbix-20231231.xsd#nbix_A2019VoyagerAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A2019VoyagerAgreementMember" xlink:to="lab_nbix_A2019VoyagerAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b7879ec3-36b4-4bf0-a081-93ea27c07602_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock_13260f8c-b1e5-4e80-909c-e8a3b9741f8e_terseLabel_en-US" xlink:label="lab_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Business</link:label>
    <link:label id="lab_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock_label_en-US" xlink:label="lab_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Business Description Policy [Policy Text Block]</link:label>
    <link:label id="lab_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description Policy [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock" xlink:href="nbix-20231231.xsd#nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock" xlink:to="lab_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_dcae2cd3-471e-45ca-90a5-caac8c5c5358_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_356c7212-16aa-436d-8a56-e3c9e8a8556c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AuditorInformationAbstract_label_en-US" xlink:label="lab_nbix_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_nbix_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_nbix_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AuditorInformationAbstract" xlink:href="nbix-20231231.xsd#nbix_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AuditorInformationAbstract" xlink:to="lab_nbix_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_80bce656-af04-4d55-8a33-b64ad33ced87_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_56e22c32-3315-4e52-86c9-0b1cd064c55e_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_d689e072-a92e-4aff-8ed5-7efb51f01932_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c0a01d62-ac09-4e7b-a726-6d5e4b59bed0_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5fa20426-1078-4879-a64d-4d5ed474210b_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_abfe848e-21a0-4850-8ca5-a5917273f761_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_0da1bc3e-e82c-4181-baf3-418d871ab085_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5bd2b34-e997-4242-bab7-239c89b62f9c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_c8ad0c85-965a-4422-ba0a-e2c654360a7b_terseLabel_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL &#8211; Portela &amp; Ca, S.A.</link:label>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_label_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL &#8211; Portela &amp; Ca, S.A. [Member]</link:label>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_documentation_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL &#8211; Portela &amp; Ca, S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember" xlink:href="nbix-20231231.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BIALPortelaCaSAMember" xlink:to="lab_nbix_BIALPortelaCaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b2bf083c-329e-4033-ab0a-75e713d417b7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_d4582732-0a03-4af7-8b35-741de996fd01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a5f5a1ff-4cf9-4793-a023-cd0e5733e5c8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b6096bce-f4c9-470d-9f05-33a78918c947_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_9b570daa-727d-47bc-8428-4484e6ee1322_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2025</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:href="nbix-20231231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3e96bda5-6661-407b-9bfb-f0d87b8e8d7f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5de027d9-a225-436d-94cf-195741d84cc0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PerformanceBasedRestrictedStockUnitMember_2d43a752-afb4-498a-8aa1-0fb28e69b36a_terseLabel_en-US" xlink:label="lab_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PRSUs</link:label>
    <link:label id="lab_nbix_PerformanceBasedRestrictedStockUnitMember_label_en-US" xlink:label="lab_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Unit [Member]</link:label>
    <link:label id="lab_nbix_PerformanceBasedRestrictedStockUnitMember_documentation_en-US" xlink:label="lab_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units which are awarded to employees after certain performance targets are met.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:href="nbix-20231231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:to="lab_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a99cd7a6-484f-4ba0-a026-854b90990163_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Outstanding (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_53cf82b6-4886-48c8-ad6c-06d04eb14b79_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Outstanding (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_974a1599-39c4-4888-ac70-3fec2056e182_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c28abac8-649c-4385-bbd3-b0e6a32769fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_67e96614-80e5-403b-a54c-f925053dde7d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_bd06bff1-f104-4869-9328-e311c9fbd752_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_54b777fa-d12b-41a6-ac57-ebc621a3a797_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4f80bc60-57ef-4b48-84ce-2fd8916201c8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_93fde388-da0d-4bc4-9d25-0ddfcf9e6466_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_82e34d90-7593-477c-8f30-044761392254_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_adf70b2c-5524-471b-bfac-5612349ff5b0_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_cd429cbc-48ad-4fdf-b5a7-c55730a3a9b4_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration of the statute of limitations for the assessment of taxes</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_031adf55-8fe4-4937-8f93-92a4fa32150c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_d8b12201-cf95-4c6c-a9ff-da1c99319a71_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e28c2e6-5236-4fac-b7ec-418fa5631e2b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial ownership (as a percent)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bbafde21-6408-4d8f-a94c-7332a7662ceb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_2f5d55df-478a-4803-9edf-a086213ab1f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_ebb90a60-c077-4f69-9a0a-1662252557d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and reserves</link:label>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Marketing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_f4fe5f41-29dc-4825-9cb5-93940f2f4bd8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables write-off</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4ef01353-13f8-47cd-bd7b-3b1d01ce8e94_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0b83198-79d1-4c62-a762-791f389a48e5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c4e71f00-b3e8-4b89-a629-07331c212993_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_71debda1-06eb-4ad3-ba34-e2feb98e4ed7_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ESPPPurchasePeriod_6f30f8a7-ee57-4ec5-9670-11a591c5fd70_terseLabel_en-US" xlink:label="lab_nbix_ESPPPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase period</link:label>
    <link:label id="lab_nbix_ESPPPurchasePeriod_label_en-US" xlink:label="lab_nbix_ESPPPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Purchase Period</link:label>
    <link:label id="lab_nbix_ESPPPurchasePeriod_documentation_en-US" xlink:label="lab_nbix_ESPPPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ESPPPurchasePeriod" xlink:href="nbix-20231231.xsd#nbix_ESPPPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ESPPPurchasePeriod" xlink:to="lab_nbix_ESPPPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4bd3d058-38c5-4f0f-9ae3-9127d1d7fb01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary and Changes in Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_0ebc3b91-a3b8-4212-a962-6c5ad7736357_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_33318b1c-5f18-4e5a-a394-79395a07855e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ac987a32-7055-485b-9338-69af647d20c7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b534b6fa-4330-4a7e-a09d-5acc209ef9b3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_822cbee9-888e-49ce-9edf-689efb7ca04c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_80f0784c-1e4f-4710-8262-6a5ca4bf72fd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3ac6f24e-1d49-4e28-b671-3a9812694e0c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_62deb61f-8a08-4a47-ab53-03cfd3fff6ec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_5f6d375e-2e21-4a17-8878-fda9f9b195f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_5f9cfcf0-402f-4468-9a1e-34a7a9471365_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7c24b99c-740c-477e-a804-030e595b364b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_fb2596df-921c-4452-ab7e-950116bc06da_negatedLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_5683d441-bde6-44ee-8b41-b58a91818cb7_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed product rights</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1dbb85be-5517-49e0-a5ba-0cde33474176_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_6942542b-7fdb-4ab2-9844-e02d0fcf4fba_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired tax attributes</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_label_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Expiration Of Tax Credits</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_documentation_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation, expiration of tax credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxReconciliationExpirationOfTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:to="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0c20985e-0d0d-47da-b41c-78e027275951_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9fb4bd7f-7a36-4b31-b640-322a4d28f049_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Accretion) amortization of (discount) premium on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_dffd791c-3e23-48f2-8f1f-bcf3b6170c0d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_36371f94-9dc1-4b63-9629-b0a1ad179c60_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_575010b8-6067-4e68-8303-8a1810bb9e21_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e3ab8748-9276-489a-9c88-0f4fb08d1fb4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_862d9d80-bf4b-4579-bf92-36af9ed4864b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_04a63133-3b8f-489d-9408-102536c6d006_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_36022f61-2799-421b-98f7-923fd340bafa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_0db4bb95-a771-4c14-ba07-febab88c868f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities purchase date fair value amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_2aad4bf7-4496-4849-ab70-618b82640bf8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_df579e0f-36bd-4ef5-a854-7363d17dfa0c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_abaf7ad1-04db-4e2d-8dae-f394a5e53224_terseLabel_en-US" xlink:label="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_label_en-US" xlink:label="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Loss On Extinguishment Of Convertible Senior Notes</link:label>
    <link:label id="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_documentation_en-US" xlink:label="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Loss On Extinguishment Of Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" xlink:href="nbix-20231231.xsd#nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" xlink:to="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_09e8351f-9fce-4b77-aca0-556098501fe7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_2f05f948-c687-43f2-905b-84c0acbcfc43_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7473513b-872f-4c0d-9e16-bcb5c99e11e0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_55b28a32-a551-4278-a6e3-ce83f56cc53a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_877bc1bc-d2ec-4c75-8a23-3aa082f75f86_terseLabel_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTPC</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_label_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_documentation_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the Mitsubishi Tanabe Pharma Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:href="nbix-20231231.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:to="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1d115ecd-5dd0-4b0e-8795-0cb4dd7ae29e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised in period intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_08f3015d-5d1c-46dd-bd0d-fd7e8904db47_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_7402cf8a-4c18-4eec-af33-e7db6eb11253_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_bd1cce52-e994-45de-a6b9-3e5e6a1c12ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_266ddb9f-3ba7-4c56-8933-f9f8a58c063d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePayments_da093234-7353-4fed-b010-03c7b3eebb39_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_label_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential milestone payments to be paid under a license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments" xlink:href="nbix-20231231.xsd#nbix_PotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePayments" xlink:to="lab_nbix_PotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d8efec9d-e164-4831-9d8d-181bd363827b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_743de2e4-4066-4b46-8d87-e11f7b531483_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_cc794caa-f4df-410b-9470-f759512d572c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e4e18a3a-9fe6-4079-869b-c5941bb02f72_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6304d6cd-84e5-42b7-9c4e-dd1e9c30cdc2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_f596d976-6820-4120-89c6-71a5e83f8c31_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfUndisclosedPrograms_d1438fc4-dc8c-4f51-b9a1-cfa330e153d3_terseLabel_en-US" xlink:label="lab_nbix_NumberOfUndisclosedPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of undisclosed programs</link:label>
    <link:label id="lab_nbix_NumberOfUndisclosedPrograms_label_en-US" xlink:label="lab_nbix_NumberOfUndisclosedPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Undisclosed Programs</link:label>
    <link:label id="lab_nbix_NumberOfUndisclosedPrograms_documentation_en-US" xlink:label="lab_nbix_NumberOfUndisclosedPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Undisclosed Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfUndisclosedPrograms" xlink:href="nbix-20231231.xsd#nbix_NumberOfUndisclosedPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfUndisclosedPrograms" xlink:to="lab_nbix_NumberOfUndisclosedPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b94d6c8e-7e6f-4485-b048-e29db4c64388_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5912df62-4469-42ca-8e7e-c64a4d2a65ff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_d3d63262-8303-4b11-ad31-b324780e7130_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f9ebc631-273e-4982-a5de-a398a49b5ee5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_5f61f48e-a8e7-42ed-849c-a445d127f242_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_377f7b77-ecda-4d5d-9208-d68d75f267fc_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded prescription drug fee</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_label_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Branded Prescription Drug Fee</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_documentation_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation nondeductible expense branded prescription drug fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:to="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_2968355b-03e9-42b6-b1a5-b79de3768d98_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_52f880e5-1b8d-49f2-b821-a6fa258f46fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5d380917-c7c3-4d95-817e-3cd416031b68_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57f89be2-ce00-493a-a37d-7c1063638765_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5423d6ed-07de-4dbe-84ee-00e9ac9fd992_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of PRSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_a5d1ad9a-baa8-4787-a917-8040b4fa5b15_terseLabel_en-US" xlink:label="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_label_en-US" xlink:label="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Capitalized Research And Development</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_documentation_en-US" xlink:label="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs capitalized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_28750194-84df-48ee-9d51-4b612652408d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_17a2943a-bd12-48eb-abd5-3da346b17062_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_408be120-82c9-4ea4-9b2b-8059962d3517_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfGeneTherapyPrograms_9a091521-078d-4559-92ec-6e138ded63f6_terseLabel_en-US" xlink:label="lab_nbix_NumberOfGeneTherapyPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of gene therapy programs</link:label>
    <link:label id="lab_nbix_NumberOfGeneTherapyPrograms_label_en-US" xlink:label="lab_nbix_NumberOfGeneTherapyPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Gene Therapy Programs</link:label>
    <link:label id="lab_nbix_NumberOfGeneTherapyPrograms_documentation_en-US" xlink:label="lab_nbix_NumberOfGeneTherapyPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Gene Therapy Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfGeneTherapyPrograms" xlink:href="nbix-20231231.xsd#nbix_NumberOfGeneTherapyPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfGeneTherapyPrograms" xlink:to="lab_nbix_NumberOfGeneTherapyPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_346ce897-7d29-4c74-a15f-b7cd205a2a90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4ab2a42b-dddb-4398-95e0-7baecf174446_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_aa3bffb8-be73-4843-8f46-cff5c3a36fcd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_221a7838-4aa2-428f-8988-fc4aa0ac6472_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_f7bb4b3a-505c-47ac-a9a1-bd01c04588bc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ca09369a-dbde-4aee-8294-cf5ec66d197f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_51c1f4ef-32a4-43dc-8510-b44558a5e315_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_678c55ee-700b-4b59-beb4-08c907ecf9c7_terseLabel_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares increased returning shares subject to any full value award (in shares)</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_label_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To An Award</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_documentation_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To An Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" xlink:href="nbix-20231231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" xlink:to="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_66c2c0ac-6425-4a44-8c51-5cacca8323db_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_b2b215d1-dffe-4888-acc1-08e8b2288f79_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market price of common stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b7c3de85-a138-4d23-acc5-dfd68ade2d35_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under stock plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_563539b8-3119-4b17-a544-e505a277aa6a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_86ed5609-d61a-4e78-b647-85cd19e20869_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e1b667af-319d-4d56-9073-5414d2bcca16_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ea1ee9eb-54b5-46ff-a48b-60db47fc649b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1de66840-dbaa-45b2-ba10-b944d23d8799_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b9f08ae5-1633-4bc4-84de-6c81a42b5d56_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) included in earnings</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_f83cbde0-f293-4a70-98ab-322b583c4931_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_43b6b8ca-f04a-465e-8906-467d70b393d0_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_e71d3162-4f31-4dfc-a446-7a41d90c52a3_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2028</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:href="nbix-20231231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_Amended2020EquityIncentivePlanMember_f310eaaf-c569-4bbe-a8ea-3890eeeada05_terseLabel_en-US" xlink:label="lab_nbix_Amended2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Equity Incentive Plan</link:label>
    <link:label id="lab_nbix_Amended2020EquityIncentivePlanMember_label_en-US" xlink:label="lab_nbix_Amended2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_nbix_Amended2020EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_nbix_Amended2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_Amended2020EquityIncentivePlanMember" xlink:href="nbix-20231231.xsd#nbix_Amended2020EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_Amended2020EquityIncentivePlanMember" xlink:to="lab_nbix_Amended2020EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b06c0d85-cb71-4161-9d1d-240b715f24c6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxesTable_c5fe90a1-9220-4b01-86bc-9f8d599e637f_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_nbix_IncomeTaxesTable_label_en-US" xlink:label="lab_nbix_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_nbix_IncomeTaxesTable_documentation_en-US" xlink:label="lab_nbix_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesTable" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxesTable" xlink:to="lab_nbix_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dcd2ee34-442e-4dc4-bf9e-74ac58728a02_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bfefad76-91e1-4989-aba4-7926afe96264_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationInterestAccrued_9ae53638-5af4-49db-85cc-6d955ce6aae9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest accrued</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationInterestAccrued_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_66c54714-03f5-4bed-b281-51a393808d03_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b6d49390-9e7a-48d4-9460-a305580da5ef_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_Amended2018EmployeeStockPurchasePlanMember_28bcc080-a8d3-49d1-93ce-5ebccaf5254f_terseLabel_en-US" xlink:label="lab_nbix_Amended2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2018 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_nbix_Amended2018EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_nbix_Amended2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_nbix_Amended2018EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_nbix_Amended2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2018 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_Amended2018EmployeeStockPurchasePlanMember" xlink:href="nbix-20231231.xsd#nbix_Amended2018EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_Amended2018EmployeeStockPurchasePlanMember" xlink:to="lab_nbix_Amended2018EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b43e7d8d-6ceb-49e9-b9fa-6a55bd124583_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_GeorgeMorrowMember_label_en-US" xlink:label="lab_nbix_GeorgeMorrowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">George Morrow [Member]</link:label>
    <link:label id="lab_nbix_GeorgeMorrowMember_documentation_en-US" xlink:label="lab_nbix_GeorgeMorrowMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">George Morrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_GeorgeMorrowMember" xlink:href="nbix-20231231.xsd#nbix_GeorgeMorrowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_GeorgeMorrowMember" xlink:to="lab_nbix_GeorgeMorrowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_378fc7ad-409c-4c99-9b48-27947768b5cc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_74df82ed-4b96-43ba-9553-f885147fdb6c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cdedab42-d2f1-43ee-ad2d-bc912e7ad736_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ShaliniSharpMember_label_en-US" xlink:label="lab_nbix_ShaliniSharpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shalini Sharp [Member]</link:label>
    <link:label id="lab_nbix_ShaliniSharpMember_documentation_en-US" xlink:label="lab_nbix_ShaliniSharpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shalini Sharp</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShaliniSharpMember" xlink:href="nbix-20231231.xsd#nbix_ShaliniSharpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ShaliniSharpMember" xlink:to="lab_nbix_ShaliniSharpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_14645a9a-d1c6-4ea7-931e-14d434853224_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_abb4ba3c-63bc-44ff-8fac-3b45a3e60b4b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_acad5bb4-f278-4bcb-97a6-9aafaa5508d1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued employee related costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3c59bb63-a3f9-42c8-902f-60a5dde9a584_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_d4ef7216-3c15-4b13-ac9a-252beb8c6dbc_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AgreementTerminationByCounterpartyMinimalContractualTime_c584ea40-1695-4bfc-b3ab-dc5f2ad3d6a4_terseLabel_en-US" xlink:label="lab_nbix_AgreementTerminationByCounterpartyMinimalContractualTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination by counterparty, minimal contractual time (in days)</link:label>
    <link:label id="lab_nbix_AgreementTerminationByCounterpartyMinimalContractualTime_label_en-US" xlink:label="lab_nbix_AgreementTerminationByCounterpartyMinimalContractualTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination By Counterparty, Minimal Contractual Time</link:label>
    <link:label id="lab_nbix_AgreementTerminationByCounterpartyMinimalContractualTime_documentation_en-US" xlink:label="lab_nbix_AgreementTerminationByCounterpartyMinimalContractualTime" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination By Counterparty, Minimal Contractual Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationByCounterpartyMinimalContractualTime" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationByCounterpartyMinimalContractualTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AgreementTerminationByCounterpartyMinimalContractualTime" xlink:to="lab_nbix_AgreementTerminationByCounterpartyMinimalContractualTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_304cc161-fff8-4326-ad75-ad0be4ae60f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d5a99e3c-3dcd-4c8b-985c-0ecc04cc1ec7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8fed4a16-fa11-4fa4-84a0-e292416f931b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_ac0bcd24-04b3-4cc7-ad43-ed3458485132_terseLabel_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_label_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager Therapeutics [Member]</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_documentation_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager therapeutics.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember" xlink:href="nbix-20231231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_VoyagerTherapeuticsMember" xlink:to="lab_nbix_VoyagerTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dc36dda0-5079-4348-a147-d637d9e7e12f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_11f7d2ba-d5ce-46ba-bd2f-17090e1eda5a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_94b8a912-bcc3-493b-b981-16922f5e2979_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2025</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ConversionPeriodOneMember_c4ea933b-52dc-4a98-b9e1-9931ab6e3857_terseLabel_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:label id="lab_nbix_ConversionPeriodOneMember_label_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One [Member]</link:label>
    <link:label id="lab_nbix_ConversionPeriodOneMember_documentation_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember" xlink:href="nbix-20231231.xsd#nbix_ConversionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ConversionPeriodOneMember" xlink:to="lab_nbix_ConversionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_d9d5e5e0-f317-4199-b795-93b831a4658e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5561c318-6011-4651-b47c-7e26068ea715_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_587b8dc4-8832-4c1b-aaa0-f7f4d2cde71b_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c6835a4-48ce-48a6-8573-f8bfb3efe4cb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_16ac4cad-99ab-4053-975c-ea46ed8f9409_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of business, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8dfe3431-abef-4e95-a656-ca6347425af3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_9e77cf92-e3e0-4f21-a77a-29d6d29504d2_terseLabel_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares increased by returning shares subject to appreciation award (in shares)</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_label_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To Appreciation Award</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_documentation_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" xlink:href="nbix-20231231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" xlink:to="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_cbd4de45-fbb9-4e06-a860-7e321a50d338_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_3996ac43-ea57-4ef8-bdf6-11dd8fada419_terseLabel_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain, noncurrent</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_label_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_documentation_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:to="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_51f46d50-3509-401c-ae44-646358418d25_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ScientificEquipmentMember_4d63379e-9090-4b31-95be-500a6815e9d7_terseLabel_en-US" xlink:label="lab_nbix_ScientificEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific equipment</link:label>
    <link:label id="lab_nbix_ScientificEquipmentMember_label_en-US" xlink:label="lab_nbix_ScientificEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific Equipment [Member]</link:label>
    <link:label id="lab_nbix_ScientificEquipmentMember_documentation_en-US" xlink:label="lab_nbix_ScientificEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ScientificEquipmentMember" xlink:href="nbix-20231231.xsd#nbix_ScientificEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ScientificEquipmentMember" xlink:to="lab_nbix_ScientificEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_4fe16d64-0a5f-4615-90f6-c6ab9d884feb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations and Asset Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ee7bf3ba-9ade-49fc-8b1d-c6336acd29af_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_f6cc2b3b-8ecb-40c0-bf0c-26f6f5684f66_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3f21f32c-9e6f-4785-bb44-7b57a121d5c4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fe4d6fa8-9cd9-40d4-adaa-54c12cbe6ad9_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_3e4426c0-6c7b-410c-bf9d-0f018f383550_terseLabel_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nbix-20231231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxesLineItems_319ac04e-12cc-4bbf-93fc-26ef66b41acb_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_nbix_IncomeTaxesLineItems_label_en-US" xlink:label="lab_nbix_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_nbix_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_nbix_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesLineItems" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxesLineItems" xlink:to="lab_nbix_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a3e30248-8faf-41d1-993a-e390d290a6f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_efd7bb11-6ecf-4764-9215-73e82c9d251d_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_555cbdb2-8180-4976-85c6-cc193b980a90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8aa11ed5-56bc-4c00-8361-c6f777723672_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7ffa0c7d-9738-4665-9cd6-1478cee01394_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_5e2be56c-dca8-4ff9-9ad6-7018eb2c3ecf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_15a1e876-5a59-43fd-bd88-24f57d029bba_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_56b1c536-9052-4022-b9fe-15d1a590db5b_terseLabel_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_label_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd [Member]</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_documentation_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:href="nbix-20231231.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:to="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_83e00573-5a70-46f4-a902-91de49c66179_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c041660d-fdbf-4534-bd66-c27eefeb0e56_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_f9ffa436-a81b-4f5e-aa61-7d61080a1d77_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_72355bd7-e0e2-4925-bec2-8039b48ff6d2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_b6dab504-56a4-474f-9504-13ffc4939368_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BoardOfDirectorsMaximumDurationTerm_e17be9a6-303a-498f-b6f5-f9b66f6f6e81_terseLabel_en-US" xlink:label="lab_nbix_BoardOfDirectorsMaximumDurationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of directors maximum duration term (in years)</link:label>
    <link:label id="lab_nbix_BoardOfDirectorsMaximumDurationTerm_label_en-US" xlink:label="lab_nbix_BoardOfDirectorsMaximumDurationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Of Directors Maximum Duration Term</link:label>
    <link:label id="lab_nbix_BoardOfDirectorsMaximumDurationTerm_documentation_en-US" xlink:label="lab_nbix_BoardOfDirectorsMaximumDurationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Of Directors Maximum Duration Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BoardOfDirectorsMaximumDurationTerm" xlink:href="nbix-20231231.xsd#nbix_BoardOfDirectorsMaximumDurationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BoardOfDirectorsMaximumDurationTerm" xlink:to="lab_nbix_BoardOfDirectorsMaximumDurationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_69b34a86-af6c-4cdc-bc2c-1e6cd76cbd55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LeslieNorwalkMember_label_en-US" xlink:label="lab_nbix_LeslieNorwalkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leslie Norwalk [Member]</link:label>
    <link:label id="lab_nbix_LeslieNorwalkMember_documentation_en-US" xlink:label="lab_nbix_LeslieNorwalkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leslie Norwalk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LeslieNorwalkMember" xlink:href="nbix-20231231.xsd#nbix_LeslieNorwalkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LeslieNorwalkMember" xlink:to="lab_nbix_LeslieNorwalkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9219ab9f-4350-4505-8cf4-aa19393c5e8a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4436a7a4-84c9-4bd6-b934-333ce84a8e5d_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_05c859c5-4290-4d32-8e36-e54e939b2418_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_086752a8-1f74-4fd6-a9a9-2b1305fcf411_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments (sublease income)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_88f6e7b6-348b-409c-8175-6865987b364e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4a3ccc77-925d-4e45-8c14-0fb624499859_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxAssetsLiabilitiesGross_0d2e7120-e7c8-4a5e-8b1c-6d95072504c4_totalLabel_en-US" xlink:label="lab_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net of deferred tax assets and liabilities</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsLiabilitiesGross_label_en-US" xlink:label="lab_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Liabilities Gross</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsLiabilitiesGross_documentation_en-US" xlink:label="lab_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets (liabilities) gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxAssetsLiabilitiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:to="lab_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8a21ddbe-2147-4bbe-b02b-c2a620868d02_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_de25b649-bf38-42b0-895c-63252e560a8a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5100d487-525c-4e90-9e48-7b64e241bc40_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted purchase price percentage of common stock authorized for issuance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_f8af726a-58f9-48cd-ae2f-410adc1bc8b7_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_6fa8dfe2-803d-42db-83f0-f475e869fb76_terseLabel_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_label_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember" xlink:href="nbix-20231231.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_XenonPharmaceuticalsIncMember" xlink:to="lab_nbix_XenonPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_f14d9552-bb42-4e93-ae00-c42cd8110716_terseLabel_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_label_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two [Member]</link:label>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_documentation_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember" xlink:href="nbix-20231231.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ConversionPeriodTwoMember" xlink:to="lab_nbix_ConversionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets_df211ec8-548a-4922-aa0d-3293dd1d4c1a_terseLabel_en-US" xlink:label="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets_label_en-US" xlink:label="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Operating Leases Assets</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets_documentation_en-US" xlink:label="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets operating leases assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxAssetsOperatingLeasesAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:to="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b160d1ed-835f-4768-bcce-27de95d41d03_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_81ba3fbc-54ba-4f83-8cc1-120d4e59fe89_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_ba354097-a76f-4e30-ac79-179fadfde4a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4a8c6e95-74d0-4bd0-8357-fab830f74f9a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5f969a6d-e3a1-4d7c-aac7-a312695371ca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_61e697ec-41be-464b-b00b-307516d280da_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2c054b18-38e1-4622-a3ed-ef27fcfe6a60_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9d9abb8c-acc4-4837-be7e-edf0416ac95c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_45b7ad7f-9b91-4dda-9723-ff64eb48838e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AgreementTerminationDueToMaterialBreach_5bbc5d59-f968-4709-9846-66105a7038d5_terseLabel_en-US" xlink:label="lab_nbix_AgreementTerminationDueToMaterialBreach" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination, due to material breach (in days)</link:label>
    <link:label id="lab_nbix_AgreementTerminationDueToMaterialBreach_label_en-US" xlink:label="lab_nbix_AgreementTerminationDueToMaterialBreach" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Due To Material Breach</link:label>
    <link:label id="lab_nbix_AgreementTerminationDueToMaterialBreach_documentation_en-US" xlink:label="lab_nbix_AgreementTerminationDueToMaterialBreach" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Due To Material Breach</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationDueToMaterialBreach" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationDueToMaterialBreach"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AgreementTerminationDueToMaterialBreach" xlink:to="lab_nbix_AgreementTerminationDueToMaterialBreach" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e20c9c48-c573-41bf-9074-f07a0ba66a9f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_bb4d764a-74ac-4ac5-8dac-a55e727663e3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_f4196e28-3ff4-461d-87fc-37778b67522c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_1d2dab13-d9d1-4838-a805-4efa44543c09_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_053289ec-a072-4ddf-a8f6-d670bedcc130_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_062d5ca5-a850-485a-a04b-940afece947a_terseLabel_en-US" xlink:label="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Restricted Stock and Convertible Senior Notes</link:label>
    <link:label id="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Restricted Stock And Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, restricted stock and convertible senior notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:href="nbix-20231231.xsd#nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:to="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_92c7e9c8-12fc-4e2c-9607-d42ef2312fc8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fe3b56a-2638-4875-9c45-77b320dc8aba_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_320b1b20-96c7-41c1-a7b8-0b7367e262c1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_045cc0a2-6fb7-4e2f-b078-4bf345ba1ffb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_bb677e9b-3474-4994-8be5-3d1297496fbc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_fe3474da-c34a-40f5-8b76-590987ff6c84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>nbix-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a3353234-f254-4413-b1f0-e8e01a8cce8f,g:81591885-31e3-4e25-a8db-e5a73f7fd8a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/CoverPage" xlink:type="simple" xlink:href="nbix-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_10fcbd4c-8d10-4401-a9ad-386bb42b0012" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_DocumentType_10fcbd4c-8d10-4401-a9ad-386bb42b0012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_10ff362c-bdb4-40f4-a606-1893b99f9398" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_DocumentAnnualReport_10ff362c-bdb4-40f4-a606-1893b99f9398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ba1eefba-c175-4560-96af-a7f98bebbbb9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_DocumentPeriodEndDate_ba1eefba-c175-4560-96af-a7f98bebbbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_813b4402-5cc3-4c86-b5e6-19fedf032aa0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_CurrentFiscalYearEndDate_813b4402-5cc3-4c86-b5e6-19fedf032aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_973e14ac-9e17-4a30-be5c-84e1ba85e90f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_DocumentTransitionReport_973e14ac-9e17-4a30-be5c-84e1ba85e90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b4d33878-ca8d-4cb4-84cf-bd92d1d8644a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityFileNumber_b4d33878-ca8d-4cb4-84cf-bd92d1d8644a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_07c02839-0a0a-4f4f-87a8-a99d8476f177" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityRegistrantName_07c02839-0a0a-4f4f-87a8-a99d8476f177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4c216053-2a9a-41ca-a053-78bdb363498e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4c216053-2a9a-41ca-a053-78bdb363498e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ed23c8d9-ce0b-4f12-8afb-dc6da379237a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityTaxIdentificationNumber_ed23c8d9-ce0b-4f12-8afb-dc6da379237a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d4fb3185-7a8c-47cf-ad19-c8d41f3df917" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityAddressAddressLine1_d4fb3185-7a8c-47cf-ad19-c8d41f3df917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bb8498b8-0b94-410c-970f-b461a9b58210" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityAddressCityOrTown_bb8498b8-0b94-410c-970f-b461a9b58210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5ab44d0c-a021-4328-82ae-a23554e8294d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityAddressStateOrProvince_5ab44d0c-a021-4328-82ae-a23554e8294d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c0687cc6-d3d8-4e1f-a63a-0185a95b0043" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityAddressPostalZipCode_c0687cc6-d3d8-4e1f-a63a-0185a95b0043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_52d86438-da2b-4da5-a010-b9cd4b24bfc9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_CityAreaCode_52d86438-da2b-4da5-a010-b9cd4b24bfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cb3ce8c7-b58d-4d81-83eb-5e489f762ea9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_LocalPhoneNumber_cb3ce8c7-b58d-4d81-83eb-5e489f762ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b990ed23-efd2-4d40-8482-35f5142e51b9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_Security12bTitle_b990ed23-efd2-4d40-8482-35f5142e51b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4bace50a-0bd6-4ee5-93bc-18b309fd8651" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_TradingSymbol_4bace50a-0bd6-4ee5-93bc-18b309fd8651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_48a53fe2-81d9-43e2-8a55-e89587410daa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_SecurityExchangeName_48a53fe2-81d9-43e2-8a55-e89587410daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a6e3b18c-9f87-478d-adf1-dd90185762c4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a6e3b18c-9f87-478d-adf1-dd90185762c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_b3c58b26-20ff-48ac-9ad1-c75e244783f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityVoluntaryFilers_b3c58b26-20ff-48ac-9ad1-c75e244783f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b7d7856e-4ff4-4da5-9c91-9ccbebbeb0a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityCurrentReportingStatus_b7d7856e-4ff4-4da5-9c91-9ccbebbeb0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c5a080b8-344b-4717-9cbd-38d3b3e1aa6c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityInteractiveDataCurrent_c5a080b8-344b-4717-9cbd-38d3b3e1aa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_afa2cae5-b230-49d8-a0ec-51070e8eaef7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityFilerCategory_afa2cae5-b230-49d8-a0ec-51070e8eaef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b026a9af-e2d7-40e9-b3ae-ee2f5339f3a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntitySmallBusiness_b026a9af-e2d7-40e9-b3ae-ee2f5339f3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_aca8e9d2-0c86-4089-896f-28aa8282adb3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityEmergingGrowthCompany_aca8e9d2-0c86-4089-896f-28aa8282adb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9520037a-8c3b-43a0-837b-b736ace9b6c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9520037a-8c3b-43a0-837b-b736ace9b6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_f70449bc-2e5a-4d18-bc5b-744d8e109471" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_f70449bc-2e5a-4d18-bc5b-744d8e109471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_286488bc-1cf2-40bd-9147-63117861828d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityShellCompany_286488bc-1cf2-40bd-9147-63117861828d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_38fef317-59c8-4514-bd32-d3b41d36a2fd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityPublicFloat_38fef317-59c8-4514-bd32-d3b41d36a2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bf547db4-38fe-4cbb-9dbd-14c941c31c52" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bf547db4-38fe-4cbb-9dbd-14c941c31c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_a6761bc1-7efe-4bf2-b19d-3a65bfee0c41" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_a6761bc1-7efe-4bf2-b19d-3a65bfee0c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d3bfb149-b941-4eab-a746-7612997a4f35" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_AmendmentFlag_d3bfb149-b941-4eab-a746-7612997a4f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_29a82702-aeaf-4f49-961d-ae3635efe39b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_DocumentFiscalYearFocus_29a82702-aeaf-4f49-961d-ae3635efe39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5139fc3c-f0b8-4529-a934-4e2b32c3e905" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5139fc3c-f0b8-4529-a934-4e2b32c3e905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7381a835-9347-4fea-826a-e4cc8c61e5a5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e0339213-91b6-45a6-bd1a-92c874278ffe" xlink:to="loc_dei_EntityCentralIndexKey_7381a835-9347-4fea-826a-e4cc8c61e5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/AuditInformation" xlink:type="simple" xlink:href="nbix-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AuditorInformationAbstract_f66571af-5348-4a53-900a-b8affff9688e" xlink:href="nbix-20231231.xsd#nbix_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_bcf097e4-3d4e-48a0-bc23-972adb106ba1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_AuditorInformationAbstract_f66571af-5348-4a53-900a-b8affff9688e" xlink:to="loc_dei_AuditorFirmId_bcf097e4-3d4e-48a0-bc23-972adb106ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_e08ea847-39db-494e-841d-f8f3ab75444f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_AuditorInformationAbstract_f66571af-5348-4a53-900a-b8affff9688e" xlink:to="loc_dei_AuditorName_e08ea847-39db-494e-841d-f8f3ab75444f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_3ed68157-7750-438c-acfc-c729c0916f9b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_AuditorInformationAbstract_f66571af-5348-4a53-900a-b8affff9688e" xlink:to="loc_dei_AuditorLocation_3ed68157-7750-438c-acfc-c729c0916f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1ccaba09-3a9f-49a5-991f-1168febda660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_38515f64-3977-4258-9d1f-8e3fb672848f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1ccaba09-3a9f-49a5-991f-1168febda660" xlink:to="loc_us-gaap_AssetsAbstract_38515f64-3977-4258-9d1f-8e3fb672848f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9a81cea7-e90d-4fc5-91fd-f639b1f9cb38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38515f64-3977-4258-9d1f-8e3fb672848f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9a81cea7-e90d-4fc5-91fd-f639b1f9cb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31ec2ee6-36a5-47aa-85c7-97d2f65ab787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a81cea7-e90d-4fc5-91fd-f639b1f9cb38" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31ec2ee6-36a5-47aa-85c7-97d2f65ab787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fc7e2416-79c7-4026-8c23-1545557e1c07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a81cea7-e90d-4fc5-91fd-f639b1f9cb38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fc7e2416-79c7-4026-8c23-1545557e1c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_ef5e24b7-89c9-4281-86bd-c83b6f5114fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a81cea7-e90d-4fc5-91fd-f639b1f9cb38" xlink:to="loc_us-gaap_ReceivablesNetCurrent_ef5e24b7-89c9-4281-86bd-c83b6f5114fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b50f4fba-6d00-4599-b399-d52983b03ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a81cea7-e90d-4fc5-91fd-f639b1f9cb38" xlink:to="loc_us-gaap_InventoryNet_b50f4fba-6d00-4599-b399-d52983b03ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_14821b48-7285-4c34-9776-730d74490605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a81cea7-e90d-4fc5-91fd-f639b1f9cb38" xlink:to="loc_us-gaap_OtherAssetsCurrent_14821b48-7285-4c34-9776-730d74490605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f308416f-8360-48b9-8229-a1d83ac05c71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a81cea7-e90d-4fc5-91fd-f639b1f9cb38" xlink:to="loc_us-gaap_AssetsCurrent_f308416f-8360-48b9-8229-a1d83ac05c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_9c018ae9-3c75-4f0d-9cb1-c28a707eae7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38515f64-3977-4258-9d1f-8e3fb672848f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_9c018ae9-3c75-4f0d-9cb1-c28a707eae7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_84095f45-8a27-43e0-878d-d6971b752dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38515f64-3977-4258-9d1f-8e3fb672848f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_84095f45-8a27-43e0-878d-d6971b752dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_95ff537c-9d5a-4a36-8b68-5389a4d56ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38515f64-3977-4258-9d1f-8e3fb672848f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_95ff537c-9d5a-4a36-8b68-5389a4d56ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6c8694ad-56e9-4f48-a236-5cd42fd5ecd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38515f64-3977-4258-9d1f-8e3fb672848f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6c8694ad-56e9-4f48-a236-5cd42fd5ecd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_93e30e08-2df7-4ca7-98d3-eceff6d903ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38515f64-3977-4258-9d1f-8e3fb672848f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_93e30e08-2df7-4ca7-98d3-eceff6d903ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fff8ce43-d934-46f1-89e1-4dd2f93d23cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38515f64-3977-4258-9d1f-8e3fb672848f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fff8ce43-d934-46f1-89e1-4dd2f93d23cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f9e623fa-71f4-4ce5-a485-70c7b6eb5cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38515f64-3977-4258-9d1f-8e3fb672848f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f9e623fa-71f4-4ce5-a485-70c7b6eb5cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b75804cb-d082-4d75-8a85-989a3745ba07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38515f64-3977-4258-9d1f-8e3fb672848f" xlink:to="loc_us-gaap_Assets_b75804cb-d082-4d75-8a85-989a3745ba07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07c82e0e-d7e8-46e0-a6ee-02cf591a1e21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1ccaba09-3a9f-49a5-991f-1168febda660" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07c82e0e-d7e8-46e0-a6ee-02cf591a1e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4e3c3e73-e814-4c77-b558-14b68cd6d286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07c82e0e-d7e8-46e0-a6ee-02cf591a1e21" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4e3c3e73-e814-4c77-b558-14b68cd6d286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_698f6a6a-9775-4957-9cd7-52f631def9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4e3c3e73-e814-4c77-b558-14b68cd6d286" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_698f6a6a-9775-4957-9cd7-52f631def9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_617d3c77-fa82-4123-945b-c57629c2fd28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4e3c3e73-e814-4c77-b558-14b68cd6d286" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_617d3c77-fa82-4123-945b-c57629c2fd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0aa95206-e9a8-442a-a522-a297ae4cc4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4e3c3e73-e814-4c77-b558-14b68cd6d286" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0aa95206-e9a8-442a-a522-a297ae4cc4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c27b6ee0-2e07-479c-9c94-f2be4d5291ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4e3c3e73-e814-4c77-b558-14b68cd6d286" xlink:to="loc_us-gaap_LiabilitiesCurrent_c27b6ee0-2e07-479c-9c94-f2be4d5291ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b754ef2a-c0bc-4a49-a458-3a5d05871dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07c82e0e-d7e8-46e0-a6ee-02cf591a1e21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b754ef2a-c0bc-4a49-a458-3a5d05871dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c9ddb174-d8a6-4c7a-a9ae-c7fa576144f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07c82e0e-d7e8-46e0-a6ee-02cf591a1e21" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c9ddb174-d8a6-4c7a-a9ae-c7fa576144f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2dc2cd3a-b2ea-4d7e-9ec7-62a40bcf09d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07c82e0e-d7e8-46e0-a6ee-02cf591a1e21" xlink:to="loc_us-gaap_Liabilities_2dc2cd3a-b2ea-4d7e-9ec7-62a40bcf09d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_683da5be-f4a2-4b76-b783-42cd8d8038c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07c82e0e-d7e8-46e0-a6ee-02cf591a1e21" xlink:to="loc_us-gaap_StockholdersEquityAbstract_683da5be-f4a2-4b76-b783-42cd8d8038c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5629ca51-3599-4ce3-923d-02d63a6f9d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_683da5be-f4a2-4b76-b783-42cd8d8038c4" xlink:to="loc_us-gaap_PreferredStockValue_5629ca51-3599-4ce3-923d-02d63a6f9d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a19cffbf-8bd2-499e-91a5-fb5e60e64d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_683da5be-f4a2-4b76-b783-42cd8d8038c4" xlink:to="loc_us-gaap_CommonStockValue_a19cffbf-8bd2-499e-91a5-fb5e60e64d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3891612d-5c0e-4339-b669-44cb60a02f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_683da5be-f4a2-4b76-b783-42cd8d8038c4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3891612d-5c0e-4339-b669-44cb60a02f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5d428da9-bfce-4dc8-9907-8abdd37dce74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_683da5be-f4a2-4b76-b783-42cd8d8038c4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5d428da9-bfce-4dc8-9907-8abdd37dce74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d25ccef3-5f55-42c0-b7f6-fc4f7fb6bbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_683da5be-f4a2-4b76-b783-42cd8d8038c4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d25ccef3-5f55-42c0-b7f6-fc4f7fb6bbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6e677300-5f3a-46e6-b364-0f76eb81ddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_683da5be-f4a2-4b76-b783-42cd8d8038c4" xlink:to="loc_us-gaap_StockholdersEquity_6e677300-5f3a-46e6-b364-0f76eb81ddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b07d9ac9-84ea-49f8-a7bc-4cad8fae4d74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_07c82e0e-d7e8-46e0-a6ee-02cf591a1e21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b07d9ac9-84ea-49f8-a7bc-4cad8fae4d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0df567b7-cba5-4f47-b423-02649916dfe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_89bbf2a7-d18c-4570-9ac6-c15a9403eeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0df567b7-cba5-4f47-b423-02649916dfe5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_89bbf2a7-d18c-4570-9ac6-c15a9403eeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_870c1003-f168-410a-9d6c-ba20a081cfb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0df567b7-cba5-4f47-b423-02649916dfe5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_870c1003-f168-410a-9d6c-ba20a081cfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c6332882-59e5-433d-b8d5-55b68b6a6b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0df567b7-cba5-4f47-b423-02649916dfe5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c6332882-59e5-433d-b8d5-55b68b6a6b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_85bd6c71-8088-406f-8a68-9e7c324790f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0df567b7-cba5-4f47-b423-02649916dfe5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_85bd6c71-8088-406f-8a68-9e7c324790f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f64cf7bf-0319-41ac-97b9-23189f3e93c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0df567b7-cba5-4f47-b423-02649916dfe5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f64cf7bf-0319-41ac-97b9-23189f3e93c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e6d764ed-1be4-43b2-a34e-c9815a1022ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0df567b7-cba5-4f47-b423-02649916dfe5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e6d764ed-1be4-43b2-a34e-c9815a1022ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c292dec5-a253-462f-bbe9-6753fd4f98ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0df567b7-cba5-4f47-b423-02649916dfe5" xlink:to="loc_us-gaap_CommonStockSharesIssued_c292dec5-a253-462f-bbe9-6753fd4f98ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3fc2853d-7ea8-4105-9aa9-e32ead0323ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0df567b7-cba5-4f47-b423-02649916dfe5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3fc2853d-7ea8-4105-9aa9-e32ead0323ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConsolidatedStatementsIncomeandComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_86b1e782-e9fb-4281-ac17-a5c1a0de2b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5d0c2dd2-33c0-4cd2-bbb4-fe7f868a40fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_86b1e782-e9fb-4281-ac17-a5c1a0de2b26" xlink:to="loc_us-gaap_StatementTable_5d0c2dd2-33c0-4cd2-bbb4-fe7f868a40fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6a3bce82-156f-4c37-96c4-e013e8ba51c1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5d0c2dd2-33c0-4cd2-bbb4-fe7f868a40fe" xlink:to="loc_srt_ProductOrServiceAxis_6a3bce82-156f-4c37-96c4-e013e8ba51c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_19c87576-40cb-4108-83f9-bee601f7c96e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6a3bce82-156f-4c37-96c4-e013e8ba51c1" xlink:to="loc_srt_ProductsAndServicesDomain_19c87576-40cb-4108-83f9-bee601f7c96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b8af9f38-52cb-450f-aaef-dd1bb54de03d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_19c87576-40cb-4108-83f9-bee601f7c96e" xlink:to="loc_us-gaap_ProductMember_b8af9f38-52cb-450f-aaef-dd1bb54de03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_0e44d826-9adf-4760-89ee-98f937d7a832" xlink:href="nbix-20231231.xsd#nbix_CollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_19c87576-40cb-4108-83f9-bee601f7c96e" xlink:to="loc_nbix_CollaborationRevenueMember_0e44d826-9adf-4760-89ee-98f937d7a832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5d0c2dd2-33c0-4cd2-bbb4-fe7f868a40fe" xlink:to="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_fa4cf05c-4e27-4a34-9a6d-7478f73301c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_RevenuesAbstract_fa4cf05c-4e27-4a34-9a6d-7478f73301c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8027554-c23f-4945-8502-2afe0c8dd255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_fa4cf05c-4e27-4a34-9a6d-7478f73301c8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8027554-c23f-4945-8502-2afe0c8dd255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_525f90e0-454d-4c85-8e8d-f8eeab3fe639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_525f90e0-454d-4c85-8e8d-f8eeab3fe639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_eeec82f2-d6a1-410b-ba2c-a7bc9760628b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_eeec82f2-d6a1-410b-ba2c-a7bc9760628b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_bd0bffac-adb2-45b3-8fd2-11808306f121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_bd0bffac-adb2-45b3-8fd2-11808306f121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e03b3e46-7a2c-4f9a-94fe-c9aac76478be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e03b3e46-7a2c-4f9a-94fe-c9aac76478be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cd95134c-9531-450c-b95c-c597c31c1703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d89be913-ee9b-4c10-b424-5e74c21d4add" xlink:to="loc_us-gaap_CostsAndExpenses_cd95134c-9531-450c-b95c-c597c31c1703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b3bc0521-0142-45ce-81bf-89b8498f7275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_OperatingIncomeLoss_b3bc0521-0142-45ce-81bf-89b8498f7275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f1ae5b34-b3e2-4abb-ae68-c45a911efa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:to="loc_us-gaap_InterestExpense_f1ae5b34-b3e2-4abb-ae68-c45a911efa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3c400494-0ca7-49a8-af23-f531b10a1a65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3c400494-0ca7-49a8-af23-f531b10a1a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5ae8c987-d6e5-42d0-be58-38463623360f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5ae8c987-d6e5-42d0-be58-38463623360f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_057aa6a8-4823-4e95-87f2-1fbcf990d883" xlink:href="nbix-20231231.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_057aa6a8-4823-4e95-87f2-1fbcf990d883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3fd41ab8-ac8e-443f-8a17-3d8840ba17da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a6cbc4a4-4069-4b8b-8555-7051a73c2927" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3fd41ab8-ac8e-443f-8a17-3d8840ba17da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4538bd94-d41c-4e9b-b1a5-6c30fef39fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4538bd94-d41c-4e9b-b1a5-6c30fef39fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4dc33444-96f3-4f9d-97a7-3671e86ed6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4dc33444-96f3-4f9d-97a7-3671e86ed6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e14d0caf-0ba8-4efa-b912-bb5afa155b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_NetIncomeLoss_e14d0caf-0ba8-4efa-b912-bb5afa155b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_de178cde-4a22-4148-b778-5030012152cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_de178cde-4a22-4148-b778-5030012152cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6b9e248e-a463-4d57-9be7-0000066223f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6b9e248e-a463-4d57-9be7-0000066223f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ccb35277-3b83-45fe-8583-0708393c90c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ccb35277-3b83-45fe-8583-0708393c90c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_126af9ed-8900-4fdf-b62d-480ceeb4e142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_EarningsPerShareBasic_126af9ed-8900-4fdf-b62d-480ceeb4e142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_32511626-9f7f-4aff-94d0-3d94647705ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_EarningsPerShareDiluted_32511626-9f7f-4aff-94d0-3d94647705ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6be25821-5682-4afa-adef-8e7bf6eec529" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6be25821-5682-4afa-adef-8e7bf6eec529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_10e2d311-23e7-4fad-9754-b8bf804d138b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cdfacd6-252b-4b6e-b1c7-5bb43ffecc05" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_10e2d311-23e7-4fad-9754-b8bf804d138b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8d9be5c1-0ab2-46d1-bc06-24a781b159c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_73d9b714-5d82-4f2d-bb2c-799d47e06424" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8d9be5c1-0ab2-46d1-bc06-24a781b159c1" xlink:to="loc_us-gaap_StatementTable_73d9b714-5d82-4f2d-bb2c-799d47e06424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b3a0a7fa-8c25-4de7-b316-210dc89db86e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_73d9b714-5d82-4f2d-bb2c-799d47e06424" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b3a0a7fa-8c25-4de7-b316-210dc89db86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_15882ed5-67f3-49c3-9951-70f5549cd404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b3a0a7fa-8c25-4de7-b316-210dc89db86e" xlink:to="loc_us-gaap_EquityComponentDomain_15882ed5-67f3-49c3-9951-70f5549cd404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_29fc5c0d-994c-41a3-b0a7-d8ffb87c36c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_15882ed5-67f3-49c3-9951-70f5549cd404" xlink:to="loc_us-gaap_CommonStockMember_29fc5c0d-994c-41a3-b0a7-d8ffb87c36c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9f68ed66-9972-49d8-b6c6-ee8ca00bdfec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_15882ed5-67f3-49c3-9951-70f5549cd404" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9f68ed66-9972-49d8-b6c6-ee8ca00bdfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9970c0fc-473e-49f2-ba64-3734337adad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_15882ed5-67f3-49c3-9951-70f5549cd404" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9970c0fc-473e-49f2-ba64-3734337adad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6d4cb9af-dc1a-4afa-b30f-e2cf386b916f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_15882ed5-67f3-49c3-9951-70f5549cd404" xlink:to="loc_us-gaap_RetainedEarningsMember_6d4cb9af-dc1a-4afa-b30f-e2cf386b916f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0adb1c63-5102-4768-af35-eee96e6714a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_73d9b714-5d82-4f2d-bb2c-799d47e06424" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0adb1c63-5102-4768-af35-eee96e6714a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8aaaba4d-60d2-462d-b991-8d15fcd38d93" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0adb1c63-5102-4768-af35-eee96e6714a8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8aaaba4d-60d2-462d-b991-8d15fcd38d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_21007123-fcb4-4b79-95ee-44cc12b1b271" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8aaaba4d-60d2-462d-b991-8d15fcd38d93" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_21007123-fcb4-4b79-95ee-44cc12b1b271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4508530b-7b3b-4897-a547-31a5438596a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_73d9b714-5d82-4f2d-bb2c-799d47e06424" xlink:to="loc_us-gaap_StatementLineItems_4508530b-7b3b-4897-a547-31a5438596a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_3d294b68-9cc8-4b1f-bdaf-df02ebcf8803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4508530b-7b3b-4897-a547-31a5438596a2" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_3d294b68-9cc8-4b1f-bdaf-df02ebcf8803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4508530b-7b3b-4897-a547-31a5438596a2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f0d9fa09-903b-436a-ad22-76ece8035bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_SharesOutstanding_f0d9fa09-903b-436a-ad22-76ece8035bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_77cf0416-0eea-435f-a19f-4acf32b65f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_StockholdersEquity_77cf0416-0eea-435f-a19f-4acf32b65f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4c2bb2c2-f197-4cb1-8f05-8f3ec38d9637" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_NetIncomeLoss_4c2bb2c2-f197-4cb1-8f05-8f3ec38d9637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27cd9f93-f14a-4d00-9132-9f5a7170134a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27cd9f93-f14a-4d00-9132-9f5a7170134a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dd91621f-aa6a-4e28-bba9-bb1f37019ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dd91621f-aa6a-4e28-bba9-bb1f37019ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_39bad6c3-8913-4299-8ef9-c109600b1310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_39bad6c3-8913-4299-8ef9-c109600b1310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8b1d89d8-45af-4d87-aadd-fd42a8acee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8b1d89d8-45af-4d87-aadd-fd42a8acee0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_61b36183-144a-46b1-af74-59739c8333cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_SharesOutstanding_61b36183-144a-46b1-af74-59739c8333cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_212c5b04-3c11-460f-80cb-15faa09f31a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d235c43-af38-49fc-9720-abbe1096d75e" xlink:to="loc_us-gaap_StockholdersEquity_212c5b04-3c11-460f-80cb-15faa09f31a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2f5c1641-2052-4c03-b773-7fded6a48509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_970399ea-a086-45c7-a81e-37340de73938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f5c1641-2052-4c03-b773-7fded6a48509" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_970399ea-a086-45c7-a81e-37340de73938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bfa43e3a-5be6-4b5a-b91f-bc9a39650488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_970399ea-a086-45c7-a81e-37340de73938" xlink:to="loc_us-gaap_NetIncomeLoss_bfa43e3a-5be6-4b5a-b91f-bc9a39650488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_970399ea-a086-45c7-a81e-37340de73938" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5383ce4b-4624-46c4-8407-d3ea7141fc56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:to="loc_us-gaap_ShareBasedCompensation_5383ce4b-4624-46c4-8407-d3ea7141fc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_67e0f9fb-c93f-44c2-986a-2ddb645010c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:to="loc_us-gaap_Depreciation_67e0f9fb-c93f-44c2-986a-2ddb645010c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d290852b-352e-4eab-9bc9-accb77752291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d290852b-352e-4eab-9bc9-accb77752291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6a55cfbd-8d2b-4860-a9f0-d13a8cf7ef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6a55cfbd-8d2b-4860-a9f0-d13a8cf7ef9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7618eabe-9417-4fac-bb6f-2c08e7ddecf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7618eabe-9417-4fac-bb6f-2c08e7ddecf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_34276083-8840-4d8d-96cd-8b332a6b725c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_34276083-8840-4d8d-96cd-8b332a6b725c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3970b35c-f193-432c-aa75-74b77717f7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3970b35c-f193-432c-aa75-74b77717f7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4e5f2341-36c9-497d-bd39-d0c81ba31978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4e5f2341-36c9-497d-bd39-d0c81ba31978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_30ef6eac-a870-49b3-a3c6-4f2d01252fea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_30ef6eac-a870-49b3-a3c6-4f2d01252fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d82057b2-987d-4bb8-bf67-2a7e5d5fe3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d82057b2-987d-4bb8-bf67-2a7e5d5fe3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2491d8e3-dd28-49ae-98f5-f386a516046a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41960b75-6530-4502-8715-018fd19f862c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2491d8e3-dd28-49ae-98f5-f386a516046a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_56d0970c-becc-4927-8307-48ac77ce1dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2491d8e3-dd28-49ae-98f5-f386a516046a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_56d0970c-becc-4927-8307-48ac77ce1dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_82e166e2-3bcd-48a2-8b5f-007fb136ebd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2491d8e3-dd28-49ae-98f5-f386a516046a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_82e166e2-3bcd-48a2-8b5f-007fb136ebd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_48f77f9c-36b2-47b7-811b-326f8cabcb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2491d8e3-dd28-49ae-98f5-f386a516046a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_48f77f9c-36b2-47b7-811b-326f8cabcb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_75b7a48d-e1f5-4430-ac57-0ce36c1a692f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2491d8e3-dd28-49ae-98f5-f386a516046a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_75b7a48d-e1f5-4430-ac57-0ce36c1a692f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30d0cacb-eed7-4d46-8654-383f58b1a7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_970399ea-a086-45c7-a81e-37340de73938" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30d0cacb-eed7-4d46-8654-383f58b1a7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f77fb8c4-d0cd-4ae0-8ee9-21f4b1e5582f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f5c1641-2052-4c03-b773-7fded6a48509" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f77fb8c4-d0cd-4ae0-8ee9-21f4b1e5582f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3e6d136c-c619-41cd-8133-4070e3ea240d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f77fb8c4-d0cd-4ae0-8ee9-21f4b1e5582f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3e6d136c-c619-41cd-8133-4070e3ea240d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b5a9118a-4f6b-45f2-885d-61e51fa0f8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f77fb8c4-d0cd-4ae0-8ee9-21f4b1e5582f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b5a9118a-4f6b-45f2-885d-61e51fa0f8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e7df5aae-4812-4b9e-a5b7-a5186f6413de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f77fb8c4-d0cd-4ae0-8ee9-21f4b1e5582f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e7df5aae-4812-4b9e-a5b7-a5186f6413de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_970956be-8e9b-41c9-aa53-82ab2d093ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f77fb8c4-d0cd-4ae0-8ee9-21f4b1e5582f" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_970956be-8e9b-41c9-aa53-82ab2d093ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b3ca9f60-dddd-4898-9a3f-c080162f8fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f77fb8c4-d0cd-4ae0-8ee9-21f4b1e5582f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b3ca9f60-dddd-4898-9a3f-c080162f8fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f6ab6ac7-a553-44af-92dd-f58d7c670a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f77fb8c4-d0cd-4ae0-8ee9-21f4b1e5582f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f6ab6ac7-a553-44af-92dd-f58d7c670a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_70584d8d-4a1d-489c-88e0-7fabf0cb582b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f5c1641-2052-4c03-b773-7fded6a48509" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_70584d8d-4a1d-489c-88e0-7fabf0cb582b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_38ee4e44-8e3b-4d7f-8ba7-0dcdb9df2bee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_70584d8d-4a1d-489c-88e0-7fabf0cb582b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_38ee4e44-8e3b-4d7f-8ba7-0dcdb9df2bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_7938df90-7b06-4a38-8fea-d432c3320d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_70584d8d-4a1d-489c-88e0-7fabf0cb582b" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_7938df90-7b06-4a38-8fea-d432c3320d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04199f6f-db3c-4889-a461-4e1268a17e55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_70584d8d-4a1d-489c-88e0-7fabf0cb582b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04199f6f-db3c-4889-a461-4e1268a17e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9948a7b1-5151-431d-9f91-a7be39c767b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f5c1641-2052-4c03-b773-7fded6a48509" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9948a7b1-5151-431d-9f91-a7be39c767b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1c0718c1-bb32-491a-82a8-ac1fafe0d8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f5c1641-2052-4c03-b773-7fded6a48509" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1c0718c1-bb32-491a-82a8-ac1fafe0d8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73e44d69-6458-4892-b826-7b5b4797ab5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f5c1641-2052-4c03-b773-7fded6a48509" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73e44d69-6458-4892-b826-7b5b4797ab5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c5bdea3-0413-4dd6-81a5-149531d5e243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f5c1641-2052-4c03-b773-7fded6a48509" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c5bdea3-0413-4dd6-81a5-149531d5e243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5aa4b212-0f1d-41a5-900e-4cea7aa58f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f5c1641-2052-4c03-b773-7fded6a48509" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5aa4b212-0f1d-41a5-900e-4cea7aa58f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_23609c2c-6f07-4aa6-aad5-70e4d77b61be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5aa4b212-0f1d-41a5-900e-4cea7aa58f4b" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_23609c2c-6f07-4aa6-aad5-70e4d77b61be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c6c389b3-f4f3-4b61-9864-7314f5e2f4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5aa4b212-0f1d-41a5-900e-4cea7aa58f4b" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c6c389b3-f4f3-4b61-9864-7314f5e2f4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_0b0fc45d-2912-43d8-b5ba-c4a597fada50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5aa4b212-0f1d-41a5-900e-4cea7aa58f4b" xlink:to="loc_us-gaap_InterestPaidNet_0b0fc45d-2912-43d8-b5ba-c4a597fada50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_85d12920-2c8a-43f2-860d-0ce19ded7d89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5aa4b212-0f1d-41a5-900e-4cea7aa58f4b" xlink:to="loc_us-gaap_IncomeTaxesPaid_85d12920-2c8a-43f2-860d-0ce19ded7d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nbix-20231231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bbbe40e7-78ee-4432-aa9e-67b4cc910ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_01854d36-beb4-4286-a8aa-74ac573c841a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bbbe40e7-78ee-4432-aa9e-67b4cc910ae4" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_01854d36-beb4-4286-a8aa-74ac573c841a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="nbix-20231231.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_68f35a67-0233-455b-9377-c9f83f2a3d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4f9bd134-dcc6-4fb0-843b-449a80f9b050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_68f35a67-0233-455b-9377-c9f83f2a3d7c" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4f9bd134-dcc6-4fb0-843b-449a80f9b050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecurities" xlink:type="simple" xlink:href="nbix-20231231.xsd#DebtSecurities"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8d30cd44-1f57-49e6-91cb-cfe6aa5948a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0a5717a1-773b-44f2-b32b-936006df334d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8d30cd44-1f57-49e6-91cb-cfe6aa5948a5" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0a5717a1-773b-44f2-b32b-936006df334d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nbix-20231231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c4da8d5a-5cda-45c4-a300-287e1aa19802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_68771c33-4102-4d58-81c8-733d0495434e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c4da8d5a-5cda-45c4-a300-287e1aa19802" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_68771c33-4102-4d58-81c8-733d0495434e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConvertibleSeniorNotes"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f40e8acd-be71-4564-a4f8-7a8a293b0f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5add15ec-3a70-4652-ab56-4de8d99bb67f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f40e8acd-be71-4564-a4f8-7a8a293b0f3b" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5add15ec-3a70-4652-ab56-4de8d99bb67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="nbix-20231231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75d5e31d-2112-4b2a-a9b3-662e02e7d776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5b0faaab-c77c-4791-9543-2ece5dd193b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75d5e31d-2112-4b2a-a9b3-662e02e7d776" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5b0faaab-c77c-4791-9543-2ece5dd193b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_133e1974-b047-40ac-82a8-faf062e8b34f" xlink:href="nbix-20231231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_2a90f020-c24e-4278-9861-246bac13ca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_133e1974-b047-40ac-82a8-faf062e8b34f" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_2a90f020-c24e-4278-9861-246bac13ca9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsPerShare" xlink:type="simple" xlink:href="nbix-20231231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_35eb7251-6cf5-4b1b-b89c-4e18729e8df6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1b0c53ce-ac3a-4004-b228-17c87630531d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35eb7251-6cf5-4b1b-b89c-4e18729e8df6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1b0c53ce-ac3a-4004-b228-17c87630531d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee998c5c-c7d2-4b26-9f55-a004ae8854cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7dd12e2d-1c74-4a3b-a584-12f91011a225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee998c5c-c7d2-4b26-9f55-a004ae8854cb" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7dd12e2d-1c74-4a3b-a584-12f91011a225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f74f373f-76cc-4ce2-98c6-c60be8e821e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4b8edf92-b6a9-4fd5-a511-e582d9d0e282" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f74f373f-76cc-4ce2-98c6-c60be8e821e8" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4b8edf92-b6a9-4fd5-a511-e582d9d0e282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Leases" xlink:type="simple" xlink:href="nbix-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bea3bad1-051c-44b0-81a5-e429c2258265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_027fde90-971d-4cea-a788-3039f0ca2cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bea3bad1-051c-44b0-81a5-e429c2258265" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_027fde90-971d-4cea-a788-3039f0ca2cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/RetirementPlan" xlink:type="simple" xlink:href="nbix-20231231.xsd#RetirementPlan"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/RetirementPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2f2887a5-1509-4223-964c-b92e32474871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_4fdb34a7-8686-42ca-97c9-a7c0c9898185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2f2887a5-1509-4223-964c-b92e32474871" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_4fdb34a7-8686-42ca-97c9-a7c0c9898185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LegalProceedings" xlink:type="simple" xlink:href="nbix-20231231.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d07f1d0-937f-491d-8de2-04a243ef5a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3d36cd1e-79c4-40bc-8134-12ff47082b14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d07f1d0-937f-491d-8de2-04a243ef5a69" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3d36cd1e-79c4-40bc-8134-12ff47082b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nbix-20231231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock_ccd673ce-32a4-48bf-8a21-d3b58ce2e0f8" xlink:href="nbix-20231231.xsd#nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock_ccd673ce-32a4-48bf-8a21-d3b58ce2e0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_7d6d84bf-e08b-4f3d-af09-9d3fef48e8db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_7d6d84bf-e08b-4f3d-af09-9d3fef48e8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_69f6fd4c-cb7e-4094-998f-c3a061ef78c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_UseOfEstimates_69f6fd4c-cb7e-4094-998f-c3a061ef78c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e2b12220-3f79-4907-bc8e-79658c6a2c46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e2b12220-3f79-4907-bc8e-79658c6a2c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_b410cb4f-eaa5-4233-ba30-928229d86b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_b410cb4f-eaa5-4233-ba30-928229d86b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_51282f5e-9370-40b4-8081-175ff39d98ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_51282f5e-9370-40b4-8081-175ff39d98ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_c654f7c0-88b2-4796-ae62-ac955e4ce0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_c654f7c0-88b2-4796-ae62-ac955e4ce0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_c4034dcf-ec74-4e65-8fd1-21128d622e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_c4034dcf-ec74-4e65-8fd1-21128d622e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_4a406d44-279a-42e6-89cf-806167e2c8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_4a406d44-279a-42e6-89cf-806167e2c8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c047d021-d502-45e3-b14f-93e51768969f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c047d021-d502-45e3-b14f-93e51768969f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_69609cd5-7fd9-4014-a256-53a88f4e6216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_69609cd5-7fd9-4014-a256-53a88f4e6216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_01a81bdf-0acc-4f3b-a2a0-35542efa40c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_01a81bdf-0acc-4f3b-a2a0-35542efa40c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_20163b8e-2eb8-4d47-91cd-63e848639c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_20163b8e-2eb8-4d47-91cd-63e848639c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_cea79a89-3c20-4688-88ce-78710ce27248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_cea79a89-3c20-4688-88ce-78710ce27248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c68b121c-67a1-4479-a5c4-0bd3bb4c6f86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c68b121c-67a1-4479-a5c4-0bd3bb4c6f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_083bcf17-d2d4-459b-aeaa-33c3a1a2c57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_083bcf17-d2d4-459b-aeaa-33c3a1a2c57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_998bf1b9-2c7b-4af6-bc37-6fd02d770c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_998bf1b9-2c7b-4af6-bc37-6fd02d770c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_bbdf76d8-4e62-43c6-88f9-cd604e9393a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_bbdf76d8-4e62-43c6-88f9-cd604e9393a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_6198c7cc-1bf3-4a05-a3aa-e03ba85e2abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_6198c7cc-1bf3-4a05-a3aa-e03ba85e2abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4a0f95d3-10f0-4b11-8fbe-45290498a2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4a0f95d3-10f0-4b11-8fbe-45290498a2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5c7aa446-f520-483b-ad58-9d8b7bb6cdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5c7aa446-f520-483b-ad58-9d8b7bb6cdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9c65a569-ef74-4494-a920-420caa954316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42711024-5013-4665-acde-e19da5a4500b" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9c65a569-ef74-4494-a920-420caa954316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="simple" xlink:href="nbix-20231231.xsd#DebtSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2986b2eb-44d0-497d-a92c-436c42a275da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_c6b64856-2217-4291-98a6-75ba7afb1ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2986b2eb-44d0-497d-a92c-436c42a275da" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_c6b64856-2217-4291-98a6-75ba7afb1ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_96034d37-3f78-4097-9827-d5b1f2c0f3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2986b2eb-44d0-497d-a92c-436c42a275da" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_96034d37-3f78-4097-9827-d5b1f2c0f3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nbix-20231231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e5d5c274-7dba-4e49-9b83-77ff8a6babd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_a0519754-a601-4dd4-9cb4-7ae435714090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5d5c274-7dba-4e49-9b83-77ff8a6babd2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_a0519754-a601-4dd4-9cb4-7ae435714090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConvertibleSeniorNotesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_88c722de-f3da-4470-8dd6-808aac99cf76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_d688a356-a39f-4cdf-8b03-680807a7a787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_88c722de-f3da-4470-8dd6-808aac99cf76" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_d688a356-a39f-4cdf-8b03-680807a7a787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="nbix-20231231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4340033d-04a3-4e62-9367-515a1c08cab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_6191e011-8f52-430f-b6b4-ef04b5d15a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4340033d-04a3-4e62-9367-515a1c08cab5" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_6191e011-8f52-430f-b6b4-ef04b5d15a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_22d1e0ed-4d7d-4f23-a717-bd64397c5ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4340033d-04a3-4e62-9367-515a1c08cab5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_22d1e0ed-4d7d-4f23-a717-bd64397c5ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_570e8fef-befb-4bb2-822d-05872b6309ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4340033d-04a3-4e62-9367-515a1c08cab5" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_570e8fef-befb-4bb2-822d-05872b6309ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_abe36f2b-89f2-482b-8e97-486f8cbec60d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4340033d-04a3-4e62-9367-515a1c08cab5" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_abe36f2b-89f2-482b-8e97-486f8cbec60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_cd239764-9f22-453d-bf5f-40e44e1bc0ae" xlink:href="nbix-20231231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_57b476b2-8354-4ffd-8b55-d087574db594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_cd239764-9f22-453d-bf5f-40e44e1bc0ae" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_57b476b2-8354-4ffd-8b55-d087574db594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_dea8627f-f43f-44b8-826a-045798f6d848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_cd239764-9f22-453d-bf5f-40e44e1bc0ae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_dea8627f-f43f-44b8-826a-045798f6d848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f6ef7bef-c1a6-4f56-9c14-dc9314ad8d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_cd239764-9f22-453d-bf5f-40e44e1bc0ae" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f6ef7bef-c1a6-4f56-9c14-dc9314ad8d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock_0e00687f-b3f0-4dca-a339-877c162bd9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_cd239764-9f22-453d-bf5f-40e44e1bc0ae" xlink:to="loc_us-gaap_OtherLiabilitiesTableTextBlock_0e00687f-b3f0-4dca-a339-877c162bd9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_b9f82528-44c4-47f5-87a3-ccf09b8a9002" xlink:href="nbix-20231231.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_cd239764-9f22-453d-bf5f-40e44e1bc0ae" xlink:to="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_b9f82528-44c4-47f5-87a3-ccf09b8a9002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="nbix-20231231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4d9a49aa-67ee-4e66-a628-2b636037ddc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9a0412d6-b74e-4777-94bc-7f50acd9e701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4d9a49aa-67ee-4e66-a628-2b636037ddc0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9a0412d6-b74e-4777-94bc-7f50acd9e701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8eaf8104-33bb-49ca-b93d-e73f274429cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2bcb0dd8-1f2c-468d-bdf4-a8527654ca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8eaf8104-33bb-49ca-b93d-e73f274429cc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2bcb0dd8-1f2c-468d-bdf4-a8527654ca9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9c48e2ea-62e9-4160-84d7-6502d94df152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8eaf8104-33bb-49ca-b93d-e73f274429cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9c48e2ea-62e9-4160-84d7-6502d94df152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_369635b7-f132-401a-bf16-f8031e7f8664" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8eaf8104-33bb-49ca-b93d-e73f274429cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_369635b7-f132-401a-bf16-f8031e7f8664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_bd09a1d0-c017-4a55-bcb0-41f2ccf27303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8eaf8104-33bb-49ca-b93d-e73f274429cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_bd09a1d0-c017-4a55-bcb0-41f2ccf27303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fffb59fe-e478-4876-a5c6-28ea52856cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_b9d6011d-1cab-4e9d-ac04-9903924f99b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fffb59fe-e478-4876-a5c6-28ea52856cd0" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_b9d6011d-1cab-4e9d-ac04-9903924f99b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2aabb5c7-7b72-419f-9662-f615e317446c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fffb59fe-e478-4876-a5c6-28ea52856cd0" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2aabb5c7-7b72-419f-9662-f615e317446c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2e7a584f-5ad9-44c7-86b6-9b0defbce5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fffb59fe-e478-4876-a5c6-28ea52856cd0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2e7a584f-5ad9-44c7-86b6-9b0defbce5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e557fffe-5895-43a0-b93c-5297fc316bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fffb59fe-e478-4876-a5c6-28ea52856cd0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e557fffe-5895-43a0-b93c-5297fc316bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_68fd5423-324a-4941-9465-8718d291a6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fffb59fe-e478-4876-a5c6-28ea52856cd0" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_68fd5423-324a-4941-9465-8718d291a6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesTables" xlink:type="simple" xlink:href="nbix-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d2805a67-026c-426b-9915-5405bdd35f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_cd365b25-3180-4604-a57c-fde06375fa95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d2805a67-026c-426b-9915-5405bdd35f70" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_cd365b25-3180-4604-a57c-fde06375fa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5e5fae7e-cb7c-4313-bc5e-59b767b168d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d2805a67-026c-426b-9915-5405bdd35f70" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5e5fae7e-cb7c-4313-bc5e-59b767b168d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_86ac763e-32fe-4df6-8a44-e10135050567" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:href="nbix-20231231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_86ac763e-32fe-4df6-8a44-e10135050567" xlink:to="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd181c39-c08a-48c7-85c4-37f855a860cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd181c39-c08a-48c7-85c4-37f855a860cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36fbfaa1-0eaf-40fc-ba00-2502aaee3f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bd181c39-c08a-48c7-85c4-37f855a860cc" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36fbfaa1-0eaf-40fc-ba00-2502aaee3f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_3af83b65-23b2-405c-a3da-f9d109f07963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36fbfaa1-0eaf-40fc-ba00-2502aaee3f75" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_3af83b65-23b2-405c-a3da-f9d109f07963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e32969e3-2dbe-441f-a4e6-0a6aae6d1e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36fbfaa1-0eaf-40fc-ba00-2502aaee3f75" xlink:to="loc_us-gaap_AccountsReceivableMember_e32969e3-2dbe-441f-a4e6-0a6aae6d1e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_382425ef-8bc4-4bb3-94fc-a74023d03152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_382425ef-8bc4-4bb3-94fc-a74023d03152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2f872314-a88e-474b-a0c2-90741a4ead90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_382425ef-8bc4-4bb3-94fc-a74023d03152" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2f872314-a88e-474b-a0c2-90741a4ead90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a2589897-5d4f-4904-9cf9-f1ee919325a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2f872314-a88e-474b-a0c2-90741a4ead90" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a2589897-5d4f-4904-9cf9-f1ee919325a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a3596232-0764-4587-9a4f-113031baa2b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_srt_MajorCustomersAxis_a3596232-0764-4587-9a4f-113031baa2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5779befc-9c11-4a81-a55a-d8f3e9b4cfb7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a3596232-0764-4587-9a4f-113031baa2b1" xlink:to="loc_srt_NameOfMajorCustomerDomain_5779befc-9c11-4a81-a55a-d8f3e9b4cfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LargestFourCustomersMember_32a2928c-b2b5-4d2f-9a72-bdaceb02ecc5" xlink:href="nbix-20231231.xsd#nbix_LargestFourCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5779befc-9c11-4a81-a55a-d8f3e9b4cfb7" xlink:to="loc_nbix_LargestFourCustomersMember_32a2928c-b2b5-4d2f-9a72-bdaceb02ecc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f9cea44d-e823-44da-bef4-5fbc579be137" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_srt_RangeAxis_f9cea44d-e823-44da-bef4-5fbc579be137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3632bbb3-93cc-4129-a9ce-7a55fb0f8d8d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f9cea44d-e823-44da-bef4-5fbc579be137" xlink:to="loc_srt_RangeMember_3632bbb3-93cc-4129-a9ce-7a55fb0f8d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7514593a-bfae-4106-b052-ad0cce6619f3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3632bbb3-93cc-4129-a9ce-7a55fb0f8d8d" xlink:to="loc_srt_MinimumMember_7514593a-bfae-4106-b052-ad0cce6619f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_44429323-b8fe-4972-b518-721e4ee3e28d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3632bbb3-93cc-4129-a9ce-7a55fb0f8d8d" xlink:to="loc_srt_MaximumMember_44429323-b8fe-4972-b518-721e4ee3e28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_475d49fe-9cf0-4959-8de0-cb44add744a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_475d49fe-9cf0-4959-8de0-cb44add744a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ce8800d-6dcf-408d-81df-fff1e76523ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_475d49fe-9cf0-4959-8de0-cb44add744a1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ce8800d-6dcf-408d-81df-fff1e76523ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8c3c50d7-94ec-4e39-aa47-63a558b44ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ce8800d-6dcf-408d-81df-fff1e76523ca" xlink:to="loc_us-gaap_EmployeeStockMember_8c3c50d7-94ec-4e39-aa47-63a558b44ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9432cda8-294a-4024-9c6a-84275086d8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_us-gaap_DebtInstrumentAxis_9432cda8-294a-4024-9c6a-84275086d8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bdc1ccfe-e03e-4625-a180-ce0265a788f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9432cda8-294a-4024-9c6a-84275086d8a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bdc1ccfe-e03e-4625-a180-ce0265a788f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_21db5337-9643-4033-987a-e2ce103a090a" xlink:href="nbix-20231231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bdc1ccfe-e03e-4625-a180-ce0265a788f7" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_21db5337-9643-4033-987a-e2ce103a090a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:href="nbix-20231231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_999ce292-fd90-484b-8f1c-a5b3bbbc81a3" xlink:to="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_47f4cae4-1a96-4a31-857b-17ef01356a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_NumberOfOperatingSegments_47f4cae4-1a96-4a31-857b-17ef01356a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_010805d2-791b-4765-9efb-9ef8b1d8173f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_NumberOfReportableSegments_010805d2-791b-4765-9efb-9ef8b1d8173f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_c2e85b9b-77b2-46cf-ac03-acb21c5b024d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_c2e85b9b-77b2-46cf-ac03-acb21c5b024d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_c72666ba-8ec2-41d2-8155-6b2c90357299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_InterestReceivableCurrent_c72666ba-8ec2-41d2-8155-6b2c90357299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_724b39af-b92b-4d1f-8e2b-b37cd5ef998a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_724b39af-b92b-4d1f-8e2b-b37cd5ef998a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7d66eb64-87ff-47fd-b88c-2386291b7256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7d66eb64-87ff-47fd-b88c-2386291b7256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3289a184-cdfd-4bbd-8058-25da3bc564e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_Depreciation_3289a184-cdfd-4bbd-8058-25da3bc564e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fcd0811c-aebf-4e3f-ac5b-33530c4f8740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fcd0811c-aebf-4e3f-ac5b-33530c4f8740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_45a1aded-0f23-4f3a-9ba0-6a6ebfa04714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_AdvertisingExpense_45a1aded-0f23-4f3a-9ba0-6a6ebfa04714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_796f680a-3537-4d2e-8c02-78c8a6e4fffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_796f680a-3537-4d2e-8c02-78c8a6e4fffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ESPPPurchasePeriod_f185d59d-057a-4e13-9161-b29f2e881dc7" xlink:href="nbix-20231231.xsd#nbix_ESPPPurchasePeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_nbix_ESPPPurchasePeriod_f185d59d-057a-4e13-9161-b29f2e881dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1c54d765-38ec-4879-900d-fd70ab061620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1c54d765-38ec-4879-900d-fd70ab061620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_45b64f84-893f-41af-8dbd-ec677b70f5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_94a566a9-2b5d-402f-b704-ee6182c4affe" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_45b64f84-893f-41af-8dbd-ec677b70f5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8584802e-150f-4de0-9ad3-efd2feb8d861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8584802e-150f-4de0-9ad3-efd2feb8d861" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d1a0583a-4f58-496e-81f6-a3e7c7180dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d1a0583a-4f58-496e-81f6-a3e7c7180dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc522c99-b0ef-47a8-aad0-30d210b91274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d1a0583a-4f58-496e-81f6-a3e7c7180dbe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc522c99-b0ef-47a8-aad0-30d210b91274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_141ee9ac-602d-446e-aab7-039859c5aab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc522c99-b0ef-47a8-aad0-30d210b91274" xlink:to="loc_us-gaap_CollaborativeArrangementMember_141ee9ac-602d-446e-aab7-039859c5aab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_250d3d01-4273-4f28-929a-057a79e5aa71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_srt_CounterpartyNameAxis_250d3d01-4273-4f28-929a-057a79e5aa71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_250d3d01-4273-4f28-929a-057a79e5aa71" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_HeptaresTherapeuticsLimitedMember_cf3939bc-30cc-4e97-bd16-a79c9b342570" xlink:href="nbix-20231231.xsd#nbix_HeptaresTherapeuticsLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_HeptaresTherapeuticsLimitedMember_cf3939bc-30cc-4e97-bd16-a79c9b342570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_aed11e36-4b91-406a-b645-858b8d99eb6b" xlink:href="nbix-20231231.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_aed11e36-4b91-406a-b645-858b8d99eb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_8a829b97-6033-469d-b144-cdd77d89501f" xlink:href="nbix-20231231.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_8a829b97-6033-469d-b144-cdd77d89501f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_e8f727b8-7e45-4359-b46b-4acfd5dff7ce" xlink:href="nbix-20231231.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_e8f727b8-7e45-4359-b46b-4acfd5dff7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_00297e07-5292-440b-9f20-98676cee00b4" xlink:href="nbix-20231231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_VoyagerTherapeuticsMember_00297e07-5292-440b-9f20-98676cee00b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A2019VoyagerAgreementMember_7d2eddae-75b8-43e9-a6da-ba55d97a92ec" xlink:href="nbix-20231231.xsd#nbix_A2019VoyagerAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_VoyagerTherapeuticsMember_00297e07-5292-440b-9f20-98676cee00b4" xlink:to="loc_nbix_A2019VoyagerAgreementMember_7d2eddae-75b8-43e9-a6da-ba55d97a92ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A2023VoyagerAgreementMember_4a996b35-9360-4497-bd84-b185a9e3d849" xlink:href="nbix-20231231.xsd#nbix_A2023VoyagerAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_VoyagerTherapeuticsMember_00297e07-5292-440b-9f20-98676cee00b4" xlink:to="loc_nbix_A2023VoyagerAgreementMember_4a996b35-9360-4497-bd84-b185a9e3d849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember_6fb504aa-fcae-42ef-99a3-92e7635133d0" xlink:href="nbix-20231231.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_BIALPortelaCaSAMember_6fb504aa-fcae-42ef-99a3-92e7635133d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_ab1fdff2-ae42-4538-ba5e-f99598a38f25" xlink:href="nbix-20231231.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_ab1fdff2-ae42-4538-ba5e-f99598a38f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember_833b6324-050f-43da-8de5-3f72c9947cbe" xlink:href="nbix-20231231.xsd#nbix_AbbVieIncMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da5e35e2-9084-43bd-9756-ba12f34acb08" xlink:to="loc_nbix_AbbVieIncMember_833b6324-050f-43da-8de5-3f72c9947cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7d9a46bc-8c97-445e-a7b0-9bd0d7a8f7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7d9a46bc-8c97-445e-a7b0-9bd0d7a8f7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_69ac7de0-3306-40b0-a4a0-1e7d7429115d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7d9a46bc-8c97-445e-a7b0-9bd0d7a8f7ca" xlink:to="loc_us-gaap_EquityComponentDomain_69ac7de0-3306-40b0-a4a0-1e7d7429115d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7cb0e6b0-0079-4bdb-8712-e5baa6a8bffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_69ac7de0-3306-40b0-a4a0-1e7d7429115d" xlink:to="loc_us-gaap_CommonStockMember_7cb0e6b0-0079-4bdb-8712-e5baa6a8bffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c9b54842-7089-470a-bbf2-1f075757db62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c9b54842-7089-470a-bbf2-1f075757db62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8dea2092-5f1b-4ff5-bc2c-3495c88f450c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c9b54842-7089-470a-bbf2-1f075757db62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8dea2092-5f1b-4ff5-bc2c-3495c88f450c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_c796b890-a783-499e-b561-81ab27fa8ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8dea2092-5f1b-4ff5-bc2c-3495c88f450c" xlink:to="loc_us-gaap_PatentsMember_c796b890-a783-499e-b561-81ab27fa8ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e5f03846-9d9b-4a07-affe-5d92ad6a9175" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_srt_ProductOrServiceAxis_e5f03846-9d9b-4a07-affe-5d92ad6a9175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f83a37b3-b4fa-42b8-ad24-359ea7e296af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e5f03846-9d9b-4a07-affe-5d92ad6a9175" xlink:to="loc_srt_ProductsAndServicesDomain_f83a37b3-b4fa-42b8-ad24-359ea7e296af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_8de1a682-cdea-47f0-b179-7195b0b1cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f83a37b3-b4fa-42b8-ad24-359ea7e296af" xlink:to="loc_us-gaap_RoyaltyMember_8de1a682-cdea-47f0-b179-7195b0b1cd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f704967d-9b02-4d57-8bab-160eeff629d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_srt_RangeAxis_f704967d-9b02-4d57-8bab-160eeff629d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_67252507-3c16-44ec-bdd9-ebb000be366d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f704967d-9b02-4d57-8bab-160eeff629d3" xlink:to="loc_srt_RangeMember_67252507-3c16-44ec-bdd9-ebb000be366d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c5d55f2-7820-4719-b0ee-778bb57e5fca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_67252507-3c16-44ec-bdd9-ebb000be366d" xlink:to="loc_srt_MinimumMember_5c5d55f2-7820-4719-b0ee-778bb57e5fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e1752ee-766f-4791-9b51-ba282f262a98" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e1752ee-766f-4791-9b51-ba282f262a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_071cf25e-c52c-44a8-a9a9-0d13a7a93dc1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e1752ee-766f-4791-9b51-ba282f262a98" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_071cf25e-c52c-44a8-a9a9-0d13a7a93dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_84563773-b1af-479a-baf0-5d0c176e6c63" xlink:href="nbix-20231231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_071cf25e-c52c-44a8-a9a9-0d13a7a93dc1" xlink:to="loc_nbix_VoyagerTherapeuticsMember_84563773-b1af-479a-baf0-5d0c176e6c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be233840-9c18-4994-848b-6ff683413de3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_207b9484-da7d-4709-a882-2ea00aa1306f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_207b9484-da7d-4709-a882-2ea00aa1306f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a8900b4e-9634-4000-a401-4558ba2d2696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a8900b4e-9634-4000-a401-4558ba2d2696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_4b62ec21-6a03-4f5e-b831-122bf874a2c5" xlink:href="nbix-20231231.xsd#nbix_PotentialMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_PotentialMilestonePayments_4b62ec21-6a03-4f5e-b831-122bf874a2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationMinimalContractualTime_57ce055a-07f3-4c7c-8c0b-fde648c9b8a0" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationMinimalContractualTime"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_AgreementTerminationMinimalContractualTime_57ce055a-07f3-4c7c-8c0b-fde648c9b8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationContractualTimeThreshold_30aac5ba-373e-417d-b071-e1e4830734fd" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationContractualTimeThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_AgreementTerminationContractualTimeThreshold_30aac5ba-373e-417d-b071-e1e4830734fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold_d42dd9cc-9dc9-46f9-bccf-c82120deb1a9" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationByCounterpartyContractualTimeThreshold"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold_d42dd9cc-9dc9-46f9-bccf-c82120deb1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationByCounterpartyMinimalContractualTime_8ca23f5b-3406-4bd2-8069-443193d14308" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationByCounterpartyMinimalContractualTime"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_AgreementTerminationByCounterpartyMinimalContractualTime_8ca23f5b-3406-4bd2-8069-443193d14308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfNonClinicalStageCompound_3bdffc7f-37c5-4893-a58a-004847e03730" xlink:href="nbix-20231231.xsd#nbix_NumberOfNonClinicalStageCompound"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_NumberOfNonClinicalStageCompound_3bdffc7f-37c5-4893-a58a-004847e03730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AgreementTerminationDueToMaterialBreach_4efdaafd-6d6c-47d9-9b8f-5bc95fe86597" xlink:href="nbix-20231231.xsd#nbix_AgreementTerminationDueToMaterialBreach"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_AgreementTerminationDueToMaterialBreach_4efdaafd-6d6c-47d9-9b8f-5bc95fe86597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfPreclinicalCandidates_eb08e93b-72e1-433a-b9b3-6098fafa0c6f" xlink:href="nbix-20231231.xsd#nbix_NumberOfPreclinicalCandidates"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_NumberOfPreclinicalCandidates_eb08e93b-72e1-433a-b9b3-6098fafa0c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_780ef89f-5934-475e-a69a-7f54a244ef65" xlink:href="nbix-20231231.xsd#nbix_SaleOfStockNumberOfSharesSoldInTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_780ef89f-5934-475e-a69a-7f54a244ef65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_e9be2fed-b56a-4e07-a88c-5d745fb0e0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_SharePrice_e9be2fed-b56a-4e07-a88c-5d745fb0e0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_59bb4fa5-2d99-4222-a7ed-824dcc10561b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_59bb4fa5-2d99-4222-a7ed-824dcc10561b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_87bc681c-89ed-4032-ac6a-70912c3e04e1" xlink:href="nbix-20231231.xsd#nbix_MilestonePayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_MilestonePayment_87bc681c-89ed-4032-ac6a-70912c3e04e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_ef7af634-b1ee-4cfc-a029-098c77a21076" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_ef7af634-b1ee-4cfc-a029-098c77a21076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfUndisclosedPrograms_43861e9b-d376-4f18-a540-4c64ab7014b6" xlink:href="nbix-20231231.xsd#nbix_NumberOfUndisclosedPrograms"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_NumberOfUndisclosedPrograms_43861e9b-d376-4f18-a540-4c64ab7014b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VotingRestrictionPeriod_1f7582d4-9789-445c-94b4-e43f569a0908" xlink:href="nbix-20231231.xsd#nbix_VotingRestrictionPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_VotingRestrictionPeriod_1f7582d4-9789-445c-94b4-e43f569a0908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfGeneTherapyPrograms_b455a82a-3f17-4121-b24b-f4dddd4e407b" xlink:href="nbix-20231231.xsd#nbix_NumberOfGeneTherapyPrograms"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_NumberOfGeneTherapyPrograms_b455a82a-3f17-4121-b24b-f4dddd4e407b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_bc458ae7-cfab-4f7c-8485-dcfa72769e0c" xlink:href="nbix-20231231.xsd#nbix_UpfrontPaymentsMade"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_UpfrontPaymentsMade_bc458ae7-cfab-4f7c-8485-dcfa72769e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BoardOfDirectorsMaximumDurationTerm_0b498d56-12fc-4cc8-8275-f81c981bd16f" xlink:href="nbix-20231231.xsd#nbix_BoardOfDirectorsMaximumDurationTerm"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_BoardOfDirectorsMaximumDurationTerm_0b498d56-12fc-4cc8-8275-f81c981bd16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_affe9cb0-18fe-4527-9ea6-e9343ff9ceaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_affe9cb0-18fe-4527-9ea6-e9343ff9ceaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_12da6dfe-3825-4fd3-8003-85bfa1e18454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_12da6dfe-3825-4fd3-8003-85bfa1e18454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6ea46239-75b6-4048-9905-573eb0edf3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6ea46239-75b6-4048-9905-573eb0edf3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_75571bbe-fc63-494d-a2e7-a2123bc2f9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_InventoryValuationReserves_75571bbe-fc63-494d-a2e7-a2123bc2f9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3aacba76-a66d-422b-b4e7-72dc45e50017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3aacba76-a66d-422b-b4e7-72dc45e50017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_927ad5f4-74b9-49bf-82fa-e56227853083" xlink:href="nbix-20231231.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_927ad5f4-74b9-49bf-82fa-e56227853083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm_8853cdb6-9d59-415a-b3f3-1c71129be1e9" xlink:href="nbix-20231231.xsd#nbix_PatentTerm"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94f6956d-e924-4c77-b146-792fe4bf9c3f" xlink:to="loc_nbix_PatentTerm_8853cdb6-9d59-415a-b3f3-1c71129be1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d1a23356-2778-4433-99ff-b6d2a1e30319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a3f49e47-6dee-4fe6-94fd-bed69da9c310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d1a23356-2778-4433-99ff-b6d2a1e30319" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a3f49e47-6dee-4fe6-94fd-bed69da9c310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b47710de-a9cf-491c-b65c-4e38c13bef24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a3f49e47-6dee-4fe6-94fd-bed69da9c310" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b47710de-a9cf-491c-b65c-4e38c13bef24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffca9d80-3c9f-47d2-99a3-e6c5906d6fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b47710de-a9cf-491c-b65c-4e38c13bef24" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffca9d80-3c9f-47d2-99a3-e6c5906d6fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a1b0f80d-f2ff-4125-be57-f2fad3c39ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffca9d80-3c9f-47d2-99a3-e6c5906d6fbe" xlink:to="loc_us-gaap_CommercialPaperMember_a1b0f80d-f2ff-4125-be57-f2fad3c39ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_65d177bd-cd86-45c8-a8af-8703afa8c78e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffca9d80-3c9f-47d2-99a3-e6c5906d6fbe" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_65d177bd-cd86-45c8-a8af-8703afa8c78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0294c337-cb9e-427c-86c9-eac041d1231f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffca9d80-3c9f-47d2-99a3-e6c5906d6fbe" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0294c337-cb9e-427c-86c9-eac041d1231f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a3f49e47-6dee-4fe6-94fd-bed69da9c310" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_02f1e824-7a0e-45de-a56d-18a62ef93546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_02f1e824-7a0e-45de-a56d-18a62ef93546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_1c4dabf6-9a5b-4222-a51c-c369e64873cd" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_1c4dabf6-9a5b-4222-a51c-c369e64873cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_c19317a5-01c6-4196-b527-10e8bcd46fea" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_c19317a5-01c6-4196-b527-10e8bcd46fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_7d3a2603-edf4-48d6-af18-f6e90e864127" xlink:href="nbix-20231231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_7d3a2603-edf4-48d6-af18-f6e90e864127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_a387e467-92c8-4435-8ca6-d0a7481c772d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_a387e467-92c8-4435-8ca6-d0a7481c772d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_c5f6bd18-3d50-4b9b-b3ec-b5ba9ebb819b" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_c5f6bd18-3d50-4b9b-b3ec-b5ba9ebb819b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_9d718078-f28d-4551-ae69-ef6c8e443945" xlink:href="nbix-20231231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_9d718078-f28d-4551-ae69-ef6c8e443945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_9b87a64c-7f31-4cac-8ae3-32c7cb17be48" xlink:href="nbix-20231231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e9b32641-bcea-4411-a24e-d84052b3792a" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_9b87a64c-7f31-4cac-8ae3-32c7cb17be48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bd58c048-0835-48e6-9b8d-d7be56e2049f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d002fb1-84d6-4eec-b5e6-3864dcde0fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bd58c048-0835-48e6-9b8d-d7be56e2049f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d002fb1-84d6-4eec-b5e6-3864dcde0fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7a55b677-aa65-4c3e-9380-fae50d5cc619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d002fb1-84d6-4eec-b5e6-3864dcde0fc8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7a55b677-aa65-4c3e-9380-fae50d5cc619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63afdd25-ae96-47a3-b4dc-6eb33e7deddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7a55b677-aa65-4c3e-9380-fae50d5cc619" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63afdd25-ae96-47a3-b4dc-6eb33e7deddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3355d07c-732c-4e75-8ef3-be7b2b01d702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63afdd25-ae96-47a3-b4dc-6eb33e7deddf" xlink:to="loc_us-gaap_CommercialPaperMember_3355d07c-732c-4e75-8ef3-be7b2b01d702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c048cbbe-f5d9-4af6-834f-9e4fb30aaa96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63afdd25-ae96-47a3-b4dc-6eb33e7deddf" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c048cbbe-f5d9-4af6-834f-9e4fb30aaa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_23b7796d-9cdc-49bf-907d-30dccdcf6bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63afdd25-ae96-47a3-b4dc-6eb33e7deddf" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_23b7796d-9cdc-49bf-907d-30dccdcf6bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d002fb1-84d6-4eec-b5e6-3864dcde0fc8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_86baca8d-938e-4c15-bfd6-b889b2ad43e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_86baca8d-938e-4c15-bfd6-b889b2ad43e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_19c95a1f-8ef9-426d-9a60-1bbb313e4cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_19c95a1f-8ef9-426d-9a60-1bbb313e4cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_13da3300-308d-4e3f-a1f3-03c51ca4ec92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_13da3300-308d-4e3f-a1f3-03c51ca4ec92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_82aa770e-4c69-4ce9-a938-5002070baaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_82aa770e-4c69-4ce9-a938-5002070baaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b1166eb8-9d3e-4d72-98d1-69feeae0b5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b1166eb8-9d3e-4d72-98d1-69feeae0b5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_ded2e7dd-9198-4604-a990-d9c3ffc246fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c9eff077-4d5b-470f-8af2-57947601377e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_ded2e7dd-9198-4604-a990-d9c3ffc246fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_34353eb5-1d77-47c3-8bcc-782067435a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_34353eb5-1d77-47c3-8bcc-782067435a3c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0947a21e-2553-4504-8fe2-4216dd033abd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0947a21e-2553-4504-8fe2-4216dd033abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_088645a4-1e41-4f3c-b351-b3d33e76b728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0947a21e-2553-4504-8fe2-4216dd033abd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_088645a4-1e41-4f3c-b351-b3d33e76b728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_aca48c18-e10c-44b5-bc34-75d8d72340b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_088645a4-1e41-4f3c-b351-b3d33e76b728" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_aca48c18-e10c-44b5-bc34-75d8d72340b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_005b0b00-b32c-45e6-a9d5-85bd1f704d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_088645a4-1e41-4f3c-b351-b3d33e76b728" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_005b0b00-b32c-45e6-a9d5-85bd1f704d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3fd12cda-0571-4623-ac8b-7482c476593a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3fd12cda-0571-4623-ac8b-7482c476593a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3aa4d5a9-b229-459c-ab9e-2d5d978984ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3fd12cda-0571-4623-ac8b-7482c476593a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3aa4d5a9-b229-459c-ab9e-2d5d978984ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_16ddca48-028f-4a86-ac52-98fb7e482d97" xlink:href="nbix-20231231.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3aa4d5a9-b229-459c-ab9e-2d5d978984ee" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_16ddca48-028f-4a86-ac52-98fb7e482d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_9fd350d0-6725-43ff-9b4f-6387723a8ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3aa4d5a9-b229-459c-ab9e-2d5d978984ee" xlink:to="loc_us-gaap_CertificatesOfDepositMember_9fd350d0-6725-43ff-9b4f-6387723a8ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_29f470d0-7811-4281-a6e9-abcf59af3689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3aa4d5a9-b229-459c-ab9e-2d5d978984ee" xlink:to="loc_us-gaap_CommercialPaperMember_29f470d0-7811-4281-a6e9-abcf59af3689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_561eb429-ffcf-4b0b-be4f-fec44c8cc035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:to="loc_us-gaap_FinancialInstrumentAxis_561eb429-ffcf-4b0b-be4f-fec44c8cc035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd6dc94f-6041-423a-b3d6-cbfe7c11e109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_561eb429-ffcf-4b0b-be4f-fec44c8cc035" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd6dc94f-6041-423a-b3d6-cbfe7c11e109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f5563dda-3e7a-42a7-b7a5-f7cc560cd89f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd6dc94f-6041-423a-b3d6-cbfe7c11e109" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f5563dda-3e7a-42a7-b7a5-f7cc560cd89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7fb6d78e-de42-4ca1-81bc-d0a4473eadae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd6dc94f-6041-423a-b3d6-cbfe7c11e109" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7fb6d78e-de42-4ca1-81bc-d0a4473eadae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_95d9ebb2-ac05-49b9-aef0-f8c699a1e008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd6dc94f-6041-423a-b3d6-cbfe7c11e109" xlink:to="loc_us-gaap_EquitySecuritiesMember_95d9ebb2-ac05-49b9-aef0-f8c699a1e008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2a341ebe-136c-4b89-bbb4-f50779698e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2a341ebe-136c-4b89-bbb4-f50779698e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_570c698c-ee09-4ab0-a27e-98c3e8f975ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2a341ebe-136c-4b89-bbb4-f50779698e53" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_570c698c-ee09-4ab0-a27e-98c3e8f975ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fd99101b-f3e3-430a-b309-b1cbf5a1b164" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_570c698c-ee09-4ab0-a27e-98c3e8f975ec" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fd99101b-f3e3-430a-b309-b1cbf5a1b164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea34854f-d54e-4d1b-a708-3d0903b81e51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14eb34e2-76d8-4c8a-abba-c1b0740d2344" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea34854f-d54e-4d1b-a708-3d0903b81e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_0cc8d8a1-028d-4800-8921-1b74e61cd83c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea34854f-d54e-4d1b-a708-3d0903b81e51" xlink:to="loc_us-gaap_Investments_0cc8d8a1-028d-4800-8921-1b74e61cd83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6aa3bae6-7b2d-41ae-9420-4834c5fe7699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea34854f-d54e-4d1b-a708-3d0903b81e51" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6aa3bae6-7b2d-41ae-9420-4834c5fe7699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConvertibleSeniorNotesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_568d5659-1fbe-438d-8a7f-82104c4a631e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_101c07e1-27b3-4700-bbc1-a5e9ec99b17d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_568d5659-1fbe-438d-8a7f-82104c4a631e" xlink:to="loc_us-gaap_DebtInstrumentTable_101c07e1-27b3-4700-bbc1-a5e9ec99b17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_55ab7631-e396-4fd0-a907-caa5118b09c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_101c07e1-27b3-4700-bbc1-a5e9ec99b17d" xlink:to="loc_us-gaap_DebtInstrumentAxis_55ab7631-e396-4fd0-a907-caa5118b09c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3be48499-8bc0-4752-b836-77aeb99ceb62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_55ab7631-e396-4fd0-a907-caa5118b09c8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3be48499-8bc0-4752-b836-77aeb99ceb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_abf1c564-f174-4607-bd27-45e5a776c544" xlink:href="nbix-20231231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3be48499-8bc0-4752-b836-77aeb99ceb62" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_abf1c564-f174-4607-bd27-45e5a776c544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis_6b3c9282-fd63-4111-b8a1-8207b7514932" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_101c07e1-27b3-4700-bbc1-a5e9ec99b17d" xlink:to="loc_nbix_DebtInstrumentConversionAxis_6b3c9282-fd63-4111-b8a1-8207b7514932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_71cc9213-f91b-4aa3-b7a8-cb71f7da20e4" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionAxis_6b3c9282-fd63-4111-b8a1-8207b7514932" xlink:to="loc_nbix_DebtInstrumentConversionDomain_71cc9213-f91b-4aa3-b7a8-cb71f7da20e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember_69dd9364-c440-41e2-b51f-85fbdb1995a0" xlink:href="nbix-20231231.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionDomain_71cc9213-f91b-4aa3-b7a8-cb71f7da20e4" xlink:to="loc_nbix_ConversionPeriodTwoMember_69dd9364-c440-41e2-b51f-85fbdb1995a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember_e824cf23-9fa4-45f4-b5de-578c4e8122ef" xlink:href="nbix-20231231.xsd#nbix_ConversionPeriodOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionDomain_71cc9213-f91b-4aa3-b7a8-cb71f7da20e4" xlink:to="loc_nbix_ConversionPeriodOneMember_e824cf23-9fa4-45f4-b5de-578c4e8122ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_101c07e1-27b3-4700-bbc1-a5e9ec99b17d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_835c7106-1105-4c41-be75-409101284ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_835c7106-1105-4c41-be75-409101284ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_271ccc8c-6405-48e4-b8d8-7410b9b487e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_271ccc8c-6405-48e4-b8d8-7410b9b487e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_810c37ca-a3a4-4c7f-9a5e-252d53fb4f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_810c37ca-a3a4-4c7f-9a5e-252d53fb4f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_d50de18d-47b4-4a9e-b04c-022530284750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_RepaymentsOfDebt_d50de18d-47b4-4a9e-b04c-022530284750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8c927736-7cfb-45da-a913-9022e320041d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8c927736-7cfb-45da-a913-9022e320041d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_adb6ba87-6b37-45c4-9bba-355489b43b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_adb6ba87-6b37-45c4-9bba-355489b43b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_ce437ba7-42f7-4465-a329-863b6624d1bc" xlink:href="nbix-20231231.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_ce437ba7-42f7-4465-a329-863b6624d1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5da03276-88c5-4724-b09c-97d238518a72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5da03276-88c5-4724-b09c-97d238518a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_253cdefe-b20d-4b58-b6bd-2dce5f67ea01" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_253cdefe-b20d-4b58-b6bd-2dce5f67ea01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_e3c329c7-09d5-44f5-85fd-cbcda0008b08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_SharePrice_e3c329c7-09d5-44f5-85fd-cbcda0008b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4ce727c3-e707-4f84-ad5c-fa70d30efd19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4ce727c3-e707-4f84-ad5c-fa70d30efd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_dd14b7ef-05e9-48ef-a67a-b741fd69e715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_dd14b7ef-05e9-48ef-a67a-b741fd69e715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5143d309-1f1a-438d-af17-77680023ee25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5143d309-1f1a-438d-af17-77680023ee25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_a2f829b3-c41c-4b43-b63c-573fa6665509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_a2f829b3-c41c-4b43-b63c-573fa6665509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_c215747a-eaf6-4c10-9e0d-46a92fb94bbf" xlink:href="nbix-20231231.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_c215747a-eaf6-4c10-9e0d-46a92fb94bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_fe7b8128-94e6-449c-925a-e36f7e9f3e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ff50ed29-4e3d-4748-8a3f-c2508c4fd125" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_fe7b8128-94e6-449c-925a-e36f7e9f3e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConvertibleSeniorNotes2024NotesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_62ad564b-6eb6-4496-a109-5ee3cb20f8db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_74f9911d-4cf6-4173-b5ce-4eb85a8376fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_62ad564b-6eb6-4496-a109-5ee3cb20f8db" xlink:to="loc_us-gaap_DebtInstrumentTable_74f9911d-4cf6-4173-b5ce-4eb85a8376fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2893f76d-7643-48ab-aabf-c6d366266006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74f9911d-4cf6-4173-b5ce-4eb85a8376fc" xlink:to="loc_us-gaap_DebtInstrumentAxis_2893f76d-7643-48ab-aabf-c6d366266006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d8b997f5-498e-47bd-9a47-83d2772e6349" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2893f76d-7643-48ab-aabf-c6d366266006" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d8b997f5-498e-47bd-9a47-83d2772e6349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_f8352ddb-92c6-43d5-b5d3-723e990e8377" xlink:href="nbix-20231231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8b997f5-498e-47bd-9a47-83d2772e6349" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_f8352ddb-92c6-43d5-b5d3-723e990e8377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e4cf98a6-9458-44f3-9279-03f7bcbeae99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74f9911d-4cf6-4173-b5ce-4eb85a8376fc" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e4cf98a6-9458-44f3-9279-03f7bcbeae99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_798c6939-a22f-4888-a136-b33107a14478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4cf98a6-9458-44f3-9279-03f7bcbeae99" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_798c6939-a22f-4888-a136-b33107a14478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a5cf445d-857b-42da-9bcb-c21cd0c075b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4cf98a6-9458-44f3-9279-03f7bcbeae99" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a5cf445d-857b-42da-9bcb-c21cd0c075b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_74d4c13d-f308-4089-8f1d-205932ddf28a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4cf98a6-9458-44f3-9279-03f7bcbeae99" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_74d4c13d-f308-4089-8f1d-205932ddf28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_0899ef52-d34c-4391-a7f2-e14c593f0f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e4cf98a6-9458-44f3-9279-03f7bcbeae99" xlink:to="loc_us-gaap_DebtInstrumentFairValue_0899ef52-d34c-4391-a7f2-e14c593f0f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ConvertibleSeniorNotesInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_76aa5cc5-ea89-40ff-aa34-f0ff28df2433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentCouponInterest_e682c3f0-6262-45ff-8620-a32c8edb2954" xlink:href="nbix-20231231.xsd#nbix_DebtInstrumentCouponInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_76aa5cc5-ea89-40ff-aa34-f0ff28df2433" xlink:to="loc_nbix_DebtInstrumentCouponInterest_e682c3f0-6262-45ff-8620-a32c8edb2954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a21e2902-de9f-42a2-a3ff-442f25583ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_76aa5cc5-ea89-40ff-aa34-f0ff28df2433" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a21e2902-de9f-42a2-a3ff-442f25583ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e60c71b9-29cf-4ba2-a007-ea3ea2ee4741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_76aa5cc5-ea89-40ff-aa34-f0ff28df2433" xlink:to="loc_us-gaap_InterestExpense_e60c71b9-29cf-4ba2-a007-ea3ea2ee4741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0faeabc2-6b7c-479c-8b90-045a1e017bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_df65d20a-b053-4c3d-ae29-28800229cca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0faeabc2-6b7c-479c-8b90-045a1e017bbe" xlink:to="loc_us-gaap_GoodwillRollForward_df65d20a-b053-4c3d-ae29-28800229cca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_05d43f3e-be6d-4efe-9f9d-740f2d717afa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_df65d20a-b053-4c3d-ae29-28800229cca7" xlink:to="loc_us-gaap_Goodwill_05d43f3e-be6d-4efe-9f9d-740f2d717afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_376d5820-33bc-4f00-b64e-c06890ea50d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_df65d20a-b053-4c3d-ae29-28800229cca7" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_376d5820-33bc-4f00-b64e-c06890ea50d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_676006bd-eb4f-43c3-bac8-684d7c747946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_df65d20a-b053-4c3d-ae29-28800229cca7" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_676006bd-eb4f-43c3-bac8-684d7c747946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_85f31d71-4f4c-409a-9156-8396ed491d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_df65d20a-b053-4c3d-ae29-28800229cca7" xlink:to="loc_us-gaap_Goodwill_85f31d71-4f4c-409a-9156-8396ed491d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f45d67d-a36f-484d-aadb-3fb383b10e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_9fc74be3-6eac-4b60-b4b2-28889e12f8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f45d67d-a36f-484d-aadb-3fb383b10e86" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_9fc74be3-6eac-4b60-b4b2-28889e12f8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff023bc8-3678-42f3-9aae-7639a0a3716a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9fc74be3-6eac-4b60-b4b2-28889e12f8b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff023bc8-3678-42f3-9aae-7639a0a3716a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04e8f961-9257-431e-ad68-0dce6b92c727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff023bc8-3678-42f3-9aae-7639a0a3716a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04e8f961-9257-431e-ad68-0dce6b92c727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_ad348835-1d15-4e9a-985a-e4681b66672c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04e8f961-9257-431e-ad68-0dce6b92c727" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_ad348835-1d15-4e9a-985a-e4681b66672c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3e230cc-f5da-4d04-a655-a689f1588818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9fc74be3-6eac-4b60-b4b2-28889e12f8b7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3e230cc-f5da-4d04-a655-a689f1588818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68eea50f-7ba3-4969-bd11-071ddef6bce2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3e230cc-f5da-4d04-a655-a689f1588818" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68eea50f-7ba3-4969-bd11-071ddef6bce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_887c5af7-8625-4273-83f2-7bdcbe698ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68eea50f-7ba3-4969-bd11-071ddef6bce2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_887c5af7-8625-4273-83f2-7bdcbe698ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9fc74be3-6eac-4b60-b4b2-28889e12f8b7" xlink:to="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78f715a1-1c25-43b4-a8e8-dbad643c4bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_78f715a1-1c25-43b4-a8e8-dbad643c4bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9c7401fb-abd3-4945-85d4-5c2042371ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9c7401fb-abd3-4945-85d4-5c2042371ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_63aaa622-ab1e-423f-ad84-32ec2d07d983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_63aaa622-ab1e-423f-ad84-32ec2d07d983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_abf69605-e9f7-4b41-aac0-9add7e4f6d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_abf69605-e9f7-4b41-aac0-9add7e4f6d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_31f9874e-a431-4498-9ece-7bb976512604" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_31f9874e-a431-4498-9ece-7bb976512604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09226ec9-5f00-4165-808d-cee18d81867e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c3f890c9-d10a-4bf9-a355-72a1286ea507" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09226ec9-5f00-4165-808d-cee18d81867e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dd2892b0-e777-4b20-9476-e06f3c883d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1c00ce0a-3698-47c4-8f59-d2e5e60e2e20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dd2892b0-e777-4b20-9476-e06f3c883d7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1c00ce0a-3698-47c4-8f59-d2e5e60e2e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_11182273-5181-4871-b722-293e684ac21b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dd2892b0-e777-4b20-9476-e06f3c883d7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_11182273-5181-4871-b722-293e684ac21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c16f78d0-6baa-433b-a437-ed8a15d2669c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dd2892b0-e777-4b20-9476-e06f3c883d7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c16f78d0-6baa-433b-a437-ed8a15d2669c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ab01f53e-3fae-4fe0-8629-2ffe0a16454a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dd2892b0-e777-4b20-9476-e06f3c883d7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ab01f53e-3fae-4fe0-8629-2ffe0a16454a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a1082341-a769-4b34-8ea2-7a59eb225ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dd2892b0-e777-4b20-9476-e06f3c883d7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a1082341-a769-4b34-8ea2-7a59eb225ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_4b52b7e4-4e64-4da7-9ed2-11892e01660d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dd2892b0-e777-4b20-9476-e06f3c883d7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_4b52b7e4-4e64-4da7-9ed2-11892e01660d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetailsInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_ad0c67dd-b1c5-4f7e-b242-7dfd1e154135" xlink:href="nbix-20231231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_986d1e6c-db99-47f2-ad61-465cbe20a732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_ad0c67dd-b1c5-4f7e-b242-7dfd1e154135" xlink:to="loc_us-gaap_InventoryRawMaterials_986d1e6c-db99-47f2-ad61-465cbe20a732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_96ac9f35-a597-4b75-8b6b-5df93b998c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_ad0c67dd-b1c5-4f7e-b242-7dfd1e154135" xlink:to="loc_us-gaap_InventoryWorkInProcess_96ac9f35-a597-4b75-8b6b-5df93b998c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_428f85f8-fcb5-4ff6-b8b0-9d67e1665a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_ad0c67dd-b1c5-4f7e-b242-7dfd1e154135" xlink:to="loc_us-gaap_InventoryFinishedGoods_428f85f8-fcb5-4ff6-b8b0-9d67e1665a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_2d112296-7af6-4dd3-af2f-f26fe8e89c11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_ad0c67dd-b1c5-4f7e-b242-7dfd1e154135" xlink:to="loc_us-gaap_InventoryGross_2d112296-7af6-4dd3-af2f-f26fe8e89c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_c2716285-33c9-4bd0-bc87-39976d548932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_ad0c67dd-b1c5-4f7e-b242-7dfd1e154135" xlink:to="loc_us-gaap_InventoryValuationReserves_c2716285-33c9-4bd0-bc87-39976d548932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_140ac098-f99f-4908-93d6-82d987295d01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_ad0c67dd-b1c5-4f7e-b242-7dfd1e154135" xlink:to="loc_us-gaap_InventoryNet_140ac098-f99f-4908-93d6-82d987295d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetailsPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_71f3ab25-c8c7-4c71-8401-019e9e753b67" xlink:href="nbix-20231231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_815d670f-ab50-4199-a726-6423aaac99b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_71f3ab25-c8c7-4c71-8401-019e9e753b67" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_815d670f-ab50-4199-a726-6423aaac99b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bbd9f6f-75ae-489d-aee9-7910c9f590a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_815d670f-ab50-4199-a726-6423aaac99b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bbd9f6f-75ae-489d-aee9-7910c9f590a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7ac4e1-e384-4262-9ac9-e7d6c5ffd800" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bbd9f6f-75ae-489d-aee9-7910c9f590a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7ac4e1-e384-4262-9ac9-e7d6c5ffd800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_aadf96a4-2557-4975-ae60-dee0c85f6a64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7ac4e1-e384-4262-9ac9-e7d6c5ffd800" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_aadf96a4-2557-4975-ae60-dee0c85f6a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ScientificEquipmentMember_b789e73e-8d0d-4863-bab1-72a36c5e4858" xlink:href="nbix-20231231.xsd#nbix_ScientificEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7ac4e1-e384-4262-9ac9-e7d6c5ffd800" xlink:to="loc_nbix_ScientificEquipmentMember_b789e73e-8d0d-4863-bab1-72a36c5e4858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_898d5300-a939-4161-94e3-329d7a54735d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7ac4e1-e384-4262-9ac9-e7d6c5ffd800" xlink:to="loc_us-gaap_ComputerEquipmentMember_898d5300-a939-4161-94e3-329d7a54735d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d7b00554-bd81-4ddb-81c5-875ec5c1ff58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b7ac4e1-e384-4262-9ac9-e7d6c5ffd800" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d7b00554-bd81-4ddb-81c5-875ec5c1ff58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3229c9fc-ea78-4973-b7a0-ff32d6966cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_815d670f-ab50-4199-a726-6423aaac99b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3229c9fc-ea78-4973-b7a0-ff32d6966cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d768dd87-3f67-4cef-ae47-688155d0210f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3229c9fc-ea78-4973-b7a0-ff32d6966cd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d768dd87-3f67-4cef-ae47-688155d0210f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_592c300a-1079-4d44-bcda-8596541a71d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3229c9fc-ea78-4973-b7a0-ff32d6966cd3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_592c300a-1079-4d44-bcda-8596541a71d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ef44e638-fec7-4f8d-bd36-68a358f4ebf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3229c9fc-ea78-4973-b7a0-ff32d6966cd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ef44e638-fec7-4f8d-bd36-68a358f4ebf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_f608edd4-5802-4292-8f7a-990ded53aa15" xlink:href="nbix-20231231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_8863789a-ceb5-4301-845e-9f070c6ea793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_f608edd4-5802-4292-8f7a-990ded53aa15" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_8863789a-ceb5-4301-845e-9f070c6ea793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b8c23c8f-757b-417b-8f8a-bed4166043a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_f608edd4-5802-4292-8f7a-990ded53aa15" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b8c23c8f-757b-417b-8f8a-bed4166043a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedBrandedPrescriptionDrugFee_3f2c94a1-98fb-4bcd-8b19-188c4c2bd793" xlink:href="nbix-20231231.xsd#nbix_AccruedBrandedPrescriptionDrugFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_f608edd4-5802-4292-8f7a-990ded53aa15" xlink:to="loc_nbix_AccruedBrandedPrescriptionDrugFee_3f2c94a1-98fb-4bcd-8b19-188c4c2bd793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent_44233993-4974-4c6c-a9e0-bf0c5ba54df8" xlink:href="nbix-20231231.xsd#nbix_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_f608edd4-5802-4292-8f7a-990ded53aa15" xlink:to="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent_44233993-4974-4c6c-a9e0-bf0c5ba54df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_a4349c5d-cc39-46f6-8659-9356a5c106eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_f608edd4-5802-4292-8f7a-990ded53aa15" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_a4349c5d-cc39-46f6-8659-9356a5c106eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_5303345c-2457-446f-b184-a0954f958844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_f608edd4-5802-4292-8f7a-990ded53aa15" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_5303345c-2457-446f-b184-a0954f958844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d3adf61b-c73c-435f-8607-385daf06b94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_f608edd4-5802-4292-8f7a-990ded53aa15" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d3adf61b-c73c-435f-8607-385daf06b94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_8c1e23b1-166e-4ad0-b6d1-b28872d3fd40" xlink:href="nbix-20231231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_193d2dc9-6be0-4567-96f0-d6a65066e2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8c1e23b1-166e-4ad0-b6d1-b28872d3fd40" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_193d2dc9-6be0-4567-96f0-d6a65066e2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrescriptionDrugFeeNoncurrent_78b6ded1-8b02-442d-a982-1e34907d43a6" xlink:href="nbix-20231231.xsd#nbix_PrescriptionDrugFeeNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8c1e23b1-166e-4ad0-b6d1-b28872d3fd40" xlink:to="loc_nbix_PrescriptionDrugFeeNoncurrent_78b6ded1-8b02-442d-a982-1e34907d43a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1d392e94-bd8b-4d2b-838e-c1c8767386fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8c1e23b1-166e-4ad0-b6d1-b28872d3fd40" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1d392e94-bd8b-4d2b-838e-c1c8767386fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_93a75651-44a0-41fe-a425-1a845bea588f" xlink:href="nbix-20231231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6c3d1a2a-2fec-494f-8d7a-2259620c1448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_93a75651-44a0-41fe-a425-1a845bea588f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6c3d1a2a-2fec-494f-8d7a-2259620c1448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_96d36fd1-55e2-42a9-ad35-0b0ce6cd334d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_93a75651-44a0-41fe-a425-1a845bea588f" xlink:to="loc_us-gaap_RestrictedCash_96d36fd1-55e2-42a9-ad35-0b0ce6cd334d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_05429b6e-f44d-47a8-a191-4b9a9e2e3bed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_93a75651-44a0-41fe-a425-1a845bea588f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_05429b6e-f44d-47a8-a191-4b9a9e2e3bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#EarningsPerShareScheduleofNetIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b751ba5d-e591-4fd1-8346-93ba716db717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d3d97766-5212-483e-9025-51e006f19d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b751ba5d-e591-4fd1-8346-93ba716db717" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d3d97766-5212-483e-9025-51e006f19d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c256bf03-e259-4df2-a83b-9faec258ac3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b751ba5d-e591-4fd1-8346-93ba716db717" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c256bf03-e259-4df2-a83b-9faec258ac3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_046bc929-7643-4827-8e6a-9521577683c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b751ba5d-e591-4fd1-8346-93ba716db717" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_046bc929-7643-4827-8e6a-9521577683c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6b13305e-296c-49b9-a1f2-3acfa7a0534e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_046bc929-7643-4827-8e6a-9521577683c3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6b13305e-296c-49b9-a1f2-3acfa7a0534e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_47a72fe2-ef08-417c-bc93-67ddbb1e96f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_046bc929-7643-4827-8e6a-9521577683c3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_47a72fe2-ef08-417c-bc93-67ddbb1e96f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e78a0c8f-f2d6-4290-9a54-2499dbb46cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_046bc929-7643-4827-8e6a-9521577683c3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e78a0c8f-f2d6-4290-9a54-2499dbb46cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_39bfa936-4762-4751-8e9b-7146788122f7" xlink:href="nbix-20231231.xsd#nbix_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b751ba5d-e591-4fd1-8346-93ba716db717" xlink:to="loc_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_39bfa936-4762-4751-8e9b-7146788122f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f3b79350-b275-49bf-bacd-6027fefea1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_39bfa936-4762-4751-8e9b-7146788122f7" xlink:to="loc_us-gaap_EarningsPerShareBasic_f3b79350-b275-49bf-bacd-6027fefea1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ba8033a0-0969-40b9-9ac4-8c7f2f7cda68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_39bfa936-4762-4751-8e9b-7146788122f7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ba8033a0-0969-40b9-9ac4-8c7f2f7cda68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8b0386ac-36e2-4981-b60f-5fecb6d0ef79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fce817f3-5058-46c8-9311-bd1a4feb21bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8b0386ac-36e2-4981-b60f-5fecb6d0ef79" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fce817f3-5058-46c8-9311-bd1a4feb21bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d55863d0-49b4-4817-a3f7-fa193d603b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fce817f3-5058-46c8-9311-bd1a4feb21bd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d55863d0-49b4-4817-a3f7-fa193d603b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa9a3cc7-828f-42fb-8e25-960614e44763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d55863d0-49b4-4817-a3f7-fa193d603b62" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa9a3cc7-828f-42fb-8e25-960614e44763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_61edc6de-0c94-4abc-8edd-40f356b79a11" xlink:href="nbix-20231231.xsd#nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa9a3cc7-828f-42fb-8e25-960614e44763" xlink:to="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_61edc6de-0c94-4abc-8edd-40f356b79a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_18e3f1d4-e5fd-4cd9-ae27-9dce4b6869f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fce817f3-5058-46c8-9311-bd1a4feb21bd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_18e3f1d4-e5fd-4cd9-ae27-9dce4b6869f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8c7fc8c3-0eae-4987-beaa-5b61feb5843c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_18e3f1d4-e5fd-4cd9-ae27-9dce4b6869f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8c7fc8c3-0eae-4987-beaa-5b61feb5843c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09e7d8db-056a-41bc-a39d-3ba9ea3c72a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdcb73e-2b1b-4822-8723-6387958eb086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09e7d8db-056a-41bc-a39d-3ba9ea3c72a6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdcb73e-2b1b-4822-8723-6387958eb086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_005d086c-e0e8-4c09-a1d1-f1f34f79dae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdcb73e-2b1b-4822-8723-6387958eb086" xlink:to="loc_us-gaap_PlanNameAxis_005d086c-e0e8-4c09-a1d1-f1f34f79dae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a0dd43c8-a7a2-4ff6-9575-5ba967d758ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_005d086c-e0e8-4c09-a1d1-f1f34f79dae7" xlink:to="loc_us-gaap_PlanNameDomain_a0dd43c8-a7a2-4ff6-9575-5ba967d758ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_Amended2020EquityIncentivePlanMember_07427fd0-4416-459f-aa50-5789f4fde7dd" xlink:href="nbix-20231231.xsd#nbix_Amended2020EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a0dd43c8-a7a2-4ff6-9575-5ba967d758ed" xlink:to="loc_nbix_Amended2020EquityIncentivePlanMember_07427fd0-4416-459f-aa50-5789f4fde7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TwoThousandAndElevenEquityIncentivePlanMember_c61c0340-ac25-488c-b2cc-554574cf382e" xlink:href="nbix-20231231.xsd#nbix_TwoThousandAndElevenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a0dd43c8-a7a2-4ff6-9575-5ba967d758ed" xlink:to="loc_nbix_TwoThousandAndElevenEquityIncentivePlanMember_c61c0340-ac25-488c-b2cc-554574cf382e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_Amended2018EmployeeStockPurchasePlanMember_69183a90-1cb2-4b09-b760-15ab5f6b1c40" xlink:href="nbix-20231231.xsd#nbix_Amended2018EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a0dd43c8-a7a2-4ff6-9575-5ba967d758ed" xlink:to="loc_nbix_Amended2018EmployeeStockPurchasePlanMember_69183a90-1cb2-4b09-b760-15ab5f6b1c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_da52123a-0b23-427e-892e-d8466d9a314b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdcb73e-2b1b-4822-8723-6387958eb086" xlink:to="loc_us-gaap_AwardTypeAxis_da52123a-0b23-427e-892e-d8466d9a314b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94fa65e2-f2c1-4c76-87e8-5835c013e4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_da52123a-0b23-427e-892e-d8466d9a314b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94fa65e2-f2c1-4c76-87e8-5835c013e4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7a872726-26df-4299-9900-d2697d647fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94fa65e2-f2c1-4c76-87e8-5835c013e4a7" xlink:to="loc_us-gaap_EmployeeStockMember_7a872726-26df-4299-9900-d2697d647fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b974820f-c76f-4edd-8e23-454a7d88b2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94fa65e2-f2c1-4c76-87e8-5835c013e4a7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b974820f-c76f-4edd-8e23-454a7d88b2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_74fda9a4-942c-4fb2-9839-483208a479e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94fa65e2-f2c1-4c76-87e8-5835c013e4a7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_74fda9a4-942c-4fb2-9839-483208a479e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_093bb4e3-9030-4446-bfc2-26d8f6eee0b8" xlink:href="nbix-20231231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94fa65e2-f2c1-4c76-87e8-5835c013e4a7" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_093bb4e3-9030-4446-bfc2-26d8f6eee0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dbfdfda4-621a-4bee-bd11-ea978875d2ab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdcb73e-2b1b-4822-8723-6387958eb086" xlink:to="loc_srt_RangeAxis_dbfdfda4-621a-4bee-bd11-ea978875d2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a859426-886b-481d-bf55-c5ffec51fdb2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dbfdfda4-621a-4bee-bd11-ea978875d2ab" xlink:to="loc_srt_RangeMember_2a859426-886b-481d-bf55-c5ffec51fdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_80f7f2d8-70c1-460f-a3d9-21d484603c02" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2a859426-886b-481d-bf55-c5ffec51fdb2" xlink:to="loc_srt_MinimumMember_80f7f2d8-70c1-460f-a3d9-21d484603c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_086ca74f-3e43-4503-8f86-a3fd1ec66aa8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2a859426-886b-481d-bf55-c5ffec51fdb2" xlink:to="loc_srt_MaximumMember_086ca74f-3e43-4503-8f86-a3fd1ec66aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdcb73e-2b1b-4822-8723-6387958eb086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b7089b2c-ea48-4e98-b578-41aa888ce1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b7089b2c-ea48-4e98-b578-41aa888ce1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_8b921408-e307-4c70-b02d-69d255c90065" xlink:href="nbix-20231231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_8b921408-e307-4c70-b02d-69d255c90065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_7e29a883-ca7e-4b53-b7c8-285b15198a38" xlink:href="nbix-20231231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_7e29a883-ca7e-4b53-b7c8-285b15198a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_c072b7da-0248-4e65-9b99-217ff160fa59" xlink:href="nbix-20231231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_c072b7da-0248-4e65-9b99-217ff160fa59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_52dd51f1-e9da-4e7f-8a15-a12e804ff799" xlink:href="nbix-20231231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_52dd51f1-e9da-4e7f-8a15-a12e804ff799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_398abc81-f1fd-425a-9e4a-97704f978361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_398abc81-f1fd-425a-9e4a-97704f978361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5e5759b1-f994-44d0-af88-93f6ec7a948a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5e5759b1-f994-44d0-af88-93f6ec7a948a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_57b3f3cf-5c75-4691-a4a9-70808bacc140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_57b3f3cf-5c75-4691-a4a9-70808bacc140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cded89df-4ab1-4254-afef-c8812ca2c3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cded89df-4ab1-4254-afef-c8812ca2c3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03aa832b-60ac-4e7b-97a2-0d0b1c547e74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03aa832b-60ac-4e7b-97a2-0d0b1c547e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f287bd22-3f61-4203-b0b4-34792da93c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f287bd22-3f61-4203-b0b4-34792da93c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_28a2a607-4948-49cd-b8df-d25c8db3f7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_28a2a607-4948-49cd-b8df-d25c8db3f7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_14b00507-6dcb-4b82-9870-9150056ad8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_14b00507-6dcb-4b82-9870-9150056ad8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_80dea01b-1c67-459f-9a2a-79948756d8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ee8f7fcd-dc5b-43ef-a4e1-87aaa991509a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_80dea01b-1c67-459f-9a2a-79948756d8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_78c63aa4-79d1-4c35-bb63-4250c852c9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c2e9b6eb-9d87-46b4-8bca-268daf44937d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_78c63aa4-79d1-4c35-bb63-4250c852c9fe" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c2e9b6eb-9d87-46b4-8bca-268daf44937d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_230e7c3b-8b8a-4ab2-9df8-4f1531f136ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c2e9b6eb-9d87-46b4-8bca-268daf44937d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_230e7c3b-8b8a-4ab2-9df8-4f1531f136ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_07cdb56b-9af2-4ba3-9d17-42576f761d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_230e7c3b-8b8a-4ab2-9df8-4f1531f136ea" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_07cdb56b-9af2-4ba3-9d17-42576f761d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8b74d972-e206-424a-b916-89ec74fad792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07cdb56b-9af2-4ba3-9d17-42576f761d82" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8b74d972-e206-424a-b916-89ec74fad792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_71254528-788d-4629-a3c4-ffb10e9658fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07cdb56b-9af2-4ba3-9d17-42576f761d82" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_71254528-788d-4629-a3c4-ffb10e9658fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_219c8037-5ebf-488a-b5e6-8c5d5717399b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c2e9b6eb-9d87-46b4-8bca-268daf44937d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_219c8037-5ebf-488a-b5e6-8c5d5717399b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f14f531c-f3ed-4972-adfb-765c33b960a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_219c8037-5ebf-488a-b5e6-8c5d5717399b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f14f531c-f3ed-4972-adfb-765c33b960a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28d3bbd9-da14-43cd-bccf-a57f53031648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837246fb-e598-4d19-873b-94710327cc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28d3bbd9-da14-43cd-bccf-a57f53031648" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837246fb-e598-4d19-873b-94710327cc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2b01947b-fc9d-452b-b38a-5382e6747c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837246fb-e598-4d19-873b-94710327cc0e" xlink:to="loc_us-gaap_AwardTypeAxis_2b01947b-fc9d-452b-b38a-5382e6747c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a58c6afb-2d69-41a5-8f8a-5d4e3769e6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2b01947b-fc9d-452b-b38a-5382e6747c4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a58c6afb-2d69-41a5-8f8a-5d4e3769e6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ccf95b76-de13-49fa-aec6-d77b4655799e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a58c6afb-2d69-41a5-8f8a-5d4e3769e6dc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ccf95b76-de13-49fa-aec6-d77b4655799e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f48e6c83-e9a8-404c-9a8e-3ce0e867f53b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a58c6afb-2d69-41a5-8f8a-5d4e3769e6dc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f48e6c83-e9a8-404c-9a8e-3ce0e867f53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_86996379-9670-4dea-ad5e-3989b3a229ba" xlink:href="nbix-20231231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a58c6afb-2d69-41a5-8f8a-5d4e3769e6dc" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_86996379-9670-4dea-ad5e-3989b3a229ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_06e60d04-e88a-42d7-bc3a-059d261622e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a58c6afb-2d69-41a5-8f8a-5d4e3769e6dc" xlink:to="loc_us-gaap_EmployeeStockMember_06e60d04-e88a-42d7-bc3a-059d261622e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1a461bd1-6283-49fd-83ae-486e4cfb7512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837246fb-e598-4d19-873b-94710327cc0e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1a461bd1-6283-49fd-83ae-486e4cfb7512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a6ec44bb-0bcd-4a1c-bd6d-d115d67daad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1a461bd1-6283-49fd-83ae-486e4cfb7512" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a6ec44bb-0bcd-4a1c-bd6d-d115d67daad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e4f5f12-fa21-4b4b-bdca-deb97f5e5c70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a41afc9a-c508-40a8-99aa-34d0cd77f790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e4f5f12-fa21-4b4b-bdca-deb97f5e5c70" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a41afc9a-c508-40a8-99aa-34d0cd77f790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d2c236d7-eec6-4c19-8c1b-3d0939f71f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a41afc9a-c508-40a8-99aa-34d0cd77f790" xlink:to="loc_us-gaap_AwardTypeAxis_d2c236d7-eec6-4c19-8c1b-3d0939f71f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd56ee7a-fa60-4ca4-bb43-cbe9b37507fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d2c236d7-eec6-4c19-8c1b-3d0939f71f87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd56ee7a-fa60-4ca4-bb43-cbe9b37507fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4392968c-e6e3-4d31-8aed-174226c40c44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd56ee7a-fa60-4ca4-bb43-cbe9b37507fb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4392968c-e6e3-4d31-8aed-174226c40c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6d9991d2-8195-414a-81f6-14a47ec9b385" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd56ee7a-fa60-4ca4-bb43-cbe9b37507fb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6d9991d2-8195-414a-81f6-14a47ec9b385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_05519619-0f10-4323-87da-80a220eb0119" xlink:href="nbix-20231231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd56ee7a-fa60-4ca4-bb43-cbe9b37507fb" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_05519619-0f10-4323-87da-80a220eb0119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9bd7e15b-0bc7-4ea2-9d54-3710413ca6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a41afc9a-c508-40a8-99aa-34d0cd77f790" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9bd7e15b-0bc7-4ea2-9d54-3710413ca6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e61dc0da-7a15-4017-a666-514498c05c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9bd7e15b-0bc7-4ea2-9d54-3710413ca6dc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e61dc0da-7a15-4017-a666-514498c05c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c7d99835-d569-446a-8dc8-368f7e1bf559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9bd7e15b-0bc7-4ea2-9d54-3710413ca6dc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c7d99835-d569-446a-8dc8-368f7e1bf559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10f29f89-fa0d-47f9-b647-9cb82a9b5d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ce95f69-daf4-43c6-97dd-ecf2ef039039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10f29f89-fa0d-47f9-b647-9cb82a9b5d70" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ce95f69-daf4-43c6-97dd-ecf2ef039039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_336360ec-1e38-474f-b403-dc9f4fd5d55d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ce95f69-daf4-43c6-97dd-ecf2ef039039" xlink:to="loc_us-gaap_AwardTypeAxis_336360ec-1e38-474f-b403-dc9f4fd5d55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339c369f-5a68-4400-a066-817c6857886c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_336360ec-1e38-474f-b403-dc9f4fd5d55d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339c369f-5a68-4400-a066-817c6857886c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_adfc8f54-3119-47a7-a3f4-d37b2e8b8281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339c369f-5a68-4400-a066-817c6857886c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_adfc8f54-3119-47a7-a3f4-d37b2e8b8281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cce782fe-2b52-4839-b010-938e594858ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ce95f69-daf4-43c6-97dd-ecf2ef039039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cce782fe-2b52-4839-b010-938e594858ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_81a8b583-5307-417f-9ce6-5d8f3401bfef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cce782fe-2b52-4839-b010-938e594858ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_81a8b583-5307-417f-9ce6-5d8f3401bfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_804170d9-b764-4ec3-bcdc-357469a23f93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cce782fe-2b52-4839-b010-938e594858ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_804170d9-b764-4ec3-bcdc-357469a23f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6842e541-e46d-4749-87ac-4206ebae5092" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cce782fe-2b52-4839-b010-938e594858ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6842e541-e46d-4749-87ac-4206ebae5092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_65a047b2-76c6-4ac8-82ad-d4868ff402cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cce782fe-2b52-4839-b010-938e594858ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_65a047b2-76c6-4ac8-82ad-d4868ff402cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c85969dc-5dc6-4137-8f96-acbc1d47add1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_59844d39-9559-41c0-9060-bff85b00d334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c85969dc-5dc6-4137-8f96-acbc1d47add1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_59844d39-9559-41c0-9060-bff85b00d334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ba82ec30-6285-42da-ac81-0f10c735fd93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_59844d39-9559-41c0-9060-bff85b00d334" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ba82ec30-6285-42da-ac81-0f10c735fd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dda5a80b-a185-4a14-a682-fa0c78ba8d78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_59844d39-9559-41c0-9060-bff85b00d334" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dda5a80b-a185-4a14-a682-fa0c78ba8d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6145a8cb-6f31-474f-8e14-868cbc8342f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_59844d39-9559-41c0-9060-bff85b00d334" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6145a8cb-6f31-474f-8e14-868cbc8342f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_383c9593-e68e-4755-ae41-9d5515680b88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_59844d39-9559-41c0-9060-bff85b00d334" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_383c9593-e68e-4755-ae41-9d5515680b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_533c1dcf-d80d-48bc-86b2-fa6ff80f2de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_59844d39-9559-41c0-9060-bff85b00d334" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_533c1dcf-d80d-48bc-86b2-fa6ff80f2de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_ce3d0af2-390d-46f9-9f08-66d5b9713d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c85969dc-5dc6-4137-8f96-acbc1d47add1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_ce3d0af2-390d-46f9-9f08-66d5b9713d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10542ee3-ba6b-4883-83e1-3be18f4bc19a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c85969dc-5dc6-4137-8f96-acbc1d47add1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10542ee3-ba6b-4883-83e1-3be18f4bc19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28ff51a6-c95e-41c5-9a14-12463bfae4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10542ee3-ba6b-4883-83e1-3be18f4bc19a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28ff51a6-c95e-41c5-9a14-12463bfae4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_61effcbb-36f4-4c4b-96a7-42479b7b8741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10542ee3-ba6b-4883-83e1-3be18f4bc19a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_61effcbb-36f4-4c4b-96a7-42479b7b8741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_88c304e1-4226-420c-bbcc-8523f09eb93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10542ee3-ba6b-4883-83e1-3be18f4bc19a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_88c304e1-4226-420c-bbcc-8523f09eb93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e33e01e9-a1ef-4724-9f0e-ae751f0509c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10542ee3-ba6b-4883-83e1-3be18f4bc19a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e33e01e9-a1ef-4724-9f0e-ae751f0509c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e4c0c0d7-0f24-4a00-b341-a21e482fa5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_10542ee3-ba6b-4883-83e1-3be18f4bc19a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e4c0c0d7-0f24-4a00-b341-a21e482fa5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_992b0b2c-dbb5-41af-bb72-0f10008b71a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c85969dc-5dc6-4137-8f96-acbc1d47add1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_992b0b2c-dbb5-41af-bb72-0f10008b71a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2f0fb84c-a5e5-44b5-83b0-5ef9887bb315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c85969dc-5dc6-4137-8f96-acbc1d47add1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2f0fb84c-a5e5-44b5-83b0-5ef9887bb315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dd4c6019-e666-4e8b-9ac7-49306d801af4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2f0fb84c-a5e5-44b5-83b0-5ef9887bb315" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dd4c6019-e666-4e8b-9ac7-49306d801af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6173e7ff-ee8b-45cf-bd1f-090154c28194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2f0fb84c-a5e5-44b5-83b0-5ef9887bb315" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6173e7ff-ee8b-45cf-bd1f-090154c28194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8b960c35-c759-4201-9c90-b3dd660c556a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2f0fb84c-a5e5-44b5-83b0-5ef9887bb315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8b960c35-c759-4201-9c90-b3dd660c556a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4d742183-2473-4fa2-b44a-d2c669e1c788" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2f0fb84c-a5e5-44b5-83b0-5ef9887bb315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4d742183-2473-4fa2-b44a-d2c669e1c788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f809ae6-21ac-43f9-9854-836486e12c03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4688d840-494b-48d9-83b8-2f195c3798fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f809ae6-21ac-43f9-9854-836486e12c03" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4688d840-494b-48d9-83b8-2f195c3798fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_78b0c669-fca8-4c89-9ee9-950927e2f4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4688d840-494b-48d9-83b8-2f195c3798fc" xlink:to="loc_us-gaap_AwardTypeAxis_78b0c669-fca8-4c89-9ee9-950927e2f4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7951edb-1fcf-4ebc-a317-da38e8953884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_78b0c669-fca8-4c89-9ee9-950927e2f4e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7951edb-1fcf-4ebc-a317-da38e8953884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7deeb5c6-2ae0-4118-9318-a9d8842248d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7951edb-1fcf-4ebc-a317-da38e8953884" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7deeb5c6-2ae0-4118-9318-a9d8842248d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_f2000d0b-0b74-4412-9c47-3814af616e99" xlink:href="nbix-20231231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7951edb-1fcf-4ebc-a317-da38e8953884" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_f2000d0b-0b74-4412-9c47-3814af616e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68412f0f-449a-4edb-ae4d-94c8956b47da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4688d840-494b-48d9-83b8-2f195c3798fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68412f0f-449a-4edb-ae4d-94c8956b47da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68412f0f-449a-4edb-ae4d-94c8956b47da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_317410f5-1fb5-456d-b289-ada6290137ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_317410f5-1fb5-456d-b289-ada6290137ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21f82125-422b-45e8-912f-41ff80af788b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21f82125-422b-45e8-912f-41ff80af788b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_024b694a-f1bc-4b23-9416-0701c4f9170b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_024b694a-f1bc-4b23-9416-0701c4f9170b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d519f219-f583-4ee3-a1f6-a66b5f4929d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d519f219-f583-4ee3-a1f6-a66b5f4929d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d2762317-0824-4bf5-bcd4-a1ce7ca7f8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_af10d23e-1c9f-429a-8b41-6f414a502a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d2762317-0824-4bf5-bcd4-a1ce7ca7f8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68412f0f-449a-4edb-ae4d-94c8956b47da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e3069428-9aad-422b-b132-7e19069f7420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e3069428-9aad-422b-b132-7e19069f7420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_daa82137-c673-464e-b2e1-674c18675593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_daa82137-c673-464e-b2e1-674c18675593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35c72edb-19be-496e-965c-35a42bea3cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35c72edb-19be-496e-965c-35a42bea3cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02194346-7823-41eb-b9b4-90cb1a7cb5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02194346-7823-41eb-b9b4-90cb1a7cb5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5af94038-2d45-4313-9499-127068eb4d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eccdf3c9-1d54-4491-83d2-65f89115037f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5af94038-2d45-4313-9499-127068eb4d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e20ac2a9-8e12-44fb-b8dc-0e86e899c924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68412f0f-449a-4edb-ae4d-94c8956b47da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e20ac2a9-8e12-44fb-b8dc-0e86e899c924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c0e5a71d-1c1d-42f1-946f-754438a885c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e20ac2a9-8e12-44fb-b8dc-0e86e899c924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c0e5a71d-1c1d-42f1-946f-754438a885c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f82850dd-1e6c-4070-9e40-b7890eb4d548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e20ac2a9-8e12-44fb-b8dc-0e86e899c924" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f82850dd-1e6c-4070-9e40-b7890eb4d548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_aabf8446-03ef-4485-a0e3-71a253095115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6caf1e44-fe7f-48b6-94d4-f4ee538c977a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aabf8446-03ef-4485-a0e3-71a253095115" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6caf1e44-fe7f-48b6-94d4-f4ee538c977a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6eb14ed4-3445-44b8-8f03-53a5b0762cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aabf8446-03ef-4485-a0e3-71a253095115" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6eb14ed4-3445-44b8-8f03-53a5b0762cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fd5ac71f-81ec-4158-9fbb-0340e51fce78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aabf8446-03ef-4485-a0e3-71a253095115" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fd5ac71f-81ec-4158-9fbb-0340e51fce78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_30a316bd-d4c4-40f1-bd25-dcf5fb9a7685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_2703f39a-3408-4898-ae23-d00fe22471f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30a316bd-d4c4-40f1-bd25-dcf5fb9a7685" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_2703f39a-3408-4898-ae23-d00fe22471f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c8c16575-6c17-4b83-9877-71d7d44ff9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_2703f39a-3408-4898-ae23-d00fe22471f1" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c8c16575-6c17-4b83-9877-71d7d44ff9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c520217e-c41d-4cf7-acaa-c086bf214221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_2703f39a-3408-4898-ae23-d00fe22471f1" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c520217e-c41d-4cf7-acaa-c086bf214221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f4a8999f-ee7d-4005-93f4-43e9fcd12b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_2703f39a-3408-4898-ae23-d00fe22471f1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f4a8999f-ee7d-4005-93f4-43e9fcd12b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_ef85ca24-108e-45d2-b209-8857112d851a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30a316bd-d4c4-40f1-bd25-dcf5fb9a7685" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_ef85ca24-108e-45d2-b209-8857112d851a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7ac55231-4f44-451b-a35b-a82e773f920e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_ef85ca24-108e-45d2-b209-8857112d851a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7ac55231-4f44-451b-a35b-a82e773f920e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_708e153c-57dd-4f2b-a84a-4ea09d556b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_ef85ca24-108e-45d2-b209-8857112d851a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_708e153c-57dd-4f2b-a84a-4ea09d556b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_18e50610-0a38-4c06-8ffc-ffa8fc5456f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_ef85ca24-108e-45d2-b209-8857112d851a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_18e50610-0a38-4c06-8ffc-ffa8fc5456f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6d9fc3c3-5beb-4145-a6ae-c4a55e8b525d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30a316bd-d4c4-40f1-bd25-dcf5fb9a7685" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6d9fc3c3-5beb-4145-a6ae-c4a55e8b525d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_716d9ae0-925c-43be-8665-1bd2a7af9b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_716d9ae0-925c-43be-8665-1bd2a7af9b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_bf055f8a-91ae-44e0-9da3-6d0c23c34959" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_bf055f8a-91ae-44e0-9da3-6d0c23c34959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_80b45161-0119-4943-8393-750bec8412bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_80b45161-0119-4943-8393-750bec8412bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_b5884a03-cfab-4681-b622-959f7ed2070c" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_b5884a03-cfab-4681-b622-959f7ed2070c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_9d871d0c-9ba0-4a48-a807-447ece4407fc" xlink:href="nbix-20231231.xsd#nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_9d871d0c-9ba0-4a48-a807-447ece4407fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_312c0648-b5ba-4ca2-b861-5f1cfaabafaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_312c0648-b5ba-4ca2-b861-5f1cfaabafaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_e721facd-47e3-46a9-b54a-0e4321968605" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_e721facd-47e3-46a9-b54a-0e4321968605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_3f39dba7-58c8-4a31-be46-8ef79371566e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_3f39dba7-58c8-4a31-be46-8ef79371566e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_0a2401a4-984d-4c5b-b792-9e84c39d8aa9" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxReconciliationExpirationOfTaxCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_0a2401a4-984d-4c5b-b792-9e84c39d8aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2db5d962-51a6-4636-b1a4-e86c3545f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2db5d962-51a6-4636-b1a4-e86c3545f5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6d61ed38-5c5a-42b2-b740-27ddd743270b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6d61ed38-5c5a-42b2-b740-27ddd743270b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_2db802b1-0325-423c-9add-fc27838d8413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_2db802b1-0325-423c-9add-fc27838d8413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_24f1f4dc-8a0c-4a80-80cd-df557edbde32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fde248d5-7261-43c8-a9ed-454cd25b8872" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_24f1f4dc-8a0c-4a80-80cd-df557edbde32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_155148ba-4dfe-46cd-8c19-6d24f622cb91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bb4809fb-e01b-402b-8267-f73d37dbf1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_155148ba-4dfe-46cd-8c19-6d24f622cb91" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bb4809fb-e01b-402b-8267-f73d37dbf1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6dfb092c-b420-4e78-8743-5cfca2036c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bb4809fb-e01b-402b-8267-f73d37dbf1ef" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6dfb092c-b420-4e78-8743-5cfca2036c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b67dafdf-4523-4725-9f7b-0a56e94863d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bb4809fb-e01b-402b-8267-f73d37dbf1ef" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b67dafdf-4523-4725-9f7b-0a56e94863d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_b22b0400-c083-41e3-a88d-55e482c16a35" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bb4809fb-e01b-402b-8267-f73d37dbf1ef" xlink:to="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_b22b0400-c083-41e3-a88d-55e482c16a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_6ca7c8eb-c9a3-4c4e-9323-ccc9d3f35596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bb4809fb-e01b-402b-8267-f73d37dbf1ef" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_6ca7c8eb-c9a3-4c4e-9323-ccc9d3f35596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets_ea4b33b2-f2e3-4ccb-9eca-2dad5f59d69a" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxAssetsOperatingLeasesAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bb4809fb-e01b-402b-8267-f73d37dbf1ef" xlink:to="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets_ea4b33b2-f2e3-4ccb-9eca-2dad5f59d69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d04528d7-4579-456a-a8f0-5c7357b32caf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bb4809fb-e01b-402b-8267-f73d37dbf1ef" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d04528d7-4579-456a-a8f0-5c7357b32caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0777485a-2783-4000-a309-cef7bac579ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bb4809fb-e01b-402b-8267-f73d37dbf1ef" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0777485a-2783-4000-a309-cef7bac579ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_57f2a5d3-2f52-4f42-a36e-f24668cd1ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bb4809fb-e01b-402b-8267-f73d37dbf1ef" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_57f2a5d3-2f52-4f42-a36e-f24668cd1ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_121cbc42-64ed-470b-a146-4766ca9c0f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_155148ba-4dfe-46cd-8c19-6d24f622cb91" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_121cbc42-64ed-470b-a146-4766ca9c0f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_620c80ce-ea7e-4c3f-9c24-537e62005488" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_121cbc42-64ed-470b-a146-4766ca9c0f6f" xlink:to="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_620c80ce-ea7e-4c3f-9c24-537e62005488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_ee51b92c-be1b-4ea3-ba25-810e9d6a60b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_121cbc42-64ed-470b-a146-4766ca9c0f6f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_ee51b92c-be1b-4ea3-ba25-810e9d6a60b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a3e4d105-d212-4d3c-8a14-08b3933adade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_121cbc42-64ed-470b-a146-4766ca9c0f6f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_a3e4d105-d212-4d3c-8a14-08b3933adade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsLiabilitiesGross_58717362-500c-4fc4-b133-5060edb9fdd0" xlink:href="nbix-20231231.xsd#nbix_DeferredTaxAssetsLiabilitiesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_155148ba-4dfe-46cd-8c19-6d24f622cb91" xlink:to="loc_nbix_DeferredTaxAssetsLiabilitiesGross_58717362-500c-4fc4-b133-5060edb9fdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_02b56863-3582-4d17-9ab5-c6af08d98f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_155148ba-4dfe-46cd-8c19-6d24f622cb91" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_02b56863-3582-4d17-9ab5-c6af08d98f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9fb4a8c6-d97a-405b-82ef-2fa0128e4007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_155148ba-4dfe-46cd-8c19-6d24f622cb91" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9fb4a8c6-d97a-405b-82ef-2fa0128e4007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2023ac4d-369a-4109-9986-a91ff6579073" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesTable_3af2ae7e-495f-4bd7-81ba-0169cccff4be" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2023ac4d-369a-4109-9986-a91ff6579073" xlink:to="loc_nbix_IncomeTaxesTable_3af2ae7e-495f-4bd7-81ba-0169cccff4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f4ee6596-d901-43e8-81f7-a49229eb62fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesTable_3af2ae7e-495f-4bd7-81ba-0169cccff4be" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f4ee6596-d901-43e8-81f7-a49229eb62fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2bba3332-087c-4695-9376-0102c44b3feb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f4ee6596-d901-43e8-81f7-a49229eb62fb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2bba3332-087c-4695-9376-0102c44b3feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_c77d483a-ba07-45a1-879f-b072786e23c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2bba3332-087c-4695-9376-0102c44b3feb" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_c77d483a-ba07-45a1-879f-b072786e23c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_4d7fa6fd-4287-4ea6-bc83-a6853fa127e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2bba3332-087c-4695-9376-0102c44b3feb" xlink:to="loc_us-gaap_ForeignCountryMember_4d7fa6fd-4287-4ea6-bc83-a6853fa127e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_e9df3cce-4542-4044-833b-eae232e6957a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2bba3332-087c-4695-9376-0102c44b3feb" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_e9df3cce-4542-4044-833b-eae232e6957a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:href="nbix-20231231.xsd#nbix_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesTable_3af2ae7e-495f-4bd7-81ba-0169cccff4be" xlink:to="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c1f2859a-942c-4b60-85fb-9094dec4ec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c1f2859a-942c-4b60-85fb-9094dec4ec9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5b0f3a9e-77ec-4f1b-8873-3f81e0e1a185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5b0f3a9e-77ec-4f1b-8873-3f81e0e1a185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d5a1154b-c448-49ee-9dfd-7d408dc0eaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d5a1154b-c448-49ee-9dfd-7d408dc0eaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c17d6875-8c16-48d6-b83c-16c192f4b9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c17d6875-8c16-48d6-b83c-16c192f4b9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationInterestAccrued_6f2bfcf7-08d2-4690-a6e3-e541b9537c95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_IncomeTaxExaminationInterestAccrued_6f2bfcf7-08d2-4690-a6e3-e541b9537c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued_4b4631a2-84da-4e39-a362-00d116d7cabe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued_4b4631a2-84da-4e39-a362-00d116d7cabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95a6035e-4da0-4684-9850-98081b1057db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_81430011-80c6-40b7-a5f2-ea0e9869e1d6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95a6035e-4da0-4684-9850-98081b1057db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_78381893-0e10-455b-974b-35e56a497f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_da690ea5-209f-4802-b886-fae66429cfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78381893-0e10-455b-974b-35e56a497f8e" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_da690ea5-209f-4802-b886-fae66429cfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6d683cd3-607e-4aef-a61a-59919f3f0c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_da690ea5-209f-4802-b886-fae66429cfd6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6d683cd3-607e-4aef-a61a-59919f3f0c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_7684fc4d-ec3c-4e49-b12d-9dd0fb7ae95d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_da690ea5-209f-4802-b886-fae66429cfd6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_7684fc4d-ec3c-4e49-b12d-9dd0fb7ae95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_bb8cebf9-66ca-4b4f-9deb-371360bc56ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_da690ea5-209f-4802-b886-fae66429cfd6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_bb8cebf9-66ca-4b4f-9deb-371360bc56ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_afc876e9-a75e-42a2-aa98-2311bf4d128e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_da690ea5-209f-4802-b886-fae66429cfd6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_afc876e9-a75e-42a2-aa98-2311bf4d128e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_6627af13-34a5-4990-a220-0d23015f7cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_da690ea5-209f-4802-b886-fae66429cfd6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_6627af13-34a5-4990-a220-0d23015f7cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a5e7a36c-1eab-4cbf-8836-6ac2cd22962c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_da690ea5-209f-4802-b886-fae66429cfd6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a5e7a36c-1eab-4cbf-8836-6ac2cd22962c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#LeasesSupplementalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8e4cb0d0-d505-4e3a-a4bb-1cd0b53ad754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a7ea6817-151c-410a-a470-a16fb803119c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e4cb0d0-d505-4e3a-a4bb-1cd0b53ad754" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a7ea6817-151c-410a-a470-a16fb803119c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c30fc153-ac54-40c2-9b10-b4f2eb52f22c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a7ea6817-151c-410a-a470-a16fb803119c" xlink:to="loc_us-gaap_CreditFacilityAxis_c30fc153-ac54-40c2-9b10-b4f2eb52f22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_780f4af5-fdec-40c9-935f-119459f739c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_c30fc153-ac54-40c2-9b10-b4f2eb52f22c" xlink:to="loc_us-gaap_CreditFacilityDomain_780f4af5-fdec-40c9-935f-119459f739c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_33d4a3e2-3696-46a9-b46b-6475db1c036a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_780f4af5-fdec-40c9-935f-119459f739c0" xlink:to="loc_us-gaap_LetterOfCreditMember_33d4a3e2-3696-46a9-b46b-6475db1c036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a7ea6817-151c-410a-a470-a16fb803119c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c7346dae-28a2-4477-9bce-51959ac9f1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_OperatingLeaseCost_c7346dae-28a2-4477-9bce-51959ac9f1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_3655e1c5-38ef-424c-85c5-8035ca4c0823" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_SubleaseIncome_3655e1c5-38ef-424c-85c5-8035ca4c0823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OperatingLeaseCostNet_331ca52c-cd7d-4ea8-b362-ced4643bdf72" xlink:href="nbix-20231231.xsd#nbix_OperatingLeaseCostNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_nbix_OperatingLeaseCostNet_331ca52c-cd7d-4ea8-b362-ced4643bdf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a91baec9-acbb-453a-a955-a881b08ca51f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_OperatingLeasePayments_a91baec9-acbb-453a-a955-a881b08ca51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7c20053c-69f7-4339-b9b3-0644ee74d277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7c20053c-69f7-4339-b9b3-0644ee74d277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f9f4f6bc-e74f-4457-877f-ccec9a4970fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f9f4f6bc-e74f-4457-877f-ccec9a4970fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bd259cfa-572e-4954-bc88-8031c19a463e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5898090a-e5ee-4863-8f36-127a415fa523" xlink:to="loc_us-gaap_RestrictedCash_bd259cfa-572e-4954-bc88-8031c19a463e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c20438e7-f292-457a-b935-8778fc1eec11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_f09c9c77-6e66-4a49-9c5c-e13f2f85624d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c20438e7-f292-457a-b935-8778fc1eec11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_f09c9c77-6e66-4a49-9c5c-e13f2f85624d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c20438e7-f292-457a-b935-8778fc1eec11" xlink:to="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7fbd099a-7915-429a-b5ac-d04ca127b52a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7fbd099a-7915-429a-b5ac-d04ca127b52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0b6446cc-029d-456a-b062-27404e4a7e32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0b6446cc-029d-456a-b062-27404e4a7e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7407bb54-26d6-4e20-9eee-d72dd5f82e34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7407bb54-26d6-4e20-9eee-d72dd5f82e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_51ffc566-4f9c-4509-a09d-07750e365c52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_51ffc566-4f9c-4509-a09d-07750e365c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_70825478-0c9d-4838-a640-1e3c1c1fe65e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_70825478-0c9d-4838-a640-1e3c1c1fe65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_03863876-d105-4205-850e-ed00134683bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_03863876-d105-4205-850e-ed00134683bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6c11f0f-bd14-4604-bbe8-3d17ad639a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6c11f0f-bd14-4604-bbe8-3d17ad639a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_13852841-3e2e-4169-88bf-18f8f327c121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_13852841-3e2e-4169-88bf-18f8f327c121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_17680521-7da7-401c-9a34-2d4a25c925f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:to="loc_us-gaap_OperatingLeaseLiability_17680521-7da7-401c-9a34-2d4a25c925f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f405e1e-6f80-457a-bacd-d47ed0dba557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f405e1e-6f80-457a-bacd-d47ed0dba557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9cbf04ac-b24c-4764-b659-9dc7c8ee2706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_78133c5a-1555-4c90-8a45-420cc52494ac" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9cbf04ac-b24c-4764-b659-9dc7c8ee2706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_01b59d5b-63be-4e96-957c-319b692316c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c20438e7-f292-457a-b935-8778fc1eec11" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_01b59d5b-63be-4e96-957c-319b692316c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_6409ba64-e5a4-4241-9afc-7ae216ddcf36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_01b59d5b-63be-4e96-957c-319b692316c7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_6409ba64-e5a4-4241-9afc-7ae216ddcf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_d820c254-6ab3-449c-9445-681dd2cad417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_01b59d5b-63be-4e96-957c-319b692316c7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_d820c254-6ab3-449c-9445-681dd2cad417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_1d969c46-35f8-4ce4-bef9-1c1627808dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_01b59d5b-63be-4e96-957c-319b692316c7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_1d969c46-35f8-4ce4-bef9-1c1627808dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_5f6a04bc-9ed6-4a45-b01d-6eb47f206c40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_01b59d5b-63be-4e96-957c-319b692316c7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_5f6a04bc-9ed6-4a45-b01d-6eb47f206c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_990ae989-5851-403b-ac68-604410bfae59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_01b59d5b-63be-4e96-957c-319b692316c7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_990ae989-5851-403b-ac68-604410bfae59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_f3708d3d-df0e-4135-b71a-408f95e81a28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_01b59d5b-63be-4e96-957c-319b692316c7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_f3708d3d-df0e-4135-b71a-408f95e81a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_40494b86-41b7-4580-9545-e263658b9ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_01b59d5b-63be-4e96-957c-319b692316c7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_40494b86-41b7-4580-9545-e263658b9ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_9f718717-4079-4730-a41f-1ebf8238fb81" xlink:href="nbix-20231231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c20438e7-f292-457a-b935-8778fc1eec11" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_9f718717-4079-4730-a41f-1ebf8238fb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_b67f8fef-d5fd-4589-9318-616de38916c8" xlink:href="nbix-20231231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c20438e7-f292-457a-b935-8778fc1eec11" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_b67f8fef-d5fd-4589-9318-616de38916c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_ae1913b9-39e1-4514-aabd-75fc0150e5e4" xlink:href="nbix-20231231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c20438e7-f292-457a-b935-8778fc1eec11" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_ae1913b9-39e1-4514-aabd-75fc0150e5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_a60d9e43-bacf-4630-94ff-06db6c2bf105" xlink:href="nbix-20231231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c20438e7-f292-457a-b935-8778fc1eec11" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_a60d9e43-bacf-4630-94ff-06db6c2bf105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour_1ea68a59-bcfd-4fce-9cd8-faf786881a18" xlink:href="nbix-20231231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c20438e7-f292-457a-b935-8778fc1eec11" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour_1ea68a59-bcfd-4fce-9cd8-faf786881a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="nbix-20231231.xsd#LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#LeasesNarrativeInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9c84041f-9223-4448-9932-292486f55a96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6ea03738-355a-4aac-81c5-2b453a2a8ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c84041f-9223-4448-9932-292486f55a96" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6ea03738-355a-4aac-81c5-2b453a2a8ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae8fc868-fb6d-4701-9829-5e5749c9d8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6ea03738-355a-4aac-81c5-2b453a2a8ebc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae8fc868-fb6d-4701-9829-5e5749c9d8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e81f7cfc-f75e-482c-93be-f48125f90869" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae8fc868-fb6d-4701-9829-5e5749c9d8ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e81f7cfc-f75e-482c-93be-f48125f90869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_bcf5d383-78bc-4ffa-9676-194ef1991b65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e81f7cfc-f75e-482c-93be-f48125f90869" xlink:to="loc_us-gaap_BuildingMember_bcf5d383-78bc-4ffa-9676-194ef1991b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f5a0f51a-3532-40b2-8c1b-71fd59a14525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6ea03738-355a-4aac-81c5-2b453a2a8ebc" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_f5a0f51a-3532-40b2-8c1b-71fd59a14525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding_5b989cdf-0da7-47c9-afde-5a06b6f0593c" xlink:href="nbix-20231231.xsd#nbix_LesseeOperatingLeaseOptionTermToConstructBuilding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f5a0f51a-3532-40b2-8c1b-71fd59a14525" xlink:to="loc_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding_5b989cdf-0da7-47c9-afde-5a06b6f0593c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ef0b3d0a-1001-440a-af9f-1f4e245a0b89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f5a0f51a-3532-40b2-8c1b-71fd59a14525" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ef0b3d0a-1001-440a-af9f-1f4e245a0b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4e7dd397-9199-4520-9f19-0123c657e65f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f5a0f51a-3532-40b2-8c1b-71fd59a14525" xlink:to="loc_us-gaap_OperatingLeaseLiability_4e7dd397-9199-4520-9f19-0123c657e65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20231231.xsd#RetirementPlanAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80c3ad0a-0ede-46f3-8a31-0821be9558ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_6f95543f-4f54-4edd-a533-1f5a67484e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80c3ad0a-0ede-46f3-8a31-0821be9558ea" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_6f95543f-4f54-4edd-a533-1f5a67484e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_5d2124fb-4f45-4e83-a120-ffd97d121edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80c3ad0a-0ede-46f3-8a31-0821be9558ea" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_5d2124fb-4f45-4e83-a120-ffd97d121edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:href="nbix-20231231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EricBenevich2023PlanMember" xlink:href="nbix-20231231.xsd#nbix_EricBenevich2023PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_nbix_EricBenevich2023PlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EricBenevich2024PlanMember" xlink:href="nbix-20231231.xsd#nbix_EricBenevich2024PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_nbix_EricBenevich2024PlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_GeorgeMorrowMember" xlink:href="nbix-20231231.xsd#nbix_GeorgeMorrowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nbix_GeorgeMorrowMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EricBenevichMember" xlink:href="nbix-20231231.xsd#nbix_EricBenevichMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nbix_EricBenevichMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IngridDelaetMember" xlink:href="nbix-20231231.xsd#nbix_IngridDelaetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nbix_IngridDelaetMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LeslieNorwalkMember" xlink:href="nbix-20231231.xsd#nbix_LeslieNorwalkMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nbix_LeslieNorwalkMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShaliniSharpMember" xlink:href="nbix-20231231.xsd#nbix_ShaliniSharpMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nbix_ShaliniSharpMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RichardPopsMember" xlink:href="nbix-20231231.xsd#nbix_RichardPopsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nbix_RichardPopsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>nbix-20231231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !Q <@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _+C]KSP'XG^"/Q,F&GZYK"^&=6+7
M6G-]MEVQ<_/!G=_ 3Q_LE?>O#AX]\3?]#%JW_@=+_P#%5^MW[07P;L?C?\-M
M0T"X5$OU4SZ?=,N3#. =ISZ'H?8U^06N:+>>&]:OM*U"%K>^LIWMYXF'*NK$
M$?F*[J<E..NY_77 F=T,]R]4J\5[:E92T6JZ2^>S\_5&C_PGGB;_ *&+5O\
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M;OVHO^"MGQ!^(>M7FD_"V=O _A6-VCCOT16U"[7IO+,"(@>H"C</[W:O8O\
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MVJ>)+?3EG@\J.QN+A8A_H\>=H4XZYZ5^ZMK:PV-M%;V\206\2A(XHU"JB@8
M '0 4R33[6:0O);0NYZLT8)- '\SO_"7?%+_ *#7B_\ \"KK_&E_X2[XI'IK
M/B__ ,"KK_&OZ7_[+LO^?.W_ ._2_P"%?!?_  4]_;(MO@5X17X?>#)+>+QS
MKD+?:KJ  2:9:D8W# XD?)"^@!/<4 ?D ?BMXX5B&\8^( 0<$'5)_P#XJOZ1
MO@?<2W7P9\"S32/--)H=D[R2,69F,"$DD]37XQ?\$V_V+9OVE?B,?%WBNS:3
MX>Z#.)+CSP=NIW0.Y;<>JCAG/H0O\1Q^Y]K:PV-M%;V\206\2!(XHU"JB@8
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MZT5J_#?P+9_#3P/I'ANQEDN(;"$1M<3',D[GEY'/=F8DGZT4 =-7P;_P4&^
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M/[/P[K%GXCT "3PMKZ?:K1XQ\L3GEHCZ8SP/J.U8?PW\:7O@'Q/9:O9,0T3
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MX>A+SQ6\?[S4+,#+)QRSIRR_B.]?GY_P3P_;!N?V9?BI'IVLW<I\!:\ZP:E
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M/M]8UN:^NXI+J2612520A1@,!P*^G?\ AVS^SM_T3NT_[_R__%4 ?"W[*?\
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M(M/_ $2M?G'KO_!%&36O$&HZF?BJL1O+J6Y\L:,3MWN6QGSNV<5^F/A/0_\
MA%_"VCZ/YWVC^S[2*U\[;MW[$"[L=LXH _-C_@KG^R#%JNC_ /"Z/#%GC4+3
M;!KUM!'_ *V/HMQP.J]&/H17QE^P-^UU>_LK_%R"2^GFE\#ZTZ6VL68;*Q@G
M"W"C^\F><=5R.>*_?[6-'LO$&EW>FZE:Q7VGW<30SVTZADD1A@J0>H(K\SO&
M7_!$W3-8\5:K?:%\1FT;1[BX>6UT^32_.:W0G(3>)!D#H.!Q0!^F6E:I9ZYI
MEKJ.GW$=Y8W42S07$+;DD1AE6!]"#7X6_P#!6K_D\K7/^P;9?^BA7ZU_LD?
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M6/L!DGZ5^C_@7P=9> _"]CHM@H$5NF&?&#(Y^\Y]R?Z5XO\ LD?",>&/#?\
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M2"EZ7OH%%%%8GDA1110!\I^,?^"?^A>//%&I^(-9\9:U=:GJ$[3S2>7&!D]
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M2_V>=;\DD?:)H('P<?*T@S7OM>"?MOZ3+JW[/.N^4"?L\L-PV!_"K@FMJ/\
M$CZGKY/;^T:'-MS1_,V/V=O#GD_LS^&M-MII+=[G2V99K=S&Z/)N.Y6'(()Z
MUYE^PM\0-?UB3QQX5\4ZU?:UJVD7ORR:A<O/(J@LCC<Y)P& XKUG]E;5TUK]
MG_P9.F,+9^2<#NC%3_*O!=%D_P"%/_MT:];EUMM.\1V3W"(HPI)3> ??>C'\
M:Z$N9U(O??[F>["/UAYAAIKWM9+O>,M?O3-1?&7B3X@?MRC0[#7]4M_#.AQA
MKFRM+V1+:0QQ[CYD:L%;+L%.1VKI?BQ^S)X_^*GQ"U._/Q0OM!\+R[3:Z;:R
M2MY>% 8&,,B]1G.2>:Y7]A/2Y/$OB7XB?$*[3,FHWK6\,GJI8R./_0*HZ[^T
MC\7/BQ\5-=\+?"6PL;>QT9WCENKE(V9PK;2[-)P 6!  %:M252T++E6YZ%2G
MB*>-=+!.,?8TXQE*5K)Z-O5/6^AQNA?\)I^S!^TWX;\)2^,[[Q)HFK/")8KB
M20H\<C%<F-F8*X(R"#6U^VQ_R<1\-O\ ME_Z/%><^*/^%BC]J3P%_P +,>U?
M7//M/+-H(POE>:=OW !G.:]&_;8_Y.(^&W_;+_T>*W2_>0;W:9[<86Q^&J2<
M7.5*=W'9NSUTL3_\%%H[B7Q-\.DM'$5TS3")VZ*^^/!/XU!\5/V7_B7H_@C5
MO&VL?%K4M1UZPA-T]K%),D0 Y*QOO&WV 0"K_P#P4$_Y';X8_P#7:3_T9'7T
MM^T+_P D2\9_]@V7^58*I*$*:76_YGB4\=6PF"R^-*WO.2=TGISK37;?H>+?
M";]HC6K?]D+5/&>KW']IZYI'G6D4UQR97&!&7/<_-R>^*\T^%/P!\??M%^#9
M/'NN_%#6-.O;R23[%;QM(Z@*>#Q(H1<CA5'%8G@G_DP'Q=_V%&_]#2M_X"V/
M[1L_PIT-O!>IZ%!X:*-]DCNDB,@&\YSF,GKGO6CCR*3@TG?J>C.@L+'$U,+*
M%.7M6KRM:UKV6C/2/V/_ (F>*/$'A/QQX:\4:I/J>I^'7>.&\GD+3;0&!!<_
M,<,O!)SS7B?P)T7XP?M!V_B33+7XGZEI>AV=X/M,MS>32W!)R B-G=MP.5W
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;?Q9>K"BBBI,0HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>nbix-20231231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "7 0<# 2(  A$! Q$!_\0
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M5?\ T6*^_P P_@83UC^2/RO*O]ZQ_I/\V>"_!W_DI&A_]=OZ&OL.OCSX._\
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M@9)-?,?A3_D;-)_Z_8O_ $8*^CO$FEOK7A_4;"-_+DN('B5LXP2"!^&:_!N
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MKX3_ !(/P_N]-\1Z]XTDT^/4;/1= TMKN>]1W90D6"!N 1V.XJH522:3P/\
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M@Y 5G4D 'F@#\SK+17;X0_ K4Y=*DT[PYXF^/XUK1--NXMOEZ9/*_DC:?X2
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MO70].75%U,:?:C4EA^S+>"%?.$6<^6'QG;GG;G&: /R__9MO+GP[^RR+>_\
MVH!\-+7PY#=V.M^";GP_I+7%A,)9!)#ME7S96D))!.2Q?'7@=C:^%OA[HOPT
M_9K\,S^._'/PPU^+3[^[\'^/-0M;>Q2-)WWR6EVC2-&&DC,>V//(V<C)6ON/
M7O@3\-_%/BJ+Q-K/@+PWJOB*(JR:K>:5!+<@K]T^8RELCMS6]XP\"^'/B%HC
MZ-XHT'3?$6DN0S6.J6B7$)(Z'8X(R/6@#Y9_99^)?BR\_:2\9^ /$/BWPO\
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JBB.VM9AHMLT&GZ=9P+B.VMU<[V&>2S<G X&#DHH ]WHHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>nbix-20231231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "A 5,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH\^+H^RG>UKI_.Z.;$TZ5*IRT9\\>]K!1117IG(%%%% !1110 4444 %%%%
M!1110 4444 %%%% !17@GQ U>^M_CEI5M%>3QV[26P,*2,$.2,Y&<5[W756H
M.C&$F_B5SCH8E5YU(I6Y78****Y3L"BBB@ HKE/'FI3V5C=>6NY8;"XO A)V
MRN@7:AP02/FR1WXK$^'^LWEY)OE@%HWVQK5[<1F(E?*W[C%N;:01C/<'Z5NJ
M+<'4.:5>,:BI=6>C4445@=)7O[07]C<6S,R+-&T993@C((R/>O$[CX.^%?!5
MM_:7BO6IKLYW"+.WS#_= Y9NWI7NE<-XR^$^E>-/$%IJFH33*D,>R2W1L+(!
MR,GM[XZBN["UW2;BYN,7O;<\W&X=5HJ2@I26U]M?S/(5U#4/&WG:=X/TN'PY
MH$0/GWGW#LYR9)>N,9^4'\Z]*^#_ (\LM2LWT 7,ER^FA8HKR5=JW"YPN/3T
M /) ^M<3XNU]_'.H0^!O!=LD&DQMB>:%=J/CJ21_ /4]35#Q%H<<?BC1/ ?A
MMV1K659KR[7[SSX!+GV1<X';)KVJE.-:'))<O7S2[R?GV/GZ=6>'J>T@^;[+
MZ)M_9BNRWN?25%>1>&OBK?MK7BBUEB6]TK1H9)8I"<3,J$+@MG!SR<FM5OC=
MIR>#X/$#Z==B":=K;8"IVR 9Y.>A]<=CQ7B2P=9.W+?;\5<^BCC\/)7YK;_@
M[,](KE_'6J:O#H%ZOAE([O6(BH:,,I:($9SM/4D#@'KFN5\:?%R\\+:GH<XL
M(Y/#NH1K,;L9+E2.5QT!&0<5RWB;PWKWP_UX^+O"US)J>EWF))8V8R$ACG#=
MV4YX/4?SVH85WC*;2OM?9M='V,,1C(VE&FF[;VW2?5=SHO WQ(7QQJ@T'Q%X
M< U- 2S-;AHQMYRRL/E_Q->L5G:0HOK>UU.YTY;'4I8 )%8 R(#@E"P[9[5I
M5R5YQE+W(\J[7N=N&ISIP_>2YGWM;3S/G/X,_P#)7M4^MQ_Z$:^C*^7_ (<^
M)=-\*_%#5+S5+C[+;;IU\S8S<EC@84$U[/\ \+M\%_\ 09'_ (#3?_$5ZN8T
M:M2LG"+:LMD>+E6(HTZ#C.:3N]VCN:*X;_A=O@O_ *#(_P# :;_XBMOPSXXT
M3Q@UPND7OVLVX4R?NG3;NSC[P'H:\F5"K!<TH-+T9[D,11J/EA--^31<U?Q)
MI>@F,:C?0V9DSL\UL;L=<5XGX \0:=IOQ*U6_NKN."SF-QY<SG"G=("/S%>N
M^*O NE^,FMSJ(F)@!">5)MZXS_*O%?!?@W3]<\>:AI%SYIM+<S;0KX8A'VC)
MK\BXFGF?]IX14X0Y5/\ =ZO5V5^;LK]C[G*8X3ZI7YI2OR^]MHK]#W72?%6D
M:].\.GZA#=RHN]EB;) SC-);^+='NM8?2HK^)]10LK6XSN!')[5G^%_AYI'A
M"]ENM/$XEDC\MO-DW#&0?Z5\^:UXHF\&_&#7M4MX5GN$GG2-6Z;F7 )]<9Z5
M^JY+A\7C*,EC4HU$GI%Z>6Y\'FV+HX&<'0NX-VUW\]CZ0\0^,M%\*H&U348;
M5B,B-CES_P !'-8.G_&GP?J%RL":LL;MT,T;(OYD8KB/"7P1F\2XUSQC=W$U
MY=?O/LJMAE!Y&X]N/X1TK7\2?L\Z#?:?(-(,NGWJK^[+2%XV/HP//Y&O7]E@
MH/DG-M]UL><ZV837M*=-)=GN>JQ2I-&LD;K)&PW*RG((/<&L[7O%&E>&8!-J
ME_#9(WW?,;EOH.IKY\^'GQ4NOAS:ZSI&JI),UN&^S0L<[)@P!3/93R?P]ZZ3
MPK\(;SQ\Y\1>,+N<O=#?%:QG#;#TR3]T8Z #I3E@8T)-UY6AT:Z^@H9E+$14
M</"\WNGM'U_0[BU^-W@ZZF6(:MY9;HTD+JOYXKMK6ZAOK>.>WE2>"0;DDC8,
MK#U!%>::U^SWX9OK)TL%GT^YP=DBR%USVR#V^E<9\&=?U#P9XVNO"&I/F!I&
MC52V5CE'(*^S?U%*6&H5J<IX:3O'5I]AQQ>)H58T\7%6EHFN_9GT'2,P52S$
M  9)/:@L%!). .IKYT^(7Q U?XD>(CX:\-^8;+>8\1'!N"#RS'L@Q_C7)AL-
M+$R:3LEN^QW8O%PPD$VKMZ)=SUO5_BYX3T64Q3ZQ$\@."L ,F/Q4$5'IOQD\
M(:I-Y4>KQQ.>!YZ-&#^)&*Y/P[^SAI%K;(^L7<][='!986V1CU'3)^O%3Z[^
MSEH-[;O_ &;<7%A<?P[F$B?0C&?UKL]G@+\O/+UMH<'M,S:Y^2/I?7_(]7AF
M2XC62)UDC895T.01Z@T^OFCPSXKU[X+^*!HVLAGTMF^:-CE=A./-C/\ 3\.*
M^D[>XCNK>.:%Q)%(H='7HP(R"*Y<3A98=IWO%[,[<'C(XI-6Y9+=/H25F:WX
METOPW")=3OX;-3R/,;D_0=3^%<[\4_B''\/]!$T:K+J-P2EM$W3..6/L.*\H
M\%_"O5OB=,?$'B6]GCM9CN3/^LF'^SG[J^GZ5I0PL90]M6ERP_%^AEB,9*-3
MZOAX\T_P7J>G'XZ>#1)L_M1NN-WD/CZ]*ZK0_$^E>)(3)IE_!>J.2(V^8?4=
M1^-<A'\!?!R1JIL)G(&-S7#Y/OP<5QWBCX,7_@N3^W?!E[.);;]XUJYRY Z[
M3_%W^4BM%3P=5\M.3B_.UOP,G6Q]%<]6$9+KRWO^)F_$;_DOFD?]=;7^8KW^
M\O(=/M9;FX<101*7=R#A0.IKY:_X2Y_&WQ2\/ZG+!]GG,UM'*@Z;U8 D>QKZ
MHN+>.ZMY8)4$D4BE'5NA4C!%:YA!TU1A/HC'+*BJRKSI[.6A0T3Q-I?B1)7T
MR]BO%B(#F,_=STS^5:=?.G@:XD^%GQ=NM$N&*V-X_D!F/!#<Q/\ R'MDU]%U
MQ8K#JA-<KO%JZ9Z&"Q+Q,'SJTHMIH*Q]:\7:/X=FBAU+4(;261=R)(3DC.,U
MKLP4$DX Y)KYQL1_PMSXTM,PWZ99ON'!QY,9^7_OHX_.C"X=5N:4W:,5=BQF
M*EA^2--7E)V1]!7EC;ZQ;Q%RW'SQ2QDJRY'4'Z'H>#W%-L]'BL[AKAI);FY8
M;?-F()"^@   _ 5?HKCN]COY5N%%%%(H*3KP:6B@#G[?PQ9^%[75KG0=.B2_
MN@TNP':'DQP,GH,]NG)KSOX7^%;_ ,)Z?XD\5:]#(FK,LI"S#+X4%F;WW'&/
MI[U[)45Q;17EO)!/$DT,@VO'(H96![$'K77'$2C&47KS6OWLNAQ3PL)3C-:<
MM[+I=]3Y_P#A3H[W/PV\<Z@<%[J"6)?;;&S'_P!"%2^ ='7Q7\"]9T]!FXM[
MB2>/CHP 88^HR/QKW"UT'3K'3YK"VLXK>SEW!X8EVJ=PP>!TX]*CT'PQI7AB
MTDM=+LH[.WD;>\<><$XQDY]J[)XY2<FEJY)KY'GT\M<5"+=THM/SN>5_#O38
M?B9\(9=#OE*W%F[1P2N.4.-R,#^)'TKOOAKX6O\ P=X5@TR_O5O9(R2NT'$8
M/.P$]0#G\ZZ>&&.WC6.*-8HUX"(H 'X"GUR5L3*IS16D6[V.[#X2-'EDW>25
MK]T%%%%<9WGROX)\'V/C;XDZII^H-,MOYD[_ +E@K9#'')!KU7_AG/PK_P ]
M=0_[_+_\37"_!G_DKVJ?6X_]"-?1M?09AB:U*JHPDTK(^7RO"4*U!SJ03=V>
M6?\ #.?A7_GKJ'_?Y?\ XFNH\#_#?2O #7C:8]PQN@@D\]PWW<XQ@#^\:ZNB
MO)GBJ]2/+.;:/<IX/#TI*<()-!7B/PR_Y*UK7_;U_P"C17MU>(_#+_DK6M?]
MO7_HT5^<\1?\C#+?^OGZ(^NRS_=L5_A_4]NKYCCTN+6?V@IK:8;HO[2>1E(R
M"%&[!^N*^G*^>?"JAOVCM0R,XGN#_P".FOU/+Y.*K-?RL^ S2*E*A%_SH^AJ
M***\@]T^7O$F@QZA\=I+"12\5SJ"-(H]"03^E?4"J%4 # '  KY]NO\ DY&/
M_KNO_HNOH.O8S"3<:*_NH\'*XI2KR7\[_K\0KYR\<2M:_M!6DD6%<75KV]40
M'^9KZ-KYO^('_)?K;_KZM/\ T&.EEO\ $G_A?Z#S?^%3_P :_4]?^+FLR:'\
M/=7GB8I*\8A5E[;R%/Z$UQO[-_AV&WT"\UEU#75S*858CE47!Q^)/Z"NJ^-6
MFR:G\.-52+)>()-@#J%8$_ID_A6#^SGJT-YX,GLE;]_:W!++_LL!M/Z&G3NL
MOFX_S:^@5+/,X<_2+MZ_\,>KT445XY[IYE^T!X<AU;P/)J!4"YT]UD1\<E68
M*R_3D'\*F^ >M2:M\/X8I26:SE:W!;NO##_T+'X58^.6K1:;\.=1CD;$ET4A
MC'&2=P8_HIK/_9YTV2Q\ ^=)P+JY>5/]T +G\P:]??+_ 'NDM/N/"LEFGN=8
MZ_><!\08V\<?'"WTB4L;6*2*W*]PF SXY]S7T7#"EO"D4:A(T4*JJ,  < "O
MG7Q9<_\ "'?'R/4+D[+:2:.4R$<>6RA6/X<_E7T8K!@"#D'D$48Z_LZ*6W+^
M/4,MLZN(;^+F_#H+1117D'NGS1XK\/P^'OCK8Q6ZA(+B\@N50=!N8$CV^;-?
M2]?./CS58M6^/6FK"P*VMU;0,R]V5@6'YDC\*^CJ]?'\SA1<M^4\++%%5,0H
M;<QXO^T9X5:XT^R\0VRD36C"*9EZ["<JWX-_,5Z#\-_%2^,/!]A?EMUP%\JX
M]1(HP<_7@_C6SKFD0:_H]YIUR,P7431-CJ,CJ/<=?PKPKX(ZQ/X.\<:EX4OR
M46:1D4'H)4[Y]"/SXHA_M.$</M4]5Z=0J?[)CE4^S4T?^);'HOQK\6?\(OX)
MN%B?;=WW^C18Z@$?.?RX_$5F?L_^$_[#\(G49DQ<ZDV\9ZB,9"C\>3^5<-\1
M+F3XG?%JST"U<FSM'\AF7D#',K_AC'_ :^A;6VBLK6&WA01PQ((T0= H& /R
MHK?[/A8T>L]7Z= H?[5C)U_LP]U>O4EHHHKR#W0HHHH **** "BBB@ HHHH
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M?#6YU>.QC\1$QRW?V"/4C8W T][C?L\M;LQ^227^4$/@G@'/% 'JE%<;X_\
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M;?,3@D$YXSS7EGP)^,0D_9OL?'7C_7H8$BGU#[9J=T%C4)'?SPQC"@9.U44
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HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>nbix-20231231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20231231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "% / # 2(  A$! Q$!_\0
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M-K=P7UM%<6TJ3P2J'22-@RLIZ$$=14U=&^I_*=24IS<I[MZ^H4444&84444
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M_81E_P#04K ^,W_)T'PZ_P!R+_T:];_['/\ R2FX_P"PC+_Z"E8'QF_Y.?\
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E%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>nbix-20231231_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20231231_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "D 1\# 2(  A$! Q$!_\0
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M=>R+X'ISCE[G+9O\K_YA1117@GZ*%%%% !1110 4444 %%%% !1110 4444
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M_9]U#XB^./ =KX2\&W,7AG2-/DE:_P!>E3>[/(Y81QC'4 CIS[CC/H'[*?\
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MQ8^@7V&BBO,K5/:RYDK'U>#PKPE+V;FY:[O^F%%%%8G<%%%% !1110 4444
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MJ7B3X0:EXJN]<OWN;BZ836329M?*%QL"*F/EQ@$$<\>]=GKQ_<?"7_KZ@_\
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MMO#KQ7K6BW;@V\TL<FU9#N !)0$C/3/% %2W\1:W>Z7I6GVGB&Y./%$NEIJ
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M^G-=IK^J:LWB<6=OJ]Q8VX:TA\N%(S_K4F+G+*3G]VN/2G85S6\9>#I-8O\
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M"_,I &68\<@DXK4L[6.PLX+:$;8846-%SG"@8'Z"IJ* "BBB@ HHHH ****
M"BBB@ HHHH *H:YIHUC2;BT-U<V?F+_K[.3RY4P<Y5NW2BBFMP.>\)^!K72]
M2;6)[[4-7U/RS;I<:C,)#%'G)5   ,GKQFNPHHH>XEL%%%%(84444 9/BKP]
M:^*_#][I-XTBVMTH1S"P5L @\$@^E:<,8AA2-?NJH49]A113Z /HHHI %%%%
H !1110 4444 %%%% #%A19&D"*';@L!R?J:?110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>nbix-20231231_g6.jpg
<TEXT>
begin 644 nbix-20231231_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,M!&P# 2(  A$! Q$!_\0
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ME=?M-?%#P'XYN&N/#,_B/5-&\(:K]EACCMKJTW2-8NR*,EH61D:3)8H5!8G
MX3PC^T%\;?BM\+_V6[33/B9_PC'B;XA7?B*#5]>_L&QN]XM)W\@^0T:H,(FW
MY-F<Y.37L;_L4:EKW@?XV:/K6I:?;ZIXH\:77C'PKJFGRRF72;G -K*Y**4D
M5@0VS=\KL W-<-HO[%_QE^'_ ,-/V>K7PGJG@6;QC\,KC7+BY.LW%ZVGS_;9
MF:,)Y<(D;".<YV8;&-PH ]2^"/Q"^)O@7]HW5O@M\4/%5E\0'N/#Z^)]$\46
M^EQZ;.T8F6"6VF@BR@P^YE(YP"2QW!4Y/X._M/>-O$W[0D-_K=]%-\&_'6HZ
MIH?@U8[:)1!<V!11*TP4.PN?*NBH9F^90!CH-&S_ &<?C5KVH_$/XC>+/$?A
M#_A;>K>&'\)>';?0_M4.D:1;.P=Y_,D1Y3*7+,/D."N,D/A,#7O^"8_@CPS\
M-])N?AC9P:#\8M#^P7>G^*K_ %*\:"2]@DC>226+>Z!9-C\+'A2PP,#% 'VU
M14-FUPUG ;M(X[HQJ9EA8L@?'S!20"1G."0/H*FH **** "E3[R_6DI4^\OU
MH Z*BBB@ HHKE?'?Q0\+_#2S2X\1ZQ!IPD&8X6R\LG^[&H+$>^,#O32<G9(U
MI4JE::ITHN4GT2NSJJ*^=[O]N;X?6TFV.QUZZ7^_#:Q ?^/2@_I4/_#=W@'_
M *!'B3_P&M__ (_71]6K?RGN+A_-6K_5Y'O,FFS-(S#;@DGK3?[+F_V?SKPC
M_AN[P#_T"/$G_@-;_P#Q^C_AN[P#_P! CQ)_X#6__P ?H^K5OY1_ZO9K_P!
M\CW?^RYO]G\Z/[+F_P!G\Z\(_P"&[O /_0(\2?\ @-;_ /Q^C_AN[P#_ - C
MQ)_X#6__ ,?H^K5OY0_U>S7_ *!Y'N_]ES?[/YT?V7-_L_G7A'_#=W@'_H$>
M)/\ P&M__C]'_#=W@'_H$>)/_ :W_P#C]'U:M_*'^KV:_P#0/(]W_LN;_9_.
MC^RYO]G\Z\(_X;N\ _\ 0(\2?^ UO_\ 'Z/^&[O /_0(\2?^ UO_ /'Z/JU;
M^4/]7LU_Z!Y'N_\ 9<W^S^=']ES?[/YUX1_PW=X!_P"@1XD_\!K?_P"/T?\
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M/(]W_LN;_9_.G2Z;,\C$;<'WKP;_ (;N\ _] CQ)_P" UO\ _'Z/^&[O /\
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M.O"/^&[O /\ T"/$G_@-;_\ Q^C_ (;N\ _] CQ)_P" UO\ _'Z/JU;^4/\
M5[-?^@>1[O\ V7-_L_G1_9<W^S^=>$?\-W> ?^@1XD_\!K?_ ./T?\-W> ?^
M@1XD_P# :W_^/T?5JW\H?ZO9K_T#R/=_[+F_V?SH_LN;_9_.O"/^&[O /_0(
M\2?^ UO_ /'Z/^&[O /_ $"/$G_@-;__ !^CZM6_E#_5[-?^@>1[O_9<W^S^
M=']ES?[/YUX1_P -W> ?^@1XD_\  :W_ /C]'_#=W@'_ *!'B3_P&M__ (_1
M]6K?RA_J]FO_ $#R/=_[+F_V?SH_LN;_ &?SKPC_ (;N\ _] CQ)_P" UO\
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M &?SH_LN;_9_.O"/^&[O /\ T"/$G_@-;_\ Q^C_ (;N\ _] CQ)_P" UO\
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M-;__ !^CZM6_E#_5[-?^@>1[O_9<W^S^=']ES?[/YUX1_P -W> ?^@1XD_\
M :W_ /C]'_#=W@'_ *!'B3_P&M__ (_1]6K?RA_J]FO_ $#R/=_[+F_V?SH_
MLN;_ &?SKPC_ (;N\ _] CQ)_P" UO\ _'Z/^&[O /\ T"/$G_@-;_\ Q^CZ
MM6_E#_5[-?\ H'D>[_V7-_L_G1_9<W^S^=>$?\-W> ?^@1XD_P# :W_^/T?\
M-W> ?^@1XD_\!K?_ ./T?5JW\H?ZO9K_ - \CW?^RYO]G\Z/[+F_V?SKPC_A
MN[P#_P! CQ)_X#6__P ?H_X;N\ _] CQ)_X#6_\ \?H^K5OY0_U>S7_H'D>[
M_P!ES?[/YT?V7-_L_G7A'_#=W@'_ *!'B3_P&M__ (_1_P -W> ?^@1XD_\
M :W_ /C]'U:M_*'^KV:_] \CW?\ LN;_ &?SH_LN;_9_.O"/^&[O /\ T"/$
MG_@-;_\ Q^C_ (;N\ _] CQ)_P" UO\ _'Z/JU;^4/\ 5[-?^@>1[O\ V7-_
ML_G1_9<W^S^=>$?\-W> ?^@1XD_\!K?_ ./T?\-W> ?^@1XD_P# :W_^/T?5
MJW\H?ZO9K_T#R/=_[+F_V?SIS:;,R(/ER/?WKP;_ (;N\ _] CQ)_P" UO\
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M &?SH_LN;_9_.O"/^&[O /\ T"/$G_@-;_\ Q^C_ (;N\ _] CQ)_P" UO\
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M / /A?3]<^,&E?%/PZN=$\3:)*+I003!=AHLAL$_,0K*0. T39/S"O(OAI\
M;+Q%X9\2>,KWPS-XVOYM4N+:PT*/4Q81E%F >5Y<@AAA\#)&.Q)!7FCBEJY>
M7WGSU'B:GS3E75HI05MGSMR3BVVDK-;NVFMSY8HKZL\1?LZ>&M#^-WP\M'TJ
M>VT#Q-',USH5Q=,[6LL4.YHQ,CY(!9.C'D'D@@#.^&_P<\'Z]^TEXZ\*W^D>
M?H.FVEQ+:6GVF9?+99854[PX8X#MU)ZUK]9A:_E?]#T5Q#A)4G5BI-*'/TVY
MN6V^]UZ>9\R45])^ _ ?P]TW]FU_'WB3PS)KFHV]V\7EQZA-;^?F4(J$JV%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOQ4\/>(? _A::PTG2,;TOKIWN;XE2LC/EF2,X) "\9Y/4*OJV@?M(?"OPO\
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MO^@OX;_\";C_ .,4?6:/\P?ZPY5_T$1/G&BOH[_AA'Q]_P!!?PW_ .!-Q_\
M&*/^&$?'W_07\-_^!-Q_\8H^LT?Y@_UARK_H(B?.-%?1W_#"/C[_ *"_AO\
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MZS1_F#_6'*O^@B)\XT5]'?\ #"/C[_H+^&__  )N/_C%'_#"/C[_ *"_AO\
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M^@B)\XT5]'?\,(^/O^@OX;_\";C_ .,4?\,(^/O^@OX;_P# FX_^,4?6:/\
M,'^L.5?]!$3YQHKZ._X81\??]!?PW_X$W'_QBC_AA'Q]_P!!?PW_ .!-Q_\
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MVRHC$H<JPPP'*D=J7+$E4*,M$>H?\)?9_P#/*?\ [Y7_ !H_X2^S_P">4_\
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MH6?B'Q!J6FZA>7T$R+!;:=#=?;'CSLY6X@CB$ARF7.-P(- 'LE%>9^&?VCO
M7C#5([#2M1U*>:XM)KZRDET*_A@U."(*7>QFD@6.\&UE8?9VD+*0RY'-<?\
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M8+O1?BEI?A31OL+6VGZ9<>(O%=Y=1M)]ATY%988T D0+--(&*EL@)!*2IXH
M]8HKYS^ /[3>L>,OV;;SXC^/M.L-/U>T?Y]+T9)%WM+'#+:6ZK([,9Y!<0QX
MSR[@ #.*;H_[17BJW_9GL/&NL6.AWOCO7K^72/#VE:2LPLKR\DN9(+1068NT
M9">:\GRGRU9MJ8V@ ^CJ*\C^$?CWQ=\8/@39ZU;7VA:+XV:>ZL+FXDTR>ZT^
M&YM;V2WG MOM$<A4^2X4&8$%E;+ 8/&_";Q_\9_'-GXNUJ;4_!VKZ9X=US4=
M(M]+TSPU<6MSK?V,^6WE7$NJ-';L\RR1@NKJNS)/.  ?1U%>%>$?B;\1-#^*
M7@_PA\0!X9O+OQ5I-WJ2V?AVVFAFT1[<1%XYFDGE%S&?.$8G581O0?(=_P G
M3_$CXH:AX3^*OPT\)V"6?D>(7U*[U2:ZB=V@L;.UWN\95@%;SI;9<L"-KMQG
M% 'IU%>6_#_]ISX;_%'5-%L?#&OS:DVM6KW>F71TN\AM+U44-(D-S)$L3RQA
MOGB5S(A5PRJ48#D?@1^UIX?^*%O86^JWT=MJ^M:WJECI"6>F78LY(H+BY$$+
MW95H/M1MH!*T7F!^<[%&!0!] 45\Y^*/VJK7P[XP\#6EMJEMKNC>)-<UNU8Z
M;X=OYKU;;3HS#-#!!&SRW,R7>T-+'&4\H2,$"H9*[[4/CIX8OM!\&:UHGB2"
M33_$9ENK,IH]W?RWUM!;R3W$21Q;7AF5(V_UBDAU,?EF1@M 'IU%>!_#/]KS
MPQXL^%_AOQ7KD6HZ9>>(KJ\72]'L="U&ZO+NWC<NDT%NEN9IXQ;M SSQH8@T
MF-P) KL+[]I+X<Z?X?\ "NM-XA-Q9>*1*-&6SL+FYN+UXU+21)!'&TOG+M93
M$5#AE*%=P*T >F457T^^CU*PMKR%9DBN(EE1;B%X9 K $!HW 9&P>58 @\$
MU8H **** "BDIID"T /HJ(W"KV--:\1>S4%<K)Z*JG4(U_A;\A33JD0_A?\
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M ,NM_P#]^T_^+I^SEV']1Q/\C.]HKS\_&K1%_P"774/^_:?_ !=-/QNT(?\
M+IJ'_?N/_P"+H]G/L/ZABOY&>A45YVWQRT%?^734?^_<?_Q=,/QVT ?\NFI?
M]^H__BZ/9S[#_L_%?\^V>CT5YL?CUX?'_+GJ7_?J/_XNF?\ "_O#W_/GJ?\
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M]1]7J_RC_L/,O^?#/?:*\ /[:G@@?\PKQ!_X#P?_ !ZFG]MCP./^85X@_P#
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MV7<23OY:76JW+/-=S3+OQ&TC!0C  8Y_97^R[S_GTG_[]M_A1_9=Y_SZ3_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Y[X@^"[/XB>#=5\.WQ9+>^BV>8O6-P0R./7:P4X[XKX \6_LS
M_$/PSJTMFOAVZU:%7VQW>FH9HI!V/'*_\" K](**ZJ.(G1NEL?39/G^*R=2A
M22E%ZV??NCY6_98_9JU;P;KR^,/%4 L[V*-DL+#<"\98%6DDQP#M) &?XCG%
M?5-%%95:LJTN:1YN99C7S3$/$8C?:RV2[(****R/+"BBB@ HHHH **** "BB
MB@ HHHH **CFF2WA>20[449)KB]3UZXOY&"NT4/0(IQGZU48N1O2HRJO0[BB
MO-,YZ\T5?L_,ZOJ?][\#TNBO-**/9^8?4_[WX'I=%>:44>S\P^I_WOP/2Z*\
MTHH]GYA]3_O?@>ET5YI11[/S#ZG_ 'OP/2Z*\THH]GYA]3_O?@>ET5YI11[/
MS#ZG_>_ ]+HKS2BCV?F'U/\ O?@>ET5YI11[/S#ZG_>_ ]+HKS2KMCK%UI[@
MI(S)GF-CD&CV8I81VT9WOTZUGZ;'JRS,;^>REBV_*MM"Z-NR.I+GC&>U6;&\
M34+5)H^C=1Z'TJQ61P--.S,VVCU=;XFXGLGL\MA(X763';YBY'IGB@QZO_:&
MX3V7V'=]SR'\W;Z;M^,_A6E10(S;N/5VO ;:>R2TXRLT#M)[\AP/TI=2CU9I
ME.GSV<46WYA<PN[9SV(<<=*T:* *&I)J;+%]@FM(CSYGVF%GSTQC##'?KGM1
M=)J;64(MIK1+L8\UY8F:,\<[0&!'/J35^B@"@R:G_9JJLUI_:'>0Q-Y77^[N
MST]Z(4U,:?(LLUHU]SL=(F$0],KNR>_>K]% %"Q34UMYA>36DDY_U300LJCC
M^(%CGGT(I--35%9_[0FLY5Q\GV:%T(/?.YC6A10!FZ?'JZW!-]/9208.%MX'
M1L]N2Y&.O:B"/5QJ!::>R:QW-^[CA<2[>=OS%\9Z9X]>E:5% &;)'J_]H!DG
MLA8[A^[:%S+M[_-OQGKVHO8]7:Z!LY[*.VXRLT+L_OR' _2M*B@#/U*/56D3
M^SY[.),?,+F%W)/MM<4M^FIM%"+*:TCD _>FXA9P>GW0&&._7-7Z* *%PFJ&
MPB$$UHM[D>8\D3&,\'.%# CG'4FC9JG]F[?.M/[0S_K/*;RNO]W=GI[]:OT4
M 4+=-3%C*)YK1KWGRWCA98QQQE2Q)YSW%&GIJ:QS?;IK223_ )9FWB9 /]X%
MCGMTQ5^B@#/TV/55D?\ M">SE3'RBVA="#[[G--LH]76Z)NY[*2VYPL,#J_M
MR7(_2M*B@#-CCU?^T"SSV1L=Q^18'$NWL-V_&>G:B:/5SJ :&>R6QW+E'@<R
M[>-WS!P,]<<>E:5% &;J$>KM< V,]E'!@96X@=VSWY#@8Z=J?J2:HS1_V?-:
M1+@[_M,+N2>V-K#%7Z* *%\FIM;PBSFM(YQ_K6GB9E/'\(##'/J31,FIG3XU
MBFM%ON-[O"QB/KA=V1^=7Z* *"IJ?]FLK36AU#/RR"%O*Z]UW9Z>]%JFJ+9S
M"YFM'NSGRFBB98QQQN!8D\^A%7Z* *&FIJ:K+]OFM)3QY?V:%DQUSG+'/;IC
MO3=-CU99F.H3V<L6WY1;0NC9SW)<\=:T:* ,VUCU=;TFYGLGM,G"10NLGMR7
M(_2@1ZO_ &AN,]E]AW?ZOR7\W;_O;\9_"M*B@#-NH]7:^!MY[)+/(RDL+M)C
MO\P<#U[4:E'J[3*;">RBAV\BYA=VW9/0AQQC%:5% %#4DU1O*^P36D7!\S[3
M$SYZ8QAACO1>)J;6D(M9K1+D8\UIH69#QSM 8$<^I-7Z* *#IJ?]FJJ36@O_
M .*1HF,77LN[/3WHC34_[/=9)K0W_P##(L3"(?5=V?UJ_10!0LTU-;687<UH
M]R<^4T,3*@XXW L2>?0BC34U-6D_M":TE'&S[-"R8]<[F.:OT4 9NFQZNLY-
M_/92P[>%MH'1MV1W+GC&>U%O'JXOR9Y[)K++82.!Q)CG'S%R,],\5I44 9K1
MZO\ VAN6>R%CN^X8'\W;Z;M^,_A1>1ZNUX#:SV26O&5F@=G]^0X'Z5I44 9V
MI1ZJTB?V?/9Q1X^87,+N<^Q5QQ3M034VCB^PS6D3_P#+3[1$S@],8PPQWZYJ
M_10!0NDU1K&$6\UHEYQYKRQ,T9XYVJ&!'..I-!34_P"S0HFM/[0SS)Y+>5U_
MN[L]/?K5^B@"A FIC3Y!--:->Y/EO'"PC'IE2Q)[]Z+%-36&87DUI)-_RR,$
M3(HX_B!8YY],5?HH S]-CU17?^T)K.5,?(+:%T(/ON8TVPCU=;EC>SV4EO@X
M6WA='SVY+D?I6E10!FQ1ZO\ V@6DGLC8[FQ&L+B7;SCYM^,],\421ZN=0#1S
MV2V.X91H',NWC(W;\9Z]JTJ* ,V^CU=KH&RGLH[? RL\+N^>_(<#]*=J4>JM
M(G]GS6<28^87,+N2?;:PK0HH H7R:FT,(LYK2.;_ ):F>)G4\?P@,,<^N:)T
MU,Z?$(9K1;WCS'DB8QGUPH8$=N]7Z* * 34_[,*F:T_M#M)Y3>5U_N[L]/?K
M1;)J:V,PN)K1[PY\IXX66,<<;E+$GG/0BK]% %#3TU-8YOMTUI(__+,V\+(!
MU^]ECGMTQ3=-CU59'_M">SECQ\HMH70Y]RSGBM&B@#-LX]76[)NY[)[7G"PP
M.K^W)<C]*%CU?^T-S3V1L=Q_=B%_-V]OFWXS^%:5% &;<1ZN;\-!/9+9;ERD
MD+F3'&[Y@X&>N.*-1CU=IP;">RBAV\K<0N[;N>X<<=.U:5% %#4DU-FC_L^:
MTB'._P"TPL^?3&UABB\34VM81:36B7 QYK30LR'CG: P(Y]2:OT4 4)4U/\
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MK2HH S1'J_\ :&XSV7V'=]SR'\W;Z;M^,_A1<1ZNU\#;SV2V65RDD#M)CO\
M,' ]<<5I44 9NI1ZNTZFPGLHH=O*W,+NV[)[AQQC':GZDFIMY?\ 9\UI$.=_
MVF)GSTQC:PQWJ_10 BYVC/7OBEHHH **** "BBB@#&\52,NE8'1G4'Z<G^E<
M;7?ZK8_VA8R0]&/*GW%<%+&\,C1NI5U."I[5M#8]7"R7(UU&T445J=P5Y_\
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MH/AO2]-GN6O9[.UC@DN6>9S*RJ 7W322R')!/SR.W/+,>3IT459T!110 6(
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MY'!([UR'Q.\91>(O&'CKX@72)-X,^"^F7TMDK@,EYKXM3)+*H88)MHB(5/\
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MMUO-P3R#( ^3T&/7FB\\0:9I]T+:YO[>WN#C$<D@5CGIP:O[1G..:"H/49H
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M;>_MYKD9S"D@+<=>/:@>(-,-_P#8A?V_VS=L\CS!OSZ8]:O[1G..:-HSG'-
M%"X\0:9:7HM)[^WANB0!"\@#9/3CWS1J'B#3-)F6*]O[>UE9=P2:0*2,D9Y^
MAJ^5!ZC-!4'J,T 4M0US3])\O[;>P6OF9*>=(%W8ZXS]11=:YI]C:PW-Q>P0
MV\V#'+)( KY&1@]^*N[0>U&T=,<4 4GUO3X]/6^:]@6S;A;@N-AYQU^M$>MZ
M?+I[WR7L#V:<-.K@H/J:N[1C&.*-HZ8XH IVFMZ??6LMQ;7L$\$.?,DCD#*F
M!DY/;BDT[6]/U=I!97L%V8\%A#(&VYZ9Q5T*%Z#% 4#H,4 4-/\ $&F:K,8;
M._M[J4+N*12!B!P,X'U%%OX@TRZOC9PW]O+=@E3"L@+Y'48]L&KX4#H,4;1G
M..: *#>(=,6^^Q&_MQ>;MGD&0;]WICUHNO$&F6-V+6XO[>"X.,122 -STXJ_
MM&<XYH*@]1F@"CJ&O:;I,BQWM];VKL-RK-(%)'KS3M0UO3]+6)KR]@MEESL,
ML@4-C'3/7J/SJX5#=1FC:.F.* *5QK>GV=G%=SWL$5K+CRYGD 5LC(P>_ H.
MN:>NG"_-[ +(G N/,&SKCKTZ\5=VC&,<4;1C&.* *4.N:?<6,E[%>P26D9(>
M=9 47'7)_$4MEK>GZE#+-:WL%Q%%_K'CD#!>,\XZ5<VCICB@*%Z#% %+3]<T
M[5F=;*]@NV0980R!B![XIMCX@TS4K@P6E_;W$Z@DQQR!F '7BKX4#H,4;1G.
M.: *$?B#3)K\V4=_;O>!BA@60%]PSD8]1@_E1)XATR&^%E)?VZ7A8)Y#2 /N
M.,#'J<C\ZO[1UP,_2C:,YQS0!0O?$&F:;<"WNK^WMYR 1')(%;!Z<&EU#7=.
MTF1$O;Z"U=QE5FD"DCU&:O%0>HS05#=1F@"E?:WI^FQ12W5[!;QR\QO(X4-W
MX/>EGUO3[6QCO);V".TDQLF:0!&SR,'\*N;1TQQ1M&,8XH I_P!MZ>=.-^+V
M#[".MQY@V=<=?KQ26^N:?=V<MW!>P2VL6?,F20%5P,G)[<&KNT8QCBC:.F.*
M *5CKFGZI'*]I>P7*1<R-%(&V]>N/H?RI-/U[3=6D:.ROK>Z=1N989 Q ]>*
MO!0O08H"@=!B@"A9^(-,O[HVUM?V\]P,YBCD!;CKQ0OB#3)+_P"Q+?VYO-Q3
MR/,&_(ZC'K5_:,YQS1M&<XYH H3>(-,MKX64M_;QW995$+2 /DXP,>^11J'B
M#3-*F$-Y?V]K*5W!)9 I(Y&<'Z&KY4'J,T%0>HS0!2U'7-/TAD%[>P6ADR5$
MT@7=CKC-%YKFGZ?;PSW-[!!!-S'))( K\9X/?BKI4-U&:-HZ8XH I2ZYI\-B
ME[)>P)9N<+.9!L/X_A0NMZ?)I[7RWL#62\&X#C8.<=?K5W:,8QQ1M'3'% %.
MUUO3[ZTFNK>]@FMX<^9+'("J8&3D]N*33];T_5O,-E>P77EX+^2X;;G.,X^A
M_*KNT#M0%"]!B@"AI_B#3-6F:*RO[>ZE5=Q2&0,0,@9X^HHM_$&F7EX;2"_M
MY;H$@PI("V1UX]JOA0.@Q1M&<XYH H?\)!IGV_[%]OM_MF[9Y'F#?N],>M%Q
MX@TRSO!:3W]O#=$@"&20!N>G'O5_:,YQS05!ZC- %#4-?TW295BO;ZWM9&7<
M%FD"DCIGGZ4_4-;T_21$;V]@M1+G9YL@7=C&<9Z]1^=7"H;J,T;0>U %*ZUO
M3[*TANKB]@AMIL&.5W 5\C(P>_'-#:YIZ:>M\U[ +)C@7'F#8><=>G6KNT=,
M<4;1C&.* *46N:?-8O>QWL#V<9PTZR HOU/XT6>N:?J%O-/;7L$\,(S))'(&
M"<9Y(Z<5=VCICB@*%Z#% %+3M<T_5V=;*]@NS'@L(9 V,],XIMAX@TS5)S#9
MW]O<S*-QCBD#$ <9P/J*OA0.@Q1M&<XYH H0^(-,N+XV45_;R789E,"R OD9
MR,>V#^5#^(-,CO\ [$U_;K>;@GD&0;]QZ#'K5_:,YQS1M&<XYH H7GB#3-/N
MA;7-_;V]P<8CDD"MSTX-+J&O:=I,BQWM]!:NPW*LT@4D>HS5XJ#U&:"H;J,T
M 4K[7-/TR.)[N]@MDEYC:60*&Z=,]>HI;C6]/M;**\FO8(K67&R9I $;(R,'
MZ U<VCICBC:,8QQ0!2_MO3_[.^W_ &V#[%T^T;QLZXZ].O%+!K>GW5C)>0WL
M$MI'G?,L@*+CDY/;K5S:,8QQ1M'3'% %*QUS3]2BEDM+V"YCA&9&BD#!>_..
MG0TFGZ[IVK2.EE?6]TZ#++#(&('KQ5X*%Z#% 4#H,4 4++Q!IFI7!M[6_M[B
M< DQQR MQUXHC\0:9-?FR2_MVO Q3R!(-^X=1CUX-7]HSG'-&T9SCF@"A-X@
MTRWOQ927]O'>%E00-( ^6Q@8]3D?G1?>(-,TVX$%W?V]M,P!$<L@4D'H<&K^
MT9SCF@J#U&: *6H:YI^DLBWM[!:,XRHFD"Y^F:+S7-/T^"&:ZO8+>*;F-Y)
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M.;>4EX3+$L<IC;E#(5[4 >@T444 %%%% !1110 4444 %%%% !1110 4444
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M+\1OX=?T\?\ ;-?_ (S3Y/-%?58_\_8_>_\ (]#HKS=M#^)?;Q#IH_[9K_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'=J7]FY\NU_M#^YYC>5U_O;<]/;K1;MJ1L93/':K><^6L<C&,\<9)7(YSVH
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M:\BLO!</C'6-,O;C4+\VJ"U\N"(B2<,A7*G!;<#S3N4JCTNMSZT\'_$SP?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY4A7<%V,>,D=A[4 :-%4=2UNRTEHQ=S>49,E?D9LX^@I+S7+*QMH;B>;9#,
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M* +U%4;K6K*RLX;J:;9;S8V/L8YR,C@#/2AM;LETU;\S?Z(QP)-C>N.F,]:
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M)SC@"5!DG<%Z*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **X[Q/\
M&#P9X-OC9:QXAL[.[4@-!N+NF>FX*"5_&M_P_P")-+\5::FH:/J%OJ=DY($]
MK('7(Z@XZ$>AYJG&25VM#HEAZT(*K.#47L[.WWFE1114G.%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!E>);=KC2GVC)C8/C^?\ZXFO2NO!Y%<UJ7A1FD:2
MS90#SY3<8^AK6$K:,[\-6C%<LCFJ*T_^$;U'_GW_ /'U_P :/^$;U'_GW_\
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M:0Q>?#A&D@=@Q();[;^'/P]TGX7^$;3P]HXF>WA:2::ZNG#W%W<2R-)/<3,
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M4N-\T:<E2A9>4O\ Y(E\'Y<FHNI.[\X__(GU=_PO?P-_T'/_ "4G_P#B*/\
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M;_H.?^2D_P#\11_PO?P-_P!!S_R4G_\ B*^1:*/]>LR_Y]P^Z7_R0?ZFY?\
MSS^^/_R)]=?\+W\#?]!S_P E)_\ XBC_ (7OX&_Z#G_DI/\ _$5\BT4?Z]9E
M_P ^X?=+_P"2#_4W+_YY_?'_ .1/KK_A>_@;_H.?^2D__P 11_PO?P-_T'/_
M "4G_P#B*^1:*/\ 7K,O^?</NE_\D'^IN7_SS^^/_P B?77_  O?P-_T'/\
MR4G_ /B*/^%[^!O^@Y_Y*3__ !%?(M%'^O69?\^X?=+_ .2#_4W+_P">?WQ_
M^1/KK_A>_@;_ *#G_DI/_P#$4?\ "]_ W_0<_P#)2?\ ^(KY%HH_UZS+_GW#
M[I?_ "0?ZFY?_//[X_\ R)]=?\+W\#?]!S_R4G_^(H_X7OX&_P"@Y_Y*3_\
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MN'W2_P#D@_U-R_\ GG]\?_D3ZZ_X7OX&_P"@Y_Y*3_\ Q%'_  O?P-_T'/\
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MH_X7OX&_Z#G_ )*3_P#Q%?(M%'^O69?\^X?=+_Y(/]3<O_GG]\?_ )$^NO\
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M&_Z#G_DI/_\ $5\BT4?Z]9E_S[A]TO\ Y(/]3<O_ )Y_?'_Y$^NO^%[^!O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110  D'(X-?</A&\DU'PIHMU+DRS
MV4,CYZY* FOC#PWH%UXHURTTRS0O-<2!/91W8^P%?;VGV4>FV%M:1?ZJWB6)
M/HH '\J_6N Z53FKU?LZ+YZ_E^I^8\:U*?+1I?:U?RT_/]"=E#*01D'@@UXE
M\0OV=8]6NI;_ ,.3QV<TA+R6<^1&23DE& .WZ8Q[BO;J*_2LPRS"YI2]EBHW
M2V?5>C/S_ YAB<NJ>TP\K/KV?JCY'D^ OCB-RJZ.L@_O+=PX/YN*;_PHCQS_
M - /_P FX/\ XNOKJBOCO]1<M_Y^3^^/_P B?5?ZY9A_)#[I?_)'R+_PHCQS
M_P! /_R;@_\ BZ/^%$>.?^@'_P"3<'_Q=?75%'^HN6_\_)_?'_Y$/]<LP_DA
M]TO_ )(^1?\ A1'CG_H!_P#DW!_\71_PHCQS_P! /_R;@_\ BZ^LIK^W@;#R
MJ#Z#G^51_P!KVG_/7_QT_P"%9O@G*EHZL_\ P*/_ ,B6N+\R>JI1^Z7_ ,D?
M*/\ PHCQS_T _P#R;@_^+H_X41XY_P"@'_Y-P?\ Q=?5W]KVG_/7_P =/^%'
M]KVG_/7_ ,=/^%+_ %*RG_G]/_P*/_R(_P#6[,_^?4?NE_\ )'RC_P *(\<_
M] /_ ,FX/_BZ/^%$>.?^@'_Y-P?_ !=?5W]KVG_/7_QT_P"%']KVG_/7_P =
M/^%'^I64_P#/Z?\ X%'_ .1#_6[,_P#GU'[I?_)'RC_PHCQS_P! /_R;@_\
MBZ/^%$>.?^@'_P"3<'_Q=?5W]KVG_/7_ ,=/^%']KVG_ #U_\=/^%'^I64_\
M_I_^!1_^1#_6[,_^?4?NE_\ )'RC_P *(\<_] /_ ,FX/_BZ/^%$>.?^@'_Y
M-P?_ !=?5W]KVG_/7_QT_P"%']KVG_/7_P =/^%'^I64_P#/Z?\ X%'_ .1#
M_6[,_P#GU'[I?_)'RC_PHCQS_P! /_R;@_\ BZ/^%$>.?^@'_P"3<'_Q=?5W
M]KVG_/7_ ,=/^%']KVG_ #U_\=/^%'^I64_\_I_^!1_^1#_6[,_^?4?NE_\
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MN">#1K9[2&9@[QFXM9%W8QD!V(!QC)'7 ST%?1G]KVG_ #U_\=/^%*NK6C'
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M_J+EO_/R?WQ_^1#_ %RS#^2'W2_^2/D7_A1'CG_H!_\ DW!_\71_PHCQS_T
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M'_Y$/]<LP_DA]TO_ )(^1?\ A1'CG_H!_P#DW!_\71_PHCQS_P! /_R;@_\
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M8NC6E@^T8R\<*J[?4L"?QH [2BBB@ HHHH **** "BBB@ HHHH **2D^;TH
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M#_XNF_;/$/\ SXV__?0_^+I?65_++[F/ZN_YE]Z.@HKG3>^(^UA;_P#?0_\
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M^</&7['?P:^(7Q&C\=^(? 6G:GXG5XY&NI))5CF9#\K30*XBE/8F1&R  <@
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MR9..Q5B/SQ2:;J%S>LXGTVXL HR&F>-@WTVL?UH OT5G6&I75U<&.;2KFR0
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M;P#XL\46N@Z9K4TUW>O-%874FFW<-AJ,D6?,2TO7B%O<LH5SMAD<X1SC",0
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M(GQ.^)EGXR\3:7XM\#^$O!VD:[J6F6CZSX8NKMS;V4K0R7$LXU.! -\<O\
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MG_"D_M:U_P">O_CI_P *7M(?S(/9S[%NBJ7]L6G_ #V_\=/^%)_;5E_SV_\
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M  H_L'3?^@=:_P#?A?\ "KU%'LJ?\J^X?M:G\S*']@Z9_P! ZT_[\+_A2?\
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M!O#?_0OZ7_X!1_\ Q-'_  @OAO\ Z%[2O_ *+_XFMRBCZKA_^?<?N0?6:_\
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M]2M]'TV[O[R3R;2UB>>:3:6VHJEF. "3@ ]*^:O^'F'[-O\ T4?_ ,H6I?\
MR-5QQ527PQN2\/".\C[(^V6__/>/_OL4?;+?_GO'_P!]BO!/B'^TY\,OA3XP
M\.^%?%'BB/3?$/B$1MINGK:7$\DRR2>7&3Y4;! SY4%]H)5O[IQZC4O%S6KB
M/ZM%[2.J^V6__/>/_OL4?;+?_GO'_P!]BN5HI?7)=A_58]SJOMEO_P ]X_\
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M*VIWUV""/+N&0J/?A0<_C1#H\D.H&Z.IWLJ[F;[,[)Y7.>,!<X&>.>PK2HH
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M[ZY7G]S,R%.?HH/'UK2HH S8]'D34#=?VG>LNXM]F9D\KGMC;G'XT3:/)-J
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M;?:/)>W0F74[VT  'E0,@0X[\J3^M.U+2I-0D1DU&\LMHQMMF0!O<[E-:%%
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M+.Z,S:G?72D$>3.R%!GZ*#^M$>CR1Z@;HZG?.FXM]F9D\KG/&-N<#Z]JTJ*
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M!'A_PKI D&EZ'I\&FVOFD%S%#&L:EB  6(49( YSQ0!NT444 %%%% !1110
MASVIC-)V45)12&0,T_9%_P _C4;27?:)?S_^O5NBIY?,KF\BBTU]VA0_C_\
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M%L3_ ,#'_P =KN:*CZC+_G_/[U_\B5]<C_SYA]S_ ,S@FUCX@=M#L#_P,?\
MQVHSK7Q$[:#I_P#W\'_QVO0:*G^SY_\ 01/[U_\ (E?7H_\ /B'W/_Y(\[;6
MOB/VT#3O^_B__'J8VN?$OMX>TT_]M%_^/5Z/14?V;/\ Z":GWQ_^1+_M"/\
MT#P^Y_\ R1YH=>^)W;P[IG_?Q?\ X]3&U[XI=O#>E_\ ?Q?_ (_7IU%3_9<_
M^@JI]\?_ )$K^T8?] ]/[I?_ "1Y<WB#XJ]O#.E_]_%_^/U&WB'XL]O#&E?]
M_5_^/UZK14?V5/\ Z"JOWQ_^1*_M*'_0-3^Z7_R1\7^.;S4[[Q5J4VLQK#J9
ME(GB0Y5".-HY/  &.37-S5]5?$SX+VOCJ[_M&TN1I^I[0KLR[HY0.!N Y!QQ
MGT'2N1\,_LT&'48Y]>U&*>VC.?LUH&_><\ L0,#Z#\:_)L=PKF<L9*-./-&3
M;YFUUZOS[Z>A^G8/B3+HX2,IRY6E\*3Z=%Y=M?4]3^&MQ<77@#0);LDSM9QY
M9B22,8!)/<C!_&NEID<:0QI'&H2- %55&  .@%/K]QP]-T:,*3=W%)7[V1^.
M5JBJU95$K7;=O4****W,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBHYITMXR\AVJ*3=E=C6NB(YM/MYVW/$I;U''\JC_LBT_P">7_CQ
M_P :HRZ^^[]W$H'^US4?]O7']R/\C_C7#*MA[ZJ_R.Q4JUM'^)I?V1:?\\O_
M !X_XT?V1:?\\O\ QX_XUF_V]<?W(_R/^-']O7']R/\ (_XTO;8?^7\!^RK]
M_P 32_LBT_YY?^/'_&C^R+3_ )Y?^/'_ !K-_MZX_N1_D?\ &C^WKC^Y'^1_
MQH]MA_Y?P#V5?O\ B:7]D6G_ #R_\>/^-']D6G_/+_QX_P"-9O\ ;UQ_<C_(
M_P"-']O7']R/\C_C1[;#_P OX![*OW_$TO[(M/\ GE_X\?\ &C^R+3_GE_X\
M?\:S?[>N/[D?Y'_&C^WKC^Y'^1_QH]MA_P"7\ ]E7[_B:7]D6G_/+_QX_P"-
M']D6G_/+_P >/^-9O]O7']R/\C_C1_;UQ_<C_(_XT>VP_P#+^ >RK]_Q-+^R
M+3_GE_X\?\:/[(M/^>7_ (\?\:S?[>N/[D?Y'_&C^WKC^Y'^1_QH]MA_Y?P#
MV5?O^)I?V1:?\\O_ !X_XT?V1:?\\O\ QX_XUF_V]<?W(_R/^-']O7']R/\
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ML=,BADNKA84FY1B#\WZ>]7Z* *-QKEC:V,5Y+<*EK+@)(0<'(R/Y4G]N6/\
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MX-_\74;>#M3/_,R78_!O_BZCV^(_Y\O[X_YE>QH?\_5]S_R.LHKD&\%ZH?\
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M9]U,?A)_\=IC?"CQ$?\ FH&J#\)/_CU3]=QW_0(__ H?YE?5,'_T%+_P&?\
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M=)M)]PHHHK<Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8QQC%8GB+X/> O%UWI-UKO@CPYK5UI"JFG3:CI-O</9*I!586="8P" 0%QC
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M@T:!\#]=\1>/]9\(6UWIZ:EI43RS2RR2"%@K(IVD(23EQU [UM[>E:_-TO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:6MT[:.]NC7K<^K=5U"V\.WWP<\"3W45WXATO4+>:]6!]XMNPC)]?FZ>B@\
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M)RJD\ D\57E^,7@^'XJ0_#=M94^-);#^TUTM8)6Q;Y8!FD"^6I.QB$+!B%)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[KR> -?\%>+=1N+*QU#P:-2N!$%#E/\ 3Y8UM9V0KM=8OF!#95.E>U2?LO\
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M34OA_P"%M:M]:M]0\-:1?P:V\<NJQ7-A%(M^\:HL;3AE(E*K'&H+YP$4#H*
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M\X/^^6_QH_X2V\_YYP?]\M_C1:8N:CV-+_A$K/\ YZ3_ /?2_P"%'_")6?\
MSTG_ .^E_P *S?\ A+;S_GG!_P!\M_C1_P );>?\\X/^^6_QHM,.:CV-+_A$
MK/\ YZ3_ /?2_P"%'_")6?\ STG_ .^E_P *S?\ A+;S_GG!_P!\M_C1_P )
M;>?\\X/^^6_QHM,.:CV-+_A$K/\ YZ3_ /?2_P"%'_")6?\ STG_ .^E_P *
MS?\ A+;S_GG!_P!\M_C1_P );>?\\X/^^6_QHM,.:CV-+_A$K/\ YZ3_ /?2
M_P"%'_")6?\ STG_ .^E_P *S?\ A+;S_GG!_P!\M_C1_P );>?\\X/^^6_Q
MHM,.:CV-+_A$K/\ YZ3_ /?2_P"%'_")6?\ STG_ .^E_P *S?\ A+;S_GG!
M_P!\M_C1_P );>?\\X/^^6_QHM,.:CV-+_A$K/\ YZ3_ /?2_P"%'_")6?\
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M9?C!JVK>(/%'AO2_A#J]C\/)?!6EK8ZA#.UU<2<^>3;96"W4Y"QKEDWG;NK
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M+P;;:&=<;4KBT36+];T0)HL-U=):VCN-C;VEE9@J97B)SG@9N?$K]H-?A_\
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M[_AE0?A_]:H6AU'M<1C\/_K55O,GF\C1HK):WU?^&ZA'X#_XFHFM=<[7D(_
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M[=KJ]@HHHJ#I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_'U_QH_X1W4?^??_ ,?7_&NVHHYV'U>'<XG_ (1W4?\ GW_\?7_&E7PWJ#,
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MB2?55U (EI:M9;@/.-PPDV]SMV8SUXS1>SZK'=!;6TM9K? R\MPR-[_*$/\
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M+Z]A?^?L?O7^9TM%?'7Q_P#CEJ7B'Q%=:/H6IM;Z%:$();&;'VIN[EU/*Y.
M <<9^GF?@WXI^)/ .K17NF:G<;%;,EK+(7AE&>0RGCGUZCL:]:GE=2=/GO9]
MC\XQGB#@<+C'AE2<H1=G)-?.RZKYJY^B-%97A7Q#!XL\-:7K-LK)!?6Z7"HQ
M!*;E!VG'<'C\*U:\9IQ=F?J%.I&K!5(.Z:NO1A1112- HHHH **** "BBB@
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MB%M(AFB-X=Y;99[ECCC#."J E5Q@ALFOM+_A#O\ I[_\A?\ UZ/^$._Z>_\
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M:HOW5  _"JVGZ7;Z:A$*_,>KMR34\=S%,VV.5'/7"L#64I<QVTJ?LUKN<?\
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M5 ^<;=PS^5'M)]R?J]'^1?<C"/P_T!NMA_Y&D_\ BJ8WPY\.MUT__P CR?\
MQ5="]S%&VUY45O[K, :)+B*$@22(A/3<P%/VD_YF3]5P[_Y=K[D<X?AIX;;K
MIO\ Y'E_^*IA^%_AANNF?^3$O_Q5=-)<11 %Y%0'IN8#-#3QK&':150]&+#!
M_&G[6I_,_O)^IX;_ )]1^Y'+'X4^%FZZ7_Y,2_\ Q5,;X2>$VZZ5_P"3,W_Q
M==9]HB\OS/,7R_[^X8_.A;B)HRZR(4'5@PP/QH]M4_F?WD_4,)_SYC_X"O\
M(Y$_!_PBW72?_)F;_P"+IA^#7@YNNC_^3,W_ ,778QW$4BL4D1PO4JP.*([B
M*8D1R(Y'7:P-/VU7^9_>1_9V"?\ RXC_ . K_(XO_A2O@P_\P;_R:F_^+IK?
M!#P4W71?_)J?_P"+KMDN8I&VI*C-_=5@30+F(R>6)4+YQMW#/Y4>VJ_S/[R?
M[+P'_/B'_@*_R.&/P+\#MUT3_P FY_\ XNFGX"^!3UT/_P FY_\ XNN[:YB6
M3RS*@?.-I89_*B2YBA;;)*B'KAF I^WJ_P [^]D_V3E[WP\/_ 8_Y' GX ^
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MW'[:IV/=/^$BT[_GX_\ '&_PH_X2+3O^?C_QQO\ "N&DE2&-Y)'6.- 69F.
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MMT4 5+;2;&S@DAM[.W@AD^_''$JJW&.0!SQ18Z38Z:SFSLK>U+\,8(E3./7
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M9(IU[I%AJ3*UW96]TRC"F:)7('MD5;HH J76DV-]%'%<V=O<1Q_<26)6"]N
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MNS,:T7.-D<714MQ9S6K%98FC/^T*BK<\O8****8CY\_;_P#^3/?B5_UY0_\
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MZ8>'_#NE>$]'MM)T/3+/1M*M5*P6.GVZ001 DDA$0!5&23P.I-9WA/X<>$_
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MJ\(Q^+O$WB?Q5I&B^-==U3Q"VO65]JVD0RS:7B"V@BBA>3>5*+:1'>NTD@'
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M(T 5<LS$X'4D]Z -2BBB@ HHHH **** "BBB@!#GM4;-+_"H-2T4"*C27?\
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M6-A@;5.YN   .3QWKD9:^W?C)^SO9?$R^_M:QO!I6LE521V3=%.!P"P'(8#
MW>@ Q7">#?V.6M]6BN?$VKP75G&VXV=BK?O>> SL!@>H _$=:^BI9A05)-NS
M73_(_#\QX*SB6/G"E'GC*3:FVMF]Y=;]]/2Y[7\';N[OOA;X6GOBS7+:?%N9
MB2S +A6)/4D $_6NQID,*6\*11(L<4:A511@* ,  >E/KY2<N:3EW/Z-PM%X
M>A3HR=W%)7[V5KA1114'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4456OKZ+3[<RRGCH%'4F@3=E=EFBN/N/%-Y*W[K;"OH!D_K4/_"1
M:C_S\?\ CB_X5IR,Y_K$#MJ*XG_A(M1_Y^/_ !Q?\*/^$BU'_GX_\<7_  HY
M&+ZQ#L=M17$_\)%J/_/Q_P".+_A1_P )%J/_ #\?^.+_ (4<C#ZQ#L=M17$_
M\)%J/_/Q_P".+_A1_P )%J/_ #\?^.+_ (4<C#ZQ#L=M17$_\)%J/_/Q_P".
M+_A1_P )%J/_ #\?^.+_ (4<C#ZQ#L=M17$_\)%J/_/Q_P".+_A1_P )%J/_
M #\?^.+_ (4<C#ZQ#L=M17$_\)%J/_/Q_P".+_A1_P )%J/_ #\?^.+_ (4<
MC#ZQ#L=M17$_\)%J/_/Q_P".+_A1_P )%J/_ #\?^.+_ (4<C#ZQ#L=M17$_
M\)%J/_/Q_P".+_A1_P )%J/_ #\?^.+_ (4<C#ZQ#L=M17$_\)%J/_/Q_P".
M+_A2KXDU!6R9@WL47_"CD8?6(':UG:=K2:E,T:VEY 57=NN+=HUZCC)[\U!H
M_B!-0;RI5$4W;'1JV*AJVYT1DI*Z,ZWUI+F^-L+2\C8$CS)+=ECX_P!KI0=:
M1=0^R?9+W=NV^;]G;R_KNZ8]ZT:*11G76M):7@MS:7LI./WD5NSIS_M"EU'6
M5TV58VM+RXW+NW6]NT@'L2.]:%% %'4-673EB+6UW/YF2/L\#2;<8ZXZ=?YT
M76K+:V<-R;:ZD$F,1Q0,TBY&?F4<BKU% %%M65=-%Y]FNBI_Y8B!O-ZX^YUH
MAU99K"2[%M=*J9_=/ PD/T7J:O44 4+/5EO;>:5;6[B\L9*30,C-QGY0>M&F
MZNNI,ZK:W=OM&<W,#1@_3/6K]% &=I^M)J%P8A:7L! )W7%NR+],GO1#K23:
M@;06EZC;F7S7MV$?&>=W3!QQZ\5HT4 9TFM)'J M#:7A;<%\U;=C%SWW=,47
MNM)8W0@:TO)B0#YD-NSIS[BM&B@"AJ6L+ILB*UK>7&X9S;0-(!]2.E+?:LMC
M%"YMKN82<A8(&<K_ +P'2KU% %&XU9;>QBNC;7<BR$#RXX&:1<@GE>HZ4?VL
MO]F_;/LUUM_YX^0WF]<?<Z^_TJ]10!1M]66XL9;H6UU&L>?W<D#+(V!GA>IH
ML=674(Y76VNH?+_AG@:,M] >M7J* ,_3=834I'1;6\MRHSFYMVC!^A-)9ZTE
MY=& 6E["1GYYK=D3C_:/%:-% &<FM(^H&T^R7JMN*^:UNPCX[[NF/>B;6DAU
M 6AM+UVW*OFI;L8^<<[NF!GGTYK1HH SM0UI-/N!$UI>SD@'?;V[2+^8[T[4
MM67360-:W=QO!/\ HT#2 ?7'2K]% %&\U9;*WAE-M=3"3HL,#.R\9^8#I1-J
MRPV$=W]FNG5\?ND@8R#ZKU%7J* *"ZLK:<UY]ENPJG'DF!A+UQPO6EM=66ZL
MYK@6UW&(LYCE@97; S\JGDU>HH HZ?JRZBLI6VNX/+P?](@:/=G/3/7I_*FZ
M=K*:E*T:VEY;E5W;KBW:,'V!/>M"B@#.M=:2ZO#;"TO(F!(\R6W98^/]KI1_
M;2?VA]D^R7F[=M\W[.WE?7=TQ6C10!G7.M):WHMC:7LA) \R.W9H^?\ :%&H
MZTFFS+&UI>3EEW;K>W:1>IXR._%:-% %'4M673?+W6UU<>9G'V:!I,8QUQTZ
MT76K+:6D,YMKN42XQ'% S.N1GYE'2KU% %%]66/3UN_LUTRM_P L5@8RCG'*
M]:(]6673WNQ;72JO_+%H&$I^B]35ZB@"C9ZLMY;33"VNHA'G*30,CMQGY0>M
M&FZLNI-(%MKNWV8/^DP-'G/IGK5ZB@#.T_6DU&8Q+:7L!"[MUQ;M&O4<9/?F
MBWUI+B^-J+2]C;+#S)+=ECXS_%TQQQ6C10!G-K2+J'V3[)>EMP7S1;L8_KNZ
M8HO-:2SNQ;FTO)2<?O(;=G3G_:%:-% &?J.L+ILBHUI>7&X9W6\#2 >Q([T[
M4-673UB8VUU.),X^SP,Y7IU Z=:O44 4;C5EMK&*Y-M=R"3&(XX&:1<C/*]1
M0=64::+S[-=[2<>3Y#>;UQ]SK_\ 6J]10!1AU99["2Z%M=H$)!B>!ED./13R
M:+'5EOH99%MKJ'R^JSP,C-QV!ZU>HH H:;JZZD[JMK=V^T9S<P-&#],]:;8Z
MTE]<F$6EY 0"=\]NR)Q[GBM&B@#.BUI)=0-I]DO5;<R^:UNPCXSSNZ8..#1+
MK21:@+0VEZS;E7S5MV,?..=W3'/-:-% &=?:TEC<B%K2]F) .^"W9TY]Q3M2
MUA=-D16M;NXW#.;:!I /KCI5^B@"C?:LMC#%*;:ZF$G18(&=EXSR!THFU98+
M&.Z^S73J^/W20,9!GU7J*O44 41JRG33>?9KK:/^6/D-YO7'W.OO]*+?5EN;
M&6Y%M=QB/.8Y(&61L#/"GDU>HH HZ?JRZ@DK+;7<'EX.+B!HRW7IGKTING:P
MNI2,BVMY;[1G=<6[1@^P)[UH44 9UGK27EV;<6E[$1G]Y-;LB<?[1XH76D;4
M/LGV2\5MQ7S3;MY?UW=,5HT4 9T^M);WXM3:7CDLJ^;';LT?..=PXP,\T:AK
M2:=,(FM+V<E=VZWMVD7J>,COQ6C10!1U+5ETUHPUM=W&_)_T:!I,8]<=*+S5
MEL[:&8VUW*).0D,#.Z\9^8#D5>HH HR:LL>GI=_9KME8X\I8&,H^J]:$U99-
M/:[%M=!5_P"6+0,)3SCA>M7J* *-KJRW=I-<"VNHA%G,<L#*[8&?E4]:--U9
M=2\W;;75OY>/^/F!H\YSTSUZ5>HH SM.UI-2F:-;2\@*KNW7%NT:]1QD]^:+
M;6DN;TVPM+V,@D>9);LL?'^T>*T:* ,[^VD_M#[)]DO=V[;YOV=O+^N[ICWH
MNM:2UO!;FTO9#D#S(K=FCY_VA6C10!GZCK*Z;*L;6EY<;EW;K>W:0#V)'>G:
MAJRZ:L1:VNKCS,X^SP-)MQCKCIU_G5ZB@"C=:LMK9PW!MKJ02XQ'% S.N1GY
ME'(H;5E735O/LUV5)QY(@;S1SC[G6KU% %&'5EFT^2[%M=JJ''E/ PD/T7J:
M+/5EO;>:9;:[B$?)2:!D9N,_*#UJ]10!0TW5EU)G"VUW;[ #_I,#1@_3/6FZ
M?K2:A<-$+2\@(7=NN+=D7KTR>]:-% &=#K23:@;06EXC!F7S7MV6/C/.[I@X
MXH?6DCU 6AM+TMN"^:MNQCY[[NF/>M&B@#.O-:2RNA UI>RDX_>0V[.G/N*7
M4M8739$1K6\N-PSNMH&D ^N.E:%% %&^U9;".)VMKN<2<@00,Y7IU Z=:+C5
MEM[&*Z-M=2+)C]W' S2+D9Y7J*O44 4?[67^S?MGV:ZV_P#/'R&\WKC[G7W^
ME%OJRW%C+="VND6/.8I(&60X&>%ZFKU% %&QU9;^*9UMKN'R^2L\#(6_W0>M
M-TW6$U*1T6UO+<J,YN;=HP?H36A10!G66M)?71@%I>PD G?-;LB<?[1XHCUI
M)-0-I]DO5;<5\UK=A'QWW=,<=:T:* ,Z;6DAU 6AM+QV+*OFI;L8N<<[NF!G
MGTYHOM:2PN!"UI>3$@'?!;LZ_F*T:* *&I:LNFLBM:W=QN&<VT#2 ?7'2EO-
M66RMX93;7<PDY"PP,[+QGY@.E7J* *,VK+#81W7V:[=7('E) QD'U7J*%U96
MTTWGV:[V@X\DP-YO7'W.O_UJO44 4;75ENK.:Y%M=1B/.8Y8&61L#/RJ>31I
M^K+J*RE;:Z@\O'%Q T9;.>F>O2KU% &?IVL)J4K(MK>6Y4;MUQ;M&#[ GO26
MNM)=7AMQ:7L3<_O);=E3C_:Z5HT4 9PUI#J'V3[)>AMVWS?L[>7]=W3%%QK2
M6U\+8VEZY) \V.W9H^?]H<5HT4 9VH:TFFS+$UI>3DKNW6]NTB]2,9'?BGZE
MJRZ;Y>ZVNKC?G_CV@:3&,=<=.M7J* *-WJRV=K#.;:ZE$F,1PP,SKD9^91R*
MLVMP+JWCE"21AQG;*I5A]0>E2T4 %%%% !1110 5R'BFX:34?*S\D:C ]SSF
MNOKD_%5HT=XMQC*2 #/N.WY5<-SGKWY-##HHHKH/,"BBB@#RW]J#XI:K\%/@
M-XN\;:';V=UJND6\<L$.H([P,6FC0[PC*Q&'/1ASBO&)/VU]1UGX._"?Q5HF
MG:?!KNO>-]/\&^)M)U&&7=IDT@E%RBH'5D<%%9-Y;"N-RD]/5OVP/ &O?%+]
MF[QQX6\,6']IZ]J5M%':VGG1Q>8PGC<C?(RJ/E4GDCI7S[\=/V1_&U_\5OA9
MXH\$6AGTB77-%U3QAI/VJ&)(+FQ"QI>IO<;CY,DR.$R240X8G(AWZ&\.6VI!
MXA_;&^*DWQ&^)&C:5XG^"'A;3?"VLW&F6]MXXU"ZL[^[2/D.BK-A\CC("C=D
M8KT7PO\ M8>*?$LG[-;R>'K'28_B8E^VJV]S'*TD MX0\;VYWC:DA^<;P_R.
MOU/E3?!OQYX3^*OQ6O[[]EKP_P#%[3_$7B.XU+3M9U?6M*ADCMVX5%699'4'
M&[^$@GI6U\)_V6?B)X!7]EZ'4+&&[7PA>ZY>ZY]GO(VBTI+M-T,*[WW28)*G
M9O 8-R1ABM2VH6_KL?6'Q9^*%A\(_!L^OWVGZGK#B1+:UTO1K1[F[O;ASB.&
M*-1RS'UP!7SMX=_;.\2WG[(#_%*_\.Z:WC"]U>31-,T:%GBMC<M=&"$2,S%B
M%'S-@KNV$#9G(]M^#_P-_P"%0WVL7/\ PL'QUXU_M((/)\8:U]OCM=I8YA&Q
M=F=V#UR%7TKYPT7]ESX@3?L6/X.DTNWT_P >:5XDE\1Z=IUW=QM%<-'>M-'&
MTD;,H\R,D#+##%=Q49(;N9QY>IWG@GXR?'#Q1<?$7X>7&E^ [+XN^%VL+JWN
MRUZ=!O+.Y&[. 3.'4*X[ L1P #GCO O[7'Q5T>T^,^N_$+2/!FJ^%?AU;26I
MO_"'VN*.^U<>6?LB2W#,=JE]DC>7\K,I&X=>P^$O@OXJ2>*OC%\6O$GA&U\*
M>+]>TN#3] \+1ZE!?21FV@?89+A2(CYDK+C.,8.[ Y+?"_[+>IW'["$OPEN]
MFE>+-4TB26\DO)Q(!J<DGV@F66,ON7S=JEEW?*. >E&I7N]?+_@E3X:_'KXV
M:OXIU+X?>+-%\$6/C[4O":^*?#-Y8-=_V609!&8+L%FDWJS GRSC .">"<_X
M=_&C]H[Q+\:O%OP\OK'X8WT_A_17N;O5-'CU'[):7\L+FRMYGD?<=SA&=40D
M1[L,&&*T_@#\/?BCXF^.%E\1OB7X/M/ ::!X1C\+V&EPZG#?R7<IE622ZWQ$
MB-<*5"$D_,.3@D]K^QW\,_$?P]^&^L7WC;33IGCCQ/K]_KFL0O/%.RR2RE8U
MWQNZE1$B$ -@;CT.:-1.ROL>;>"_C]\=K']H*Y\#>.+3X<WNA:#I#ZWXFO\
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M+IA^#7@YNNC_ /DS-_\ %T_W'=_A_F9N69](T_OE_P#(FS_PG7AO_H8-*_\
M V+_ .*I/^$\\,CKXBTD?]OT7_Q58G_"E?!A_P"8-_Y-3?\ Q=-;X(>"FZZ+
M_P"34_\ \71^X[O[E_F1S9MTC3_\"E_\B;?_  G_ (8'7Q)I'_@=%_\ %4G_
M  L+PM_T,NC_ /@?%_\ %5A'X%^!VZZ)_P"3<_\ \733\!? IZZ'_P"3<_\
M\73MA^\ON7^9#EG/2%+_ ,"G_P#(F]_PL3PI_P!#/H__ ('Q?_%4G_"Q_"0Z
M^*-%'_<0A_\ BJY\_ 'P$W70O_)RX_\ CE,;]GOP W70/_)RX_\ CE.V&[R^
MY?YF;EG?2%+_ ,"G_P#(G0_\+*\(_P#0U:+_ .#&'_XJD_X6;X/'7Q7H?_@Q
MA_\ BJYT_L[_  ]/7P__ .3MQ_\ '*8?V<?AVW7P]_Y.W/\ \<IVPW>7W+_,
MASS[I"C_ .!3_P#D#P3X_P#QRU+Q#XBNM'T+4VM]"M"$$MC-C[4W=RZGE<G
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M>J((KFZ6::=_+W;O+0RNWE(6P2J;0=J9!V+CZ1_LVS_Y](/^_:_X4?V;9_\
M/I!_W[7_  I<Z[!["7<\:^'_ ,-_#OPMT.;1_#&GG3=.FNYKYX3<2S%II6+R
M/ND9FY8DXS@=@*X_X??LK_"GX5>.]0\9>%/!=EHWB*^$@DNH9)65!(VYQ%$S
MF.$'IB-5XX''%?2O]FV?_/I!_P!^U_PH_LVS_P"?2#_OVO\ A1SKL'L)?S'
M45W_ /9MG_SZ0?\ ?M?\*/[-L_\ GT@_[]K_ (4_:"^K/N<!17?_ -FV?_/I
M!_W[7_"A=.M%.1:P@^HC'^%'M ^K/N<IHNBR:A,KNI6W4Y+'^+V%=GTX%'"C
MT K/T[7K+59FBMFE9U7<=\$D8QG'5E [UG*7,=5.FJ:LBOXP\':)\0/"^I>'
M/$FEVVM:'J,)@N[&[0/'*AYP1Z@@$$<@@$$$ US/A7X%^#O!]_?ZA9VFI7^J
M7MFVG2ZEKFMWVJWBVK'<T$<]U-))%&S ,4C9065202H(ZZWU^RNKXVD;RF<$
MC#02*..OS%<?K0?$%D-0^Q%Y?M&[9C[/)MS_ +VW'ZU)J<?KGP#\!>)/@]!\
M+-0\/K-X$@LX-/BTI;F:/;!#M\M1,KB7(V#+;]S<[B<G-KQI\%_"7CZ;2KG4
M[*\MK_2XF@L]2T75;O2[V&%@-T(N+66.4Q-M4F,L5)521E01TUUK]E9W@M97
ME$Q(&%@D8<]/F"D?K2ZCKUGI4RQ7+RJ[+N'EP22#&<=54^E &=X(\ Z#\.='
MDTWP_IXLK>:=KJXD>5YY[J=L!YIYI&:2:5@JYDD9F.T9/ K'M?@CX)L[RUNX
MM$59[;Q#<>*HF:YF;&J31R127!!?#$I-(H4Y5<C:HVKCJ]0UJTTM8C<M(HES
MMV0N_3'7:#CJ.M%UK5I9V<-U*T@AFQL*PNQY&1E0,CCU% '):S\#? _B#3?%
M5AJ&A)<0>*+^/5-58W$RRRW<<<,<4R2!P\+HMO#L,13:4W+AB2<?2_V8?AMI
M/]I-'H$UU<:G>:=?ZA>:AJEY>7-[/83>=9O/--*TDOEOT#L00 K J !Z*VM6
MB:<M\6D^S-T;R7W=<?=QNZ^U$.M6D^GO>HTAMTSN)A<-Q_LD9/Y4 <)J?[.?
MP_UCQ3=:]>:)--<7EXFI7=A_:5VNF7=VBHJ7$U@)1:RRCRXB)'B+9C1LY12,
MO4OV3_A=J^K/J%YX?NIR=777TLFUJ_\ L,.HB83?:XK03^1%,7!)=$4L'D!)
M$CAO3[/6K34+>::!I#'#R^Z%T/3/ (!/X4FFZW::LSK;-(Q09;S(7C_]" S0
M!QD7P#\#0ZY?:N-)G:ZO-:A\1RQOJ5TUN-1B5E2Y2 R^5&^&.[8H#E4+!BBD
M5YOV<_A]<>,#XDET*22].H_VP;)]1NCIAOL8^U_V?YOV7S\_/YOE;]_SYW_-
M7<Z?X@LM3N##;O*T@&XA[>1!@>[*!WHA\065Q?FS1Y3<;F7!@D"Y&<_,5QV/
M>@#F9O@KX,N/#=]H$FBA](OM;_X2*YMC<S8FO_MBWOG,V_)'GHK[,[,*%V[1
MMK-U;]G7P!K?BR\\0W>C7#7E]<PWM[:1ZI=Q:??7$6WRYKBQ246T\B^7'AY(
MV.8T.?E7'<2:_91Z@+)GE^T;@N/(D*Y/3YMNWOZT7FOV6GW0MYWE64X("P2,
M.>G(4C]: -&BL_4M<L])D1+EY%9AN'EP22<?\!4TM]K5IIL<,D[2*LHRFR%W
M/;J%!QU[T 7Z*HW&M6EK8Q7DC2""4@*5A=FY!/*@9'3N*/[:M/[-^W[I/LV<
M;O)?=UQ]W&[K[4 7J*HV^M6EU8RWD;2&"/.XM"ZMP,G"D9/7L*+'6K34HY9+
M=I&6+[V^%T/X!@,].U %ZBJ&FZY9ZM(Z6SR,RC)\R!X^/^!*,TVSU^RU"Z-O
M \IE&20T$B#CW*@4 :-%9T?B"RDU V2O+]HW%,&"0+D=?FVX[>M$WB"RM]0%
MD[RBX+*N!!(5R<8^8+CN.] &C16=?^(++3;@07#RK(0& 2"1Q@^ZJ13M2UNT
MTED6Y:12XROEPO)_Z"#B@"_3742(RG(##!VD@_F.E4[W6K33[>*:=I!'+]PK
M"[GIGD*"1^-$VM6D%A'>NT@MY,;2(7+<_P"R!D?B* ./T7X#^!?#O_"$_P!G
MZ$L \&6LUEH8^U3N+6&7R_,5MSGS<F&)LR[B&0,"&YK6\._#/PWX3\&W?A72
MK![30[I[R6: 74S.[W4LDMPWFLYDRSRR-G=D9PN  !M+K5HVFM?!I/LRG!/D
MONZX^[C=U]J+76K2\LYKJ)I###G>6A=3P,G"D9/X"@#GM!^$OA3POJ/AZ^TS
M2?LT_A[1O^$?TD?:)7CLK']WF*.-G*J3Y,(+XWL(T!8@ 5GWGP'\"ZA8365S
MH7G6TVO/XFFC:[G_ 'NH-G?(YWY9&5BAB.8RA*%"GRUV.GZU::HLIMFD818+
M;X73KGIN ST/2FZ=KUGJLK1VSRLZKN/F021C'U910!1\/^!=$\+ZYXCUC3+(
MV^I>(KN.]U.X::20W$R0QP(V&8A0(XHU"K@?+TR22_PWX+T;PA<:Y/I%D+.;
M6]0?5=0<2.YN+IHXXS(=Q./DBC7 P $&!5JUU^RO+PVL3RF89!#02*..OS%0
M/UH&OV3:A]B#R_:-VW'D2;<_[VW;^M '%^-/@#X.\>^,T\6:DFN6GB)=/32_
MM^B>)=2TIVM5D>58F%I<1!@'D9N03R.>!BQ+\"O \_@+4?!TNB&30]2G2[OM
MUY.;NZN4:-DN9;OS//>=3#"1,TAD'E)AOE&.LN/$%E:7PM)7E$^0,+!(R\]/
MF"X[^M&HZ]9:5,L5R\JNR[AY<$D@QDCJJD=J . T_P#9F^&VGZ3XPT[_ (1Y
M[Z'QA9QV&OS:GJ-U>W&I11B18_.GFE>1G43.%DW;P-@#81-M#_ADOX82-K<M
MWHFH:K=ZWI<FB:C?:MX@U&^NKFQD>-VMVGFN'DV;HEP-WRY8# =L^HZCK5II
M/E_:6D7S,E?+A>3I_N@XZ]Z+O6K2QM8;B9I!%-@H5A=CR,\@ D?B* +B(L:*
MB*%51@*HP /2G51?6K2/3UOF:3[,W1A"Y;KC[N-WZ41ZU:3:>]ZK2&W3@DPN
M&_[YQN_2@"]15&SUJTOK6:XA:0Q0YWEH74\#/ (!/X4:;K5IJS2"V:1C'C=Y
MD+Q]?]X#/2@"]16=I_B"RU28Q6SRLX7<=\$B#&0.K*!WHM_$%E=7QLXWE,X+
M+AH)%7(SGYBN.WK0!HT5G-K]DNH?8B\OVC=LQY$FW/\ O;<?K1>:_96-V+:9
MY1,<8"P2,.>G(4C]: -&BL_4==L]*D6.Y:568;AY<$D@Q]54T[4-:M-+6)KA
MI%$N=NR%WZ8Z[0<=>] %ZBJ-SK5I:64-W*T@@EQL*PNS<C(RH&1^(H.M6@TT
M7^Z3[,3C=Y+[NN/NXW=?:@"]15&'6K2XL)+Q&D-O&2&)A<-Q_LD9/7L*+'6K
M34(9I8&D*1<OOA=#TSP& )_"@"]15#3=;M-69UMFD8H,MYD#Q_\ H2C--L=?
MLM2N#!;O*TB@D[X)$&![LH% &C4-Y:0ZA:S6MS$LUO,C1R1N,JRD8(/L152+
MQ!93:@;)'E-P&9,&"0+D9S\Q7;V]:)/$%E#J LF>7[06"8%O(5R<8^8+COZT
M":4E9GSUXK_9'N+C4)'T#68([-VR(;]6W1CN-R@[OR']:] ^#GP#T_X6S2:C
M/<_VGK<J&/[1LVQQ(>JH.3DXY8_IS7HM]X@LM.N1!.\JRD _+!(XY]U4BG:E
MKEGI,B)<M(K.,CRX'D_]!4UVSQE>I#V<I:'RV%X8RK!XKZY1I6FMM6TO1;?Y
M="_15&^UJTTZ&*6=I DO*;(7<],\A0<?C1/K5I;6,5Y(T@@DQM*PN6Y]5 R.
MG<5Q'U1>HJC_ &U:?V:;_=)]F'\7DONZX^[C=U]J+?6K2[L9;N-I#!%G>6A=
M3P,G"D9/7L* +U%4;#6K34XY7MVD98N6WPNGKT# 9Z=J;IVNV>K2.ELTK,HW
M'S()(^/JRB@#0HK.L_$%E?W1MH7E,HSPT$BCCKR5 _6A=?LGU#[$'E^T;BN/
M(D"Y'^UMV_K0!HT5G3Z_96]^+.1Y1<%E7 @D*Y.,?,%QW]:-0\066ESB&X>5
M9"N[Y()'&/JJD=J -&BJ.I:U::2T8N6D4ODKY<+R=/\ =!Q1>:U:6-M#/,T@
MBFY0K"[GIGD $C\: +U%4)=:M(=/2]9I/L[G"D0N6_[Y R.GI2KK5I)IS7P:
M3[,O5C"X;KC[N-WZ4 7J*HVNM6E[9S7,32&&'.\M"ZG@9. 0">/04:=K5IJO
MFFV:1O+QN\R%X^N?[P&>AZ4 7J*SM.UZRU69HK9I6=5W'?!)&,9QU90.]%KX
M@LKR]-I$\IG!(PT$BCCK\Q7'ZT :-%9W_"067]H?8M\OVC=LQY$FW/\ O;=O
MZT77B"RL[P6LKRB<D#"V\C#GI\P7'ZT :-%9^HZ]9Z5,L5R\JNR[AY<$D@QG
M'55/I3M1UJTTH1&Y:11)G;Y<+R=,9SM!QU'6@"]15&ZUJTL[.&ZE:00S8V%8
M78\C(RH&1QZBAM:M$TY;XM)]F8X#>2Y;KC[N-WZ4 7J*H1:U:3:>]ZK2?9T.
M&)A<-_WR1D]?2BSUJTOK>:>%I#'",N6A=#TSP" 3^% %^BJ&FZU::LSK;-(Q
M0 MYD+Q]?]X#--T_7[+5+AH;=Y3(J[B'@D08SCJR@=Z -&BLZ#7[*XOS9QO*
M;@,RX,$@7(SGYBN.WK0_B"RCU 63/*+C<$QY$A7)Z?-MQ^M &C16=>>(+*PN
MA;S/*LIQ@+;R,.>G(4C]:74==L])D1+EI59AN'EP22<?55- &A15&_UJTTR.
M)[AI%67E=D+OZ=0H..O>BXUJTM;&*[D:002XVE879N1D94#(Z=Q0!>HJC_;5
MI_9OV_=)]F_O>2^[KC[N-W7VH@UJTN;&6\C:0P1YW%H7#<>BD9/7L* +U%4;
M'6K34HII(&D98N7WPNA_ ,!GIVI--URSU:1TMGD9E&3YD#Q\?\"49H OT5G6
M/B"RU"Z-O \IE )(>WD0<>[*!1'X@LIM0-DKR_: Q3!MY N1G/S%<=O6@#1H
MK.FU^RM]0%D[RBX+*N!!(5R<8^8+M[CO1?:_9:;<""X>59& (V02.,'W52*
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M!_ ^N:?HGB/QGX?T#6=0VFST[5-4@MKBYW-L7RXW<,^6^48!R>.M '64444
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MTX>TE'0^7PO$^58S%?4Z-:\WMHTGZ/9_KT/5****XCZD**** "BBB@ HHHH
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MPV]\_P 3/B/;_%9Q-!<:2T_AFUTTZ9*@E5Y$\HMN9Q(!N."H4X^\:\]_8%\
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M45\P?OH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSX;M/B#9:?X-U3Q@/&-W:Q^'-VHWLQOH[M[>[O#<XFC.P(&$22 1P@NR(R.
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MPH_X2VS_ .><_P#WRO\ C1_PEMG_ ,\Y_P#OE?\ &CWP_<A_PB5G_P ])_\
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MHJA9Z-!8P30QO<,DHPWFW$DA'&."Q)'X4:;HT&EL[0R7+EQ@^?<R2C\-S'%
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M';Z7,TL,ET[,NTB>ZDE&,@]&8C/'6BVT&VM;TW2271D))VO=2.G/^R6Q^G%
M&C16=_8-O_:'VSS+KS=V_;]JD\O/^YNVX]L476@VUW>"Z>2Z64$'$=U(B<=/
ME#8_2@#1HK/U'0[?5)5DFDND95VCR+J2(8^BL!3M0T>#5%B$TEPOEYQY-Q)%
MG..NTC/3O0!>HJC=:/!>6<-L[W"QQ8VM'<2(YP,<L""?Q-#:/ ^G+9%[CR5Z
M,+F02=<_?W;OUH O451AT>"'3Y+-9+DQ.<EFN9&<?1R=P_ TEGH\%C;S0QO<
M,DHPQEN9)&'&."S$C\* +]%4--T:#2V<PR7+[P ?/N9)1QZ;F./PIMAH5OIM
MPTT,ETS$%<374DBX^C,10!HT5G0Z%;V^H&\62Z,I9FVM=2,F3G/R%MN.>F.*
M'T&VDU 7ADNA+N#;5NI!'D?[&[;CVQ0!HT5G7F@VU]="XDDNDD&!B*ZDC7C_
M &58#]*74=$M]4D1YI+E&4;1Y%S)$/Q"L,T :%%4;[1X-1CB25[A1%PIAN)(
MR>G4JPST[T7&CP75C%:/)<"*/&UDN)%<X&.7!W'KW- %ZBJ/]CP?V;]AWW'D
M]=WVB3S.N?OYW?KTXHM]'@M[&6T5[AHI,Y9[B1G&1V<MN'X&@"]15"QT>#3X
MIHXI+EEE&&\ZYDD(^A8DCKVI--T6WTN1WADN7+#!$]S)*/P#,<4 :%%9UCH-
MMI]T9XI+IG((VRW4DB\_[+,11'H-M'J!O%DNO-W%MINI#'D]?D+;<<],4 :-
M%9TVA6\^H"\:2Z$H96VK=2+'D8Q\@;;CCICFB^T*WU&X$\LETC@ 8ANI(UX]
ME8"@#1HJAJ6BV^J,C3/<H4&!Y%S)%^>UAFEO-'@O[>&&62Y58N%,5S)&QXQR
M5()_&@"]15";1X)[".S9[@11D$,MS(K_ (N&W'KW-*NCP+IIL?,N?))SN-S)
MYG7/W\[OUH O451M='@L[.:U22X:.7.XR7$CN,C'#$Y'X&C3]'@TQ95B>X<2
M8W>?<22],]-Q..O:@"]16?IVAV^ERM)#)=.6&TB>ZDE'Y,QP:2UT&VL[PW,<
MET9"2=LEU(Z<_P"R6(_2@#1HK.&@VRZA]L$EUYN[?M^U2>7G_<W;<>V*+C0;
M:ZOA=O)=+*"#B.ZD5..GRAMO;TYH T:*SM0T*WU2999I+I&5=N(+J2(8R3T5
M@,\]:?J6CP:IY9F>X3R\@>1<219SZ[2,].] %ZBJ-YH\%[:PV\CW 2+&UH[B
M1'.!CE@P)_&K-K;K:6\<*%V1!@&1R[?B2<G\: ):*** "BBB@ KFO%6HN)%M
M$;"XW/COZ"NEKC?%$;)JK,1PZJ1^6/Z5<-SGKMJ&ADT445T'F!1110 5X_\
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M,S2PWUL3*0@C:..1@&8JAPI^5CT'-=AX9O\ 3=1\._M.W?@3Q7XB^)/P^NO
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M[;XA:O=:]XC\:?#?X.IXEFAEUJ^\@ZIJ$D]PJ21";Y@JVCJR$%60H&!\N/:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7<X#^S;S_GTG_P"_;?X4?V;>?\^D_P#W[;_"N_HH]HP^K+N<!_9MY_SZ3_\
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MC>V ,FJ@^&_A(6*V0\+:*+-=/CTA;?\ L^'RQ91G,=J%VX\E3TC^Z.PKHZ*
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>nbix-20231231_g7.jpg
<TEXT>
begin 644 nbix-20231231_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
M'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O
M^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_
MPUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W
M]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'
M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
M'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O
M^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_
MPUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W
M]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'
M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
M'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O
M^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_
MPUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W
M]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'
M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
M'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O
M^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_
MPUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W
M]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'
M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
M'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O
M^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_
MPUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W
M]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'
M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
M'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O
M^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_
MPUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W
M]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'
M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
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M* "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: /B?0/\
MD!67_7I'_P"@BK=5- _Y 5E_UZ1_^@BK= !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7TE_P3V_YF_\ [A__ +<U\VU])?\ !/;_
M )F__N'_ /MS0!])4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
ME'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M 'Q/H'_("LO^
MO2/_ -!%6ZJ:!_R K+_KTC_]!%6Z "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OI+_@GM_S-_P#W#_\ VYKYMKZ2_P"">W_,W_\
M</\ _;F@#Z2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_
M^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: /B?0/^0%9?\ 7I'_
M .@BK=5- _Y 5E_UZ1_^@BK= !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\F_\%0_^9&_[B?\
M[:5]95\F_P#!4/\ YD;_ +B?_MI7N\-?\CNE_P!O?^DL_=/HU?\ )Z\J_P"X
M_P#ZC5CY-HHHK]7/]7#ZR_X)>?\ ,\_]PS_V[KZRKY-_X)>?\SS_ -PS_P!N
MZ^LJ_*.)?^1W5_[=_P#24?Y1_25_Y/7FO_<#_P!1J(4445X1^%A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5])?\$]O^9O_ .X?_P"W-?-M?27_  3V_P"9O_[A_P#[<T ?25%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/\ \FC^/?\ L O_ .AK
M7J]>4?MS_P#)H_CW_L O_P"AK0!\3Z!_R K+_KTC_P#015NJF@?\@*R_Z](_
M_015N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_#1'B2Q;2]"-EH^C&=--:;_ %TYD\O>[X.%_P!6F%&<<Y)SQZ#X.^%'QO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4T=MIT$4;2Z:C,56-0"2>IXZUH_\+M\6?] W1_\ P51UPF@?\@*R_P"O2/\
M]!%6Z .P_P"%V^+/^@;H_P#X*HZ/^%V^+/\ H&Z/_P""J.N/HH [#_A=OBS_
M *!NC_\ @JCH_P"%V^+/^@;H_P#X*HZX^B@#L/\ A=OBS_H&Z/\ ^"J.C_A=
MOBS_ *!NC_\ @JCKCZ* .P_X7;XL_P"@;H__ (*HZ/\ A=OBS_H&Z/\ ^"J.
MN/HH [#_ (7;XL_Z!NC_ /@JCH_X7;XL_P"@;H__ (*HZX^B@#L/^%V^+/\
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M_P""J.C_ (7;XL_Z!NC_ /@JCKCZ* .P_P"%V^+/^@;H_P#X*HZ/^%V^+/\
MH&Z/_P""J.N/HH [#_A=OBS_ *!NC_\ @JCH_P"%V^+/^@;H_P#X*HZX^B@#
ML/\ A=OBS_H&Z/\ ^"J.C_A=OBS_ *!NC_\ @JCKCZ* .P_X7;XL_P"@;H__
M (*HZ/\ A=OBS_H&Z/\ ^"J.N/HH [#_ (7;XL_Z!NC_ /@JCH_X7;XL_P"@
M;H__ (*HZX^B@#L/^%V^+/\ H&Z/_P""J.C_ (7;XL_Z!NC_ /@JCKCZ* .P
M_P"%V^+/^@;H_P#X*HZ/^%V^+/\ H&Z/_P""J.N/HH [#_A=OBS_ *!NC_\
M@JCH_P"%V^+/^@;H_P#X*HZX^B@#L/\ A=OBS_H&Z/\ ^"J.C_A=OBS_ *!N
MC_\ @JCKCZ* .P_X7;XL_P"@;H__ (*HZ/\ A=OBS_H&Z/\ ^"J.N/HH [#_
M (7;XL_Z!NC_ /@JCH_X7;XL_P"@;H__ (*HZX^B@#L/^%V^+/\ H&Z/_P""
MJ.C_ (7;XL_Z!NC_ /@JCKCZ* .P_P"%V^+/^@;H_P#X*HZ/^%V^+/\ H&Z/
M_P""J.N/HH [#_A=OBS_ *!NC_\ @JCH_P"%V^+/^@;H_P#X*HZX^B@#L/\
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M_P""J.C_ (7;XL_Z!NC_ /@JCKCZ* .P_P"%V^+/^@;H_P#X*HZ/^%V^+/\
MH&Z/_P""J.N/HH [#_A=OBS_ *!NC_\ @JCH_P"%V^+/^@;H_P#X*HZX^B@#
ML/\ A=OBS_H&Z/\ ^"J.C_A=OBS_ *!NC_\ @JCKCZ* .P_X7;XL_P"@;H__
M (*HZ/\ A=OBS_H&Z/\ ^"J.N/HH [#_ (7;XL_Z!NC_ /@JCH_X7;XL_P"@
M;H__ (*HZX^B@#L/^%V^+/\ H&Z/_P""J.C_ (7;XL_Z!NC_ /@JCKCZ* .P
M_P"%V^+/^@;H_P#X*HZ/^%V^+/\ H&Z/_P""J.N/HH [#_A=OBS_ *!NC_\
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M51P!5BBBOGVVW=G\_P!2I.K-SFVY-W;>K;>[;[A1112("BBB@ HHHH ****
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N#_:'^._A_P"
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MW=V2LD4445PGPX4444 %%%% !1110 4444 %%%% !7TE_P $]O\ F;_^X?\
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MHXGB+ 1R+):"P.54G[E"#UF_YZTMZDW:[NVD[;M<S****\D_)PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YO_;H^ 5_J=M%^T#\.DD@U
MS0PDFI?9>))(8R"LZX_CBP,G^X/]@ ^C?LN?'[3_ (^?#J/59WCCUK3PL&MV
MJ<8DQQ*H_N. 2/0AE_AS7I+HDJ&.1 RL,,K#((]*^-_BAX:U_P#8?^/UI\4O
M ]G))X3UN5EFLD/R!&.Z6U/H1]^,GT YVMGZ+!R6;X+ZE-_O(:TWW76'^7_
M/Z)X.KT?%O@S_4O&R2S'"*4\!4D_CBE>>%DWW2O3OM:UU&-G]DT5G^%?%&A^
M-?#EEXL\-7Z7-AJ%NLUK.G\2D=_0CH0>000>E:%?/2C*$G&2LT?SW7H5L+7E
M1K1<9Q;4DU9IIV::>J:>C04444C(**** "BBB@ HHHH **** "BBB@ HHHH
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M5GMOF>QA?@,,<^:_1!U'WO[N;_['7[,D7P5\,'Q9XLM5?Q1JT(-T6Y-E$>1
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MK)3]AKX))IY\&^;K1\$G6CJW_"N3J(_L3[69O/SY.SS#%YW[W[,9/L^_GRJ
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MP4_Z$O6/_!BO^%<?10!V']M?!3_H2]8_\&*_X4?VU\%/^A+UC_P8K_A7'T4
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M_P"A+UC_ ,&*_P"%']M?!3_H2]8_\&*_X5Q]% '8?VU\%/\ H2]8_P#!BO\
MA1_;7P4_Z$O6/_!BO^%<?10!V']M?!3_ *$O6/\ P8K_ (4?VU\%/^A+UC_P
M8K_A7'T4 =A_;7P4_P"A+UC_ ,&*_P"%']M?!3_H2]8_\&*_X5Q]% '8?VU\
M%/\ H2]8_P#!BO\ A1_;7P4_Z$O6/_!BO^%<?10!V']M?!3_ *$O6/\ P8K_
M (5\5_MG?#NV_9]^-&G?M3_L_:-=6FERWBMK6FW,FY(KECA\E,'R9P2#Z.3@
MC<H'U)5#Q/X:T3QEX>O/"OB.P2ZL;^W:&Z@?HR,,?@>X(Y! (KT,MQ\L!B>=
MJ\7I)=T]_P#@'Z!X;<=5N N(EBIP]KA:L72Q%)ZQJT9Z3BT]+I:Q?=6>C:>W
M\)?C1^SG\8/ -AX]\-^#]7\F\B_?0'5%+6TPX>)N.JGCW&"."*Z3^VO@I_T)
M>L?^#%?\*^!?AQXAU_\ 8;_:!N?AKXRO))?".N2*T5Y(/E$9.([H=@R_<D [
M GG"U]D1R1S1K-#(KHZ@JRG((/0@UIFF C@ZRE3=Z<]8OR[>JZG=XH\"T.#<
MYIU\MG[7+L7'VN%J[\U-_8;_ )Z;?+)/79M*]EV7]M?!3_H2]8_\&*_X4?VU
M\%/^A+UC_P &*_X5Q]%>6?F)V']M?!3_ *$O6/\ P8K_ (4?VU\%/^A+UC_P
M8K_A7'T4 =A_;7P4_P"A+UC_ ,&*_P"%']M?!3_H2]8_\&*_X5Q]% '8?VU\
M%/\ H2]8_P#!BO\ A1_;7P4_Z$O6/_!BO^%<?10!V']M?!3_ *$O6/\ P8K_
M (4?VU\%/^A+UC_P8K_A7'T4 =A_;7P4_P"A+UC_ ,&*_P"%']M?!3_H2]8_
M\&*_X5Q]% '8?VU\%/\ H2]8_P#!BO\ A1_;7P4_Z$O6/_!BO^%<?10!V']M
M?!3_ *$O6/\ P8K_ (4?VU\%/^A+UC_P8K_A7'T4 =A_;7P4_P"A+UC_ ,&*
M_P"%']M?!3_H2]8_\&*_X5Q]% '8?VU\%/\ H2]8_P#!BO\ A1_;7P4_Z$O6
M/_!BO^%<?10!V']M?!3_ *$O6/\ P8K_ (4?VU\%/^A+UC_P8K_A7'U!J6I6
M&CZ?/JVJWD=O:VT+2W%Q,X5(T499B3T  S32;=D5"$ZDU""NWHDMV^R-GXE_
M&#]FWX4>"[WQSXM\+ZQ%:6<>=HU)=\SG[L:#NS'@#\3@ FOCGX">!I/VT/C[
M=_'GXX:)=KX+T^Z*VFBVT_$H4YCLT=NL:Y#2/C+$D  L2N-XHUGQ=^WQ\<8_
M"7AJ6>S\%Z')O><K@+%G!G8'K+)@A%/W1VX<U]>>$O"F@>!O#=GX2\+Z<EI8
M6$ BMH(^BJ.Y/<DY))Y)))Y-?22:R'"<B_WBHM?[D7T_Q/\ #\_Z0Q$H>!/"
MKPM-K^W\=3]]K?!T):\B?2O46K>\5M:T7/OX]5^"$,:PP^!]61$4!574%  '
M0 8IW]M?!3_H2]8_\&*_X5Q]%?-'\W-MN[.P_MKX*?\ 0EZQ_P"#%?\ "C^V
MO@I_T)>L?^#%?\*X^B@1V']M?!3_ *$O6/\ P8K_ (4?VU\%/^A+UC_P8K_A
M7'T4 =A_;7P4_P"A+UC_ ,&*_P"%']M?!3_H2]8_\&*_X5Q]% '8?VU\%/\
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M_P"197_P2_\ 26?NGBC_ ,FSSO\ [ \3_P"F9GZ%T445^,G^-(4444 %%%%
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M** "BBB@ HHHH **** "BBB@ HHHH *"0H+,< =2:*^6?VK?VD?$/Q"\1_\
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MQ:H4%ZOI%=W^BZGSW$W$V6\+9;+&8R7E&*^*4NR_5[):L^M**^2_V,OVS?\
MCT^$/Q>U;^[#HFMW#_@L$S'\E<_0]C7UI1F^48O)<6Z%=>CZ27=?JN@<,\39
M;Q3EL<9@Y>4HOXHR[/\ 1[-:H****\L^A"BBB@ HHHH **** "OI+_@GM_S-
M_P#W#_\ VYKYMKZ2_P"">W_,W_\ </\ _;F@#Z2HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[
M_P!@%_\ T-: /B?0/^0%9?\ 7I'_ .@BK=5- _Y 5E_UZ1_^@BK= !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !117S]^V!^U9/X 4_"/X5S-<^*M0"Q3S6HWM8!^%50.3,V1M'500>I6NO!8
M.OC\0J5):O[DN[\CZK@S@[/..\_IY3E<+SEJY/2,(+XIS?V8QZOJ[))R:3S/
MVO/VHM5BU$_ #X)/+=Z_?R"UU&[L?F> MQ]GB(_Y:G.&8?<''WLE>U_91_9<
MTKX#>'?[8UQ(KKQ/J$(^WW0^9;9#SY$9] <;F_B(] *S/V0_V5(?@_IP\?>/
M(5N/%=_&2V\[_P"ST;JBGO(<_.__  $<9+>Y5Z6/QE##T/J.#?N?:EUF_P#Y
M%=%_3_2N/>,<CX?R-\$<'SOA(N^)Q"TEBZJWU6U&+^"-[/?5>](HHHKPC\+"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O!/VX/V=9OB1X77XG^"K5AXC
MT&+>ZVX(DN[93N*C')=#EEQR?F')*X][HKJP6+K8'$QK4]U^*ZI^I]1P9Q=F
MW W$E#.<NE:I2>J?PSB])0EWC)73[;JS29Y!^Q[^T3%\<O (T_7;I?\ A(]'
M18M30\&X3HEP!_M8PV.C ] 5KU^OC_\ :*\!>(_V3?C58_M#?"VTVZ-J%V1?
M62<11R/S) P'2.0 LO\ =8'&-JU]3?#SQ[X=^)W@VP\<^%;OS;+4( Z9^]&W
M1D8=F5@5(]17H9MA*,5'%X;^%4_\EEUB_P!#[[Q6X1RFA'#\6\.1_P"$S'W<
M8_\ /BMO4H2MM9W<.CC=1NHW>U1117BGXR%%%% !1110 4444 %%%% !1110
M 55UK6M*\.:1<Z]KM_%:V=G TUU<S-A8T49+$_2K5?(G[2OQ;\4?M._$NV_9
MN^"LOGZ9'=8U.]C;]U<R(?F=F'_+"/KG^)AD9^3/H9;@)X^ORWM%:RET2_K8
M_0/#G@+%\>YX\.YJCA:,?:8BM+X:5*.LI-O3F:345U>OPJ367>W'B_\ ;]^.
M:V-FUS8>"=!?);&#'"3]X]O/EQ@#^%1WVG=]A>'?#VB^$M"M/#7AS3H[2QL8
M%AM;>(85$ P![^Y/).2:P_@W\)/"_P %/ EKX'\+PY2(;[NZ90'NIR!NE;W.
M, =@ .U=36N:8^&*E&E07+2AI%?J_-_UU/5\3N/<)Q/B*.4Y+!T<JP:<,/3[
M_P U:IWJ5'=MO5)VW<FRBBBO*/RH**** "BBB@ HJMJVL:1H-B^J:YJEM96T
M0S)<W<ZQQH/=F( KR#XA_MY_ #P-YEKI>MS^(+M,CR=&AW1Y]Y7*H1[J6^E=
MN#R['YA/EPU*4_1:?-[+YGE9GGF3Y+3Y\=7C37]YI-^BW?R3/:*AU'4M.TBS
MDU'5K^&UMXAF6>XE"(@]2Q( KY+N/VP?VJ/C?.^G? 3X4-8V[,5%]';&Z=#T
MYFE"PI^*_C3]._8<^/WQ:O(]:_:!^,#QC.X6@N'O)4]5 )6*/_@.X>U>\N&8
M8/7,L3"C_=3YY_\ @,?\SX]\?5<S?+D.!JXGM-KV=+_P.?Y61J_MG?M;^'F\
M%GP/\%_B39W%Y=S-%J\NGK([+;D=(YE'E\G@X)..F*^.:_0WX>?L1_L]_#_R
M[AO"1UJ[3!^U:[)Y^3_USP(__'<^]>2?MD_L71PQW/Q8^#>C*B(IDUC0K2/
M '6:%1^;(/J.XKZ_AGB#AW 5%E^'YDI/XY)+FEV=MEVOZ'YEQ[P9QOG%&6<X
MQPE*"_A4W)\D%NU?=]9);[KL?)M?H=^QE_PN3_A3=I_PM[_9_L3[1G[5]EQ\
MOG9_\=S\VWKVKR7]C+]C+_CT^+WQ>TG^[-HFB7"?BL\RG\U0_4]A7UI7F\<<
M0X3&_P"PT$I<KNY=GVC^K^1[WA)P5F657S?&2E3]I&T:>UXO[4U_Z2MUN^P4
M445^;G[H%%%% !1110 4444 %?27_!/;_F;_ /N'_P#MS7S;7TE_P3V_YF__
M +A__MS0!])4444 %%%% !1110 445XK^U9^TIK_ ,)/'WPS^!W@9],M/$/Q
M2\07&GV&M:Y TMIIL-O")9I#$CH9I6W1QQ1[U#/("3@;6 /:J*^=/V>O&'[4
MVFW/@9_&?C'2?&'A?Q3J^KV&IWDVCO;:EI4\'VV6&3S$E:.:%_LQC(9%9"R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]% '8?\ "MO"?_17-'_[]R?X4?\ "MO"?_17-'_[]R?X5Q]% '8?\*V\)_\
M17-'_P"_<G^%'_"MO"?_ $5S1_\ OW)_A7'T4 =A_P *V\)_]%<T?_OW)_A1
M_P *V\)_]%<T?_OW)_A7'T4 =A_PK;PG_P!%<T?_ +]R?X4?\*V\)_\ 17-'
M_P"_<G^%<?10!V'_  K;PG_T5S1_^_<G^%'_  K;PG_T5S1_^_<G^%<?10!V
M'_"MO"?_ $5S1_\ OW)_A1_PK;PG_P!%<T?_ +]R?X5Q]% '8?\ "MO"?_17
M-'_[]R?X4?\ "MO"?_17-'_[]R?X5Q]% '8?\*V\)_\ 17-'_P"_<G^%'_"M
MO"?_ $5S1_\ OW)_A7'T4 =A_P *V\)_]%<T?_OW)_A1_P *V\)_]%<T?_OW
M)_A7'T4 =A_PK;PG_P!%<T?_ +]R?X4?\*V\)_\ 17-'_P"_<G^%<?10!V'_
M  K;PG_T5S1_^_<G^%'_  K;PG_T5S1_^_<G^%<?10!V'_"MO"?_ $5S1_\
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M>$_^BN:/_P!^Y/\ "N/HH [#_A6WA/\ Z*YH_P#W[D_PH_X5MX3_ .BN:/\
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M  H_X5MX3_Z*YH__ '[D_P *X^B@#L/^%;>$_P#HKFC_ /?N3_"C_A6WA/\
MZ*YH_P#W[D_PKCZ* .P_X5MX3_Z*YH__ '[D_P */^%;>$_^BN:/_P!^Y/\
M"N/HH [#_A6WA/\ Z*YH_P#W[D_PH_X5MX3_ .BN:/\ ]^Y/\*X^B@#L/^%;
M>$_^BN:/_P!^Y/\ "C_A6WA/_HKFC_\ ?N3_  KCZ* .P_X5MX3_ .BN:/\
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M<]?*N!>%\HG[6EAU*IOSS]^3?>\KV?I8Z]?AIX010B?%K1@ , "*3 'Y4O\
MPK;PG_T5S1_^_<G^%<?17AGUQV'_  K;PG_T5S1_^_<G^%'_  K;PG_T5S1_
M^_<G^%<?10!V'_"MO"?_ $5S1_\ OW)_A1_PK;PG_P!%<T?_ +]R?X5Q]% '
M8?\ "MO"?_17-'_[]R?X4?\ "MO"?_17-'_[]R?X5Q]% '8?\*V\)_\ 17-'
M_P"_<G^%'_"MO"?_ $5S1_\ OW)_A7'T4 =A_P *V\)_]%<T?_OW)_A1_P *
MV\)_]%<T?_OW)_A7'T4 =A_PK;PG_P!%<T?_ +]R?X4?\*V\)_\ 17-'_P"_
M<G^%<?10!V'_  K;PG_T5S1_^_<G^%'_  K;PG_T5S1_^_<G^%<?10!V'_"M
MO"?_ $5S1_\ OW)_A1_PK;PG_P!%<T?_ +]R?X5Q]% '8?\ "MO"?_17-'_[
M]R?X4?\ "MO"?_17-'_[]R?X5Q]% '8?\*V\)_\ 17-'_P"_<G^%>\_L1^'=
M*\.R>)DTKQ7::J)ULS(UHK 0[?/P#GUW''^Z:^5J^DO^">W_ #-__</_ /;F
M@#Z2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_P#DT?Q[
M_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: /B?0/\ D!67_7I'_P"@BK=5
M- _Y 5E_UZ1_^@BK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !116!\2_B5X3^$W@^Z\;>,]0$%I;+\JCEYY#]V-!_$Q[#ZDX )
M%PA.K-0@KM[(ZL#@L9F6,IX3"4W4JU&HQC%7<I-V226[;*?QD^,/A'X(^"I_
M&?BVY^5?DL[.-AYMW,1\L:#^9Z 9)KYF^#7PI\<?MF?$F7XX_&@2)X;MYMEE
M8J2J7 5CBWB](E/WWZL<C.2Q6OX$\&>/_P!O'XJR?$;XA":Q\':7,8X+6-R%
MVY!^S1'NQX,DG\OE ^Q-(TC2] TNWT31;"*UM+2%8K:V@0*D:*,!0!T %?15
M9PR&BZ--WQ$E[S_D7\J\^[/Z)S+&8+P(R6>4Y=.,\^Q$+8BM%IK"4Y*_L:4E
M_P O6OCFOAZ?9:DM;6UL;6.RLK:.&&&,)##$@544# 4 <  <8J2BBOFMS^;9
M2E*3;=VPHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH **** "OI+_@GM_S-_\ W#__ &YKYMKZ2_X)[?\ ,W_]P_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ2_P"">W_,W_\ </\
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MK-.(\UK9EF55U:]5N4I/=O\ ))+1)6222222"BBBLCRPHHHH **** "BBB@
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M80Q<JF-B])U$GS1Y>3EG&-H\KA[K2LNJL]3["6!P\L)]7Y;1\OO_ #/F;7_
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MMY_WR/\ &C_A4'Q,_P"A-O/^^1_C6/\ \)#K_P#T'+S_ ,"7_P :/^$AU_\
MZ#EY_P"!+_XT ;'_  J#XF?]";>?]\C_ !H_X5!\3/\ H3;S_OD?XUC_ /"0
MZ_\ ]!R\_P# E_\ &C_A(=?_ .@Y>?\ @2_^- &Q_P *@^)G_0FWG_?(_P :
M/^%0?$S_ *$V\_[Y'^-8_P#PD.O_ /0<O/\ P)?_ !H_X2'7_P#H.7G_ ($O
M_C0!L?\ "H/B9_T)MY_WR/\ &C_A4'Q,_P"A-O/^^1_C6/\ \)#K_P#T'+S_
M ,"7_P :/^$AU_\ Z#EY_P"!+_XT ;'_  J#XF?]";>?]\C_ !H_X5!\3/\
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M ;'_  J#XF?]";>?]\C_ !H_X5!\3/\ H3;S_OD?XUC_ /"0Z_\ ]!R\_P#
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MWD_Z^X_)>*.*,ZXRSRMFV:U74K57=OHETC%=(Q6D4MEYFQ_PJ#XF?]";>?\
M?(_QH_X5!\3/^A-O/^^1_C6/_P )#K__ $'+S_P)?_&C_A(=?_Z#EY_X$O\
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M'Q,_Z$V\_P"^1_C1_P *@^)G_0FWG_?(_P :Q_\ A(=?_P"@Y>?^!+_XT?\
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M/_ E_P#&N ]@V/\ A4'Q,_Z$V\_[Y'^-'_"H/B9_T)MY_P!\C_&L?_A(=?\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"_VJ_VP=+^#\3^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445Y3^TO\
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M)-SGR=2M[?/_ #QM$./^^@:R[OXJ_$2]SYWBZ\7/_/%_+_\ 00*Y^BOMLO\
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M  3V_P"9O_[A_P#[<U\VU])?\$]O^9O_ .X?_P"W- 'TE1110 4444 %%%%
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M=XT^SEWEV73\3\OJXC,/$6LZ&%<J66Q=I3VG7MO&':GT;Z[=TLWX%? /P1\
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MOP.JHHHKRCZ$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^W]9FD\YM.>4R0(YYS*S<SMGKGY>N=W6OHRWMX+2!+6U@2**- L<<:A550,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#!5'1_PNWQ9_T#='_\%4= ''T5V'_"[?%G_0-T?_P51T?\+M\6?] W1_\
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M_P#!5'1_PNWQ9_T#='_\%4= ''T5V'_"[?%G_0-T?_P51T?\+M\6?] W1_\
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M/I/'MD7\&%=/]LY%C/\ ?,$HO^:D^7_R5Z?B<'^K'%V5ZY7FLIQ7V,1%5/\
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M1-UL74_B59;O^['^6"Z)=EV27'T5V'_"[?%G_0-T?_P51T?\+M\6?] W1_\
MP51UX9]:<?178?\ "[?%G_0-T?\ \%4='_"[?%G_ $#='_\ !5'0!Q]%=A_P
MNWQ9_P! W1__  51T?\ "[?%G_0-T?\ \%4= ''T5V'_  NWQ9_T#='_ /!5
M'1_PNWQ9_P! W1__  51T <?178?\+M\6?\ 0-T?_P %4='_  NWQ9_T#='_
M /!5'0!Q]%=A_P +M\6?] W1_P#P51T?\+M\6?\ 0-T?_P %4= ''T5V'_"[
M?%G_ $#='_\ !5'1_P +M\6?] W1_P#P51T <?178?\ "[?%G_0-T?\ \%4=
M'_"[?%G_ $#='_\ !5'0!Q]%=A_PNWQ9_P! W1__  51T?\ "[?%G_0-T?\
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M ''T5V'_  NWQ9_T#='_ /!5'1_PNWQ9_P! W1__  51T <?178?\+M\6?\
M0-T?_P %4='_  NWQ9_T#='_ /!5'0!Q]%=A_P +M\6?] W1_P#P51T?\+M\
M6?\ 0-T?_P %4= ''T5V'_"[?%G_ $#='_\ !5'1_P +M\6?] W1_P#P51T
M<?7TE_P3V_YF_P#[A_\ [<UX[_PNWQ9_T#='_P#!5'7O/[$?C/5?&4GB:35;
M:TC-JMF(_LEJL0._S\YQU^Z,>G/K0![W1110 4444 %%%% !6=XH\(>$_'&D
MOH/C3POIVL6,A!>RU2RCN(F/J4D!!_*M&B@#E/A%\$?A9\"?#9\*?"KP3IVC
M6;S/+,MC91Q-*S.SY<HHW8W$#/1< <"M/Q)\/? /C*XCNO%_@?1]5EA0I#)J
M6F13LBYS@%U) SV%;%% &3_P@?@;_A&O^$+_ .$,TG^Q\Y_LG^SHOLV=^_\
MU6W9]_YNG7GK69_PHSX)?]$=\*_^$];?_$5U-% &-XL^'/P]\?:1#X?\=> ]
M&UJPMW#P6.K:7#<PQL!@%4D4JI X! Z5H:1HVD>'],AT70-*MK&SMDV6]I9P
M+%%$O]U54 */8"K-% !1110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)
MH_CW_L O_P"AK0!\3Z!_R K+_KTC_P#015NJF@?\@*R_Z](__015N@ HHHH
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MLD]Y<WD@GM=&O?O2_P!UIU_A0#&V$8&  0 -I^J(XXX8UAAC5$10%51@ #H
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M0 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\
M^AK0!\3Z!_R K+_KTC_]!%6ZJ:!_R K+_KTC_P#015N@ HHHH **** "BBB@
M HHHH **** "BBB@ JCXF\3:!X-T&Z\3^*=6AL;"SB,ES=3MA47^I)X '))
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG,A'NYY'_ 0*XB:::XE:>XE9W<Y9W;))]237YEBN'/''Q2J^VXLS-97A9?\
M,-@W>LX_RSQ+NHOHU23A);H^*XIXVS+BK-)9AF=:6*KO:4](Q7:%-6C&/DDM
M==STKQ)^T/="#^S? NBQV,"C;'-,BE@/]E!\J_CFO/M8UW6?$%T;W6M3FNI3
M_'-(3CV'H/854HK]$X+\+^!?#^G;)<%&G4?Q57[]65]^:I*\W=ZM74>R1\=B
M<;BL4_WDKKMT^X****^_.4**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KZ2_P"">W_,W_\ </\ _;FOFVOI+_@GM_S-_P#W
M#_\ VYH ^DJ*** "BBB@ HHHH *^5_\ @I3\>+WX,^)_@_H_C+Q'JF@?#+Q-
MXSFM/B+K^DW4MM)%&L -K;O<0D20PR2EFD*,K&.!AG&X'ZHKE?B=X=^$OQ2L
M9/@1\5=%T[6;?Q'I5S.^@ZC!YBW5M!) DL@XX*/<088$,K.I7D9 !X9^R;\"
MK73-%^'GQA^#/C35K729-4UE/$^DP>))[C2]5L'-\+><022/'YB3"V*R1A2R
MLVXL,8Q/^"S5UX^\+_LB77C[P+\6O$GA^2RUS3+>>QT2^6WBO(YKI8G65T03
M$$/]T2!3M&5/.?(?V7=,^+W[ WQB^&7@[P5XZN?$/PD^+_B?5-(B\'ZF[23^
M&;V&>8)+:N228BJ!F[8#[@6VO7L?_!:__DP;6_\ L9-%_P#2^&@#W_\ :-^,
M>F_L]_ ?Q=\;=5M1<1>&- N;];4MC[1(B$QQ9[;WVKGMNKY;LO!7Q+N_^"<3
M?MI2_$36S\7Y/!K>/8_$7]J3B-<1&^73UM=_DBS-L!!]GV;#G?C?\]>U_P#!
M2'X?Z]\3_P!A7XH>#?#-J\]_-X5FN+>WB4EYC;E;@HH'5F$14#N2!7GL?Q%\
M/#_@BH/&D-Y']F7]G?[*"&X%R-(^S>5]?.^3ZT 8/QF_;4U[XW^ /V=?A[\*
M]7NO#U_^T!?02ZY?:5<E+K3-+@CCDU&&"4?-%*68Q+*.5"N1AL$;_P 5/$T?
M[$G[77PAT/P/>7L7@7XK7ESX:U[0;O4IKF&VU-1&;&]@\YV,<KO(8I<$!UPS
M!G -?//@?X1^*/@=X@_8)\:^-+*6"U@M[[2-0\]2/LEYJ<!FM87S]UV\YUV]
M08B*]O\ ^"DNA7WQ"_:R_95^&V@(TM\OQ.DU^9(QDQVFG?9IYG/]T;0>3WH
M^Q:*** "O*/VY_\ DT?Q[_V 7_\ 0UKI/C-HGQRUO3+*+X'>-]%T.[2=C?2Z
MUIC7*RQ[>%4 C:<\YKY\_:M\&_MIV'[.OBZ\^('QG\'ZAHL>DL=1LK'PX\4T
MT>Y<JCEOE.<<T >#:!_R K+_ *](_P#T$5;K?\'ZM\(HO".EQ:IX2U66Y73H
M!<RQ7X57D\M=Q QP"<\5H_VU\%/^A+UC_P &*_X4 <?178?VU\%/^A+UC_P8
MK_A1_;7P4_Z$O6/_  8K_A0!Q]%=A_;7P4_Z$O6/_!BO^%']M?!3_H2]8_\
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MFKVLESYQGV89[]76*=U0A[.%ND.>=2VK?VJDOD[= HHHK[(\8**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KZ2_X)[?\S?_ -P__P!N:^;:^DO^">W_ #-__</_ /;F@#Z2HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]
M7KRC]N?_ )-'\>_]@%__ $-: /B?0/\ D!67_7I'_P"@BK=5- _Y 5E_UZ1_
M^@BK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MTE_P3V_YF_\ [A__ +<U\VU])?\ !/;_ )F__N'_ /MS0!])4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1
M^W/_ ,FC^/?^P"__ *&M 'Q/H'_("LO^O2/_ -!%6ZJ:!_R K+_KTC_]!%6Z
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7TE_P3V_YF
M_P#[A_\ [<U\VU])?\$]O^9O_P"X?_[<T ?25%%% !1110 4444 %%%% !7R
M7\1/VHOBS\8?B7X]^'7P=\<V'A+3OAK\0?".@7TYTXW6HZE<W^JVD4LAW2*D
M-JJR-'LVLTVU_G0<'ZTKXI_X**_L.ZLGBR#]L[]EKQA)X9^)!\1^'K74-,D;
M.E^)9CJME#9_:TSA3'-]G<MAE(A&5#?. #WKP7\1/VB-#\$_$"U^)/A33-?\
M1^$]1:V\,/X9L9;:+Q$CV<$ULQBEDD\AVEF,,A\PQH8V;<%&1X+\4_B+_P %
ME_@U\)M<^,GCW6OV;+72_#VBS:EJ,*1ZVTX2.,N8U&-K2'&U1NP6(&><U[#^
MPS^V%JG[4GASQ#X8^)'P\F\(?$3P%J2:9X[\-2-NCM[A@QCFA;)W0R!'*Y)(
MVGEUVNT'[;*_\+,\1_#+]E2#YX_'/C&/4?$D/\+:)I.V^N5;'(62=;.#W\\B
M@#<UKX[>._A/^R#I?Q=^,=EI*>-[O0K%'TF'-K:R:Y>"..&S'F.Q1/M$JHS%
MCM57<X ..?\ @!:_\%.9?B+97G[2GB/X'R>#?L\KW:^!8=5>_F<QGRA&UR%C
M5=Q5F8[C@8 YR/1/VA?V9?@E^U5X*B^'GQY\%_V[H\%X+N&S.HW-L$G",BR9
M@D0E@KL!D\;C7S)\"?@[XY_X)X_MM^$_V=/A[X[UC7/@_P#%32]5DT?0M;NC
M/)X:U&QA%PXB<](G0[1P-Q?YLL@=@#[7HHHH *\H_;G_ .31_'O_ & 7_P#0
MUKI/C-\3?%_PRTRRO_"'P=UKQC)=3M'-;:+)&K6ZA<AVWD<$\<5X?\>OC%\<
M_C/\'?$'PMMOV-_'&GR:WI[6R7DDEM((B2#N*AQGITR* /G/0/\ D!67_7I'
M_P"@BK=>W>'OV&M?70+%;OQ+?0RBSB$L3:&N4;8,K_Q\=CQ5S_AAO5_^ANO?
M_!$O_P D4 >"T5[U_P ,-ZO_ -#=>_\ @B7_ .2*/^&&]7_Z&Z]_\$2__)%
M'@M%>]?\,-ZO_P!#=>_^")?_ )(H_P"&&]7_ .ANO?\ P1+_ /)% '@M%>]?
M\,-ZO_T-U[_X(E_^2*/^&&]7_P"ANO?_  1+_P#)% '@M%>]?\,-ZO\ ]#=>
M_P#@B7_Y(H_X8;U?_H;KW_P1+_\ )% '@M%>]?\ ##>K_P#0W7O_ ((E_P#D
MBC_AAO5_^ANO?_!$O_R10!X+17O7_##>K_\ 0W7O_@B7_P"2*/\ AAO5_P#H
M;KW_ ,$2_P#R10!X+17O7_##>K_]#=>_^")?_DBC_AAO5_\ H;KW_P $2_\
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M%>]?\,-ZO_T-U[_X(E_^2*/^&&]7_P"ANO?_  1+_P#)% '@M%>]?\,-ZO\
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M ((E_P#DBC_AAO5_^ANO?_!$O_R10!X+17O7_##>K_\ 0W7O_@B7_P"2*/\
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M*/\ AAO5_P#H;KW_ ,$2_P#R10!X+17O7_##>K_]#=>_^")?_DBC_AAO5_\
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M]7_Z&Z]_\$2__)% '@M%>]?\,-ZO_P!#=>_^")?_ )(H_P"&&]7_ .ANO?\
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M% '@M%>]?\,-ZO\ ]#=>_P#@B7_Y(H_X8;U?_H;KW_P1+_\ )% '@M%>]?\
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MEEH=A)!I^C03-&UP8A*[R2S2F*(/,Q7Y(U543+E_2:* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F3M
M.L#M:QH\H0F-)'*JS8X!(!P,]\'Z&GT4 ?.W[,'[2OQQ^)_[8'QI^ 7Q;T7P
M[86OP[BT3^R(- >:7<M[!+<%Y)I0ID;88APB $' [GI_V@M;_:T\3>*8_AC^
MRM_PC.AM;:>E[KOC+Q?:37$,1D=UBM+6"+'FS?NV>1G.V-&CX8N-OEW[*G_*
M5/\ :K_Z\_!7_IIKZD\4>*/#W@GPY>^+O%FL0:?IFFVSW%]>W+[8X8E&68GZ
M4 ?./[%7[5/[07BOXX>.?V/?VM_#.BP^.O!-G!J-MKWAE76QUC3IBH68*YRC
M NG3&=Q!52ASZK\4/B3KVE?&3PA\/O#NJM:VL=CJ7B+Q@\5JLK-I=K"(4@P5
M8JTES<PN"N&*VLH!ZUS7[,?PDUFZ^*'C?]KSXA:'-INN_$%K6VT;1[N/;-I&
MA6J;;:*5>J3S$M<2I_ 72/K&<Z_P _XKSXE_$/XZ2_/!?:VOAGP_(>1_9^E-
M)%(1_O:A+J'(^\JQGG H \.^.WQ0_P""K/@#X?:G^U)X>T?X;V_A[1K-]5NO
MA?=VEQ+J4>F(ID<3708*UTL66=8\("I"^80 _HOQ$_;^\'>#OV'-'_;&TSPM
M/=2^*--L1X9\,23A9;K4KO"Q69?&,*^_<X'W(V8 \ ]%^U[J6O\ CCP+=_LP
M?#*=#XJ^(&F3:?+.5W)HNDRCRKO4IO0)&S)$O!DF9%' =D^=?^"HGPST+X2?
M!_\ 9K^&WA2S>#PCX8^,OAS3FC<[@D444D<;2'N=BR98]2Q]: /7OB)\>/C=
M^R;K7P_U[]HCQ=H>O^&_&_B&#P]K]QI6BM9#P]J=RC-;R0L97,MF71XW\WYU
M^1]YY2NR_;=^,/Q<^ 7[-GBGXP_!_P />']0O_#NCS7\P\0W4RQI'& 25CB7
M,S8W':9(QP.3GCP[_@NP+J?]AN/3M+5CJ%WXZTF'2UC^^;@O(5"^_!KV#_@H
MWN'[!7Q:#D%O^$"U#)'KY)H [G]G7QMKGQ+_ &?? OQ'\3O$VI^(/!NF:EJ+
M01[$,\]I%+(57^$;F.!V%>-_ WX\_&K]J_X.:_\ M%?#?XG:%X:L;75M4M?#
MWAR[T(7*1)9RO&IU.1I%DWR[!(5A,7EQRIRY!8^G?L;?\F@_"K_LFVA?^F^"
MO@KXB?"+XEZHGQ$_;)_8(T>]O_A#KVOSQ>.?ABFL2PIXV@MIG74;VR$0#6\3
MR(\85&\R15EP-CB!@#[\_93^.9_:7_9T\(?'9O#<FD/XET=+N;39'+>1)DJX
M5B!N3<I*M@94J<#->@UP'[+'Q?\ AA\>?V>O"?Q4^#6FI8^&M3TE%TS34@6(
M6"Q$PM:[$^5?*>-H\+\OR<<8KOZ "BBB@ HHHH **** "BBB@ HHHH ^?/\
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M#_A[/\6/VC]9_;=\2:;);6UQX;C\,_#BTN(BDIT=9FGEU"1&&4:YF;,8(#+
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MN_;-_9NT"U\1:_\ #Y[NQUGPA=:E'9MJVFW2%'$,TI$:2J'EQO(!+*<_)M8
MV]*_:(^)7P9_:\T']E7X[ZW8ZYI_C[1KF]\ ^++;319S&[M1NN;"ZC5C&Q$>
M)$E0)]X(5)(:OH.O@[XP^)?B3^TK_P %2O@'X$O_ (63^%Y/AYI6J^*=<M+G
M5[>[NK.VG5(T%Q]E,D,6Z6WC10LKEA,"0HQG[QH **** "BBB@ HHHH ****
M "BBB@!D[3K [6L:/*$)C21RJLV. 2 <#/?!^AKYY_9@_:5^./Q/_; ^-/P"
M^+>B^';"U^'<6B?V1!H#S2[EO8);@O)-*%,C;#$.$0 @X'<_1-?)G[*G_*5/
M]JO_ *\_!7_IIH ]1_:"UO\ :T\3>*8_AC^RM_PC.AM;:>E[KOC+Q?:37$,1
MD=UBM+6"+'FS?NV>1G.V-&CX8N-O"?L5?M4_M!>*_CAXY_8]_:W\,Z+#XZ\$
MV<&HVVO>&5=;'6-.F*A9@KG*,"Z=,9W$%5*'/T=XH\4>'O!/AR]\7>+-8@T_
M3--MGN+Z]N7VQPQ*,LQ/TKR']F/X2:S=?%#QO^UY\0M#FTW7?B"UK;:-H]W'
MMFTC0K5-MM%*O5)YB6N)4_@+I'UC.0#I?BA\2=>TKXR>$/A]X=U5K6UCL=2\
M1>,'BM5E9M+M81"D&"K%6DN;F%P5PQ6UE /6O /CM\4/^"K/@#X?:G^U)X>T
M?X;V_A[1K-]5NOA?=VEQ+J4>F(ID<3708*UTL66=8\("I"^80 _N/P _XKSX
ME_$/XZ2_/!?:VOAGP_(>1_9^E-)%(1_O:A+J'(^\JQGG JK^U[J6O^./ MW^
MS!\,IT/BKX@:9-I\LY7<FBZ3*/*N]2F] D;,D2\&29D4<!V0 YWXB?M_>#O!
MW[#FC_MC:9X6GNI?%&FV(\,^&))PLMUJ5WA8K,OC&%??N<#[D;, > :OQ$^/
M'QN_9-UKX?Z]^T1XNT/7_#?C?Q#!X>U^XTK16LAX>U.Y1FMY(6,KF6S+H\;^
M;\Z_(^\\I7D/_!43X9Z%\)/@_P#LU_#;PI9O!X1\,?&7PYIS1N=P2***2.-I
M#W.Q9,L>I8^M;_\ P78%U/\ L-QZ=I:L=0N_'6DPZ6L?WS<%Y"H7WX- 'KGQ
MWU7]M/QYXRO/ W[*EWX1\+Z?HD40U7Q5XRL9[I[R\D02BVM8(\*(TC:,R3/G
M+2!$&4<USW[!?[67Q?\ C/K7Q"^!'[37A#2]'^(?PLU2WM=>N-$9OL&H6]PD
MCP7,0<DIN6-F()P59&PN2B^[^.O'?AOX9^#[SQMXSU#[/8V$0:9HXV=Y')"I
M%&B@M)([E42-06=V55!) KPKX?? CQMX4^#OQF^-OBC23:?$3XL65[J=[I\3
MAWTR**Q>#3=/WJ</)#%MWLO!EDDVDJ%- &?\,OVB_P!HC]JGX:^+OVB_V?-7
MT/3O#>DZE?6O@'0]1T9KEO$Z6>5>>XF$JM"D\BO'&L:@QX#,9,[![!^R[^T+
MX1_:I^ OAOX]>"8GALO$%CYKV<KAGM)T9HYH&(QDI*CKG W  @8(KQG_ ((P
M/IZ?\$T?AN]HZ!535C.<XP_]K7F[/^>F*YC_ ((2QW__  PJ+V9&6SNO&^K2
MZ4"./L^]%^7V\Q9/QS0!]ET444 %%%% !1110 4444 %%%% !6/X\N?'5IX5
MO)_AMI.EWNLB%OL4&LWLEO;E\'!=HXY&QG'  SZCK6Q0W0_2@#PO_@F_^T=X
M^_:R_9%\/?'CXF6^GPZQK5[J0G@TJW:*")(KZ>*-$5F9L!$49+$G&2:YWXN:
MQ_P4I^(M_K/BK]F*X^'_ (:T'2+NXM]!TGQ;8SSW_B%H'9'E=P1';12.C"$#
MYF0J[,H<!</_ ((A?\HVO W_ %^ZO_Z<[FOH#XW_ !4E^%O@_P _0-'_ +8\
M3:K(;+PEX?C?#ZE?LI*(3_!$H!DED/$<2.YZ<@'$_L$?M6WG[8O[/%G\5=>\
M(_V#KEKJ5SI/B324+&.WO[=@)/++?-L(96 .2NXJ2VW<8]>^-'Q>G\4_$.]^
M%^AQZ\FCWVF^%O"&A3[8K:?6FC-Q>7D\ZH7%O%'<P*^"<?8IPH+L!4_P0^&G
MA?\ 8-_9'GM?$6K_ &]O#NF7^O\ B[5HX]K:A?/ON;J55_VGRJ+UVA%Y-=3^
MS/X#UOX=_!/1-'\7(HU^]CEU7Q.5Z'5+V5[N[P>ZB>:15]%51VQ0!\T>/?VD
M_P#@H!^QC\4/!6L?M5W/@+QC\//&_B:WT&]O?!^F7%I<Z#>7!/E$"1B9(L!C
M\VXL(R,HQ7=[-^T1^T?XG\-_'#P)^RA\'FL$\8^.5N;V[U34K=IX-"TFV1FE
MNFB5E,LKLIBB4L%WY+<+M:A\8_!EO^UO\<O"W@*&)9O!7PN\4Q>(/%-^!E+[
M6X$86>FQGHXB,IGN.H7$,?WF<)Y;J$%U#_P7:L9]<SY<OP$;^QB_0XOG#!??
M/G$_7WH ]=^&G[0?C#PS^U3J/[''QJU.SU#59O"\?B3P9XDM++[+_:ECYC0S
MV\T09E6XBD4G*$*\9#;4*G=P/Q<\8_\ !4;Q#X?U/XY? .U^'FE>'[**6\\/
M^!->T^YGU36+*/+*\\H95AFF0;U@7;L#JCN&#$87[1 O+K_@M'^S]#I():U\
M#:]-J>WM;M;7B)N]O,P![XKZ'_:1^(?B+PSX,;P)\,;>.\\=>*X9K'PG8NWR
MQ2%0LE]/C[EM;!Q)(W?Y(UR\L:L 4_V.OVE+3]KG]F/PS^T'HWA_^SI==LI?
M/TR68E8+J&:2"5 ^W)3S(FVMC.T@D9XKA_V9_P!I;XY?$O\ ;(^,O[/OQ:T7
MP[86?P^M=%?2(= >:;>+V&2X+232A3(VPQCB- "IP#U/J7[-WP)\*?LR_ OP
MS\"/!;M)I_AO3%MEN)%"M<RDEYIV X#22N\A X!<@5X'^R]_RE;_ &H?^P5X
M-_\ 370!]9T444 %%%% !1110 4444 %%%% !1110!\Y_'#]I?X\?#7]N3X.
M? "#0?#4'@[XB7&L":^2::?4)?L-D92I#*D< +21' \PG:?F7H?4_CYXO^+'
MAKPI:Z1\"_"NGZIXLUR_%EI3:U)(FGV'[MY)+N[,8W^4B1GY4^9W>- 1NW#P
M7]LW_E)/^R1_U^>,_P#TV6U?6= 'QUI/[2O[;W[,7[4?@7X+_MA/X.\6>%?B
M?>OIWA_Q3X0TZ6TET[40!MAEB<D%"64>N&W!_D9*^A_VF/'?B7P%\(KZ7P'>
M)!XFUFZMM$\+S/"L@BU&]F2VAF*,"KK$9/.8$$;(6SQFN!U'P9;_ +4_[4OA
MKXFM&)/!'PBN+TZ1==4UKQ#*OD2/'_>@LT5UWCAKAV49\EL]-XO_ .+C?M7^
M&/!J_/I_P_T2;Q-J2]0-0O!+8Z>#VXA&J.0>A$1]#0!R7QBO?V_OB)XCU/2?
MV6]:\$^%M#T!OLD6M>-K":YNO$%XB R-&D2A+>W5R8BY4LSQN54(%W0?L/?M
MI^(OCI\'_&>K_M#^%K/PGXK^%VN7ND^/HK5V-G&]LF][B,DL0FT/D;FY0D$A
MA7L_Q5^)FA_";P;/XMUFWGNI-ZP:9I5DF^YU.\D.(;2!/XI9&P!V'+,0JLP^
M9_B+^SQXL^"O_!-GXY7.L-#-XY\=:)XA\4>-9-/8M$MY=0.\MM">K10P*(5_
MO;"V!OQ0!=\._M/_ +3GQ'_98U;]N[P5%HUMH%K;WNKZ#\.KS2F:?4-$M)'#
MM/=B3='=RQ1221[%,:9C4K)DM7HWB3X^_$?XP?![P;XF_8XTK2;S4?'^FC4-
M/UGQ2)!I^BV(C1I9KA8?FDF5I(XE@4@F1F)(6-ZXO]F*YT:U_P""1WAV[#)]
MDB^"LC7!_AR+!S+G_@0;-)_P1NM]5L?^":_PS37-RR&UU*2/S.HA;4[MHSSV
MV%2/;% &'\)/VFOVPO@U^V+X>_9#_;,@\+:_;>/M,N[OP1XT\)6<EL&FMHFE
MFMYXG.!A%Z@<%TY8,=G<?&K4?V^_B5XJU;3_ -E?4O _A'0="E-M!JOC*PN+
MJXUV[5 9/*1!M@MD<^5O(9V>-R!M"EIO!?@J#]H[]JFP_:PNX0WA;P)HUYH_
MPVE8?\A.YNB%O]50_P#/ HB6\)Z2 2RC*-$S>L?%7XF:'\)O!L_BW6;>>ZDW
MK!IFE62;[G4[R0XAM($_BED; '8<LQ"JS  \E_X)]_M9^._VH? 'B32_C)X&
MMO#WCOP#XIN/#WB^PL&)M7N8L?O8<LQ"GYAMW-RA()#"O?:\E_8]^ &J? KX
M?ZMJ/C5[:7QCXY\37GBCQK+9MNA34+M]QMXF/)BA0)$I_BV%L#<17K5 !111
M0 4444 %%%% !1110 4444 8_CRY\=6GA6\G^&VDZ7>ZR(6^Q0:S>R6]N7P<
M%VCCD;&<< #/J.M>1_\ !-_]H[Q]^UE^R+X>^/'Q,M]/AUC6KW4A/!I5NT4$
M217T\4:(K,S8"(HR6).,DU[HW0_2ODW_ ((A?\HVO W_ %^ZO_Z<[F@#<^+F
ML?\ !2GXBW^L^*OV8KCX?^&M!TB[N+?0=)\6V,\]_P"(6@=D>5W!$=M%(Z,(
M0/F9"KLRAP%Z[]@C]JV\_;%_9XL_BKKWA'^P=<M=2N=)\2:2A8QV]_;L!)Y9
M;YMA#*P!R5W%26V[CVWQO^*DOPM\'^?H&C_VQXFU60V7A+P_&^'U*_9240G^
M")0#)+(>(XD=STYXSX(?#3PO^P;^R//:^(M7^WMX=TR_U_Q=JT<>UM0OGWW-
MU*J_[3Y5%Z[0B\F@"#7OC1\7I_%/Q#O?A?H<>O)H]]IOA;PAH4^V*VGUIHS<
M7EY/.J%Q;Q1W,"O@G'V*<*"[ 5XQX]_:3_X* ?L8_%#P5K'[5=SX"\8_#SQO
MXFM]!O;WP?IEQ:7.@WEP3Y1 D8F2+ 8_-N+",C*,5W?2_P"S/X#UOX=_!/1-
M'\7(HU^]CEU7Q.5Z'5+V5[N[P>ZB>:15]%51VQ7G_P 8_!EO^UO\<O"W@*&)
M9O!7PN\4Q>(/%-^!E+[6X$86>FQGHXB,IGN.H7$,?WF<( 7_ -HC]H_Q/X;^
M.'@3]E#X/-8)XQ\<K<WMWJFI6[3P:%I-LC-+=-$K*99793%$I8+OR6X7:T?P
MT_:#\8>&?VJ=1_8X^-6IV>H:K-X7C\2>#/$EI9?9?[4L?,:&>WFB#,JW$4BD
MY0A7C(;:A4[O(M0@NH?^"[5C/KF?+E^ C?V,7Z'%\X8+[Y\XGZ^]._:(%Y=?
M\%H_V?H=)!+6O@;7IM3V]K=K:\1-WMYF /?% &[\7/&/_!4;Q#X?U/XY? .U
M^'FE>'[**6\\/^!->T^YGU36+*/+*\\H95AFF0;U@7;L#JCN&#$>B?L\_M4^
M(_VH/V.="_:.^%7P]C?7?$%HT5OH5[>E+>WODN6M93)+C/V>.1'D+*I<QK\J
MER%KIOVD?B'XB\,^#&\"?#&WCO/'7BN&:Q\)V+M\L4A4+)?3X^Y;6P<22-W^
M2-<O+&K7OV;O@3X4_9E^!?AGX$>"W:33_#>F+;+<2*%:YE)+S3L!P&DE=Y"!
MP"Y H ^?S\<_VYOV>/VL?AU\*OVA-7\&>-?"GQ2O+JQL[OPKH4UA<Z->0Q>:
M1L>63S(0IY9B3M5F)4KA_K>OBC]K?Q'^U7^R_P#M:_#S]J#QAX@\,^-?A[?:
M[%X3.C6_AQK2Z\-C4)%5KF!FEE+R.(U#2[ANVB/8H?-?:] !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %)(9!&QB4,V#M#-@$^YP<?E2T4 ?/?P+_9I^-_PU_;!^)O[2_B?5?"MQ8?
M$Z/2X[O2+"YN?.TQ;"V^SQ%)'B G++]X$1\G((Q@Q?M8_ ?]M+XQ?$G1-8^#
M7QC\$:#X9\/NEW::+KVA3WIN[]>5N9P&"/Y3<Q)@JK 2'+JA3Z)HH ^>OA=\
M*/\ @H7IOB.^\2?&G]I+PCKL5GH%XOAS0]#T!]/MY-5=-L$UY( [O"@+_( 1
ME@^TE%KU7X=?#C4?A#\#-*^&/@BZMKC4=#\/):6=WJ>_RKF\6+!GGV?,?,ES
M(Y')W-W-=A10!\>^$_V8_P#@J9X-U;6?$&E?M6_#&34?$%^;K5=0N_!,\LTI
M&1'$&9_EBB4[(XQA5&3C<S,WJ'BC]D37OCC^R/<?L_\ [3/Q/FU_Q+J+M>7?
MB_3[80FSU%9S-;SVL0P(DAQ&@08W*K;CEV)]RHH \&\0?LU?%KX]^*? =W^T
M_KOAJ?1OA[K$6MV^F>'$G8:]K$,;)!>7 F51;1Q[W<6R^;EF&92J[3UG[7WP
ME\>_'O\ 9\\3_!+P%>Z193>*M)FTZYU+5Y9=MI%(NUG6.-"9&QD %E X//2O
M3:* .&_9L\!^-OA5\#/"_P *O'LVE7%YX7T&STA+W2)9&BNXK>WCB68K(BF-
MFV$E,L!_>YP///@'^SQ\;OV3O %W\"?@S?\ A75?"$&HWEQX0NO$%U<P7>A1
M7,SSM;R111.M\J2R2,K>;;LRD*<?>KWRB@#A/V:/@'X8_9B^".A?!+PE>RW5
MKHT,IEO9XU1[JXFF>>>8JO";I9'8*.%!"C(%=W110 4444 %%%% !1110 44
M44 %%%% 'B/_  4!_9Q^(W[7/[-^L_LZ^!M:T728?$+VIU#5]6>9V@6WNX;E
M5CBC3#%FA +%Q@9X.>.^FL?C4GP;ETG1IO#5EXTCTSR+&ZE:>XTY)P HF9=J
M2%>K>7ZX7=_%7844 ?'7@/\ 9?\ ^"I_PYTFZTWP]^UI\-&FU"]DO-4U.[\$
M2RW5[=28#32R,WS-@*JC&U$1$551%4>X?#OX(?$32O&WA#Q9\4O'\?B.;PKX
M*FLVOY 5EO=9O)HWO;PQ[0D486%$A53\B3RIA5 SZK10!X)^V=\#_P!K'XZS
MZ+X?^"'Q3\(>'_#=E*MUK.G^(='FO#JTZL2D4RJ0K6ZX1_+/#L,/E1M-;X1?
M"+_@H/#\3M(UK]H3]I_PKJGA;3I))[S1/"GAEK*:_E\MEB225B2(E=@Y52-Q
M0*<J2*^A** /$3^SE\0?A-\>O%_QS_9SN_#Y7XA6ML?%?ASQ)+/#;IJ%NK)%
MJ$$D".<LCE982JB0J&\Q#G/1?LL_LVZ/^S5X&U+1QKC:SK_B7Q#=^(/&'B&2
MV$+:GJ=T^^641@MY<8X5(]QVJHR222?3** /GG0?V:?CGIO[>NI?MA7>I^%&
MTS5/!<7A>3P_'=7/GPVRW*3_ &@3&':\F5/[O8JD-C<,;J]D^(,WQ9%HEI\*
MM-\.M/,C+)?^(+Z=4M&XVN((8B;@=25\V'H!NYR.BHH \S_9Z_9E\-? FYU[
MQE?:]<^)/&OC"\6[\8>,=2B5+C4)%&V.)$7Y8+>)?EC@4D(O4L<L?3*** "B
MBB@ HHHH **** "BBB@ HHHH 20R"-C$H9L':&; )]S@X_*OGSX%_LT_&_X:
M_M@_$W]I?Q/JOA6XL/B='I<=WI%A<W/G:8MA;?9XBDCQ 3EE^\"(^3D$8P?H
M2B@#YV_:Q^ _[:7QB^).B:Q\&OC'X(T'PSX?=+NTT77M"GO3=WZ\K<S@,$?R
MFYB3!56 D.75"DGPN^%'_!0O3?$=]XD^-/[27A'78K/0+Q?#FAZ'H#Z?;R:J
MZ;8)KR0!W>% 7^0 C+!]I*+7T+10!Q_PZ^'&H_"'X&:5\,?!%U;7&HZ'X>2T
ML[O4]_E7-XL6#//L^8^9+F1R.3N;N:^;?"?[,?\ P5,\&ZMK/B#2OVK?AC)J
M/B"_-UJNH7?@F>6:4C(CB#,_RQ1*=D<8PJC)QN9F;["HH \-\4?LB:]\<?V1
M[C]G_P#:9^)\VO\ B747:\N_%^GVPA-GJ*SF:WGM8A@1)#B- @QN56W'+L3!
MX@_9J^+7Q[\4^ [O]I_7?#4^C?#W6(M;M],\.).PU[6(8V2"\N!,JBVCCWNX
MME\W+,,RE5VGWFB@#YI_:-^ '[=WQ,^.-E\0OA3\<? .BZ!H"'_A&]#UKP[/
M>F&X9=KWLGS!6N,%T1L8C1F"X+NS==^SC\,?VR?#WC:_\5?M3?M Z%XFM%TS
M[+HNC>&-#-C;Q2/(&EGF!YD<"-%3)(4-)@#=S[110!\Y>&/V2?C#\$_!GC+X
M&_L[^,_#VF^"_%VIWEYI5SJD4YO?"/VP?Z3%:PQCR[M Q:2$.\/ELY#>:!S[
M!\"/@MX'_9U^$'A_X)_#BS>'1O#NGK:VGFL#)*<EGE<@ %W=G=B  6<X Z5U
MM% !1110 4444 %%%% !1110 4444 %9WBM_%::!<'P1:Z?-J93%JNJ7#Q0!
MC_$QC1V('7:!SC&1UK1HH \*_P"">O[,_P 2/V/?V>-._9[\<Z[HFL0:-<74
MMAJ^E-,CRB>XDF9)(I$PNTR$!@YR,<#&3P/B+]G'_@I=>?&C6OC#X;_:0^&=
MG+?H;32+2\\)W%U_9-@&#"VA9V^7<P5Y7 #2NJ[OE2-4^LZ* /G_ ,-?L\?M
M1>)O '_",_M'_&_2/%-YJ?C;3KW6CINGM96<.BV;K<+900!3NDEN(PLK.1OB
ME92QV*I]"_:5\+_'KQM\)[_PE^SEX\TCPOXBU B$:_JUK)-]B@(.]X43_EMT
M"LW"Y)P2!7?44 ?(?A7]F3_@J#X4\)V?PY\/_M9?#C1-%MXA &T;P,_VF&(M
MF21'E+AICEF,C[BSL68DDFO7?CG^S)=^-?B!X$^/'PQUNWT_QQ\/'FBTVXU<
MR26^JZ?/%Y5Q8W3KF3##YTEPYCD&[:V2#Z_10!X[\-?V<O$EM\>]=_:Q^+5]
MI5YXUU'P]'H.@Z=IC2-8Z%ID<C3&!)9%5YY))F+R3%$XPJH #N\DM/V:O^"H
M>F?$+7_B5I7[4'PP34=?F4227'@RXG-I:IGRK.$NY*0)EB%'WF9G8LS%C]>T
M4 >?_LZ>"/CAX&\ 3P_M _%*V\7^*[[4IKJZO[&S^RV<*85(K>"(#]VBHBD\
M$EW=CG->=?!']FGXX?#K]L;XD_M-^)M5\*W&G_$JWTN"[T>QN;GSM,6QMQ!&
MR2/$!.64$L"L?)X(Q@_0M% !1110 4444 %%%% !1110 4444 %%%% 'SW^T
M/^S3\;OBS^U7\+/V@O"NK>%K2P^%D^J/::9J%Q<F;5!?01PR[W2+$&U8_EP)
M.>3Z#K/VM_AU^TI\6OA8/ 7[//Q(T/PA?:@^S7-6U&&>:06V!NAMS$5*%^5,
MG#!<[=K$,OK%% 'RMX+_ &>/^"E.GOHG@[Q#^U/\/].\'V4]K#?Z?X0\$FSN
M1IT;*'MK:0DB M&"BNH!3(*D$"O=?A1\-M9\'^(O&?C3Q5>VUSJGBSQ,UX&M
M69E@L888[:S@!90<B*(2, ,"6>7!8')[2B@#Y;^+O[//_!0WQ?\ M 7/Q?\
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M5(U3L_#7[/'[47B;P!_PC/[1_P ;](\4WFI^-M.O=:.FZ>UE9PZ+9NMPME!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB'_P4 O/A+X*\*_&[XC? 35M.^'7BW5K2RL]<&J))J5DETI:WN;JP5/W43@
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M3M_ 6LV7BOPW<',VDWRV$PDA<$ E#R48@;E/(#!E7MO&_P"T=X:_9O\ @O\
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MWQ.]WJXL+#2A<!FMX)9_+E<W$J*SK&L3 (-S,F5SC_"#]M/PY\7/#/C5-/\
MACXAM_&GPZO#:>+OAX'M3J,$O)1H7>9()HI%5F23>H8*> < @'M-%?)VB?\
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MN:3XG6_M[5XK=IQ!/F"(K,RJVT)YD9"N1(=H!Y_X6?M5Z)\1/VFOB7\#]*^
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M98E4%O<\U%HWPL^&'AS54UWP]\.-!L+V+=Y=Y9:/!%*FX$-AU4$9!(//()H
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MH6B31[AG#;7!&1D\^],T#P?X1\)Z?+I/A;PMIVFVLSEYK;3[&.&.1B "S*@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556763280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San&#160;Diego,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,507,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days following the end of the registrant&#8217;s fiscal year ended December&#160;31, 2023 are incorporated by reference into Part III of this Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556752928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556826144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 251.1<span></span>
</td>
<td class="nump">$ 262.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities available-for-sale</a></td>
<td class="nump">780.5<span></span>
</td>
<td class="nump">726.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">439.3<span></span>
</td>
<td class="nump">350.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">38.3<span></span>
</td>
<td class="nump">35.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">97.8<span></span>
</td>
<td class="nump">79.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,607.0<span></span>
</td>
<td class="nump">1,453.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">362.6<span></span>
</td>
<td class="nump">305.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Debt securities available-for-sale</a></td>
<td class="nump">687.5<span></span>
</td>
<td class="nump">299.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">276.5<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">161.9<span></span>
</td>
<td class="nump">102.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">70.8<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">35.5<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">49.6<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,251.4<span></span>
</td>
<td class="nump">2,368.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">448.8<span></span>
</td>
<td class="nump">347.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="nump">170.1<span></span>
</td>
<td class="nump">169.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">35.9<span></span>
</td>
<td class="nump">20.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">654.8<span></span>
</td>
<td class="nump">537.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">258.3<span></span>
</td>
<td class="nump">93.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">106.3<span></span>
</td>
<td class="nump">29.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,019.4<span></span>
</td>
<td class="nump">660.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 220.0 shares authorized; 98.7 and 96.5 shares issued and outstanding, respectively</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,382.0<span></span>
</td>
<td class="nump">2,122.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(157.1)<span></span>
</td>
<td class="num">(406.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,232.0<span></span>
</td>
<td class="nump">1,707.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 3,251.4<span></span>
</td>
<td class="nump">$ 2,368.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556770496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="nump">220,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">98,700,000<span></span>
</td>
<td class="nump">96,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">98,700,000<span></span>
</td>
<td class="nump">96,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556554960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Income and Comprehensive Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,887.1<span></span>
</td>
<td class="nump">$ 1,488.7<span></span>
</td>
<td class="nump">$ 1,133.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">39.7<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">565.0<span></span>
</td>
<td class="nump">463.8<span></span>
</td>
<td class="nump">328.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">143.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">105.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">887.6<span></span>
</td>
<td class="nump">752.7<span></span>
</td>
<td class="nump">583.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,636.2<span></span>
</td>
<td class="nump">1,239.7<span></span>
</td>
<td class="nump">1,031.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">250.9<span></span>
</td>
<td class="nump">249.0<span></span>
</td>
<td class="nump">102.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4.6)<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="num">(25.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain on equity securities</a></td>
<td class="nump">28.4<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(70.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_InvestmentIncomeAndOtherNet', window );">Investment income and other, net</a></td>
<td class="nump">57.4<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">81.2<span></span>
</td>
<td class="num">(35.1)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">332.1<span></span>
</td>
<td class="nump">213.9<span></span>
</td>
<td class="nump">101.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">82.4<span></span>
</td>
<td class="nump">59.4<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">249.7<span></span>
</td>
<td class="nump">154.5<span></span>
</td>
<td class="nump">89.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent', window );">Foreign currency translation adjustments, net of tax</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on debt securities available-for-sale, net of tax</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 264.6<span></span>
</td>
<td class="nump">$ 148.3<span></span>
</td>
<td class="nump">$ 86.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in USD per share)</a></td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted (in USD per share)</a></td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">97.7<span></span>
</td>
<td class="nump">95.8<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">101.0<span></span>
</td>
<td class="nump">98.9<span></span>
</td>
<td class="nump">97.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,860.6<span></span>
</td>
<td class="nump">$ 1,440.9<span></span>
</td>
<td class="nump">$ 1,090.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 26.5<span></span>
</td>
<td class="nump">$ 47.8<span></span>
</td>
<td class="nump">$ 43.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_InvestmentIncomeAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment income and other net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_InvestmentIncomeAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205553767616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,126.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1,849.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="num">$ (725.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">89.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">134.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">1,374.0<span></span>
</td>
<td class="num">$ (32.3)<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">2,011.4<span></span>
</td>
<td class="num">$ (106.8)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(635.8)<span></span>
</td>
<td class="nump">$ 74.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">154.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">173.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">44.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">1,707.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">2,122.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
<td class="num">(406.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">249.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">194.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">65.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 2,232.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 2,382.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="num">$ (157.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205651106432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 249.7<span></span>
</td>
<td class="nump">$ 154.5<span></span>
</td>
<td class="nump">$ 89.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">194.3<span></span>
</td>
<td class="nump">173.1<span></span>
</td>
<td class="nump">134.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">(Accretion) amortization of (discount) premium on investments, net</a></td>
<td class="num">(18.3)<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Changes in fair value of equity securities</a></td>
<td class="num">(28.4)<span></span>
</td>
<td class="num">(30.8)<span></span>
</td>
<td class="num">(20.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(56.7)<span></span>
</td>
<td class="nump">19.1<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(89.3)<span></span>
</td>
<td class="num">(162.2)<span></span>
</td>
<td class="num">(28.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">64.3<span></span>
</td>
<td class="nump">114.6<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other assets and liabilities, net</a></td>
<td class="nump">47.8<span></span>
</td>
<td class="num">(17.2)<span></span>
</td>
<td class="num">(9.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="nump">389.9<span></span>
</td>
<td class="nump">339.4<span></span>
</td>
<td class="nump">256.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of debt securities available-for-sale</a></td>
<td class="num">(1,379.9)<span></span>
</td>
<td class="num">(621.2)<span></span>
</td>
<td class="num">(800.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of debt securities available-for-sale</a></td>
<td class="nump">972.4<span></span>
</td>
<td class="nump">511.0<span></span>
</td>
<td class="nump">697.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of business, net of cash acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(42.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Purchases of equity securities</a></td>
<td class="num">(31.3)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(28.3)<span></span>
</td>
<td class="num">(16.5)<span></span>
</td>
<td class="num">(23.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash flows from investing activities</a></td>
<td class="num">(467.1)<span></span>
</td>
<td class="num">(177.1)<span></span>
</td>
<td class="num">(130.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuances of common stock under benefit plans</a></td>
<td class="nump">65.3<span></span>
</td>
<td class="nump">44.7<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repurchases of convertible senior notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(279.0)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash flows from financing activities</a></td>
<td class="nump">65.3<span></span>
</td>
<td class="num">(234.3)<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents and restricted cash</a></td>
<td class="num">(11.6)<span></span>
</td>
<td class="num">(73.3)<span></span>
</td>
<td class="nump">153.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">270.7<span></span>
</td>
<td class="nump">344.0<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">259.1<span></span>
</td>
<td class="nump">270.7<span></span>
</td>
<td class="nump">344.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Non-cash capital expenditures</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">200.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 51.5<span></span>
</td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205558016256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc. and its subsidiaries (Neurocrine Biosciences, the Company, we, our or us) is a neuroscience-focused biopharmaceutical company focused on discovering, developing and delivering innovative therapies to help ease the burden of debilitating disorders and diseases.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single business segment, which includes all activities related to the research, development and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine and neuropsychiatric disorders and reflects the way in which internally-reported financial information is regularly reviewed by our chief operating decision maker to analyze performance, make decisions and allocate resources.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Neurocrine Biosciences as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments that are readily convertible into cash without penalty and have an original maturity of three months or less at the time of purchase to be cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks, and any allowance for credit losses. Our estimate for the allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, actual payment patterns of our customers, and individual customer circumstances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We perform an assessment of the recoverability of our inventory on a quarterly basis and write down any excess and obsolete inventory to its net realizable value in the period in which the impairment is first identified. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale were $11.2 million and $4.7 million, respectively, as of December&#160;31, 2023 and 2022. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2023, 2022 or 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity security investments at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deem transfers between levels of the fair value hierarchy to have occurred at the end of the reporting period during which the event or change in circumstances that caused the transfer occurred.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We account for certain equity investments subject to the equity method of accounting, or through which we have the ability to exercise significant influence (but not control) over the operating and financial policies of an investee, under the fair value option. In assessing whether we exercise significant influence, we consider the nature and magnitude of such an investment, the voting and protective rights we hold, any participation in the governance of the investee and other relevant factors, such as the presence of a collaborative or other business relationship. Such investments in publicly traded companies are currently classified within Level 1 of the fair value hierarchy and carried at fair value, with any changes in the fair value of such investments recognized in earnings.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $17.8 million for 2023, $15.1 million for 2022 and $10.9 million for 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. In addition, costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as selling, general and administrative when incurred.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (IPR&amp;D) and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually, as of October 1, and more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceed the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with a finite life are typically comprised of acquired product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We determine if an arrangement is a lease at contract inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that such options will be exercised. </span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As none of our operating leases provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease payments used to determine our ROU assets may include prepaid or accrued lease payments and any lease incentives received and are recognized in ROU assets in our consolidated balance sheets.</span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in lease agreements are expensed as incurred.</span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases are reflected in ROU assets, noncurrent operating lease liabilities, and other current liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in retained earnings during the period, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income (loss) in the accompanying consolidated statements of stockholders&#8217; equity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for such goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the U.S., we sell INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) primarily to specialty pharmacy providers and distributors. We recognize net product sales when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors, and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#8217;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant categories of sales discounts and allowances are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Discounts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates for discounts including under the Medicaid Drug Rebate Program and Medicare Part D. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations, and relevant contractual terms, as supplemented by management&#8217;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor and Pharmacy Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel, and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Financial Assistance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To help patients afford our products, we offer financial assistance to qualified patients with prescription drug copay requirements. We accrue for patient financial assistance based on estimated claims and the cost per claim we expect to receive in connection with inventory that remains in the distribution channel at period end. To date, actual patient financial assistance has not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor and Other Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the sales of our products, we pay distributor and other fees, which are generally recorded as a reduction of revenue, to certain customers that provide us with inventory management, data, and/or distribution services. Costs associated with such services are expensed as selling, general and administrative to the extent we can demonstrate a separable benefit and fair value for such services. To date, actual distributor and other fees have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring product, provided it is within a specified period of the product expiration date, as set forth in the associated distribution agreement. Where actual returns history is not available, we estimate a returns allowance based on benchmarking data for similar products and industry experience. Such estimates are recorded as a reduction of revenue in the period the related sale is recognized. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration and license agreements under which we out-license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of the out-licensed products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use, and benefit from, the license. For licenses that are bundled with other promises, we assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development, regulatory, and/or commercial milestones, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Amounts for milestones that are not within our control, such as when achievement of a specified event is dependent on the development activities of a third party or approvals from regulators, are not considered probable of being achieved until such specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, and under which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, accounts receivable and debt securities available-for-sale. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio with low-risk investment-grade debt securities with maturities of up to three years and by placing our investments with high-credit-quality financial institutions to maintain liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in connection with these financial instruments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 91% of our total product sales for 2023 and approximately 98% of our accounts receivable balance as of December&#160;31, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues includes third-party manufacturing, transportation, freight, and indirect overhead costs primarily for the manufacture and distribution of INGREZZA drug product sold, manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with Mitsubishi Tanabe Pharma Corporation, royalty fees on net sales of elagolix, amortization of intangible assets, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development, or R&amp;D. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses primarily consist of preclinical and clinical trial costs, payroll and benefits costs, including stock-based compensation associated with employees involved in R&amp;D activities, certain facility-based costs, and costs associated with our collaborative arrangements, including event-based milestones. All such costs are expensed as R&amp;D when incurred.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions of assets (or groups of assets) that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets (or group of assets) acquired on the basis of their relative fair value(s) on the measurement date. No goodwill is recognized in an asset acquisition. Intangible assets acquired in an asset acquisition for use in R&amp;D activities which have no alternative future use are expensed as IPR&amp;D on the acquisition date. Future costs to develop these assets are expensed as R&amp;D when incurred.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $159.9 million for 2023, $149.7 million for 2022 and $139.8 million for 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units (RSUs) and performance-based restricted stock units (PRSUs). Additionally, we allow employees to participate in an employee stock purchase plan (ESPP).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. RSUs are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest is recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally <span style="-sec-ix-hidden:f-374">three</span> to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP is recognized and amortized on a straight-line basis over the purchase period, which is generally six months. PRSUs vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax provision is computed under the asset and liability method. Significant estimates are required in determining our income tax provision. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share are computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed using the treasury stock and if-converted methods and reflect the weighted average number of common and potentially dilutive shares outstanding during the period, excluding those which effect would be anti-dilutive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024 in cash upon conversion and to settle any conversion premium in either cash or shares of our common stock. As a result, only the shares required to settle any conversion premium are considered dilutive under the if-converted method. Further, PRSUs for which the performance condition has not been achieved are excluded from the calculation of diluted earnings per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205559837360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">Collaboration and License Agreements<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heptares Therapeutics Limited, or Heptares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We entered into a collaboration and license agreement with Heptares, which became effective in December 2021, to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, for which we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Heptares retains the rights to develop, manufacture, and commercialize all compounds comprised of M1 receptor agonists, subject to certain exceptions. With respect to such rights retained by Heptares, we retain the rights to opt in to profit sharing arrangements, pursuant to which we and Heptares will equally share in the operating profits and losses for such compounds in Japan. Subject to specified conditions, we may elect to exercise such opt-in rights with respect to each such compound either before initiation of the first proof of concept Phase 2 clinical trial for such compound or following our receipt from Heptares of the top-line data from such clinical trial for such compound. We are responsible for all development, manufacturing, and commercialization costs of any collaboration product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Heptares $100.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;D in 2021 as the license had no foreseeable alternative future use. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA's acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in June 2022, we paid Heptares a milestone of $30.0 million, which was expensed as R&amp;D in 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Heptares may be entitled to receive potential future payments of up to $2.6 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which the royalty term for such licensed product has expired in such country. On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a licensed product and terminate on the later of (i) the expiration of the last patent covering such licensed product in such country, (ii) a number of years from the first commercial sale of such licensed product in such country and (iii) the expiration of regulatory exclusivity for such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or with respect to one or more targets upon 180 days&#8217; written notice to Heptares during the research collaboration term and upon 90 days&#8217; written notice to Heptares following the expiration of the research collaboration term. Following the expiration of the research collaboration term, Heptares may terminate the agreement on a target-by-target basis in the event that we do not conduct any material development activities outside of Japan with respect to a certain compound or licensed product within the applicable target class for a continuous period of not less than 365 days and do not commence any such activities within 120 days of receiving written notice. Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited, or Takeda.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into an exclusive license agreement with Takeda, pursuant to which we acquired the exclusive rights to develop and commercialize certain early-to-mid stage psychiatry compounds, including luvadaxistat, NBI-1065845, NBI-1065846 and four non-clinical stage compounds. Luvadaxistat and the four non-clinical stage compounds have each been designated as a royalty-bearing product. NBI-1065845 and NBI-1065846 are currently each designated as a profit-share product. We are responsible for all manufacturing, development, and commercialization costs of any royalty-bearing product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to NBI-1065845 and NBI-1065846, we and Takeda will equally share in the operating profits and losses. Takeda retains the rights to opt-out of the profit-sharing arrangements, pursuant to which Takeda would be entitled to receive potential future payments upon the achievement of certain event-based milestones with respect to such compounds and receive royalties on the future net sales of such compounds (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out right for such compound immediately following the completion of a second Phase 2 clinical trial for such compound, or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase 3 clinical trial for such compound.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in 2022, we paid Takeda a milestone of $5.0 million, which was expensed as R&amp;D in 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $1.9 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any royalty-bearing product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any royalty-bearing product, the royalty term has expired in such country; and (ii) for any profit-share product, for so long as we continue to develop, manufacture, or commercialize such licensed product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a royalty-bearing product and terminate on the later of (i) the expiration of the last patent covering such royalty-bearing product in such country, (ii) a number of years from the first commercial sale of such royalty-bearing product in such country and (iii) the expiration of regulatory exclusivity for such royalty-bearing product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or in one or more (but not all) of the U.S., Japan, the European Union (EU) and the United Kingdom (UK) (collectively, the major markets) upon six months&#8217; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. We may terminate the agreement in its entirety or in one or more (but not all) of the major markets upon 12 months&#8217; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. Takeda may terminate the agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd., or Idorsia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into a collaboration and license agreement with Idorsia, pursuant to which we acquired the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker in clinical development for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. We are responsible for all manufacturing, development, and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement, in its entirety or with respect to a particular compound or development candidate, upon 90 days&#8217; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals Inc., or Xenon. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Xenon to identify, research and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates, which compounds we have the exclusive rights to develop and commercialize. We are responsible for all development and manufacturing costs of any collaboration product, subject to certain exceptions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we purchased approximately 1.4 million shares (at $14.196 per share) of Xenon common stock in 2019. The purchased shares were recorded at a fair value of $14.1 million after considering Xenon&#8217;s stock price and certain transfer restrictions that were applicable to the shares on the measurement date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approval of our clinical trial application in Europe for NBI-921352 for the treatment of focal onset seizures in adults in 2021, we paid Xenon a regulatory milestone of $10.0 million, including a purchase of approximately 0.3 million shares (at $19.9755 per share) of Xenon common stock. The purchased shares were recorded at a fair value of $4.6 million after considering Xenon&#8217;s stock price and certain transfer restrictions that were applicable to the shares on the measurement date. The remaining $5.4 million of the milestone payment was expensed as R&amp;D in 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA's acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol in 2022, we paid Xenon a regulatory milestone of $15.0 million, including a purchase of approximately 0.3 million shares (at $31.855 per share) of Xenon common stock. The purchased shares were recorded at a fair value of $7.7 million after considering Xenon&#8217;s stock price on the measurement date. The remaining $7.3 million of the milestone payment was expensed as R&amp;D in 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product. Xenon retains the right to elect to co-develop one product in a major indication, pursuant to which Xenon would receive a mid-single digit percentage increase in royalties earned on the future net sales of such product in the U.S. and we and Xenon would equally share in the development costs of such product in the applicable indication, except where such development costs relate solely to the regulatory approval of such product outside the U.S.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular licensed product and country, the license obtained by us with respect to such product and country will become fully paid, royalty free, perpetual and irrevocable. We may terminate the agreement upon 90 days&#8217; written notice to Xenon, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc., or Voyager.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Voyager Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2019, we entered into a collaboration and license agreement with Voyager (the 2019 Voyager Agreement), pursuant to which we retain certain rights to develop and commercialize the Friedreich&#8217;s ataxia program and two undisclosed programs. We are responsible for all development and commercialization costs of any collaboration product under the 2019 Voyager Agreement, subject to certain co-development and co-commercialization rights retained by Voyager.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2019 Voyager Agreement, we purchased approximately 4.2 million shares (at $11.9625 per share) of Voyager common stock (the 2019 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement (defined below). The 2019 Purchased Shares were recorded at a fair value of $54.7 million after considering Voyager&#8217;s stock price and certain transfer restrictions that were applicable to the shares on the measurement date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2019 Voyager Agreement, Voyager may be entitled to receive potential future payments of up to $1.3 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the 2019 Voyager Agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product under the agreement or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the 2019 Voyager Agreement. We may terminate the 2019 Voyager Agreement upon 180 days&#8217; written notice to Voyager prior to the first commercial sale of any collaboration product under the 2019 Voyager Agreement or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product under the 2019 Voyager Agreement.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Voyager Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2023, we entered into a collaboration and license agreement with Voyager (the 2023 Voyager Agreement), pursuant to which we acquired the global rights to the gene therapy products directed to the gene that encodes glucosylceramidase beta 1 (GBA1) for the treatment of Parkinson's disease and other diseases associated with GBA1 (the GBA1 Program), and three gene therapy programs directed to rare central nervous system (CNS) targets, each enabled by Voyager's next-generation TRACER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsids. With respect to collaboration products subject to the GBA1 Program, we are responsible for all development and commercialization costs of any such products, including in the U.S., where Voyager retains certain co-development and co-commercialization rights. Voyager may elect to exercise such rights, pursuant to which we and Voyager would equally share in the operating profits and losses of such products in the U.S. (in lieu of Voyager being entitled to receive potential future payments of certain event-based milestones upon their achievement in the U.S. and receive royalties on the future net sales of such products in the U.S.), following Voyager&#8217;s receipt of the top-line data from a first Phase 1 clinical trial for each such product. Irrespective of Voyager&#8217;s election to exercise such rights, Voyager may be entitled to receive potential future payments upon the achievement of certain event-based milestones outside the U.S. and would be entitled to receive royalties on the future net sales of any such product outside the U.S. With respect to collaboration products subject to the three gene therapy programs directed to rare CNS targets, we are responsible for all development and commercialization costs for any such products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2023 Voyager Agreement, we paid Voyager $175.0 million upfront, including a purchase of approximately 4.4 million shares (at $8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement. In addition, as part of the collaboration, Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine, was appointed to Voyager's board of directors with an initial term expiring in 2024. Mr. Onyia (or another individual designated by us) will be nominated for election to Voyager's board of directors annually for a maximum duration of 10 years from the effective date of the 2023 Voyager Agreement. As a result, our strategic investment in Voyager became subject to the equity method of accounting, and Voyager became a related party under ASC 850, following our purchase of the 2023 Purchased Shares, after which, together with the 2019 Purchased Shares, we owned approximately 19.9% of the voting stock of Voyager. We elected the fair value option to account for our strategic investment in Voyager as we believe it creates greater transparency regarding the investment's fair value at future reporting dates. The 2023 Purchased Shares were recorded at a fair value of $31.3 million after considering Voyager&#8217;s stock price on the measurement date. The remaining $143.9 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2023 as the license had no foreseeable alternative future use. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. We recognized unrealized gains of $15.5 million for 2023 and $14.5 million for 2022 and an unrealized loss of $8.7 million for 2021 on our strategic investment in Voyager. As of December&#160;31, 2023, the fair value (Level 1) of our strategic investment in Voyager was $72.4 million.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2023 Voyager Agreement, Voyager may be entitled to receive potential future payments of up to $6.1 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the 2023 Voyager Agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product under the 2023 Voyager Agreement or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the 2023 Voyager Agreement. We may terminate the 2023 Voyager Agreement upon 180 days&#8217; written notice to Voyager prior to the first commercial sale of any collaboration product under the 2023 Voyager Agreement or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product under the 2023 Voyager Agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A., or BIAL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2017, we received from BIAL a license to commercialize and market ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone) in the U.S. and Canada. We launched ONGENTYS in the U.S. as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations in 2020. In 2023, we provided BIAL with written notice of termination of the license agreement to commercialize and market ONGENTYS in the U.S. and Canada, and recognized reserves for ONGENTYS inventory obsolescence totaling $5.2 million in cost of revenues in connection with the termination, which became effective in December 2023, as management determined the cost cannot be recovered.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation, or MTPC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015. In 2020, we entered into a commercial supply agreement with MTPC, pursuant to which we supply MTPC with valbenazine drug product for commercial use in such markets. MTPC is responsible for all development, manufacturing, and commercialization costs of valbenazine in such markets.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MTPC launched DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan for the treatment of tardive dyskinesia in June 2022 and subsequently in other select Asian markets, where it is marketed as REMLEAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine). We receive royalties at tiered percentage rates on MTPC net sales of valbenazine. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $20.0 million in 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC&#8217;s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with MTPC, we may be entitled to receive potential future payments of up to $30.0 million upon the achievement of certain sales-based milestones and are entitled to receive royalties at tiered percentage rates on future MTPC net sales of valbenazine for the longer of 10 years or the life of the related patent rights. MTPC may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc., or AbbVie. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (elagolix tablets) in the U.S. for the treatment of moderate to severe pain associated with endometriosis in August 2018 and ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $16.7&#160;million for 2023, $21.2&#160;million for 2022 and $22.3&#160;million for 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with AbbVie, we may be entitled to receive potential future payments of up to $366.0 million upon the achievement of certain event-based milestones and are entitled to receive royalties at tiered percentage rates on future AbbVie net sales of elagolix for the longer of 10 years or the life of the related patent rights. AbbVie may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205562636112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Debt Securities</a></td>
<td class="text">Debt Securities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">780.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">735.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">726.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">684.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">687.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses on our available-for-sale debt security investments were primarily due to changes in interest rates. These investments are of high credit quality, and we do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recognized as of December&#160;31, 2023 or 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2023, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2022, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205561569568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of financial assets, which were measured at fair value on a recurring basis.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">867.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">867.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,468.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,398.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205561545840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text">Convertible Senior Notes<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% fixed-rate convertible senior notes due May&#160;15, 2024 (the 2024 Notes) and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we repurchased $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. In 2022, we repurchased $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash, which resulted in the recognition of a $70.0 million loss on extinguishment.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the interest expense of the 2024 Notes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $1,000 principal amount and equivalent to an initial conversion price of approximately $75.92 per share, reflecting a conversion premium of approximately 42.5% above the closing price of $53.28 per share of our common stock on April&#160;26, 2017.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130% of the conversion price then in effect (equal to $98.70 as of December&#160;31, 2023) for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price (equal to $98.70 as of December&#160;31, 2023) on each applicable trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the&#160;five business-day period immediately after any&#160;five&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2017 Indenture) per&#160;$1,000&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time. On January 4, 2024, we provided notice to the holders of the 2024 Notes electing to settle all conversions of the 2024 Notes in cash. As such, upon conversion, holders will receive the principal amount of their 2024 Notes and any conversion premium, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in cash.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the 2017 Indenture) occurs prior to January&#160;15, 2024, we would, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2017 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205559305792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of goodwill. Goodwill is included in other assets in our consolidated balance sheets.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill recognized in connection with business combination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information relating to our recognized intangible assets as of December&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed product rights</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate future annual amortization expense for our finite-lived intangible assets as of December&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2026</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556632240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Other Balance Sheet Details</a></td>
<td class="text">Other Balance Sheet Details<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less inventory reserves</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales rebates and reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current income taxes payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent income taxes payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent branded prescription drug fee</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205561545840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share were calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 4.7 million for 2023, 4.6 million for 2022 and 4.1 million for 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205561502528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, our stockholders approved an amendment of the 2020 Equity Incentive Plan (as so amended, the Amended 2020 Plan). The Amended 2020 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other awards. As of December 31, 2023, 10.5&#160;million shares of common stock remain available for future grant under the Amended 2020 Plan.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Amended 2020 Plan, the number of shares of common stock available for issuance will be: (i) reduced by (a) one share for each share issued pursuant to an appreciation award (as defined in the Amended 2020 Plan) granted under the Amended 2020 Plan and (b) 2.13 shares for each share issued pursuant to a full value award (as defined in the Amended 2020 Plan) granted under the Amended 2020 Plan on or after May 18, 2022; and (ii) increased by (a) one share for each share subject to an appreciation award that becomes available again for issuance under the terms of the Amended 2020 Plan and (b) 2.13 shares for each share subject to a full value award that becomes available again for issuance under the terms of the Amended 2020 Plan on or after May 18, 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2011 Equity Incentive Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2011, we adopted the 2011 Equity Incentive Plan (the 2011 Plan). The 2011 Plan was a stockholder-approved plan pursuant to which outstanding awards have been made, but from which no further awards can or will be made.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, our stockholders approved an amendment and restatement of the 2018 Employee Stock Purchase Plan (as so amended and restated, the Amended 2018 ESPP). As of December 31, 2023, 0.5&#160;million shares of common stock remain available for future issuance under the Amended 2018 ESPP.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of stock-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by award-type <span id="iae12b1f8f345443688fcf6efba5f4f06_8127"></span>follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, unrecognized stock-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.729%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, stock options have a 10-year term and vest over a <span style="-sec-ix-hidden:f-775">three</span> to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, term and interest rates. The weighted-average grant-date fair values of stock options granted were $45.19 for 2023, $32.05 for 2022 and $45.02 for 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected option term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 years</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average valuation assumptions were determined as follows:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected volatility of common stock is estimated based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risk-free interest rate for periods within the contractual life of a stock option is based upon observed interest rates appropriate for the expected term of our employee stock options. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have not historically declared or paid dividends and do not intend to do so in the foreseeable future. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summary of activity related to stock options.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised was $39.9 million for 2023, $39.7 million for 2022 and $58.0 million for 2021. Cash received from stock option exercises was $55.5 million for 2023, $37.0 million for 2022 and $20.7 million for 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs typically vest over a four-year period and may be subject to a deferred delivery arrangement at the election of eligible employees. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. The total fair value of RSUs that vested was $101.0 million for 2023, $72.4 million for 2022 and $64.3 million for 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to RSUs.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRSUs vest based on the achievement of certain predefined Company-specific performance criteria. Any unvested PRSUs will expire if it is determined the related performance criteria has not been met during the applicable <span style="-sec-ix-hidden:f-833">three</span> to four-year performance period. The fair value of PRSUs is estimated based on the closing sale price of our common stock on the date of grant. The fair value of PRSUs that vested during 2023 was $34.4 million. No PRSUs vested during 2022 or 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to PRSUs.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PRSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended 2018 ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of 85% of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of common stock on the purchase date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205555997312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents income from continuing operations before provision for income taxes for domestic and international operations.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of income tax expense (benefit) for continuing operations.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal income taxes at 21%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of our deferred tax assets. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">530.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of deferred tax assets and liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, our deferred tax assets were primarily the result of net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. As of December 31, 2023 and 2022, we recorded a valuation allowance of $88.9 million and $67.0 million, respectively, against our gross deferred tax asset balance.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. As of December&#160;31, 2023, management determined there was sufficient positive evidence to conclude that it is more likely than not deferred tax assets of $362.6 million are realizable. The recorded valuation allowance of $88.9 million consisted primarily of state and foreign net operating loss carryforwards and state credit carryforwards for which management cannot conclude it is more likely than not to be realized.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had state and foreign income tax net operating loss carryforwards of $286.0 million and $134.3 million, respectively. We had no federal income tax operating loss carryforwards as of December&#160;31, 2023. California net operating losses will begin to expire in 2029 unless previously utilized and the net operating losses related to other states will begin to expire in 2026. Swiss net operating losses will begin to expire in 2030 unless previously utilized. UK net operating losses will carry forward indefinitely.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had state R&amp;D tax credit carryforwards of $85.6 million. California R&amp;D tax credits carry forward indefinitely, while R&amp;D tax credits related to other states will begin to expire in 2033 unless previously utilized.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the future utilization of our net operating loss and R&amp;D tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. No ownership changes have occurred through December&#160;31, 2023.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to income tax matters in income tax expense. We had accruals for interest related to income tax matters of $3.1 million and $1.2 million, respectively, as of December 31, 2023 and 2022. We had accruals for penalties relates to income tax matters of $2.2 million and $0.4 million, respectively, as of December 31, 2023 and 2022. Accruals for interest and penalties related to income tax matters were not material as of December 31, 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the U.S. and various state and foreign jurisdictions. Tax years for 2020 for federal, inception for California, 2016 to 2020 for other significant state jurisdictions, and 2021 and forward for foreign are subject to examination by tax authorities due to the carryforward of unutilized net operating losses and R&amp;D tax credits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to unrecognized tax benefits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease related to prior year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of the statute of limitations for the assessment of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $105.3 million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate, subject to changes in the valuation allowance. We do not expect a significant change in our unrecognized tax benefits in the next 12 months.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the OECD announced an Inclusive Framework on Base Erosion and Profit Shifting including Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15%. Subsequently, multiple sets of administrative guidance have been issued. Many non-U.S. tax jurisdictions have either recently enacted legislation to adopt certain components of the Pillar Two Model Rules beginning in 2024 (including EU Member States) with the adoption of additional components in later years or announced their plans to enact legislation in future years. We are continuing to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in the non-U.S. tax jurisdictions we operate in.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205561569568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases that have commenced have terms that expire beginning 2025 through 2036 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our ROU assets or operating lease liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental operating lease information for operating leases that have commenced.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash related to letters of credit issued in lieu of cash security deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate future non-cancelable minimum lease payments under operating leases and sublease income as of December&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease<br/>Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments (sublease income)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1022">Less current operating lease liabilities included in other current liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts presented in the table above exclude $15.4 million for 2025, $23.6 million for 2026, $24.3 million for 2027, $25.1 million for 2028 and $223.5 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Campus Facility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, including a six-year option for the construction of a fifth building. This campus facility, comprised of office space and research and development laboratories, will serve as our new corporate headquarters.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The construction of the campus facility is phased. We recognized ROU assets of $199.0 million and operating lease liabilities of $189.8 million in association with the commencement of operating leases following the completion of the first phase of construction relating to office space in December 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we begin to occupy our new campus facility, we will sublease certain of our existing leased premises when we determine there is excess leased capacity. Certain of these subleases contain both lease and non-lease components. Sublease income is recognized as an offset to operating expense on a straight-line basis over the lease term. Income related to non-lease components is recognized in operating expenses as a reduction to costs we incur in relation to the primary lease.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205558020912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text">Retirement Plan<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a 401(k) defined contribution savings plan for the benefit of all qualifying employees and permits voluntary contributions by employees up to 60% of base salary limited by the IRS-imposed maximum. Employer contributions were $12.5 million for 2023, $10.3 million for 2022 and $8.1 million for 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205557288640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Legal Proceedings</a></td>
<td class="text">Legal Proceedings<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, 2022, and 2023, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., (iv) Sandoz Inc. and (v) Zydus Pharmaceuticals (USA) Inc. that each company had filed an abbreviated new drug application (ANDA) with the FDA seeking approval of a generic version of INGREZZA. These companies represented that their respective ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by the manufacture, use or sale of the medicine for which the ANDA was submitted.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed suit in the U.S. District Court for the District of Delaware during 2021, 2022 and 2023, against (i) Teva Pharmaceuticals, Inc., Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (entity dismissed), collectively, "Teva", (ii) Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc. and Lupin Atlantis Holdings S.A., collectively, &#8220;Lupin&#8221;, (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., collectively, &#8220;Crystal&#8221;, (iv) Sandoz Inc., Sandoz International GmbH (entity dismissed) and Sandoz AG (entity dismissed), collectively, &#8220;Sandoz&#8221; and (v) Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC (entity dismissed), collectively, &#8220;Zydus&#8221;. We also filed suit in the U.S. District Court for the District of New Jersey during 2021, 2022 and 2023 against Zydus.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023 we entered into settlement agreements resolving the foregoing litigation with each of (i) Sandoz and Crystal, collectively, the &#8220;Sandoz Parties&#8221;, (ii) Teva, (iii) Lupin and (iv) Zydus. Pursuant to the terms of the respective agreements with the Sandoz Parties, Teva, Lupin, and Zydus, each of Teva, the Sandoz Parties, Lupin, and Zydus has the right to sell generic versions of INGREZZA in the United States beginning March 1, 2038, or earlier under certain circumstances. The settlements with Teva, the Sandoz Parties, Lupin and Zydus resolve all patent litigation brought by us against the companies that filed ANDAs seeking approval to market generic INGREZZA, and all cases have been dismissed.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205553064128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 249.7<span></span>
</td>
<td class="nump">$ 154.5<span></span>
</td>
<td class="nump">$ 89.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205552290240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from October&#160;1, 2023, to December&#160;31, 2023, our executive officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.519%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Action</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Arrangement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shares Authorized <br/>to be Sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration <br/>Date</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rule 10b5-1*</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Rule 10b5-1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">George Morrow</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adopt</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/14/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/15/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Director)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eric Benevich</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Terminate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/30/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,341&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Chief Commercial Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adopt</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/29/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/27/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ingrid Delaet</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adopt</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/29/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/7/2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Chief Regulatory Officer)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leslie Norwalk</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adopt</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/28/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/28/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Director)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shalini Sharp</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adopt</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/27/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/31/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Director)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Richard Pops</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adopt</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/21/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/30/2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Director)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* Intended to satisfy the affirmative defense of Rule 10b5-1(c)</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) On November 30, 2023, Eric Benevich, Chief Commercial Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1 (the &#8220;Benevich 10b5-1 Plan&#8221;). The Benevich 10b5-1 Plan was entered into on February 23, 2022, with an expiration date of December 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=nbix_GeorgeMorrowMember', window );">George Morrow [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">George Morrow<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">(Director)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">12/14/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">337 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=nbix_EricBenevichMember', window );">Eric Benevich [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Eric Benevich<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">(Chief Commercial Officer)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=nbix_IngridDelaetMember', window );">Ingrid Delaet [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Ingrid Delaet<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">(Chief Regulatory Officer)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">11/29/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">648 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=nbix_LeslieNorwalkMember', window );">Leslie Norwalk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Leslie Norwalk<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">(Director)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">11/28/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">366 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">9,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=nbix_ShaliniSharpMember', window );">Shalini Sharp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Shalini Sharp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">(Director)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">11/27/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">186 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=nbix_RichardPopsMember', window );">Richard Pops [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Richard Pops<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">(Director)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">11/21/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">375 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">42,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=nbix_EricBenevich2023PlanMember', window );">Eric Benevich 2023 Plan [Member] | Eric Benevich [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">February 23, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">11/30/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">131,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=nbix_EricBenevich2024PlanMember', window );">Eric Benevich 2024 Plan [Member] | Eric Benevich [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">11/29/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">169,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,818<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nbix_GeorgeMorrowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nbix_GeorgeMorrowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nbix_EricBenevichMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nbix_EricBenevichMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nbix_IngridDelaetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nbix_IngridDelaetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nbix_LeslieNorwalkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nbix_LeslieNorwalkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nbix_ShaliniSharpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nbix_ShaliniSharpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nbix_RichardPopsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nbix_RichardPopsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=nbix_EricBenevich2023PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=nbix_EricBenevich2023PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=nbix_EricBenevich2024PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=nbix_EricBenevich2024PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205552951680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock', window );">Organization and Business</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc. and its subsidiaries (Neurocrine Biosciences, the Company, we, our or us) is a neuroscience-focused biopharmaceutical company focused on discovering, developing and delivering innovative therapies to help ease the burden of debilitating disorders and diseases.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single business segment, which includes all activities related to the research, development and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine and neuropsychiatric disorders and reflects the way in which internally-reported financial information is regularly reviewed by our chief operating decision maker to analyze performance, make decisions and allocate resources.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Neurocrine Biosciences as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments that are readily convertible into cash without penalty and have an original maturity of three months or less at the time of purchase to be cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks, and any allowance for credit losses. Our estimate for the allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, actual payment patterns of our customers, and individual customer circumstances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We perform an assessment of the recoverability of our inventory on a quarterly basis and write down any excess and obsolete inventory to its net realizable value in the period in which the impairment is first identified. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Debt Securities</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Allowance for Credit Losses</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale were $11.2 million and $4.7 million, respectively, as of December&#160;31, 2023 and 2022. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2023, 2022 or 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity security investments at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deem transfers between levels of the fair value hierarchy to have occurred at the end of the reporting period during which the event or change in circumstances that caused the transfer occurred.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We account for certain equity investments subject to the equity method of accounting, or through which we have the ability to exercise significant influence (but not control) over the operating and financial policies of an investee, under the fair value option. In assessing whether we exercise significant influence, we consider the nature and magnitude of such an investment, the voting and protective rights we hold, any participation in the governance of the investee and other relevant factors, such as the presence of a collaborative or other business relationship. Such investments in publicly traded companies are currently classified within Level 1 of the fair value hierarchy and carried at fair value, with any changes in the fair value of such investments recognized in earnings.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $17.8 million for 2023, $15.1 million for 2022 and $10.9 million for 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations and Asset Acquisitions</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. In addition, costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as selling, general and administrative when incurred.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions of assets (or groups of assets) that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets (or group of assets) acquired on the basis of their relative fair value(s) on the measurement date. No goodwill is recognized in an asset acquisition. Intangible assets acquired in an asset acquisition for use in R&amp;D activities which have no alternative future use are expensed as IPR&amp;D on the acquisition date. Future costs to develop these assets are expensed as R&amp;D when incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill, Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (IPR&amp;D) and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually, as of October 1, and more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceed the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with a finite life are typically comprised of acquired product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We determine if an arrangement is a lease at contract inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that such options will be exercised. </span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As none of our operating leases provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease payments used to determine our ROU assets may include prepaid or accrued lease payments and any lease incentives received and are recognized in ROU assets in our consolidated balance sheets.</span></div><div style="margin-bottom:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in lease agreements are expensed as incurred.</span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases are reflected in ROU assets, noncurrent operating lease liabilities, and other current liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in retained earnings during the period, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income (loss) in the accompanying consolidated statements of stockholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for such goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the U.S., we sell INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) primarily to specialty pharmacy providers and distributors. We recognize net product sales when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors, and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#8217;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant categories of sales discounts and allowances are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Discounts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates for discounts including under the Medicaid Drug Rebate Program and Medicare Part D. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations, and relevant contractual terms, as supplemented by management&#8217;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor and Pharmacy Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel, and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Financial Assistance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To help patients afford our products, we offer financial assistance to qualified patients with prescription drug copay requirements. We accrue for patient financial assistance based on estimated claims and the cost per claim we expect to receive in connection with inventory that remains in the distribution channel at period end. To date, actual patient financial assistance has not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor and Other Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the sales of our products, we pay distributor and other fees, which are generally recorded as a reduction of revenue, to certain customers that provide us with inventory management, data, and/or distribution services. Costs associated with such services are expensed as selling, general and administrative to the extent we can demonstrate a separable benefit and fair value for such services. To date, actual distributor and other fees have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring product, provided it is within a specified period of the product expiration date, as set forth in the associated distribution agreement. Where actual returns history is not available, we estimate a returns allowance based on benchmarking data for similar products and industry experience. Such estimates are recorded as a reduction of revenue in the period the related sale is recognized. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration and license agreements under which we out-license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of the out-licensed products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use, and benefit from, the license. For licenses that are bundled with other promises, we assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development, regulatory, and/or commercial milestones, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Amounts for milestones that are not within our control, such as when achievement of a specified event is dependent on the development activities of a third party or approvals from regulators, are not considered probable of being achieved until such specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, and under which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, accounts receivable and debt securities available-for-sale. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio with low-risk investment-grade debt securities with maturities of up to three years and by placing our investments with high-credit-quality financial institutions to maintain liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in connection with these financial instruments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 91% of our total product sales for 2023 and approximately 98% of our accounts receivable balance as of December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenues</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues includes third-party manufacturing, transportation, freight, and indirect overhead costs primarily for the manufacture and distribution of INGREZZA drug product sold, manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with Mitsubishi Tanabe Pharma Corporation, royalty fees on net sales of elagolix, amortization of intangible assets, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development, or R&amp;D</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development, or R&amp;D. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses primarily consist of preclinical and clinical trial costs, payroll and benefits costs, including stock-based compensation associated with employees involved in R&amp;D activities, certain facility-based costs, and costs associated with our collaborative arrangements, including event-based milestones. All such costs are expensed as R&amp;D when incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expense</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $159.9 million for 2023, $149.7 million for 2022 and $139.8 million for 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units (RSUs) and performance-based restricted stock units (PRSUs). Additionally, we allow employees to participate in an employee stock purchase plan (ESPP).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. RSUs are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest is recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally <span style="-sec-ix-hidden:f-374">three</span> to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP is recognized and amortized on a straight-line basis over the purchase period, which is generally six months. PRSUs vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax provision is computed under the asset and liability method. Significant estimates are required in determining our income tax provision. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share are computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed using the treasury stock and if-converted methods and reflect the weighted average number of common and potentially dilutive shares outstanding during the period, excluding those which effect would be anti-dilutive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024 in cash upon conversion and to settle any conversion premium in either cash or shares of our common stock. As a result, only the shares required to settle any conversion premium are considered dilutive under the if-converted method. Further, PRSUs for which the performance condition has not been achieved are excluded from the calculation of diluted earnings per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Description Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479391/326-20-30-5A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-3C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479366/326-20-35-8A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-3D<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479175/326-30-30-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 13A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479148/326-30-35-13A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479391/326-20-30-4A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479148/326-30-35-7A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-7<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-17<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.Q4)<br> -SubTopic 20<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483530/326-20-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205561556160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">780.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">735.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">726.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">684.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">687.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2023, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2022, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205559300336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of financial assets, which were measured at fair value on a recurring basis.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">867.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">867.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,468.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,398.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205562650512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Notes Net of Discount and Deferred Financing Costs</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the interest expense of the 2024 Notes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556629744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of the Carrying Amount of Goodwill</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill recognized in connection with business combination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Information Relating to our Recognized Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information relating to our recognized intangible assets as of December&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed product rights</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Information Relating to our Recognized Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information relating to our recognized intangible assets as of December&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed product rights</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Annual Amortization Expense for our Finite-Lived Intangible Assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2026</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556626432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Net</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less inventory reserves</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales rebates and reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current income taxes payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Schedule of Other Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent income taxes payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent branded prescription drug fee</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of reconciliation of cash cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205559348784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Income Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share were calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205552260720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of stock-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:</span><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by award-type <span id="iae12b1f8f345443688fcf6efba5f4f06_8127"></span>follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, unrecognized stock-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.729%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected option term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary and Changes in Stock Options Outstanding</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summary of activity related to stock options.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary and Changes in Restricted Stock Units Outstanding</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to RSUs.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to PRSUs.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PRSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205562497200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents income from continuing operations before provision for income taxes for domestic and international operations.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of the Provision for Income Tax Expense (Benefit) for Continuing Operations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of income tax expense (benefit) for continuing operations.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Provision For Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal income taxes at 21%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of our deferred tax assets. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">530.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of deferred tax assets and liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Activity Related to Unrecognized Tax Benefits</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to unrecognized tax benefits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease related to prior year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of the statute of limitations for the assessment of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556760160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Description of Operating Lease</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental operating lease information for operating leases that have commenced.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash related to letters of credit issued in lieu of cash security deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liability Maturity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate future non-cancelable minimum lease payments under operating leases and sublease income as of December&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease<br/>Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments (sublease income)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1022">Less current operating lease liabilities included in other current liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts presented in the table above exclude $15.4 million for 2025, $23.6 million for 2026, $24.3 million for 2027, $25.1 million for 2028 and $223.5 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205557048880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 02, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff', window );">Accrued interest receivables write-off threshold period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff', window );">Accrued interest receivables write-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,800,000<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="nump">10,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,900,000<span></span>
</td>
<td class="nump">$ 149,700,000<span></span>
</td>
<td class="nump">$ 139,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_ESPPPurchasePeriod', window );">ESPP purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based compensation arrangement by share-based payment award, award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based compensation arrangement by share-based payment award, award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue, Product and Service Benchmark | Customer Concentration Risk | Largest Four Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk | Largest Four Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ESPPPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ESPP Purchase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ESPPPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 72: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period when accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), is considered uncollectible and written off, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nbix_LargestFourCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nbix_LargestFourCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205551222832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>geneTherapyProgram </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>non-clinicalStageCompound</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>preclinicalCandidate </div>
<div>undisclosedProgram </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 143.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 105.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) included in earnings</a></td>
<td class="nump">28.4<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">161.9<span></span>
</td>
<td class="nump">102.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,887.1<span></span>
</td>
<td class="nump">1,488.7<span></span>
</td>
<td class="nump">1,133.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Common Stock [Member] | Voyager</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Beneficial ownership (as a percent)</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Heptares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">$ 2,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationMinimalContractualTime', window );">Agreement termination, minimal contractual time (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationContractualTimeThreshold', window );">Agreement termination, contractual time threshold (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold', window );">Agreement termination by counterparty, contractual time threshold (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">365 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationByCounterpartyMinimalContractualTime', window );">Agreement termination by counterparty, minimal contractual time (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationMinimalContractualTime', window );">Agreement termination, minimal contractual time (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationContractualTimeThreshold', window );">Agreement termination, contractual time threshold (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NumberOfNonClinicalStageCompound', window );">Number of non-clinical stage compounds | non-clinicalStageCompound</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Idorsia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationMinimalContractualTime', window );">Agreement termination, minimal contractual time (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationDueToMaterialBreach', window );">Agreement termination, due to material breach (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Xenon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationContractualTimeThreshold', window );">Agreement termination, contractual time threshold (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NumberOfPreclinicalCandidates', window );">Number of preclinical candidates | preclinicalCandidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.855<span></span>
</td>
<td class="nump">$ 19.9755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Equity securities purchase date fair value amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity securities cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Xenon | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction', window );">Sale of stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Voyager</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) included in earnings</a></td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="num">$ (8.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">72.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | 2019 Voyager Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationMinimalContractualTime', window );">Agreement termination, minimal contractual time (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationContractualTimeThreshold', window );">Agreement termination, contractual time threshold (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.9625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Equity securities purchase date fair value amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NumberOfUndisclosedPrograms', window );">Number of undisclosed programs | undisclosedProgram</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_VotingRestrictionPeriod', window );">Voting restriction period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | 2019 Voyager Agreement | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction', window );">Sale of stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | 2023 Voyager Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 143.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">$ 6,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationMinimalContractualTime', window );">Agreement termination, minimal contractual time (in days)</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationContractualTimeThreshold', window );">Agreement termination, contractual time threshold (in days)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 8.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity securities cost</a></td>
<td class="nump">$ 31.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_VotingRestrictionPeriod', window );">Voting restriction period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NumberOfGeneTherapyPrograms', window );">Number of gene therapy programs | geneTherapyProgram</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payments made</a></td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_BoardOfDirectorsMaximumDurationTerm', window );">Board of directors maximum duration term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | 2023 Voyager Agreement | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction', window );">Sale of stock (in shares) | shares</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | BIAL &#8211; Portela &amp; Ca, S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves</a></td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | MTPC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationContractualTimeThreshold', window );">Agreement termination, contractual time threshold (in days)</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | MTPC | Patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PatentTerm', window );">Patent term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | AbbVie Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AgreementTerminationContractualTimeThreshold', window );">Agreement termination, contractual time threshold (in days)</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | AbbVie Inc. | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 16.7<span></span>
</td>
<td class="nump">$ 21.2<span></span>
</td>
<td class="nump">$ 22.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | AbbVie Inc. | Patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PatentTerm', window );">Patent term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AgreementTerminationByCounterpartyContractualTimeThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination By Counterparty, Contractual Time Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AgreementTerminationByCounterpartyContractualTimeThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AgreementTerminationByCounterpartyMinimalContractualTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination By Counterparty, Minimal Contractual Time</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AgreementTerminationByCounterpartyMinimalContractualTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AgreementTerminationContractualTimeThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination, Contractual Time Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AgreementTerminationContractualTimeThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AgreementTerminationDueToMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination, Due To Material Breach</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AgreementTerminationDueToMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AgreementTerminationMinimalContractualTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination, Minimal Contractual Time</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AgreementTerminationMinimalContractualTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_BoardOfDirectorsMaximumDurationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Board Of Directors Maximum Duration Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_BoardOfDirectorsMaximumDurationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments made for milestones under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfGeneTherapyPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Gene Therapy Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfGeneTherapyPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfNonClinicalStageCompound">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Non-clinical Stage Compound</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfNonClinicalStageCompound</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfPreclinicalCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Preclinical Candidates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfPreclinicalCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfUndisclosedPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Undisclosed Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfUndisclosedPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PatentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PatentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePaymentReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential later stage milestone payments and royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePaymentReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments to be paid under a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares sold by the collaboration partner per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_SaleOfStockNumberOfSharesSoldInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_UpfrontPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments made under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_UpfrontPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_VotingRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Voting Restriction Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_VotingRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=nbix_VoyagerTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=nbix_VoyagerTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_HeptaresTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_HeptaresTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_IdorsiaPharmaceuticalsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_IdorsiaPharmaceuticalsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_A2019VoyagerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_A2019VoyagerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_A2023VoyagerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_A2023VoyagerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_BIALPortelaCaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_BIALPortelaCaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_AbbVieIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_AbbVieIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205552254032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">$ 781.7<span></span>
</td>
<td class="nump">$ 735.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized gain, current</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized loss, current</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(9.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent', window );">Fair value, current</a></td>
<td class="nump">780.5<span></span>
</td>
<td class="nump">726.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost, noncurrent</a></td>
<td class="nump">684.6<span></span>
</td>
<td class="nump">304.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Unrealized gain, noncurrent</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Unrealized loss, noncurrent</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent', window );">Fair value, noncurrent</a></td>
<td class="nump">687.5<span></span>
</td>
<td class="nump">299.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">53.5<span></span>
</td>
<td class="nump">156.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized gain, current</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized loss, current</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent', window );">Fair value, current</a></td>
<td class="nump">53.5<span></span>
</td>
<td class="nump">156.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">382.1<span></span>
</td>
<td class="nump">296.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized gain, current</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized loss, current</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent', window );">Fair value, current</a></td>
<td class="nump">381.2<span></span>
</td>
<td class="nump">293.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost, noncurrent</a></td>
<td class="nump">483.5<span></span>
</td>
<td class="nump">259.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Unrealized gain, noncurrent</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Unrealized loss, noncurrent</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent', window );">Fair value, noncurrent</a></td>
<td class="nump">486.0<span></span>
</td>
<td class="nump">255.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">346.1<span></span>
</td>
<td class="nump">283.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized gain, current</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized loss, current</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent', window );">Fair value, current</a></td>
<td class="nump">345.8<span></span>
</td>
<td class="nump">277.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost, noncurrent</a></td>
<td class="nump">201.1<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Unrealized gain, noncurrent</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Unrealized loss, noncurrent</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent', window );">Fair value, noncurrent</a></td>
<td class="nump">$ 201.5<span></span>
</td>
<td class="nump">$ 44.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtSecuritiesAvailableForSaleFairValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556881056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">$ 265.1<span></span>
</td>
<td class="nump">199.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">183.8<span></span>
</td>
<td class="nump">299.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="nump">448.9<span></span>
</td>
<td class="nump">498.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">214.6<span></span>
</td>
<td class="nump">107.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">198.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="nump">231.3<span></span>
</td>
<td class="nump">306.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (7.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205553032240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value Measurements Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">$ 1,889.0<span></span>
</td>
<td class="nump">$ 1,398.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">867.2<span></span>
</td>
<td class="nump">548.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">547.3<span></span>
</td>
<td class="nump">321.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">161.9<span></span>
</td>
<td class="nump">102.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">251.1<span></span>
</td>
<td class="nump">262.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">53.5<span></span>
</td>
<td class="nump">156.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">421.0<span></span>
</td>
<td class="nump">372.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">161.9<span></span>
</td>
<td class="nump">102.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">251.1<span></span>
</td>
<td class="nump">262.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">1,468.0<span></span>
</td>
<td class="nump">1,025.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">867.2<span></span>
</td>
<td class="nump">548.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">547.3<span></span>
</td>
<td class="nump">321.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">$ 53.5<span></span>
</td>
<td class="nump">$ 156.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205552464992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">$ 517,500,000<span></span>
</td>
<td class="nump">$ 170,400,000<span></span>
</td>
<td class="nump">170,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate percentage</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Aggregate repurchase price paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="nump">0.00131711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 75.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtInstrumentConvertibleConversionPremium', window );">Conversion premium</a></td>
<td class="nump">42.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market price of common stock (in USD per share) | $ / shares</a></td>
<td class="nump">$ 53.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible Senior Notes Due 2024 | Conversion Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PrincipalAmountOnConversionRate', window );">Principal amount on conversion rate</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice', window );">Minimum percentage of common stock price trigger</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible Senior Notes Due 2024 | Conversion Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of common stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger', window );">Common stock price trigger (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold common stock trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive common stock trading days | d</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConvertibleConversionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConvertibleConversionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PrincipalAmountOnConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal amount on conversion rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PrincipalAmountOnConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205553291152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes - 2024 Notes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 02, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Net Carrying Amount</a></td>
<td class="nump">$ 170,100,000<span></span>
</td>
<td class="nump">$ 169,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">170,400,000<span></span>
</td>
<td class="nump">170,400,000<span></span>
</td>
<td class="nump">$ 517,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized Issuance Costs</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="num">(1,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Net Carrying Amount</a></td>
<td class="nump">170,100,000<span></span>
</td>
<td class="nump">169,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value, Amount</a></td>
<td class="nump">$ 295,700,000<span></span>
</td>
<td class="nump">$ 268,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556780016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Interest Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtInstrumentCouponInterest', window );">Coupon interest</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense, Total</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 25.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentCouponInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Coupon Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentCouponInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205562487120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, at beginning period</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recognized in connection with business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, at ending period</a></td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205557119552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets Amortized Over Estimated Useful Lives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">$ 35.5<span></span>
</td>
<td class="nump">$ 37.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 35.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205562497584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated Annual Amortization Expense for Finite-Lived Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Year ending December 31, 2024</a></td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Year ending December 31, 2025</a></td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Year ending December 31, 2026</a></td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Year ending December 31, 2027</a></td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Year ending December 31, 2028</a></td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 13.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205552940560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 21.5<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">12.3<span></span>
</td>
<td class="nump">17.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
<td class="nump">43.5<span></span>
</td>
<td class="nump">35.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less inventory reserves</a></td>
<td class="num">(5.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory, net</a></td>
<td class="nump">$ 38.3<span></span>
</td>
<td class="nump">$ 35.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556043936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Property and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 153.8<span></span>
</td>
<td class="nump">$ 124.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(83.0)<span></span>
</td>
<td class="num">(66.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">70.8<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">37.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_ScientificEquipmentMember', window );">Scientific equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">79.6<span></span>
</td>
<td class="nump">58.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_ScientificEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_ScientificEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556640208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Sales rebates and reserves</a></td>
<td class="nump">$ 139.3<span></span>
</td>
<td class="nump">$ 131.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee related costs</a></td>
<td class="nump">86.2<span></span>
</td>
<td class="nump">72.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AccruedBrandedPrescriptionDrugFee', window );">Current branded prescription drug fee</a></td>
<td class="nump">45.7<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued development costs</a></td>
<td class="nump">44.3<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Current income taxes payable</a></td>
<td class="nump">24.4<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">108.9<span></span>
</td>
<td class="nump">67.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 448.8<span></span>
</td>
<td class="nump">$ 347.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AccruedBrandedPrescriptionDrugFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Branded Prescription Drug Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AccruedBrandedPrescriptionDrugFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205559440144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Other Long-term Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Noncurrent income taxes payable</a></td>
<td class="nump">$ 96.0<span></span>
</td>
<td class="nump">$ 19.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PrescriptionDrugFeeNoncurrent', window );">Noncurrent branded prescription drug fee</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 106.3<span></span>
</td>
<td class="nump">$ 29.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PrescriptionDrugFeeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prescription Drug Fee, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PrescriptionDrugFeeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205562323136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 251.1<span></span>
</td>
<td class="nump">$ 262.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 259.1<span></span>
</td>
<td class="nump">$ 270.7<span></span>
</td>
<td class="nump">$ 344.0<span></span>
</td>
<td class="nump">$ 190.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205562409920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Schedule of Net Income (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income - basic</a></td>
<td class="nump">$ 249.7<span></span>
</td>
<td class="nump">$ 154.5<span></span>
</td>
<td class="nump">$ 89.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income - diluted</a></td>
<td class="nump">$ 249.7<span></span>
</td>
<td class="nump">$ 154.5<span></span>
</td>
<td class="nump">$ 89.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">97.7<span></span>
</td>
<td class="nump">95.8<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">101.0<span></span>
</td>
<td class="nump">98.9<span></span>
</td>
<td class="nump">97.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205560029488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember', window );">Stock Options Restricted Stock and Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from diluted per share amounts (in shares)</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205552191424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair values of stock options granted (in USD per share)</a></td>
<td class="nump">$ 45.19<span></span>
</td>
<td class="nump">$ 32.05<span></span>
</td>
<td class="nump">$ 45.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Stock options exercised in period intrinsic value</a></td>
<td class="nump">$ 39.9<span></span>
</td>
<td class="nump">$ 39.7<span></span>
</td>
<td class="nump">$ 58.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from stock option exercises</a></td>
<td class="nump">$ 55.5<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
<td class="nump">20.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Discounted purchase price percentage of common stock authorized for issuance</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term of stock options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Total intrinsic value vested in period</a></td>
<td class="nump">$ 101.0<span></span>
</td>
<td class="nump">72.4<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of PRSUs vested</a></td>
<td class="nump">$ 34.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nbix_Amended2020EquityIncentivePlanMember', window );">Amended 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward', window );">Number of shares reduced pursuant to appreciation award (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted', window );">Number of shares reduced pursuant to any full value award granted (in shares)</a></td>
<td class="nump">2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward', window );">Number of shares increased by returning shares subject to appreciation award (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward', window );">Number of shares increased returning shares subject to any full value award (in shares)</a></td>
<td class="nump">2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nbix_TwoThousandAndElevenEquityIncentivePlanMember', window );">2011 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock authorized for issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nbix_Amended2018EmployeeStockPurchasePlanMember', window );">Amended 2018 Employee Stock Purchase Plan | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To An Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Award Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nbix_Amended2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nbix_Amended2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nbix_TwoThousandAndElevenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nbix_TwoThousandAndElevenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nbix_Amended2018EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nbix_Amended2018EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205557286192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 194.3<span></span>
</td>
<td class="nump">$ 173.1<span></span>
</td>
<td class="nump">$ 134.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">126.3<span></span>
</td>
<td class="nump">115.4<span></span>
</td>
<td class="nump">85.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 68.0<span></span>
</td>
<td class="nump">$ 57.7<span></span>
</td>
<td class="nump">$ 48.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556730640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 194.3<span></span>
</td>
<td class="nump">$ 173.1<span></span>
</td>
<td class="nump">$ 134.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">91.6<span></span>
</td>
<td class="nump">62.6<span></span>
</td>
<td class="nump">60.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">93.4<span></span>
</td>
<td class="nump">86.4<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205553193888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 94.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Recognition Period</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 162.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Recognition Period</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 22.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205562497168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of common stock</a></td>
<td class="nump">40.80%<span></span>
</td>
<td class="nump">42.60%<span></span>
</td>
<td class="nump">45.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205553078832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Activity Related to Stock Options (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance, Outstanding (in shares) | shares</a></td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance, Outstanding (in shares) | shares</a></td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance, Outstanding (in USD per share) | $ / shares</a></td>
<td class="nump">$ 79.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">103.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share) | $ / shares</a></td>
<td class="nump">66.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in USD per share) | $ / shares</a></td>
<td class="nump">98.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance, Outstanding (in USD per share) | $ / shares</a></td>
<td class="nump">84.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in USD per share) | $ / shares</a></td>
<td class="nump">$ 78.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 467.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 361.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205552392528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested (in shares) | shares</a></td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares) | shares</a></td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested (in shares) | shares</a></td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Unvested (in USD per share) | $ / shares</a></td>
<td class="nump">$ 92.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">103.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in USD per share) | $ / shares</a></td>
<td class="nump">93.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled (in USD per share) | $ / shares</a></td>
<td class="nump">95.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Unvested (in USD per share) | $ / shares</a></td>
<td class="nump">$ 97.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested, weighted average remaining contractual term (in years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Unvested, aggregate intrinsic value | $</a></td>
<td class="nump">$ 312.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested (in shares) | shares</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares) | shares</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested (in shares) | shares</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Unvested (in USD per share) | $ / shares</a></td>
<td class="nump">$ 101.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">97.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in USD per share) | $ / shares</a></td>
<td class="nump">98.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled (in USD per share) | $ / shares</a></td>
<td class="nump">115.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Unvested (in USD per share) | $ / shares</a></td>
<td class="nump">$ 89.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested, weighted average remaining contractual term (in years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Unvested, aggregate intrinsic value | $</a></td>
<td class="nump">$ 33.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205557152960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="nump">$ 409.2<span></span>
</td>
<td class="nump">$ 218.0<span></span>
</td>
<td class="nump">$ 101.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(77.1)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">$ 332.1<span></span>
</td>
<td class="nump">$ 213.9<span></span>
</td>
<td class="nump">$ 101.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205553632496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of the Provision for Income Taxes for Continuing Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 115.0<span></span>
</td>
<td class="nump">$ 17.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">28.1<span></span>
</td>
<td class="nump">20.3<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income taxes</a></td>
<td class="nump">143.1<span></span>
</td>
<td class="nump">37.4<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(45.2)<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(15.5)<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(60.7)<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 82.4<span></span>
</td>
<td class="nump">$ 59.4<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205552357440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes, rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes at 21%</a></td>
<td class="nump">$ 69.7<span></span>
</td>
<td class="nump">$ 44.9<span></span>
</td>
<td class="nump">$ 21.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">17.5<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee', window );">Branded prescription drug fee</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="num">(3.9)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(11.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost', window );">Officer compensation</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rate</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxReconciliationExpirationOfTaxCredits', window );">Expired tax attributes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(42.2)<span></span>
</td>
<td class="num">(29.9)<span></span>
</td>
<td class="num">(22.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 82.4<span></span>
</td>
<td class="nump">$ 59.4<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Loss On Extinguishment Of Convertible Senior Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncomeTaxReconciliationExpirationOfTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation, expiration of tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncomeTaxReconciliationExpirationOfTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense branded prescription drug fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense officer compensation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205553075216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 36.4<span></span>
</td>
<td class="nump">$ 27.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">55.3<span></span>
</td>
<td class="nump">108.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">178.7<span></span>
</td>
<td class="nump">91.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation expense</a></td>
<td class="nump">52.7<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DeferredTaxAssetsOperatingLeasesAssets', window );">Operating lease assets</a></td>
<td class="nump">72.0<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">110.0<span></span>
</td>
<td class="nump">80.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">530.1<span></span>
</td>
<td class="nump">405.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(66.3)<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(12.3)<span></span>
</td>
<td class="num">(11.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(78.6)<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DeferredTaxAssetsLiabilitiesGross', window );">Net of deferred tax assets and liabilities</a></td>
<td class="nump">451.5<span></span>
</td>
<td class="nump">372.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(88.9)<span></span>
</td>
<td class="num">(67.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 362.6<span></span>
</td>
<td class="nump">$ 305.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxAssetsLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets (liabilities) gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxAssetsLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxAssetsOperatingLeasesAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating leases assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxAssetsOperatingLeasesAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating leases liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205557836464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 88,900,000<span></span>
</td>
<td class="nump">$ 67,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets</a></td>
<td class="nump">362,600,000<span></span>
</td>
<td class="nump">305,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">55,300,000<span></span>
</td>
<td class="nump">108,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationInterestAccrued', window );">Interest accrued</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAccrued', window );">Penalties accrued</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would affect effective tax rate</a></td>
<td class="nump">105,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">286,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">85,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">134,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556035776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1</a></td>
<td class="nump">$ 84.5<span></span>
</td>
<td class="nump">$ 64.6<span></span>
</td>
<td class="nump">$ 60.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to prior year tax positions</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">36.7<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Decrease related to prior year tax positions</a></td>
<td class="num">(3.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Expiration of the statute of limitations for the assessment of taxes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 121.0<span></span>
</td>
<td class="nump">$ 84.5<span></span>
</td>
<td class="nump">$ 64.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205552355904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 17.1<span></span>
</td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="nump">$ 15.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OperatingLeaseCostNet', window );">Net operating lease cost</a></td>
<td class="nump">16.4<span></span>
</td>
<td class="nump">16.3<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 17.9<span></span>
</td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">10 years 9 months 18 days<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OperatingLeaseCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Cost, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OperatingLeaseCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205553107088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Lease Payments Under Operating Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ending December 31, 2024</a></td>
<td class="nump">$ 33.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ending December 31, 2025</a></td>
<td class="nump">34.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ending December 31, 2026</a></td>
<td class="nump">34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year ending December 31, 2027</a></td>
<td class="nump">34.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Year ending December 31, 2028</a></td>
<td class="nump">35.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">211.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments (sublease income)</a></td>
<td class="nump">383.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less accreted interest</a></td>
<td class="nump">93.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">290.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current operating lease liabilities included in other current liabilities</a></td>
<td class="nump">32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">258.3<span></span>
</td>
<td class="nump">$ 93.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract', window );"><strong>Sublease Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">Year ending December 31, 2024</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">Year ending December 31, 2025</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">Year ending December 31, 2026</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">Year ending December 31, 2027</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears', window );">Year ending December 31, 2028</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter', window );">Thereafter</a></td>
<td class="num">(4.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total operating lease payments (sublease income)</a></td>
<td class="num">(12.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2025</a></td>
<td class="nump">15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2026</a></td>
<td class="nump">23.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2027</a></td>
<td class="nump">24.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2028</a></td>
<td class="nump">25.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for thereafter</a></td>
<td class="nump">$ 223.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205559638336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Feb. 08, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276.5<span></span>
</td>
<td class="nump">$ 87.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding', window );">Lessee option term for construction of fifth building</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_LesseeOperatingLeaseOptionTermToConstructBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of term of lessee's option for the construction of a fifth building under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_LesseeOperatingLeaseOptionTermToConstructBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140205556824112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution plan, maximum employee contribution percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, employer contribution amount</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="nump">$ 10.3<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *&+25@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "ABTE8)T%[_>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O38KHJ'+B^+3!H(#Q;>0W+9@TX3DI-VWMXU;A^@'\#%W__SN
M=W"M#D+[B,_1!XQD,=V,KNN3T&'-CD1! "1]1*=2.27ZJ;GWT2F:GO$ 0>D/
M=4#@574+#DD910IF8!$6(I.MT4)'5.3C&6_T@@^?L<LPHP$[=-A3@KJL@<EY
M8CB-70M7P PCC"Y]%] LQ%S]$YL[P,[),=DE-0Q#.:QR;MJAAK?MYB6O6]@^
MD>HU3K^2%70*N&:7R:^KA\?=$Y.\XDU1\:*ZWW$N^)UHFO?9]8??5=AY8_?V
M'QM?!&4+O^Y"?@%02P,$%     @ H8M)6)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@$*A+0,VPRNL@%)+9&3\[CB#_D@+/)^?V!^<=^-ECQ6L!/U.2EUGP:< E7#
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MT)(#6N)%^U.OF80*UT]%%V!B/3M+)ND)H&V49),@Z_^X:=,#;>JE_4MH6KZ
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MW"1,>^?DYI\4GZE<\5I!%[&$@=!/@0>Y._??W6BQ:8_.'X36HFHOUXP"O#&
M[Y<"6M#]C3F-/_SW9?$?4$L#!!0    ( *&+25B.QQW?ZP(  $T*   8
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M,J>S8"9G@Y#9;<ALG?<V9*J(U99.95G6R=,&>][:@$R=^K%0P&S/,]9#6*"
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M%B4 OG]D3+Q<E#_0/L"Q^0]02P,$%     @ H8M)6"Q'DAC$!P  V4@  !@
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M5J<EXZ:BO]<SHVZ;BP3.S9,5??]>'^1ID-K#!L!"/X"5%7S/Q+I4*'+-;0H
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M.*\=:G!=0R<Z7G3NT'8XR*9J\@9@TK>BG0!KA9-NQSKOZB/]ZYK$."[YR,1
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M*,99LH(B<RBX1P$F7\P"D!Z[G<EDQL8BX7, -YD(6KD D($5B/E8:+0"L 5
MD(H;<"P+ IRH^5SH1/),_BE8(G0!3@FO+E29IP8^Y7A%YE/P0>/]8KD0S/D'
M #\O3<(U_)RP]P#[_1&QEI8\@^\'[X_ !25 (ESC4Y5+4P"EX!0=M;>"S3A
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M)*=M2G5/V;J\M3M_OF>FW P5C2(?6;]3SMQX?A<P0X9<XD^QM%T39Y.\]X+
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M(]X OT\4F)'[@@C"'[=X\6]02P,$%     @ H8M)6*YQ\91(!0  6@X  !D
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M0=1.@=8KI>P1N W&9W7U+U!+ P04    " "ABTE8?'[%+S8)  !R&@  &0
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M;.TZ1+H#KC)S.LX(36_'-<C;DBKNHJ&(SI7+K)[O)9'Q8"?*$<ZU;8F.$ )
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M> /Z/M?:;1<^P&YVGOX-4$L#!!0    ( *&+25@ ->4L%P,  -X&   9
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MX[[+U#>V6/!GRTEA;9'QY5Q)! =-P/-I4=CZAC9HOF-?_P=02P,$%     @
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M<9X$STR1&E=6LF8$T-3J#;>[S)9+T"DQ@Y@IEH^Q^E_&!6_= XW+4KO5FK
M"0#HG;)>$]"!<@T7%\9#WQI+,<5N!RR3?GU.W3#C3 #B&=([]".9 (F$@0%%
M1Z?BPV*A4V7WUU]$4T'9?0[FURM9+,E\SB,.!AA0;C/]$,O>W&\T@8L62.^M
MGI=M'>O?(;A^0K)*FZY$"@*--.V/$X)P/[D(JL&>TY;,.YF702=)49=%J@)>
M*2DHNSX $@@Z\H1"58OZ$20?+2P.14W#4Q)QV2\RIK0T;X3T8@\XIS"1?1\B
M;[ZE?"'>$[Q"/8(V:(XNU,0I*YR0Z8T?J<!GZ@YCW(9!4_MU,H$[XN$,,+Z6
M&^UEKO\',?8077Q.B+R(X<@G831)L'1,!>?#3DN%]94%XIPBE$SAV+>%1R@9
MO]6[.![BY0R5IXI=0F%,*-\^&ZC9Y4PQ&0VAV'@X =6>RW(MYSK77BOX[;$V
MK9>H=5.":Q\9#8 %R7UDSRADPNRT2_H> SAHBL5H3%C\/E2 +EW)LVW"\21&
MGH_@DPOQ>P><^[,90W]Z3IH1XRZN%/X$"83?(7G^-8-O#V.$JL$A/(JMXIZK
M,>3K_(%!#3!@2B8^Q3>($ZFT5(2-W4J;N0'N.U"4&N?Q3J9_E3JTE\?A)F^0
M%@&7@6O--#ID!5-1?@R@-J2EQE(EE9WE  Q.R(5U?C'Q"7FS?C(@A3>*=QKY
M ]1=8EOD/+MJ:<G8;QV&345.[&L=E82Y5FV,91=EJ(,#3/P%MD@A[Y#8.J-6
M5F#/H^YP#>J!F!N_$AOC- EGU0JUE'0S0 PD$98Y3$,;1'NDS"7QSM4=@#M>
MZ6D\QNX.[@_ >CA:>@Z"HZ5PIC 58NM"I"O"QE92FZ9VH.E]HW-M"_5?6)GF
M9::"ZHBG=F)-PURNORI&E2RH0W4BD (50-Q$JF55#E=_7K6B_5VQ9K<[SVVV
MAC86.6[9Y.U%-9 >0GB-15X<R+J@RGUDN]( 03OHLB!C&Z\<<0B<-Z^-5=F1
M$ 'P*YEU6-":9I\TAOR4S*:[% A)$8_&Z J=61&)/X+@PC1S34OB<==UVQ*A
M\^0:JPHM.U1&:=Q"$[AE2<.%H?:"(D)=']07HBQRY &UX3MM2@=GEEZ'^L-%
M!5CI9&I5+@D0X&BXS+,KCPJ;1N)VJYW[NUJ.AD>TC,27?QYAN%=?P0X9HPOM
M.13?!XY//\OUYI>;@^4U9,MDEV][ ?F6VAW1:4#@S[MD_HC#1Z.C?GN=@2_O
M5DEPJP*&):$H5/6O(Q4('4_ZAI1=+*C05[RQDL>^"O1K^4 )V]JW2$JBHD1>
MY'J-5N@YAS:E=25-A5CQ-FRT<TQG=ZK CN7:H"C<AI,N)T:SA'4;S1!)Y(QL
M-6"S+= [5GHC4IY]7;LYF#0M+4_@C2LB\=YT$*TD"C8OY]J[LJ9<KKHRDRJM
M7F]DRM)A6HGR:CWZ8COK0P\@9P?9K5=600W,M"7ZZ#Q4;4S(G)R>U^;20B,O
MY-J4Y!YN&*$X/@_%\3D5Q^>[XNC 2W)#*C=4L4J*VKP>57)UQVZ6]Q1H6?J5
ML>B#0,M3RC,.2<R^GGI!]7J%0# 2N5)+,1D^"[5;KXS)R#ES10(;Y;A0-FS"
MX0K;B<AB/)8Y#WVMG&BIM,;NB$:$?46KL;JIP#)-+6#FJKU+Q?\X1^ZM&)'W
MRSWV9H=&H"<&KVYE'MOGCFB3[(0';8;8MORP-J\[??)W?,[S+Z$ #Y35R-)N
MJ3&;3I-)*_>I.#"6JB3D,S"2?H>1 ^6KHUW_65KM,IU69TITU/F H3E8 #E#
MOJA:[8 T5N&(@![OZC3I%$])AX:F*K*M'6F0OB=Q4#LOKK7BFLXR*PT?V:CN
M)<;!8"9E'0UN59:1=ULG,.U*2BXLBZ8S=_:[[H+LHN/;;EE_DN *15BAL;<5
MY+)H93/QK<YA?O0$[RI,_%3 _B%1Z"&9CNUF8VS?3L1TS+NOZ9!WM3"!=I@M
M;3!_PK<4XKWJ@[(/W(^Q;Z7CCR["M#KZZR*=@BZ>()-H>PQ+OE]J?T2[U<='
M,'Q2T_3/W7D;3]:[MA9 2J\?;4;X!.4QTWY,IX@M[[5<3@<LM.5^Y,>G!IR3
M>#C93:H!8P>"S9UE0-6\W8.*K)FUP;2]Q2*K%%_2YJ8^TQJT,Z'NIE6R=VQ$
MN$9DANL)E6_0R?TSHN8$BX:4P\I7(@IU[^$H=$?Z;!,!)PS),/Q\>'-]0Z.'
MH39'MA&,\M*1_K]:N5;TA8U:]!6!XPTVM'7-_6@-G4O>KO2"\U'S/H6N/L*S
MP,SGK1'O,*1@9"ESQ?M@77 N0NXR-]@$T^<MO2[7X>0S;(%2.&*'D:8X$H:H
MZV,J0$5NOCA@/X=M<P4L29ZJ6?)I(JCBR3-,X.7<J;]*0(U: K/8\+%GV#K*
MC*CH^Q ';EGJC/'&(\]<*=1FYTKJS^]D\8#(%,^Y2I.[]RICH%":JRCBP@(%
MNDA*.95C7G5YL(>&OLQL$,UJNM@_^2/;#_B1I]XBN)PB.:;*4_O^S1?Q+N">
M3Y91B+90)J0;B:M<*9LIN"T7_"CY;=5,$((=,L!!HTDC#[DQLTE[!H&XFG:9
MNNETK>\@1!< K\+(QT-B. +I<%'5@;-PZ+;GNB#^@(-JW!^.$BI!:"2415'7
M-[RSUO?5M0+NZ"NRHYFY\.%3:_.T^5#].GR?W2T/7[G? ;:ZH$EP =)A=#[I
M"1N^'(<;;S;\M79NO#=KOEPIB=Y-"_!^88RO;TA \_G^\O]02P,$%     @
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M.ATEEV?TPW?S=)S^N+U_Q$[5=[:3.4LN>C+OA5LA^#H+01"E:3AR$9BPG/&
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M+PX_OSUC;G"A%R*86Z\0663GV\%LL3],Y(#IU17JI,,06WJL4 +'_ I]I^-
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MF<1BK1GE,)-(K<N2R)<Q,+$=>;ZW6WB@JT+;!9S$%5G!'/1C-9-FAEN6G);
M%14<25B.O'M_F$8VW@7\HK!5>V-D.UD(\60G/_*1U[4% 8-,6P9B'AN8 &.6
MR)3QI^'TVI06N#_>L7]SO9M>%D3!1+#?--?%R+OS4 Y+LF;Z06R_0]-/S_)E
M@BEW1]LZMA=Y*%LK+<H&;"HH*:^?Y+G180_@]T\ @@80O :<RA V@/!20-0
MG-2X;L7ID!)-DEB*+9(VVK#9@1/3H4W[E-MCGVMI=JG!Z61&7M!&H1E(]PKQ
M#%!*5<:$6DM G]'C/$775S?H"E&.II0Q<U@JQMJDM@0X:]*,ZS3!B31^@*:"
MZT*AKSR'_)  FYK;PH-=X>/@+&,*60>%_B<4=(/P2$&3R^'!$7AZ.=P_TTW8
M'D/H^,+_.89C<M=TT7$ZZQ5#59$,1IXQ P5R U[R\8/?[WXY)M5[DJ7O1'8@
M8]3*&)UC3WX:GZ0\$R6@:Z.=NCDF74W1<Q36%3=)$ TZMS'>[&OR-LKO19W>
M853Z-NINT.D-]J\647>$][[5$N3*>9Y"F5AS7;_][6IKJ_?.35ZMCXW=UN[X
MCZ;VZBF1*\H58K TE-W.K:E/UOY73[2HG",LA#;^XH:%^66 M %F?RF$WDUL
M@O8GE/P%4$L#!!0    ( *&+25B5K:3X!0H  .I0   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(R+GAM;+6<:V_;.!:&_PKA 09)D<:B;G'2)$!J=78+;*=!
MFKT B\5"L6A;J"QY*3EI!O/CEY1M44RH0RL]F@_36-9Y2;ZBR.?0E"Z?"OZ]
M7#)6D1^K+"^O1LNJ6E^,Q^5LR59Q>5JL62Z^F1=\%5?B(U^,RS5G<5('K;*Q
MZSCA>!6G^>CZLCYVRZ\OBTV5I3F[Y:3<K%8Q?_[(LN+I:D1'^P-WZ6)9R0/C
MZ\MUO&#?6/7W]2T7G\:-2I*N6%ZF14XXFU^-;NA%%+HRH#[C'RE[*EM_$]F4
MAZ+X+C]\3JY&CJP1R]BLDA*Q^.>135F62251C__M1$=-F3*P_?=>_;>Z\:(Q
M#W')ID7VSS2IEE>CR8@D;!YOLNJN>/HKVS4HD'JS(BOK_Y.G[;F!.'FV*:MB
MM0L6-5BE^?;?^,?.B%: >]81X.X"W!<!M*L$;Q?@O0B8.!T!_B[ KYW9-J7V
M(8JK^/J2%T^$R[.%FORC-K..%LU/<WG=OU5<?)N*N.KZL[B"">/DGL=)FB_(
M#>=QOF#BRE8E>4_*9<Q9>3FN1%$R8#S;R7[<RKH=LA[Y4N35LB2?\H0EAO@(
MCJ<N(# 6;6P:ZNX;^M$%%2,V.R4>/2&NXWJ&"DWA\"\Q;\)=4WO>7+K6&J^Y
M;%ZMYW7HF2[7"7EX)I_S)'U,DTV<F2[:5M0WB\HAYJ)<QS-V-1)C2,GX(QM=
M__H+#9T/)L,PQ2(D,<U,OS'3A]3%M:T83^.,W#.^*DDQ-]T-)CM!V;YV8HI%
M<(.C#9>MJY:,K$7+BX3,>;$B7V=5\2#&@ETW/2%5043'92MYT&N.%AM.V \V
MV\@16[@U3V>,ER3.$Y*D7(SGA?R4%.N*):3@1)@K!JY8?IJ)>YJ+H5[TU30O
M*[ZI!_]2GO7$TZIB.5EGL3@PEW&R>AL^6XIA79Y1QIDLKBZ_%,6+@)2)DDJ2
M%U+\04YB%^3W>,7JRMRGE0BXV<XO8G!DILM*[HM*7/EO]3A';C;5LN#I'T+M
MTX]URN,Z]FXC=*CS$+RG[\CO1?Z^?> =^0L3TRX3XQ67_>Y&-IQ0=TS]L?2+
M_(OXSHGC.(32,0WD,9\<13NCCLDGGL[(1Y:SQW2VK'M@[14YHL<RPG/V*E1<
M <^G4MJCVX-'TV7*YF1:K%:,SV0/_KJ]&L?[:H@3SQN!\/QD0B?UP;-M/3[G
M"YXFXB)GL4 ,0XRWK?KYN X(]B7>L<4FBT7]GU6)?V-EEC+A#W^*L^\ML<E>
M[/R$.J$ZI-D@+H#HI6E](=:MX+.F]G5PL&N[%GLGG(MY0FZ+==D*I8W_KHAU
ME)M:\'^U_\@[X8GHAF+.D;V_%!V@G#_773$6#96@(3N]  N!/G5O;/6%H]DQ
M>2=[2"5Z]\^(R&O_-1="C[M[S]G?>UIO.2%=U_^D?=/%I-KU^[C5[ZME7)$G
M<?.\O:KD2)[WZR\3UW4^-%UX]]VMN(_KK^B'XU-R+TXTG5'70%2'<5$!49."
MB/OM-_; -P)"B6RQG&]/!!152W%3BW&GN2L3>9>("KT:H4Z!*2%HIH0 '"%?
MW.7:B'&S'=I,$P(L.H^SDIF&?C"L[]"/)*;9%C:VA6^VK1G:C,[!NIW.@6%]
MG4,2TYP[:YP[ UNH3R+__E)WZ?^8G )U^D('IEB$)*;Y-VG\FPP!Q!-,,S'%
M(B0QS<SSQLQS^#86"&5R"X[2NK#)'S"\KS](8IH_U%%9LP.VM69+8UH,QRGP
M,!D$!_=U"$M-MZBUL$#!IKYA^K0HBGS!. G 8;UM0U+3;7.5;2[8R-J>?<9B
M- F.5YF'T2HPN+=52&JZ56H-A(*K M?M7B52VAH+C8[!,IYW)F#RV;3*-85#
M>_LUQ"H'5<L<%$[[;Q8+SA82FV\>XS2+'SJ&L*U*6*O(=>/':U\D@<[E^%&S
M!G7!PEJHWF;%\11F;CV]AK@*%NK+ JAJ$9::;J*B>AH. 5<4D\ZGJ&H1EIKN
MJ*)]"N-^%V%9PK3>;#0)%>BQU'23%-)3$'(!R(+CNI?%C):A8CN6FFZ9 G<*
M,_C!4R(LXX5^]Y2(BO%8:OIO0HKC79C']050:'J A?H.9JAJ$9::;J(B?9<.
M,3VXF-@^156+L-1T1U42X,(0WS4]6,*TWFPT"17_L=1TDQ3^NS"W=TX/EKCN
MWS",EJ%F %AJNF4J W#A#. -.;E%L2LGA\-ZVX:DIMNFD@@73B*L.;DE7OVD
M9K0*-57 4M.M4JF""Z_4'PH@%IG0GW0""!S:VZ\A$@%7)0(N3/0'YN0[E79Z
M[!ER<KBPWM;8"M7;K+C>A?G\Q2_%('6A+M"CJD58:KJ+"O7=\T&H"Q/?IZAJ
M$9::OJ5*)0,>G QT49<E3._.QIU2J+2/I::[I&C?@U?A.['+$@?_] $'][9H
M"'SW%+Y[,(>_ ;,LBEV8!8?UMFT(H/=:>QHMZ_DVS++$J\U&1JMP]RL. ?*>
M GG/LI1_(&999+PP[,0L.+2W7T,0O*<(WK,0_&&8M5-I$\\Y=<(7E 67U=L9
M2YEZBQ6(>S!!ZQOJ(,:"A7KO"D:E<RPUW41%Y][9$(SEH>[1056+L-1T1Q7[
M>S#[=S(6'*;U9J-)J&B/I::;I-#>@Y??NQ$+CK,@%BJK8ZGI._85J_LP=+\!
ML2R*78@%A_7>F#\$O/L*WGT8PJV(98E76[*-5J%"/)::;I6">-^R$>= Q++(
MT$DW8L&AO?T:@MY]1>^^A=X/0ZR=2AMWZ&O$@LOJ[8RE3+W%K<>&+*OI[><.
M(,*"=7H_*(0*YEAJNH<*S/U@",+R43?KH*I%6&JZHPK\?<L>_ ["LH2U.[/1
M(U2NQU+3/5)<[\.K[IV 98F# 0L.[FW1$*#N*U#W8>)^"V#!BIV A8KN6&JZ
M;0K=?<L&'"M@P?'JP36C5:@(CZ6F/V&E$#Z @?M0P++(>&=!)V#!H;V?K!J"
MW0/%[H&%W0\#K)V*MI/6I:]^*H0+ZVV-K5"]S0K" YB>]>V[]?.<]6.#>]HB
M?Y+#=_C"9?6%!E2U"$M-]UG!>S#(^P0"U!<*H*I%6&JZHRHY""PK]+:) ([O
M[1U<FU>/U!H=&R(5"%J/W,)K]&][<-0BV@4=<%COOC8$\@<*^0.8W?<.@=T-
MEE"O&C"ZA0K_6&JZ6PK^ Y0M-\'KW2_4HYY/7TZDJ-1O+U5OM>+Y *;O5S.I
M_S,S*>JV'%2U"$M-]UDE ,$@VW("U&TYJ&H1EIK^2@&5)X3H2_T6Q:Y) 0[K
M_3J!(=*%4*4+X4\N]5OBX4VK<'!OJX98Z@]5EA%:EOH/FQ%V*MK8')Y/Z.3%
MC "7UML;:ZG;5H];+X%;,;ZH7Z97DEFQR:OM:]*:H\T+^V[JU]2]./Z17DRW
MK]U3,MNW 'Z)^2+-2Y*QN9!T3L\$]O#MB_6V'ZIB7;]J[J&HJF)5_[ED<<*X
M/$%\/R^*:O]!%M"\WO#Z_U!+ P04    " "ABTE8PMKS^G$I   <BP  &0
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MJB]@75-5S*'*#K?1V@JF*' [N G$%]/F6W\<G(-6AN/O;)N7IM(;@YVF('(
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M.3O<18ZSX^6#K@L<"%@1( ,"D6C  /JTY08 7<&M=7V+J +WW&U;:[,=JS[
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M>46*Q;V:I43H-YT E#69:%UXDTQ&PH44F MBKY':GG")R&32(>I<9/>:7'?
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MD8#.E&'VFDMT)I=$ EN#V'E&'BOU"_LM<=1ZL R:LA+-G5AM3??R&+G!D^P
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MIXY)N?5E4RQCW^B049//OI)F!;[GAEI GD:C4IP;2?2@U'J*37/9O;"CX]=
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M! ?'[]K82+L3C1:4W!TE8%N,2'B -3_[OAL@/%;\[ \KA1:D1$@$QV#O/QI
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MT K=AXU@K0[M8V>*T*9$/,Q2"U9CGA+M39H#R>B5-Q#),AF)W_&9[DV3E\!
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M#6"*_($+7#?M9]K>B_\#4$L#!!0    ( *&+25C=@\<%_ 0  "(.   9
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M:F= ^W-%:6XG+D#W14]^ U!+ P04    " "ABTE82O9%TL@#   &#   &0
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M&6J>0.-SI>SVA1VT_YZ,_P902P,$%     @ H8M)6+$IGJ^4!@  DQ(  !D
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M"D"\46]\GM^CUZ_>H%>9QV,81<I C#VIZ&5!>DM-Y?V1"FFDLG11@-\BXI/
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MJ.=KQN3+(#L&+8Z]I_\#4$L#!!0    ( *&+25AE:.@B#0<  )L_   9
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M4)H/15-E:WT6;#9:;@+V1$6=AN5#,4VEA%SDX=,WI>7X*"W'SI#,#O4%-59
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M>8[G5YUO,4A,4G&BAN]F,?KV^61H2S6])K&3:JK+<BKOR%0Q)!W4=4\U<=<
M'[\=[AG@<3/\&C\AQ]-HMW>(MI5EM6]>[9M7T'6/9C.7:$*%Y+DJ HE^_U0!
M:"(A$W],UI1LOIE-U_:YV. $1I8J7@%\"U;T]9,;.M]-1K5)%K=$=N!BMW:Q
MV\0>W:A];8PY?R)TA2XREE-I,J\D<9V"16]DV\CM.:ZC?T-[NV^-*30<^(;0
MN#&U#PKW:^%^HW"OXP5?T-'BBW,HRL]D1B/Q>Y^D-LGBEL@.# UJ0X-6ZS%H
MT\4VR>*6R Y<#&L7P\;'<LH)3<@&IPW%6#*$A[5H*K#QFR/C\'75!FXO. P]
M4-2K%?4:%=U1G#%58O]@@29"Y)@FH.I.2&'2UGN5\5G7I,P05^Y&+X4U)O?!
MQ>S7TOMM;*Y]TRH9]U9#Y)&MM3&Q#\H>U+('C;*O,.'H'J<YG#:H'KQ^XKQ!
MT#/)-H6&?>-R-V;V7MWVWJE.'\&O,5\1*E *2T7O='IJI^#EL;;L2+8I#GIS
M)M6QL6BNU9< <!V@[B^9>KE4'7UVK+\MHO]02P,$%     @ H8M)6.4\6+[C
M @  . @  !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&ULK59=;]HP%/TK
M5E9-K=0E).&CZP )FD[K0Z>JK-O#M >37,"J8S/;@6Z_?M=.FM$04!_Z0F+[
MG.-[KIU[&6ZE>M0K $.><B[TR%L9L[X, IVN(*?:EVL0N+*0*J<&AVH9Z+4"
MFCE2SH.HT^D'.67"&P_=W)T:#V5A.!-PIX@N\IRJ/U/@<COR0N]YXIXM5\9.
M!./AFBYA!N9A?:=P%-0J&<M!:"8%4; 8>9/P,NE;O -\9[#5.^_$.IE+^6@'
M-]G(Z]B @$-JK +%QP:N@',KA&'\KC2]>DM+W'U_5O_LO*.7.=5P)?D/EIG5
MR+OP2 8+6G!S+[=?H/+3LWJIY-K]DFV)'2 X+;21>47&"'(FRB=]JO*P0PC[
M!PA118B:A.X!0EP1XM<2NA6AZS)36G%Y2*BAXZ&26Z(L&M7LBTNF8Z-])NRQ
MSXS"588\,[Z28@/*L#D',@/!I")?I0%-/I ;84"!-N3Z"2^9!G*:@*&,ZS-<
M?)@EY/3DC)P0)L@MXQP/40\#@R%9X2"MMI^6VT<'M@\C<BN%66ER+3+(7@H$
MZ*4V%#T;FD9'%1-(?1*'YR3J1'%+0%>OIT<M].3U]/"(F[@^GMCIQ0?UYH8D
M3*=<ZD(!^3F9:Z/P8_G5ENM2J]NN90O(I5[3%$8>5@@-:@/>^/V[L-_YU):G
MMQ1+WDCL10Z[=0Z[Q]3QBA=KK#"LNLYMB2L%>D[ %LK-./8_#H/-;C[V,;TF
M)MG'7/B]&O,B^EX=?>]H])-<XN?YE[HJ*1=8T_!&9'@C9"$,H2(C3.N"BA1(
M*K5I_0;+'08[877\0</>/B;THX:]%LS C]O]]6M__:/^FE7FG'R3AO(V&_V]
M[';]?L/&/F;@APT;^YBHYU\T; 0[-34'M72]21.7]K(:U;-U^YNXJM^8GV);
M++O8?YFRI]Y2M61"$PX+E,0CP9!4V:?*@9%K5[GGTF ?<*\K;.V@+ #7%Q)+
M=36P&]1_%L;_ %!+ P04    " "ABTE8''Z![N@"   2"   &0   'AL+W=O
M<FMS:&5E=',O<VAE970T,2YX;6RM5EMOVC 4_BM65DVMU)$0;E4'D8#NTH=*
M5:MN#],>3')(O#IV9AO2[M?OV D9T, Z:2_$E_-]_CY?SF%<2O6H,P!#GG(N
M],3+C"DN?5_'&>14=V0! F>64N748%>EOBX4T,2!<NZ'03#T<\J$%XW=V*V*
MQG)E.!-PJXA>Y3E5SS/@LIQX76\S<,?2S-@!/QH7-(5[, _%K<*>W[ D+ >A
MF11$P7+B3;N7\Y&-=P%?&)1ZJTVLDX64C[9SG4R\P H"#K&Q#!0_:Y@#YY8(
M9?RL.;UF20O<;F_8/SKOZ&5!-<PE_\H2DTV\"X\DL*0K;NYD^1EJ/P/+%TNN
MW2\IZ]C (_%*&YG78%20,U%]Z5.]#UN [O  (*P!X3Z@?P#0JP$]9[12YFQ=
M44.CL9(E438:V6S#[8U#HQLF["G>&X6S#'$F^B1E4C+."14)N1:&BI0M.)"I
MUF T>4?F5*EG)E(RS>5*&"*7I,&<7H&AC.LSC'NXOR*G)V?DA#!!;G 6#TF/
M?8,:[4I^7.N957K" WJZ(;F1PF2:?! ))+L$/IIK'(8;A[/P*.,5Q!W2ZYZ3
M, A[+8+FKX>'1^3TF@WO.;[>WS;\VYW$7[R+)57)][:=JHCZ[43V>5_J@L8P
M\?#]:E!K\**W;[K#X'V;R_]$MN.YWWCN'V-O/)\3:L@"4B:$O5$%*":3-N<5
MW<#1V3RTC@:=_MA?;QNJ8KK!5E#0A.S('#0R!Z^2B=DIEJE@OR"QESF60M1)
MIV0F(XN51J#6.)$OF*!VILW$T<7^]?@JLM'.CH3M=H>-W>%1NWCU,,FAOY52
M(.)G8A05FM,JO28_,/E@NC:MCWCX0D[PXH#:8@Y('C621Z^_2""2X[=HU'*+
M+O9$ML7T]T3Z6^DU!Y6ZJF./'_-AE8>:T::P35T^WQN?8<&KZM,?FJI:WE"%
MKT(3#DND##HC5*2J"E1UC"Q<$E](@R7!-3,LVJ!L ,XOI32;CEV@^1L0_090
M2P,$%     @ H8M)6'3OJ14Z P  #PT  !D   !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&ULK9=M3]LP$,>_BI4A!!)K'OH(M)%*N[%*L%4PMA?37KC)M;5P
MXF [+>S3STY":$H(I<J;UHY]?]_/=XXO_37C]V()(-%C0$,Q,)921F>F*;PE
M!%@T6 2A&IDS'F"INGQABH@#]A.C@)J.977, )/0</O)LREW^RR6E(0PY4C$
M08#YTP50MAX8MO'\X(8LEE(_,-U^A!=P"_(NFG+5,W,5GP00"L)"Q&$^,(;V
MV<AVM$$RXQ>!M=AH(XTR8^Q>=R;^P+"T1T#!DUH"J[\5C(!2K:3\>,A$C7Q-
M;;C9?E;_FL KF!D6,&+T-_'E<F#T#.3#',=4WK#U-\B VEK/8U0DOVB=S;4,
MY,5"LB S5AX$)$S_\6.V$1L&=NL- R<S<'8U:&8&S00T]2S!&F.)W3YG:\3U
M;*6F&\G>)-:*AH0ZC+>2JU&B[*1[R9B_)I0B'/IH$DH<+LB, AH* 5*@SR7/
MA@'CDOP#'_U8 4=?A"1J.U7W3L \INA*Q46@HS%(3*@X5AIWMV-T='",#A )
MT;5:3050]$VI_-=>F%[FZT7JJ_.&KV/P&JAIGR#'<IHEYJ/=S9VBN:EV+=\Z
M)]\Z)]%KOK=U?Z[4")I(",3?,JI4IE4NH\_IF8BP!P-#'40!? 6&>_C)[ECG
M98PUB16(FSEQLTK=_<DDIBJ&>4;@)"-.4 BR##Q5:R=J^GVR<IOM1KMOKC:!
M2B9U&TX^J>!H*W>T5>GHT'N("5<I.9G>'.(@.A^7N5>I\=&XU"16P&WGN.UZ
M,K%=)W%-8@7B3D[<J0SP=W7!C3#G3R1<Z!=2')8F8.=U;C4Z6_E7N=">&-T<
MHUN),8:5ND@CE:@19W[L2<3UM5/Z;JQ4^FCL:A(K0/=RZ%X]V=JKD[@FL0+Q
M:4Y\6AGF_&*<0QEGM;%MH2? O"PG1I66>T+9UDOI8%5Z=LF9$+L<PTQGZR(X
MW3J(U:OM2[-1"-GOW!E>',0TJ62R$@?K2K,4*)7J; "UMFDJ5]N7YJ4VL2L+
M@5U?D)E*(3+VZ\C46G28&]6J_E2XQGQ!0H$HS)6\U>@J;WA:?:<=R:*D@)TQ
MJ<KAI+E47RS ]00U/F=,/G=T39Q_ [G_ 5!+ P04    " "ABTE8]88_^XD"
M   0!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6R=E6%OVC 0AO^*
ME553*ZTD! BL"Y%H:;M*JU2UZZ9IV@>3',2J8V>V(=U^_<Y.B-B65H@OQ&?[
MWGONL,]Q)=63S@$,>2ZXT%,O-Z8\\WV=YE!0W9,E"%Q92E50@Z9:^;I40#/G
M5' _#(+(+R@37A*[N3N5Q')M.!-PIXA>%P55O\Z!RVKJ];WMQ#U;Y<9.^$E<
MTA4\@'DL[Q1:?JN2L0*$9E(0!<NI-^N?G4_L?K?A"X-*[XR)S60AY9,U;K*I
M%U@@X) :JT#QLX$+X-P*(<;/1M-K0UK'W?%6_<KECKDLJ(8+R;^RS.13;^*1
M#)9TS<V]K#Y"D\_(ZJ62:_=+JF9OX)%TK8TL&F<D*)BHO_2YJ<..0QB^X! V
M#J'CK@,YRCDU-(F5K(BRNU'-#ERJSAOAF+!_RH-1N,K0SR374F85XYQ0D9$;
M8:A8L04',M,:C":GY%(;ALE#1F9"K"DGLT(JPWY35]3+9SP=&@B>#G+%!#-P
M^@FKW"5U/ =#&=<GY(@P06XQ*"KHV#>8AH7QTP;YO$8.7T">0]HC@_X[$@;A
M@#P^S,GQT<G?,CY6H2U%V)8B=+J#PTHQ9SKE4J\5D.^SA38*#]2/+OHZRK [
MBKUD9[JD*4P]O$4:U :\Y.V;?A1\>"6'09O#X#7UY!M014!D3*P(U@F*!:AM
MK89=L+7<R,G9"[Q)!KTH]C<=#,.687@PPZB+H98;[\,P:AE&!S-$70RC_1FB
MEB$ZF&'<Q1#MSS!N&<8',TRZ&,;[,TQ:ALFK#)]SP.=B:4!U!9S\=P#[@][[
M?R+Z.PW.OA6W5*V8T(3#$MV"WAC]5=U_:\/(TO6\A3380=TPQR<+E-V ZTLI
MS=:P;;1]!),_4$L#!!0    ( *&+25C":2.8R@(  #0(   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0T+GAM;*V6;4_;,!#'OXJ5H0DDR&.3%M9&@E8(I*$A
M.L:+:2_<]-I:.'9FNRU\^]E)FJ7$5&A:7S2V<_^[WYV?,MQR\2Q7  J]Y)3)
MD;-2JKCP/)FM(,?2Y04P_6;!18Z5[HJE)PL!>%Z*<NJ%OI]X.2;,28?EV+U(
MAWRM*&%P+Y!<YSD6KU= ^7;D!,YNX($L5\H,>.FPP$N8@GHL[H7N>8V7.<F!
M2<(9$K 8.9?!Q7A@[$N#'P2VLM5&)I,9Y\^F<SL?.;X! @J9,AZP?FQ@#)0:
M1QKC=^W3:4(:8;N]\WY=YJYSF6$)8TZ?R%RM1L[ 07-8X#55#WQ[ W4^L?&7
M<2K+?[2M;/L]!V5KJ7A>BS5!3ECUQ"]U'5J"X#U!6 O"CPJB6A"5B59D95H3
MK' Z%'R+A+'6WDRCK$VIUMD09F9QJH1^2[1.I=_4"@2ZPA2S#-"T7#@34)A0
MB<[0+=L 4UR\HN-Z\$2//DXGZ/CH!!TAPM =H53/AQQZ2N,8IUY6A[ZJ0H?O
MA)Y YJ(H.$6A'T86^?CC\G!?[NDB-)4(FTJ$I;_H'RKQ\W(FE=!+[I<MS<IO
MS^[7;,,+6> ,1H[>9Q+$!IST\Z<@\;_8DOY/SO9*$#4EB YY3Q_P5J\M!8)@
M:IW02AZ7<G,^;-(P<..AMVEG4!D%?LLJ"!N;/;!> ]8["/:DCP*SV K!,Y!6
MM,I!OQ7TW$W.]WYO.+N*V$WLG''#&1_DO":,Z+TX1TO.YU;,N!,T"-WH#9G%
MJ-\J\QY:TJ E!]&:K7R*EH+;:YATXO:BSO1VC:+8#>QP_0:N?Q#NJYY4/;^[
MPZ9>V5;&?B?\6>R&;Q@KHZ1EY-L!!PW@X"#@=ZXP_4MXBA@H&]V@LT&B06=Z
M+4;="GJM,]W<IW=8+ F3B,)"RWRWK_6BNJ.JCN)%><S/N-*71ME<Z6L=A#'0
M[Q><JUW'W!S-AT+Z!U!+ P04    " "ABTE8&BIB<IL#   ?$0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T-2YX;6RU6%V/FS@4_2L6K5:M- 4,X2.S"=).
MIJ-6:K51TW8?5OO@(3<3JX"I;9+IOU\;"(&$H$9B\I 8N/?DG.-KYSJS/>,_
MQ!9 HN<TR<3<V$J9WUJ6B+>0$F&R'#+U9,-X2J2ZY$^6R#F0=9F4)I9CV[Z5
M$IH9T:R\M^31C!4RH1DL.1)%FA+^ZPX2MI\;V#C<^$*?ME+?L*)93IY@!?);
MON3JRFI0UC2%3%"6(0Z;N?$7OEW@0">4$=\I[$5KC+241\9^Z(N/Z[EA:T:0
M0"PU!%$?.UA DF@DQ>-G#6HTWZD3V^,#^D,I7HEY) (6+/F'KN5V;H0&6L.&
M%(G\PO8?H!;D:;R8):)\1_LZUC907 C)TCI9,4AI5GV2Y]J(5@*>7$APZ@3G
M=Q/<.L$MA5;,2EGW1))HQMD><1VMT/2@]*;,5FIHIJ=Q);EZ2E6>C/Z66^#H
MCB0DBP&MRLJY!TEH(M [M.2J7KC\A4BV1N]_%C17,RC1FSKBK0KYMKI';UZ_
M1:\1S=!GFB1J<L3,DHJ;_@8KKGG<53R<"SSN(3:1BV^08SMN3_KB]].=;KJE
M'&EL<1I;G!+/O8!W$'Z#ELH9>:+_WT\J''V4D(K_^J16V)-^;+TP;T5.8I@;
M:N4)X#LPHC]>8=_^LT_X2& =&]S&!G<(/>K,/QST]TFN<+P21V\=NPA[KAG.
MK%U;2T^4,S&G352'Y*0A.1DD^0F$4-M!7*1%0B2LU2I65L24Z'VBCVL%Y[=8
MO O=$Z953-".\7W3[6?J-4R]0:9?F20)RGM-O4$9]#KKG3$)[#-CSX.\T/3[
MV?H-6W^8+62Z]&FJ".] <^Q=UX,@UQ;[2& =O4&C-WC!-1^,:<-(8!T;PL:&
M<*0U'YX5G1N:^*0R>X*"2RM^VE"<#E)<Q511HAL:#Q,<1+EV3D8"ZPC&]O%G
MVG[!XJS!1W)B++2N%:V.!8]4H#509^^<FMZT_3HIUYX4M9.&_?6*C^T$'OR9
MCA8LS0NI.JUAOJ,V#F.A=24?6P?LOF3%#C8F5ULQ$EK7BF.#@H<[E"LJ]KSO
M<#S3.2W2GBAL>A>*]-B=X.'VY*'@&94%AY+GAC[K<7\O/PAT]>R,A-:5?6QS
ML/^2A3IJ_S,66M>*8P>$!SN+:PHU.&_E;?-L-SV/\LW@I$ZMUNE5_W7PF? G
MF@F4P$9EV6:@TGEU&J\N),O+ ^TCD^IX7 ZW0-; =8!ZOF%,'B[T&;GY3R3Z
M'U!+ P04    " "ABTE8#!T7 R4#  !C"0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6RMEEUOFS 4AO^*Q:JIDS8('P'2)4AMHFF35BUJUNUBVH4#
M)XE5@YEMDO;?SP;"2"!9-.T&L#GORW..OQCO&'\2&P")GE.:B8FQD3*_L2P1
M;R#%PF0Y9.K-BO$42]7D:TOD''!2BE)J.8.!;Z689$8T+OOF/!JS0E*2P9PC
M4:0IYB]W0-EN8MC&ON.!K#=2=UC1.,=K6(!\S.=<M:S&)2$I9(*P#'%838Q;
M^V8ZTO%EP#<".]%Z1CJ3)6-/NO$IF1@##0048JD=L+IM80J4:B.%\:OV-)I/
M:F'[>>_^H<Q=Y;+$ J:,?B>)W$R,T$ )K'!!Y0/;?80ZGZ'VBQD5Y17MZMB!
M@>)"2);68D60DJRZX^>Z#BV![9T0.+7 N53@U@*W3+0B*].:88FC,6<[Q'6T
M<M,/96U*M<J&9'H4%Y*KMT3I9/1%;H"C.TQQ%@-:E!-G!A(3*M [=!O'K,BD
M0'/\@I<4$,X2W<D+2-!G@I>$$DE H.M:\T:)'A<S='WU!ETADJ%[0JD:+C&V
MI*+5W[3BFNRN(G-.D,T@-I%KOT7.P'%[Y-/+Y<ZAW%(U:@KE-(5R2C_W'PKU
MXW8I)%<S\F=?FI6OU^^K5^F-R'$,$T,M0P%\"T;T^I7M#][W)?V?S Y*X#8E
M<,^Y1PM,U5!S6&*I[GHJU-_H'=W*:UAZZ;UD&]GNR%0CN6WGTQ=EFZ,FZ@#4
M:T"]LZ#[&0II3MD+@.*DBCE!,1.R%[;R"UH8H6\Z1ZS=H, QPW[488,Z/(LZ
M+3B'3*(E5_54A'K88D[R<H]+>+%&*X ^XF$'QAN:P1%Q-\@)S&$_L=\0^Q<5
M-X&M.@/R5-.?K*O?I?0Z<Z ;I":*W4\9-)3!174E6<Q20!(_JRF;5[M8'VC0
MK91G>D>@59#?"CHQ4<.&,OQ;+:O]-6_MKZS<:7!=9OIGE^WC#CO<]B!LK9\*
MO!OE!ZUA.& ?->RCL^Q?F<148W8SN)!]U%G[GA>V%E3%WHURO<#TC^"MUA&H
M?S_N,5^33" **Z4;F($RX-617C4DR\M3<<FD.F/+QXWZ"P*N ]3[%6-RW] '
M;?-?%?T&4$L#!!0    ( *&+25A*0.U+AP(  ),&   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0W+GAM;*U576^;,!3]*Q:KIE9:^4S2IB-(3:)ID]HM:M3M
M8=J#@9M@U=C,=C[Z[V<;PFA#JVK:"_C:YQS.O;8O\8Z+!UD *+0O*9,3IU"J
MNO(\F1508NGR"IA>67%18J5#L?9D)0#GEE12+_3]D5=BPIPDMG,+D<1\HRAA
ML!!(;LH2B\<I4+Z;.(%SF+@CZT*9"2^)*[R&):C[:B%TY+4J.2F!2<(9$K":
M.-?!U6QH\!;PG<!.=L;(9))R_F""+_G$\8TAH) IHX#U:PLSH-0(:1N_&TVG
M_:0A=L<']4\V=YU+BB7,./U!<E5,G$L'Y;#"&ZKN^.XS-/E8@QFGTC[1KL'Z
M#LHV4O&R(6L')6'U&^^;.G0(P> %0M@0PK<2HH80V41K9S:M.58XB07?(6'0
M6LT,;&TL6V=#F-G%I1)ZE6B>2KZI @2:8HI9!FAI#\X<%"94HG-4K]YPMCY7
M($IT0W!**%$$)#IM8&<:=[^<H].3,W2""$.WA%*]0S+VE#9H/N-EC9EI;29\
MP<P<,A=%P0<4^F'40Y^]G1X^I7NZ+&UMPK8VH=6+_J$V/Z]3J80^A+_ZTJQU
M!_VZYF)>R0IG,''TS9,@MN D[]\%(_]C7]+_2>Q)":*V!-%KZLE7SK*-$,"4
MWMF,EX 4WNO-K_ C3BGTY5X+!KY5-$UDFXQ'L;?MIE1CAAU(,'8O6] 3JX/6
MZN"M5E.!60XY,@7)!*ELP\C%9HU6T.NY5K[H^O'=Z)GI8]#8'?=['K:>AZ]Z
MKD\8;>\7_7N_^FP.C\OFCXY\'J/"L7OQS*C7:1FF7=]BL29,(@HK3?/="\T7
M=0NL \4KVT52KG1/LL-"_S5 &(!>7W&N#H%I3.U_*/D#4$L#!!0    ( *&+
M25@9WK9YRP(  *0)   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;*U6
M74_;,!3]*U:&)I!8OM,":R-!TVE[0$-T; _3'MSDMK%PXF"[+?OWLYV0I1"Z
M,O4EL>-S3NX]UU^C#>/W(@>0Z+&@I1A;N935A>.(-(<""YM54*J1!>,%EJK+
MEXZH..#,D KJ^*X[< I,2BL>F6\W/!ZQE:2DA!N.Q*HH,/]]!91MQI9G/7VX
M)<M<Z@]./*KP$F8@[ZH;KGI.JY*1 DI!6(DX+,;6I7<QC33> +X3V(A.&^E,
MYHS=Z\Z7;&RY.B"@D$JM@-5K#1.@5 NI,!X:3:O]I29VVT_JGTSN*I<Y%C!A
M] ?)9#ZVSBR4P0*OJ+QEF\_0Y&,"3!D5YHDV#=:U4+H2DA4-6450D+)^X\?&
MAP[!"U\A^ W!WY<0-(1@7T+8$,)]"5%#,*D[=>[&N 1+'(\XVR"NT4I--XS[
MAJW\(J6>)S/)U2A1/!E_E3EP=(4I+E- ,S,U$Y"84($^H%M(69D22K"I*EN@
M"1;YJ7FBZ<.*K#&%4@J$RTR!A>0DE9#5X\>-SHD2NILEZ/CH!!TA4J)K0JF2
M$R-'J@QT'$[:1'M51^N_$FT"J8T"[Q3YKA_TT"?[T_T>>K(_W>NA3_>GN]MT
M1U6M+9W?ELXW>L%_E.[GY5P50ZW"7WTFU[IAOZ[>F2Y$A5,86VKK$<#78,7O
MWWD#]V.?Y8<42PXI-CV0V%9Q@K8XP2[UV*P O2I2W8"_2Z6O'K549*3TQKZ.
M_<BSU11;=XWN00U\^WP;E>P,ZZT.'DALR\&P=3#<Z6!G.]$>]OE6"PPZCIP]
M\ZQ&##N(H?T,D^P,XZV.'4ALR[&H=2S:Z=@W)C$U9IV^F'9F+O)_6QKU3,7S
M%U.Q!S5T[>$S8VN4YW9@01AN@Z8OI;QSUPY:5.V$TSGA]/WE&O,E*06BL% \
M]6LEP.L[0=V1K#*'WIQ)=82:9JZN4< U0(TO&)-/'7V.MA>S^ ]02P,$%
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M*BK%IT['"RT*&&_HN^DVIXX$,2HE)VL2G]>)^V<2]WSTPBJY%NBYRDE^3."
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M0\)5 +Q?,B8/#?4'[54S^1]02P,$%     @ H8M)6.)J);?J @  GP@  !D
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M?:(99/L"CO*B-<3?&3+Q3RHFD-HH\#X@W_6#GH"FKZ?[/?3D]73O1#9!6][
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M2)ZV99D!9E31C-P6]8K2F7D?@Z(LDQ_0Z,M33-Z_^T#>$5:0>Y9E:""GKL)
M-)R;-)/>U),&)R;U W+/"[61Y+<BA?08P$4&+8W@A<9-8$6,(1F0T/^%!%X0
M&@):G.\>&-SC\]U]"YNP34I8X87VI/Q]A^/D5D$N_S&)7(,,S2"Z8%S+DB8P
M<[ B2! [<.8__^1'WJ\F@2X)%E\([$B\82O>T(8^_[,$@2NW6)-,RT@2+I5)
MO1IE5*'HZKB;^^,!9F_75<5@% W"8Z/88#3J&!VQ&+4L1E863]ME'3XK$IZ#
MB4 -,.Y,^]$;C'L$:J.H8^3UHK=9'(4>M:%'UM#_P-.*GYF$Z <.J.^PQ\%H
MU$^"P>AD$L8MD[&5R8+*#2DI2PF60T)SOBV4U!G)MEBV= U4&R Y,MR*JG02
MOOJ!>L;HDF5,,3!6RK%I&5[U%# 817VCV& 4#"*S I-6@8E5@:_5N8E<Z0Y9
MK0&/>GV9.+!3('(3+3NL[Y%GH$*2*Y+7!X$_(2E]-BFTL$.-&R2$;*""X2FH
MV KUQKITU4IY]3HI4R83O:((+A?C!J_Q?+^[-0?>J%^C3ICU-X@UNC=R][W#
M-<.SLG\$J01+-/\$=Y7QSE CZ$=+9-+CVMAT%_EXT#.*[:&\E6KG1N5;J=Z!
MPEVA2\%"0,J,=<\.\=JS^Z)H\:70CN4+#O(%E[C\-"B74O"2:/&ET(X5/-P>
M?>O]ZJR]%O[_/EJ<8Q3;8WDM5[?3R>0@UE5'*$E5)^MNH!UMN\Y/5:_5&[_1
MW6C5(1U@ZE;VGHHU*R2>7RN$Q!L3\A-U=UA_*%Y6_=*2*^R^JM<-=M0@M '^
MO^)<O7SH"=H>??X?4$L#!!0    ( *&+25BH<5;-!@4  "$<   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;+69[V^C-AB _Q6+G:96:@,V(4F[)-*U
MW6DGW6W19=TTG?;!(4YC'>#,-DW[W\\& @FXOJM5OK3AAU^_SVMC'F"Z9_R;
MV!(BP5.:9&+F;:7<7?N^B+<DQ6+ =B131S:,IUBJ3?[@BQTG>%TT2A,?!<'(
M3S'-O/FTV+?@\RG+94(SLN! Y&F*^?,-2=A^YD'OL.,+?=A*O<.?3W?X@2R)
MO-\MN-KRZRAKFI),4)8!3C8S[SV\OD43W: XXR]*]N+H-] H*\:^Z8V/ZYD7
MZ(Q(0F*I0V#U[Y'<DB31D50>_U5!O;I/W?#X]R'ZAP)>P:RP(+<L^9NNY7;F
M33RP)AN<)_(+V_]&*J!(QXM9(HJ_8%^=&W@@SH5D:=5899#2K/R/GZI"'#5
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MEI)S(RGLCM4D'$1M4FLFKJ2-T4"K0BBE$4)9=<R))&N%HX:-"&GD01V>JW"
MVCA]& MLE 7:7<$\<'9GN*EBGLS)JV#0OCG9NW9%:^0"6F_GY4@=+,A"J.=D
MDJ^+T03L%>YT4R5PLOYWQK</YX"-=$"[=?S.LA\H@1$NZ@YR-.D.<GE:=#K+
MFXOV-._&+>#(JH;+PX+QL5@PC F^D2I4''V(!VS, [JKA]$.JWC'PW,).S9E
M[]65JO$/Z"X@1D6$70,Q4?6A(+!Q$.@N(49-A%T+,5'UH2&HT1!DUY!7RR+J
MFHF!RMZK*U4C)L@N)J\61M2U$!-5'Q*"CEZKV"7$KHRH*QZ7P\[";>_"%:$1
M#^0B'J\S1M3UD$N(.@\L]DQ<21L/078/4;?@RQAG,4FP?JFS*=\:IM5;PQ9W
M7KPU;)5%@(Q)\$PD4*50Y\7*53:,O[B*5@D=UP5&G4<&>]JN96G,!'W73/HK
MBW$91@:C"3L/@_:T7<O2B ^ROU7IM2SF=;S[7@89EHL^_ @U?H3L?M1K6<PW
M@JY@H6@ VV7I0[!0(UC(+EC]E47:;S&3CO4CU'U6MV?_VNKX1]]O],>SSY@_
MT$PHCHT*'PS&*AU>?H\J-R3;%9]T5DQ*EA8_MP2K(N@3U/$-8_*PH;\2U5\%
MY_\#4$L#!!0    ( *&+25CI![A1#0,   \-   9    >&PO=V]R:W-H965T
M<R]S:&5E=#8V+GAM;*V776^;,!2&_XK%JJF5VO"5D- E2&M0M4KM5K7J=C'M
MPB&'Q*K!S':2]M_/-A21C*)&XB;!<-[W^#R8@YGN&'\6:P")7C*:BYFUEK*X
MM&V1K"'#8L *R-65E/$,2S7D*UL4'/#2B#)J>XX3V!DFN15-S;E['DW91E*2
MPSU'8I-EF+]> 66[F>5:;R<>R&HM]0D[FA9X!8\@GXI[KD9V[;(D&>2"L!QQ
M2&?65_<R#G6\"?A)8"<:QTA7LF#L60]NEC/+T1,""HG4#EC];6$.E&HC-8V_
ME:=5I]3"YO&;^[6I7=6RP +FC/XB2[F>61,++2'%&RH?V.X;5/6,M%_"J#"_
M:%?&!B,+)1LA65:)U0PRDI?_^*7BT!"XPW<$7B7P/BKP*X'_4<&P$@P-F;(4
MPR'&$D=3SG:(ZVCEI@\,3*-6Y9-<W_9'R=55HG0RN@4%3: +]!USCO4]0#=Y
MN9KT;3F-06)"Q9F*>'J,T>G)&3I!)$=WA%(5(*:V5+/07G929;PJ,WKO9+R&
MQ0 YDW/D.9[7(I]WRV-(!LAWC=QOD<<?EQ]DMQ6ZFI]7\_.,G]_-[_>M.H]N
M)&3B3QN2TF38;J(?[4M1X 1FEGIV!? M6-'G3V[@?&D#U*=9W)/9'CR_AN=W
MN4>FR5RP]&(C &$A0+:NITZ38^&59B-CIGOB-O+&P6 TM;=-*F64ZS3")N,Z
M9J_885WLL+/8'P7H!RQ?(:K7S#FB!"\()?*UK>9.KV-K+LW&S9I#9^ ?U-Q3
MRCTXHQK.J!/.U8;0I6+3AJ)3>2R*/LWBGLSVB 4UL:"/QA/T":]/L[@GLSUX
MXQK>N'.YW8)J-H!885YR$GB&U#L/)>J%)OFFW)&P%*4DE6NTZ%B;W6D"] J8
MM_6T>:?P6)0]F>VAG-0H)WWT\$Z38]=A:18T^ID;A@?=K*>$>TS"FDG88ZOO
M]#H63?C?Z\V=A(/) 9R>4I9P[,;N4W\JW&&^(KE0M:?*WAF,U6QXN?TN!Y(5
M9D.Z8%)M;\WA6GVQ -<!ZGK*F'P;Z#UN_0T4_0-02P,$%     @ H8M)6/<T
M&^RW @   0@  !D   !X;"]W;W)K<VAE971S+W-H965T-C<N>&ULK55M;]HP
M$/XK5E9-G=21-V!5!Y&@V;1^J(1:=?LP[8-)#K#JV)EM2OOO=[9#!BQEW=0O
MX)=[GKM[SKD;;:2ZURL 0QXK+O0X6!E37X2A+E904=V3-0B\64A548-;M0QU
MK8"6#E3Q,(FB85A1)H)LY,YF*AO)M>%,P$P1O:XJJIZFP.5F',3!]N"&+5?&
M'H39J*9+N 5S5\\4[L*6I605",VD( H6XV 27^0#:^\,OC+8Z)TUL9G,I;RW
MFZMR'$0V(.!0&,M \>\!+H%S2X1A_&PX@]:E!>ZNM^R?7>Z8RYQJN)3\&RO-
M:AR<!Z2$!5US<R,W7Z#)QP582*[=+]EXVP^#@!1K;635@#&"B@G_3Q\;'78
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MK,@ ]1F@/L;+ADRJ#Q;'[A/KPYYI'(=A%&$5G4RL"B98W:((_NQLF#;PP.)
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MD;B;1JWMN1./=%8]OWOV%"?;KNWCO%BEY,\8B]6*.AM+YZG/*TL7.IORU_#
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M-OXC;O$"4$L! A0#%     @ H8M)6 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "ABTE8)T%[_>\
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ H8M)6#1@\X(2!@
MB1D  !@              ("!O1(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( *&+25B.QQW?ZP(  $T*   8              " @049
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "ABTE8P7T@
M. H'  #,(0  &               @($F'   >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ H8M)6"Q'DAC$!P  V4@  !@
M ("!9B,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( *&+
M25@=LB8T> @  .0H   8              " @6 K  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " "ABTE8L!@G%/PG  #;?P  &
M        @($.-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( *&+25AQ?).,L@,  &,)   9              "
M@7B&  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ H8M)
M6#F*MGR-!   1PL  !D              ("!88H  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " "ABTE8 #7E+!<#  #>!@  &0
M        @($ECP  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( *&+25@";28H<@H  -,>   9              " @7.2  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ H8M)6)A9D85C"P  RA\
M !D              ("!')T  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " "ABTE8\B6!"<X&  !'$0  &0              @(&VJ
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( *&+25C(<XL7
MEP(  ,T%   9              " @;NO  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ H8M)6%UCSD>4!@  U0\  !D
M ("!B;(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "A
MBTE84>++B&0"  "0!@  &0              @(%4N0  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( *&+25B5K:3X!0H  .I0   9
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M970R-BYX;6Q02P$"% ,4    " "ABTE82O9%TL@#   &#   &0
M    @('U^P  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M *&+25@C">;5" 4  !8.   9              " @?3_  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ H8M)6& +I@O? @  / 8  !D
M             ("!,P4! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " "ABTE8-5A['1@&  !)$0  &0              @(%)" $ >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( *&+25BQ*9ZOE 8
M ),2   9              " @9@. 0!X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ H8M)6!3$P%:+!   Q@L  !D              ("!
M8Q4! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "ABTE8
ML6"/J2('   5/   &0              @($E&@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( *&+25@;+P24!Q   .JW   9
M      " @7XA 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ H8M)6 @"OYQ/!0  8AT  !D              ("!O#$! 'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "ABTE8Y!S=.'<$   "%P
M&0              @(%"-P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( *&+25AE:.@B#0<  )L_   9              " @? [ 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ H8M)6,B/.:Q7
M!@  OC   !D              ("!-$,! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " "ABTE83,D&F@\#  !G#   &0
M@('"20$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( *&+
M25CE/%B^XP(  #@(   9              " @0A- 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ H8M)6!Q^@>[H @  $@@  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( *&+25@,'1<#)0,  &,)   9
M  " @45@ 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MH8M)6$I [4N' @  DP8  !D              ("!H6,! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " "ABTE8&=ZV><L"  "D"0  &0
M            @(%?9@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( *&+25@ WI#9OP,  '8.   9              " @6%I 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ H8M)6.)J);?J @
MGP@  !D              ("!5VT! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " "ABTE8I37WV8@'   ^.@  &0              @(%X
M< $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( *&+25A\
M1*?N80,  (8.   9              " @3=X 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ H8M)6,LSD.CE P  LA4  !D
M     ("!SWL! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *&+25@@Y82$\0(  '((   9              "
M@460 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ H8M)
M6+/]BV!J P  :PP  !D              ("!;9,! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    " "ABTE8V)G56)<$  "K$   &0
M        @($.EP$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( *&+25@P*,05] ,  +H.   9              " @=R; 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ H8M)6)F^'8+I P  %!(
M !D              ("!!Z ! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    " "ABTE8IN<H=*(#  !O"P  &0              @($GI $
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( *&+25A^%J^)
MW ,  *\/   9              " @0"H 0!X;"]W;W)K<VAE971S+W-H965T
M-C0N>&UL4$L! A0#%     @ H8M)6*AQ5LT&!0  (1P  !D
M ("!$ZP! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " "A
MBTE8Z0>X40T#   /#0  &0              @(%0L0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( *&+25CW-!OLMP(   $(   9
M          " @92T 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#
M%     @ H8M)6&],8EUA P  NA8   T              ( !@K<! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " "ABTE8EXJ[',     3 @  "P
M    @ $.NP$ 7W)E;',O+G)E;'-02P$"% ,4    " "ABTE8JUOXHT8%  !G
M+   #P              @ 'WNP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ H8M)6,A<P5(@ @  T"<  !H              ( !:L$! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ H8M)6.(A,D+Q 0  &2<
M !,              ( !PL,! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ $L 2P"$%   Y,4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>224</ContextCount>
  <ElementCount>422</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements Income and Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome</Role>
      <ShortName>Consolidated Statements Income and Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecurities</Role>
      <ShortName>Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Convertible Senior Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotes</Role>
      <ShortName>Convertible Senior Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Other Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetails</Role>
      <ShortName>Other Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesTables</Role>
      <ShortName>Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/DebtSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Convertible Senior Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesTables</Role>
      <ShortName>Convertible Senior Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/ConvertibleSeniorNotes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Other Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables</Role>
      <ShortName>Other Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/OtherBalanceSheetDetails</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/EarningsPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/ShareBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails</Role>
      <ShortName>Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails</Role>
      <ShortName>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Convertible Senior Notes - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails</Role>
      <ShortName>Convertible Senior Notes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Convertible Senior Notes - 2024 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails</Role>
      <ShortName>Convertible Senior Notes - 2024 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Convertible Senior Notes - Interest Expense (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails</Role>
      <ShortName>Convertible Senior Notes - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Goodwill and Intangible Assets - Intangible Assets Amortized Over Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets Amortized Over Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Goodwill and Intangible Assets - Estimated Annual Amortization Expense for Finite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated Annual Amortization Expense for Finite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Other Balance Sheet Details - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails</Role>
      <ShortName>Other Balance Sheet Details - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails</Role>
      <ShortName>Other Balance Sheet Details - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Other Balance Sheet Details - Other Long-term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails</Role>
      <ShortName>Other Balance Sheet Details - Other Long-term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Earnings Per Share - Schedule of Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails</Role>
      <ShortName>Earnings Per Share - Schedule of Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Earnings Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails</Role>
      <ShortName>Earnings Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails</Role>
      <ShortName>Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Share-Based Compensation - Summary of Activity Related to Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Activity Related to Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails</Role>
      <ShortName>Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Income Taxes - Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails</Role>
      <ShortName>Income Taxes - Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Income Taxes - Components of the Provision for Income Taxes for Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails</Role>
      <ShortName>Income Taxes - Components of the Provision for Income Taxes for Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Leases - Supplemental Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesSupplementalInformationDetails</Role>
      <ShortName>Leases - Supplemental Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Leases - Narrative Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesNarrativeInformationDetails</Role>
      <ShortName>Leases - Narrative Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="nbix-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Retirement Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Retirement Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="nbix-20231231.htm">nbix-20231231.htm</File>
    <File>nbix-20231231.xsd</File>
    <File>nbix-20231231_cal.xml</File>
    <File>nbix-20231231_def.xml</File>
    <File>nbix-20231231_lab.xml</File>
    <File>nbix-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nbix-20231231_g1.jpg</File>
    <File>nbix-20231231_g2.jpg</File>
    <File>nbix-20231231_g3.jpg</File>
    <File>nbix-20231231_g4.jpg</File>
    <File>nbix-20231231_g5.jpg</File>
    <File>nbix-20231231_g6.jpg</File>
    <File>nbix-20231231_g7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="864">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nbix-20231231.htm": {
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "nbix-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "nbix-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "nbix-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nbix-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 369,
   "keyCustom": 53,
   "axisStandard": 27,
   "axisCustom": 1,
   "memberStandard": 37,
   "memberCustom": 30,
   "hidden": {
    "total": 18,
    "http://fasb.org/us-gaap/2023": 8,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://xbrl.sec.gov/ecd/2023": 6
   },
   "contextCount": 224,
   "entityCount": 1,
   "segmentCount": 70,
   "elementCount": 695,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 864,
    "http://xbrl.sec.gov/ecd/2023": 43,
    "http://xbrl.sec.gov/dei/2023": 38
   },
   "report": {
    "R1": {
     "role": "http://www.neurocrine.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.neurocrine.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
     "longName": "0000005 - Statement - Consolidated Statements Income and Comprehensive Income",
     "shortName": "Consolidated Statements Income and Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "longName": "0000008 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.neurocrine.com/role/CollaborationandLicenseAgreements",
     "longName": "0000009 - Disclosure - Collaboration and License Agreements",
     "shortName": "Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.neurocrine.com/role/DebtSecurities",
     "longName": "0000010 - Disclosure - Debt Securities",
     "shortName": "Debt Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.neurocrine.com/role/FairValueMeasurements",
     "longName": "0000011 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotes",
     "longName": "0000012 - Disclosure - Convertible Senior Notes",
     "shortName": "Convertible Senior Notes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.neurocrine.com/role/GoodwillandIntangibleAssets",
     "longName": "0000013 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetails",
     "longName": "0000014 - Disclosure - Other Balance Sheet Details",
     "shortName": "Other Balance Sheet Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.neurocrine.com/role/EarningsPerShare",
     "longName": "0000015 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.neurocrine.com/role/ShareBasedCompensation",
     "longName": "0000016 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.neurocrine.com/role/IncomeTaxes",
     "longName": "0000017 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.neurocrine.com/role/Leases",
     "longName": "0000018 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.neurocrine.com/role/RetirementPlan",
     "longName": "0000019 - Disclosure - Retirement Plan",
     "shortName": "Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.neurocrine.com/role/LegalProceedings",
     "longName": "0000020 - Disclosure - Legal Proceedings",
     "shortName": "Legal Proceedings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbix:OrganizationAndBusinessDescriptionPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbix:OrganizationAndBusinessDescriptionPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.neurocrine.com/role/DebtSecuritiesTables",
     "longName": "9954472 - Disclosure - Debt Securities (Tables)",
     "shortName": "Debt Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsTables",
     "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables",
     "longName": "9954474 - Disclosure - Convertible Senior Notes (Tables)",
     "shortName": "Convertible Senior Notes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables",
     "longName": "9954475 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables",
     "longName": "9954476 - Disclosure - Other Balance Sheet Details (Tables)",
     "shortName": "Other Balance Sheet Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.neurocrine.com/role/EarningsPerShareTables",
     "longName": "9954477 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationTables",
     "longName": "9954478 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.neurocrine.com/role/IncomeTaxesTables",
     "longName": "9954479 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.neurocrine.com/role/LeasesTables",
     "longName": "9954480 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9954481 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
     "longName": "9954482 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-82",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
     "longName": "9954483 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)",
     "shortName": "Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
     "longName": "9954484 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)",
     "shortName": "Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-99",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-99",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9954485 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:Investments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:Investments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
     "longName": "9954486 - Disclosure - Convertible Senior Notes - Additional Information (Details)",
     "shortName": "Convertible Senior Notes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-148",
      "name": "us-gaap:DebtInstrumentRepurchasedFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
     "longName": "9954487 - Disclosure - Convertible Senior Notes - 2024 Notes (Details)",
     "shortName": "Convertible Senior Notes - 2024 Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ConvertibleDebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-150",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
     "longName": "9954488 - Disclosure - Convertible Senior Notes - Interest Expense (Details)",
     "shortName": "Convertible Senior Notes - Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nbix:DebtInstrumentCouponInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nbix:DebtInstrumentCouponInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails",
     "longName": "9954489 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)",
     "shortName": "Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails",
     "longName": "9954490 - Disclosure - Goodwill and Intangible Assets - Intangible Assets Amortized Over Estimated Useful Lives (Details)",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets Amortized Over Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-157",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails",
     "longName": "9954491 - Disclosure - Goodwill and Intangible Assets - Estimated Annual Amortization Expense for Finite-Lived Intangible Assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Estimated Annual Amortization Expense for Finite-Lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails",
     "longName": "9954492 - Disclosure - Other Balance Sheet Details - Inventory (Details)",
     "shortName": "Other Balance Sheet Details - Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails",
     "longName": "9954493 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details)",
     "shortName": "Other Balance Sheet Details - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails",
     "longName": "9954494 - Disclosure - Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)",
     "shortName": "Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedMarketingCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedMarketingCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails",
     "longName": "9954495 - Disclosure - Other Balance Sheet Details - Other Long-term Liabilities (Details)",
     "shortName": "Other Balance Sheet Details - Other Long-term Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "longName": "9954496 - Disclosure - Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails",
     "longName": "9954497 - Disclosure - Earnings Per Share - Schedule of Net Income (Loss) Per Share (Details)",
     "shortName": "Earnings Per Share - Schedule of Net Income (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails",
     "longName": "9954498 - Disclosure - Earnings Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)",
     "shortName": "Earnings Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-166",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-166",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "longName": "9954499 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails",
     "longName": "9954500 - Disclosure - Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)",
     "shortName": "Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-173",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
     "longName": "9954501 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)",
     "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-179",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
     "longName": "9954502 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-191",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-191",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails",
     "longName": "9954503 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)",
     "shortName": "Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-179",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-179",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails",
     "longName": "9954504 - Disclosure - Share-Based Compensation - Summary of Activity Related to Stock Options (Details)",
     "shortName": "Share-Based Compensation - Summary of Activity Related to Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
     "longName": "9954505 - Disclosure - Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)",
     "shortName": "Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-196",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-196",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails",
     "longName": "9954506 - Disclosure - Income Taxes - Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations (Details)",
     "shortName": "Income Taxes - Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails",
     "longName": "9954507 - Disclosure - Income Taxes - Components of the Provision for Income Taxes for Continuing Operations (Details)",
     "shortName": "Income Taxes - Components of the Provision for Income Taxes for Continuing Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails",
     "longName": "9954508 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)",
     "shortName": "Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails",
     "longName": "9954509 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Components of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9954510 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IncomeTaxExaminationInterestAccrued",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails",
     "longName": "9954511 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails",
     "longName": "9954512 - Disclosure - Leases - Supplemental Information (Details)",
     "shortName": "Leases - Supplemental Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails",
     "longName": "9954513 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails",
     "longName": "9954514 - Disclosure - Leases - Narrative Information (Details)",
     "shortName": "Leases - Narrative Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-206",
      "name": "nbix:LesseeOperatingLeaseOptionTermToConstructBuilding",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails",
     "longName": "9954515 - Disclosure - Retirement Plan - Additional Information (Details)",
     "shortName": "Retirement Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "nbix_A2019VoyagerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "A2019VoyagerAgreementMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Voyager Agreement",
        "label": "2019 Voyager Agreement [Member]",
        "documentation": "2019 Voyager Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_A2023VoyagerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "A2023VoyagerAgreementMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Voyager Agreement",
        "label": "2023 Voyager Agreement [Member]",
        "documentation": "2023 Voyager Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_AbbVieIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AbbVieIncMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AbbVie Inc.",
        "label": "AbbVie Inc. [Member]",
        "documentation": "AbbVie Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update [Extensible List]",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r238",
      "r239",
      "r240",
      "r288",
      "r289",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r386",
      "r503",
      "r504",
      "r505",
      "r539",
      "r540",
      "r550",
      "r551",
      "r552",
      "r558",
      "r559",
      "r560",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r590",
      "r591",
      "r595",
      "r596",
      "r597",
      "r598",
      "r608",
      "r609",
      "r613",
      "r614",
      "r615",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r945"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and other accrued liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Accretion) amortization of (discount) premium on investments, net",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "nbix_AccruedBrandedPrescriptionDrugFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AccruedBrandedPrescriptionDrugFee",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current branded prescription drug fee",
        "label": "Accrued Branded Prescription Drug Fee",
        "documentation": "Accrued Branded Prescription Drug Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income taxes payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r147"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent income taxes payable",
        "label": "Accrued Income Taxes, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r147"
     ]
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedMarketingCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales rebates and reserves",
        "label": "Accrued Marketing Costs, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "nbix_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued development costs",
        "label": "Accrued Research And Development Expense Current",
        "documentation": "Accrued research and development expense current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r191",
      "r688"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r106",
      "r197",
      "r684",
      "r712",
      "r716"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r33",
      "r562",
      "r565",
      "r635",
      "r707",
      "r708",
      "r932",
      "r933",
      "r934",
      "r942",
      "r943",
      "r944"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r505",
      "r722",
      "r942",
      "r943",
      "r944",
      "r1017",
      "r1038"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r465"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash from operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising Expense",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising expense",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r854",
      "r864",
      "r890"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r857",
      "r867",
      "r893"
     ]
    },
    "nbix_AgreementTerminationByCounterpartyContractualTimeThreshold": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AgreementTerminationByCounterpartyContractualTimeThreshold",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement termination by counterparty, contractual time threshold (in days)",
        "label": "Agreement Termination By Counterparty, Contractual Time Threshold",
        "documentation": "Agreement Termination By Counterparty, Contractual Time Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_AgreementTerminationByCounterpartyMinimalContractualTime": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AgreementTerminationByCounterpartyMinimalContractualTime",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement termination by counterparty, minimal contractual time (in days)",
        "label": "Agreement Termination By Counterparty, Minimal Contractual Time",
        "documentation": "Agreement Termination By Counterparty, Minimal Contractual Time"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_AgreementTerminationContractualTimeThreshold": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AgreementTerminationContractualTimeThreshold",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement termination, contractual time threshold (in days)",
        "label": "Agreement Termination, Contractual Time Threshold",
        "documentation": "Agreement Termination, Contractual Time Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_AgreementTerminationDueToMaterialBreach": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AgreementTerminationDueToMaterialBreach",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement termination, due to material breach (in days)",
        "label": "Agreement Termination, Due To Material Breach",
        "documentation": "Agreement Termination, Due To Material Breach"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_AgreementTerminationMinimalContractualTime": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AgreementTerminationMinimalContractualTime",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement termination, minimal contractual time (in days)",
        "label": "Agreement Termination, Minimal Contractual Time",
        "documentation": "Agreement Termination, Minimal Contractual Time"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r858",
      "r868",
      "r885",
      "r894",
      "r898",
      "r906"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r510"
     ]
    },
    "nbix_Amended2018EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "Amended2018EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended 2018 Employee Stock Purchase Plan",
        "label": "Amended 2018 Employee Stock Purchase Plan [Member]",
        "documentation": "Amended 2018 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_Amended2020EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "Amended2020EquityIncentivePlanMember",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended 2020 Equity Incentive Plan",
        "label": "Amended 2020 Equity Incentive Plan [Member]",
        "documentation": "Amended 2020 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r83",
      "r114",
      "r425"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r425",
      "r611",
      "r936"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount and issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r611",
      "r802",
      "r803",
      "r936"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r57",
      "r63"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Anti-dilutive shares excluded from diluted per share amounts (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r195",
      "r228",
      "r272",
      "r279",
      "r283",
      "r327",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r554",
      "r556",
      "r594",
      "r681",
      "r745",
      "r816",
      "r831",
      "r976",
      "r977",
      "r1021"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r201",
      "r228",
      "r327",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r554",
      "r556",
      "r594",
      "r816",
      "r976",
      "r977",
      "r1021"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of assets on recurring basis",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.neurocrine.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r850"
     ]
    },
    "nbix_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.neurocrine.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r850"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.neurocrine.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r850"
     ]
    },
    "nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain, current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current",
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain, noncurrent",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent",
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized loss, current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current",
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized loss, noncurrent",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent",
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities available-for-sale",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r354"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities available-for-sale",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r292",
      "r354"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "nbix_BIALPortelaCaSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "BIALPortelaCaSAMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BIAL \u2013 Portela &amp; Ca, S.A.",
        "label": "BIAL \u2013 Portela &amp; Ca, S.A. [Member]",
        "documentation": "BIAL \u2013 Portela &amp; Ca, S.A."
       }
      }
     },
     "auth_ref": []
    },
    "nbix_BoardOfDirectorsMaximumDurationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "BoardOfDirectorsMaximumDurationTerm",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of directors maximum duration term (in years)",
        "label": "Board Of Directors Maximum Duration Term",
        "documentation": "Board Of Directors Maximum Duration Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations [Abstract]",
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations and Asset Acquisitions",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Summary of Significant Accounting Policies",
        "label": "Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash capital expenditures",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r188",
      "r786"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "nbix_CashAndMoneyMarketFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "CashAndMoneyMarketFundMember",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and money market funds",
        "label": "Cash And Money Market Fund [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r116",
      "r226"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Change in cash and cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r116"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r823",
      "r824",
      "r825",
      "r826"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "nbix_CollaborationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "CollaborationRevenueMember",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenue",
        "label": "Collaboration Revenue [Member]",
        "documentation": "Collaboration revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r166",
      "r177"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r823",
      "r824",
      "r825",
      "r826"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/LegalProceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Legal Proceedings",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r388",
      "r389",
      "r781",
      "r973"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r820",
      "r821",
      "r823",
      "r824",
      "r825",
      "r826",
      "r942",
      "r943",
      "r1017",
      "r1036",
      "r1038"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r733"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r97",
      "r733",
      "r751",
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 220.0 shares authorized; 98.7 and 96.5 shares issued and outstanding, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r683",
      "r816"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r207",
      "r209",
      "r216",
      "r674",
      "r694"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r49",
      "r81",
      "r82",
      "r287",
      "r780"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r49",
      "r81",
      "r82",
      "r287",
      "r717",
      "r780"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r49",
      "r81",
      "r82",
      "r287",
      "r780",
      "r914"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r168"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r49",
      "r81",
      "r82",
      "r287"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r49",
      "r81",
      "r82",
      "r287",
      "r780"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r791"
     ]
    },
    "nbix_ConversionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "ConversionPeriodOneMember",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Period One",
        "label": "Conversion Period One [Member]",
        "documentation": "Conversion Period One"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_ConversionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "ConversionPeriodTwoMember",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Period Two",
        "label": "Conversion Period Two [Member]",
        "documentation": "Conversion Period Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible senior notes",
        "terseLabel": "Net Carrying Amount",
        "label": "Convertible Debt, Current",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r809",
      "r1035"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenues",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r669"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenues",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r407",
      "r431",
      "r636",
      "r788",
      "r790"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for Credit Losses",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r362"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r237",
      "r243",
      "r249",
      "r331",
      "r337",
      "r503",
      "r504",
      "r505",
      "r539",
      "r540",
      "r561",
      "r562",
      "r563",
      "r565",
      "r566",
      "r567",
      "r572",
      "r575",
      "r577",
      "r578",
      "r633"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]",
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r237",
      "r243",
      "r249",
      "r331",
      "r337",
      "r503",
      "r504",
      "r505",
      "r539",
      "r540",
      "r561",
      "r562",
      "r563",
      "r565",
      "r566",
      "r567",
      "r572",
      "r575",
      "r577",
      "r578",
      "r633"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]",
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r237",
      "r243",
      "r249",
      "r331",
      "r337",
      "r503",
      "r504",
      "r505",
      "r539",
      "r540",
      "r561",
      "r562",
      "r563",
      "r565",
      "r566",
      "r567",
      "r572",
      "r575",
      "r577",
      "r578",
      "r633"
     ]
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r940",
      "r1016"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current income taxes",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r538",
      "r544",
      "r940"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r940",
      "r1016"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r287"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Senior Notes",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r227",
      "r403",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r419",
      "r426",
      "r427",
      "r429"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r91",
      "r92",
      "r146",
      "r149",
      "r233",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r612",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r938"
     ]
    },
    "nbix_DebtInstrumentConversionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "DebtInstrumentConversionAxis",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Conversion [Axis]",
        "label": "Debt Instrument, Conversion [Axis]",
        "documentation": "Debt Instrument, Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_DebtInstrumentConversionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "DebtInstrumentConversionDomain",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Conversion [Domain]",
        "label": "Debt Instrument, Conversion [Domain]",
        "documentation": "Debt Instrument, Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_DebtInstrumentConvertibleConversionPremium": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "DebtInstrumentConvertibleConversionPremium",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion premium",
        "label": "Debt Instrument Convertible Conversion Premium",
        "documentation": "The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price (in USD per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r406"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion ratio",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r68",
      "r132",
      "r133",
      "r406"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleStockPriceTrigger",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock price trigger (in USD per share)",
        "label": "Debt Instrument, Convertible, Stock Price Trigger",
        "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold consecutive common stock trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold percentage of common stock price trigger",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold common stock trading days",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "nbix_DebtInstrumentCouponInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "DebtInstrumentCouponInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coupon interest",
        "label": "Debt Instrument, Coupon Interest",
        "documentation": "Debt Instrument, Coupon Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Principal Amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r86",
      "r404",
      "r612",
      "r800",
      "r801"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value, Amount",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r593",
      "r800",
      "r801"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stated interest rate percentage",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r405"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r428",
      "r612",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r938"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r233",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r612",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r938"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption rate",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount repurchased",
        "label": "Debt Instrument, Repurchased Face Amount",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r68",
      "r69",
      "r83",
      "r84",
      "r86",
      "r88",
      "r131",
      "r133",
      "r233",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r428",
      "r612",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r938"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest receivables write-off threshold period",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, Threshold Period, Writeoff",
        "documentation": "Period when accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), is considered uncollectible and written off, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestWriteoff",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest receivables write-off",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest Writeoff",
        "documentation": "Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost, current",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r953"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost, noncurrent",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r953"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 Months or Longer, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r361",
      "r797"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "12 Months or Longer, Unrealized Loss",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r361"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less Than 12 Months, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r361",
      "r797"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Than 12 Months, Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r361"
     ]
    },
    "nbix_DebtSecuritiesAvailableForSaleFairValueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleFairValueCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, current",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Current",
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Current"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleFairValueNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value, noncurrent",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Noncurrent",
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r359",
      "r797"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r360"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r797",
      "r960"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unamortized Issuance Costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r979"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r520"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r140",
      "r173",
      "r543",
      "r544",
      "r940"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "nbix_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r148",
      "r532"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1015",
      "r1016"
     ]
    },
    "nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development",
        "label": "Deferred Tax Assets Capitalized Research And Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs capitalized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "nbix_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_DeferredTaxAssetsLiabilitiesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "DeferredTaxAssetsLiabilitiesGross",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net of deferred tax assets and liabilities",
        "label": "Deferred Tax Assets Liabilities Gross",
        "documentation": "Deferred tax assets (liabilities) gross."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "nbix_DeferredTaxAssetsOperatingLeasesAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeasesAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets",
        "label": "Deferred Tax Assets Operating Leases Assets",
        "documentation": "Deferred tax assets operating leases assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r1014"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r1014"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "verboseLabel": "Research and development tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r1014"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r1014"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Deferred tax assets, valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "DeferredTaxLiabilitiesOperatingLeasesLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Liabilities Operating Leases Liabilities",
        "documentation": "Deferred tax liabilities operating leases liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r1014"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, employer contribution amount",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, maximum employee contribution percentage",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r64"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed product rights",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r468",
      "r499",
      "r500",
      "r502",
      "r811"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r850"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r850",
      "r886"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "nbix_ESPPPurchasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "ESPPPurchasePeriod",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP purchase period",
        "label": "ESPP Purchase Period",
        "documentation": "ESPP Purchase Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share, basic (in USD per share)",
        "verboseLabel": "Basic (in USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r251",
      "r254",
      "r264",
      "r265",
      "r266",
      "r270",
      "r578",
      "r579",
      "r675",
      "r695",
      "r793"
     ]
    },
    "nbix_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share:",
        "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]",
        "documentation": "Earnings Per Share, Basic and Diluted EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share, diluted (in USD per share)",
        "verboseLabel": "Diluted (in USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r254",
      "r264",
      "r265",
      "r266",
      "r270",
      "r578",
      "r579",
      "r675",
      "r695",
      "r793"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r267",
      "r268",
      "r269"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal income taxes, rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r522",
      "r546"
     ]
    },
    "nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of convertible senior notes",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Loss On Extinguishment Of Convertible Senior Notes",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Loss On Extinguishment Of Convertible Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued employee related costs",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Recognition Period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r181",
      "r211",
      "r212",
      "r213",
      "r234",
      "r235",
      "r236",
      "r239",
      "r246",
      "r248",
      "r271",
      "r331",
      "r337",
      "r433",
      "r503",
      "r504",
      "r505",
      "r539",
      "r540",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r577",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r635",
      "r707",
      "r708",
      "r709",
      "r722",
      "r772"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beneficial ownership (as a percent)",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities purchase date fair value amount",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiCost",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities cost",
        "label": "Equity Securities, FV-NI, Cost",
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r592",
      "r678"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on equity securities",
        "negatedLabel": "Changes in fair value of equity securities",
        "verboseLabel": "Unrealized gain (loss) included in earnings",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r958"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r827",
      "r828",
      "r829",
      "r1040"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "nbix_EricBenevich2023PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "EricBenevich2023PlanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eric Benevich 2023 Plan [Member]",
        "documentation": "Eric Benevich 2023 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_EricBenevich2024PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "EricBenevich2024PlanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eric Benevich 2024 Plan [Member]",
        "documentation": "Eric Benevich 2024 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_EricBenevichMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "EricBenevichMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eric Benevich [Member]",
        "documentation": "Eric Benevich"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r854",
      "r864",
      "r890"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r851",
      "r861",
      "r887"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r583",
      "r586"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r583",
      "r586"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r143"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r583",
      "r640",
      "r641",
      "r642",
      "r800",
      "r801",
      "r807",
      "r808",
      "r809"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r583",
      "r584",
      "r585",
      "r587"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r447",
      "r452",
      "r583",
      "r640",
      "r807",
      "r808",
      "r809"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r447",
      "r452",
      "r583",
      "r641",
      "r800",
      "r801",
      "r807",
      "r808",
      "r809"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r640",
      "r641",
      "r642",
      "r800",
      "r801",
      "r807",
      "r808",
      "r809"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r587"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r20"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r342",
      "r343",
      "r344",
      "r345",
      "r350",
      "r358",
      "r362",
      "r363",
      "r428",
      "r432",
      "r568",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r693",
      "r797",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful Life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r382"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r381",
      "r382",
      "r384",
      "r670",
      "r671"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r671"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r62"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r670"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r858",
      "r868",
      "r894"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r858",
      "r868",
      "r894"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r858",
      "r868",
      "r894"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r858",
      "r868",
      "r894"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r858",
      "r868",
      "r894"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of convertible senior notes",
        "negatedTerseLabel": "Loss on extinguishment of convertible senior notes",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r66",
      "r67"
     ]
    },
    "nbix_GeorgeMorrowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "GeorgeMorrowMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "George Morrow [Member]",
        "documentation": "George Morrow"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Goodwill, at beginning period",
        "periodEndLabel": "Goodwill, at ending period",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r367",
      "r672",
      "r798",
      "r816",
      "r962",
      "r969"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill recognized in connection with business combination",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r798"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, Intangible Assets and Other Long-Lived Assets",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r55"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r798"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "nbix_HeptaresTherapeuticsLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "HeptaresTherapeuticsLimitedMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Heptares",
        "label": "Heptares Therapeutics Limited [Member]",
        "documentation": "Heptares Therapeutics Limited"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r850"
     ]
    },
    "nbix_IdorsiaPharmaceuticalsLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "IdorsiaPharmaceuticalsLtdMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Idorsia",
        "label": "Idorsia Pharmaceuticals Ltd [Member]",
        "documentation": "Idorsia Pharmaceuticals Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired IPR&amp;D",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r545"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before provision for income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r107",
      "r151",
      "r272",
      "r278",
      "r282",
      "r284",
      "r676",
      "r690",
      "r795"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r545"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r387",
      "r756"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r756"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r514",
      "r523",
      "r530",
      "r536",
      "r541",
      "r547",
      "r548",
      "r549",
      "r721"
     ]
    },
    "us-gaap_IncomeTaxExaminationInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest accrued",
        "label": "Income Tax Examination, Interest Accrued",
        "documentation": "The amount of estimated interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penalties accrued",
        "label": "Income Tax Examination, Penalties Accrued",
        "documentation": "The amount of estimated penalties accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforIncomeTaxesforContinuingOperationsDetails",
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r175",
      "r247",
      "r248",
      "r276",
      "r521",
      "r542",
      "r697"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r517",
      "r518",
      "r530",
      "r531",
      "r535",
      "r537",
      "r719"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r522"
     ]
    },
    "nbix_IncomeTaxReconciliationExpirationOfTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "IncomeTaxReconciliationExpirationOfTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired tax attributes",
        "label": "Income Tax Reconciliation Expiration Of Tax Credits",
        "documentation": "Income tax reconciliation, expiration of tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal income taxes at 21%",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Branded prescription drug fee",
        "label": "Income Tax Reconciliation Nondeductible Expense Branded Prescription Drug Fee",
        "documentation": "Income tax reconciliation nondeductible expense branded prescription drug fee."
       }
      }
     },
     "auth_ref": []
    },
    "nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officer compensation",
        "label": "Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost",
        "documentation": "Income tax reconciliation nondeductible expense officer compensation cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "nbix_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r41"
     ]
    },
    "nbix_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "documentation": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets and liabilities, net",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r266",
      "r467"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r383"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Carrying Amount",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r125"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r858",
      "r868",
      "r885",
      "r894",
      "r898",
      "r906"
     ]
    },
    "nbix_IngridDelaetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "IngridDelaetMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ingrid Delaet [Member]",
        "documentation": "Ingrid Delaet"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r910"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r910"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r910"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r61"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r153",
      "r214",
      "r275",
      "r610",
      "r757",
      "r830",
      "r1037"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r224",
      "r225"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest receivables",
        "label": "Interest Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Tax Authority",
        "label": "Internal Revenue Service (IRS) [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory, gross",
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, net",
        "totalLabel": "Total inventory, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r787",
      "r816"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r187",
      "r198",
      "r364",
      "r365",
      "r366",
      "r668",
      "r792"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserves",
        "negatedTerseLabel": "Less inventory reserves",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r931"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "nbix_InvestmentIncomeAndOtherNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "InvestmentIncomeAndOtherNet",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income and other, net",
        "label": "Investment Income And Other Net",
        "documentation": "Investment income and other net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Investments",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value",
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r154",
      "r155",
      "r178",
      "r290",
      "r293",
      "r588",
      "r589"
     ]
    },
    "nbix_LargestFourCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "LargestFourCustomersMember",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Largest Four Customers",
        "label": "Largest Four Customers [Member]",
        "documentation": "Largest Four Customers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Description of Operating Lease",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesOperatingAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Leases, Operating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_LeslieNorwalkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "LeslieNorwalkMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leslie Norwalk [Member]",
        "documentation": "Leslie Norwalk"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails",
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails",
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Liability Maturity",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease payments (sublease income)",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less accreted interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "nbix_LesseeOperatingLeaseOptionTermToConstructBuilding": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "LesseeOperatingLeaseOptionTermToConstructBuilding",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee option term for construction of fifth building",
        "label": "Lessee, Operating Lease, Option Term To Construct Building",
        "documentation": "Description of term of lessee's option for the construction of a fifth building under operating lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease Income",
        "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating lease payments (sublease income)",
        "label": "Lessor, Operating Lease, Payment to be Received",
        "documentation": "Amount of lease payments to be received by lessor for operating lease."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Year ending December 31, 2028",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Five",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Year ending December 31, 2027",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Year ending December 31, 2024",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Thereafter",
        "label": "Lessor, Operating Lease, Payment to be Received, after Year Five",
        "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Year ending December 31, 2026",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Year ending December 31, 2025",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r228",
      "r327",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r555",
      "r556",
      "r557",
      "r594",
      "r732",
      "r794",
      "r831",
      "r976",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r150",
      "r686",
      "r816",
      "r939",
      "r959",
      "r1018"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r186",
      "r228",
      "r327",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r555",
      "r556",
      "r557",
      "r594",
      "r816",
      "r976",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r806",
      "r980",
      "r1033",
      "r1034"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r393",
      "r462",
      "r667",
      "r704",
      "r724",
      "r725",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r782",
      "r783",
      "r796",
      "r804",
      "r810",
      "r818",
      "r978",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "nbix_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "MilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "label": "Milestone Payment",
        "documentation": "Payments made for milestones under a collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r393",
      "r462",
      "r667",
      "r704",
      "r724",
      "r725",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r782",
      "r783",
      "r796",
      "r804",
      "r810",
      "r818",
      "r978",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "MinimumPercentageOfTradingPriceToLastReportedSalePrice",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum percentage of common stock price trigger",
        "label": "Minimum Percentage Of Trading Price To Last Reported Sale Price",
        "documentation": "The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage."
       }
      }
     },
     "auth_ref": []
    },
    "nbix_MitsubishiTanabePharmaCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "MitsubishiTanabePharmaCorporationMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MTPC",
        "label": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "documentation": "Information related to the Mitsubishi Tanabe Pharma Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r806",
      "r980",
      "r1033",
      "r1034"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "verboseLabel": "Net income",
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r118",
      "r152",
      "r184",
      "r205",
      "r208",
      "r213",
      "r228",
      "r238",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r262",
      "r272",
      "r278",
      "r282",
      "r284",
      "r327",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r579",
      "r594",
      "r691",
      "r753",
      "r770",
      "r771",
      "r795",
      "r830",
      "r976"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income - basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r241",
      "r242",
      "r243",
      "r244",
      "r251",
      "r252",
      "r263",
      "r266",
      "r272",
      "r278",
      "r282",
      "r284",
      "r795"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income - diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r253",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r266"
     ]
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for thereafter",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, After Year Four",
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2028",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five",
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2027",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four",
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2026",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three",
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2025",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two",
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r858",
      "r868",
      "r885",
      "r894"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_NumberOfGeneTherapyPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "NumberOfGeneTherapyPrograms",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of gene therapy programs",
        "label": "Number Of Gene Therapy Programs",
        "documentation": "Number Of Gene Therapy Programs"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_NumberOfNonClinicalStageCompound": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "NumberOfNonClinicalStageCompound",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of non-clinical stage compounds",
        "label": "Number Of Non-clinical Stage Compound",
        "documentation": "Number Of Non-clinical Stage Compound"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "nbix_NumberOfPreclinicalCandidates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "NumberOfPreclinicalCandidates",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of preclinical candidates",
        "label": "Number Of Preclinical Candidates",
        "documentation": "Number Of Preclinical Candidates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "nbix_NumberOfUndisclosedPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "NumberOfUndisclosedPrograms",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of undisclosed programs",
        "label": "Number Of Undisclosed Programs",
        "documentation": "Number Of Undisclosed Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r278",
      "r282",
      "r284",
      "r795"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails": {
       "parentTag": "nbix_OperatingLeaseCostNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r815"
     ]
    },
    "nbix_OperatingLeaseCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "OperatingLeaseCostNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net operating lease cost",
        "label": "Operating Lease, Cost, Net",
        "documentation": "Operating Lease, Cost, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails",
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "terseLabel": "Operating lease, liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less current operating lease liabilities included in other current liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/LeasesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r625"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r815"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r815"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "nbix_OrganizationAndBusinessDescriptionPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "OrganizationAndBusinessDescriptionPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Business",
        "label": "Organization And Business Description Policy [Policy Text Block]",
        "documentation": "Business Description Policy [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Organization and summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "documentation": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r816"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "nbix_OtherBalanceSheetDetailsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "OtherBalanceSheetDetailsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Balance Sheet Details [Abstract]",
        "label": "Other Balance Sheet Details [Abstract]",
        "documentation": "Other balance sheet details."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign currency translation adjustments, net of tax",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r12",
      "r142"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on debt securities available-for-sale, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r19",
      "r206",
      "r209",
      "r215",
      "r601",
      "r602",
      "r607",
      "r673",
      "r692",
      "r932",
      "r933"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r816"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Liabilities",
        "label": "Other Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Operating Activities, Cash Flow Statement",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r856",
      "r866",
      "r892"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r859",
      "r869",
      "r895"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r859",
      "r869",
      "r895"
     ]
    },
    "nbix_PatentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "PatentTerm",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent term (in years)",
        "label": "Patent term",
        "documentation": "Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of debt securities available-for-sale",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r219",
      "r291"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of business, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of equity securities",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r222"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Capital expenditures",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/RetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r809"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "nbix_PerformanceBasedRestrictedStockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "PerformanceBasedRestrictedStockUnitMember",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PRSUs",
        "label": "Performance Based Restricted Stock Unit [Member]",
        "documentation": "Restricted stock units which are awarded to employees after certain performance targets are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008"
     ]
    },
    "nbix_PotentialMilestonePaymentReceipts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "PotentialMilestonePaymentReceipts",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payment receipts",
        "label": "Potential Milestone Payment Receipts",
        "documentation": "Potential later stage milestone payments and royalties."
       }
      }
     },
     "auth_ref": []
    },
    "nbix_PotentialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "PotentialMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payments",
        "label": "Potential Milestone Payments",
        "documentation": "The amount of potential milestone payments to be paid under a license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r430"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r733"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r430"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r733",
      "r751",
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r682",
      "r816"
     ]
    },
    "nbix_PrescriptionDrugFeeNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "PrescriptionDrugFeeNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent branded prescription drug fee",
        "label": "Prescription Drug Fee, Noncurrent",
        "documentation": "Prescription Drug Fee, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_PrincipalAmountOnConversionRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "PrincipalAmountOnConversionRate",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount on conversion rate",
        "label": "Principal Amount On Conversion Rate",
        "documentation": "Principal amount on conversion rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances of common stock under benefit plans",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and maturities of debt securities available-for-sale",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r952"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received from stock option exercises",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r17"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net product sales",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r669",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r785",
      "r805",
      "r817",
      "r915",
      "r974",
      "r975",
      "r980",
      "r1033"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r669",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r785",
      "r805",
      "r817",
      "r915",
      "r974",
      "r975",
      "r980",
      "r1033"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r190",
      "r689"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r677",
      "r689",
      "r816"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r169",
      "r172",
      "r687"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r393",
      "r445",
      "r462",
      "r494",
      "r495",
      "r496",
      "r643",
      "r667",
      "r704",
      "r724",
      "r725",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r782",
      "r783",
      "r796",
      "r804",
      "r810",
      "r818",
      "r821",
      "r972",
      "r978",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r393",
      "r445",
      "r462",
      "r494",
      "r495",
      "r496",
      "r643",
      "r667",
      "r704",
      "r724",
      "r725",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r782",
      "r783",
      "r796",
      "r804",
      "r810",
      "r818",
      "r821",
      "r972",
      "r978",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r851",
      "r861",
      "r887"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchases of convertible senior notes",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate repurchase price paid in cash",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r407",
      "r431",
      "r636",
      "r789",
      "r790"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Writeoff",
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r1009"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r513",
      "r1029"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development, or R&amp;D",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r852",
      "r862",
      "r888"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r853",
      "r863",
      "r889"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r860",
      "r870",
      "r896"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r937",
      "r1030",
      "r1032"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r134",
      "r685",
      "r711",
      "r716",
      "r720",
      "r734",
      "r816"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r234",
      "r235",
      "r236",
      "r239",
      "r246",
      "r248",
      "r331",
      "r337",
      "r503",
      "r504",
      "r505",
      "r539",
      "r540",
      "r561",
      "r563",
      "r564",
      "r567",
      "r577",
      "r707",
      "r709",
      "r722",
      "r1038"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r277",
      "r280",
      "r281",
      "r285",
      "r286",
      "r287",
      "r442",
      "r443",
      "r669"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r784"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_RichardPopsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "RichardPopsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Richard Pops [Member]",
        "documentation": "Richard Pops"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r815"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "nbix_SaleOfStockNumberOfSharesSoldInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "SaleOfStockNumberOfSharesSoldInTransaction",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock (in shares)",
        "label": "Sale of Stock, Number of Shares Sold in Transaction",
        "documentation": "The number of shares sold by the collaboration partner per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueProductLineMember",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Product and Service Benchmark",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of the Provision for Income Tax Expense (Benefit) for Continuing Operations",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Notes Net of Discount and Deferred Financing Costs",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r68",
      "r69",
      "r83",
      "r84",
      "r86",
      "r88",
      "r131",
      "r133",
      "r800",
      "r802",
      "r941"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Income Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Provision For Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Based Compensation",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information Relating to our Recognized Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r62"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r798"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Carrying Amount of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information Relating to our Recognized Intangible Assets",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r125"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory, Net",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r103",
      "r104",
      "r105"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r466",
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary and Changes in Restricted Stock Units Outstanding",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary and Changes in Stock Options Outstanding",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r71"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity Related to Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r1012"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Annual Amortization Expense for our Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "nbix_ScientificEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "ScientificEquipmentMember",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scientific equipment",
        "label": "Scientific Equipment [Member]",
        "documentation": "Scientific equipment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expense",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.25% Convertible Senior Notes Due 2024",
        "label": "Senior Convertible Notes Two Point Two Five Percent Due In May Two Thousand Twenty Four [Member]",
        "documentation": "Information related to the 2.25% Convertible Senior Notes Due in May 2024."
       }
      }
     },
     "auth_ref": []
    },
    "nbix_ShaliniSharpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "ShaliniSharpMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shalini Sharp [Member]",
        "documentation": "Shalini Sharp"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, award requisite service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance, Unvested (in shares)",
        "periodEndLabel": "Ending Balance, Unvested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance, Unvested (in USD per share)",
        "periodEndLabel": "Ending Balance, Unvested (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested, weighted average remaining contractual term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Released (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total fair value of PRSUs vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Released (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility of common stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r466",
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for future grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares increased returning shares subject to any full value award (in shares)",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To An Award",
        "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To An Award"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares increased by returning shares subject to appreciation award (in shares)",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To Appreciation Award",
        "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To Appreciation Award"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares reduced pursuant to appreciation award (in shares)",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Appreciation Award",
        "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Appreciation Award"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares reduced pursuant to any full value award granted (in shares)",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Award Granted",
        "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Award Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options exercised in period intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average fair values of stock options granted (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance, Outstanding (in shares)",
        "periodEndLabel": "Ending Balance, Outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance, Outstanding (in USD per share)",
        "periodEndLabel": "Ending Balance, Outstanding (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r472",
      "r491",
      "r492",
      "r493",
      "r494",
      "r497",
      "r506",
      "r507",
      "r508",
      "r509"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in USD per share)",
        "verboseLabel": "Market price of common stock (in USD per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value vested in period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual term of stock options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected option term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounted purchase price percentage of common stock authorized for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r31",
      "r181",
      "r211",
      "r212",
      "r213",
      "r234",
      "r235",
      "r236",
      "r239",
      "r246",
      "r248",
      "r271",
      "r331",
      "r337",
      "r433",
      "r503",
      "r504",
      "r505",
      "r539",
      "r540",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r577",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r635",
      "r707",
      "r708",
      "r709",
      "r722",
      "r772"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r271",
      "r669",
      "r718",
      "r723",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r733",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r752",
      "r754",
      "r755",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r772",
      "r822"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r271",
      "r669",
      "r718",
      "r723",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r733",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r752",
      "r754",
      "r755",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r772",
      "r822"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r855",
      "r865",
      "r891"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances of common stock under stock plans (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r96",
      "r97",
      "r134"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r96",
      "r97",
      "r134",
      "r478"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances of common stock under stock plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r96",
      "r97",
      "r134"
     ]
    },
    "nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "StockOptionsRestrictedStockAndConvertibleSeniorNotesMember",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options Restricted Stock and Convertible Senior Notes",
        "label": "Stock Options Restricted Stock And Convertible Senior Notes [Member]",
        "documentation": "Stock options, restricted stock and convertible senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r100",
      "r101",
      "r121",
      "r735",
      "r751",
      "r773",
      "r774",
      "r816",
      "r831",
      "r939",
      "r959",
      "r1018",
      "r1038"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails": {
       "parentTag": "nbix_OperatingLeaseCostNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r815"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash",
        "label": "Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]",
        "documentation": "Summary of reconciliation of cash cash equivalents and restricted cash."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Balance Sheet Details",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosure:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "nbix_TakedaPharmaceuticalCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "documentation": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r428",
      "r432",
      "r568",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r693",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "nbix_TwoThousandAndElevenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "TwoThousandAndElevenEquityIncentivePlanMember",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2011 Equity Incentive Plan",
        "label": "Two Thousand And Eleven Equity Incentive Plan [Member]",
        "documentation": "Two Thousand And Eleven Equity Incentive Plan [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities of government-sponsored entities",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1031"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at January 1",
        "periodEndLabel": "Balance at December 31",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r524"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expiration of the statute of limitations for the assessment of taxes",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would affect effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "nbix_UpfrontPaymentsMade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "UpfrontPaymentsMade",
     "crdr": "credit",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payments made",
        "label": "Upfront Payments Made",
        "documentation": "Upfront payments made under a collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r165",
      "r167",
      "r170",
      "r171"
     ]
    },
    "nbix_VotingRestrictionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "VotingRestrictionPeriod",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting restriction period (in years)",
        "label": "Voting Restriction Period",
        "documentation": "Voting Restriction Period"
       }
      }
     },
     "auth_ref": []
    },
    "nbix_VoyagerTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "VoyagerTherapeuticsMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voyager",
        "label": "Voyager Therapeutics [Member]",
        "documentation": "Voyager therapeutics."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "totalLabel": "Diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r266"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "verboseLabel": "Basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r266"
     ]
    },
    "nbix_XenonPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurocrine.com/20231231",
     "localname": "XenonPharmaceuticalsIncMember",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Xenon",
        "label": "Xenon Pharmaceuticals Inc [Member]",
        "documentation": "Xenon Pharmaceuticals Inc"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b),(d)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479567/321-10-45-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.M.Q4)",
   "SubTopic": "20",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483530/326-20-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479391/326-20-30-4A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479391/326-20-30-5A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479366/326-20-35-8A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-17"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-21"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3C"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3D"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479175/326-30-30-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479148/326-30-35-13A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479148/326-30-35-7A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3C"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3D"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0000914475-24-000054-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-24-000054-xbrl.zip
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M2$9<^JZ:_R&^YOV?M]PZ@"]D(QR)^X?=$0\]^']\%K#!EJ/.Y^<M.-##OO_
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MG!/[6)7/][&;V-K/37F52'?(H@V#<FE-(G!KQ A.%J@'OOE9N"1GY&%^PX,
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M8K$F8+P4LI?.V##W?#_S*/#YA9#W+'CY*/GU8/OFF"!>&!HOA>Z;8U:X&;+
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M-/.&ZC1:^X^'GST_<&561,4+5&YY,DEG9;Z!-[>AM153FYWC>P44<45IM;-
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M(=EK;AU]Y@,6.$!.7$XELUZ4GJ32?T5,OHN8(.!V?AQ+4*<B)AM 3+:WCK[
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MY0\'?]=^;RKF%*^Q^?KFZOK\XK?/IQ7F/0?SAA-/"E=@]+G0R&=R2 RJG<:
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MM;#ZD1\9<W;()<SIC\9)@-7U3&%D<IJC"36=//.T8C\S]#9KFV;FZE2F%YP
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MBZTEI(85!225A6AARF&KU=K;V=U??TD5O1"[I@JQ<-29ZT#T*<V "AQ@X6G
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MQY*?:+9/?Y0P)>P[8S>S3'3YLZ>(4&!7GB@_?[8EIU1681+/$W$CK^IBAO\
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MD:2 J)\S0;W15,*Z[O*H9]8_-^"G#]/?[S;V=MHS?VDV6DM^W^DL]\:\-1W
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M5@_GIZ:[9TUZ%5* VU8(6L8Q+U.D'9.K\ >.[C@MN\W>R+H:[%4S3%7TPD)
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M+^7805M:P>AW#%!8%'M!*W)S9XS-]#L_6=+<L755)SR.-8KE: M$2:3!2@E
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M5$L]L8#Y)!><;Q2;_281FMLU "!WGJ,VXC^3+@ EH0GZ;MJ7HNA_ ZL/$/?
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M*-9E;M$$TN_7%.>%+X6_S!=E&B0/?G3>9E%]+([UF'$7Z'EE;'V/B IXXE5
M *@\"3/Z@8<Z]WJ1D9I3G'2BCQL6RKVH=M^1R-DK07[@<?.&Y_@^"Z_JIK_Z
ME5?I\"F-6_+HU:^/J97VV=.O_WCZY.2KV:,7']X]GB%;H(A%R^)KDJI/3Q)&
M*C;YFGH[_*8BL)GN3@I'W9DV?(*7@"V2$W_ZY,F)NS/=]^5C%>+QCU>0>:1<
M#XLLNBA_50)B;Y]I[263+JGV)WA$>@<* >NBDKY5P;2Y4P%IQ5(@;=-C]-K0
M<+SG&-$]XNOWC[\+=R"@#*7LA/L3-ALD(P2YE%Z'D!$U;"-!T#$4'EO*:KIS
M+[=\T^O@,2Y'-(7*#DH]NC,ZCNK*+9+,C(>_);@,%0,:<2Z/+VN UW[X^5U<
M= H@HBZ,[JI&=/<0"H<?)B@ ZNKHO"Z\%G,8 ,V0\TD30"%N;UB2 2W4#X5E
M EYS<&6N4 SOAC)PZ3O"^-FFM*D]ST%*><HLU_O/N0=G*<_X4EVUP4Y]FO@/
MC(!5=*^-*'U1[4;#.;ZT._^*<GBY9\>S[Z5#+N/4,V5&*A[1>" 7E-DQEK^;
MI-!QH\L&P \S/Q4=P8,APQ&=DJ!:4Q:4\">OJE!9'V83'FP6.YHW#. [86<=
MG_#8&FGI[%"V,0,E@E'RY663KO*KNOFX91Z>/<23[HWWZ<]LE-/NS4$W$0:0
MRP&B)WAD1J(O4Z%-OUBV!'&S1V_.'@=[*%3!;I7Z\,K=XLU9')0%+V 0GL&K
MX@/!?7K;+>U"=;=W]\\+!(8JHTG)F4;>(]CZ-*-FW[8+]2WW!.[1M!?-1V)Z
MH$Q]@1&E _(.^JX[--_DR+A*+?!1ED\^AXM^E/<I/!O%A'W7@P%_49]717QN
M/X:D[ILS35(%X4'>_=$@6K1W<+<>Q@$T/7,"]0@8,E&K6P9/PXV-3FGO KK<
M/?X+4MQF668%[KJSH?!P2((-1U]XI2W_9T3T_<AKU]&<NP \SW2-G'XSGNYU
MV;N1J)NKU#GTKQ=NUU3L$_Q4Y(L+MV+<.BHJ-Y%O#2(E\C-?P,_\YI3\S"=2
MBI\>#WFFOH2R>%0^M\P"6OFF#SPJ'D\9 *H64"$9QX6@GRN+GU#&ZD=%\=A^
MS<OBI%Z?:7QY?,U]#YIS O]OTO5FZDD>G7UX\[9]S-7.1\6EN9OPN$$O@WUB
M0N)TBA8D4V"\1\_KA9#N]=_^>/;ZY?N$3-V"BM=5[J8[RT6ADBXF0CP >J3S
M'#0);G/71P7Q>^6&8$=^D6W:4&I& JZ@W*]>AWV8_\33\UWUNAKB#TC]"$=/
M8MQ5Y5P?7%_H \1-&J\AIJ 1T^ K*)2R82P,O[\QN!8_O'5%UFNQ:G7E#XW
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M-WF^\\:-K<^VATRUO^6\IHDPMM)R0(HR?"B*G23NRR1YQ.,':/B2FFP1J[
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M@SWZWV^H[B9+6@T0.25U;=@8,S^2\DD*7L3][KDV6#"*D)5R99C)W)#W;B]
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M4MB[6-NW,Q+O>S<RSC5^4!O2!0!NI^6Z" %?%J0-' !M898:;%B1*UG+PCE
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MT@Y\;=4+I3V?C]3%"0G>>H7<R]195;<15WE:M39QSPV?O,SP[*TX\5[@75]
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MVM>\:%;G(M2QHF9S&+Z4'TIM&R09EWAQ.(Z+M.4&77Q4>./47K:!H<#B2K=
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M7UP/.N;M.ZFW"37FL$I1AMZRF)6G**:Z]#P,(>%]XR8MQBN7L0)CYAE-7JP
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M@4 Z;/'/:^K:MM%YBP7O'UDRXX ]<IORZJ(N9>\A6_ 8QR]H"8I.X!'.K_<
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M204V#5$=B/0X$YZ,\#/U_["^]%G:8&+'S5D#@L>@*^]@&A1^BW[!_T.5P@K
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M1MSQI5<"=G83TM8TI6"&K5&UW '#(?A&!L6[V;+"3K,\>J?N_(<&0W*Y8>N
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M:HTY,C;E\"6M8X2)L;JRIV?%$@N,+JLF@WSA:DT(J(W)C0IJ[_'FG=ICL=Z
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M<=!<<8^8KHTV^'+0&<@8!5$,^]ZVC1\$(C: "^JE1:TC/G$[+X_9QVO.\HB
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MV?V2Y[% L;CA"'E->0'7+&6TU2SPF3\>C@YV=G#G.4LG7J?-W3R"@ZIH?%2
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M8'Z-X"TI?(&8\ S_\3^0;O49_.^]PV>8[H??): %W^'-$H/VVGK]Z[OG8)_
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MO:,;#Y2["RYL_?[QW<DC=^*>__W#WXY?#^?M:YRWO\0XC!N<IK\T<#-A>;)
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MB-5=BI65),TD6SGXFEGA(5+2CTB)>A)[G>[0FU]>;3_=V]T_V$-E/RWPST@
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M68HZI*[C-+>$A0@>N_+X29F"W*4Q820+U2)IQIMP<_8IJ]LJQ7Z+RSZ$ 5$
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M"F(IM+A$3L37!^]O7">G9J4C7+,@,)+_\)SYEB5E@4Q:>1+QQLNK'&P.VM;
M_Z>ZH./2!*GS,,'QD:#1/Q!F=5EBGSBCU[@D;9;TQEVI?@KV#@FALK$P(B>P
M2I_+_!V--P+#.: '*;.;,QNE/@"7O!=I&IU1@GZ "8XV5L#!=I",0X?"BZ&S
M$ !L]W-(8HT^47877(O)<DO**1G;#W$)#1X))YH35<%A$3'0P9/W@6?^06MF
ML!;Q1"N8P#P?Z<H:^QYA(J'_'=\(.XSOUJSOH&KF6UQF*5>6PB;Z$I-WHZ/O
M+[B!^>(U+[TB5*(%;:=6A$JVNC6O/#+J[^UG,[-H7U::R[.)[&<47:SD(0-A
M4()PF^*[0");&3HKB (!FC_*Q'2%)S#\<,#W*O*K,C?27@YCX6?:?!+I-@/Y
M3L#>BJ2!2 #W,O",XXWM7R%[B;2LJR9U @>=%.0@A)\O4<C5O8!F"250R# K
M/D(>T7_-A()HD-Z@.%.&;AYY46MC,E5QQ+? B+":68#S_"GW',Z!-[B\T6QQ
M@W1P73M]V4:1/JD8L@BF%_W"&5)!$ RJ?[=L=(:Z<@/E+D-7<+R<^)Y4YN@'
M6!XF9P0O)E+21W2["\]FF =<-1TNNM/8M%5[CADH]#E?[<G9\V+UL4B#,P@%
MF$06VZOD4%!J&249S"ES:5L:JQ)NA,^0,VKL_HG>?3A9C^X(.N(0J52'+AC<
M0VWRXL"FK4Q*9AQ[]RGODG87J0J><R.5[R)K_$%N(G: 0Q0\E?!6=#4%HH(O
M"$-ZL2>4GIJZ!_8#*$XAQV72%J^92YG2,H-Y+M_*--?MP*/RAMAN1P4!QF1C
M.'!#QY7Q']) 8#N'ME3_)"_%6Z&L6'*11JXN=(+?;K)G4EMD0],-.!^-$\D3
M\DF98*PGQ-))FO#$=KRI*K^U'*/74?$&J_B2Y&PZ][E %N[3:XX 7LW!#4[N
M@!6QXL(<"HK0R(UUQUC)28R;+M)U! C#,N@P9VV35_!JCRK<S7EVJ9[+ "&<
MT57L3<J#J;U-6M%V_O,YUWG"V^E[/D)73.9N*G<R97F,HF-.KAIZ,/],@>ND
M344[D,KI?EPRUV(\H!W(KKF>[-[B_#8CNRLX#ZM[_E;:7>.5FN=_SQ"%)")3
MA(0G?#!6?W^-?<'6.?DN?^="@Q]N^.<> PX;[K@*I?U DW&+*>^/R?] !X$K
MXZH8#L4H_LA- L)JV$?E.)%A9^">"ERN?Y:-'U<> ML1"5A)U-O(VY1$GN32
MB.@Q$%+-,M43$XB2W%:ZM&-J R.7S;%AK-B8KH13E IXHV%5AE8:XQS= 8@'
MPT%F^#YT*)1^ARM3$167 K<^_1+I5%ZNQAX9=="N],&PFVPN JMW>^S"I>]@
M@JEUA5G,]?] '![["2:)'I\82#@Q*\R2#<B/33(3TV3I]O:]I5D_>%=3(!?U
M.'KJT79,W[A4>:6F/K)=UAK25AE3@BVU>=A%@E\J?!':%U%?[HO8YG+IE'+G
MP=CO92;+$_)VH7W3BL==K ,AJ]]ICR4*CZ]V9+]>T^AOI&E\?G\>2-^3Z\N?
M/VXN?EQ=7UI?KF[N+JXNKR\N[\K6U?7%<DF1E\E?77^]_/^L^QOK_N^7UL7-
M]=W-]ZNOY_>77ZUO5]?GUQ=7Y]^MNWOXX/?+Z_N[=5<\-FZ@JN._4L^'6,!1
M@PFJ:)N&XI/ZQV?'#:=C^^63Z]',Z*'/R9.&X>;[2]#>\=<QNU=KS/*R/YE\
ML_RZ"E_]MOAYOUEM].NI7]6JZ9\O&ZI5;=?Z*T=:TSUM93.[Q9]MVJT.3N3]
M*0M.@B?F@+W,AL@G\FKBKTIGMR#8$TU,-MR:;=O7:.F?LO31Z&UNQ35+_ZN=
MF[E8H(R._JOT?S:0R/4&6LBH#U'LUJB8_B$>0$6F\,WM; !WB)E*]<T-)G_]
MS3[;D\>=Y('UX?;B_.:+=?7UD_57]_F3YWO7,THDHM ;[,X/W(5AI5ZR/'L"
M,W.$^^D<%//(#W !5TZ)+JY1I0E*2JOQU]\2HYQ]G%,JYCNW9D+&*;<&<?MR
MUB[H>TOZ[C1-4C4.LQ!..3^\-A5#Q<ZQ+_:8/+]WCT(@GG+JJ18LFH.Y;'G*
MG79^6%2(_!S>?N:RS>'UYEC4,!Y)H:#P"9J1%UBX+AZ%%Z+GB;\H./@X.!B(
MH-/)#P<7A[?%X37J*SGX#CMDR.HZF:%F75)3FX)YC^;\.]V">0_S\%HKF3?N
M"50PZ]&<=Z=7,.MA'EZW=,85J3(')<&Y:?&7@FN/YN [_55<N]!(>WEL\Z1C
MTHU,8M+H%,Q;3!KAC7,3]WQU1&"C-"$,4>]I8?<L>$VC1K<=_N+;@<,M00/!
MN;KPQ[68!?XP0(2U+ZY/;6RHEG5EM\[W3XM*7^[-U/6,JO_T*R8W:UB:VD79
M/C8&;G0/5VI;[KTP6(9QBPZDAS@D#_&Z V1P)H+WKGV^X"'IK_KGCS(U2./[
MJ4PDHA>&2^)ZYK%"A8IG$2:T<#=V@@T33C#^ JO*%FULV3B6.^G%/1_GP&2,
MM+.YK&1N-+<P^[(F=S5QQJ[Z@(%[S@KC+NXRFYHRI(Q-6ILVJ[:/,(5\@C\E
M&BQOF'4KL?DH?PNKU%S*^(ZSO&2]A*PFCX=0EYG:&7F:6""QZ@CCW= 9MIC]
M;J E4..^*,SX%+B&%9.+\90IK?!G]:Z:AIR0"K&0)]FSE&^I#ZG)O.4T" F"
M@T(4(!"_NK9&7C#J%(V+YH9R.^$]4F!_8$@)%FGA1QD5_E@VJ4"75E(2HL?)
MU5'@CRU,N$POO$GG_G)<V $RA6@R40L#Z[M2[[C@=U3P@P?&COL6V!/QRP_^
M)/0=K@"5\P1"B 0E*]YQZB<M-GBP/5FZH??F'M$,0#?AIQ@5Y$.C5F]:(S7\
M1UG\3+6A=)=+(R,!D=N7$'7B&;DN)$ =:^;]"S.9*7E6\BYCB^:KAT#ZA?=%
M8TC(JR]',UZ*AK ,UP33>J5L0HIP99E@4L!ITHX+B:O6#?=J,Y_B;%YYT@1.
MDM0-YH=+G9&F?4),19[F0D""7["FS+.&O!J!4HA5@TIMU/S.F1NJ+MN$%QN(
M!&Y_&J24$@I+9 G)456>;>174Q6CDO=F4?IL+).KC?I&M<MW\?.$&O0L$YH-
MUE-#TIKRQ")+Y3)6EC"&=7R.FTMF6J9U3R U\;>J<E]A)$S'-F\-W(0:XH5>
M1:@GU!G-!(U!])2 R[JH8.+7HY#(#2NX8Q2PQ-3: 9Z)^DE9CX&87TC\08 H
M:PCG A-A+M&+EY6E<K:RPF<H'*KA(#5(5P9B1GVX]+5JG](FO69*97/#YJ?
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M(P!I,SDLMUP+Z);.^MUJ+R=*0*$GOI\8W(@\>F!9]W/CPC^!L.J]C_62&4A
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M)YAWK5[+XWW\58Q$$ A'E[+9SSM=O0>KP.YV]2[)EU"[RP6=][BWYYX#_[V
M#]U4NZ?3*)VU.RG.YZT!80N;)T\VS]K<Z>TI!2M)^D4^]5&2R]I\ZNW)I54Z
M.\YNQ3EW0*,29%&Y+E:$S]SP$;/BN$VQ1Y,D&$SAN7[ :+9%G/>5-B_JG"'N
MMPAOO,O$?G,"Q!;.HTX[,^=18=WDD)(V3:#>@*86::=3.NO6=@<)+P@GAX2S
MYFK.5 9U\R:#3BAP?!,]BN"T@L-O8@33/MXH1)QS#8B#P)O?QOZO.P70G\8
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MG"\O/T.L14G)N$GCCV;IK-GK9X;VOTWO];S;0J=,<NM;P.Y <RV@N68_L[S
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MQSP"^=2C3NB>V@^B,@B$_6?%'L$2/]GC7_9+B%1GDAC0E[GM\SO&^W+VUT&
MU+HXUZ74VMD+L2[D!-,V7U_^_'%S\>/J^M+Z<G5S=W%U>7UQ>5>VKJXOEA-C
MCI=S<W]YQ_+J_L:Z__NE=7%S?7?S_>KK^?WE5^O;U?7Y]<75^7?K[AX^^/WR
M^OYN<94;DA8&#];M39-*!K+=B<9&.U&O2K'-POQZ-H%QAHNF0/*2^#(+8:0P
M_"K"8>!.462<>\XY2+.9AQ&56Q!?0U>$]S#&ES$U:%&71Y<O)->;"><\DI_A
M&V H>XJ2)9B)TME-\&![[K]MNL^P9O=N-H$]>\$BW3N@'W<$MX$76?$[+?52
M=3')M<PQ'7PGW\]CZWGA'%)FUM#7ZYJ]\0;P,W/:L",I^T2S?.'_3=F>WOQ&
MO"_1:/:A$3]A6I8[W(",%HY+K;RJPS;[N!VNQ2SP8><]87UQ_1"H WO!@=CR
MAE6:IAN%5C@;A*[CV@'0CO5AV2/1H[ N^+(N6[]$V?)G@>4'UBS\:+FA95L>
M/BA_7QGYPUD(M_? ]:>/=C"QAV)&^HLE+WQ+_0+VRW'#H0\*#A!Q&72S)S'V
MIX3J#Q-TQ-CEKRS7\_PGNLAQ,H$]=5E=>!3CJ46953C'P2QPA(=LX@@*:'+J
M%;R#JERX ![^P@=6*!(+LGM/]_L?0N:/$5RA;0%5/8QQE4Q>5B@>4"6"(WET
MAX_HJ!K/''B]/1X;71$L4H%@MV&[<)," >L/AH]ZNW$,QD'T)\#EJ&\I:D94
M@,01AN02PV$BT TB>A1^1.<_]A_P)V7^2WB.)"4<FCZ:AB_#1]?&@KBY,PG$
M:"R&0(\X,N@9N%ZU*+@I/5C12R404S](JH6NQRD>),QPI0^SL1V,7^!?3Z[X
MA43X0L0*[Q4C(QL/K8 0GYK8?XH M\:&E[S\6R * HT)E%RF;_5O>:HP%7^(
M1P+["",/%PAI7@)O=;E<:/57B\L40=G?7%"^*?5N*2AO@1R&[G3,;;(22]VO
MJ+P'JEMK>"C^(AJU^>JEA:1+3<L.050B)X9$@;\>?2!BR_^%J:*FV*U:Y^,Q
MT[F2CU$ BV'+DHEN8(^YD^>C#1)P($#(@6P$[9MFBUBFB<W,D"!_AN)F=!E&
M8#-'"((O2;!5.TP2A.7@D>D%[9_NIB#6[$"+VR64A\>$8LF-7JQ?;O2H"!!E
MV31FJP?A@81#.H/OQ502!Q+L3\_%O^YP4*+:<SI^V_KPM_/SVX\@S?XU<T&D
M@<CSP/0CP0Y2D02@4+O% C ,9Y,ITV;T:,/5P>C[Q!83Y@HMJN7;4U>%@RE>
M2CH"@"6&T0Q^#1.:C>&GL-8QWMSPIH#[_T2/?FC,+%,9S*7;\R"(2X1Q:T%]
M/PQ.H""7L;[]<L(?+(!=[$N,ZLLC? =4/'9A@DA%V&.>J89)+L#[UW9@(HEV
MBR!%?88U0B;Q9Q%<YW"O ],@L9'PA+7Y@0N' N0%I#,+D*6 'Z+'0 AK C-]
M#%&W':.&93-9 Y&1V%!M'I$S!F)I*XGW/N#T+<V2)7Z(H8!5PA8OYX/&85IO
MY^HFC]>X7U;0$PKTA"2]#U%C1EV:=&XPH6 OF5_\7ZP>H'(^!?$X!<+G+G9L
M8.%X96R'$CP(]$;#'R3*0=?03]/#PT X;F2-_1 M).L&%!<E8[7FO^()98H
MDZ D9TTE-%P6P#BH89516W<$J#P3*IT9V-(<%,]N2)<:$B0ZU_$64$O!G^/,
MDY].[0A-!+K42-67^R+7Z'I AJZ#3^@=&[K!<#:!J\A;5-]S: ?2*3Q/"8F
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M]'Y!*L$OEE\>J=]@^H_)P&;-'*0> I'\B0Z!Z-'VZ/HAMRH\]<L=CUE?IWB
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MP;-47R@K-VLBRK>H-X3S4TX&9G0<-4//U6V M!J]W([A$,X]!R7 =%6.0OM
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MJ'0<9$ZJS;*LA1(DG@A.S8R3Q/"0*#7AIV@V&U$0;;QH7"FT"5+60$=A0ES
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M2O$0")GV9;(7E6/(7V #%]^K\%^H=(, IT(&G:1LYD)CO$CUJIE[1)<!F>H
M>C2?\5+[!Z@&)*#UER;6X<)LYR/ 2P*[6QC@N3B5A1N1!=1(0<28\JF,YR*3
M@U=I3&7#WE8_GZL!7"?F.%50I^OA0>-5.9E-YL5N$K9EO7_%T+<696E2=FY7
M^NX'L+?>A;Q+[XVF*N>>0W^.S52A%-OH4,OA>>5:C7CKX/N6=9*Y",?/!\T#
M62@SEBUU=+<LY5C6.ID!%ODL:W (#8L2X;D7BE0_E_,3Z9PAYS='+W$[H;EI
M((*2&T9^0*6\$G,+_3#3V%2+RX "(8N\5#J^*AZ*8Z^Z5YAR?R'<6%P$0<5W
MND6+G@E>=3(E >PT] =*$!@E#9;-/]XJ/A-<DDK8-O=N<:+2V3N;S,:R[9LQ
M%ZY8E[? '&+,7'H!MM21W)#H=9> YJ22:ODNX:R"F?J WK*/VHED=JY)'+;1
MY@8]@NC-PBQK$6@_,M<!9=ND@P[F&]C5%])'\ ?LR(7$TU\JY%)R,#O-0TV,
M5-3Y@V^@_?<6^\.P+@BP"&>GU2#=DH)K*D-5L450MW"0%!+!T!"EU.L:38:%
M-"';$AWTDEF 6DECGS-CI9,!1!)+\2&7ZL,O%UX7\WSR:E<6[0B&@G,24RX3
M_61]<#]J""KMK_H ?"/C0&K5G^&7YD\E^ZL J^%,TGY;-1H]"L\F>P08C=/8
M>8P_>_J83#9=^)%R'V_\:A1]'YX^+AYLR"?[@;3@C[CG(8P1KEP:!1A];TRP
M]0H@(;FCLC$VO3TTW4<:D#\!WRG1MM)(@>-NA&\^9EM[G@14_D"2X'X99:1R
MM]0AYB) N:64N(8+XE8&%Q$T:L_%I%>R1UOUKDIN+L(\O;K^VX_+__?_SM]D
M9IUJ>X.II3@E(G_ZJ=*DI^?;TH,6CP,@!D6]V_J\UQW]\&2/!\*S_PU??40N
M!UK$9F$(*,M)UECZSJU-7Y3/,6X0&P7N8,90I GY[5'M/],-HWYO),G1MI*/
M*05,YFX1DNG4=SEI  $$RD94G/+]9!?<E[F!<LF&*P_EAY*1Y/E/;F-:@ROT
MO@;HKA,A]MU H"J)CJ_Q/0V,=]6;]9=1!$] $)3(H:ME#3&J$K",AE%@P_I!
MPEHFJ 0.TN%%2*6[1@I_8#B<36=SC.:/:\5P #:QU7 ('U2BN\:#PW[*<PUM
MDY@-R;9.\_4!7+' JG-%>([1)D7B$E#K"]IKC$]X#H:*@H2%, \]\)%2$L,9
M[#:ILHP5NZ1KB^ 4PQLF4,H!QJ.26T5>[F7'&<FJ">G\2=Y8L;?)<GS!N5&R
M#R0>0< 9 K1#AJ4TI1HRA5&R>.,OM$Q>\G:I5:D=PBCV,%+)>&ET5R8?VD"8
M5?\X)/H_9)=E-^G64O8*GPWK(Z0-*+P "=P<IX<E+_UD&)T1,>VQ#MTGLJ0,
M<TIIHH8Z1[H#[B_))DYBDMD)RB:3;3E5FT]<*]B/Q PP8[,_IV]TCN.4!CO9
MTA-V_(6S$<F8DU2@'U$GQ)T_5>?&V+S6)NYB:K$V#O.?B8/LDDA2P&P"/Y X
M#$P22T4<M; ()4K>QK!X>0+,4BK85[7$_:IA:CK&CIOR/=&&4(9X68>>:[F7
M;!J*IS@G;\Q8E+J?%ELWRLQ#3*HB7I0"5/UR;JIZFC@90Q2BT1>X#+L1YU7*
M"4J0=JV[Q*'->]6H475;7'@A\60LCH6S()"3,N  Z?-ONCD46,"#Q"KV!CH3
M:-M1)I3:V.V>)D>4$1]0?-HQALOO E.S7,?Z&LP>Y**0[A\"FS,]^ ?PDEM0
M>:RO?'_&Z&O:2:!>:6)V@L[AD[68Z&4T'-ON1"M]V*Q-ML+3@'1(XS!'C.82
M!(X!\.6I01>0Y.D%K*G%>9CF1O"%Q[$.0V.<UW)6ZW22^DTGK'S%X(6=?&7C
M]:0^6A/WN<S?,<:.<*@>4?:GBQ/,=;&-V>M4]3A]C>+%4[-4?RB8[5"]<:X2
M557QX!XE '<HJ8VU1/(HR,R3)(91*-0N$'DPI%]2#T'A5QG;#RJRQ ?&:B!-
M$HZ2P2I)/[;A!'C'/N@<7=A#0>GW9E-FWWO ;'O.N;>X18KID_I8U;W=8VI(
MMEL+292B,),Y>$H52FH2LAR*O;D+[UD4D'$C.?W>$Y"0%W%+X?V*QOM$TKX&
M9:/X(K8/E&J_PLKGQ-(H]HV2R\4PK\.%>SU.YU3\JB!7EPV;5 M2WT %!(3F
M9/3@-:N="2U0=F[&&-+P3T[?0XF0&#]1@TU9SK+5:7Q"AMC\M52S,'\?MV76
M/&7*JD2#-:4@+!B>OE=YY+)6FK#VKI!U!]]X8KS(3>8L=F.C(B%G94).(_<)
M.12+6I6NTTY-U^GD+V*UQ @BI0$YY%;Y(P]"V:2+%"Y+I%\,Z&J#E;7-J5Z6
M=K-JW]L"2FVL46R@>I430DCJ$_%$$*B/YC%!(%8%IRASCB1LIH?EF#0WV4Y2
M_GJ@G<+D[5LP@A;7=$)W_2TP'JHW<7N%\Q!U?ZJ%W._E[\/U.9YBG87+20%8
M?^\D;ENZ\WQV4.D%V'H!R<M8#T1^5LP#'@;NE$$2T' :^LP)NE,=DS3GH;*!
M+C<K]5UI]RI;2;&*@3J+D-;3TN M,((G6)&EF1K=PF/32OO(TJY>U%:DQBN\
M%+5VY3J437:\-/\UC@49Z";?Q+Z%\]7BV7/RN.Q$NT#Y2*_.W&)DTST1>UM1
MX,=%DNMM)@+/5H4+L:I+Q*<2^6?A/&W&EFR9H*!)%/_FS^F&<?;!!>$)S2?Z
MD!M"!ZA? P>4]+!3QWD,MTW87Q]1B9J8VE1IIUO;DTD?%]EIAXB!BC['0LNW
M_21N#6D7_!#1+/#VK]/P%9 TS72=,<U1X0C'4>,86, 20<#X Q9B^2H:GM@/
M<;ER6:7&N11:TY]*AG!D&$<&)&W5R!D'T$$,MB9Y5C22K1%ZV#G$M5K$5O.%
M(0DNTOG25,N$$0.E-M%Q2/7J1<$.Z"*99&6IK7\?]ZK3EYB&K=?0[B;PO;9V
MV0:4V NQ5SK5_Y:YM^8&9ZQ-U% NA]"8)-@!3,M_27/L)(GCR'@V/3WF(H:S
MADU7<?N]Y]'1SI.UK#)TAXF)<D[OD#-2XSH!MD>TI\>?81HZ_TI=79+CI<M'
MG?@0&R XW'/6G\\$H+@R18(TR(=1LQD:61RZ8$G%C\A_0R7$'H&%$];'?,^K
M3U1R$8@13)\9<C:M 'E1YC[/'J^0SR8Z4UDYF7V,K<I+-<:+0D!5H$M\JPKT
M<"X;4+X]IC1HV,4X&"VG9&R8EG$Y)^LE_7EX$;0P[ ](67+(X@IG><\ZW4BZ
M*_ET)3&ZYD2G"I8[65K(D$W<T0WH5E?62O#$96F-$D$CSD,P"%B#I2035VGH
MI81).HW*M=15^6I!.E5*?8!)Z(N0GCH8J6TA]0%ACHV%K%_F:U:I93BQLCDZ
M-T8=JR/7^4 #F/98Z9 :71(3;4,3'(G2,K@K@4J>(-0YOJ53]G,5=!(G@;H*
MAXTCPT%*\A<NB;HBZ=_QFJC]#>@C>!?'B*IQ5]<I1O!4SHW9"%:=($=>-CU#
M]L^HSN44))+=:CDMF=]%49N%?B5J!1HWJ&QD>"3&,;91AL-DU":1F4(IL@<H
M;'Y7LG;/*N]YI&H[&"P MYY.SD08D.@M,AGJ-3=*F-[M'H$/Q9/N(J1_S>W5
M->:<3FDRP[EF I,$I9O+FUK,Y(X+3B;H09$ 6G(0U50 460VRJ1B,I095=SM
M3.='R48D<S@I2@>/;]J4=*^%:5>M<YE1Q65U>I<2#?FDP2 +]3"W- ;,)=G*
MFRT46*5I63"&#_=0P+053]<HF>".!F F/1^K/-0TBZ00K%A&;35E2#1>V7!F
MX4QAJ(&@2@&>GT+;9+-Y;HJ<%[NLXD#?;"Q1;6T5K$G=EP0P<,=C=8.\)G<V
M3_+EA]+9]BM>\))-ZKV&*&$]4K9PTTHF7]RF5CZG%$CD.>9Y"<3@^ BC@30<
M8?<MWW@RUE[Y"EFBNLBT+/P%]:_ (A6MDIBV8Z@8')9&]2EQT?+2FY]G$_KR
M8A_K!$R>W NY2BEU)5:/]$>Q>O"!/,>!Q+W2GV-6 XILF3@#7ZEJOM0-3IK0
M*<[F>)P%9=^084GC2BO^UE<=9C?Z!B>3.Y-9.2I=E!(69;-9!B=-V/"N%Q\J
MYM!2P=V?GO_+4^[)V*:228_T^/RN) :*;Q-L,()!GD4+WR0@F;BT>\PY&6,N
MHLZ)J',S]U%GBB"GQ96[V_:FN/ IV9/9Z(<;_GE!;1_Q7W$-9NLPP> 3:T,1
MPFNS<''[=1=],T!R=>=-&9@PH 558ANGQ0WGER,[= :P')7I:+B%\0>("<?=
MU>;;NNN::!8J6KU=WX*5S"]V=AFE$@\SUZ$"*YHJN:19"#V# $";"A=@S!=!
M"[%P*'1'5)_,S@35P<U"LPVDJ.NS)0S2M$*/Q3^I/' KT[GYTL\G:!IK37$V
M98T*F[138RDVS4$@C^WAXKOE&(]P7!6><86!5%\2V,8@7*.9AM32Z4IC%W;9
MP=KI6)"K-HDHL6/7,J/_R#W!PFV).^GX,I-TC.JH+HK$?90 D?!8(BW?V-:4
MJ"M[_T9I%)<+S7)[OZKA/56IM(FH CK09'FBJNE5,1)O-AFP@K55H9TJ;IBO
M<M/*B7Z?'8@X#]5(?_M&<&*C^2]B?#HAVP@_JWJ5I1VP> WS3;#:-;,)5F.M
MG+_5*2EUW?:JTHAE?KMTUE_LUO4?:@>X TYR'U3;,=ZMG193SW8Q'5C,8K\T
MO9@T8:@ ,1CW_BM\@1/]S_]3[]0^-^ME6FB6^ @81KX94;GO4BR$[F&B'EQ(
M4.1\A&K4;'11O/8LF8VGX34SM.#)@UEFIPA>2K(5T"B@(<LJ;DCMNLDO^BAL
M1_88BN]B):;B4452QLR++<KCT=Q%_6(3,Y)O2!'WE",_HUI]&- H-$Z.R08N
M>VM,0XK&^-V-0/6 B]VU[FW/!CN7D_^L"S^8RE^6M?%(?O7YT S8!P] QL]E
M!6:MM9:41DZ<_1"CIE!M)K=JH90$M!Q$),P$HD1R1)RR$3NYI3JETY7@JN1K
M52$4IQF?Z,+W9Y$J+'0$C)QI*Z8?LG/)N>=\C5U;EYP:,M<3KM,[3';_879G
M^6IZ:^%89?^-_8H U01$IN28G*KT: HE$.HS)7>2$JW^B-#29@ZDHNS EUU+
M9+@G5-_%-4Z$L2,](5@T#*^54>&YO"$QF8[]%T%BZ<D?/TE,M86>064='0:9
M0-5/>O10L=0P-3-ICN>?DI%A<]+D\Y3#QF[?JG4^ENY1^8*YY"8UV2W[F:79
MN=0"\4#(GJ"[K/.X8]7^4Q(2N(?&Q,A_S@A4Z--#4,&I\>%'%IW2$)D@(!C[
MX@DJ7V.#:U#Q.*S!/9<56%7<81%=9"!Q!R_QKQ8[?)FDI^&&C6"$8JJ4(.[\
M8LRUZ'X-,J0@\?U4BV#ER3+2YA +2/Y81@0U$&_5NO:-9ACSG<9M3R)5)QHO
MKFD=EO(,G=B,8&%3>%^W/B.;$G:#\!MX$7QQ$8#V'%O&O8]\;W[KY=J^2;1_
M[I#HJ^B+2B")@?Y?P^X[8"6>.X3F@F1&V99+%>3^8=Z8QOHLJ0OL5W:8$TH7
M\MLWM+3,0=^JK[;Q#KF1VS9\[M:P475_@X[/6;?7SF#N<%G66_UJ=Q]=MC.8
M?@.FW^QOT-E\7;/MK:3+'=@VX@MJ.1>&9G9#^0C4,E6B(6"?^_F^S=WF8;K&
M[T@?I45;YJKWKK(\!.C2Y 8K1LL"50DEM=?)!%/PZ4>8]3QV^7:-E6<VKM$H
MC[UWH2]'5\I%_/, $VS=(6-CXJC("*!/_+C[&7(+4R.XJ@*:2YZYI8=0W*G6
M9>,7W5/ZE_%2JEA#D#)W*B'^[7A.JL>,6O<4B,_Z<'EW>_OQ(+RV*]K^) ^7
MD)^0 T.51A.&,^$8J!"X:$/'_#*V@73OAH\^N1IHF HFJN /&)!PK@LVG7K5
MPG.A>XQFDFRH#<:='W*N&D$<C18)+7W0^X7E,71J(K"CVRG!"I]DSR>S0XCG
M;-7RBRJ[0FQ:)<LZYE+S[5]V8&+IQC4S"6J TQU6W.?*H^LXPON$TJQ5.J,X
MB:0PG.]*6=IN;B9,SV,+\\M+_)-;SO,]Q_G2__Q0*[OCA=W2NNJ)BP2G_<F9
M!;_\P F%%XOB=NELA*=&,9[Y*\'H?JK8G]S]H4K$H6 5'UW"0$?&B_M^4.W
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ME+2&^>ATK_"SH0)(B#>)DJ/C+\'BF;BS":G++A5OTAA^H(EYT64+=PP#=*#
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MT3F$-31IQ06^]8*7ZI#FW/3NY98YHCX#:MB=MRSP-H8#(7-E<7B2HX3![C!
MRTPC)J=+NTO:52F,02D88FF)P':C(8?K,M/5/O"86PQ\4<BR:S%1<300C\<U
MYD4@X)A)T?3#4#?/PGGI0]=N3' N9IJ%9D>C,]^\!"?$+!;4O:<\PO $5C#"
M+B'[4AQ3/J-QJ6;&=1##5?/HY+:7X%B+XA>):[@=-\!^?5PS5C7^@(_BQW(/
M)T: 9$Y)_.U9Y0-4I@3-'2S/)O%(,):? 8+>\IK\M40-_^;1Q]$8/:.7S_D3
M-Y.]*$C4\ 44A=_C@%9)(F1+P@8-?-#^WO6C@XUD6,BQ#%[ \R5HN24A^6PP
M<+%Z(C;!HE\",LFB1;WAP#('V5^&[)G%Y02>>QU'L=E3XR?EH@+C@@H#ILT^
M,XOUR_PSG/+1W;[CW6Z3NVUJ+;!QDPZ1*#;02W38N,=[>/+!@>S[1F1*:-/5
M?L]0)$%F/[6UZ[NL/8)'8WH5:P9LBM!P'-B4%3]P!^EZ2DEVWDLWRS:,8FN<
MXR?#B;& !6^^>5^>1[KF6:;DIENR'AN)CK4D2(6L1^$Z9-">V]V/#9-K"^&O
MXI1>I%]W2^AUX\O%"5-,R2'&43K')][(*CG'^,VV!=J* Y,[AO8VK=:-;"6O
MC*L1Y-NX_A7#;:2KJ'LSH7:4C2ZC]^N$X"6)4*0ZVP=!7M(![K<=#I:W[KC@
M5Q8TA5T!1>+Q<9R5,IYX"E]MZTW,6B7A)N2Z4# S!C#O7HQJF7C">P5\$Z5O
M66746@J71._=+T^A2B_810G-"(<^J4A;7Z@PV=,;]4:CGCC9\TC^R7HV$">2
M61>V$R!VMA_G.]*<3\2&33(^P]X!,SYCHS,9J(0/'H$9#7*@=,]0/TBZ9XQI
M;Q&:BC3IGB+3X@2X2L(4 8\!,*NOF+97^43"EG3!VSB G=Y79'[R K7 @V,9
M#9F S<R,%UU8*;8V,08=,V'4>T\.[&;9:H$#*WHX3I]'K#/7OH[>8\[^]_90
MW"=/"J> R?:0R2EZ4LL)G8J/:937J?@,E?;>EO8>GD+:NR],>YM' \=K.5F'
MV"V9_-RK*7A9;%CL8O$ZEN@_N]^[5W%9,8-766'P%Y;WIXO$>O7AS]=)W @^
M0G?H?T J;!#75W_^SVOM%:9Y>.DTHCF%#,L9[7*<+,M@)BMDRL9MY@,W85;&
MYC:8E>)T661XLGE#F\DAL!IRHS77FHV+]5CZQ]QQD):1%US-AFQE!AQ5>JT-
M-KB'G7+7,E1LM%.@Q0@M<3HK-<$;+RQ6G;F\6/EJ6>AL#XR_QJ3M\&BMC!OC
MQI1'!YBBRF6H.,NVR*+K 923XM$6WKT1&V;\T(99P#FSO^,L78TD7?0*VW)U
M"=TS272^T$PJG2\\LC(;9=0W?(1<%"RW^^Y+80Y=O#5DG9+K.?2U+HR-S"2M
MF+O-9677%LLSLU<X:0 #D)OKX=W^F5<65TZED^9PC9MI7QYFY#*SJ<TJO!S?
MM.@FA2(FA=->%Q?)]OS V<RF!MKOH=UEU(J^(&L2M7K36[20*LG4^X4W17"=
M)&V!<5++&.D]\XK-)0ZY*HH;VI!0+'!/>'\;@^/W&6@<=6D8!>_O>!L<=LYB
M7R]H)]>EP&'8P,D#JDFT-BO_PK@L^)TL^,#"]GB2TJ6SH,N NV51A4 2L\,9
M(3SJNPZQ'P31%^#><"CL,X56I:Q9RBA76>PT%J!#!D^-PP1/L=!/!.<L3?"T
M$5/)ZF9>52D*)1%Z[VI!_+7JN:SFF"&\!I\"5VY\#_O[*A@=[U)(&1\[*8[!
MVC%-XD(LT#HL(9H[L1GP%7$6?'HALH_0,*A21%>!-.]7],[[([KW.W;K<KI8
MA7316*RFL&H.">%3;\YC 5BAP5?#0FE5C+%U^R>3_65\DM\-O,'&(Z30W36-
MG?^/ JURILXG=\9-'?;GXX*0,T-''S<R=/@JL<P/<6*<^<M56C#,IVSRLK#
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M1!5@P5,>I(H?B1\S71N%5=D7T<NQ8_#/ )S*58CZ=AIM 'LJ2LV]"PZ"#7P
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MWY.@5$4?7?%^(W8FV3S(Q=:0M*=&S7V95B..?(EC0;0OGW_[\/GN']]/K[(
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M7]<?"E I$F'9+BD;NPQ/AZW,7)-2 R^?T=IZ0S=+BGB #N2%A0:^S)%"M4F
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M[>+V8Z0$<W>[.I'C;UC]^$,#=\N)YKF;YR(SI,D*"<YJRU@:<H9E4_:*LGL
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MQ%H\R]CRE$:YVD&RS1\[ I2#P87#9X.OY 7OCO;5;.:OJ/V[0Z;.P@D=&A2
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M!./0#7.DVBR$;1;,XBIOI!C+/[F!K41;>.[]=4C]1]4[H7HG5.^$ZITX]38
MU3LA2^_$Z6:-/GONK';B2%6%JZKPG5-G*<>)+/)19S(>MI874;T5<C"4DJ*V
M,XO;I<CJ3/3Q"4 #'F%VM+3';[7ZX?H%'!>13MI6'">H!=TN/6.&ZBM+XDBE
M'0]4#E>33\##P!(.6;+31_!DCIAD](HC>HU<%I6;4+F)MER?S?CY=F6BXZ$C
M G@\Q52$2B8J@9508$N\K'H"B\-.QJWUF9U'ZI#94=]7CX_$?_DR_T;A:S,@
M)D.[_3*_)<$#_C]BWST!.=TPN'&Q_2"$6X;4QK^)DXRC7E_Z).-=-G>H\40A
M^G*X3(UH_AHQ,-DX@^5>L7\9P&Q$D1C5)J()_[M/EYZ/OST[X8/CLCPE)BZ1
M"5A__I0LB#NC6O! *=PC?"# (JM'+?38=T-N-/$$9P!;!7^</6CDD5=J!0_>
MLZN)[AN$\!\V[S=^8VT.*PRZ*C>J<J.GD_=1N5&5&U6Y484K5]@[AP<;'KR;
MI[&:<K^GY9^-3U$2!$#. B-WT^P-;XGOOP U_B*+E0":8-0S<?*FKF;=JV2H
M2H:V)%(#$*FAH1#G9.*+;^N>KNJWW/&<68^BB+A_V)E8S0MK5%)3/M8HT9?E
MK#'J3$;G!ATGL]+C.<SJ\;]6@\G*E&I*F;-1'!5\EPTK:UV7Y*+WF6^*](R%
M/DT+D$$M;J;<[HZ28"7!35VE5B5XC(")O<-D/??M8&W/=^+O2&O'7;&,W5K"
M,=JOD0$;NO0"![_PAF%E.T\T35#]LIZFC);92R\A4UC4*BR^)!<Q/E)RTS(W
MRJHR_^+K(G\X,TJ(9=NZ8?>I2>8VF0ULTAO;(X-8U)I9_ZN;X()'5SWX:9+E
MGEY/?4I^7),Y+/$-63R3EP#W*9OC==SK+-DW*<;I,OG;U,?]S;]K/EV<<MW;
M/2>0C;( /*=Q5ZO7H/N!^"Y(0?"5^M\?B"](F^L]KC" B:E]$T:?7>=&G\5W
MTN!6&KM77AZR)-V0C?1Q<.N=A[EM+N<="9P9@A(Z*")V066 +ISC=API2<BX
M!#(&N ;MF<(_H()FT>AN$D1% L')MA</C:YQYBET*5^J[%9-\OKZX#03^_^@
MQ-<^L+Z)B\_Q7VGTYXR"-91J'YN$1*7^5>J_;NI?$:T2T?2C]I(?HUV-)FWB
MU]H4[3,6KK2YA:9F\*F<;E&@0M\>J #&XLVMOWM!</-$G 6S]KU;[_'1<[^'
M8/$_> N@6!!Y X+@A&X<Z968HR)ZH3Y"08MJQ*7/0!^SHN/"%< 9ZP#C $K
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M'!28NI40?*IVGIRXJ)25V>\L*E9G,K2:PY#)TZ.DN";EFK)FA9VY9MR9#%H
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M:[Z7%"V9+74R7#*;53NNJ_/9J->9]$?-JXT4FYT5FU4[X6NPF=[*T7X(+KN
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M\"5<ZCFL@&Z!J_#0-S PL"9R,G\< [:$5^/=/5@E%Q0C=N9Y</PX!+:/(T?
M4L*:((@+'TKF%FHA7_-1RPE^6OJR=EV[G3AAN.XHS<:24=:UWW];\L IV V/
M ^WI %T@W>R9&-,62+";_V"C\:<O"ZV"S8NJM<NRKB< V@U0G*TE:&&*XN>G
M'R[9]!KJ0;=HT5Y"T::YC##+3U^V37X00%5/M3PF%E,0D$LBX@*%B.+A6>+#
MQ1P,T#21SX8KJ6.7%'TC]H38(HS[_T:H#I<S5$]>#-+1=49@(D<D\<=Q$,;8
M*0RNN$!/#(Q:N^$/W(NY=N8#?KGE1"6A9G8-&IO9!58!R<ERAKD_\<":&#IC
MS0)P<\_#O+G@6U:,S8QS2U'7+OV"FX8,T#M=3D!\&/CQ_7"1?"X]'2#8=D9C
MX#)<(H;2P>)!!.9F7D$E7C/-%PN4^RG@L%:>-HK!/.T+X'[O"142T;4NS)3#
MCVSDQ[B'9.((L'DDP.81@LVC#&R&\"Q&)E0\1L 2(VGU$S^+RQ^(%M@C4B.+
MHZ$?@/D&-MIS@R=FQM=,C],9(/X= K40.Q/R95JK\3>!A9VA[]NX.'V.+TP'
M5_Z]_2,W370G@3F*^P#L,>; 0FC1Y05?;LE 8D=H>4\OI*POFH(N9ED!\&HH
M^X#+YR]_XH9MMUQ+2EA!CP3&A1S)*0Z/VVNK( R2%1QTWYJ#:1MS, !'UXW5
M_4O/^ Z+MWR6BL+=[?EU,I27+I@)=M.2!7N337_U))KO3AH%341>ONNGA1R^
MC@0A5SG*7/@"I!@H[N*WZGLA3M%5E8,KB&=$'$2HQ=_KMW5:G0<6("(L\#/\
M.PZ<T'8$7*EK0 #:$R!EL<*P#@WZ(&W$&JXH'],K\.L,^N*:Z6T<0WJ/Q*U.
MUEA5O'WJC;5D<_5D5 23Z9URA#-SY!E]D@Y&QZ/4N;C[=DP>3)Q]'OSA%L=>
M:DT6VFC%&#*<(807MM;]W<LT/"QR4F#WQG?=KV*("[KKMEM%W75+V$:7P2Z-
M@#?(;XB<_H!.[!PWQKDEH 7NRT689[63_6BEVVK5FYWBGPZGE6XI![6\?_&*
M;6(+<T3UUG[VS/T72&WMW,,8A6J?J]KGJO:Y:[;/58NVTJ+I5>LY_%ED,:#W
MZ%?FQ8AO]*T=W#RPK,RUIU^5I,L%UD"1#8V1^^;K3T#NR1%UQ4F*DV8B@)V-
ML5+GW4F[^?K#!HJ5%"N59M[KL)+>W1@K=8&5&J_O:*(*6VRHQXD54(G*G+=M
M'#A^0+[<J:"C:A:UF#U>Q!W)VF.*2>RB/_EKX(^N<?6O8<@^7GN=+'X1*_4P
MO%>63NNJ<-LF">J9/,4M450'BU>K1KH'25'F;BA*QT#NID[IJ@HH+U+HE.#E
M19M2Z7M;[V)7*OU,K/]J#(-'9-NE:5BE:JB45:NO1518WK=5D!2DB&K_B6J3
MBGTMHFHB6#RP;LXKJ_;-9]*LVL_D!0:[./=>";-]K9I6+U/RR19,L\XMCR*7
MSB2&?SC1\(Z2ND^S_+(B#L(3I:\J'ZPLK1(*Y)=I^9=2U<JG^#KM=R";NX9N
M?"J).:;(;O<X8/MDURD;V57 "W".Q_O2DV^8THP9U'%$%0>R VDB5QM_GBDL
MP1ZKUJEJ^[#AAMNQ2%V?8K5OF(Y\-3@=CUU8BK[+;\5.70V^9?NT#K]U-\9O
MRMPK(>V]#%V\%?'U%/'M&?&M9S"]#&2\COKFJ*S;P#.!\RY2531XJTFLN<,!
MJF:PJCZZXYK!JZ<<=75L;E?4PG$?JXZJ6L&*6TO(K1M+6^\:FTE;5\RJF%4Q
MZ[8SX[OF9C+C2\&M*Q3TWK<2T NJ1FZRB,D"8KD;LN@/+$AU0369SJF(K?.
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M6 4HV@=S_\$A<(D0W0[B>_3"NO @VL'WIY=?X%FI)?3URZD6<OZ#G%GHK7W
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M1+UEX\=QX(]B]YX<CS0,T6E(=#Y$4^W\T1HR[YZ##B1%J?=,%0$_2+FAYGV
M^D\=)U3Z[P#TG[%4_\TUHM\W_2=ZW)6&@Y0FJ/R\#T4#&C_]]%/U-E2IP(-3
M@44:,%QF E*OM174H]X5[(_'TLZP79"5:S]KMAJBOJ7MCZ.97K535_8:[22J
M=\N"/O-X>'3UZ/*G1&\:C8:A[,9#%#9JWM-:\YA:,9W,-]9ZL^[)A:UP2]-2
MN3,C G+_[J Y\HEJMZ7:;6T5Y6Q3!F7,M-&7M^K=UBHH9EZ*P7)\/#+K>@$O
M]%G(!0+[KP(04"YD^N;@O*P+H2#ZRA"]UQ$0_9+'@0\[[''ML^.'EH.)W"%A
MWWV>5@W;XM2U,Y=-^LSZH5W[KF,]D[LW@WS4H:YR(5B]H=<O+F^K!]U+Y!_9
MP>PO",)J__WYYAOP=!A1)_HOOA5CI9NZ1J=*]$]DRSO)S[;\&3[ .&1S9LZ"
MI.7R!5H4(,S0 _&%14S[Z@"H3KHZ8[=<>EW$[D7?7*R98V-7[XD3#=-G9.-*
MWE<_1*^DLI@K/^\#H634(+=GOU1O2Y4&223U'7OT/7_TI)T_1MP+J2JY->0C
MEJF40Z1\)<LJ/^\#H624X6>GWZJWI4J&+Y'A9\RU8E<DVGQSO!_HO5,2_1 )
M0<W[T"@9)?J7\Z_5VU(ET9=(]"]\X'B.$N@'3P=JWH=&R2C0OYU^KMZ6*H&^
M1*!_8WWN*EE^T"2@YGUHE(RR_/KFO'I;JF3Y$EE^+6I2*W_+X5."FO>A4;+>
M4,T6*C;[,Q]&HEVS^T6I+^\'?C!BD6P4E9?^F/&"V3,NS ,SSZ-$&_!4&SB>
MN!L_6S 6!C?;F&J3U((%$+%")V>]]=)U%2GKVTV2I0=^=")XH_6J;-$SS-'O
MRQ_HW-,WQX*5Y-KI?<"I?U>XE33IETWEW4E1VF_A!K;WCB_65FX'-Z'*YI+6
M=774=J>S5WG\;]4C(&DEJ>-GLYVUDFR8:2M)M/-EE<&\>DI5DNPB^6L,N$!O
M46.4QESOR-,^:F(!,;RD6^2W^)&/^GX<W&NW=58/ZFZ=;IIJ-!EJ;(3U#*GV
M^VE\'X>1$&4F]>_3=748]Q#%D>JB\$P7!=13,_6G_S/4_A&S %C,?2KHH?"/
MZ1Y&+='F]1#MV*HRC9KWH5$R<+FAT*A"HPJ-IFC4R'<V/T5L2"@45.,*_A-T
M;($*%#A22R#DPA;G2V!K'K4J"'J(,DA!T.<AJ*$@J&(:->\#AZ"F@J *@BH(
MFD)0L\@A6HPWA7/T.X.W3KDM6RGF_.Y$8=QWPJ&CW3&/];EV/63!B(%*%1HX
M>;CJ-';@$D<!SN<!IZD IV(:->\#!YQ-A3<5WJP"WM1;[6:KU]![C89A&EV!
M-_FCWFC]V36,=6'FK\RCSNA&ES!F+\68__2?V#T/M+LA#]B8Q[#EH:R#IY!E
M!62+0I;/(\O6#+*D\G&=3Z%VZ@%7N07@\K<,7'[E_8!8KR,X[Q#U<E691\W[
MT"@9N;UZ^ZD I@*8&<!L_]E,$CMO(Q_K(,?P(*90I5(0"E5N#E6V%:I4S*/F
M71%4V:[>?BI466E4:;3;#2-#E?J?'0DJL\S,2[^NZ:OF9^8/$S7+@S=58]M2
MS%LASO5/!:6(<\4X^:\Q7&'T%B/.9-ZJ&4XIZ01(H*/R]100J0002?+UB+;T
M;IJOUVBTS<9LOM[YH^7&(98W68X[#,H2:J2XXX[]X#:3:7D6X0ZPW)-S(M^<
MD4/5438)038KXLK.NDJMKY_XMJY:3XX\"=I6>GWO" 5HH*OT>M7TNFZ46Z\O
M']^K]3HI=MW,\O!U(U^8I+%NAM2E_X =^P+-$$H^._KY"Q]'+( ER7L7E')7
MROU-;/;&1L)$.ITM,0REW?>.4H (>DJ[5TV[5]QJ-_%SLWG\ERXZ=>N-OQYG
MZSRLG_U,:2J&^>9A Z762\>V9=#MLR42UC7<\=R:L-I-U:!^3YF%()Y2[B65
M$DJYO[ER-]?*/%4:76GT$FGTU[KB7Z+1#?V@5/IQA"T#DGG#/S/3[1BP8V,_
MI#:/'P..#7P?^*>)8T=#N5OYNT29_X^-[!;6#WTWCA;?,B5TPW@T D$SG_&S
M:4[4&\]1HH$#[75G""/W[S#(EO:>'_4#SGX<L0$,]B-S)^PIQ$7.373D>$?Y
M59U=$#'#D[_W@^-949EL#NPM=7A(5SL +7%DH64V#OG'Y,,GVPG'+GOZZ%"7
MB".ZZ1,L[#T,06Y1:SS/]+CHXN=L</6&&* 4TO+-\N<Z_'0\_WVG;IAFX2\
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M8^KXBV$<W_.1S5Q^Y/$X\($<//YH^:,1%R#D##\&EL/<J02]M&!?5QP?J*&
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M8/@]*N:>/C)%)[AU$<SF^,*'V=Q</7MG?GY3%/RWP,=T*(\Z/Z&Y@;D?OAS
MJA%>W$J7U=_\?6.]K*#+!&E+0!=KV8O4) D]S?Z+T92$VI!05V*4)4;;7J1N
M5*(7*4R,QEN4K@:6^/C%J0.K#JX7*X=F!87Z:ZXFA%GQE GTE@UBJP,>L? U
MKRF!INU:*F,QO%Y]2L4$\X)7L2S3:#]  _\NT/AI+;R+I5FH;"#8"IM,9+@"
M;,S%[Z$BF&R<B.>%R#'*D(0VG<10XB!D^.<9[N0S/64#)1\Y?OX1?B=*84SC
M7.(!JP M"(]]_&2"<*^ C$_$W9R%9W#JCT!OH(L5:9F0\MHIS^7/4#/S?<NE
M;F:.6RMNXC\K!4FL89@N'^I(5DIV'8#8D:4(KZ$O,;I4JR9M!FV-"+9"J_12
MO2A&$&J!4YX-6G@4:(6L+8AB*Q48#]9;42SW(1C]'W.TEHFW%WP\9LJ,)_C=
M@@#32*Z8"VWJW8._\1)LO:8^5LAE MHIR)4 #!>(<?0[4A&]KK4RD9KA.+=4
ME$2:$E2UZW!,#BT7#%I+,1=>;)BA5Y>Q%2#EEQJDQZ18#K[N<M9<P@S-[%Q4
M96BS9_9[ RE[;K<H\HQ8O,C%(XJ.G C,78:B9TR "B_KN!L+LQH_$U!.&=^R
MH$Z*-ST\5J"3\ @O&GD(YO/P>^4OZ^"5N%D-G D!1[>AH&E7G#O?LZ/&7L;?
MKP(-S74+ F;!S+P<T(4Y=OI#@*<2^<YB8EZ])#.N:<%60&3"LRM )'8 0C5(
MI$=8AL2:$*,*6>H2O>YZ,EW#IORS_VXH M%;'+TSCKY3A:V"'[E\Z1Q2QLIJ
MYTSX?6GG)=O.SQ[K-\PWX]_7X&FU8286GKK1OK->_F^[S_X)G<\Y5!F?A+^%
MD*'NYA$\8:&?9&R-GVO_,SSTC%&0 5-<NL,G><MF(Z9V"!WY6E%'?]G1*F [
M1- 9BX]VYQ((/#XWPL^\AP3XA7=^,@^++?#C[6X0!NIVB!\ =ZZ#<.=6!O,O
M.V%QKMELA^BPN%8FC</OG[AR1KFXAI?(*?S\>VZ%(C__;KR>\'R7EWQ]FDZ^
M-A?K#=FS/O.D\S/9!&/J^<LV:%3&:[::CL54:+C?)<Y<L:Y+^Q8V0F'YQBL4
M/HF)JF @/Q<2!GDQ,47/%JLBT1QNDH:^!XCDNS!IQ;^'R=^! H'R RKT4)HR
M9N^>%;?+VPA_I4;VC>P*3?QW-M=8=#@%EV?.@+?CW_ 9<'3+QX\*A*T81P8P
MB3E\;H[[!D+?B=7 AZ'=0O-;Z>RUXP)W977\:A2>Z/BRXYC;SVK9<R8%3'MJ
M4:'"E^,Q<_3R6^1#^HSZKH]PWR7XN8!+<TE&E$*%)P;NQ.4SC@8!]Z?(%4;"
M@N\L%K3:VPBO ZQ4V[ML]'I-?W9]>C.02C./GM.'T_(.5%"X%9TF6AW!3."@
MUS1A=^.AHIA?@/E,;"AO**8@SU%]%V]&,X\+4;$IN]=LBWFHS-O-0M C%"Y4
MW+,%.+N!V94*WT0[4S US,%/=<)>8CB\]N2TF4[O/6<E;]$%M^P,T^^8[U\P
M'U8L89J@]+BS"/]K=P,WYM<6ER\1F(?5!D,*OVC8R2_[6B;5>-5=E5D:!G:A
M.?5NN0>>* RY<4BF>((N(6GKW+QVO^\]>V0"[RXL7Z854[1BJLALVZZ'\OSX
M.\ %5JQ*OKE%7W7&QPM!KT&P"O!YPE])+*\5F_%@5M("U5G4:(77FP\O87+&
M7;5'[DS+P9M7\O5 6QVST2T+L.9E5#E3&/,OH&=YTMS&$7FDYP' $ANRP&RU
M>+1U/ )@+>>X"Q5,KA@#[]RQ5-U"U=;*)M&XO[=_@''&ZOA-4[0!Q]#JY]AR
MX77*A3LL5S*UO^+#.NJ?#,::&;QWF/M/@/"5#%2AQ9L7U%:0E%^BOKQ+N$(O
MV8!32R>YT]'H=XXK^O+>DBG6"O\D?0H?KUUV<+0.3[1?#AY.H]H4C@(U.+RW
M'SU\DL.I#/ Z$M#PTD.'$8/8>@%V07?YD=F'O9I,6F'FO%OE$[W/<8)98)*$
M<NZG#_/@P0.USOF-"FEI;T^MAI=[)*7?R;$N.U_*];T[5E,SX.E8,_5F\VU*
M6ELGW92?=5C;,SMLFV=6&)RX9PX#SWF#L,:*LJ4#QVD $,'S <O->MO,6D;Q
MWAT>QW<8GO"4W7K,]$%Z[K48*BI\ZH3RBX*T-5B\=TPU'84(YE+$MZ57#EVL
M$[5UEV:CJ<CL]C<ZN44<&S"\JT^F"XS?!",S76Z(^$PH+I'V9AR:ZD&\+&5;
MQRSXZ3)W?Z]_?#F;>W+!F.FO@T Y4YQIK3-1'0ZM\)17.[/67=DS&*'@84Z\
MIQ *#7%OZ]B10?HYG7,=>OGYH<#JG:8"J[;VHC 6N@%<*E"VU6G%'#"PSRU0
M+&ZI^LGT52 L23/E-*T8'G[,QTH*'2\Q;JE;;+W<LFVUUPV#7L;6UTOAQ1M#
MIF9#>2Z-)^/HLX![F)M06.T-.+U_+MWR Z*H(Q>&[&QQCDX)4W.J],*L,*F'
M![*QT@'UAGQ6TG4W9OC^C3&@.E*\>!V6*/+^"E^[4OF<#L"=GU''9-N!LC?:
M,MY8R5HQY*2_8UXA=:%USO,]!V]/N0,Y]\M-DE.P%0$+ILPB' 9BDS.4<^E-
M>;UJ,&@7Z.R.ZMT8UG!,I:_@;,('+F3=5@?XU;*BWSKUK8H&[QV467<Q$!C?
M63'L"DJW%4F-[BGSQV)'I7E!;75Q3S%)X7>YH!.FENZ9)7Q11M**@?J&J@G,
M);B#<1[X&D9699EBRRA:4:5ES&A_K_;F;#7:5E03UDD>9]^E>J+>3XO)\HJV
MP2\ZDS 3W(TO.,P-&ISI6_J,(\=%)+AT"5&)]OW7%ION:G^#%ESN:E=(B&E<
M3EN'X<*O35FVP^QT[[TI=ODP&"P#V^7'"O.*OC_6F_0%AE-5$ME\!4EMQ3M^
MM-#7^"Q<^9P*UT"YS%DMI7F!R_JZ-0U/H25RM,V!M.&3'$@.:X@GB?YA=,SI
M(F#7XI8N$ME4PR=XOD"_I'PV;%Q,*]P!6'=YT -P^36WU#^G9!N< 7"6^Y]K
M^]?%)*TPRY#^9&XJ1(@K:RH6E0X"5Z=O1773]Q[<">L)G$*"5E0H+P[?0"B_
MO<'[/&UA%!S*6W >%:?>&7B.SK16;7/IW[^J>6>#$(FGS[PPT[*<IIF(N0M0
M$'Y4ATTS*J-P'#I*.-K#L/& 9X/-;9V!*/8L[82O9#B8>QD,XV_M9C[)MW$R
M44Y;7<Q&,J]?<8U:**>E&1OIY-*2H_OI@FV%2,7S-K8<_[IL6FK@Y(=-4EMQ
ML-3*OUC#XI2_@&,K'*6BB?'",*@[G<94K:C:@\,Q!CSFSO*C\A9C%A.THD+Q
M'/]#N.$M<9@<)B>*SHJS4$MIWMTE2*3[);)C4]-RXDV5O,&*C-HZ8E^+B>+N
M!7@OS +7O))M" C$D!LHYD2NZ#E^A\>E99<D6:C>':I1N")YLU>Y>4H(6C&:
M?&-23=BM5$H^E=<DKV0;@):W9DTMS3%([$^E5[QPJL?D_5>_<3_YQ@0+L;6H
M/ GDTKQ[S[+G3#9BU*HLW]_$!:E2E\]S'O*X&^.163,-%1N])I>V9L0TLD'Z
M6F>8\X6TU;5XP_O1VG-36UO2UFZAEP4C[D_YD HZ8N'>P+E4\^@>J_(YN#)Y
M*WR+/YB0(I5@;;TJPT+TMA4S5TS[SI3-Z-=?_A]02P,$%     @ HHM)6'F@
MA'FH*@  ;JX! !4   !N8FEX+3(P,C,Q,C,Q7V-A;"YX;6S=?5ES6\FQYKM_
MA:;G==*J?7'8OB&I)8<BU"U%2SV^\X2H)4N$#0*Z6+3XUT\6%@HD01)+'?"H
M;URK10@\YZO*KW*KK*R__M?7R]&3SSB=#2?CO_W$_\Q^>H+C-,G#\<>__?3[
MAU?@?OJOO__I3W_]7P#__?RW-T]^GJ3%)8[G3UY,,<PQ/_DRG%\\F5_@DW].
MIO\>?@Y/WHW"O$RFEP!_7_[:B\FG;]/AQXOY$\&$VGQM\Z_3OP0IM11201%:
M@5)<0N2% 3ID/+B4T)7_\_$OCFO/G=,@.4I0*#0$ER.@#E866[(+>OG0T7#\
M[[_4/V*8X1,:WGBV_/%O/UW,YY_^\O3IER]?_OPU3D=_GDP_/A6,R:>;;_^T
M_OK76]__(I??YM[[I\M_O?KJ;+CKB_18_O2_?WGS/EW@98#A>#8/XU1?,!O^
M9;;\\,TDA?ERUA_$]>3.;]2?8/,UJ!\!%S1%?_XZRS_]_4]/GJRF8SH9X6]8
MGM3__O[;ZVNO'.-B.DG3X1C_G":73^M7GKZ8C&>3T3!7"3\/HPK]_07B?$8#
M6#YP_NT3_NVGV?#RTP@WGUU,L?SMIW$<?B4@0G*Q@O&_[W[8T^\(4QBEQ6@Y
M(6_HY_4C*YA68/'K',<95].R>>UHDJY]:52%,IEN?G,4(HZ6GPX6,_@8PJ?!
MFV&(P]%P/L390!87>, $T2D!BDD&'D4$+V1 [T6V*5Z?G3J4&8UE*<429G$I
MRO6SG]9I>XJC^6SSR7(BEY.XX_6KZ6LRDA>+Z906]:"D5!(J!LQK6F0E&0A*
M9L @>%&!*Q<['- :Q?5Q;1'CV30]F4PS3DE1_?3D"U:ELM99*TAAFFXQYOIZ
M67_CZ6QQ>;E\)@SG>+GY_3*=7+:1]GS2=*Y7(B7PI\K\[2><TKC'']\@*8P-
MJF^_3L9I#2M);F,T"ERV'%10!AS/B<9;-"\1F5&V,04>!+4/(\0/QHBVDFA'
M$#+ETZTQ;N$1TC@;L@ C=20+7 IX;P3HX%RQ 1&=:LV,.]'L0PGYHU&BS=PW
MX\*SV8RLZ$9?.6^=M&@!HR82<L?!:56 <6-9D-[EXAJ+_QJ 4T?S(LPNGHUS
M_<_+_UF0"SJBA\Z>S5^$Z?0;K</_&T8+'(C$,HL!P=@8:)1<@0]:0$0K5*21
MD_O9>)1[ >N343R>%S<9WUXF[<C_.0SIXQ&^FDS?$Z[W2&MQN2Q_QCC__M-F
M&K)2(7ID4"Q!4R(6B"+2CYBUS(9GIEIKQP,A]LF*MJ-0EW)J1J;?,"&QFU#.
M?L7YBRNE7@J3,8%0C'CM4(-CBD+:D-!HLB-1IL:4V0FD3[:T'3%.G_-FXG\]
M_DSOGDR_$9"!8\R1AQ @Y$0(;$8(7B DPYC02HAD16.I;[]_'V&K'T[81\]P
M6\?Y^H"B%$BR,&!8M5LI4(1GE07K.?TG*ZMSZ,)AOL=MVBUO_</)^\39;NPB
M$^.$9<)'B-P74-J14?$^ 7I.!D4S9+IUT+QZ<UL7GS,ON L49<3@:.%H4HY)
M6XA199&U2%KP\[GX?7!R#Y+L+=?DZ,EMQL^?L2"]/K\>I\DE?@A?5YBJEI3,
M16^E ><-+3_C2$LR;T SEV*P3)H@&PO[;C3]\TU/DGRC:3][,+.5<2B&%<5%
MAJ@$X8R<05!%0R3B>H_!)5L>*9[I9Q:HA<+H5DP=99%_JY/[MOP^P^44#%0A
MCI>@0'AC0+$LR! S#E)&$30:<K]:IU#N!=0_C_<DDK2;_&9\J+F;^;?O_'SU
M^=?AVNP]&^<MMMH<!0F/@RB>DPT4'EQ6 C(&E:.1!47K),F^V/KG)Y_$DDY$
MTHPP[Z838O'\V[M16.*I:#_5LH*EA0Q.8.8)M$](%C+589<(J09NTE)0USS1
M?!^>?8AA?AQB-)OZAMF1>1A_')+9N_*27GY-HT6M0?G'9)*_#$>C@=.68OIB
M@'#4Z,X[B"5)\"I:Y75.F;4V*OO@VH<<]L<A1W-1=)%>V5)>S.I8'!&T6$9C
M%5*"TTR#]#[;:%@R7698#C,>[L>AP>F3W4SN.PHG1&&!H3# 1&:DI"PG_K$,
MEFE!7H[(/+2V#P\5J1P1D:4T68SGLW?A6W7X21'3)],%YAT#3C%'[T0D][Z4
M6B%G(0;&0',>9$Q>9<X:#_@ >'U*VIS(EEOQ6$=":K8Z7DS&G\F85X5=(\0-
M%BPH8ZR+'0UA01JX<Z0 0N0E&$Q%-/>@=B/I4UJG,3<:3'UG13M7&79)*MOE
M3,$@)TN=K8/@H@&?3.#1:F=TZW*^.Z#T*5'3F @M)K\9$][/)^G?%Y,13>AL
M%0(.F"H9ZX@,67Y0I>Z+D2< 5N7B*?A#Q5K[2+=1G!XPKC.JRT>ORD+(DS$\
MV  <I26U&VN5E;!@G+=<!L6L:QT2[(#1)_-WHO1OAXJG37I#,W=Y.1EOH2B"
M!:%-AH"9XE0N&43F ]! @[8F,IU;)Z=O8NB3:6LL]Y.FN]V>1<[#.O8P>A>&
M^?7X1?@TG(?1%K@!Z>P2G,M@<CT3$ETUMMI!5M(*+B.IX.;;K@^BZI.I:TR,
MQB)I1Y64%I=UEC$OK3$!^C3%"QS/AI]QM0?W9C*KV8RWY4/X.BA><*V4A\"1
M'';-"T6R <%EK &NX,[Z]@'5(1#[M&?1FD0="JMAP=X\#,>87X;I>#C^.-L"
M_3.681K.!]YZF;T2$(4RQ'1-EC!A L?0QY14=BHWK]Y["%6?=C$:\Z:Q2+K(
M4#T;YQV#5D4+%U4"FD0*"6.2Q%V&D"4%&R*C9])TEZ_:B:GAF <^Z4014P97
MZCDF:6MI@_/ C' F,XLBMC;"=QZ"ZTWVZ70FW'."[* I[S*TY,XQSU@ B[J6
M-'$*<0WYA1JY*58G0X'SF4/+WN28VC/@1 '<(,)?G]Z<KS?T<YLCP^_G]&?=
M4YRM['D8YQU6_CJPP\\2[_F6]H>,CQE>H]/'OT[&DTW]Q^HU+[]^HK?BP+@D
M2^ 1;-$9%)E!"+8$R"658*)/P;5>BW>":; CC%.<S3=CXTPXG2FHR,9Z4-6X
M1Y,\%&](^>52_]=^\W<;PH%F!CK5,FU(L&/O]^A)[[22Z/?Q%,-H^!_,_R '
ML,8& R92\"4E<O22(#7J.7@;/0ADQ8<BE&A>#; ?LCX9HVYHTH&$FK&GOGU6
M7X^SM^.77^O %\/91575;TO=I1E$B@]R<0JL,)9&+CU$])JP8516<2]#:TWR
M(*@^)8RZX4Q;N9Q,E^I6+$\,S>85PFJ<Y*\MTQ&U#,I&RX.T#% CH5&9UVIM
M#J5HIF3QD4?VD*?RT$OZE.%I*_6FT]N^9OE[BFF0I,R%TYAH&!H4,PC!R0S:
MF>(L6N%S\_W1VS!.SU5]QO$"7Y%8R4N=3T.:_W,XOWBQF,WI#=.K JY:T$/_
MGVM2S1KC?60)'&=5KD&0""0GO!16NHQ6Z]:%N$? [%-P?RI_;J>SNI5:P\VW
MV;Q&LVN5,!MD'8,*6"#9FGT(JH!/3(#PEC0":HIC6W/G)H8#W:QNW?'6S#AI
MPEONN=Z,:*]2\LZ)(D(]=,(L\5"B@\A9 !=0>Z'1)=?ZX/H]<$X=*3UG2W)&
M&NY85B *F20EA(28 @.)Q6L5(QFNUL>SKP'HD\YKQ8&;##]^QMN63.T8WZO)
ME&9VO"KB2=\^3,-XMI[__*_%RJ.AX;^;3)>?S>?385S,:W7@A\F[L"HFTLI(
MSPU(A8;<FV)ICCA%0ME*5Z3/GK7>&.IN-+W2M%WQL2=DZ)S<=;G=?<;P^YBN
M)E6(F+31'(P)9'E\C!!R<.!LU$G;I&7S ^&ML/<IJCXW;SN5<S.67K<"DBF>
M6)1@2F*@G!3@@PB@B_;96&N3:UVF>(_=/29GO7G2QJ4?CA?D%*Z]P\EX]AP+
MZ9.K(^$X>_F5W'ZBXG <IM]>$X.6IRUJ,# 9C9;^Y"HC.^ 94U3.@7>6E(B)
MM5-&(O'$H(6U2GK1^@! A\/IDX=S/ =OI\_[(?^&Q_+60-=QR',<8QG.!](X
MGJ+5H&E20"6C:9*B!ZF=S=IPY*EU.<,=4'KEF[1FTFD3WUWT;XT-01L)0KA$
MIB(;\%HSB)Z)DA"=CNW/EMP7_1\WIK>EGF=<[M+C]/,PX>S]9)0'W* *VB%D
MDQ0H+<E=,^2S>1T-S37S*;0F]]UH^J0H3^+!K@Q' P$TK/:;(3VFMJ+\&3_C
M:+(\$+T>ZO=,7/J?Q7#9U.7==$)X9W48 ZZB#+P8*-PM.[.2ZQ1B !2\^!1S
M":IU+>D)</NT/]F44N<28<><6QZZW:!<NO<?+L+XP\5TLOAX\7PQ&XZ7H"\C
M^0QUBO])+OT<QV]+&13DUMGJ'W ?@!:1@:AJOI!ERTKQ7*GVW23;CJ%?,5OG
M[#R3L-M5 .+2+?T'^2/3,*JG8?/E<#R<S:N#^_EJS[ ()47TCE2X1)JH5%,>
MC$-VN2AEL3C3NK'8?LCZM.7:E%X="*9Q&-%-7.0#=^1H,Q \<8J+O 1GO 67
MT*)70@C?OB[L3'%QFQUNI5.6W"I@:'+=.LK@E#20ZKE61XY6BJV-PH,[W(_K
MR/:%CW>V]3I2>NW2<G<6@Q0TFFG. 5FLQRM\JGY2 :UT+-9CX:RU8M^SQ/1Q
M'=F^4JJ-)!^E;GQ2ZIT KT:3+R=?.;7[H5U6A=\)OE$1>'WZC2L3R,&<3X>)
M8*RO5+C^P=8WW^%T.*F-2:>U?>#/N/HO_;R*D"A4(A_T(_Y&@WE9"J;Y@#DI
MZD$#$(%Y"H]J9Q-?KVJ3/&7-L].^><;GK"-LL)%1(5!(^7E(TGW^[?=9#3&O
M-/JS1%[8^N0..J5]J2LY4ZC)F +GDJ]=M&P2IN286M?.[(^N3V:ZQQS?4<W0
MA?A;[K/MPK>JT+R.CP4G,D\:*!0@?#:0PZ%+A)@#.J$-<[&U0[T_NCZ9_!^?
MGJ>*OVMZOB+7:)RNXY/>!,:<!6-K[VS.Z_%AG2$)Q]&77#*>27ON0->KY-4/
M3\]3Q=_N1-)RB&_+]K#?CD^:X$$Q,F-M9,!9W>2(*4+07->>&4848ZT4K6L,
M.QA&K])I/P[A'YM0CZ&X(W/*:&TA.TGXL&8><0E7",YBT2A:'[0X5G$?/@_+
MK23,R^#_]6RVJ!<0ORW;37'0!I=*O8O&1$>^GRC@BZ?A1X^!R1!T\ZLV'@35
M)V>_(R;M:'W=4% -=P(_A6_+Q$$%<ZVKY, H7X27!7*I)D_5GKM2!/ QBF2D
MH7]M?T[G3CA]*[@Y!VE:2:=KM;LKW-0A%XXL@M>6@0H\0>!. S(*-E$&G7SK
M8]+'9AM.+1]EN@2M:B-"K,51%*O4=M<.8M*"<:&S8:U+)'M[;*,CAMQ_BN,0
M ;3;D;X(4WQ.SMJR 0>.9\OI&3AMG*HPD@[+Y$JD=4F##%9A+BJB2JUYOQM)
MGU(69V)% Y$TO/WLTQ33<(6 "2L\,@6R""*HQ0+.\7I'#OG(BM/[9>M"K>WW
M]RD]<"8J'#W][1I#7M:C.?]9(EAU&OAY.%OV='\WQ<OAXG*0HHW6607.VMJO
MFV(ZKV4&,NW6<)]BPM;'#AX$U:? ^DQ4:2NHCOASY5HNBW?J#1L<.479$E4-
M_6NS$U0!4C$H>' !0_,;O^_!TZ?6CX_"FA/$TQ%A;EZG,TA"I7K0"DRN^^[9
M>J#()$,H*OO ;6W@UREE;B+JT^56CT*:DT1T[K97F456=%3 "0T-6]1.ISJ#
M#FBU-T83T-9YXV9MK^PC)P9:\Z@#F75W[>^R'R7]]P5]."26&Q6,)EZ#$/6B
MMVPE1&8*H(U)"2VT<NV=X?LQ]>D.K;,YR W%=,8N:DZ:8 W1.9MZM4DH!2(/
M$3)A0EN,D,W[,3;IHN;_8"JHK:3:MA_8,=9-5=Q5I=Q T<"9)L\LHZCW[K ,
M+KH,Z&K/]YR]#\W+D_<%MU=&C_VQ%%(WDFMYEN#&%NWFAK;?,.'P<VUW,."!
MJ2BY!QM%3?8K<N!"<5"LS\Y+D61LO=>X#ZZ]Z'2^%K+GX5-S@75(I5H0-:9?
M6A9".8;1*0'6U3;=C(@=A>&@N1 H*)XLHH.#)7<#VHL\C[WSUCUYCA71&130
M?5=$#H1,R65MR.RZVN,E<XC>,8A1Q<RU9 %;U_L<AW0OGOW!LM1GD&F'_+MN
ML=<7,M4FJRB4=^@\9$G!IZHMJ)Q!#]%:;3TON936UW+LCVXOGJD_O#YK(KR6
MMVA-<2F$Z\GX=2*^AJ;K9/SL>W??NO&;98A)U)9F-"7UVJ^ %H$5%6TN0CG>
M/*=Y%-*]2*?_8*0[@U ?XZ "%DU0ZCFX(C1-2;009-0@=&+9*HS,=M M[*B#
M"D<4%*X+CCY,ULT![N[EM@SR%1>E*%'[ #MRA;Q-X(MU=:N=AZ"2<K%U,N]
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M93M[@]N'1?Y\=U"<3=6<**9SV:W-%@U]877%W-6E&L]&H\F7VNQAX#+*C-I
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M<X(K7]U?N1_2$9@?VZKO-BTJRKZB+5I"[G_S_]6T%_CF90>\4$YSP0DU&B>
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MU4?1=^'A@W/YCFMQ6"(<2Y'B4D?F0[XVK"[^+3%/E46G7V951J+10V)9$R_
M1,,L3:%V9,Y2( ?K87Y@<C2UE=1#",9=8?CEXU^$H:T#MZ>XXPVA'B8<N8*2
M;YN>>]#0$1 K1L5Y=(X$"N7.R]O2]80201-G-#C&3?73XF,@U -AS8?GTR:*
MZ:72X/*U>8&.R5+#S$>B*4>G3J(DO ^&4.&L<E'A#_7+8-^':/^QR[TJ],X5
M5#5M5$["?UW\<VB_^G9Z7N*WNWG"%4TB448D-^4"A%OBN//=<:)Q@'A,C5)S
MRY[]S(V>*BJI&,C7U2V KXOCY<MC@-L0+XHQK@&R9@V<=8'MOT+.[CIL]J6
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M=$O7TNG2CW]RR_'N0JR8@]0A^FTXG<S"<'(Z_.+'^+NY2?"Z:;\N GHNK/[
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MLC"R0+RA)227.BJ"9:!J5R"H.H"=0S4J@%F$+4@(0@(G1B><R=%ZXD/P)+)
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MUEL/V27+;MTO 2XFU#H0]QA?=PO>P:/JZJAVC;BG&GK94R#=;:C*4%PI;20
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M;3I#84^F)8SD&_SRO2RTEZU';# R.<,)<*H1HD0;P#&T 1Q$([-/QM7FR48
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MI$A""8&TS>^_>^_>>V=G9W=G]I##3";O^^8\YSSG^WR^)_0_]'G@M(&NOB[
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MI?+PI P,?OI!O<2\!B%=@% R R/HP.;O/3J@<X:ZQECU1[+D_"/+7FC%&D4
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M6L;U[5Y_1ME"F%*_4"O,@1A'JB=KD3;U\!-=?1:C*H:3PDJA-R;>ZUJ[I5R
M8FO/IGCYK-_/_E[,V?_M8$\O_M-S7ZO*N#SWHBD##I6)7NDM.@!R#<Z/;@(5
MN5G=*%(QNKLKP.G.IGBM53SL9[W$TLVU4K@K#O\@/S%6#76H+)&JX=8+.=QM
MV<RNEY:53-#,CU9^D,"?GS:Z_#@0L66-O/$9+$@'HAQKJ;P,*@T;H$T:8/$/
M:J!':$M&'<!2*UHVLA."I XI]Z1D&+4/34D"4:+W>K86R" W)),_>3M@R4+J
M[%A>[(^:3Z5-62^B=MZKW7A:)[;$+-T<RJLCQ-ZS^C134:U3T^(&?"_ <LBU
M*27IB&'3[ZQ$"#ZZS?K?^BNT4--YS2 \KC.871RSY13!L=5E/'*TV-!P.=_%
MS\TXM]!85;HAD(Q*9!A-M-2-($WY11 SM!SU>.CJE%FD=B1?^50KKXX/@P4M
M7+89U\P^]]:\P*CUO'?\KV9Y.5:\GVRW?2U]+H$),@>*#V9!5B+J%W!3,8KO
M$**CGGXXWCG=_J(I_;JFLHY3,:^9(A<J3+B5PZ$Z$XY%!6/F#J4#)9W.9M\G
M,WROJ.9^*UN:K':3/<I4(U\@"35QX*4[B(&GQ4/ZJCSZ(N3,:^^_NLZK7>L)
MKUZ B'B@*WA[H&?*RA=LM2V'_:-MY].'@AROB\1_6.*98'%\-K%NI)H(%?]P
MXY2NCLN9J=Y>V_L+69]WQS!R^T=+UHN6M=;%$.D];-<4+@Y\!3&$XVUR0,Y[
MFG0TF-7>(%@=#56FQ<L,?.QQG3[$'A_,(":M3N47T@9!I_(K1\K*OJ)^XF2N
M51;12/YGGR%4B6-"R"=5R8\FGVP^I0,*[N;G="X87X^Q#('8]73A\ \]9<T_
M/\5+%3ODV6X(C_/(_QHG*$?<&GQ]7\*%K0(LB_ACM=;%8+\YV*UV*&^UX^B!
M*ZU?)OGRJ]<'G%E!X#513,/E:'[=)T5RJ<LIHOV7)F+BS')"Q!;VTE76'^59
MG_KV%YJRI]K84ERX9_(&Z?S%>(+X (MGR[:OG:B^M-P@7R<4XWPN\0GY&?,!
M!D12)-^'11$]\+\RF0FHUP=NJ]^_]#>-;U8M) 3L7NO0$I6Z@VEQ0YW1CU_'
MA"?6N0BFA,P:V6H]^+NFN5&B]"'E_F^;\<;XO.4A1@JP@__S.YMXD]IB;#'V
MI!W,_??<14.U^BO=RX(O#A[]6'J36;V"Q)M\X7TTY-D$5^7B^BQP8=\)/,2E
MUQCY-[$_%*EC4FU3$6>>K.[TL5W%8S#',%55W:\Q8.5@;JT'QZ=BI.L]G=^>
M-O3'ICFI0W@S)2+.@7.RSX&YU!=998YYA^"@C5I9=HG;<BX]'?22UDG^P4)I
MXVS@9YKR"5,>;UG)=>+.Y7L?'&Y^ANAAG*JQON:5\;?>U%@IJM*=C+&+6O/>
M5B+X=N*J+-_Z3?JAHM*[T0O4&SN_/.\NB'V:31._&[&N=4=UCO;'"A,C,N_]
M6E,IY^]AQ33.JO.0#CA'3)9+>%2+,K7^UA^PX22;^;3./QX+?7[56N^>MP3Q
MB]H=TXZ\,T9597/4Z:T#L"#)GVSMCN:&"^21O/5)6D4*7]Z>4ZL:9I;V=WFA
M/9J1OH[U\MZ&O@.Q-O$66+E.(-WJZ\CW4M]W#S?=REY_J3PQU=*;G583DY[A
M@"F,^7W)M,NT^U''[D^%VAVUD&/T-=K8E!$QBRSW-[6& 9YJ!C7669$7743O
M9 (#0AMT@&7;N9HDL/ Y*"M);$3?W/7+_6<!4B</,'K9%?Z*IPS]ZU='>QH^
M/ED("DA.H0:#1&CM=@+8!%!T:GI*_-A;R^&3*?D1R>?"PRS/NI3Z0$]1'!9W
M_N1W@\\/'N XH!YV$J.R>U^;JAZK.=ST?W'ZU4E6?=$N1-B(K;".W$\QDX<=
MYVN.>U1R5R1!VN.IH=L>%BGN!@^+/;JWX;=4!M!@'MKH5'ZWHM3%9,]Y'E.#
M04I:X%A9[.D$\,9[$5?VS$#+#[3I,W%80? U&.^"5_J#I* ^U=^_"QRET21N
M=ZN6J?5K-S%?:#RTWQH3$3054F4/3:FE:ER5JU[4;;BM<5E7,RD7GLM]B?GF
M6J9K_F.^Y(*4DBH[IV=*'S5N1B\]9S5) F]YS2[O-^,\9M&WW5*5_@9[EF;(
M"<O#4F4XKUW[RD0I7J4#TY@%J4:"_ (QK0 6/+FSXW<K*M/PIJYCT@V /Z?>
M]NN\;UBH_-]T^<R,6?7+.6UM#G+/?*YU:3_5P4$[2=AV.E";6I8._IPW0[DQ
M6N:_WF[]LUSYR@M=D9?B7-R[/JCN2CK@K@#I1)]"NO)R4FR^#ZZ-JZ1$*EZ_
M.80-6.#\8,_.4OA#QG*Z7=7RJB";5VF"T66F-RR.4MFUYCEBOKHW=@JW1OKQ
MI."-&A!W=GI2TJKW)\/\M!\4&C4;K Y+8]1&9Z(5;T>I_8!V>4/,QMKC_VT[
M@HX7L#II-9XK_Z:^W.O-_HS=F6O^,R36<QPL%#YHDNP?W@>,.Y?<"8XOX]-7
MM02L8EKQ@,%"]'/\'Q'A?[[?XG]SWO[/H+Y6\VK0'$6)FVI5$C*GYBD+MQX*
M7'Q2XLJNJWM_W__UR:;ZX7^&M[M75*@_S&M]>.5';7UQ>>IR]^S\XF?F4\VN
M,,:_2V=O;IR_MGS^1OG#]X5_R!^N,_DXOZ/DY%N]TAK__'0ET6D!C7?F[CAQ
M)YII[_EOY;TJ/T0?L*6&I5Y<NVV2D?N[XUY?JF9-7?S>R7#KO>5ZB;,"^[<?
M>OA"H_CTO?*\;^6OMRT_'GY_^].WV^:79Q=^.!^^[;I#QN.&G89Y+XR\V/Y,
M6_QWRC^.BF7''_H?J76/WI!K'OPQ=<W$R%L^N^79+ W.[,GEN53XQC@^>4O6
MF36AWOINRA/]5I1.ZNY1SIZS^>S*X(5:%E9<\XU]]Z5K?]J]9/VVY< T\N;Y
MQ\=']F^>-WW=#[/'#[\M7OTJ^!6O3:'>CSO>6P,6\[;W3RBR]2VO9UC\<=[6
MWRE9=:H?\UO?U5B6KWBYR>N"B>_38V9N*\SE?C#;_7RT[_&GZV?N;\D_9IX\
MIRIXU=..H&=95ILW"\X/7O7:3Z)4\FIW4,W9][F[=/<_F"]1\=CA"M#ZII:*
M["!?JY=?OO097/?FEFC_I=T7+?$ZN.[J//:/X0UU9A7EC]7;3,*NY^8DA^S9
MVNFI<4JRZ+9;V28S\X0'_4MK)[LZ'3&YO.W4<17CG8>6:GY26\B?=OVS>_0O
M>07/WS7QKRX<S05&:.NOL_\VJI]^XG%$(<]ZE5"]8MSBC]>_]>[YH5OY\).-
M](KL674+N4\7F^[4^G;&[&V0V03/D^<\7L;=V+@J[];"<IDY/"F_+LVKL.F:
M;E7NZ^P?/*OB#/=*3G?NC-5WB_?F;]NK>_FCO6V=<D7_D?KM[$?B.3-^V;>L
MWU+/][+(..;>W94_A=SB36]N;&SM85@PR?]:UU].CVNF7%V"[JZ!C:X9'XT\
MW>9URGY^I.-J<:R/M5JK\&;<W_RR&Z\T%NTX/P6R/)7*^*/]K=?_/'WW_VU=
M6_]%V55TJ_PCER^?SG^_%;?B2W_;_4_^?ZS_,\0!NX$OF'9Y::QYNMMB=;U8
MW!J-15V3!19U:3 @8>;_-P%02P,$%     @ HHM)6.J -B"W-P  \3@  !0
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MM)PFYCQW+=L.C$0ZF1R\5;\"U/7R;TH4WE05D\OP?5@S0$"OW/B"49I50-9
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M_(ONPYUXBU;=%?N4I#<<)'0N3RC=G>5:BY):LU8\>$E/\J][JA$W0F1HSNL
MLSCB94+@#\HD:\]96^^#>G2'Q84'B5MU'=F<H,L$K%&3[XR'J#_'04)BO=@%
M"Q #^>;$B8GOG,QC=@3]FB96@R4'7D\,WGWGR<65!^YO0C#;G/-'2Z &@7,C
M\8C;R'Z=:? VIG3)FO2(@0SXPX4\M$!=(C20 =<%;,@ 5#@JR./TJA09\,*4
M#!A]V4H&W"'1<4R!D\!2 ^C%"M(GXLPRFAZY^MT%>31WQG_.TJI&4*7<+/J
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M9,"FY*H&_T6VFA[*LFRX/<(@KL?X=A0[VW8U=4(OYP@GG H/BGBSN,7&4LC
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M4E:^D/JE\;\V-6-5/V)D>E_<(]ZXG:9V<U\L\TQ;V@VZ.4]XDW"G"U-Q&A?
M\3<Y>6&:D$$<82$8%<TOPG5':<92(>!_AT+ UR?H&"03!G\<_ZK.-,&BUJ;]
M&A:VY:#16Y=SEGZZM[Q'3(X#DIJ0#R#V4Z=Q#,KJ <:#FSW)+ZN-]:7\1BTV
M^O+5L+2V#FM;R@;F-^9F?((:02RNL^$Y&&DOU<^,LY"9?N(#6HNWFJ#/(JVM
M!"0V!B(,0TAK,5?\TC"(I.J/N]"(*"(#CJ:SX;X$$_E25[4'^0\RM;B&)R3
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M#__=<:&NR&TNQ";L7L,D!'.XJ"#R'7\08KK2B2CN% R:>49@6.O@!9V.Q3[
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ML.!=?PSZPUVB6BJSJ"D^64,UWG<4C '%/CYY_//[SUQQFM/6EY)9H<I*EUK
MF.PHGQ%>F(#^E)H>)JI9H,Q6M*8GPM,K[9X59L9$+E*A0I*K?K-)J'05Q$"4
MGT#P$@:/!7$)D6RO)JL#F;U4OU^]$VV?'RX!5,M1]0(W)4*\G](/V]VX0-5D
M[ G!$CJ7&!%<4##G+E'*YU@=:5J)#AE87%QFZO>@2EY;><4[<)ONB>SX75CA
M\2E./)Q$"[->R75-[SZ.^;&=2$!@C1Y=6G*=?JBW]GV4(Q/_^3,7G[A4;*B=
MT;D"\2T.LN/-TY4=3J&W'EQ!@^M*S(73K_-G=<D%-<YOV['U82G6@9[A-DE
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MBN+4P:%)T8"3@/_:4LM]#R;/_#=02P,$%     @ HHM)6++'Z#A.-   >38
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M%U*/W#R@%ET<D@"F6'<-]H]M\2[?7SB=3(MGLRAU'"=)52%%AV>>O"PRX6<
MO#8?:[U4HIO":)>OO.<RF3L6/J8<U*I*& PP>.0YT]M@1E84]SA6W24.<6W)
MG%%AY+MSH/AO;[W>6,:9>B*S@A":41H K_=L]Z<QM"V/4*<Q(/BTSZ: ;(N4
M'#^P\).Z<3,J%'\_+_XK:'+3=ZU'6K>'*:O0/:#*T#GI'5%P8N)F=_#95FR"
M9[VM2B7H7:-038)?9<TQ#I<,US6\T7(TPW* V_MSVK2EP0>BR&?)@C]_.((P
MG:5KO-X7/F@'ALIENX,PTHK/KU'3+R-#4>A<=^R[.?-?]2A!:&=]O.B_6]YC
M8':RB]0@"=$09P-;?M4=X&)]>/UJ"WP'^.!P!XBOKPURU,(80ZX*99J"?= N
M8]>B:+YI/_/)PF4P/7@GZ0Z Q4G!\O;@(E@O$SU%6G VH]NUYNG'SA"G(SZ^
MR?A HG:^EV0>W@&'YW+\VY2UAL8F?^I7WP?;BFL;T8AR5?'O__)Z<K[!-.C:
M1]W+8>NB[?>Z+7Z53HKOW?NXAZER>7< .73W@4R0R9,JO]67F3SC#!7 /N-]
M+P;1NI=ZQG\339<53V6I'$F2ZRJ*C-/TZ^61FH/,Z_@'!_ZWE2*'W>6J=(Q!
MBF3BZL$\P8SA7-3Q);"$DL.*$*L]S'&RFZZ<297/=*%"R-* .HUYN0\>C>'S
M_])I-PHI)$,.P,E6ILWF&5"/&6M<(JT!,JU)#6^[2UO32CFQZ%QTYJ0<0Z:=
M/V=FAVTDA+_.^/M_W^EUQM"<3Q=FTG96QQ9N(J(/J )^[M*[LE!H735JA@M2
M([!-04&\5Z_IDBY&6D*\&3]FGK8=BWFXEU(F7A+L65<)#\S)EMF)57[S=RXQ
M5*>-F#'O:Z:_D*;[]2M!PIW148:+(S$E&"6?$M5+BS1MN\B&G'^KFPPD;&K[
MI;R*F^6QEGF<.0@:1RAE;NE36+GF1,\*J+*-"4]_;\09'3LZ22[N^MZRRKNY
MO47?TZ:PXL%J!DF/_)0%7[;_=4H[)TG.'+04&/6O/53VJQIY8= EV:3/N^PZ
ML<)/[),]@AMW@!2A%D'I*;Q?V:+E,1#!,7/7%1&O]G__ *?/K^'4FT=A&-]*
MU0U/O&5NIE?N\=LQ 25;W[C!@'-%70,471Q+./^T @&B[1W0T@PXWG(#4\(1
M"4OSC5CF[:GZM&7%DF[3$SISPK?S^^K:WSGNVQ''5>_X;B[82;!Q;6?&Q#P-
M!-RLO0':\;=D\?3,-+]_E_7DT="ORA<;K5Z^8V.U9NC5"KZH#13N'OSMHPJ@
M^X=ORQR,?W:*SJ$.PZ#T@06]E;9EE+D21 :CD'E5V[=Q"-.JLX=:E=>3103W
M,FH=GW^$Q":*9WVDS#M2U,;]$+S=8<\4:M.-;*THFA3BRACLC :*=3&*F"2;
ML^(P$M".@W('@R\';T'HKA]P<==@VVWN+"F'QX^3O587]4"*FF=+L;1KXKDO
M;^R=X)J_!RD3D\J87+H\W6?"S'V+D=)#,:B12@EV2I 7J2Z.T(0'DUA;7N/W
M*_ 0O,8L(+7X>@UNW#&;!37* G"; 48_;'P2DG=N<3'G"1HQNN3ZV66WX\&4
MMS=XF;X==N2N ,O#DMP!QNSFE=K8KRGK2P3_W@'BE'AF0P51JB;=\R)*X^Z=
M_F=2SWPL-MZH2![> 9!=H?1W )6T^\]^%HRBW=^6<)VKR>-<:EQD$S']6*(7
ME;B=T;5:TE'<[HFV[26^ WP=O0/TN_2A(<M(6+*$/H/DCSWZ/J 4XE5AI]]R
ME\Q-?S#3J>.+&GJ)KS/_G#M(U)E2LJAUKR1LYC':9;N\8I7KJD[O)F&2#5VL
MWG9\&^04+DN>0[5FV/UC&:%M:3:;2:\*OP\IO\SKT-7]G?:).2O[G&]?/^3+
MY%UKAYW6TR+MH_QN?:$YL6F^V[DZOE)3];&/V=^/U8^VYP057A10&D?+FMP!
M JOG%^US&_L<CGT^(Y2^V><8]8GVM$)NR?UG0DU+@;/=<N%%I"N578MOW5*?
M)<Y8H]LT.Q?87T*P?',&C2WMDQN:?"W.:'O$=AJ">-&C&263I85I/7NW(I8*
M+@N]J@45>^)C7L-;=$!F(=$%?DG6Y=LV#\*\"S*OZW3BAK?XQQR,DM0*TH*#
M/$+9W!-*(O)8B=NEW0//?E^K#BF)3X<*1+3H:C";<7%*R?K> 7!8%L@*414#
MUS$_^W,:1XZF)I@YL>_>MJ<\"J7,'6J'*S@$>DO^A9\H_:R--0AB3O%0CO:K
M!5.%P^1(+PHY9D@ZP_;KC\>U[*24$LF5T^KM%U]_O>*36O=OV)%;C(8W5^CR
M+!X'UQB53M>D=8XQD_[\Z4.H.%!S%#+,9![[FMHU&[G(%;8NUN'Y=1^X XLK
MI!7I95DZD-.H2G^U@.B=(&8Y_/P4[]FB/A_RLB[C1Q^AIT+HSI#=TZZ\GJEU
MVAIGTN__QI3]'+[BELF^=GBA"\\LFJ[KC8QU%%(S\4)VK^T=L=M/'0N'2X/D
M]AT_NJY9>B1QBU1?;78!K2L]:[<*UDP*'N'_29<BJ5%4H=W.@1]>(G(/^'3P
M"O4[!A8Y1VU]ESDNKLT9D<[V<PJ,6\!Z0E?]STP:22:M9K*:'/5-8,.7%JZT
MWWZ"7.2A9H5OH/3Q1682*&^SK/BZVR__6+F>F@H- ?"U%2N%:*CT /< ]3_:
M4TB"X]DXE9B0ZY_=VCZC* ?:.4Y_A7! T7!>9E*A5SEZ8QXWK+^[;9ZFZE:W
M%=O"K.>Q(B!]]4_#2@W4HV1$_22?,2:4AGM]C J/JW3_:E9#J0L("I(8E.,9
MZO0'^YIBTX!N*36VL! _+\LW[FDIAK-\!\/Z==A)*]*CKCN TXJ-A0V8;)N*
M;RK1^;P.YORA3U2AQ[UHX.B95,<5UUX8>/0<Y*3S<4$K_UU2K.G4'\I]4J7>
M]T@8Y/PD$LO/)-7(^*_5,T=*UC9Z:R+Q#J _"+G66]N4KP9MQPRE:15-PTL>
MB!/6V>C1603DG] WR7N!1C<SS/ZFKRI%9WZI16?K(%<X;?6PS)(**6(=RBIS
M6-I)C#$ZCGWP]J$N4TUGTL 3=VJ_25F'0YEZ?J3]CQ[K33_H$!M/3X&\9?(?
MV/58W(WL3?7>M=FGIPV?%%M<? 91X;$6B>]*C/?1H#-]I%U%!7MR 2F5&W;.
MHWWUCY)2CV#5%$:_#)1.S?L%C+>?K)74^^:<57/+)AJ,$\J25I7[*"\B:<+K
M2@G#8LZZF1)%CR7.N D<R&Z*=^\#+=3Y_"'KTD<%7FG5TBJPFH_KZ8E.+F!(
M\MW":&%FE.D'XR%87L\ASRO1',U;_Q;LVQ[LZ2FKTH)U;ARE"E5V( ?B^3[P
M;SU:IW!DG:9;^=LXP>+.,VM- ;+<^0_<(4S7Q9MK\M5!KS,?IFF5L5H7&3U5
M!WY6F35YH_01*E19];-[[_!OD:H:2BI[4RWSW_CO>CI.W,^P5=@KK&F%O1R(
M:5,_II#>HUDG5M !A'WNI$"Q,G0'& UY!Y_V'X8,5E';U*%<]PIBB:E03T/W
M9Q)<OM:$ 8>7E..<(*PZ!K$SEO0^W-%_$K<DZW[]9WO^R;D:&0+_6$'/S#Y=
M+[?L10Q ,QBOP"<E*9.)(JQFVY]62V@#A)P$+,*U9LT_Y:?]H_V;U-O@2>FS
M$HK281083YMC+]H%*0Y+P30ADX@Z)FT/#POW,R>.U-X/   &S[ZX_?A"_LH,
MH4YCQ/]$#NGR_BM9^/H@73A]RWR='ZL<=U\GJ4A_0%P&"TE!E&*G#W 22X\V
MNP/\" ;'*YC6JW*Z_FI,;2+II:%SNESQ3JGH">%1]W:G_=N=JD^E2Q(%A'+&
MFA$T$-3Z0RGY1PR#SZQN#SM9C'_\,$Y<R&MKW N<N[H#(/22+Y5)NWTK6>@[
M(RVRE]W<H'> %[2B'_S\4?;]/<[Z*KD)(?%\*<F)@#<IE:,8X(KP?610_9P?
M2Y."(;*!!+$\2Q5> QM^6S,E4Z%B9:"W,SJV(C_EY8.80Z!L7GIB&86NAP6R
MVF-EU>G /T'_3N&TA&U^Q;-G'7_!9/]^A_.&/LY6[35JH_.8'A!,-MCR>:H<
MS_[RI)<);74'&%BCC7K5UV.]R,5=-^7-H'#X\!RP<U97P.#0EN0 D81(;G#R
M \(?%-ID-HA_FZ MM>Y)/E2BD@AZM_HGLW[UGBO:. >=]D6&LCML><;+E1=6
M2HQ[;NO= 3I>UZ9"65*!\V!$'D;P#J#H3WZ#Z</H>O7A@__4NQ9:I]P2PJ=;
M_C'&\K8(5#W->#EZ%5K_Z$4+@5RJ[FJ!Y1V 9 =A?W50"5Z_;^:;P$JD\F"8
M8#\I:,EA1:R3D/ML17IU4NR#<C>PNKC[RV;U7(K0]I+B3Y""XI,G/QY)T&XJ
MD_3]J07:7YS? 4K40_Q!*8.B5X)6\-L>\.ZT?1Z*'I,HOGY]=<UUT B[=#-'
M@XV7J[=E_K6W%"X1 5UB=_N:"S2,Q D-NP@.(-<^O4'(JMC;DA:2Q,V0J#M
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M+ER]K5G'UB;M\<=O3%T>F^--206D]SR7D8'9, $*(/Q?'T#B18K2-[7H+)9
M/YI&:HCYW8ZX P@(V%6-IG#4:0S^-Z=E'1XR"SB%*7Q[2/DDB#LMLHJ?D3MC
M"F?M W=Q3DTCO^/CS%A5W%1UN?]!;)5U'D5-T>/>0EYJA'A_7E<]XL#)V-=B
M3P+HJ)OKOEC0&7.;V:;KBJ?3%IX?2*-M:H&< S8V+@>JZ,*?3OGCI[G[]\C]
M+>Z@\Q&2]N[0AFDEDY,/7 6C9CX( ZU*@WDS L'28LM#,Y0'$?T8??8DD.<
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MU$S5&0Q*>K6/!2<Q8IM)>C=;V2G-@@G%UWJYI>_A4JTW)H2E7TZB:_/>'5-
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M0R9R99^J<S6^".*Z=&TGP(6T;<$^V.&@LVM$:C?9R0;]JX*4G8 '07];"BS
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MS*T)WA;X"5J# >^5F)$3J<C\E/CRN7-;*:<SCE.>V1,.</H+G[+M^  R@ (
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M9,P<J]^[G(0<GY VRBV4=F@WN-#-1N=OG!>1<C[/GQ*(3&\[C^\:9MOWBFJ
M>6!*6;4+*.TP8553N?X8TBX,'%7L-4^/L#D30^?"$M<H[O YT&\-CA_T^1)4
M]$&:(AGZ4B@9Z\:U,]4=4>[-8_"3#JS?77DJ^=(Y74O-(=684@*97[^Z.LR-
M=Z4!TMZ"B7V811_$],D!>B:U_S(S7!#X[Z(TX?CJ;\7@$=O LC+4S^2S]"8W
M7%A.FG G5Z 5E?#IQBXW:BWY-/6 ;B@(#^Z_X,#S<>5G07/D1BUWB4"HPBCW
M%P;(\R9YF'XVCF>:/U;T*(+"[<^ Y'SO<=$@CU;HC#$W7D,+T4BE.7O;B. /
M)42PJUG)1PAG0!964YM<='0/P#HM$$/TD95HR?QL 29A&'=[^_OP-,O!CT/V
M37F9WT9=0=-.M11*1:2GQGOKYW?8V.Y*/L8?+C3EGY6V^7$N*WAGV5$1 9?P
MF 'JG:T__L#/ 8+,#U$B("J0T#7L"<Z!R]@A[]BX1+J,+O'6YIP&LSY36R5G
M?7;_OP6?M8YYJBIT;F[.VY228I*Y0@4[_(4Y4G%N/Z2X<(.1ZKN!;#7IWVAC
MD70BH'.@XK8T&Q)S0Y<(L+YH/:=UZ.G:>$_G[YB^;\- _C'16%D&FB"*=&4_
M@ADB-T#:GQ=<$NYJ,@6/EB0W/]_^^LM88K]G8-."8>B8;7FJ?Z6;"%SAN'A=
M-8^Q?7^L&R)<.MTB$I4>S'YG4P+*/F78'*:LA'Q%-\,^)A>;H/N11SY:K2<^
M.C7 ,MVHKT"3+;AS)$\1DJ4TE<UC&F%6KG,F9^M>Z@4#%0ZF/;X%]RALZ>PO
MA#UI#C@D=_<G&UX9D:DT^=1]6_9F]'878,2VDEW%#C%]$J*PZ,9=L'E57N9(
M?'MM44^N+3%B"<0RJY9KC^Z.L*U_F?G"I5-JG!15<%*ZKO6'7OGOL.^1ZKQ"
M5QMI8(+C])"0A[-U3*$R?T9I"$(JUQX6<V1R39:_WFH5'-;W]KEL]3M+4W47
MQ[OZ9(6\ E$?A(76U7C5]<RY-Y%"(Y_SY(1VYYHRU%F?VK ^4P?^!0.;<  J
MF/F>^O\ 9=LEKR"$U7>!N(VD(0L[/-(GM^5 ?BEU:2_F,!RWU3Y/TV:F,_9P
MVPM(.QF^0N%7'WY^JZXNY,_<B[78UR$R8@<*/Y\JQEL*(:QQ4;"EK=7*<G2P
M]'HT>:\&V;#O[B;[]&&6H_Z8-UB^<SAI= -B%N$CJGI\@L(@8GVS9DT>#^JQ
M_V[T_-1VR&:K-N810S\G^B?!S<7VWA[3==!K1:9MV"A#L'2KVS((OTT$HCR1
M]!?,_4N\VJ^'WQIQNX.;&F.UM;I&CE5;RPLXQC_D&=U]YIM7Z)]_'L&&>K4^
M\!E-Y7K<-%\ZXV;!@B40 >:\^GW+<!&4SF!%_J.IXAGA (^8NOS&M!K*:OC>
M+D)O<7[J6062 FJJMTBU3=.4VL72=G?G-/:S%5W )Y^]+8OJ?;ZVQUA0V[E2
MZU,<'/]BN/)K<%3;)!'X'EG%D-Q%F;H0/6,H'@PNITC#SG<\-$\R2GJ>SMCK
M$,6HKM?&G1(?'WYJIG$MJX"6XIKPA$:/;EGC=OJ)+LRQJFMYM)QPRT&RZ_EJ
MGOS\Q*U"(Z/&2N.FF)0GYC?AR$"$A"-VKP7N%%ZM8>JHRAN"<6573A3QH] ^
MHS[<N^8_FDZ![6N;;E'IK)3DD9M@Y&@YFFLGQ=DT#&-0D97ST2BFF/?*XDH/
M,Z<53.N#!02"G_#.1.?GO5="M3:B%HG 3_!5W)4_-^B_TF?X?V-O:E03"&Y\
MSL?J2WU6HP8)#V*+&SC5^2+"1T'#EEK[I-+2-T[V2;]IWU&S=<D[3V15:/#M
M+[?^Q!9.9<@?7NG$_>W<'B_U%L> 0_VO3Z9$T4!"C@1/,91OPRX.^-3-1ANX
M,V")CC!DELGLSUD#4P_^TW>P553$/-F>*J.Y>+0RN8M*ZK6H)LR(A-75_F?G
MZW@V&6AX,&V*7%S;@$&&(4$N29I[>S;>>-WOE;H+B/+BEBG! &M>4LKU74X'
MD5)#TI\DN$F)7HBQ,CT+C3C2NV-4-;3G86IJKK'%I_Z]+#CN<2I=5K-T_^>B
MH%*-"NSAA[6HW4:Y2U&6%09U<AUZ6[:>Y994E5G*)-3_$5W"#SER_BQQ?HK;
M6> 5?RHKIRJ(UDUP_,Y:7HAZT$,=TSX.K1M+<\E.TQ:_GJ1W$-FY8L9!^"%I
MJB(13I-XK8FWU6-#6WW'?5PN#KG\KIGT0M@, <7VC>6XY1 !&VUGUY>M:&M_
MDI[XXY9"/D5<,W(1')'.@8V4O78XM;D9HAO&^:&K=M*;-&:Q5 T[5YNY=>:#
M>E!?T5!N+&A=_O(7=P&/2SKLIZHD$>CN)R@2 5?Q<ZXCLS.1>H:0SE7#K+O*
MGY93GCGBBS7UW.&J:PVXI7;'!2) N3G5 U4YG)BN:)U3+=%T6/6G0CRMP14O
M*LC TN3PLB:[7%<*.V*Q)#/9,0A_MME-]L0IO\B_<F5==-E:%B]NR:L_&T$Y
MY"SVP33'*P;=,F:A<R8A@@+E+P=W>35Y;),9KDCF'"MT##:<)N1Y95Z8.A84
MJ4-&92)XZ?MVCVEJWA9;<=KGO0L'LY@)-%<8M^4[*8?LJQ<@EER[^.^<'[&#
MBBF>W_/^;N#,H .IMIY?AJNP)7S#Y6GNZ^5-543I3!M\R,7;DP8<=^F,S @J
MY%%!XH-&D]<[,FOFF1&OL99!NQ;3S_?9TAI[>*3O=FI:%GX3@""4]I-:5(5K
M3/VDVCW=9N1H:-!A_8-F5^R4P.7[Z;W3OIRN7BN>^!VKBLSX=\>%\*K*O'59
M9X_\N1:KM\UPT[ K@@0]2MK7RR.O2R8]PP_#FNU*0^_-G-)A4@Q..U>B-?3Q
MZV)@Z(XTB,5>5;"<':Z1Y9P_[7XHFDU/B>[2H>^9X#'BNNNQH2-T[&+O+SB<
MB9;IY[*;XTZ7EZ$9I#V@ZV7.TL+#K8/) G9A3]J>5HV*8.HJOHJ)KG#':?U1
M8^7YD[K$)L=N.Y[QA_ 0^_9"81!<SC^R//S:ANY.$H?S/?IP'QZ;AASDFTGE
M_A1+2_&I>=2:Y?UG:INOI!!.%*BRMOX$Y[+S9\OIH/-4A%)N3YD#R\QF29X2
MS\<E\%,%<!H\&I4[M>&)GG[1PEO98$7#H\.FN7"W3Y123)@WK+,><U?!W]*S
MS3-\S?_F%L/B'LG6V6>]*E.8D#F'IV,>Y6&'>T(?0F=PWA++\-$=UV(O)O+F
MT;.1JJ'[A'6IU@._UZ@*G$_"N7@!9AZ-#+6*:(7_J;\94M=0=Z#<-NX :!&!
MIB_)9]+&?Y!HY,?7*:V*G2&_KVW^V>L_P.^\HT#*W&R*S*Y2_1#NEW?RAW_*
MV4]%I!AG BW.-U$KF)B!FGU+G,/(AFM-9PG3,IURE1ON.=] EZ>O>C&U4$O'
M*;D;D@I<//AZ,-@X+K;6.U^&&,)Y8<!1"-&&R@:E+\)(N-!C'\)#_\ "_Y$I
MO=7:_936.B?4C?"3W<GKX???&28;<?:9GW]>BF^W9%%VQ+P/,M5K-/QX(?1F
M/N:G^!84R=F\O.;/<_Z*" P6&YR K1/TK=HK'4JC#!R)0!BD=MJ.")3UO_^.
M4$UDA\(L9EG;DX9T6@TF5D+H*54HA)%/L4^^8HG PFIMYH9$@^<G^R032=E5
M3PFTB'Z!S+K,'X0F$8CSPUCB*6:(P'IN(5@V^DU4IU&0!%N.P'):BJ,%?N*@
M>6+M0ENOZSSH#1$8,/BA*H7L'D#\6PJ.F_$\E](@5$,$?D0VGU$;478ZGRI<
M2IWEKCH1R+)(>KC#3P1NW58BR""/$GWU.YI/;ZL*72:[SY^1E(+//X&78_+.
MD?V$Q$92S#@A'L1*!"84G<^!<93_+]"!YO!%\]J%KB9DS0[9K6)YT=1&!+1M
M2?;5+3&E.[RV"XW0"UT5B@%!DV<GIU$K8?12A,=/2([8MB4N^H@ ?58Y([)5
MCH;6ZK<]3_/Y<;U,['[1B=\'C.$V="[)[SP6(\@JB$J+V\'7HW_QEU,??B&H
M[0\O0D^]II $@;.WRCXIJH,'9[N/P:MT4K-1+U9-E%64RZ\5Z*0:N,_4BHN5
MZ=N;;5X:!AL? O<^Z>.Q!NY2_>R-UL=SIH^GIU^N.1 !;[XO3FENYLX[($SO
MI2@BA$:<CB:YN OFE)Y)>D0JM+STY;&VG4.K<OJ/<(&B9 0K_*!C^@Q;S/<>
M1=O,LL:<#TQPJ+8;Y^/J6^'(:&45WRR'6,ZWN_$PX%V/VZ>?)]<78G*XM[UK
M&C24&+XLKJ2U--N,;5@\>X(_+VU,Y\?*G?AC;= +*N+FH\4:]?D.3#X'RD-H
MK6[P.P >'92:NEJ-@.$%<7(6:+>LEML!^?F_(:;UTK[U3@_@?O=@ <C >=8+
MQIF^.P&5S3LJ]ZH6'4PN"Q>@002$5!=&=^1.<O=!0<[\9?M_@W++U^QKJZ.R
MP.;%;<B?>N*0]2)-V8[7;R)[7)I&9:?"$[*3;"G?Y(X1&&QQ^HN.SBT7-.7#
M,N<FFW\';?\V/H)-DO*9,$#,C*.)@*W+/@A#XW VUNQS.Q!=FI2;]3(K^BID
MT+CY\0%L!"&$F17N3!;@*HEQKTZ$N'LL!"H6T;?#C2-QO2?Q(V+*AN"0!M)O
M(":'>VAM,0Z)R'OR\J2<P'[-I[LQ29<EJ"Q<*C)L%=.I.U02S)_=:HHE<$Z*
M;\]C-]X28G :B_P<A[1ESF>[LZGCP;BLMFI0.:@CC>7IH%,NDMXAIDS7AQLL
MML G>WR=L0<^;G5>A']H@5*0/I<<9%#5%3'S==4^A_V^4-I",1X+ZU%,=W&)
MYJ)XV-6+=XM#S\:N4_!(\"JL"X&LX@8Z^]F.$49B; 4C>CJJPU^WC[6/]=%[
MS4P$E@(85\5?V1_:'H[NRBVB=5E:Q2L^KV7I-1B/9_+XW:PHZO=(-^04GX1O
M>;%Z_F5G9S:K;-"K?34W.<& @)^M5DG/N6\9(-?BD#>,[&<(?ZHDBW4DVGK&
M8M8O73I__[_<N Y4D'09%6;!-G;YL/?"++&IWJXS_=_,?^FUWZ5OGW'=5U44
M4B[8]D_8;0)P2XO@C]<D5-+SZ'(V0"I12Q]7'F[TSYV%[^X6OVJJBIO#"*13
ML<.Z;H884:(I\TO9]XVWXQ?Z&<U5^L+J!G*MXJK>TK[$"]N" K[A+7=X*!PU
M6 \M[ P#RPK8?'/*XK:<MB!CE?HL]HHR16:6#IZ)G_*[?7(-.0AZB,G]^"4$
M$6#)Y:/ TD(<*(X;ZB-^?8Z1<.O)RSQ#[Y@F(M%.0>7"%K@(@X:/R-Y[^5\)
M/J4OL>*MEZ\]0J'RWCK\K>>?-F8SN3YIU)["&G9#(RO#^':/#9KUC8BZ.C:/
MS^3.8'U]O:<@@0<'HVR=)S>UO]LKLX12W/7@4<ZF79J@)3DJO8F[5)$[2MBU
M+8:+*(<S:(TX&P(TC'BQM,/2D23G)6%IKX3X8B6\4C4F(N>2?O2U+=$F/%VQ
M1(KS]LR2]'QJO.[9NE?E'X3&OR36^=\26Q)> $M^##^)0.;^WN&1^Z3MM(WR
M%BXPT+PTC.EM?9 BJE[K88+^M?-HY/+G&>2$AN4YN3#IDC@AE0BTE?Z]>7D0
ME%KT8IL7TV):FQE48_+,^MV<ABOPN_=,!4BB@:7P/$S,AS/G\*;K=DVBM?6U
MT7@=ZALADLI54QU-3E*$YW6@5SS3U.6I1K)[<0Z94*1DV<  KI(("'1U@$_H
M443@OLS:Y9E"28@](@*EIY=['R_VCG\0T3X'&I%."?5>: SXYA6S![21Q< [
M<;;8W:Y%9(A&6-Z,OIO3;9_J&:9ZT<AHRDJI7SE1.3R9)70$UU3K1F:[0WS_
ME*PX/<*H&=L55K$Z*#U"(EJ:+;"GDE9/]FH@^LO:](2(C*ZHP:C3V]W%NH!.
M(Q-KVFP_=;<+59SEXGR8D;!SB8EHFP;8XUWH6S2RKNW4O124<B(Y%&>#9P_W
M4-+U) *)IH8_5"0EU,8YK&MZGKJFYNL)H.K6V)V*3'//\C)Z+L;&+7A&9*+H
MZ5BZ41W^/BPJL>0G6":3Z.)ZCMU[L*DF8<*C,=5K!-7R4<>*^,*9TB3>7BG&
M3UC)G>AW^B!('P3G@9?UABSN9O!E1\@6%W2Z\?9M4/:J%GY["8(?"Q=I.1=;
M5]>$W0E4%]S_59_P^9B,+_-#%O?7!<>@UN&((IVHW94\F:DZ(R]MTX>?<,A]
M6!N*67K"27H:%]PK*/E"9]$FK#ZP\2(S#Y>$7/2UI)J/8>VV<U\-JU9_IR;R
M[ATCGQ?<*OD0Q>K_*YUE3-QB3Z>N 4N(=%N9^F'7<D(9>SKF^17/M:[M'K<Y
M=9%7F(DZ?O2QA> C[2"X>"#N@&;=AP0VGOJHK"QGIS5R)N!YIN:Z%Y'LTO[6
MGI)_"APLO\5;.?'/DTL=?8^95&JO,_YPW,^,0YHEJLB9)GL\AV6R^/>U9'7O
M,LCO)9_YWL?NIBWZW::3TJF([NDDJ9)_S4$Z@D>YF3&TQTS.MZ*82U.>UH6;
M@R&O#F<G?T#NU%^YI]\,I>^V_?+8DY^3]KF9$$;! UI3X^@Q=HXD'12OA/%*
M]NWN[EVOJE*KZ1,)>,Y04!H-MA>/\&QFEG&4[=700#T:%G,Y.<\6&>:Q%CH"
M_%5@(]^15DB&+LGS9LO12AH/\";-7=*=3\)EEQ)TN(AD]O;2'A0=TN-KT_O2
MS_7B);LK<*N;\DYT1>6;-_*12;<['S+MW#(LVNKMR<H:&W=LBLAL[-<<1BYS
MVQ,!LW@BH,9FDU4=9#K=P:C E/]4_T>']F,<IU)5:[C@MT__^4!7\A!3'5;:
M %KPW3%^(A%1 [W7Y.!DF:P.Z?2C<VNZ.2*#XD!HH5K/_-&RP5:O;*JE^AU(
M$HU? T#Z>YN:?K:MY._S] BW#(>_J"DY+I6=AF=SDN^'-(9N<#=V&#RJ\IU+
M4YJ9,'V,FQ?0V8G^>IT+;?$&(QSE9C36(+[8)WFVI%564R;';CPVN')AR'&_
M*[C/UN[B[E@#?X'WN$;C" AJSM=N"9TQ)UEUK9UJ]^")Z8D@[[?,;&"^T.>T
M;Z;IC^3?-_P];LQ(E5L9R]X;Q8&U6@KA,3K)*(4U"8XK2RRF\$+-!<WLM?,M
MYA]]^TT$!!?UG9!I/%FU&_X"34FZV),<'XI!F<:*N-S%V-KGL;$X8SIGC#,;
M[L-B<\BQXVWYE5&QE;"2=I=\2T$T_7VK+H[O6I7FMNK-^Z%!'GI/]!PX*D(;
MJNK3[G\6,J!&\SI\5KS(6-P+]*="/:F#O7A3&\C^!MC5L.DYW'K26KO[W*:A
M%<QMCM/L2K\][-';F:*/!YVD?= .J&3EW8^Q0"8X>G.I>$%Q_M5<(5FWFHH*
MA/5Y6DAD>]8$6=T7K(J%:6>P\Q$B",.30ZM59(998W;3ZYW3D<-H'[9*"RIL
ML_Y812^2S>'3EIL>'RK?W*?J)OG- W7*U3OYW2T_"V2$8]CM_$DJ]]OG;C7X
MKDKTR2:)O')LK0^>K*XB877=>F5V='O_S1G!S)+^ _N)R]#%>!0*_+6AU.SH
MYX;IA<A([B!!HLAR>H=E:JI7VC=$8\5 0S./;461 ,^MW2_I5!';PTO"BJEH
MJW4RI@1[T4IJ%R(+I'JA!F/NM:K7<1#(Z*VQ;^5#%JLT1>^5?W(J0+9&_)^?
MWC^:#ZU;&0]#L&<[)-6KCGH <?JBGB6N<.IU6'LQ0;O@LC&@:J#)LV<1+;[X
ML6%7+5+?D*,@\A,^]CZTW9]Y/QVUN*&L[U$ W?(<%O&2>U:D"Y,4>UB:?Z):
M4:OI-M @A=EBN.;7O*WJ?,;6!NU=O3V?!E]*5W<<#T (#Q^GB8%8-]&P>&WZ
M-+]WPR:G-!%=AF )%>,[/ PZ ]@M[WX(=C4*LR-GB8+6U7V%KFFWBER1;)<L
M<0G,C'YF=@SBW#2&@D.<]][.,F/(Z',?S2A&1MH.U6HKVR.&S!_R%0 -OONV
MO 75IQD/[^E+"1!PH-";=43@V@8$YL\](N)X<CK<A?9*I5WV*#$VQ58U?W?P
MK#;(R5"T+K[5-"E[_HTSZUU>S*?@Q[:I\0\X_:>[K!X//]^$R<P.I&^*CGTZ
M7PGX9<NOC/C&%:<?EFQM+R0[CL^$",2>@B0[F2Q_\X.]:)L(1X5Z"[,ZOB81
M'PULS=6S(U4?R'3=_;:4ZB73CRM_V#C0-.UN72EI\2)%?L'3<1?Q96 '<'5M
MH#_-4G. _Y:DRM1FWRT+ 46I9I0_Y$V]VD:;_RVF-;= 4# S'/@/]G6CQ(U'
M516\@Z7]7MH-%P>)'*1XI,#W#Q:.5@L):EC1^: +7ESK&1$PO!BK'UFMC--6
M#KA&_2OKFWQ)<X<J[3X=*JIY40A;,>;L)O.CJJZ\Z9<V*T_@U;WA@^QQY3N8
M4FYO%I.AX]JC+5]\;E1QXH!<$M\87<B=^#C%L:2)Q/"IW=J"S?0;V/D@Z?JU
MH:;!E^)B>S>!'GY2$H@*U?5#L[=3$+LF0=Q7N_%J:,3MD+P=]F@NHYX/@?=Y
M51.&>A>07)J^&;AH]J'^CV]OP(0<#UHYOUWPP7>WDNLS$/=&4]KY^$=DMGI]
M$\:V5?ON5<W0OO5N#51=YU7H$\YPL(4%B6\/2741=&]>O,["-A,22NDN6[]2
MT &T:[\Y0%EM$15\%I6>AQ$LJ3"]&CI9O!AJ]<N++F/BA'-=I2B_#FM1?1-G
MW#['DS@I8ZHGJ?2BV-F5/UGR0V1T$)>5)$'_LNDT[6@^$:X^_NX(N="R# !O
MG4T3@8<.N]+@T.2.X[\?95!,9M#<HL+)%([%<K(N9[ZKF_#4,;;2UKUK9M[B
M^MCSX\[DF\/BKQ*GM"8/!C->3]=L_>I@?X!.P6OZ0$,*LJ=;[,:-C>YU^WH^
M7;I6_YD-; #6.>GC.YLV&'J[N_U+-OY!G'ITBA890T^M.<//<B+@Y)T'&4OF
M#O- 'GD/26I%CXA=X0GH[@>K&35QX*P,L,XA&C'Y_70]TSJ8*:VP.SUW[G+S
M!TK:JWPWAD3BG+^7AB+D]DDA'G-5R<4STW[OW,)7"?:Y,*[QEE.$?M'6>%R?
M]XU4^T$VW>>:L9XE,]:?KBKT0[>E4:&*Y\%_PZ0+;'XDM2G^'F=I0,E-,?ZB
M!WCE!?P-8]RP_5U<U0%$8)&UKFGXYH]RZA^/@__.D+]\"@8)D@[87H?4-79+
M'S6?BG$ASR-<+AVL39G,_*E@,PMXVX((3+VNKNP/;;I%!():>]OA,BN?C64O
MK7<@=U2'S4M3>!4EM1J':B;J&T%^S#EW_TD1ACO"I-+<Z?>DB)&/Q,^4=PHJ
M^OH]$<6=[Z8BY=CY2'%Z;#E=DV(6ZR)>W*2GCA]"IN#CF1,(N;'ICKHGU=]Q
M2?CG&W.V25?+39K./OE0$C"U$_YLN-S#%KA_DI?O*\?\=2\JV207"DQQM0*S
MRSS_MQWSF.#I+C>'6-FF9)4J%-</CPJQ(:V)A4!O4NF4;0KV%G+:='%:R;P7
M7Q@UV9*Q>ECCSF?:I%(X.6C-Q+X'GG5G(.9$_^#,\!RTV/_1O5&S'>H\];8_
MY#@L-VW5R,6#T^,Z>1<G)2C!P#G47VI<>E:N+7ET-76*-W+PUSC:68Z=.G3%
M@ ' $P%%N!G]6I=Q74E27N5Q\&]/K*F&^>@G)1W\YYMN SRI2ZF86@7E5\7?
MDYW$G])!M9F,?UD>F5<+,0J?[R7$S/7S8TMZ.Z V.04S]H%#PC[;BRG]Z9RY
M$DEO\!]NF+[W(9"['GI30F.W/\IZ#RU[59]O(;.=:EZ\FQ?O?E^SUUUP?]<!
MBEO>4(02 ;OLOW]O^M943[>36 ?\$FN[SI#$JS12AGCR(^KV[1X\0O!-'%C0
MR:15>*\3_FH\NO)% UN^GCVG5[7VI =%[$/FPG&>?$J>@)D%(\IPA))OEE_5
MRIOJ.-->*9M/.[%?F]VX>.N?'WY>X*&'#WYS@%=(4F5<*F%=".ACWHBLRY?B
MZQH<;]3)_-EDM-7469^2_*\P/*8Q;$;75'G%R23+1C;H5;[GYZ1$7^KD(>Z"
M:K)/@*80-M59^8HT5)>[-VW0VKV_&*Z8;PC0 O<N[9BX"\WE&O?^+S]528F3
M_P502P,$%     @ HHM)6+I7K\#2+P  8#$  !0   !N8FEX+3(P,C,Q,C,Q
M7V<U+FIP9YUZ=50<3=/O$BQX0G!-D! \N$. X,%E<4)P"&Z+;I! \ 0"! _N
M$&1QUQ T++"PN+LLNK +?#SO^:Z>^YY[[U?3=>:/[IZI7U5W5]5,W<_>KP">
MJ"JJ* (P,#  [Q\NP/T\0!Z ^>C1/^V!L!X:]F-L;"PL;'Q<7)S'A/B$A 3X
M! 1$Q*1/B(B?$A,0/*%X\O09&3DY.2$))14%&14I&3G9/P_!P'R8@X6-AXV-
M1T9$0$3V_TWW78"GCP$%&(R8&$R 1T\Q,)]BW/<!& $ #&R,?Q'@/PGCT8.,
M.+B/\? )'@9 G@ >86!B/L+"_$?JA]Z@AWX UE-LTA=\LCC/M"UQF=S)^$.^
MY3YFEJOI)M?Y>\(B\,$C% ^?@I**FH;U)=LK=@Y!(6$143%Q^;<*BDK**JJZ
M>OH&0$,C8RMK&UL[>P='3R]O'U^0GW]8^.>(R"]1T8E)WY-34G^DI>?E%Q06
M%9>4EM76U4,:&IN:6WIZ^_H'!G\/_9F$3DW/P&;GX*MKZQN;6]L[NWN(T[/S
MB\LKY/7-/[@P )@8_XW^C[B>/N!ZA(6%B87[#RZ,1[[_#'B*A?V"#X=45AO7
MTOT9$W_(8S*Y;[DUW7C, CHGY!\\_N)3L BNLB+^@?8O9/]OP$+_2\C^.[#_
M@0L.(,3$># >YE. #.!6<092SDOBX"N>4NB1DB(\W.&P@2KI*(IC,_X%JT@\
M4V]O[(2 6X7J0Q5DO@CU!/^-'3X!]DN MQ=E;ZB?"9TT?I9TJ (QZI@<DNCD
M:&32-:8L,Z/XLZF"%%X>!%TJ]"S/_Z#Y$>TM9D=M]++>GVVO\>Q<1BE0O5I^
MM9)T6RLCASOX[1TJFQPL?E*-M.>,PS!1;D^SG1;"L86DU7SQ\%L\G NZ+<]F
MI*T.?HGD@3MK3$I0_O(5X9=;;OU1%DJ'>>6&MYZM'@BK<A)P:FGO1U?(_[[6
MSFG*/PHY)S\W<L$1_=*LZ;HWN+[@G*:_ZBBCZQ#@)]PZQ[V4=6RSOQ$<$O@2
M\3V;9=*ZONWK4(G1BD#-UELI*M2E3&2E;_*I;Y<,K61Z1(+_\5G=;?3^LBBU
M#'(?.".TM6Z/HJG$D4^XN2,6<#D$JZ$[9!7(@!CGE@ID6AC_!<9E1=C)@I\%
M"B)X,JBXN2[YKQTEFFB_![\';A,%%\*Z<NK9>JX[:)%'F[GA<90Z/DVU7TF2
M/3S^!NEE9X?K_;Z-[$7W/,DRQ5K,;-^YGE?LV)=)XMR%X<!6-O>5>@5J&9'/
M/H%5SU2/ CG=A#2QD&%*8[9O47IJ"R&A2G?B,N*KY4>G?NR6]3+);8Z]T[E]
MHU-(4Y<.CZ1;[;T<3!X6E,T4AV>#O9E2,PM8UB(0UL]8NQQA/=,FNT4VPN O
MD>G>P-=T5T RT#%;_4PTT?L@9L7?,]Y\FSL#77WWH!%@:' TF;8"X+_"H*N!
M<4HSI(6(<,M&'KG%TNXE2( -9?%J3+HXH3!P?8TD[C*;J1'%D^\04&Z,NT!Z
MJM7%D/&)9>7,PA0TN.J2N@9,.1*^&^MP32N*)4HX&KX%52>C TZ6-9-TLB5$
M<YO33'!.Q]2_#-Y.BMW<%74D85PX?MM,;Y5^)CE:=]"@G8VO'6HBF.2Z=5P]
MY)\9G%4.LD/IT"X*;?WE?7)&]'O1E2,;/U&@_NERH6?V\Y.#!G%D'22N2*V(
MR)[YNK&< <!<BALOQ5F0L,H]E7!FZJ=R-X-WRSD;R'>B<=6U!)@*5+>U;D;P
MRX%KWN>X6/D,[#++S\BU-L0W4P^XFW\OLZR]X/B>?2LYCE/$*8EX! IL%8S>
MCDW4-X_G<WY9V [3AZ0?>A8@ ZIV&.O0=_0G*=784&28L3+<R#*6+"P@6<$J
M\W1N#&.0(?E</7 =)3B'3.BGI(DH7L^25KN SIFH3PF5@\^_6&^#XC)=X*+2
MG\Z/U=8TX;C],D_:=#U7P>'IUL"!V<,66-6GUTKSG#FIU+A8VSZBNC,=QF3[
M5HZJ8.&E*,:*[8EA445!#SC0(W3S*FA;S/6HH(6M\ESS&*SXUT+L'M!3B-P:
MNJQ#J,ZYMMQFRJ,R;X)&P.L0XDC$/:#_'D" 5G=:78Y)M]:2]9IW1LO:=K:X
MS'T,+/ : W N.EF4-!<?V!;!% +05<EW2G_N :X#L:DP>XU8\V@=M52SJK5E
MWG%-@5T.]IK?28J)BG\0OP@KBI^'381I5 O>_,S+SQ9.H7YJVC=2@$=9EB@>
MO1),%"@)ZZ#?N4FN:E_+2"#3]/2RBS:)&_QCBA'2E#2N(TX\76!%B<O&*01M
M'A:',!N3K:LWM2X!#>(:H+Y@YHF2O.B1/7Q.SGX/07/*&7KJ;S-C'RJ*L>@C
MOSH-WP.LLU2/]9&LA0OFB^I^;C!*P*@[L_(V*9V'AE.NMDM,>5"Z1= ]X/>9
M79S60"_N<$4^NP6:AV/YFN^@7EO!,_NKM@(9X/_"&/V![Z!HA4J'7<N\GJ(E
MV8S(,SD!XM\"\S-M?V KVU%5=)SSW1\[EQ*]GX.7Q:I_EE3] 95.)G#I2+XS
MT)6G!L*GOU?#;X*5LI":*YL1,8*^QM_S=5ITDQ-<F'3/[W@'3ZOR^Y8(_J+-
M;ZP<&W(<G(5W7;F#?<P2J^6[J6]H%O*:]_22@7ZMV57$L?RH(.!BT,P]('@[
M+G@F6+#YQ+=['F%]2#Y3RN\PS'2B;\H''M6/1..WY(3*$!]*4Z/%)@5+7NBU
M@@P"YOC.5"0 ACG%BPQ=P.P[.%SP)K4;6?U<;EUCRK(IE7KUL?7X[?F^>>^*
M*ZD)J+,;+EQG_V?"'#[X"NY9GTR;ND>LM&H>?DQ'*.;CX7MA4'-Z3N;HCNT+
M7(L3]? 7X;'M<'CI J-$A*T>%O<=1]Y417F2MAT^4W%X*6U?K*7Z&@V2_OG-
MK- &F=]'L41^LE1<82Y>"(EK71"S"OFLXXX\1SN%?B^D'M!:NF%4B2E6;& H
ME%3J@K:C3'2'9*Q)J,Q ^:MT!JD5XY[YIATYS3??,8QP5VA=T3AMG:OQ$(3=
MNO=18\$\LL.,4A%:O2&P-TR:-J9!BC4?#]!95%K:R,;VE:D13G)W.AG4G=K6
MY/96UU#)V_]35K9]=T,H@Y]T*70/^*8YP'C)9PK>>0KKU!^(10B$ZSJ4FYG#
MVL='?[E5QN<F:U7JJ/*'7U? MU1X3"!5,W=I2X%L)YIQDI3N9=UK%E3@'OVB
M&MT/4+FWN[=K!RHWSD,7OW=-EP^JUYT]!\V)9HXN#A755;>(S$U &]_TR&.9
MGG2^HA]"[\/+MQ-F.]Y&KBY'67\+9=KWK!.@ V"Y;Z2?K?,ZRT%46,&^>6;C
MA5DR)5M47$+L:HG37AZNU\;M\^W5A9="DKJK]X#88&F$3[&-<Z4QB+9GIL[/
MY\H@;+2I5>.QFW]\VVF3&-U%E=, (\D==R#'Y)&D2F[@VS;$.^''=LU0B&C4
M,M7F;^P?=,2@[@$WIW=W$TNOD9%EYO-HWI,/>S?>%1$O9X38 YO,(J\4@?M7
M=:&BY#RY:R0)#2U!O>8@S5[QN+JW/<K.5:I-.L3!YS\D@YQ:&. 9L=:YY.CJ
ME..9F^4M$'DV)FF9?B''!<NQX[?+.-X3^%\'OY?Q^STY3U:0A2?&X*>RE'/P
M;<TFHY]C@<WZU&:RY[]_7S)UN-[F>)-\Z1 ]H:\.;Z/UI(SPBI-6,;X'F">+
MM$K&&RI1#6H]WAUO6I<.0;'? X8:D>'^IA8DZ-!DZ-T H@#\Z'Q 7Y_7VV/D
MS5Y@#S\8@+NJ8=JD#-2.]DF$7#3< _S(@JH\+7BSC.-Y]*PWA_/]>_;V]7UM
M#Z'RV0C&'LV8.^+:((O>G&>N;0K>CME.#O!P4_5XU1);&S9ZC,$I8"$:%UDA
MS0LBIC>V-X#IA!I VD,$(#9:Q(I^@%!BDG??X.T4'3ZWB5/RE6C=$)Q9*]@"
M$W'8UE?P<QF.-6]I2&1F&>LHK5%!RM&,C]3L@Q%K/26EN"0W#_9*V2C96#+U
MH::C]3=2&@2K.7W',3EDUM.! KF.^'4*02RIYB_:%9@F25J^/2>(ZRMG",]Y
MCU=U;(!D1#BIU%"V\/9G'*KI?O:]343@*S"3K&+5$8/A5#=Z.34>(:LD%'2$
M6?X?,\&_DL^EO*SX-"*8M H?%[0E=5YL^#6_U*4;Y"G^,F!0RCXD(>W'8V96
M:=>9T3[.>IMUQ[N$UCZYRW>N,JDLCO(RNAL&DU9-#'YE=+5*?J]4AH)],T*;
M(G.J G41G:%H 8YELX9\)N,E<XYK<;-:"1P7RLQ-P&)VYB-U'PM,2S4PG'F=
M5%&X-)N2>2&5Y<X:"K9CM4":6E";V"_>EN7[B VF"3FNJ\:6J\L*#5,D[0:
M<W8\!HIX:=4PY;PWJ<637["SV;$2>U_5-^Y<&,?XGC"O%<\&0W$'"*Z%+#HL
M06G<P]Y=+^)QP'-HCN5N<,P2!P(?6=W=\;)1 3$3AEGOP5%"*4JE\^;:@ZJ8
M.92*T?BJY1H^A-UY" %OQF4'A]*\ S_M(<Q!;03K#ZO6]<L5./;;5V4ESD/S
MI3Z:8]L(G5RX);-\W\IEV61_69#=<>;C4%X4G[\:G%NU *I=$ZL6HAWFGZ0T
MZ1DAE6R2F_]TNO%;=C.^/^&GA65>]!FGWF7MENK@],I)-9[:7'.S4^O=#VT%
M\JB%?Q>6:<'J)7B?V3>V&.3C+Q@NR4VH/P.3_NJ^8?2_]E1I1C0>))6:&9HZ
MI$IS(7T%*[E$A'OYC;=AJ.(I.G;)4+'JBE+Q$S_R.?EG![KA^:.4+;= 6Y!?
MO$%-7013LI)&O30UMU= 47:B9N,"2.<.SD@4EYKI(L2:>A<4]^U,1O+PUBD2
M)I1 <S<#='.@,4_U7M6,+'^>N'=WZ,XZ@?N<>/2@_%NVR@KPK[]9PN>+X9BA
MBO-#Z;4 M0A(MJQ];J+^P.:0^1P]9Q[@%8 08P+XUEWP58<CV>W1X=)2]#!"
M$IYF8!F?4#/"QSZY3Z64FC'4^/+@IM I;8GVY"(A_)R6B/%=N,FLT=M?O8QY
M(5/9&Q=LS4(/NZ6F&AT=_/KA'KU^#W@3WQ%:4GGXOM[ \$4\N55SN",EV]1Z
MN\= J]XV;GDRY%PJ.LT_A9/$G/A/8B*D,XWU%!+EM#4^QZ@N/MAC0;V[BL[W
M+C/KW@+[>KUJOG5:/)9TR#>LJK5MPT314ZA-/(V*4CW"+9;TMZWWZJQIC]6=
M':3SN<)_:<$MC$.(@4MUWD^V'R"N6^P:O?RI1A0[JO]O7[,#MI +>HC[QGCP
M3R?6W>NYN_$6&]BG-G"QN7TC1:J."M'IFTD%_IHQT$;L^?O'S^-_5/7V6]0[
MH>7JFD\>@KA#Z3/#J2,KZU2#=)SHF3_\T@YXEIDAF=;$0?Z,@>U09R%6_59(
MQ"[P:YTB'<F(;N5'YPK+4^?*M<:8.[^^$. I.4Q2'V]\7C6G<[\0!8==FR)*
MK*\C&$*[>LF2R?.NI"X8%F -<(N4[3'&VAS&NL@OD1;G,<>WI,E3=X,RIW)>
M.3?7S?> OY7FXT19[14O7[V/?Y7!DO=<7VR_J["Q(6*2C^XI"U]\%,UGQJ\5
M^VO3-MH>\^DJM[![@$ Q[Y YCJ&#>.JEWH+PTA$/:O?D0,U"XF[H'G#*%PB\
M!_Q"W0-V/&!_R0DIOAK7_;",?_9B84N0H.DFT[O*W[N972.K@S.8>+LXJEM2
MD9<D:JNQ=@O:*>A\6G-V#SBPN <P^<;('$B)W'U*/A>R<33.3E[E?"$UK&#I
MS#7,L)& 4>#YF4I[*MTG8XV3R$)GJH+;]HRG?MOP2->2ECIBA5^1A.'[!Z>@
M#Q5E<!@%,/1NK!O:(^;I47FY[]DGC??@1@8"+>\!50_^ 26DA!(##[U'CMX#
M+/4?E)$$;%\(2E"-.+I[&X^MQS_.7RRA1ZK2-=0U*J"4WG,W)J6D:9A.VV>4
M8@]U^*;\FRWVZMA,H/^,O<HB2N&?L(UY)#>Q12"7UP%L)YXT'QSL++([>E;C
MWP&*O--T7+_K1Z!3.B)+@H=PX=)_-P8O8YW/?(AFS\>-M_)-9L]V@ZUA2_X_
MT,\&4+2J"TFQM\Y!,J2.K\IH>)JMUCB?^A6;$F1\.*3Z)LO(GU@A1O]%:,3_
M\\VKO$_X_X9ICI@5?43UJ=DF@&G&:,-IUM!>X]2W$;SXR^;<!4!&A]$N0A2%
MXCLK!Y>Y47_IW'O <U3.S<;R;U@,B*2K93GF(3OV9Y>4Q1*7^YW*;L_EL3[\
M_1>#[9T?0]9><DOB\03TY#A:,URPDVIQT-'5I0CQ=J;A$M6#FZ*HH&7RZZH2
M@LP(R.OH=%[CYJ?B.2]_6F+;8\7BJ:@">-3U9(YJ \CI4+U@[Z\9+3U(QQT4
MM(['5;G1I+Y+&#\<]?BX_I%2!Z?( #QH)JT4=$0[JNIL $8JYENY"]I'WCJL
M8 .LT(X5S UUR&_5\WL=M/73Y[0!]A>#MR.75PI]3G4^,]A*8Z*7&S?Z#AT\
MCC&%"Z!$;E)J25;LH9 JHC$>(\P#_O !X:/#3&C@NUZ4VJKR^,N5)S*'2\W*
M]X"-F>-[P'+2/4#MU820"*->F!I,FLOQF=%@J8F\JS.G\>C52PN6K.*P[AN@
M2C%:-71,;=]DGPQ:>7#^!6+R(2$YD32'/R0>OX'RM(K1\!Z0 (Y9OB2!W ,F
M_<L18I5;=2?:)@X\&CG%"GZE?LX)YUQ]^(TEW/.W20I5N(U(7ZWFZ7I:@OEA
M;1M/=_P_EZN-?@$1/MN87XG<4N\!Y!#EU6GO&&Y2SAS"75]U9W<W&*U=4 $>
M_3,J>,&5F&BU<N@:YY=\4):YR)L=O1.]<V9XFWSW'0E,TG*5\8FAB=/,)8W^
M3*$?8<JAU58G/UT6:M"B4+51NS4KN!(AH*>VZ*C._%9=2>VOL5"KIYC1QD)N
MPO<0#;<*\6PGFD%CV!9R#GP9Q"_&O0%=P69IY2!=^.,NO!"$MMNXW#=  QUX
M/WGS(M]Y.1CLS;#&SYO6*F(I1S^*>C-.'-98O ZL]TM<7P\NY7)N$1.D]36X
MP#%X#MUAJJSN'U5=6S:<DEEE&(C+'_4DG]Z&*VHF9^62Q2:Z"<S:M5M,!C]W
M>KIO;);=7F R)U]N,N3NP)W5_;VJ;TGGC9YG_04=4&+5X@G;YV J)%0?1+%C
MXM@X\N*KC5GLIU?2<\R"HTH:TUQHLY52B)DEA#,FQ@G&]UA'-%?&;N@QF1W=
M>J*_;BTF[R"#X$R;V<HBFU:.0C3T;<?4(7S&JVF9(X27X<,ZI@_Q:Q#:J:(%
M&6>WBCJF5J&(HFJK:VN X.#@7T%5F]2WZ:R*-$!5YCX$*&G0.U(,$>'W 7=H
M ]^HSHWWB(3;V!;-TY] B2S-@?1R^2I00!^-37O<.5RJ?[&^P3/MP[='3_YX
M8! *G M-H*5:U'@CQ(GZFI_V%BDP6TTHXE7)KP'1W[$>O*"=UIW^%)+G5K S
M/%W]H'1+R;6 921GB8!"^99=*GK/RD&&#.(4)2D5%)1O,K_C?[[OZL "9-V.
M^T$:H0#'(99@X*@<[*_T,1,QG_HH*4$X(\XZ-;&H(K0$91J8E3:<'YH?&L=\
M3CA#M#+MS<D;Z3^37Q*I=F@[8W@^#](1Y4X.(\=_LZ!,YQ&0S1'$>Z?"VS>.
M>KP'_JU;2U%LY(YXIC\%&?\% BO$HQ^,!/9R<9',;Y!-CGM-;,+0IBN-.;0=
M*-&8Y/0259X"7U2TM0H[-EHF!&_X3S\<^ 1%X)TZXQQ,95? @.QOD<:'7=,Y
MKG(@U+SS$!C)ROZ;#WR/GE ]492MHE1"6K!%'N6K2_2U%!;%T2WY.]AKY:'G
MHW$X6RVEVO=;\[*ZSE#'83/ 6B<9A%!G-)'<CD7!J^$8IY_=;5.B8Z !$D<#
MI%^A?<T^34=SZ>)>CB,T'::5LH\E^7[[A99[2!?F-0RL0/FA5I)9%>I%>P^@
M TDS$N[!.EX(\[=!%TS?0;DK6P;D!A,!IHFB^_MFF9TXE2R)3OHS0H_14D*#
M\(*_^JE#=HM-<;,+SWPE/,W#Z/AZ<[C)!8;@@%&MI#YA/F0H]]-"9NW$A46N
M  U"RX:D[*P W=8=3KHQR$D9U' :TEI3N@27KS"^33^=),TV^9I!/B#[/ 1X
M/AZ9[I-S6[XU)+1]^;G"0,=O]MI2^1++E!B7)<=3!T39GXAL&=1N2EGDCJO*
ME?JJ]V$^W/G3LBZ0^X);59-\<7;(LDXE?IHU&L6V_;V&,.<3X$[048H8W-N!
MG=K;P0DMC'>*R>"DIT5)N?#0JWAN'>EW#;Y0,O4/@)JL>L+W?)-VI9FGSDTX
MY^+Z^Y.K>B(442.?OW\?A_AZCX/N ?VD()$>7WB?%O=("HKO68W6?!:PY&:R
ME8"9Q!"IXE1FX<C+4!ED5>P8SSHEB,2_]B4$8&W$5AT0KE<Z+()P*!#>19UV
M)68.4(5')NJN.% Z!+.-=BT>YBZ\Y<O\2)Q)T0J1>,RO6C&GAZ7J7!UQ$4>J
ME+XUK)?MMW7VF)"PF(4=,Y8A.:T S1X]J#=Y0;#HJC7MXK612!4\H?4J*LEV
M!&-WN;3J-)JG9S"]]T1NZ*,E=&OF0BU.>-([>^#OHH_)$U2[M,MZ=DC"#*3Z
MCGS7/Q7-8AYXQ;*O*^]V4$'6S6+U^&^FFY*YIUDAF=GG;_T.8,*\B+W38X/I
M:N_Y_1C%7Y24$L _GSM.2[0_:7H:!Y.?>(!<>]GDTV_6]>OA?WGAEYL?..N5
MNN@PT/MY>3&_:K;]?;M;35Y.IIBYZK0V3+KHK&LV)B=98VCXN'6*%&D^=^,S
MH;@'$!\XHT6J=\H]W9POHH[8TN4;/:B#3\SY0N:%:K.9:I+Z=.R=V,6_^_0<
MYL/=-U/@Q/[>A\9>#P+V+ 6RAZIK$ QSVVE-SA]\FUWD+G^%>J?\NIDEL)A^
M<#5ZZ<0U_%#R6:Y2H9%DHHD2<TN:,HO+A]GU7Z/&OQ!$\87ECL;.;87'@F=4
M37(%V$NMJ=F1":J3>0>/HE\5O,Z+?@7(B[:>]-/ZO6)=EI3P\R?N7T,&3 1+
M]NN3^(P*M4?S*CZ?1Y3[0U>_[",-;O^7Q.?%CM/V+!ML _FNXW5J'SQMRME%
MQIUT%)47NC[,I# XIJ')UH =A+7L!0OM44(+D!5+^CU$:X40=]8LUOZ.W'77
MI\BNH:H]8VMC=N6/J]"MTPF1Y+;6V,"-I(G+"C->4QC:MP0I#$/Y[*N:*2DD
M!C1S_3;P 0YLCN,/8F:Z)T7/3*)EBY"N?9VD3-.\EK\2@?%;0DUN$<HC !?3
MVR/06LT=S?RPPYI%Y%]U6H7G)P<'VA'$A)\2)J*M4XH3=&!,B.1U9(9N76KO
MR$S#TUY1!2NR%S&_^5 ]VU6.].(]8++ =R<7Y_"J?">A>T#DS/7=^&NS2 ];
MH?5PMD0I![ATZLJNI-DZ" VD#_<M+:E'W /L16-_4).%-C,S5VL:PYO:)NME
M8I88.:7:L].7&.V=C3*Y/DI.P\LT'ZS^9HP?IMX9TQ4L"'.&#*/P!&]U3DU,
M L0DFZXX0_L'I //MS]A>TDS(0PJ4J7901=X:T]!YK2_4T0XF-,:;:9\A%27
M[Y2K^V10CQT9;ZC*[IB91Q&^MU'_BHSY:":JJE=OE5;OBMF^"!%<0])("69=
M6$<(*RE6(7R?F6&E^Z8==:ZEH*15G,*U\G:/VR,7GA_JUI.VL#^4M(\XK#8'
M,+ \!]M]_!&W#QG8S4W8/4!EU!VSS]B[^N#6.[]]P4H?9?V-]O5RNPZ/;^+P
M%*!M R&'V1H_#D0H]8T&:%@\V:-Q2;4DRNQ9^MO%-9(VH"RJ&_95? ,HP7T)
M$>EM'6>, VLEZ$5O;J@)I=X^4:R[#@:FQCZ-OW6J.P&CDZNI[P&PHIQ[0!Z\
M#85R[)=^M"=.8*;8 H,7U-/XN2ZGJ8_)'>Q#TY6)2[F]-:F0O0,^B?LW<1%9
M'QJ."85U/W(RR[=62>]T2RCI^%54$^_?5,>MGAA\ U<LSO5Z%XW[^7HZ/(]V
MF&,YG: \W'.?:;' *;6@"WRK.VTPP8C&%=IF(*_Y:YNT>@:*E_ L&"U8Z$GP
M\NG?QAL"-+YQ4W\M)=^5GE(M$Q&H:44_[^@?D1K@:6?C[M%5GZ%'=94=OK$N
M-&X,.0Y':Z\@,_H:T^.+2U0G'&=$*&/X.?T4XI\$C;SNZO?6&2S8E2$)E+LC
M0+TZ7<U*KK\BED0PEK!MT04G;[=X9=.:5'^NV=GZ>\R@S3KU]9,-UT1#X,!^
M(JI).G+RZR@W#K1OB>TD'=32:SCU$E;09IN@^>QS_:F!<Y$,%R+NYUGFE''6
M5G&E@[0@XA6"Z/;S5IR?.WE<85OW<_UPS C-]<6Q?[S,X$P'$=("N^6'BW>3
M:S84Q5XXS_>MZO' PK.)[6+'L)X;S5 3+817,$>"1H)V)+#)\_+ZD4AB'QDS
MBS6#O^Y3)]5)UIE@/B'895$^5I*]FR/VATR,I%?2FIH7X /411F\ #X>?EAO
M!M1"D(^C62EI,K7-=IU!";A)+ 7.3XD_\2PIJ2XX[:O3K@ON)<E_9#W9<)OC
M_*7_K6V]AE)*4P/;C=%Q8A/INQHE8C*\%A#G2,UK_9YF'Y1YS!-\PNCE.:CZ
MQIO&/$,X:EWS2_IWXZI\EG13=],*CW?X&H&1[VMC [O],0;);GF"U&0M'NTK
M]8E'Y'M6F?9CWT)&NE>9#(=M=)'"7_FBLYU^ /MSR,[/.+@O#C.9X(L_\%[>
M Q3!3>*-JSIH 6@PHWH>TG:/9?(>T$CH[HPCNWV;"]RZ]LR:PX5@"GDCCR5-
M$'QH:7CE95J1T6X,"*B1\<?/V@%_,X.Z"[-0*T$1H3]=E6RW1F^^KC[)K3[1
MVAEQ^"+]/2/%9J9_-1MCG&G3--<Y25RCKB.0SU#6.X^IE[LW7,GF>PH@FQ_7
M<6M^@")8$%$<42VT\[/A9+_??R;&9V5^E,O#V8AX!8,5@UE*H!^@UXB@: PH
MW#4.*O[BHB&IS9.2_LGMF+5)3M;J[Q@)U@T^I'+)Z8ZP!5&47+@'C\C[ZO#+
M0N[*PP\JVZ)>F\P"]N(;+*D*'C2 5CB?W\J:<9\WH9T%H_=:M9GX8NE\3-_?
M<E9G#+38IB&8^VY.^:;.6\V$)Y?\*FHX<ATT=3.?8 Q=CO*1H]^DYT0&XI8[
M^3-&\PK1D^Z-47-O-C?QFRKQ)<O:!+H5JF#Y"$TAZPS:&A%785QK+2D2)JT!
MZY(<LT:J/?A']"=^U4((ZQ1_C9SU.,8W+?%7O;5&\J78C>XL/IZ">]1D\8#W
M(E8-G)4P2:6B_64RR2?IWAO #O7"?8FN[FE?V=/8^'L ^WHE9G/":OGP<#4V
M6N0$31,.-VLHX:'9VIJ^5*OE'JTQ07IH&IM9F4VW2=FL$=%[EU][54KHUZE
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MZEFV:LT[U+>0'L6>XPWUD]K]P1A( <0\:+8Z H_PNF2&PL^$HKG:F$8]V_Q
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M0RDAZD;LH31+*Y:9"2GOIQ1/!H\0<]-X1W5DW^3%PM6,O?*]*CTLW\[3KE*
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MZ^&=\?'#K+I<RQ\6NK#O7W)3-!_HIAF?]_)O2]TPA1^#.T'H _EQV1%TB+!
M2=LY266MVB^(";EW4MQ+7U_;WGK7B.?M;IW4$?EBH2@D1[/MUX8@B D'GZ$
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M/,ZF(P^;.TR.3;5/R.\E/)UCUD(&\U4,;S@U-(S:5PDJ6JJS)/\L3N[O7_W
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M0Q! U)4%?N-^!),F/\_<)],BJ?*%).NR7TE'()G?2NT_$V^%8RI5J SY>E,
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M!B6?^/J$W##3\=-O]XSQ*#G#FJF'*7<#>Y-$OJ6<[?P:5#^.H*VF&I+@MQ>
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M,'K<N*"'/,9!AA8MOP=QD=Z0!0BI&'"DBG^.V['M!P;8$EW#88_-A>KM7;Z
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M$W2QVMV9[MF8]5&WA*<\/XR DX&2^7$J5B9!G K4VA1)ET;/ R[*W)*F)HX
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M+9#I%SCIDWK:,/"EZ-<G9WYW$3CTZ8G4'^#-J1937Z(0EC4C#]^8![N*=^Z
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MM-F !S],!3^7DL]SA] -REFK_N!A__ZQ2Y!:[D9EEM3<<$_8(*\B/F:)CX'
MHX3+Y!@-$X/<KB@'9M;7*!9RVA2N?L9-2T';.9=]C8YX=?EEB?NIX?N@1.#Y
M/T"5\0K/[4H_/=I856G8DIA^?%_$Y.16EU,Z?]^O=T$R[@YO%$_'#-KP7!]M
MW>99VA(W#6M(@)<.]YI_UC:'@(WL(U1>1BMF45W<,^4WU1H"N!P]=*5<-6#
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M.9_'8U(5]F.+X]=2=-Q5DP/+O;W&LCZ-'HT("M^Y,..ET+@$0VJ@:+H@E8!
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M ?Y'ZG^\_MYT7HH<=WYQW8US-;>@6A*]Q1J_?$/DC538^T][9*'P ID;.-K
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M3:^P2;O:<F)>@=OML-<5FOF:3S];6]Y6]ZL?'-6@BS_77YO-4["(@:SE1I,
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M>OAZZ?32B<FX'X+!MJ!^P(=9?>DK//G1O9S5.WK,CZ!UEQXS";LN\O[6# N
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M/OA^:J%%C7H$Y32H;V#)3P8CRE6ZHKZTXJ/4;PN7T,@ED=0H=R]T:_M6VMY
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M&W])J]+(SO=U"_?\#MQQ *A39H[J_.PEC*[ZL!C9G8V6&:&!_:].KHD=0/[
MM!K3Z:O+(:'LTT0%>88J\R7);Q[*UH<='^GTS<Y!6J.#XNM91\&J/FF8TN6C
MI\/E=3[FM</(%T&M/CE;2)^.3$\U43GCU]9Z5&2_2C,]<8 &<EI/A07; $28
MC(7O3O*>T<Z-XISUFTFDF'[152!GW9?QMLN&@;#=^*DF_^\WWGK^(*_,*8ZN
M-5P $C\_RY0QG4?<7)>GXD"W?7 EXWY:7HY^/</UG6F<<+"+L[O:1EU]L>Y'
M=[=A@&VRAB\+.D&C7Q0'N-(@$#S;W),UHW9T7<;8)4\=7)CT07C]J1.[>=R'
ME^E)O\#CMUB2J+4?$OU/%\T<#E!!= CSG2N^[BG29,9>C\ZJ0PI0C:W=7)\P
M0=%,EZL8;7E$OF\_&\[/11#*795J6-9=."S;X6Y.*=M*3DA@%$]W<\Y;3^8=
MW!_]2,#UU>D0IA?Y<RG=>*T/:+'G]1+)3DVP?T"SE_ >[K@*UMX)4$#?/X@.
M?%DULE)?X8]XLA/!6%^8K0IBCGL]!+P=W@7CO/-1*,K+OP,J/#XE.]A*MD Q
MOP%%Y]E'%E4^A_E:+-+V+;T3KFXE4?U)V2BHZ_4LV<H'EG.EAP9//B45A0OF
MU& *V(Y &/:11*B;J<?S(8'8X\'.B$G?S 48A4+5!Z$OKR(_O/Q.)\49RMWB
MQXLUJ=[)CJJ_-[5.QW:SO)@ 0X/LLQ@%TSD?&IM2HIN880\R5]6_9-;=_)I^
MUGAO-6:R1L:\SN2=+U11MQ]9&:Q:JE[3/,0_0FA8S!ZA5%:I7?WPW<?4*$UA
MY^]6PYW_]0SIWZV]N&F83'@/KKR/[7]A_"S2.]_O<1K0AF:]U$\!:S]6I"H7
M>,)WOU;Q=9*.>3LD\LD,;[E920\. ([>2?_\>3/KA$E4[[)G;X=WR^^.6Y@A
M#607T089XFP7CGTAIV<^O XO=?VD?V^60G1X@VCT=PNM)[-4HM -HI4S= I^
MC*H[WSHT9?S!.E\$**Q:[0!6]X_^63F)"X=12<!_=,5ZJUX"T6V6_]F[$#9G
MC!0/20*"<("+_W&C K_I2RC,2L<!_) XP,+:J=0AWSI]PB'#JJM^(JPMDL![
M_!_MJ]) $Y>;ND80NC@ 7!L'V.GTZ_0-_V?W*B#-4N'I$PS0>]PAY6*TE+8$
MBG/^\X9E/N2?O:C"SKM:X<>N"/VTVE"X?3%)L3&9^1]MHGBYSG*PO$FN_VH;
M=<J8%';>T2:/'_TJK=8"[H"X)F#Z9XNH4+BCUE7\#\;__,&O-7LWX2SZB_SQ
M6\3KM%HIN.,LL8"IA,F??_ :=$7 5,3LHKL2!'/ VEB\^_DL] L</]X]K98,
M_GJ;L-CT7\V:GLQ6P-^/%GU>(,<2!UQ\FWK1\TS@E$0$LCN?/+P HK.K)QL\
MGRYR<*\VS06FJ7^]= 7T:-TWT-)3>>$H .SE"105N#D^.ST'&_\<IO9P_;$@
MX?MU(C#%#GPAL*T%Q&SF4+.B(21$$UG^ZS*IPM"EAZ_>:G''K1)Y+56DNF2:
M/_*RE8D?U=OB"+-+=&2__/'108]'TZ7O_#/94Q:>7&*"G2_RH-K%? +<P\?K
M?E!MD^Q&.(T6$A]1F4>=WAG7;-Q=2G% 77EJT<[R_J7*X9WJZEVK[\9/L=6%
M4MJYO+HS][-W\>E[S$=M16K _XL7@;Y.*6/@]X]4_DT!JS[ZQ"Y SHP>ZCSM
MT9)BI1S^UW.UIF5/2LD/@\6<$WB&E>"E_9M>TS13D$:); @"?BXWBU3&LGM[
M8$]Q "3J7"S[@;0<[$;W_&H1\IRB3OK<%P_CX>^FPDR#\)59'( -M).>1#PR
M/YXBM@HIQ0$"7$%D8,T^#HF3K(0=<MVZ8:@G:#&RMLI)N?<6;_A/GH;''L(?
M;VR&(8O@%N:$)F R-**Q':RPD$_&U%2-.#R(RK;U(?3VGSK'!"R'B+\CW50:
M(J0Q\Y0ZI?NW\V?V4,D7Z&R" ^=FQXJ;_)AWEH,7ZES:S&_ZW3%?=1I<<S\7
M&3V?!ME*6QZU^XO=_L72P8)6(?26P&=\_A/<C:;&K1-1,6XY)HB%:0>@^S$H
M0]E@)6[[GK'VF^3WX6S>1Q",TO[V\1'>(2:Q=OB$%*2) Z1 L+[PUBB[R%<\
MRE:(>#D)OPXY&LSL0CZ(RL1QA@<-":'2]+V#?(9.SKJ745=F,[VH]>G-ZC4G
M09$:LH_4I+-ALR4"[_UX/6U_S;"8ZC<GW^RKI6<ZO=/6I+]VO77%9MPP,TK)
MGLZV<W&+Z/O*/0U?%QS@ZDP2#B"' V!.(9%LZ,BUV;UMO$_ ,/T]%#**=#YM
M+@WU-[!L^*1)-G.=UAR=Z-G6B@.\_FISJASA!D)=^]&(M *6N.>N*Q?:>#(=
M M&0]UABI  Q8>VH*#FM@T1U?#8HK[/ L.BSGD%?:\X+P730SN7>322;TK^Q
M#5&7M/HR]3(Y70S?*:NGQ%QT6%RSGG=;:*UVGM$8F8!Z7/-)RL2H2AEA'%':
M!VU&YO>]*B2!["Y.[>CB37;T;*/<@])1_")+T2USK3I@O=KV TA,7N3)8#&]
M/[?_I!WOK\6(DLNRDO2GY/_>\+[)AA[N0SYADG& 0R+T65MTK0:2CSP,0ETK
M6^09MK8%O>:J=5/1CF.J)5X^=E;.R-8AE]L.</W$7*/TO&>P$"AS7%2/H%1<
MF:H_MIH 3*&FHX2UWCKV0?XZQ]]FE_J(#,EDB9/TYJO\FR%$_\5$[/?2SB]<
M9JV_=4#RB4YW&\'#Q5'@W_$S@@X""R!#CW,@=4/GKG5IG M(((6YPJ!FHA4-
M#C!2-84#S!N)ZKDG+9"0&=F$C4#$%4V;7UNT/MR2W;B/$-=YZ_1T68X?+")/
M5<XBQV2JIT%LTG]P%>K+]B**0A!:&R*<+O/D_;W7I0\>..FT;UZ^W73#0PTC
M4NA8+U:^H]P,HEA+YJD=+)_LX=,JZ7?5'[R7%K;1=:K07FHRI<H1\3/M\C(O
MT?U=6NG@C$F,?^,69KS%N7J.\OIKB_:-#GK4HYTKR=7!8Y&M_+#7NX<2YD^1
MU*$R:FV'H!TM[&UQ\QMBH)"N/# _])'5A&=_A%'+UO>J:Q8ND,, IF;=U_P=
M(.9H1J2GC:UL<' ]T=J$4\G.XY7G5='Z)3M="H35D/$G0A,&;5;Q^7:";6]W
M^&RORWLKS0C[3!;?-#"8(3','I=JI;)DK9.ZE* ]NGGQT5TN-MMZZDJKC.OF
MW<N_P-RGMZ<P^O/Q,>G<D4:GK49:88DMAS/<58/"<6:?/)4G[G\8CR&K*=>H
M>,X=I/?X"N>0O%7"3G).PLR#'<7BT-;< H5\S[0640NBY)_Q.?J:I0;?[&7R
M#>B_&DF(B):*T+KI_O0922TRM'>D,M58NO:(9U>H5R@Y8$IGVM%=S_W-=(]X
MEU=)R:%0KY(RP#83X,42O9DX1WX#JS58^V(^A10#:F($'=*F_]A@I/WZ8[+I
M2C'1X*3D7@61#M7FIGAII04/L^4WUGMG\:A[6,4Y7_/Y5QCE>1B670+V+70P
MKC%<-FFI^7#6AK+6_8BV^8'2 & RRH-\:P\%+!SG_R;0/5;N1)C(-,HBE%RN
M4#AN8J#JPSQ9F-YN+RY!?]CJTT><H(K6,AM-,1C!:B"OBI$S(E*G5[WU4K/6
M-.RS5]<DCY>#^E<^3^A9A]3(K+P)I '_-'83",0!KI_S8(70Q8$R?$ D@LC$
MT^5A&70PE@9MNN@A//DXG%5F,%\X]+K [%TE3??DSQLC1M/QJ82#QCW+RN3\
MD_26$?MWXC1&[[G9N)6G]%@Q@&(2V+[\(&?H\[N.54,KA]=Z%7@Z+I 'QI+3
M.H(*U6FA\R2)'7-GW<^4K\;+:M)8J\P]O/'+.QG#VI/:E#NY>ABS(>&><)+7
M2M33$YEOU,!^9!6:$1,#&>=O]OX&# X1/=.<:P Z+ZL1O*JA?R.7%@)^E#WE
M<*53.G+T]E?WUT[I4BOTF[^WZ.*::6^N7^I8:>E_F6S6NN[\_KME'5W]K9^#
M6X%US><FS9?H?MO9.U&[/,;X&LN,]E /^4^]PNF6XLIS/"!HS7WQNQE5B5VJ
M7@HE43Z'K/L7%4_G(D.CL18OCDE@QBUVE.7WB"BAY"&(DR'$Y@S>BP,\Z97I
M*=R(^H+XO?T(&]DL*K"N#0..]-OZ;%I$D"8+)>\;;+@;?7_; 93X%O-VQ9+4
MSW+B]Y[SM'N;7LS  $3LHW50JPDYWI.PCRQR3)D<O; =06]KZ%TW.BZJ;K;<
M(:['8N0E]UN=8-1XY]0>LJ5/ ]VT/SQ:Z%2/A$E_!M=%>$FV2;8Y7Q1XW%/Q
M_,(_I^ F_YF'R7_3LN&$W,$]$V_=]\(])#Z94,+9Q9WWJ2_*-5Z%X_:':(2S
M1 +U5/IKRV21,6UQJ/65Y(1B\4G]UG%QH5[?DF^ 1:PINAE3MA#]#FS*G[LX
MZ?G4@9(K\?!-X\+",LU[SCT)<+*)C5OK8$WONA B<4.^E#6E$/P(\WF!04;5
M#6B-9+FRIQC4.D$6:Z_EQ<SG(2,"DA(6J]4!C@F>]JJ\XIL:-2GUE2H>>3V1
MVQ!GZ8W,$AF)Q_]46_9MG0'6<,.C?H3^5\=<Q/X/<B(T#K YB63A;I:C&-G&
M^F1J@MGF3U%43P9DY.<#!^_-V2\$LE=>/Z)ZI4CQ,N!+Y^?K,?/=2<J-Q@A6
MK!K&%E*(B=G"<N9L?+-RKV"42WT9SO^9M[&#L[LCT#U6]6N*Q9LTC@\$3%]%
MUHW\8-9Y!5DC(%%%?QR G=16<ETV4D1S=%/,_AN?(7:<QH.B))BAS7G[(?/H
M.S_6*:P(QF/.G'C5*#!OS-.]=U2S,G:](VD+-0_;[>TIS0E3>A-=>QQ $#1@
M('R\$@:W,55HIC,3["\$6U6#FHH9\#')#A/PR/2N[/[ @SLFBD3;WPB?]=YY
MN-[7C@.(UK!(\"/LH#M$@4OSY4&^1X"/NI8WDKS8J2&-CUZZD9=<PP$&_D79
M!+X4EHI/GN6E$SQ_2;"F6;!1C+<2#_\!Q\@$PO=E%Y9_F=I![M;/ 1N#HNS=
MC-\4:\L2# 78]3]W8WG;I;I;/RSQ>=DJN[/GNZ4L<67:AG%I27G0LE?%(_'K
MXJU2[>USI/L790>ZD<WTP9'CK);\-QQC,Y5K$?VL4&OQY*,.<:#NMBJT$BOT
M[<(9RD8VBU$VE?Y =%,LJB1(4*0O6DU#PJ1T^.O( $CT!U&]DHGM^A\O1& "
MM(9M!2>FO$J)IO0M;\A3;"O"0^Y=?*?LLE5%VK6T:='>Z]4JS7A1?TELIB7)
M\0U!A!<VR-1%#ITBJ<T\_1M;-XT0<AV]@C7T!VOMO_UF_<%!5-P=9;R';TH0
ME$3A/7PB"&:=F:'E(A%?NAMLR;R_S[IPX8E.8EU\ZO1%2XG6M95CIP8K[.SO
M1/J>N=7<S@K?DSBY+4GY&F3BVNK=1[3.^^'!TN>6B(28GNH)887Z5B0]*N(H
MLV1D$WK7.GX&(BQ9Y0(-DD0X_Z[*.E59YDL79IP[WNH"1P@=AP&C0^Z)\:6#
M0/)?!0D_CS5EFZG\(&/D>R!_TW[/X4H'OX@K?79"277$HBT]Z@F>M(*?T6K)
M\8?S>OG0[SI'.4<M7!06-K9OVI\ VV%5E;M+MV[6T*-]?V4[&*'P@G).G>M*
M=D9&O)4G>$BWFB<Q,1R?2*HSI;'4)C %+'!I];G./;)9N&E9&PNL&'C)MVGY
M?1_)@+IX4G;CT@?V\#UX/_$5C<C?5'8?6L/7Q5,TG^A;*S5S2F]YF3L"'_K,
MTG+63J;C<V*A!3,.+7\XAUSZV* KRAO/9.GX4.#&%#+6%-U\\;I-DNT"F=SY
MYN0CYV5-D3^D;2%9(+DR)-?,C0.H39=UC4W[BD0\NQ))D^2\0$)B/&][OW4R
M]L7CUT[9]"OTVQ>?!<NK?5%P<UY2T7]C&N'9\4]+O>_4I6K7,C6C'<?II_0:
MN<HC@,>/R<Z).]%*!*!=@0_4/N1J +BB=IQQ:;"6^DHB;=&;4J 3A-0FY""?
M1_2PWK#,H<[JM]WV$7>:EZ=L]A0Y)-^MW5'^@(*4I]:#A+=:Z+TZ>$Y[?YPM
MR3#;WHIK?>"E_!X'L"YF]408!LWL*5?VB:)GX75#NEUC52L.;%^CLZ[(JA3W
MJ6LX=9Z,.'[AFB65N@B3E[G]9>\.NM7<-^X^Y9@!)?C/_H-./-H8= 27Y";)
M6BJQ_ P6"W'VAJI;"8LH'(#\K3S9*FTR39\HBK6!U%U/D+.65U-S&$":O!(V
M4("2;J9E+.^A*3A_'5:#5W7$^RF??B!>T;O[$XK.]7.4XO](Z$RDUQ'AG[XO
M+G&[]S#R29]3DLF?*FR:V_U%\]IN>*WS-3B*GO)? W"URGJ_O<)#:==O>!(%
MM\CH+C'56I+FGQ,70F9;: Z)U=SG?"6AZ_78Y-,Q'AS$HZW?=>T-H]+2LJ!U
M^PKCGLCHDJBWPI*79>\"G3I<A^$BD#2A7_]@] L?LQB]ESVX6*=:YLC0I H-
MDB>UK:/UQB<5(-'#/:\8A:Z*5GJD;,N%B=E7+\47]%;$'6=>,7AMW>J7EFB!
M#VDZ?V0 /TI,(R39M+=_O\N I[+*(;)/%PS1J6OIQH"0;+-\DGQK$#E$%&?R
M:N.-EH"EF^P5YZC]"S8P\PS0NOA N*4M0:B!I"3:[/M[]5S'D0=/0Q)<CI\V
MO6&B7_3#)P9W\^A.EN*_,@NX2'PJC4@=:Y/%$V%F)=YS7K^JC;_P'/;-?^0
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MAUN,:(5#[<O9KCL:)56G(ZRMQ;H=;W&J<[S^=?.J9/M!^F?BDNRQ33C^_CA
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M1EH+*K:38QX"B7:=N6AJB/W8N\^<V1%&6V?\];'PS\;'W2TJ+RS?FWU.\QQ
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M.;8Q,,<P%!+"RK63,UHKML/5V:#Q^7-$',=[JSHVL9I;AAX";X\W ^%Z_]Y
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M _HQWZY=.WJGEZ.#:-%:S9D_G?^P\19E/MZDQ%BJ)S.-74SP</E:GF\2^J-
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M4 F]Y?#M5])0L+SEUTNPK*+V5-Y8I"K(M/U@=AAUF?JT<[!I^AEGQKB7_(D
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M1S<AO63HJIWMCT@3:2!S@$5UY)]W'$3)#^6#G&U5[=>R(@M$R1<,W5$@2KP
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M\=N^55_!6@FL5=/H2F/3O=)\;[OL?Z!A??MJNGMN3E_!R]*DB-4HS8B:P8]
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M=%??C.KHV,;:WY5U)\.]&;$^YO-\O'PWX$#\L#0AGS#7"RQ1[2D\W*4L_?P
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MI?70M$&'$8POJR9$9FG/N0V0MMIUMF[WU-?^:O,)X^*HBUVS)GO76A<PAN,
M=RR9!,J "C$NW4F<GWVL'4NWO!Y&Y)ATY,KH^Y[-S9Z*U\#%A&;_.OURP]-C
M;W_F138@FW 6''OL@(*'[#;I^,IE%AO8G.'*WY5&J"' G6?V$RF""G:34^$%
MK^\Z3#WH+3:/_7"_!H:$6$[?<E.GV$K:"_-YLS2DKC2IV!"[35M.MU9GH&S_
MGFB.*]N?_7GB-]Z[7?431@.IG1_!I>GGQN#63KAR"<:@@Q81%'@)J/F2;+V(
M\2$M&7+Q->-7:)Q_6!S*NP1P_*90WMW;GDC]^_,HFA/)C.:?5T6?A%9-JY-,
M8U3:<:)A'6)B<.U:6EK$4G*R@;(FO>7S6M<TY0FS:;&#C^^A_7SBA6#U8Y<?
M*.-,JR3+<*P)16"QX[Q6!>JKUV>-S>.QRJIDPBY*PZ;[J2-3*ZE+ZS=(OG]R
M&#D&HV;3_0]!9*3-6JJ@EVA.+,<S94YYOJ&]Z9R6BP.[#L[TASL BMYL&6>"
M/A/L*TSZLNT(O0WD=M70M0,%5'PI G2L6$3VY;Q3^$G?<9?_,O*N@J7_")D]
M]TOZ9=XV6OJB(MRH\7UEK-ZBD1A,!1*LO*R ROMD*7./CH&SRO\$Z4$"=%&B
M+J[H7]63][3)MG8K;0!.[0ZHH,7R"ZW]!-#N<5E;4I6VM6DT,(',VHJZ)OO<
M^2'=P#&>AA &D3K=J5HBK=*MF9.V^<\Z"2:,34YH:&<:L $U65;"+N67D&5B
MU.$DFEHA3Z(JD_8\YEFLVJ_G%/'(\T:PLP>-!L'>K;H'0?>3F>+HKE\\&O^?
MC:M8GIZ_M$54EP8L LFLSN*&0YR6093Z&"]?K:Y00P2BRD7=^5?=FJ0^HS6;
M,C'7&-%UH= #(_DVR&T<)=8,XYVST7JK>N_:5JU^':QJGA[L:NVD5/Q^4CG7
M_ZAKP,CP61]I9>(2K_'CQ5JDRR%MIWI0@T[G"#DSVVOO(D=^JUVDP.'I(*VV
MN&#JJ.&SY>QLEU[N#N[^_L%\Z"^0Y;0M*)A!/1RKLFQ"#3XQ'#6-%H$B-^T?
MU,(0S\&K,1*\2.2R-8LD/6EOZ;.4:UR$'S&O4.L=D"JWGM F;S3G4QC6XA*
MBK9ID O)!?N/"O")>/.HU%1-WV[*C.:(*PFO>$&TQEN46I#A3=N&))1']71<
M2*NBX,&E,NJ+&!;S\I;Z5H.E:,^R,+=4OS/Y096ZRAOA/()LHOU;Z96^<=TE
M9:K9&'C7'-6HSU-G>%)/T*%*D152X*'+^8E.#'%=K;72O!CLN?+ [5(5X!-H
MFY<1]!,^OK\WEHGK&,V&70(J^;)@3\(1\JNG-@\6 KGK>H@S%GX1M\D13<A0
M>* NFIR6U:?:?#R^^\BC5;$-ZB'5]J#GMM+Q30W)YU*<=4F+I7R+@L6/FA?I
MWE\+LGB"2\_%&J++VL-4*18NX@Z,MG&W4;/^VRV<CD2V?H]JZYIC0#&3(A6(
MC6O\!R)CU^19[Y;SOYJK5I_">RQ$_D^NECN"S;6H)H;G##+WVKA+9GA(,KZX
MQ3J,"E59L_K6S=7WV.0O"4P=WS;M8OC2FH>9[TJC'A?UYN)UJ_FU7AUN4T3Y
M59G]@&^F@TO1_, ^G)^ CLV&&K#4Q(,>6.+L9HS@>8IJ"<D'DW8>XUBJX$W/
M98SR#6=+TSD&5)EH5!PJ#)2;(YJ&S=P9[[[VM#-96:\>003U.(/]0;>4,B'M
M;$N^G$K536BR>53PUAQ?32CNP\NI3I'V3"KNTR]Z[,-3=Y_;>7P],H(<@\O'
M99XC)H.6@31@J;/UE[6C;H]<O3?,8U]5!T"B...WZ%<.-%0>W^O>?'1 E\#^
MB&P29"E-6G;'Z"K7#FNR<%I-2NHK_L8(J!$J7]AUC2ID+6GM49Z>OZ!ZE0*[
M<[2_8441@)SM&681+;]D$M)T=Q%)W'%F\NF(3Z5=8$G@#@6U]8D.Y<:!:+O\
M=15 S.P*O]:&O0L]@?QNOZ?S!V$?2[1C%Y#2AV[28N(00K&)$$LL!5=VT43I
MS1BV<<',SZ]#Z6GO[H:^DJEXQB0HSU!_((8L/5>]2#F:M5Q6@C:IBX<TZ2PD
MJY=;SS&.EHFD:I$F'MWF9WR[7U7BG$#&-*/*19E:">7]X;0FZ+#?<6R+BH26
M6GM(Z37#J@R 9'A%/YAC#,GRE5M7.PV.?,INS[]@&-/W(/[G?",50:?5)8!1
MC@VAA.KIDF.K1.VPT**/\XG2B8/LD)8,:?&UCP=$JV*,$@<]R"A%#TQUV4B;
M:QJ#]R] .YMHPIYY6A\0,$(4MG@AWI[TN3;[)8S7SE*\<IIONJ1D/+;J_)X/
M27WP\REVT+?&\!<MP(MOKKXLR\K>^&,9N*CS@Y58S!3&?5J[L59P(XR=CP#L
M4W W-^Z]*<. LX4;?8?Y3&T.F**M =)1=AT,:6]X$F7MQ9).E&R[%F7816;+
M$,\*T VD9R5WZ0(XC/Y;FD60;&'XF+NFEN8+,S+8L<(E !2A.&9T' (!X9H-
MLO(3!DL='X2I^B*H0-!+@/$WF(U1R?)5Q[&C; 6E2LA@_W'8J>97.$.9K54K
M_N#;]8IA70]I3;$&PGS_G97_NW4=$G1*C=39+]M>>\]8XE*= L1'?TO?Q9K0
MQ+:,D*MN76ZM"DH_( ?[)E<3$_8%>K##;F4^2M/JM7]O_?67[=Z]8UA)ZU6O
MKBZXBH+Z1#H6FS#7VMM:+'!Z L3/-]QBX4;FZ?^]<UC!M";:PYX?=M6,S+FA
MGUNN4.#T7* 9$FVB;W*P!7*Y! A'V:MTR_ZC6U?X5IHH,D?O[[VT="P5U,=7
M\6+(/RG;Y]EVN@2D:YZGGZ:HV+1((+/U_M9-"\:HC5ZWI^F\!/SLN00PEZZ%
M0@L&<)"1/1-LB(DA%'L:-',)&%Q(UL5\FI;_ 4+A)=-C(USB\QR9L7D).$%!
MT(A#!FY(Y?HEX.F]<_@EX($.//L2('?_!(1[<5 SV<)V_$MD[QS3BO7ZAECO
M;)EC@:E?5)G@9(VA"DK'=I> C8?Y5[V@6Y%7R> R5\W(^EBLW/9"9IND\R!_
M>ER-=\-;'KFCYA+^WHL+GJ_YZB(!=$92^*<_-\^Y(O"00OU/EVU/%W# 4IDC
MV2;DJJW6A>+<?4SE= >#SL6%"0YD7(1?\35^1>ZRJQ7+D%R07Z*@JQ[2:$BD
MHZCT'K7-*UO!8JG$KR%+\G'/)!"2,@ B2=&A(9,W/G]A!&R7BUJ1C"K1^5O>
MSQJ%=B,U)!@_KC YI3\=JP>2X8:(F!4ECY"*CY#9DN>B&8YS+C]YG_P\H^AN
M?=CSH=22URQ;368TUC&Q&EYTL)>?>>9.$2*TL<CV:" N%Y5SYFIL5'TDJ[Y8
MTM4%_RARRZ%/N#K%TX(]1O"CLFQO&]8V-T^)09Y!B>%S!.#-&SH ^<=7VR=,
MLN**X8_$/:CBSJ> D=H%WR?BGI>XSS8_"^4J&?P_ZDWU7PUNR7P5\$"O>T'.
M;-SOR88'DE7GGM,NG;G-2L#^;%QOU9^\3_0E@"&;O^6\U8/R$PXN"OQG>2%9
MT;N][ZV].Z^+#)0P2293-.E_DE.O*A 5\O\DIT(QDX[_LR!4I+D&> HA..>^
MN"JT.'\ N\JL[;G*K/W7@D/_H7X5:A^$,_DI&^?WI^[AJO)%IA6]?)4;K ^Y
M2@V^!$3@@X5_%MH"_UD06=-Q"1!88.EOA72._?LBH H^T%7"*Z2[$O(_:C>S
MI]]= A)0%.8FK4O6_[8$\%_[U/N?-9>CR!^7@ $,<479/%JD]9_O#]T)4S_%
MPQ8*1!?/_W.%?Y8L'_^&K&()IW3V_BLQ>MN!]G$$.T4G6%6!?[U_]C\%:BO^
M'VJB9:]D#SA^<XY[F/"O]Q\KC;7*?W 7$P,IL?A7J3+W-NPD4DCVT]\>J_V;
M!*??Z([?('CMSD22F0\.4)O(LRKAC_>D]J#6\#(CVY?M4C$M[/'<7S9+GY7%
MQ3DWFG+U&4LS.8>%585O0^YLPA.ZAQESO:->"'YTB897WT?3I#0$_58="RN9
MEFEB6H?E6FMJ*Z>Z+3%+=:/T1US+9YC>"Y%[;B(2--%$Z3G]Y4:SO)1"NR0_
M4R(3%[0#J0CD->"\KG'!LS.\#PR_SE!(='M1.*FXE>I.3<E[B+;WV(N)O7C:
M86;F?E@TKG&#!LZKHTJ[MJB0_(&CK<<0(G4?SNL@<BI@6J==#;V?T_:S9W%/
MIR"#A$9_-3+34>083LJK<< &\#,6WE1,+OUML[-MZ5Q90?9#0Q$DJ+.10;9-
M<6<3D=OF/[EI\?5:UVN6 %06\*XUG.%3>>2F\8:P0#S!L(XDLVR$U>@3^C%P
MD!I4@X;/M<BCCC,N("4M(+^9MN4^K&H[T]'%M?RO)_?I6"ZDM2.H"-(+;2<9
MG@<G)/ 02O1_N;[B=RW^W+ <]N"+2E%@X,-5NH #O[0COU! ME.I+N)WER=?
M>VYQW:W[Q,1L;*=:$ ?=2P >!5:^F7X]*9YU$MM0]:MOOC5K\5LM-F\*731&
M\ 9%$7[Z%#O]:_1=J>Y6] !'2?M@M.]^!OK,^\T6%R%(%5XLZLG,NZOM_C2>
MY.9/K )'>K K\MG&M,$L;V7X*D!RN<SFZB8QME/*->E3N4&NN$&H)UBR=TO*
M6TMUB4]J7H-&RXC;R.'-/LHE-IP\;>GJ(@<IWZGOGO"!M:%!UYSUL39QYMY8
M:J%MO)2T8FT"#T$49>8GR9Y?5Y=[$6OUIOG3';)=[5U4,]EW_!R$-S>?(U8C
M6M*9=Q)(:BK>\GZ3D,3*?C^B(GCJ-D OLM9J$"@6UI9 3)CBY35J6ZH[-S7D
M=J.]SY'<IP\@84B6-A=WE3N0OQTO5=%OST_SCH8421R^SJQ4G@-K>IJ_-5:E
MG: B$]H86L!&F.=)G:D L-3'!*DU-8E%S?(FL$:9 M8CFPLN 9^#U*2"?BN,
M792YC_ 02QYN7F48N(T$NVY++UJ+CO4XO[CVQU(CE#H9_&*%NCQ<?[P8J.,A
MA$F,$"*JK#)(&"+K37-.36SK=&4&O\[<&A9,"YC1Q)OJ;X2\BVQ[S_7?@O7$
M:[V]R#_7WT*V\8*; WYP$C[&G#H)F>6QX*,!^JJ3%I5 V^?G8PL+>$5=BTBK
M-RTP4'5R_%#10>[3 UC\((PM%)EU[M&UOI':/FS:9I\1;IFO>66ILR"\]$LD
MOXQM6G[E7_I.H2:YXAUJ ,$;JT[W,$^N=X:>3Q/3BB5;?GD) Q>A9)-\_L/,
MXWNN67L?U/%[E6W0],0CLAVE/V/$ZT%,]^QJG_@MD5VHF, .$VFD!^(^_78@
M^(0WU=0"O$ZUGI]XD)(,G-RZODYW>!;:K #0J(?SVNV\:TI:-*U)9F1G7:P0
MDO8B(:]_WV U?KO](CSEU@<G.$O:G^09\GI3IW<<.QXDQ^4K,A^9R-R0>RJF
M>$/5&.*K;A]@DFF\ N053!D<FM\5->:F]@_W"K4]73Z@F@;B\1@W8#!MQ OC
M8B\@SMC^\RDWL/+YJ@6,5 W:#62O!MJ&%9VEO!DXT.2IY!F\QIO:.Q7Y>#RF
MO'4]H<[&*]\$#U28@T+ST%B7(. SZ\DF(O5_ R1Q-(;D"E M>.+Y_3Y^;?%]
MI$E=)S Y_#C+WKD;T2X]Q4_-9];==U-"<A-[9:7/;>,Y5:6"$+0[I@'\Y%++
ML,F8:</RIHJD7<; & 337A1AX,^^OVF=P:_>]#M[F?6'2EY=_M? !,GC8Y$D
MAU:\D8JX>_!(%\P\"\##T4KS"?VDWWU8-6FEO:-KQ;#P5\#Q-B(039YR%O1;
M>U-U;BE-F]Q9VO5*E5++G5)N):B*^$VMC3A->F))B1Y')\7L)3YIY6_R>!/M
MU_F@?1T=(_SS6!2_>8WQZ@%FYFS:!%*"6 Z/:RZ1S3=HDU8CT^UO=W6U]Y#-
M=*\PB2GZROZY0U1U[F:6%4A;U!X=IC%D L(0\;+.W:J299.+JEE'?]#XQT;S
MZDU]K44':4G9[ZP/?B"G)>0\S%:%\[I!A'<\2$$)_N=/ER5[-'=L\()*_8_^
MA&;N/JQ,(")'7(6CEYWNYS_(IW7Q/JRU2J[C./=<&YEF3.ZR.1:SW:GO%K=0
ME;9I6L=.P1N0YN5^=>\,^@^NXU4ULW./LF[$;/M/CC[5GP?AEADGU%YX3KUR
M'7H=;G@\.HJ1.=_Y,$7/W/R(T;#<2-1QJ#U,;$$E(++N\.CJ1O0FGGP._^8[
MPA?_YCL4_@!R2+:Y?8!*IO<G,"'\S.O-GXOR4MWMVP^F9HK7'I/>N&X*TE3]
M@3>_[X8B-+4J(M])J0&'3!XL1U?6)X_'V;*&F.8LSRR1^96/3(E,ZP["3V;)
MX-7?5)A<P&_5V8L\[6JRQ1PF3 VV&UB--U7)MIL__V&J?_TQU;J9S"M 5G%E
MD-">K48F, D9&?(^$N#2!2;GU];EUL%Y[>W>-\4O:B$,[:(" J*C_QBKTKES
MS[GXN3R2]%@NS>&/M8;Y.G=O=1OTEE(CW_=Z B3HZ$'#99I/J'C=!IC5'N54
MU^G%L!A]! EL(I7SMB<9FB+C\:;*.G#C^EN_!_C5R:;Q/A$1,5I;TZ!G 8CY
MR(2&5_/BK3=W_':H$8_1[J/5M^ML!9O(*SIUQ>NZY(C E&.L9,K\*0VY\^^?
MF[M<+?CMYQGRTNJHD T2WGCK!6S_0Z?Q]>]RA/A6^W\:FLL3#LOYA^&93[WV
MBW=R8.BC^HA@D#C]GT2S6]4#C+YR5ZBT-_NI]_B#"\9;J[3^/<*ZE9;$#OX'
MD:<35Y9:6F_J:2DZ(T[*T21YP(YG4R'(2Y$+YQYM/?VQ18N[;^LUP,-.X]X,
M>#JSW&S I1>]'$48%N]F.[TA_K3=FX? *Z.E2>R'$6\"(=O E=,HNLK<8+D/
MB\P\ONO::CM;V=\V["NEZ817\1A&;\BUT/D%BQZ>7:6])_%N/[4 [W7&+'0=
M=N-OT7L$OO4R"T?)1H"T\#0#%4 FD!(GQB1_6J<;>;K+?40%"&W[>O?7@<J_
MG92UB>HEO3.!J(S-75N_'Z*])$:W!/?KMG=YH-00R\R)+[55X\-9H3S=LF__
M461"T2,5-PQ=2+]C,M6W,HO8/+G7\?#7M-%[BU?^-R58W99:07ZD/OJ8,+3*
MXD@05K[8;SKM'LJA]CL;O8^T[^+%[5)[DT&SU_9C;)1/R(0"]BA*_#Z!UU7K
M)V7N+9&22F"W&TODEFZ:SM"Z5/WU7>@%(7MDD\[Z7IOCY]:[?C182=0E(*@:
M^AO:[B<T>5CU3B"XK.EI9LD0[#1\"]D@_O;)?47#B]'#TB3M55^<2>&(%G:@
M=N10VB0\O:JULQYD#[V-?80:F@_Q$5UL9#30JY8L]GGD6""7HV]^P,G'0\$]
M>/^FI?R^1.RJ'9E; Q!+=;!H7&*99>/!PHR>@R[.:NGQQ7;2(LCM'M0_6=\9
M8M>2]'SQY%DG\.+].E!LSG][42!"5&#:G2)XWPIDB6I*IR"/X(!/LSKRGY8R
MR!,-G0\3G"^ZG\,#P9;'&IC"?-P A,#GOM.BHT"G,1TFD*:^: H?@^FG5^K=
M6G?A1_/WG!JIC?/.'&[KV#B_O 1,KOBAQ1VW3;<H N=KB#_A.*S\),?Y=X[V
MKJDLQ.FYS8IWTP#?-U8&9@NQES!48HNI4<*-/"=^YK/1J-KC%11G%P7#QAP#
M V>8SR/Q8+88$XHM%L[1H=2TN@+Q>];\QW,D41T?#'<U3X+U#TSN^O7+"6("
MT<+'A2K3;J,BH& &AP3[3)M]0\5-D5]/A)OOA@=G*9!X</5R L99F# FZ(ZE
MDP@YLLWY.S*D.1C"#@B90_8XYR2?V[<R$_VTFYT?PL#9IQF*//7QZHL.]49Y
MGM;;.#^3R%P7];,C"H0WCH0@'P-I U(>C@3%IW&K>G14WA;UL27Z7,O W'PV
M0!<SF^<[T'HCRA%J+7OKANZY8[LZ0D4);5'HM,AL:/(;DZV ZDY?(CT?V'@?
M.7<\!Z:>6[H=J?S&M+HBY(L$ -Z?)H*YA3[I )+X/?:A1]5V-(MWXAC0_-5.
MQ=8X/E]WQ&RXL I9'D7E"WEZQ:'&;UG^M^@7DN9K++^4'1;-^Y\)?*Z>%>M8
M*JW-5$)MZ_V:7.5HE/)=N>_3\]Q^@$J+-Q\R.V#)3JC3=XN#2ET&YFPY,W\=
MQ[^9SMS"L&DL/NJ*?/77F*BZ"**KJ#-:;2-&Q/LXNXZDZY9A2G1 I(+'FY"%
M])N;EP *+&,FQE(YK \FXLUEQQ=;%RERL_[DY\K9Y*Q3HXE\H3$BD$KSQ3L%
M*@W"[.AL-S<)<TGJB0[.9!+0R5>&E67%Z(G7YM\6=/0H/9VR(*X$QO'DN!/3
MD2X#M17]+YFV.;\-YTT,.\S-;>^IR@YU^DLL13SEW>D)U"!@3P-0K\O17N2T
M #$=>F.'L]*O6Y4FPF[S'VB,"A07NPE1_:!)</D991C_Q.BYVO0O&L."A_6.
MTWPED,77FX+;PDJ."YL^FME*2]8/[7]$/)Y36K\%?4K*''8?Q-_M$R5D6XT)
M61XAWFSA1L$#CZ:Y1%.UUA0GEFO!F7&N!7Q/H[9<$G5OO@]I9_WJ,V<63,7R
M\LPRS00=U TDQI!VS=&@6AJ+<R-;ESR-F1\.],8KUIEQ,W)0!</Y USBKO\
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MP=)N5$^(AMT,"G53=@VKMQ.P&,72%V_1H$: 9[U8#!^+D([,8B3/J(SXDJI
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MYF2:40$V0*O -7MCY6+6;T.T\9^>"MU\JJQ;1"D&\&W5TQ\)=4VGF+>F\8K
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M(AK$G(N7@,]^-U"I<Y5N66"!#H3H9!6=C8OUV>L[LJCW79]W@LD2>3MWASV
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MQ<IL(T#GY$216^N/;LVZ#@)X"0D;)>B=7U#-NAR[P ]]@?JM 7HHW \$-[W
MSN'T,OOQEI"!UU?&%R0]U]=7):ZCM<NI=DJ1D(/RS_LR'B(3W XO'XDA[9=R
M:XU$87GY7T>-+TI\J,=$YJ=V!_2"7H^":LSKQ&.WA(Q7.2/8DFE^,#?UP;@
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M "EOXG5=S_W<YSW/&><]XSECO&.<\R$?=K)V=M;<\_^;<XW,-3=OP$AI)^Q
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M15!$&( =\:^(&0-*/CW<H?S/N-_YT_GA,=2AE4<!/,P[M4L^*KT[;,L !#(
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ME_3@5K'-/7M5NI=XYYKJI-[N0MZ<X&\68 5W64'S=O_8WT%3+T2SY).0@4U
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MZ,U.830Q>+76M]0_?5TUXK9!Y02G3..V?N#MM-0OC\9C0V3NXX*;2[NP0/X
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MM>ZH=%:R^'3RRKR^\<S0K/FG%NGT4[,B[,93'\HTHE5CAWGM/TP?W91Q:HB
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M,5@%SWMMFA_&Z<;40[SVTP$@RK .#M0NCUM-!TWO9P"B'I -=I*VUL67XAB
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MG;=/C?<_QW8ES,>NOV,[2SS"A6@^5#!R!3E7=WE#/,[+Q/9*VX$K"S^-!UU
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MO-%ZY2 ,QC304C_&CS;S]_'*]O[0M2:;015UUV5WZXZKQ%1U V?@%2E*Q=Z
MGO^/C[XZ]5H<:AM#[66@)CM3-B) KDYW"Y;3+&[0J_-VG*5%Z7KJG@C:7XJ
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M(6"GV#X+,[^"OW/\KF"1)L;C),LB D?G=Z-M;<4-N>!%*S!:1QQS&TR&!?P
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MM&)G#NG],-OZ%[5PP='<NS<+*1S&*)RP7T,#?S! PS"*";_+RK5!R&I,@%@
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MVICT%$EQ;BJQ;Z89=O'PM\#,J(T4F3M&%L[TZ'*]C%8TF)L*_$JV7EMR!1V
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M 9^/S+;,O>_PJV^9"YD_9VS5OW&8%#9U(+&W9Y0[] %.J-U_+MWELFS3(S-
MS9!VL X*0UA(@)P0\BOB>P3?^ ^]PSJ3#+]M)5,GM2X?J _OC2A#EX-IX@CN
MVZ5H9?Q0EGM#=L,[N?64Y?'((@+_1/@(9E940C8J;,FYS"M_LV92Y?ZP<T?9
MN40,)1_?[(! VS4;UM(^,>W)K; PM%2.MX92]8B[C/"0X@A4NXA:TK_^,>&C
M>.4GCZ@45:3)LB>\WF$8O35:O.BC,'2(YLBEZ5_4>DT)*J-+58ZY6AU/<Q\P
M= N@^+\XN[Q0^UAB7W>Z<"Z,5JH?02LAP*I.;JU8 -71A?QW>#P68&[O^Z#1
M-_:=+LG]=?+*W*T**8+;/B%>(K=C&[Z03P.?UX0MF^V.0NCLTQ]6>4SJJ2.<
MTR.29<F$"[Q\K*(^WR4E(#^*KJ7CKKVLM 4.:V;T5FN5[,PIW#2E&78WT7MA
M<3()#X"0WIXKLVCO8^.RY0Q_528=;Y_"T@8D0IFU&\:^%W4AMO-]UE1 (UZ?
M$Y-&*JZG,"OUV5J']/S+5:GP'CKID36&_*H?_2@P8@ASTXP2=6Z &3GW0G,:
MUCLT:\2M720[%8EA3/>ZP&=I,Z4P/]J5>[69$14W6B.X=0P&*:EE U_<3-P4
MX[$LK]$][Z-_>ZHGGHD*,+ Q*'[>1?$EQ!F*!4P4%Y>FUFV:+ZYX#@E<9#DW
M\KHB5E&.G1#X36]P1XVKMZ>)O$:<A9BP\=6;@X=EE^]S:.N\$A]$!F??-KV#
ME%J.C0D@G-N&NT1B 4L,J+)\N_1;$]+F2P/>]H7VW[9&X'<4_;IIW,V9!+2$
M7(D2TLH+HJYVGXWJ#^.?76<OGF)::.E4L)7\H:II('&55U2DLXTT)HJX_(,R
M:]1-1_+O9B0@&L3$X.%DJ^S-'R!>1^_OQ2^'W;M?C7@" DTL=4@?<;CM&*39
M#C(#0P*NHZ4F0.;V2$O=29 >2[ 'TXOG/SS4;=2&B]5Y6(/WY\=SIFTBW3<C
MC_63I)_==IGMDG',T3CGW)YG''T%>@%=F$$!EVP*"U'!_&K:*4;<'>5P!:NX
MZ8U=Q'VK3[P*] WO_/?8&RK\598.@L%D:/;LA2U?FL!&H<RME+<=_&M)D"RC
MQS?Z.F>R[&_=).*:+6!=/.2UU44 PZ0?RZ#/\L*.FE2=Y ;<SWL$=K,2BYUT
M/D]<)^%>H+5G"F;,%^AB3 &<,F@AGA6L[+$L80&M>RP=&!&7\(D QE$.9%@D
M']KLVW?FL$M1U$GZEG7Z.4UUKESA'+I2.MD)7.]+FI;5"H&W3- VD Z,!%(\
MI%$"T3K/SZX>JX'DG$CE(<C[_MJ#X3-;'/.V ?.C]W>%[QS&4%;&-LR!%,ZE
MT3Q(SR:W8D<8*9H%ZJC'5R*;D[])G3#;VP(@448F60  %+Z7C"1/6A>NH+(Z
MZ%W"/4JNV4G"WA\-0,PG!(^Z;1LJI]9&>S]_K'=ZH^_$3A@O\94\ <V^W*2V
MG!Q>%8LRE)6> '&3OY6EWTR>OSOBKN[@="=!JR["+S6U@)0L*I1#.73\SIM5
ML;76<1> P3:,%FV^./=B6:"AV!Z&>(L6J()-FFDT)CQK2-K0=./EJVC1TF=4
MRE-@?V\J9O%=_]1ZQ27#G66ZL%4(U= ^?P^I&Y>)FC09EY:#_TH\AF;+\\%-
M6:N#N3)\Q!.YJN.8=BKC+[6TE"C6(9+"?"Y*!7#G+->B=OY?0.$)L7-W<V)"
M"/M)9&EBF]7+N)% V2<H09?EH2@W-#,""W@/,E]V5&.26H*CWK;?W((/#$#'
MT2GOAB.O%3NS6Z>ZN\X\!75XQ'TV<C.?%9=!U.BB\I DCU'^2&8-"KMTYC&0
MPO*UE DGC679KW<<S5_O",2(ZE:>BU9 *]WDWNP]3*1_P>IQ&K X"A+)VCRI
M,-6WUQ433S!JL^?OJ"I78F\CPQTO[KZ\Q,WR^>ZXM,!QI[ CBS)*8S&6'%5_
MTN%K]K81F(O*/ ?#JQID!*Z5.(M_&%I_EL]4<_-ZCP2K3:"L8OQ.!S,K0A*%
M 3)XIY[;ML.HV$;1W/;4-=)B8I+>$UI$NC5*UU_'&\*?K=VEX F5-2S6K^Y?
MN/5@B-[!E!UWQ+[AI3.&ME\94!V5*ZN87!WAFWPVPA8,7V?W_78([QQI$\V&
MWXE7M+A*V;VR0P*^XNT[T:5:'O9X]$[YB T-O4>CIVN1YYL0:PJY#%<&"R6&
M9"*RMKJB)K]%+" 0K;-T[D]DB- (\X@FFU\[N#,J>)3JLY>9-CV]II]&'&;)
M\:Z4CG,JH><K^9V+") ZU#NK#7)SX?D8]8GR*-K(+7>+JYFU;G*"-K.FAN*;
M PU7A?&=+_V/7>/BL]9(S!1US<) O)DHN8[=(R;FMB<5\;J?]XYVM&NBLUDO
MKST'Z"]:_5K4S0%0:BK\EY>ZN\&MN#'ATN^Z=(2^SXF^LUP%F7_#Z;<D+.8H
M5?_@UT&$F.]Z5I9A+S''S]R:&SF!H,OSAAU>SOLM3&6ASNUI):'5LD <@MK
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M536+L5$^E[YQ=]:R6-(#XV[BT.=H>Z.GNOZ#2I02)>F(@&* -6-$DP) T\E
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M6IDWYA*2VF6DY> # @>(4F<^\4(2N8R _O6QFKFQ>8TP\\7_])E.B>&!DN(
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MMII!EL1TQ$>2?U5:H ]V_N5"Y)U85&.1C)E+6]UX *W+5J4$C]M<_KVK619
M@D>=V/_8Z/Z-37C"2&T=3-<2 %@EX([XFY%W0AZW]H&)KM*!/ JM& I"?9]%
M:U>QSX^[G.PKY2E)2U19S*9"C\29BQE*\FJT8=',')Q+9GZ+"P0L@7S?D4MQ
MQ@$JH3^',14_>@P7A^)F9<HKRU.&F"V4P)7-CPEK=T1#\.:"7ZYB!A_R2NO;
M*Y!+5&XNQU+K\<HCSA=WY>/P$W5EUOGV@ ,E>"E+UDH7[:8ROA<YV%34]73(
M@#K#\S0+;[7WLT[68&INM2VI\6D9!:6$J@#C:"^5NA;Z"GCQ_%4M*O,-#@9)
MG\#[6<OSXEIIRFXVE2_I\5A:(/'>9Q  5M,0 M[HT;&&X_V1WY^FG(/QC(E/
M4)SU.9S9*]PED<$]DN",QT>$E2)S%F>L.BKWPGODD)9$&N7T0H*@.,/1^G=]
M%[K(*9XT-B?,K\N#@R4BWZM$;O9( $]S8F4>G05H.C>1O!KIB!17J1KON%BV
MO=S3L%UU3=_P1G?WD*T.<$KT?F_L)=%W$6S8SV X:U3\>KB22\!@JT]N&D)T
M^UAP;]>45?3I(UC1EE%V9=4^Y>;9JT%@7E$;!^]8GR+B:<\#>+CQC<TIM_P]
M9LVHU;A7'],.IYON#C)QBV-O[8J?R^PN6OS7A>L)[NO)NP[3Y94F5E <9A7_
M8S"%:(CJ9+ZN_:Z6!ZUKD*D[XY"HU-&%$C[(?'J^-V]UR\IR1>Y)Q-'9GXH9
M]2,[#B7+L(QY\YK@RX)_Q1FYD1WS\<2VT@DXWUV>M!M.V]L$!+IE[?IX<]\T
M<:NZ@J7*0Q0$A=%YLD9E.@C2G6S3J#O>]?>UY]_^"ZOL@\URJB*M[+\S BBJ
M,AR/!>=!^"B1]'X<CO?@BEV>W*,'HMN[?TICX(&I%#JX@W=BV>0(/ (/J1H[
MR>!M(_[UN9/>M_HY]H$?0_(R?^JF;./=&!XX4E<+T[7ZEQO7)P84;!UP)B7V
MBQ?"\?C+[O>5XAI74%;6SZW8SB2M;8&N]LL*L^,CY]?T(V]T[W5S/[6;W,UN
M4_@ARH!W80I"(0P<P 3_PFB) UA=I/OV3/?]Z#'  <1NC^S8O;.H")M_,_5J
M/X(Z((,28D-05_G(CG-O7MC4O$F4$:NTQ,GQ:?YF/450+$=3>D7K$#ZNKOK>
M_RCXL&2;'2^KW6AM-4PG_[9_'R'>1'? G<7\FI4T];.[, -_^?&?LCP.>'1B
M^M@<-ZFW(U";]."IP=OC$QIC/-.8V*/S*M9,M+@D$R?=NCE"6%R9-R,E0JYR
MC=6Z,U?Q]LT>FWV*#ZMO@YA371(?_LN\_UAWE3ASI)3X(^!DJ5F;SL%[?O3Y
M""'8Y+?J%U::Q=.IB&U,3Q&*G-GA 4O\4>F=&IW=_"%TV[\L]XPUZG-%:1[>
MC9=$B=-_#D/Q9&&+&Z0\(GAQ7^XO5U9\X\$>F@O#FZ"9N_U7F,[>C0]+&1=_
M("NMF?6O:*/FT@!)CD\[.\Y&=-2[S",;4R:-5FD='L>G1:5?%!(BT 3>Z6W&
M>:9=BR7"&HCX)0541*76,[_AP:DET0$X!>&[XT;%G]$D]5>QCZR?B_ ..T?[
M"ND;$E4$6Q4_TTS5MR[91?C3W.IB@!>)7_MOD8]R;YD2(7^>QVFO$/=:ZKEM
M:H>IK<[U7AW!:S%%*V4#W(K=3(SO!CGH3'6CWZ@HWZ/1EEXCO+(P+MQ&T24L
M2[)M:$T+B4LROX2]'E^TH2<COG7YV97Y7DW&VQ\\8S5=*%G<G13'CU+/]V^"
M7;7$&I&SX!IM^O(>VIT*_U%Y<KK.B"6JHCH>$D8H_44+_BUPV/<>9/HSZ$R=
MPML+ =371MM2MF7Z2]VMK6MA4NT$4=HVTT[L4=_?E_O\ZOHKA/_)0>]=28%K
M)L_]WLQ'YJ@F&UQ<F0)9&P=FL$[R5@UJKQ@'' V^').AZ$I?;[*E&:D5Y?HU
M=KF$TO2)(4^&*')5A(FU,>/VV)B/A](FO]"."8R6E"75L4'@8Z[(CPQ22>[#
M_@X02:,;BF_EM&<3\V!I\1,;)RRZFSY&R0E%_2IC_>P!UXU9MTA2C3:2S)4?
MA=@KML+U3="=%XGE!L]Y'+P5S1[6IJG6ZR Z*D0!- _N/3O_&MAO]\.@RTO(
M#@<H9L]+2%[& :BML3SC@]C@8IUM82FSCI-2J;4'X0-R7)MU9,R?_4FW2-N@
M5 '=TS@ 3#OH&/]NH;/)3NU+P<E'6C\)\Z$5W-S;G?FB2)M;L@\+,3*X7FC2
M-N@1O:.^I(0#T/EV*2W[4'>>!0?HV=F?S</L>!XUALTX1*?$-$"*8U=NA/.2
M/6]KO>>HLNY=;^/C]A6=*8]Z):)N70^+@E*4=B8Z_3#Y$%_R)*NC<TT1ON7Y
M;=6--EVD$THZN^DY5< 75J5S-$^U7"JDU#-A<O.G2N[5,+?YD#2ZUYHA'.^/
MH0D@4W; _+SO(.@FAG5Y_]:BNZ4&*O%;05OILV+@W"W.F&*!Q"6%T>*'WMYY
M-9=BKBB=DV D1DH;F5&+;2FE%>[1'2?&MUR4R#BF1WFQDRQW:;4R/7==Q8FH
MY(W<LQ&.+\]V?/B609'&E-Y>Q1 +M%5/!B.*KF"MJL5LS"7<ZUOU=8MJN=4E
M<W-$;5$]J&<_B.VN+6RLF0.MI&XK#N:SUQHV@'UN<V"8YQRNEH'1?!AP)_H&
MC?.]C 9U:+,1HV?.G_^"JX0OG?O(]6N,-W*?2(KWEH\?]9N;GZMWV=TR'5.B
M%OS$4:N#K",N=5JL@'2$--_$**/=EN:?;[>!J 0I0]BNUS>*:!G15_NOC%'X
M);,Y,:2LD 70@*P!U8_57&,T9PS"U7<S;V \T58("IM9A1'?N^ZJ^I-E2J0\
M@KOV4RL>"F\Z>:S74J^1B;)>$JK,]I9'9H9ZRWRS9I(/$S34-AQ7(M_E[7D=
M9)OZIK3\4SDWW2N1/K=+ 5W>+LC,Y8(@;T.4/H*]*YH4K2Z/O(CV7VE"UGPJ
M=384YI:U_?G6 69$&ZGME13?+R=AQ^G"R$+9.GP=;=M^Z-N=LA'$4\+3J%K&
MJBFD7\S#<_;)2"9YL(-/8,<W]0=<;C3B+;U);SW[5ZE;Z,CE%C:C[9-FMLFE
MR?P1AZCD;SZ9C@J\S[FK]%&P9)F/KO$!":)OGVUR]_N28^Y  L5P@,ZG=P)>
M58P*#9HRSW/U**D"@79C?0MS<F:D15^L]:_5,2ML?#_FRGE@^XNP;:NL3*\7
MUVXA;SJU\UXCLV&/NW*[%RH*E2X?_FEWZK,/=/I]K=OVVV)PO%OX@S+Q#@AC
M,SNZOS/)B'5$PFFYR:F3+EO&,7>SOJFI:^(. _=^*$O%KNFEWJ4TIF60;>B>
MO133K[/+"\H%X(S[*-[XY0N]/3+O B7RU-PHYQND#RW45_>(;VTX#G'GH8("
MD(A7=6BGY4%MY:J*C%GU"+2JZOC7. X[1P>BV@.M.4HNSD!#?=%P6V)[ED>]
M.^*&?)UPN3JO;S.;]:5166YY T#H[JX]E2[P'A>+/->W>\RVW';O6&YZ36GE
MH63:ZD4"]R24"MUKGI<CUQIW;87+G;[)L.:J\^3?C\RW)&51N$;[X(Z?4:-V
MSR*)MT$+V5$YJN]WF'4+E26*8J&@-LX/D;&UKQ 3HS![(GH_V/6IP+.Z)2NG
MY9Z.>;G#Y>@V5KX.L:%XRJ[AJ[_*W;L-J3NKXW^8N H)UBKV]WX5?.,Q*#6C
M[B4G/<_,$W";71>MU)W!ACH)9RM?CG1[A6*+Y1:0+P2+Q,[K-SSJN,3Y3B/&
MG4-",W:% @A;'^G.LW3)JZ8OS?^]>1)K;_#U<T_Z+/DCPY_=THR]4"XT41FX
M^2%*I--';J/-80D2HG66WIR\DOIP'SMCY\CC^@-8VBE01O7LY/26][KH6JM&
MK'QBPHJ4**HF3'NEH&L>TB82,X/...Q<H$7;91LO/*MY/?O;PH$O7':>V&U\
MC]GO-]D5G6N <Y5"8W2 TA@4".1SX582;RCGT&]S%,N-)YUV#J1)^ZZYBOBZ
M.MTOUM.% X2PW\#(HC@Z;KFGJ-(MR!>YVW:<T7TK_3DKERB6F+_S8*%ZM).-
MP31NP4(FZ2G<7+Q"%!J>$AR!9<3HHO)SO;T\$'9*;9DWUI.>-TR6[&37E4\>
M>Q7NVDUVWI0E*ML6LM"*]N5\V_6Y#""U,'J<#NK44\[XEF>L;^-IL<KM:.=E
M)3!X'?6]KUXLKB3WIC0),5.=L3"X/KK+.#P6O7[:[OM4]88!6E7#CD3Q>TKW
MS*Y0>+%&Q%Q_8<.S@Y(/?7J/@8WY+ZXTF[;R$:%R3OQ171%&'*A@_V-CFL5?
M<+D:AVS=_-2\S<=H5Z6NABBXOFVR@X[QO'TR7#AE\(U0K\:][-A>DI^>B0WY
MO[:?&&_157-3-";%P0:V&:)(4>LO9SA(ZQC-6GM_?-N!VAUSB_+N/@C;&EL1
M2F1<?K]Y]W%?Q?<E?]+;4770<&^/8O<D.70":KP'RX;R+::K$ *2+'<'V)]4
M R\;J)SL?EZTU_TDL/7A\94HA7C(E\MVBZB"KF%V&^-KV+O>YJ.-)E*!^>Y6
M:HT5(Y@[5S/!P+)"'@>VF2G4:N@&F#=//O(%E6RY'L]5GZZ/4O79S4_1R2BE
ME;0SRIYH!NMFOLR.,U  C+1JF&*33L\N=]C+-[&Z7:$@T3JMD=()E/2)]#=%
MZ#. %K1[/\Q($HG''.:FYY3T1K\R*7;?3+]B.OVT*[BK-_QRLK']?K1N=3+%
M2#@?Z6!C[,X;$5H>%H"/F:R0"/'KU2=F<3F S#RQ_UF66D 0!Z#_)583(F1W
MM4=_'.HR>/N%"ZO PMY3WG>?BILY!)_M17MB^FLI.F)3]-GIK#WS6XJLM?2&
M,MU*-Y6H;9C>T2N<"IMJ F\E/G:38Y7FKKWN%YN"CEY*BE;UQ][VED&G7V3
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MVN6GBO?4[]9S$S.'95SJ!; &TOYPCUXY]9-@]3J1A'0WLX[L2XTD9EI-P'2
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M).<JYO4()1$EJ;R?V^=M)UZ7V+SMT/$$+PE1[T]N'/Z*2L5+0MEZUB446_A
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MY?C%@VA*Y#)<DV=4B:?L2 A&SM.]?69Q+_E@75R_S\"#'</9"@4BYA2OXRX
MNL,>ZLM+)%OQY',0\4G[]$#M3:0V#+UB39'DF-RH9](;?$: 6\+<:KL L(HL
M/&#1OP#H#5>HLVZA$RUJ$'-+I<8S*DKT'1R3 "',1[(/[[PA,=5GH:?7.%NE
MN9NUQ[82K<9$KQ7HXZ*[7@EN"6[>6-V5&:M*,.:ACYW[+)!N@TXQZL@+GDVY
M@T&UP&]YO#WAQK4.(<F^5.!$X/ZS:]G2ZWZBA<YJOFGS2@EBE?':YYJ)E(5[
MMCPN*DO"'@5@C,OAXR#X>R"#/*'_'BR_JY)RJS+QNE$/2T-!&'' R\JS%5_[
M4)6PDST'#OKDD7PRN/'T5HO@*1&6LW5EW.D"L'T!H#1D0IL:11^P3Q3OO.CA
M'N 98N(6II_0Z.D>PE).H ^=2Z9G6J!WT?[4NB-R!'<) :AIK=4=M=SI_4)9
MA$1\QR(QEGVBXP^5U3';]) U:^&GJ(2@RH<G7R.?]MYX[7^#?*7S)3I89_1W
M6DXG0I%:BUSGQW2=JB6!^*+5>&H1=^#8!Z!FK>Y7CP:]AILNP6FB=]/OI@.T
M14FWA=S*^F6MAH 0KYL8D@(C.M@]K'*@$X2?=$/'1?-OE+Z&BU#78?S+\ =/
M]S[(PGX8'6BIXP@<$)[@IQ/EP$!6 <;,S%Z97(ZF0D.;RN,&?.)HR#2KRE55
MY2PKU&/'[ 4&T#A;"(][&. LR3HB"%73*K.=?AJW.1+^S-JBO<\((>H&Z;U+
M>-NB<VW<G-[D:VE*1;_>Z3VL1J"49C;.MZM18,Q#WCT-%&VE+2GSY=C3+Q;5
M.9(T\R!N#;&6K+E _C<XN%1UC_9=7]2L*S\>9:PC.**K\1&6+LBIK^\"< ,V
M>F)8-WQS?(!''S9:M#C?<9MS50^-$OY"P/#9]-1@94,<3NYD/%.U? $(<A)&
M:5#^UB\OVVKDJ\ 4_11Q0U364<[/\KPH96_QIXT&615FZ(D]NJDCU^W)U'X!
M*)727]HN0UP OC@;/8Q1G_BD1K]<@=4LV3>T)1:2=W18<?5-,$U95=E_O!^N
M5S*DGG=*,B%B3/&[\0'.':D&)-H\E&1F9:H.T!X%O_Y56^*3L$Q(7>TSJK*H
M*E;;%ZJ"B&U\_8/B?) ND:,D"^?[&A/03J+0Z442C0'K;]2.QXLS^@>XD',[
M0:6F7MJ6JH:UBP.D7!^SL]!(H;J K!7\USS,</E(^L(*?JJ-118-8IBR.J8B
M;".,[X![*\LU@>8"X+0>N%-H_U*(_*'Y(&2ND?94(*:9"I;T=KS"#KU+#4M_
M9:BA,\Y60?M+),B.IMZAY;:%8'N4/*.?9=1QG#-'=9+Q3$S?E&RYK<=SVT2[
M0"'8#I:QW0(%S0?/SGPV>Z)-7HENNN40L%.T[7WWH]>X3@I#-78M%7D!N)65
M6@2SM[X^]'+X0 --.,$^OAK-],3,TI\\)L'T;M_^@P#M_;LK$5*X(.Q^5R,U
M+A/N@ *2% =\6KH!H]+&JB\F_8#Y@_-YS5>L3,J^#$(1YE\E#?G&*.[JL>B5
M^6R<\YXE@#OH6,7&I]K1ED@62'NB9= G?#3\XLY*XOTBM@$EZC1PQ>[Z*]DE
MW*$B%XNJ1FZFEF;5H$BT.FJ;0KSN*>=M-K)+DC1,37\R+@6#=3>FBAW9,VN9
M@E@H4>Z$EE&]9<(>S5\ M'"$*RQ">504)D6#V=GO9.3_3$M$\E&U8F9M/,4I
M6(*SJD3'7T_TSL^P3A1/%)UCN; 8NMQ+Q&LZTH,)*WI0>)Z*^/9GCL#6K&)"
MRI DI<F3.OSG:LEHNY!([X_(-+W[UHSB@)NSZ$EKX(U3,$*6"N:-@R!O2/+[
MB2XXG<J[FI]]B6?\[JA"/D M_O&YB6XRJH<,RN;#YF?O+&1_'+\-+UZP=AOR
M1\O<F[$^)YF0>B=EZ@(!!HC;B)<Q_=Y97-S!S".M!IM]OJC>HV@E*F5C\[;P
M>(I;0&F0GJKBAG*,K)VKSF]@LN*SK<02G5(#+<I24%H-YD[WNJ"U$F9TVE$[
ME%2WWUH=,8#MM) :LV!-3)$O,H+\-RN)H2,B_C,[A,38N&$JY<E?];+M!H@*
M(X/,^#W YWT-*A5L=_ICTBE\+FYG5U%,WN.*K',M-P1W,<+#$@=$HN-OHI\]
MT^\33]%6.9K3CWT@^NC!.X7=WHG:LS@GID)A;8P>-D,5D_1VTE8T9(B,+RI9
MR40*[2B=T"A,?2(\N//\++5_;[IK#4X#T,2;'1J:CS-I?+1HU7@]0A^SWI;*
MH:ZE6S_9V!G_:-+!4)6E]#;(,IGV+1/3>^:(Q>O.DQ'M_+.^FICB3AJ<9SI.
M1[UQ(DF]:AR*KD##3UBW=/89VEJR0'&[)/TYY+8ZB< $[^YKWVULX&66A]EM
M3?0X?6,*8EQ^1T"[RU'JS-:^G-W/U.TD<;RXI#?'G9M(RT";VM[(W#L?<%MO
M5QN /!^O=V+9]3Z OE_2A_)KC>KOOA[+"NWLX.'77^8M-T]?IF>)Z8^!D#3G
MW*I/IU5D?TXI]+8D"MTA&<P%2/L_'I =KI;;VETW_>5DGP/PKKL<T:E6[27N
M88<U#J[7R '>E'*I<O-L0/<E<1.I<R *BD"?.9YH.=YWYB)$RDM(BS=9+K@C
M.<.*S@5Q6=P)2<;5$[PB<RQ,[55E),+*3CX<L.C;>P0M-/,.O52L'H>E7@<T
M;<I-".,9VKFV0UD2GB(I%2<F.Z+I!?W-O,DGI%6@J<FJ<Q,9:P$?)QOF[%V"
M@O ORVMU%P#_U+O\,LPP,N,1Y)3?6D.!C5M6L5C%H;2W@9&!VB/QF#76!SIA
M@*7N0,_Y9<!'>,E@(=*.ZA28VM[(@R5N9!\_:'#4J@W&I@NT\[Y>1:/;!6Q-
M;EAP4;2;)-WL84_XEBJ%R\02-<_&H_4*82Y=%P"J#(Q&@ CP[K24&!#S70/1
M7M-44U-M"9^?;QVC]J</ /GM*\GUQFPO,IXE>U"98%Q:X*2GR@@T4^>LAK_(
M">2Q;)5(M2W%:C %PW?E>^;*=M^^?UI4LEEJ _I6-A&?OD6%&4UNTOFVZVA#
M(=FS,X7EDM#"BN_:PW-*U)%O/2K?R;T27^9GN,=*L0P/8RSVMML1V;V]<;S4
M'D&"#Q:4"L84HC]?*A+)D3AFN,B^VAVG5_ :!J:D_*OC'-*OR5B"7,)Q\84M
MSQ53L)\:W25"2'3$!_)< !"/@Z55=TR[9M/'>%:J=.HIS'*$DDQ!@9OYW@R-
M 9/GS,F.R"Z_>G.9S! [LHU:OPQ&XZC((SIUN_.H-=OE#/MN'^?O?]M73&\%
M8H::E^AP0)V)#QZB6%H68 MC>)U#L4Q*[5WU/+DC2M?]%IJ5Z'(CK<%1\2&;
M'4JE5\M^3H ]8+ QLR@9T2D,&Q'BH<$?A1G#>W+67!LD"U:ZT[-3P;UF^:7'
MEBWX3H(O.%W9@3_VKGBBGJ_ RQBUL]I/SB/U<-X5&9J) WXBW'MCJL[&.U@;
M2)RXBE^D?D-S5=#/[SVK16-4?.S:Q-/F+-F!LA::1=9>(DY8J<I%T)24'A1Y
MPF*Z_5X^>T$_LU1?:3B^?21M-NU7;QSQ-)>]XBZY!QTV(N*4$YX!ZT/2-&;P
M5TB+;8*A_/)JW+?14-NT%!6VL*PXZ%A@[Y.>)SG$8IT""H#W\QY>.#^RD'IN
MA#RFML5##0EF&M!>[#2F(A>9>RPS*#4@/SGRY871LI(V4(J0X*8/N^L9P>&W
M<7[1@0=C;8TWJR<KEA@@M>C8^H^P.,O2,)&TRE+#@+@']RJ%\G)U38?Z#4#1
M@EIH\E.)3[BV'-R>^HL78U8"5LYN[F LI-(U*]'PY-Q.I!Y01"@S*"&!"L))
MGXCQMS: 6R6_G#^ .J/:SNF2Y$C8(P.''!P^58F[?-F%9NF$R;H,S@._K7D+
MB0!G(UYC7T:E;\PJ^Q;:GC^PT1\L3B_R=XHSE!$=L]4GJNML.)& EWUFN]LZ
M7R?570>8[YLY)<4UY'GH&]-GY2.4,853_DZ5PQ9AQ8JC\P;*-X3402\HA$DW
MG-/)&;Y>[V,RI^N04L3LK"\3G8J<=XZ+3F+%0K*W*'J0:AK7%G !ZDW@OF\[
M?#]21CM-I*BDS@U&:NR_J;XIH_+9 I;:>1]<  "G-&,_L:8+JL@&_<,3\ 0C
MKM-6:BL_EX.(/^[&>\4PE-+MZX1:Y=>" 8>/_JT:%7FD)%:SHO_A4:;B\:]<
M!@5BUE@C=9E%XP96^++RJ76^$_O2#[%,JR:W38J#2'B8TNQD2H,=6GG2_ +
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M>Q]:O9[U^*K(MOK=174Y(P:^+W6^4'#N#5?@MNU<Q =-]Y_@I06B(%"M*H"
MPE"5$7O>^PN8"; :>2/*2[OT)HK5FN]53O,>GUF@UWU=BQ T*\E3+M/8'9KW
M]%HD_5$Q!X_:I)_\4PHDXN9 J'8$>W>PT-U2@^[B9K;X6PY;\Z-P4_FSI$.6
M(]:7CG5H2M=DQZ/]NH/#?]I9L!*!&: 4.XP/A6LRJJ.^FYD&<-IO3(^8I+=D
M=3UZ=D1:ZKDKB52]?4S[7MEH_)^V%F!//F686<W'MAL:CJ!T#'$7=9P;2478
M2'6X6I9C:APX%V0$G[%@^W,Y9PD1)JL# ABH=M^%=M8V0W#E E!29RM=\FR6
MI*+S!S^CVD^^56B^TX.NJ% /GTI4.#Z-N*RR?D8XIUE-I<8^^ACPGBF7S4@Z
MUGO@R>N1'Q,,C);53[U]5@QZZ(P-"X1Q5_->B[AY4"_0Q]Y:8/RIPP'T =;%
MKL*)38.RWBG';<_LW%#]S& +TGM\8#\7@;2Z?D"C^ E&]Q+">T1(>\[F>#^F
MR.L<O51(6RM%Z^P(!L7S,M?,F]5$S9N9^G.R840NBWYG_\98AW %[3"K>B]Z
MMD?_&5+O=YBJ$'\YC/Y3HZ]B5NML/OOLZ/5S68[WPG*,U-I.17YVEC#;].C?
MW:I/S&JCQE(/U2B.-<_\[,Y^'@X);0TLU-G-9NSMGZ^AJP\[+O=R3TF25$S\
MKL53X95\N\OK!PYCJR018XFB+*1+;Q+,$]4RS U_R..YP,"9]HMAO? J-E@8
M2;3Z]E,04K_D]OA (1)=AAF6V6[@0E:B/A7HBKN?RB^:].HHYF73..([I^J7
M =X8<2/1;8:N>D\GG2CH!CX,CFQEDRE^8Q2S&[ZY^Q)]CX,$$:?ZQE1[7?8%
M2;=,;S&%B% TM"GSN>#Q<V:@1R0$ 7W2U4>61V<5B./YFP!X/JB-C3D\/OVG
MH,1OL5FS3ET\'-Q55(:JCU!L98(,J$+:8Y**0FR=*E]H1LGLT6LAQ^^G?I5'
M?Y"7#WIM&)KTZL0RX1/[/)-5;:1RZI$XM*N2JWZXL-BVHS_:D,>76=GI 2=P
MVY_@*IQD-8?1!ZJTJADU2IKEKG1"SV3)"X1?CHO 1$%!%NY^%&=C).U1,6.Y
MV@P;5WTC;$5@? 7O*USYGCF80MC[ ]<)F'])R ;]^(UA$='=K=Z3']PM5UUS
M&EI:N"+$^%OZ3S#>;;-RG6I!U>]E\]V#PK]7J\B:1TS36[+;>#15[?OX%_>+
M0)'A@BWO5:YFK: ^ OU3Y>RO%L\GX'&2P [TMGB<-?U;^]BS)^4A7T(W&^6"
MZH/]\S[!?PKD_)AKN]*'7MW&R=K(KIA++% IWY!!(DS6%==@9K64_F05MAD4
M*Z8X F@7B^  @"\3<<:O9PY54"]KY#Y2[[_#(9/DDQ_9QE+^D%JP0/->:QK7
MW5L_KN<:6XG-^G6GJ/)%-1.0+_RC(M1H-<6J"9!RHMK71P)2(0D/@(':#-DN
M$/+<5J&/:MI7+3@P-N1MU,7V^71WWU='BTF91F=0X49D(FYVA#J''UWGPOJ#
M@VAP5]2QIL7'4!CKM:PDH!"J1[;C,$AJL.;D[\+4TFS(/SJBB=<1QTL=N20/
M;]18R26D+++*ONKA;X)V6,Q.%IWZHRFF?EH\WII-RK:*.S8(Q?1\6O4?Y:R)
MUOPKS/R*T(\FV?+'G.Y"4N!*K34I+&Y3^1\M^?F)^].XS/25CLP=YA*[REYI
MYZO+(A$./\'SQD25T1OF-\$VABJY5U)R^&<M3$&^<GR-<H!]5,"PVG]3)9X!
M+R-#TI?52=)S\?,.8TC8(<^Z(D]QT23#J57]R')CI?\=5L1K'JC5CIF2E&F<
M]HWS2P7XR1%V8]9-KVS>5>4CG@N47GRDJ*G)6!$8V]ALMW2+7PW/%"6#Y'K
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MG1> ]DI]OGR9U,.!IX>6\4(#3 4YKV;4.7[/BC\YC-];U)TGV#J#=]:*^QW
MR:S=8F<^X[]!%V&2U?RKYWZ*^6?5&:^W]^6"&>C+3+R,:NXQS6:5$(9_:,<N
MJ![6^55$;%<Z&D"=;WP^UZ^*^\[<C9/O5.DN#O:BM6;LZD3K+).F(B,H(0(L
M9,UTK#SCMH4'=QXT?3,NM]?+J)+[F[-D"8X<32_(R/<X+<GS(L.-%%MYW<:Y
M%QK 8K3JQS[!B6!574<DKG ';HWLC"S>1T0!SKP.)W61;_IJ0N0*^XB';\TV
MDF"S(K $;5B(&\E,X^AJ(HS2D3C*%F8!,VNMS7\G97NMDQX@?^\SI -[ZVG,
MFU]C9G5Q8YKC?#L%!=N[4([*1*2:?:=%&$B1E_RNRC<")L*G!2Y%7M(X+3NR
M[5T(1DF:OU._LC9L.4RYG97WL^=[2,BML?2R\#>U:A\[F=[QZ8NHLBE:$SPW
MZ)Z;K6D06P>/0M&-]VV.](\"3ZTQ2\N;L#@K\\GB>M\\&TH-^US04[MOCV8E
M2\G?1OYXYU%]Z.WU9<3X@8U^F0<5MKA-6FFH:W8W^(!$[?F$Z!(]W 929CAK
ML.$PW="VQ)XO\7GDYG"5RD"]0X[>78#.XP/^&>-FMT%?3/%E[:R0>H7BK7.1
MB3^!?**<$TZ0H!]^J]=-B9VWSU^[FA_:$:V1-PDS @X3_[4>?5B8W/2P)2]&
MT6-I<TWQ..*\0B3(=H&H7)MGLG8.GE_OY_4#CA5]"2:C%I\?+]393+\ !.:O
M["L)%4Q-PZ?Z-W**) V%.RUW; Y--WTO &$3JB)P8&I-D2Y9'MFYZ-OMJ7VV
M%-T:Y7-#U=/XO\FK-.M"5JF4&O-8PN\R)<47 (:\42L@]= \EB_NZC-]WB'W
MWRG4N;)4V9VN<Y--V:_POVQCFTQ]W9].](J*S'6A"*5H56;$6[D>T/$U(SW.
M !F^U!ID,LCSO?&YX&6S%E(/[8B6VO+$[,!/)V>\]WD=H!!R2LGK=SKO&R5K
ML'E#5!#C&?&2I_!N1+NE*-=HLJ)?;IJ=U9SBU.+T(-88[2#:^!/D1AI&7&DU
M3;4D;!OI\D2'"2YLY(-Q04TF8U^J?OH+;2H]J-;J%^LXRL@A)6*SAPT]4F;8
M'901K/L-*3Y+1>^LXP80918%^A*&*^]JB(!Q+?L;+6Q8FEWMYE=OS) %H_.G
M[CS(TUF]3*ZWJ5*<['1,?$6SUI[2GAKUO]."_VH=,___4</HD7]A)D<NX:AS
M=Y/#F>SQA%>P^V798OLJ1I:#.G+H3%>!J?W9(_[MN:&_?U+/SZIP.G!%XW)+
M_@G4_+)LF9WL^BC\Y' )H7P(7?]?^_/+_S]#W>T_VOL7S=^2]&O3NP+YF]OG
M?WYI__=W/NA2D\__:M7_,^S/_2=Z_Z+[EL2OJ?A,Z,\X_.KTS@/U:??JSX-F
M.]_N!UUE@N0(N8OM5Z<7-_P[N^<_PWS0W.WM^E8D^];]Z[)=S+]:[SGCW]F5
M_QGL0/.NV\"7D\!MC/TK4NTF'Q9[CAG);2+(-N[^I?&MQV[-[CGL2([30+&R
M_$O@6XG:R'(+?H3K G;%/I;ACMPO<0+N"LM%/W(73DS?Q2#Z-/GU^97K^KJT
MS6[?>=DB(CJ1]>W4?4O3;9?>$8R-BG&[Z,MR0E;%32(UU4; 4:'YNNG9"NN'
M^HW_9&]FB=6)?$AO_V.<N2(A+OK%KQBQB7<>"-@<[66H84L\5Z%^;=<I3;&$
M+#F&#_O6/GCR8>KWMB_=][E4!*/6M18FBTQ3DOCV,["#Z\V-V<)9CYDSCAEH
MZ4O5F'YH/])K=MOO8WYKB;](YK=+G NV7-OR(E^I\]!4GI5*&X*;W!S.<8I>
M"G20_,7>_F4_UXMKL]PZE]U\\<MW%L?:-24_A#@4'2\&F3"&5#.&//Q@WO9V
M>5-&C?U25Q/Q3Z\V>DP+9.O[%%HZ[:E'G&KI)(=+_#.;-Z@\N?94A+&]\D$^
M[RNILNW+[U;4>^_<<%W%Z-6VS9%N'[/XDCU.^RTMU-24R9S._M15EF'-7?&'
M_(TVYLN/)R[YH7YX5VQ/T>USTZY%A0@<V>2H.(V=:P5#QA/5"U_#5'KDLM<M
M:K#,7M]:Q[7OXQ8YPQT?ZIKMNQ<P)EU_>EDA^\>!H ;=@_$&-4O6\UZ8&++\
MA_R'9Z^/3*]3G'U 3GQV_)Z)JCNOIEQ<.^M5NJ>02_J49<^T/KH]F'S8;4G1
MHMU9&LPSVQ_V-Z_]>OILGC[GB\+7YM,#[L>\TEQV2$]]1V=LTLPGMW<N<9WD
M&J:N)=N@K 9L?7!M/UC_84[](6#3A*,-6$9R]MW=_V'"?X8TY[\+^_5/'[]E
M]G/&IW_^>[]7O(P%-C0[[G%\>)QY?OE<9F\S_MJ_*ZXM.V6ON=[F/\.6V@7K
M[DC6O+_W<WYU_=DYGT-,^5OM.*_N2<U]]/H^>X;X/)VMMQ2NKS/9(?=+=T'K
M34O?UPU^!A4GUZW"G_%/^W-G;/PQS5]0;6+"/H5)5W/BPZ)3Q'/S)':TG.X]
M9G!D0\QC=8NS(5> _?+HJ.W7UG[EY\T4_Y"=+[-K3;B9H,?V]U*+CEUN"U+5
MVGALP;X"08<7VG5=#,^W^K?7B5XWY7S_59_GQ:_6KX>C;:Z'APEZZ_3F/7U[
MVEA3Y<B;,S-_MW;&"$=5;6M=]OKB;;7ERZ->:687RC[A+F<ZI33/[*[,RAVR
MZ]8PALDTGS"MZF)8_+=UV=R";'7_K?]NB#T[DR7G]'>!0X1E]YEC;V<WY.X\
MYE88D]ZY/[V^-<[TNM[6]0)_C#Z4[5US5]1<JF_Y@JB8.SZA3BLKY8S.MH8R
MJR]@WEK%*\(X>]6/=(_K)9Q?=+V]-EXQ\>ZH.VLVNS1OTFU/,<.G6W*XIAZ7
M]CBJ,D_BXK+Y(;-\U8X^NYH48<HI=9,[SFW5J96&Q]^+:!LP;F)(LIYU>5&#
MX5L;^04W?$VVW9*;G:MSK3#STAZSB:L]L\7^,VBQ*11+54[*=?[4^[;!*&O!
MC_R'BDG;G _=TM@<:V>KF/N?8?/#3T>GI!O>:KW=K^KO\>_%&^W%P!0<:_[0
MOLFD.E[@UHT*Z\/?S.XI?;;?MG#;I0>]IK8/F_\N=6(T>_".[\_SZO25JR_^
M$#]<\&.1O=#R]BU+/LJ4)?OY)N8L$L_,DBYH\-U>T6_SYMR=SUUW%C58G.?_
M(_ZC^J&M=O1E$WNFBG2WRZ4G>JS6SIN_^/9!OH6284&3%RD(K;M>V,Z2>*/<
M](:KD*.0JY!.X0*N%8L9'1XP6'/58NTB@7%P;)AK:BK/&H/0-D>Y*:\TF _7
MA/[6R)"ZME#UW,R5,1D73]R>=3=9V&W?[B)'^4Z+O]K;?R1_R'?\$<VS=OF:
MZ5$MI[=EO^Z1E"R>NX!/M/A&G<KU<M=2;^&H@B=3MMCPV#E/2RR4CU[LJ/G]
M[8MM\2I-71KK@N_CNC.2%MC^_TT 4$L#!!0    ( **+25AM!2&;=BL! &.?
M 0 4    ;F)I>"TR,#(S,3(S,5]G-RYJ<&?L? =8D]V6[@<(2!%$*2(E2A$4
M 9%>8Z.+B#2I40$1$!"1'A($ >D*4A6"%.E$>I4@59KT7D.1#@DUD';SG[EW
M[OG/G'O.G)EY[LR]\V^>]3V0_7Z;W=9:[\I>WT<>(\\!IW4TM#4 *FHJX!'E
M!R!O 2PW;5V?V %V *50D2>!VP UU6_EMROU;^4$S6]7VA,G:$[0T=+1_4GH
M&4Y2A)Z.[B3320;&WPKE-V8F1N;?_OBMD7^ZE9J6AH:6D9Z.GO$?+N1&@.TD
M->Y$)PV5 $#-1D7#1D5N 4"4/M+^J7M4P/\L5-0T)VCIZ"G=8*( *DY3ND]#
M0^DT+:7'E%I_2CUP@HWVS$6IFW1G#1[3"[BQ7W_]_O-)P5LEWSD>]&.$I)^\
M#&1@Y.0ZQWU>^)*(Z.4K,K)R\@J*2K?OJ&MH:FGK&!H9FY@^-#.WL;5[:O_,
MP=']E8>GE[>/;]";X)#0MV'AL7$?XA,2DY)3,C*SLK_DY.;EEY:55U165=?4
M-C6WM+:U_^CH'!@<&AX9'1N?0,\O+"[]6EY97</N[.[M'QSBCHY_&Q<50$/U
MO\I?'1<;95S4OZT!_6_CHJ+V^@W =H+VHA3=F9L&](_=S@I<?WV2_=;[SR7?
M&02E'V XGKSL9^04DD$+8W\;VI]&]J\;6."_:63_/+#_/:X)@)F&BK)X-&P
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MSE1AGZ5&\\7^OG@[M?3Y^MUF1.7H1L0\&0B#8'((4G@-G :^)61NLCW;PLE
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MO\;8/*^,&A-]JM5_/?<DM=:0;6IFJXHX&: ]0PR&B7AOC2ZTMZ(FE)L3KJW
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M^3D=E=%[G3R:@!NKYN<UHK*\X7=#U?MD"IQXE&W'71WLJ5O9=8G#QH#H 77
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MZ7%&N%_<%=KZ O5OY?ML^>@1+V#RK5O"5">>([R]X>&KF(G$C)5Z,H#NG5*
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M30W'XP,>^9T66X*,'[9;"Q#?P^1F2!0OR2Z!_;QF>F/<&M7%[D)0?U$S)Q1
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M]D"<2P=;GA+5,[/BO('N*]*M*XWGN>-&-\7PH_W%]9,_U(+0S)U7ME[@9\F
M@/\^)(,UC-U!)PN;)'ONR^1!?$*$:4%ZXLS 5F\5ZMGV)/T!!$>3V>$(Y<EW
MA DD\(V<O^*(]E'E?\H(+2<PJ+Y>C$F!<1)8<?%X6^\UU@A$>13I\Q><OH^?
MJKP^OV7<G7MW/+LN"HCV<L<'23^R\9KA V_LXMG\(QY PL'E0K.3YS=;TGQ7
MO:X?];<LI^Z6]*:*5%T!3RR M +8:>\#- %B*=[=EPSH=4\<Y3]?\]P)/4(H
M1RY(G,4D,JF4!=J6*+Z)BWK>I&TN/W"_J75:_96';,-JQ\OJ+1Q8@_A1A0J]
M#F?$*:-#,G/&S(L%J@*)-PZ?N"78#)5TB.05@3>1@8@]X7403@J"*58+/SK2
M,8S[D#H)1DB=^Z0AS79E_]>RHMS29;E)5Y-)W\J9S:V_O86TP\;@SE!V,O!9
M\B$E3@ZGQ!F_P__3X?,?B/\""*@IWAZJ7$E$P&0<9BO &\1,*W.'ES-B3N;.
MW1]CQ1(4H!^^[]B?"%I9G(OJI!^*O]U".M^O8H=>[V7$17^7*'3=G.#)!64*
M,L/HJP7?W1#XQEP%NDHGDEK0NBH\37'<<Z!T;^=VXVJFMPE77AQ4FY>\*F%/
M*RG0\+TGKBJ14.(_G!:54X5)7-#<6,8&-<KQJV)F@_;AEW8D9V]XJ(L[7T//
MNRCE+4P]BCY9'/?G=D!L#A+*?W&4##Q&3= MHY&12*'$)J7%\'YK+34#;H7H
M%4]FU,L;RM0^3:/C;!V\_85]/XJCTPLN_[BP=V$D^0NU@E*GT?1J[T.4Q$Q!
MWO1\#'7?W-2O5&@E;%2BM7T"[;C=HT<,H02O'Z&E^E8?=0ZL$O]\CQL0*S"&
MI#??;"AT4HS$T=YO;7;TQY[_#T?<S',T.:^&4"O*G]%T=7)FTG5SDP[6ZM<P
M"U,%:&0&G,<Y3M[+&KI0/!,F/KD1A0B#GP,_G0WF9_J&[8V 2A:J.]CS>T9I
M>W4O;[4%U4G-L;;,43LM( +2Z.(.^G!X+^SR0DB89P/3X%;XQ+/*0:RH8=)&
M_V2AT[L!M>LM[X"K.@O>F698KTTLM@W,X.UHMD'@^MSQ;5DLH,2>SI.^L/31
M&\-#31?>T=&T,Y@OK^=<3XWC=)N.7YH_?'A#H#)0+3RS1K5#42A-6RA-SU\H
MY<>+3Q'$^8Q1_'M_,,5GL?8>WV83]3[;A&320VX2/,#^19A7PD@!?[$A\ZIZ
MDY%R2SQN'Q)XNNUK\YR_&1L[K?$0.T!_@^[R[._GB&-7<]?=N:[LZU\Z1O#O
MB/"Q*-M_C37]3T/X]6YH^LQ-=JC<A?)E6HWG%R$F@J<;W]6HP;IMOEP;W_^Q
MAXPO^/_X?)\^#C:%V'&R%B4#59)$B2IDKPZ1B5@#7ARI-R #+I!C*U=(6ORQ
M/CW\1RE\ 7Y\5W\O8L6/#%SJY:)8V7CPWD]>L1'X8]21$H02C$UND]Y-F<:9
M%I*:X3NO&BB0JEGBQ6JDEPP9>&\'Q^B2 6W[K33*/^LH^TD&-EC/DH$O3V'!
M_>H<N Z2S%\]9_Q7"K\K7I]P8K!!#:J8J!XE&/.P9%HMS)/P/)&WK1T?#=#W
M;;IXCJ:0FL'\^SRYOXAI:D+U"<<S;ZU5KUJ]V%'GOK@Y"6[G9Z$_I ,'(;(*
M?DE.ALYY(C/6Y,A >6]3OW!Q7G87;TKON&;/#EOI"LO2"PZBZ0D,CQK)U#Q-
M(JBKH.ZR$SVAE R($%U@^^@0]P2LBZYA<_=Q1M25G>7OPXF$ZI:]&*)?$:8#
M+MUO;=FU.B$62/Q$4E@%\3?P3N+R1[M"[P>==N+4@0_=HQ=BJ>/9OKRG\/-F
M\4&]^9XC>ETG7MU!Y"E,.G5Q/)'EU_!.=]/''//(3W9<_<@>U4%SF4'S:QGA
M8H)=?S^I1_(@#]<[[QJ3!@XZ>(*[U/:+KHYM;?0%JL/MRJ?2!+Z+,;1)AV+M
MC/*>H$K$IJ377,%-C WZTX[NO+.5B7*>^/4!LU81QHAHZ.IU@.8=B[>PWBMX
MJ<A&OP-&I D\<4Q@ZYAW-KG@P1W"LU&RS[GB3T_[%M^SQN&T\D(F;\G;+J88
M*4)0:$ >(6)7R0!S[XHU?2=EUI@5''F]T@P-6XUKNU9T-[7AW7='2#]3!T-W
ME66=FC0?8^3GVD-@=-Z,D]_3^ V$$.NR/+_NJDXMGOKI3_](&:!7B1OK5_<V
M=AQ"&@_]*:\';5;LE&2?'&_9##(8*C*Y9Q@W755'!H3*==73#=0YDI?_[E;[
M[W.\'7@KL/L%_8-GR 2XX^R$9@OX=+TF94G&,:S=W^J^)4VLC5;J=1<13%:F
MJ5\CI(X?L7VBZ_6DH;*XAMQ 9YA7'NC6J4T&5)^57R!@'UUSOO7)5-6\="#U
MO-/\IYDPH4I34]]GQ2/VF]+8KA9(>4RD#3&%1'M#LM"NQGAH.W-)(DWN5.IL
M\PE;.DF"NH8"C5<V3NR EH@HUV<:7VV0Q#2OFW]R@W]QU,^=:O[UPT?Y@2*'
ML>8-J4]4L?JR?:3NV3*O4)3]-H,/35?=J.O[>T5YP6N^1P;+[\\C6F-$OO)_
MM Z1ECU@>_C\Q">']GS/E_X63A@(Y@R1-1)J2&II?H!.HVHQ:EK"/9TL8.A,
MM=0S*;HR^,'2KG/S6;.Z[4>=_DB5CZ1SK@?F9""#8L;CZ[9)JN8S=,1X-6JH
M'%8/20EVY\ ECIX6I!YW8I['I9Z5_JHNH<*<*]V*],@B7SZ.9?WKW8[J;<9?
M!OMS1)#S,/=P+$_+5<_SWL_ON86G*N9P:SP,+XW,%+;G%I%+<2@?-''Z[332
M#73NW_4N!+[AHHK]\@33A-6KTAH/'F;=[US38'SG&ZC0JJW.PW+]@VV*YS-<
M;TN*YS<\':D/ZYUX)\2'P(4L8:6.O1GJ:2T!7\JZLW7+-X\&+&TZ9LY?E>T=
MIUF!I0N&\PW';S#)%K5HB@E<^_$8=WZY088@C#EL0X6.-IS 4@>?E< KI]<X
M6033VQ;LB?SI^>.C[0-E7-4\*"@-7$],@(G75#W;-I-Q$(8G7.[H_<"PSIN^
M?7MM=A.[YX%".]%LCF+SD'[X?I*K\2CI'"GRIR#HO +'LE'\[J=*AB<"#5?O
MG5?2J+6RUW=,-1]&!8H,[QFH0]&$Q;\Y';_ %:#-LUD$ "-5]SH383W$D=E?
MF+3\:ULZ9NN2)KZ=ID8P'U>"U6PB _105I\%)*?E9N"X&S.C!C[YGN>=H+HS
M8(!!A08B!>N=92(8XBT()C7$SVI2D]M]F\6>8P^KU8R;+QY=N %?BH2WP,-*
M6;2A?HK6C!\6KEJ+Z=RG^#J$%G+TV'XC[=R+>X81S2/S/R_5ORSDL>S:?')E
MFUE5[7 PM2ASV*I3U73# J_L.&A=M<F#];"K':G0=(JZ)/8]\0;A8TXOMA)F
M,'[/+PJEVP?<Y[@!L  9U26XB9H0X6%$QRO=#,TVMUF>IU/^+<;2EAZ9?AJI
M"@3VO/:Y'-I^=1^QNHZUIG#18NF%WZ<SBBVB)N4/*,0F!O4&?-+#=?MVT;KG
M-D[F]%="<GN?E^R:';>&I%)K/CM7P2K'-"DB;W=*KV7<E<FNM,U&>.D<,OS!
M!LJTU+QL78?2TEC7GUK2?P/FJG#=:LYP\F+%73TK18CO[3N0W<_F;C"(Z'!S
M"?98.=;V@N2O\$I36F)?*FE[M+0DB@J_OD$&-,O,TRENK$OMS7_7-RQ!P+^]
M:,V6!!AB8M"6/>[S13>N&O8XRE<$P#B,6.[VO"_WN']SS:06\U )1[B5K>U(
M6JQ#":Y52P>5_53N75U2M)14=%S<B[S0<+F'F-1>L+81^])!I7=B]R!C^,F0
M?B-KH+[X# I^H6+(90-F'U %LG\;<^3H'O+XD![D)^P'&=<\L!QHH/'VPMM8
M:A77Z^?>4IM]I697>;OW/?<>/<]'W-L]ZC*P+7C\ 2CH^ 7V,.:B10S';)NN
MJS(9*.NOS4C;X25LDP$J7MNJ&M/LF+;[S7W'T:?P"$>KIV3@B*,?KK]7K+K
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M1E[.WQYX3G>4AHLB10FY_VQ(\B<J2[*>R4GF.Z5D5\27W[YN.?VSI"UH.BE
M[(?:1=(,'% Y]<M\U7>*=*'N;HR(1N@KG\/XSL_\:Q:K5M4J=: D_<13.H9[
MYM"9KE\^9FD^<8OE1]CA!3VX3]9LQC0A3C7C\Y"'N+)669S!,!)=4?7VJ=F6
M\,FWJKIG &3L%O@Y:")S ;J= SV!NS\BM]&JON?9MMJW]\OA5A,BG"1#5#[@
MQ1&QCCNJ3@>O<8W8R"W.0/2VL+XQ$!\.QK&@-ZUWT$F/]KM+KF42AXXH\6E
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MQ_MLF-/B>.#AZC>A!N[OZ]SM];85.U[Z1GT&ZAP_H.F_3S3R 6\^QFNMD@&
MP+VX^E)3_NV^POBK I/O.Z&W7RS@"\9 ]5.OF#5PSV6?6WGW9R$O^=7+-B>C
M.)<_7/]4BE!U'%@*7ZGK:'@?7A>W$F=_%N](&C@?_<YTCJLIS[8:2U=4R:>A
MJU*>L'J)NC&)#"24VOKE(TQ.>)*!TIB-V1PH#>9AHF&T8KUZ7ANRP$J"]8/2
MV],4"N2'F'?QI:4)(X:CGF[>5C^%W9[/>J _SV?Q:N*55[*#^,#=A-3=WH^7
M]&OS]I_0]U>L_WJ8HJ #&L>9>B.C(3V2.U;@+V3  LOS=B>:X\<H@.FYY\N^
MU!-17-4R:I'UV\S+%7&4.1Y/IJA3;#$#3L' "'ISWI7%6_^>,Z15B9CPT1'A
M^^MX5> F14N>T'KWMH!QHI*-"'K7"LS489I@K65 +53YXJGMJTD+T[=-84QB
MW>[<%O_LTGM!LO/,<4*A<F V1IA> 4IKBZ2=MFHL^\WO%F8D[;CJ;<5'7::'
M9&#$<F;JJ@%RF$(;%I>)E!X_1\1$.S<P0N6<!9H,WS0$CJG1?ZY!L-D3A^F*
MGJ&^@EHA;VL#O4,/ G"M,J5I=SEW5:<:0>A=X:;VO?M-WWKW74*8++LX&"'3
M,2APC?.Z)S3Q^#"BQW\J5#+/ZM4GE(?^L(XY2O>2KT@+>')W3B2P:F+%-VKT
M;?'H:_YX%@'Z&=.)++_BM5UNN",9F%A>J(^RPTBBW1TJ7TH9-X1,]HI-GG*[
M]M"4=$0_\ZV*XN^]\&"HPLZ6#&62FG.GV\F 9.V@?W;'_D1SE^%6OMC@DW %
MFX>/HPQ. [F9 .L-4=( NAM%'&1>ZSK*_P;&T&8>_0_VW@.HR7?;%XZB(J"@
M(M*)2I6J=!02&R @(-*D1D2:2 =I(4% 0 2B(" U2A&I47H//0)"Z$B1$IKT
MA!(":3?N,W/G_O>]W[[G[GN^[SMS9C,39IYY9ZVWK&>M]?L][WK6NPK\:>V5
MZ9IJ/RK$L6XW@J2=2FE Y@UL.R:1F2G/2)]@:?L;3(3(V^V;9$6?QH5N#M-3
M"R)PO&!K8SCC_#9D$/3&N!=SV)A9O>%!\!AD0P1I$W&R9?_DZ: 2KHY8W/-E
M7@['U>T[!W:;*'VEZB*G@F1/;K9%/XT*9\FDZWTYQ 2/QD5?9/8=F8V-C8MZ
M5H_.2<P_*!!XQN!8S>QA2$VNV<V0,!VIBXPPPO,?4Z27"/L)_[;<!IY4F,NU
M/498'-E,AW^V9=LZ'9"HD^BP]"XH9S%->?.Z^YT6P!G3)(L0QX:A><,V;-Q$
M=3N$A6)"$IV7.3<QWS8:E!1?,K=UUNJ^FU^P:U4%-)!P;G1;BQACVN[M%'ST
MVMN;H$?4</0SP_B9\IDW4''R1=AHVKE5/L.8+25^>"3DW'K39KZBBOQ!U7Z,
MCI2"ZA/^+8=^P;F&[ET.D@R<\D&YF@ZPEV4@\CS\**(%.ZZ'RV\7])_;0J"=
M.P9]W\A%3E05% 0$MUJJ)TSI@'*\O)0GBXI>GP,G*#ZQ?RW,*RV806T9I@-:
M&/[CZ/%ZIG*KN0MV(H -TE_A+*?$K]?3:&7FDNNKO,-BIABCV-)EVL/-P\L?
M^!VP'X,'3SK YQP#$',IZP7,6& \U%XH!W</_JI"7]QMK[M*C4UDS8D9G:49
M[!^92Y"N$ZTGM?9UGM9SX39:J9:3YB\+U/+5:N%1%8Z=%^=5%WJ-MV\W))NO
M(2OD8BJEKCP?:AG-$L*_2JJO31X5OC$UHR?AP,IGH5D6ETNIFE<5/W\DF/B*
MF@IC@8W8LKZ96\8@C],![K_QMFPUS_MR?)Z?\XQ](_;X'<OCTN:GA)JQ'\BC
M,';2,HUEGNQ&,B3ZDH+G&^VM26""L=[(TX%=&???6/'(2GX>S;;HC-W7_1L"
MISMHS\N8/;+ASFAVV*AEY7+D'FK<%0>.V$T>0HF!+@U [7*[E$I+F J/'7T$
M#V:[Q*[UPUU6WK/&!0:D"!$RL8B-)D6*'T$LI2@@K4TOQ7! NN(&R\6A76<Q
MYXG9=E'_!(N\:W>%'*6VM0J_I'K/"B7^>;?#2TC'>;RA\;HDF]/.D&Z4!'3J
M%4RHE518")M5/ZAEG_P^FZ6*0H*?S4R <9@8.L )PAW@8T5-@-I]FK!9D1$X
MK-QK/\%O.H6^\4H-,S3:5/6_6C(QPL-#U15"Y@1EB?.XR"0WD0E?#M&&;TV_
M/W3F?L)X#>%+@"2S:4XZ(+LVAPZ8J07_S_5W^)(&<3I TT>;#D![PU_]_=AK
M]P&S'1W .MD*WS57A)/WQ4E&?QW^6X'2O]3\2\U_?35[;5 H:6O.,!3&"C^W
MUB?>D.X;9/8!$567(JCQ]ND%][;AM^P5SB/MIB8K15WK"#WQKAW0Q5Z)Q7$_
M<;-&"XG.:[^J#T3KW;M$)EW$>H$3\[C]-N1X5#/SHW#,X8MJ'-NLL6;_AGW(
MH$K@4_7GKX.SBCUS"H0Q8'NY\1-;\XY?9RJ9-T3GBWB<&FO)6G%YSUZF;G+@
MI^Z%VET6.#E4 YB5L)E"K*_AI3K0%0Q(1HPE'?+-&R:X'3HBY=^F!!MV'T76
MNV<R>!@OLQI_=8AGX9=/9V\"'@-4CS:NZS^S4&*.:*L?2<&(#I&_42&[Z$#<
M_7EIO/_EHM8,L*G)CS59:W=)L)U?VX/D%9E"'8OJ_(X\$(;&51W!('&ESG3
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M?).C/W-6= N\ .EN()<?BLMW/FXXV>7T?G$H=F?]KDQTR86T5N,$]+<\43I
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MW?HW66:G:R35:L6#L3<,/,]$-D!22%&__B9*N@UV*L=0&,S^X &0H@_$HV"
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M#TP'_D5Q#HV+N1U[R.D!WGI'4T+0 2SL:#K@5@^6P@)G'#PG"*>%IR!)Y^B
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M@6#3GMGNW17D"W#2TX U8](\+I/(IQV.JE@3?E<F'9C 0?P@! H7.D I(#M
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M.EDPINL325B_MD?A*098[[N3?Q'?>$9H7+2IE&2%SV\!,T.O<(133N?)-#;
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MDM*8[QV=6:-+4V_4=Z=-+[<RAT<QH?/5_:5K5)UI(2H-9UV'T40LY[C-.3!
M9LA8 32ES2^H:9*.P&>;3J2/%%";Q^R.C\9G+\L@=3ZBFC5\;?7GK4AKO[QH
MHUI,#*Z01>>=_Z(I08=27<A!D T&R"$+^:;8N:-#;";Y]X4GW6D#*%T[U3XB
M$66K'0->FYW[%(AB!0=S@E.>;*,KD%V"L+T"5/GGY0TK"&H=FY!(/XEMU)2/
MEO^B_M,3M;*@LV3@W)&;11<?"RN!;RC^N'0>CG*.2H%[VIYBH5B4(]F>HC_
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M3MWD$-$Q2]?\&!]'V:;"HMN!@*9[>^F##P:ET\1U:UP@]-6W-&,(+U/Z<4H
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M;]SAO7L?I :2Z6" ;.4!*PSQXRH4[X8JHX63HV@%*Y]W$2O,.:W>K=Q>M:F
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MB,ZTTZ1KA]*ZN+BG$]6 5HX\B[ >1C=SCM@V^\1LQD87[((73\A?Z\V;/L
M?41__8&\)I,%\%$.+OCSC@*3A.P-(,SB+77NDQ][0F^UZCEM5_LGV]V=PZ'+
M-KM$9;);+U4@"QL*X?(5^A8FNJH<\*S_ EWJL5N=/Q%V"L020;8&3RF'434=
ME-#A$/%P41N+P]D;_9"0;MDM$-B?:A9#]28R0,WK "SA[&!V9I9N@)6^-MGJ
M=6WTGH=*<7?&GK?CM&WC;%R'"@O;!I6[SRL%;EY<.U! YMN1JE<J,W252%P4
ME)VEEBRJG4S8^'2GQ'+L>EJ^"@BDPK+!NP#AHZ5MU[;P3<@/V/:_9_&X$25R
M.P!3@[/"9#LN084T>*>6M?N0@H"K<KM(0)MM%,:8Z@80EJU8(R"G@=JV8Z@J
MI7"1\S.6.AO:T"G1X&U5I5T),BZF070QX4'6FZEL!DC>.=N,3WQ"$<GF5I.W
M+CN ;A.^^$NF7E>M=*4<W;5&U\FLBFS@0,@8<X8JS@Y@>^YW<1WS6)>:0GVY
MM%4,;<4(:;A-!_9H!9"/_D,XV:,\T7$ZB<9:\8S'K.]I^PLKKC>$(<=W4G,J
MJ^,(J_IR+.UGYZ\@&+[<+ZM*(>1)-[>1QNL=T5$U5.-^O1/?G\&,'#(C:!C;
M'_^J M/_%=N?2K,UN/RI>IL#RZ+TGY^1EA&BG#(8<?,<^UE\YF&C7="5I9MB
MQP\3@@Y#I@;*_UC>[S]\NZP4X4' '$5<)E8,1R.<\P,C;Y>.D%,P9V9&ZH>4
M=FU-;1/LA%F&^_*/O]65;+6N/V&M3_QL9:K.RWY9\)C7N0%;_ARI6T;>AA%F
M+I5]NC)5F4JYV',,4.@,+0&WD(N:/4%A@**&T*^@SN@1)B3"/&" 7L:U59V$
MCUIXFI'!#CWRB=V5<>KB\%_/BH*#5ZVY&VT=!Z-5C6+CL8^FUU8+2BLKEUW0
MGQ)#D6+:3ISBK1_)<-,B'Y?5-6?;/IFW (Z$;@0?J!.7B$0XY_HY?ANUT E6
M^I6$%[69']ABB=7R6X_\?3]SA'"=.#N4@\=P=Q7!V\%[<BG'TCR.O*/LWVC)
M+UAZ9J"VWQ?[6L.$Q#DMO\I%NJCIW")H,H'+L^J<742"^_%O!MAG'\2H;% "
MKU%7.\X?Z0H\!FOVP':%?Y>_]5(I#KGL/9@=8&[II\DWN\E//TK2X6NY@$>D
M2!1N"KXVD;5(733.TOIF2-[.,=32QBB>R\+62]Y2J$N46:^H=VM!58@T3)ZD
MJP,??&V_6'BN)+C+Q#YJMPRXV_8X*<HMCE7D.2C+C<['V0J+_M1.5"?K$L]/
M"!.[,OV,8/LV9A72L1JTLQP=IT^L>&Q>=K<I(++0CUPE=1),MC'1#)!3H$N=
MZH?F$T68,+RTZTO1MU':F-H*-.W-YK-G^7[84@08#Q_!D.U['A#;G]>I.ZT[
M0'TX\H_<@WH_IF346ZZ+[&+;/_<ORG_Y>;Z9PA?B %-MZ^]3O!"9'B)!'91!
M<09,^"3*C,NZ45B/$.&AZ?O[$BYZ2<V;4[?S7N45GXBJ-8[9KH8WEWOJJWR[
M#'E"BV> II*\&TY<GI F05)$B@J(!,.!:2GG)^,>[+>//%._>77A\ C<J)4X
MCU=NOIFPV:[6-VF]K_I^7,;>C6J)I1'PK;DZ<])ZF\WI<9</-8L)\U&6J5]U
M:M-UJ ?8IL\E.X=;!(2;C_\P'R_5W18;GKM7+$QJ;Y5N&(N\I/06S^1V%WXJ
M^_^ =FKHU40N#(KAQ6L@,A&^8Q>G"_O,0^TM[N6O.\)NMGJ'*#FT071EO7YM
M84\@>W:N<:Y,[E\H^?DEZXG'[8A[G.0[B )@KHYR;]@+<]Q::-S9.'G)F.IQ
MTT S[#V9URB"QAU$E9^"<RZ.B3=JI^F03) T<SC2*;9N?*+(6J=4I_VA^^="
M8]I,<:TG)2A"$HM3_<^$DO]'M'\SHV\P8SX03_6M!RY-HX+WH%%U.OD.8/8Z
M?8)J$>3L\I[^0&6?EN 7CJ+:7]=NO&X6RTZ^%E5H^R+4_3,XGVD6TO"3+W$\
MA8\ +I*95G]%"HIKT>Q20W!NXYSL8/F)*[%?5::R?ET-/7"Q+,]&^PJ3[G3@
M]A=Y=O'AY]O P1#%P2+/=TKZ=AJP#XW3NFN*]::-7<2JU*MB:'!2W-&'I=H\
MI66NYQ6B8,#YP6%TG3SEK+4OY0ON9)TN?O=\1=?%B8!3)W9=INMBG+/#A\QN
M<!^_3NL];5QN!U/= (_XW ;J*2R(AX#=U/I!WZ7Y%N@1B#R N=MWEHC\N"I&
M%Z@/]0O2<YJ)?2C](J629>U@97T F'H21[\M9,D E<3]0Z5,!Q;F3#I,1OF[
MK>P0P:V30EZ6ANY\H8I'4[8K9-'E-U_==K>OW!FM7JUIL"PEFK74X@ );N2H
M$?7&4'?KKH;@A":Z!3X:]VJ82VBV?V@8%7N^Z]/Q0,SCYC1@<G.X@@%JO(D$
M+T]R,T /X!$B',2N@FZ4<LCCSU55X;I^T=6601&LI@^X[JC''O1;07$A-*!3
M$<%MKR=TR':T-/JWPZX'O_9!NF8#$>MQRU?XH0(X%_T  NHYU!X>AF/;#L!R
MPND]?#UZQ7!',W&Y\BZYPX0XP] C.ET\V4DMI3%W9=Z$-@HQ0+P:^N 578HU
MXDP/E=,O@.\%4L;&"G"VZ7'=EBI^4#DPH/W$[?YF6M2SVJ\/$P^P6ETZ])0#
ML3F%>HF4!$Y-<_Z4:&M0+$TX>D]VO3SZ>K<1I,,O[\OCBI#-'>NZ>>OZJZ\B
MF!0$D)(+"20=)9?2WB*%' [W3<JW+"KMQBK$G?J81G:<\Z#UEHO _$&4D_^S
M.%L'C'!%_<5O\B\FE'L]U<O3HK=JAI*&9<X'^)J HG,TYAH0M *$$,7Q)_)'
M@UP=\(*$:=P+C12);3<L+2$26A5[UZSR5=WBYX5[6(/_>,MP&=6X5]4D62>:
MW9KOJV>2,.NY</!["3S$+*[3NH7]Z9%NWBQ:!=&8_K+>E@$Z)$/G^8> (O)P
M(VSOQ#::RH\%#/^C^X?CD+\P&\XVDDR.)D^3J\)FHBH;V% ]B86HJ5944YTS
MG8TUCRK_F?9&PY(S#*&09SD!_N1WR<HFC*FUL,H?VJH$45(Q%4O7]H2V@VE2
M8"^\#S7U>QR]^<+DGC]K,ZI48H661^]'@<LY0TY&GAWY]<MO;_ [:F/=5D30
MOONASE?<:DW,]AY3.0Y":6%>T!C4T3K58NHQHJ<'$-;D<C+-/GN4!]W=;_62
M2^HAS^$49_;7O+??PNB'YRF*J*920-:#U-^2C.RR;4NB=V_RS87=CH[Y[N^'
M?<?YL( +6RI#7=S3H8F7K8#[.#FB\/EY?1WBTD\-UM(L2G?<-3H4?\&)GLXW
M/;0^KJ'N 473$W;76_9,-M[EL-=_UE+__,/M5E69&0P(H*5\+$8^0QQFFC"9
M7\UNG!$H)U3X:\>$9HYS8>^_9Y.&GR1>Y(CPG3E;J:/#N\WWO) !>NPV@M9U
MXZ1W3[*?OY_TL6-].FHW#C6L%ZZL)Z]!4 ]4@)]=YJ;>)W93>6\U-\++[:.W
M)[D=$WS\0WY$Q%G[N=?'5_*=8XU0VJ_R]:OIS_>NT:V!]G]8/5Z:(%5I&LRS
M017Q:$^]JM',$9[#1FS"5W\"Q 66>08L\DP['?7;G.^2H0HD0B2P%/,@N)G@
M(6Z3+L,)._Y6#*\K]2,SZBYR4EYVX&-U7)RIZ1 Z@B[MV]\FE#G@91HQCIOM
M&YY!BX35(L6&U?\E/>*E'--JKN9DOR_ZXMN%GN9>2^W4NV8%I8,-1>,-A?3'
M!19%CIMWX]R^$Q:*FRG.4SFT(_[M='8SJB1]%)!B@*[9E#! P;P,$!OY]@](
MQ KT;S40O8H-PFR)+X,!!3CQ_;&_NO_J_JO[K^Z_NO_J_N_<_4_HU:D_^\H=
MS,^8S<:J6-\D0%V[MLS$$EIQM/;%F6<(6E+[[0=ERV\6_Q239@5N X_,-V($
MO!@@3M]NXV$E&E^+"*]S')X6T)Q<._K+HNA+E$'(38>/.EPZ\6]/(:]^F=><
MY=E'@.YC@&Q11Q'G![8PPK[KK6HY40CCC/; 8^'YRV:''_9EUJ3-)*Y\TA)V
MUQ*+^*(KUZWPR>PI+*&2 7+$C<#Q.ZN.4Q6 .PEN.:P=3'ZU=JYO*V6K4G<V
MNDI[#<\>YC@#:GRVKTW;N6_A/1M$J-=5 YK1F&6]O#-:\"5$G_RQ]]VL@,J$
M[0VC*P3U9^X_#'0W/M!"&XZ<2T<(S2WK-$I8J%519>)RT2NPBG=UU%UUC6:^
M-,IDF0"D&X>1KH^) ,TAY1!@(FL[F*6;2)F^'.&ZM?LXPC=9*EF@R/7L4Y+5
M=>GCI%LQ+#)Y![@6;JK00;0T*G@*?:J+9&DR[(7A!HJM+SB6 )$M58:=[BZ/
MA% C&?>R8B3O5 I$G'8\?'"D,LIGX#\IB7FQSS2FF4.>(!^,P5?6Y]/"8 ,5
M0N!5F?>%YK)9M:'FE2$'UA2R#A+6N:QY>=,<3/*T#;.-[L[TWW*O4H3KZKS3
M]=!:*DZN&53*6+!339<7[W)XK&+F5&XO^#HP^XB4%FU19/<#P@)0?N]XN>9D
M9)&.B[V=ZVL+R^L/5&YF:K'E9MF#0* ]$S1@ SV*^X>,/$P%!")VUR+H6IB>
MLJ:],H]T=<&QP2K38)?Z,929IH"[W -555VMJF7ZX_95*%X^%,Q+%P7 !.60
MBL]CUL3LUO'Z+Y=+,ZI+TD<?C21<.:)K+G!5@S6NNM!?$KOP8]]4(5]8JJS.
MZ<:'TD,9.BEOAN+%)=N,/)X:' ^:-8I/UK]<G5Q?F AQQSP66!\<DAJ_$U86
M4G,]W4NV .7TH<%@?'^$)+94XW[FOS]6Y[],^]->M//<Z)^VJY]#8O_N&)*T
M:@9HII<:P #=YV. >H;J;?X),08!F"L,T&O>1)J_#@/T/J+*1)%S=Y\Y:O@#
M:N]P@>>_NV+*?Y=F]L=S3Z5-ES^?C5X!Z_[=0?ZWA-#^W]%D_K0MN5OY9]_Z
MGO-#[M\;Y!O4%;6KB!)A@'X>9%IJ):S9/_UJGD,D_AAP-*C_M]%(_VGI$OZK
MM7]C>H=_3/$ ;X&-1DYWMX'#D9J %]&G_;+(B?X&0>I58LR+0-7^Z*&L/*O)
MI<HW>F?&SWZXG%^J&'"Y3+^"[BD,+I*9Q@"2V!7U HG(T[0RG!V67Q>/"6=M
M08I4#"AV"*G!PQ^K%<5?1CG?QM_V"$SK?!#_2ONN\@^0YG(CB@OJ$,W9"#TN
MBQ0#C&\/4W7PFEI%=1?H B4)H_)<HB.-2F7\V;&P,Z/F41?!%]I"+[LT:NL$
M48V!2 ;H8"*@1$RQ CH(X\[D)Q5]5,W,KCRG"Q_\QPQ.J'0F#=@ZWW2OT%XY
M>=H^=?@3O1E:>3*/8N3KT0+A!]X0-]P.(VX03WY(MH^A*HFZQDS@@_GG0DI]
MKI_6D8F].>KG-;K*NEJ*(Y9IZ! [R7>#Y]'M$ 6T(4D,VC1Z+JYR;]92."36
MJRQXLOOL<V4E;,R$.@"CG%Y$\2$51ARE" 'U;*U@W;#+E:7.B4$J^#(1VY(;
ME!OY4:TQ@V8>SX^I_BXSC2,:OT.>';%!]J4SG;A$,+);9AS[XL&@#=U> 2.I
M/7S&UN27R;L8PHOGJE^W8*-\9#M G&+B*RT?AA%!\-%JLQI]Y?!E:M%=GW2;
M+IY_%W1#/*AV7UP; 7X1<010)V  "?1J%1XZTH]?C]F.]IAB@%KUY4WB='HJ
M:K,TT@4'GCS@.W;6HT_B>OE39;[=TJ^GGD.&_WE_50.+FN1&P(F=MYDS$M8X
M[MQVT=J@M\LELT.PHB;DJ_>$S@%2JR^J'1L%%Z9?HIXBL3:-N?V<;!=$)$^D
M#W7XB27T'0X_O28M;)]S.P*TV_U'3V<SCE__Z0RWWM_J2M4+9,_\<>:\?D:Q
M824[EHKPUC#I!A[4P^FARY-4+J9=%KO#&M1KL\T L2L7,$4;9\H8Q'0 ,Q%0
M?.@V:D\(BR+>P%'?7!$YJA4P3+TP@64Z5Z]U^N%$!BA6D@$*%1IDF@[7>@:H
M\033 VB!?&5YU^'$9G\<C6,8!YR%TV]FT?G=S)@.H&:'Z5?TF"Z!9]]4N5D]
MJIECB6F9E&T8H*EPU.Y9]%]B_2767V+])=9?8OTEUE]B_2767V+]Z\3Z,U^_
MQP#]04RL,>T=DG6"RA=GH5=D%%"25U3-(?OJN43BG'L+NA9B7ZDPJ;AO:>O/
M#&83W@I^":W AI[?3A/Z,IS.1T*'5< C!*&O/"-/7;-,@U"T6:S*ZI)/]+:K
M65D6Z(A% =&]%MK[B'GP6X971& 4I?^'O?<.:BIZ_P:#B'0CO1.0(E)$J2J1
M6"DB@B*]1*43(2 "00(1D-Y$!02$B#2ID=X"H:,@(EU " DJ4@():+B:$#;?
M=W9F9V=_[SOO[L[L[.SL'R>3F9O<Y)[S/)]RSSW/B1IM(7!#+58R4MS.T52:
MZU:02=+]ABS5SDF*@/BS(:3$"X3O(5W=\,#!Z]O!;2.ZLAYJG6_1DC01UO2_
M50H_N>;ZL+,>-:0\ :_H&;#EV93X><]P8ECJ<GSVK0?%OC"MUL^\ X]M13E^
MPAKA"3"$EM-NW^/9S28:I/>QA>_L"\BQ7UVG)SSR9NVBIP]Q:,(ZXYXE*'D9
M2DB===$C@%E@U.?5(3I1.NH\\,)B&F]YKW2D_%>VD]S39[[_]$3T_ /O"W=\
MU)QX]1:L*_97R?;.C3:,^?\+GN[\_T+SH)SOIB"DH46\:<H/*T?3.11D!?9Z
M_DE'BG+LMFSV,*XS@P LXR[:%^"B(:]1*7&XOM9&J\U$/>X\UY&(PRU<W_.L
MRTR^WI<]#KK4O?48,\_OO%\#M22_8DFRAHG4U%_^_N6E6QTKVA+SED$")J8A
MR1,S/'4_1QG-X5*?OXX7DU+2NEP9ZICA.P<@/\*_7:H]*P^Q;B6**NY;XJ7^
MV$[!.U9?*E_+\V_X!G?[UO65E&3BF/3/FOLSK,Z>8L.XA,*M)*1CW(GSQ+[S
MFL;GJ9:OI=.:.TE9(74S>FO)<:\T7A<?6IN4^G;)5BUXG2!JK+PQ;S]HQ8,V
MIFY5SC37?5UW.TZ+'?"K;_ -?9]X6T#L?HW*Z*=3?*3D^6&.#9?9S2'J"\=V
MH&@%,[]+%D\PR*]E7D(X^\N8=F0\F#>)\\OW?YOUN&17>%:XG"IA]F\P&$?E
M9&F,)6&.L<Y;[/9$UN#BT3#%[QCO-4OEVT(L>M&IH@^,X;K"0#7.OBXCM#4;
M<:H!3A*]G.W>(TP!)))$D1[]XXR+VPO-$5Z_M9989BKB>H1OUD+<<0:JH'[Y
M[U,0*X4F0F=1PV()]T8A],%)J-:%J2ZUR0>F\>@SRB3/]JE::IUCSN!I'"$X
M>D_)"T0%7V.XK3L=@-*A_&&,TVB= G!REX+O"]^=S_8/?=IO% ]W3)7]YI71
MN8J74O6XU1UJ58!9?H<5^*W]%,M] /(BQ"^)-J"@2J2,U"[9R3Q#HYAKHK=-
M9<PB"E)4'?YH1OIPSG8=1Z. 18;J!AS\9WM>:6!>GD BR #Q8#!B3]HN>>9*
MWWS!L*[S1WXIEQ$O5WG#W:B0OY#P'QKU^RU1IYDN !?# %6^ N[YS^02QII
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M5B*I/N!DD?_*1:Q/K.DEYPR><Z5E  RHCSTQAOAAFDXD-&+BZ2SY\6JB;3L
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M:P+[#7=?I_;-^F0+..^:='G\*6U8_?*#A)?"/5'CZLO0)Q[:'UIO]W2"Z>&
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M_"PJ,V5<!+SO *61-9$M#*3M%SCCN!KG\12SFA7U\1-9DB.@H8BV[\VD+38
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MC"OWBU*;GC4=AXH*//2S/U\\IGS20V=$\L69<Z&:0F*RV;T_GUP(;8/P,%&
MQ<I8LKP:H$W2EKH23L8<T:J@&;S,WJERY'^ZJSA2?SAR9.S#:$OQ79K+D5@&
M?/VQ-^5<,6L8(\42L2!U8OK_R?XKC\/]7KSK9V?XD2<T3^+%<%)1KAC_,=MG
MJ?=V[DA$C6&;).*[=*/&X:)=8$>F^!1>HP80>E2$<UO_.3DV)?WSI)OL?NYW
M+G&]VR4?AAZT]CZ[!HIP%=O=ZX<M)#A1QWHM;>C/J)#N%*(H^MRX<BXN9,$_
M5/+45HU"9G$A?6+Z2U+-5/&S,<T;ZW%9U\5":VA76'Q&U-5N06K5G2]=LJB,
M_O/< U7Y*":,?,'@;!Z7\/&N,1776J= R:B-8:ESUG.'0>"W[W!'@" &8N/\
M'N6<Q":!#1Z/9_%<50AIT7G"TX 02Z?/-'UGGU=)8EW#6^]OO!$_LQ4@^CVU
MEH(]QIIR8N%J ,(5@).:B_=#<VDXH_)V7/T?:+&^U?%BK9HQZC9!#Q,_=EXO
M\?.PU0GX5LFQ*6J?C+ZPWV$LC+ZYGP_59YBA;,QF5&,'YI_[GN=.D%X49FW<
M\2V$U+WS%OJN]_#,L]9KZ08/NT\.1$ 6='9[B8V%L8PSZ C@]I+P-//>/?VQ
MV!#$A2!]?D'+(IG2%N\=,LKK5FQCD<TS3F'[0.ZV<3?^VJ@YEC*6M)K"TD.?
M DX<@'BMGJ+E*OS$)5K$6<IF(?RYFJ[%[=D:-OPGX^0@V5D>GI='9 YU=*X_
M$5ITOZ+4+&9B?B$N\+$AQ8)A"*0,CE)G+P%K)&>BD G#XXM_2*L;#2PER.._
M\F[=*'D;029&?[E(H+IHI]DDWCD'N)9ZTG>'U_ZNL@[!%"]"?&_!SZ[]9]]6
M.>]^H@P4PX "2G1[6G81F<AYZ?X!:,X&[G"%WA<L<UUN=3=O:4D(DMV3=YOR
M\XG2M^KBDOT"C#\1Q P =,EC*<9GO@3@!;7[*'#K26A$"2*,5\EGUL!//M C
M(^G8R0^>LL^ZCYX#T2LU5B&)&*HU_]C3+CXJ;G [D<BA[V]$FDT)05AH7 CT
M2U(M]<BY[K3T<[W'9N_661#)*UQ4)_[BJF>DW/].L4).'8#Z5MG8F(?]_1#^
MUQL!8R:8,HTQ+-Z* Y"IR@$H.[3A /0A!-"]%O6"5>Z)'8-UP9A)K$Q,?R'@
M?0"ZA!IC2ID>@'+'EI  ^@#$%+%AI5L<@#0I[(//-M;56:X;_Q)Q>619+/]+
MAO;]A9\_.RD3B\^W,(:1"DQY$I;W -2 J=>PJ_B#]1^E>/(ZSS%.N;E=?T3!
M^&Q';-;X!SPW>S8X,=QC>R?;_2O?=Z@8XS*:%\@D,\826""@CU3C[399I$/\
MU1[0(# ;^HNOPCO)H?V)XR7E0(?'R9L:R[B%%?I#H&\%MW!Y>^4 M%E156!$
MMN_#Q+<;-)3,]0D_G<W$_3&KU5(9%$BE]B>^>7WZB&Y:3\[/L9\KE+'_8*IV
MG]PAN!CS&BT46[3V[)#WE+Y%:0S/$RF5@D1;23GS"K3,"H:;>?6+(@T>#;7P
MK%K+49=>L)ZL%7?P/'R(K_W[:878S"']W?($&(((BIHG4F\2$S%">$,D7>LF
ML=MI-">9:1@8;/ "W2S"JQAX406L(AG=9J5PVM-M8?  U!@63_!B\\$!2%"K
M%FH47.7'.MTV 3U'LI0>G5$,BH"J'S/70+_OKRS-I9IQQMV_^ ;L^Q:/(7E3
M;$/(A'DCM_V77<KHL\9RM*@44FL((]B]BI\A:&H9;B>B9R-9%#BB<5B-5C&F
MD.G0P&(GU#1+RH\@'R7-%#D /<WH_N=5%79?FX(WRUP7X7<N;RK\Y21YO:;]
MHVS:B],Y(ZXL>P5K[DY[,"ECWF(9GA9UV@\.8BK2M&].,9V+?4<C*W_1N4H-
MGE4GR4@IVYZIXL[DSG;&P,) Y(0!JWEIMH(3_JT='<5'[0->#,DKUN>Q9DTL
MQOT%L[$B7,__;3VLO1L;H>EGJQP6.O\NL!]-I(H,N)VDV3/%W8>0*\@$'*G3
M;F@YK;-F\4V7\[M39]XMU(\='J[T3,J<.O0AE:\^B\N'D_)8XZ=<,(O/5+"E
M1RZ,7D7%]6ATPDD9"2%_]18HGOK]"3:%9VOMYIT_:.9IX7@RWW-^?GZ,5ZUI
M R,*\]7F8J,S]$Q0^=<EQ#]">L!M8H^;_$0O?X&=2<IG36AOE>BM@5SEK \.
M7X*SU:LY?CVR9P]3GR>*P#9*C>PQPW@B4V <JN--&'G32..TZK5"I72&U6DG
M)\N@4PX#HET^9]Y*?KH7I'9W5=*85+-.-X:,U_ZAW+R</6-0[^)R6DI1R.(,
M,_J- "0)*\T29LJT-+4"Q33P]7%!9IG6>?Z-)D><LMQMR2[F*&OXI'[.F_\\
MFM6PG13@/OD;E^)DN.#9WM*<8='6MJ,MT/!!*2YJ5,TQ*NPNQT+L&%06_9%M
MZ!+;"/ME6NA@!@9MGX1$.Y+'Q%S6'HM8,7K>^LRLQQL9/3@ 5;KNG/5O)?ZH
M,C!7WC]#FZ4_9DL <[1&-:)9?*T:93@P']#Q9GT0Y-4<$?&N-%LEH,@K25Y5
MSMCS@7#*DZ.LY)UMH:CQO9P#D(1^1C2,"\I3J$X[$=^X$4$4Z5RJU=34*PJ4
MJEG.QIRR-Q1^VU"-$ '%!NMX!F=08^F3U-6!,0%@6H_MC8P56VCE?55]ON3M
MA&C*S>+#^)<^KC_-5).OV7F\>!S/A^(&/8FP%-L)36+[92,:.!WFB8(AK.)A
M]2>2F\:.+O1$AI/%SP^4OI_TUPI035H4*-&?3"3O.MZ_G'AT4M'SKEZ4"J;G
M^HL> L^CL7GO7D*#:4H3,6YRWM'5CW7&T*XYPUNPYU*[T3G(6*M08W)JMWK
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MI+MYK4?AJI^S@_/;3?O,W"Q1P<HCYNJ59B!ZGD8OTYOAZ<>.5*@_R9*;G@U
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M84GQ"?-WL%B6%SS1E5]X3>\SN]'M@8+P%#/=QU@[" 4[HT0VW[A2R>R'*S6
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MTUX%P\<RQ]N[+CB_><EK\QG"(P<QWH!LVC+Y68"73^K?'"\$]DC)L;52'[9
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M\%6.&J@!-%"_U8,F\&_ :AM1.'_T;[;LCLF.Y 'D2LII59;7L9M^S'8G7L-
M^GG-]<T&OT.[:E$PT?_F) \@8LSC2!MT[P'D"$X6B>T\?U--U=M?C6N&X)=K
M?VI.=6F8D:65YY0F:C;Q0D8$PG>>@?#U\@GRIF;<5JRZ&:WXZL:1BH('$5!.
MP2YEJ3;$$;0D73-FD<@*HGXH@3)OO.)0%%= <%-"HUT%S_S1SS$OAZ"@E,A6
M;1@4)4K&@Z><Z,(SU*B,]HSIP(90G0[SF.G$X3FW_4*ZCIIHGYIW][G9FVVO
MC@@Q'W'3ORU,3$12NT!U$D:$C@!-*)C.VTCG;OQ1?WO/?HWVAM>W[IO(ASUP
M9W]JL!/4E3=E4GTT-T?Y"X*#R8L5;B,[ Y'MJ[;UJ7WU8P<0$JR>=M<\ZX]M
MH(]E:E:DC=,Q-+L;49P>1$KTZ0@^_%)57^NSG4=<R;>4GI*>2W7ML]=\I*/9
M&J+,1<XW63F?[(^^*]3!,>2YJ!8./P'\[:8?4R!?BI)<SN\[@/#73@J=:+3H
M5W%_X  95,G=UDWR&\;-IEQ82?R8KO78Y7A:S!6N3_)-I>811"Z5LQ]Q5: I
MZ9UKS(T4B8\_O<;(SYY+&-V*@,J]@OPKI3J,[7[ @LJ(31UWKY(KBL4&P#O!
M@MPJ];7?U;Y$S_,QNXH<CL=SD6I.()%V@3F+%8"+]FGQ>^\L#I3XN;H\E'OA
M;7'1^>W'0\L)\2R;"4,"RKOR$PL'D'9[9<(G6]198$GG2$6YOITB[Y)NFF_C
M2;3+$ZY1(:@=EH#G1TN#5__5F?. '->'_]AI2-UWG[Y[SNCVZYOI-[@XPWPW
M3G&L#$Y-,'F#:)IT8P:V154V?C$DA @S+YQQ[P'F%7TV3P<\3K3<6!<;OHY^
MM#JHT'O]W^0GJ^YO'MA:I;9-/G)@*DW'TU&G(;);<C[Q9&F1F^SUPM7:JZ0"
M(<[M;G7C:!7QEY-AE[7*"U JX$,2*U8=D#M70-_<*<^,UOA-CQ'#".6O869F
M_]*NX<Q+M((Q/*#5:L<7Y, JP0Z5V5E>.F/O,?@X9D7<9OFCK='L)R/.3Q<4
M;Q^._K^S\VA7D,SDKJ0Y([%=S=UQ_L09S$;]=%*)KY^/)[7\VMYIQ83?6<9)
M;!Q)%RI'>)6_'GJW^'Q/Z49Y4+/Y#GPF@GYUT9NMU*[(_,*-L3L6J\6\F0;4
M!GV'AA!OS-E=ZU$G8 4*GG9B2/DP'75U#B G[QQ !!ZP4E_: 62H_@"R3,['
M;+N@JQ@EZ9A!$+/ JM9@L.I?YI&P# $  UH:'D!2X0Z5H^:@[\3F?W\+S+$N
M!&<<0*0K,S"D/AA@@=_7)M);_'V8MRKG/?Y5'!^4@;K\U7V3]J_2VS:P(20
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M'B6'Z$9PJ["KWR=O['#L&%CAMB))L003J[&<&=)*M,0$@=^_Z VW;OK"E1T
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M'LZ%4@/$JH ::BM(I*A6CI P'9<P]W*ZUF_&^V<$BKV>?;&?F+LFEV(LW74
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M0C-0(4&EZZN_\*TL>KI\C %74^^O/(PC:_SM"+;R 2D@J,(@BX=%]5_0P;X
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MFYS.-:I7I!WOJ/XGAVTO/O&BX'RWHN>G!!.Q:)8O;<#6^S6O"GJ*]77IA6[
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M30G<"7.18XE0,Z/U!<.AIBLF(GEDS5)+ 2LQP%:.NA+MHBK?754=ZHJT -6
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M2CQB#;M/T\(Q-X70O>&Y3N,L?VPBLV3HB%RCRPR(SN1I<QO$<%#7;NB=F]X
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M[I_$WNRZY(\JE:Y5FIG13&CA2E\7 5@H\FQ=K%[JBXG]"XUN!(84!E32&(K
MT"%NT+F>4@>3'?'IB-L][=-Z;ZAO2%E*SY/:8[KQL27,]UUL63#D+A&K+B<0
M^S:&Q/:)(\\%0[V,3,<ZF9VI7&&44Z-&J>L/<H1&M>7T4G+&-ISW>!G!.;F/
M 6,>'T>ZF-C5X[20ASX>/<\.J-8FULY\S=E77HC]-'VX2ME[F4<]JU)Z-%OM
M=^L\%_]:VI1&;B0=PFQA9R-&'(B%\0T=',8>8K;'(Z9<N$VCX[GI@P8Z8%O
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MTW45."#1:88-[E"FMMT;3,3(NF[+@?'LSD=%-A4&N-/VM*%_Q\0Z"/<[^M#
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MF-1-46(A(,UB A,9$Q&G>4:XL&N*<F$FF[=KFFXH6C10RW;GE(UU"5(S<O(
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MYD;.C9B@TG+>@:J6%!2UJ."78M7^YF^6B1<7,#9C6P_(C4R;+6C?&] :(>]
M(Z;'!(AA''RE-ER89=JDA6%53](1KESN&&IRMLUX+ZOVS<O^DC;VK6XXKG,=
M-B_[V)?JR^:'*!]^D-67N@]G];NH-CI>N"D\L< )I8@A!"F7:DLIHQB27,3J
MISP(DC1/N0P6*_&H(XD?+$)3)I+?Z$7$S8MXHL5X+^4W46]7;Z"MR1X ,QZ<
MU7I.=':A]8&U0H?%\?JY[?0%]*]K-0>UZG>@4;X7$EB!6GVP4?J#%H [T$
MU*/R=3@EU#[J9>)E\Q4>,Y78T\;13+P8)P$W4\]_:Y3E>6GJ3VTWL=JT-UJH
MC^Y3\[NC^#O,@A#E-((1BXGZK(4<8IPR*$),999'+$M#MZ!+'^+-S03_3U$\
M_E!K">]_BI(\UBU..\GKP,OF1+?1#_RJ'AW%:=M*.R+?+ G[%U3PK'53Z>8*
MJ(]^]1]_6W.Q= V\]/(<&'[G7FUUQ_Z:]<(R![Y8_>757Z9.1=#3<:(X39\+
MX#ULTXMPKQ3%Z1/8RT&=7F>Q[T+;^GA>WO_%?NCOFRYVM6!1+!$+,"2!U+D[
ME,"<".TZEY% -&(X,NI=>6F"N;%Y)R/HA*PKM)GWHCT+XC"1^H!F;"JT0\6J
M(^V0ZDX]:<\..%E7VB%U^GUI!Z^[)7+HI"BR^L7;4O"B+OH@U*@_%@'*$=$^
M4HH1AXC+'.(,"9@(PE.6Y"&3I'-AF-EXQG,[N!]&]SPTD@'62.H2)&0"NIDY
MY1?(B=I52RG8IOC9#^X!W]32'=73;QJ6-'K4M6EJ1:YF1CK& %E@Z#7DQV3>
M5XCPL8#C?$"/S0!N!-848MCE'NX30!<BD6F6A DD.0\AHNH_R@PA,*5IC(4(
M(RR-BN]>G6EN]DA]T/ZSSH=5VQ!2BPW4YJ+4GX]2[Q,IJ0I+SKJ,LQE'>4%O
M9$[JRK>,G%!\%0I/U')YGDFIY*JZQ]1Q_88Q0H+.'T7W*KSH7R^R.)>2DARB
M2%"(LCR 5-,+BY* A($D,M\?Y)B7^/,@FLL9S63U_HZB2&R3U'RLG!E-3;40
M,PKVN1SATR]CI?\T57B/%<R3Q/28232C0!XK".VB=^R&]GDPWWBT[E=<&9<Z
MV_6GT W#E0C+@KTL2,H(U2T69!8I>R],$:0H#J$,,65,_3LCD=41A+T,<[,$
MFZ:;IX>K/@[)AQ?CEO-N;Q!/>'2]<_#W3JW_:"0>R8/O#MVHQ\?#$LS@)-@(
M(K-#7;.A'!E0+-5?'W\5*U&2I9KCGC\5JZ+:Z##YGUVCLD4:Y"+E*89A%*00
MR3B%5!><3@4-4<HBDD=VYZY&T\Z.YQJI[\!C(W==[X0<2&Y)>6;H&[*<=TQ'
M=]VW</[:@_-0Z*ZQI4="LT+)%X>933HM;5D!<<)4=G<[.MWVQEX=I*))L10_
MU,AJBGTJWV>Q^2(?R%^+",4!#C&#.!'*-$L9A82HK7,<XXCA-&,"Q5:N.+OY
MYT97_7W5NHY48WT%0-&FQRYU>JREF\YR90R==^/A/;9+KP=U$Q1X(#LXR$2^
M TH#[3-5.GAT][F!Y\L):#G[M*Y!-VA.'(:.P[BFDRS5/]<-G_;L_;V?LE>+
M,"9AQM5VE-)$0A2@&)*41C"+"0YC'D;JOW8I)L9SSXWT>J*O5[5%\:E@=9/E
M7=LT2Z^@S4*8\=Q(\([,<0=2'^Q ]W)[+O]R V#>DEC,9YXXL<4:DM-D%_LA
MW+CL_=/S<OTB1"]@K"WQ)EC"@R23D))0F6PHE)!@*2%.>980D3+=9LR"N2[.
M-#>>:F(SU\\.14POHVE&/UXP&IEL.AD/0Y3]U[V[BH4G'KD\SZ2L<57=8XZX
M?H-K0)AZR42U^2:8*'YJMW_;0GE!@@2G49Q!QF*A;!D20!(F'(8B"T,><8%2
M*__ZQ9GFQ@C*O"RW=>90([ .I&@EM@[\N@2N&4%X@6QD@NAD!'LA[[H&[C[#
MM:X@X2T\Z](\$X=C75'W-/SJV@UN]/!&9Z&(JGHG*E86G?];O2$Z&J]8/=:^
M[T)4>\N;890F04)TZBN'*"4$$L09S!)!91PR)E.K[C36$LR-3KZ4CV35=@JJ
M]T'?MT]/I'RI<T:*QU4A"T;T4=).)=#I9,<V]FMEQD*CKL#([-3)#GK"-^[M
M4[1'VC,YP^>)TNSGGY3JG.$YID#W@6[<2XGR9\'$^2/#S^O5SSJ-L\[3J>KH
MJ/[?=>6KS^O-/X5F[K4B@_\1O,GW_+ NVU_5)5(6 <WS$,E,;=!0 !&/!*02
MYY#E6:0W: %%5N&MTXH_-U(^R<CL"7LM7WP.3X/E!G-V:SSVB>9PJ,8=V"G=
MI6AJ+=5O-^!%;,!>T;OV8:BS='O*CK#QG72-?.^FIQ'^=;;HDR[,Q7W_M%*X
M'I54FTI]=-M3YVK!J< T#D(HHSR&*(X9S*.00YEF6<99FN;$KC7ZT016GY7)
MHI_7NS*BHI73]J#C"$;3TPQW<$8_LJC:=N_OKR'B<"9Q7FUO!P]'PT]\NG!>
MN=,CA O7^6C3^$T\JP?AAV:=#VI]FU2\19**F!-,(<\SM=%'1 =Y< )QSE&
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M9)A 0A,.)0[4_\LDXL(H-OG:1'/CP?8\M16V=Y+:"6Q[''T!7]-SZ-M1F^8
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M?,O4!=NRVI+5YF%]__Q<"E8TH^GK%QG!+,OB%,9,%ZK,\TB]WIS ) RB1/*
MR<RH'.^T8L^-/AKYM971GO^6C0K@N=4!;-: ]+0 1*MA?S0\\=,Q3&;S7?.1
M>;(6&=8:@<-:#GNUP9N7-K>FN:Y5'=2ZW('VB?DBV]-NT ( .@3 PQKT,6AN
MG.538M&8;I9/RT1M[F;XU-BUTIM\\08;\TTGS71M_B9'^*!IX/2SNWD\ONHP
M.#546];[Z[K:E&)3-''Y;\1*R&+3ZUR_+RF$<"JCC%,HN0XXSE$,J7IMH8P3
M%"(B:":L^@:Y"C(W\^7;3FCP5?W!SCWBO!IFOI,I,![97.C!VPGLN923+[ \
MN5:<Q9C4[W(K6,=.F9O'<]@H?BD?R:K-$E,3?]\^/9'R13%Q\;@J9,$4_[;-
M$(K58^VWZRIK+B*!XS!("!0X22!" 88Y1@AF62I3QO,XC8U"ZVZ48VY<V-<$
M*%5 JTMM=.VU 7MU0*=/6['6IM_S#>MGL#>;9E5&9L]_FP6QV 9-LS 3[6O&
M7""[#<KML [N.&X8?KHMQ.T8'.P)/ QW0Y;AF6I#.E'WPW+]9UT,5C_="RF3
ME$N60XQB9=7C((&8XA22)(ZS0$9)2*QB+8UGGMVG2POND.1GA+*9M3X*=F-_
M8.KV7^=JF-TU1<^TX& GN><T/!NP?.;9&<T[?2*=#1QG,^6L!G!LR7&2C"5"
MR3,I&60A#B$2$6E.2BF-) UB'.9!N%""%6NNA"@W9D1T4\;6\6SCO3]OQ&.Q
MTK6  "7J#VUNBE/&VRFR:G:1)ED,<4P81!*QYJ=<1KD,&0FR*&J1?;_BD^':
MS34>JN^;Y,$1(#5C\CFG"XZ:(#AV5N KIP(:Y_]-EO3WH("M=)WLKZ+442WD
M42C[\B0X.B(HQG&*8(X%@2@E&<0XYC#.1!3S$&<!0UZ"U<WDF9OQMY-:!ZJW
M8NL#:78QLMU3&+OA\IFQSH2+,C)'#0>\[U?KZ\%JO4X@O!VX8T?'&THSCY!Y
M.^B,X^@MAW7P'']=;]2X!5G^5BR%8H=55Q[HFV"B>-Y4BX"@B%!$8) P!!%+
M$TB85/R;Y4DH*$TH,VHL8#;=W/AT)S!XZB36+;KK4YRRE=G"KW@=;@-_KE<0
M1^:_/7X[87?1#-_&P,_"_>H5QXF\K'L\ET37!ZKJ3\;)L]FTT2O7+V2IM[Y_
M]^19-49LT(%Z?93I_*3&&AVX0\WO<J#DS^O56[W96]85?;:;;2E^*U;%T_;I
MH'S;AW5Y6->M^KS>_%-L= ZC4+=S73;T@WKP%CSD7*=ZP#2D:O-,<0X5ITL8
MLCQ/PYCQ/#<JY3B*=',C?*4?9#L%@:PU5"]8K6);X''WDFU7NBW34?W'"JS6
M&_ B-K7172M;5Y-4+T)F077>'P.#+\MK+N[('R*E&MCK!AKE0*M=4Y%R5Y 2
M* 7!4;G*"B@=P3]U!XQ.R[8RKU;T-=?5XHOWFNL[T0?RE=;9[CLZUCH,?G:]
M3SK=5WHLO X^ZJ--XN8H:\K[/9"_E$VA("J63>1D?7JA6^2J)VRYNT94"Y0P
M)E+&H4B1^LJ'00H)%PBR/*)"4L0IMHIJM)Q_;M_QIC%K40NHJY[N*J!*H=9
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MO"QXE :(QP+&+- ]BXF$)"5<MRD7#/$$UQ&NYMDX%^:Q(L8)4F\>]!S'->?
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M1DF4J)<Y#B'.E 4<9"0/DB @D7Z9S=VCO;'GZ1)U=H'V43-[@1VQ&/LXR
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MQ6'?_?#G^N&'FDD9-_H4<2E^BI4^2]R\?%SI(A3*RM%'C%TS&RZI8OH,)H'
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M&-K3TS0*21:$#(9)F$"4)13F61Y!D=*0A9E$-+9+^SL[S=Q>WO; M'+,[+F
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M/CC0K3<C 4G(,X@CQ%.2Q)('9-&4*%0L4F[,2/G";#8OZ?&<X[VO;XCZ)Q.
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M:0K5[G299CELLH@F69:I$H9&6Q[+O*";01U. 7(??L)LGYLQ.$SLN7TX^X0
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M(4K=L/?+LQZB^E4-L:D^MDW*_E,4CS\V@K>9V?4?=3:2?BGJ=N"+C)($![&
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ME4[G=H#I):?H\MBM!U9C<[*#%'L.$NRZ3A1#%$<)Q"%B\JC(&8J0YSI$+_+
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M&A#R*$IJZ%E#!TQ*BXT,NA([6BX&5#IAK^FF*,0N;4F8$Y(T=6'JRD*#<9C
MQ/=BR'W7I4E*6!1H[?.'.IN;!M@A UF-5^9VYJ6,5%+WK59B64TGV.)N9-W0
MP@0-3E #;7;[#52+[H@*A-CR)QSJ:EJ'0 6ACSSZ5-XQU!XO.%O541YY\0.O
M>OY^,@/'[E^]KSU )(JB%$/F>@0B%X<0TR""G-#0<[&/HT0KJEL?PMPT39V&
M9E>6#.!.(ICF!2RQMK+1'Q1%%30JU2,KIIKE?K6RFSV:I3PCZ2ECUFQI+WT
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MU\O*7D6V+C,*_H%7&RO!]^-_16J;M+_ MS&R;K:0Z:7=-?;( #4;H!)T[/+
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M6W^7J5L*H8O>X3(K=Z:N( V9'P4<>C)_-,)N!.,XBF'*<)(FQ$W$ UKN59H
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M/.3LWH@S@R0E9UFQEICDN(>)DY&<%?$X <GY1^V6)?^8%SQ[6-_6-\CT];[
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M_4CRHH@AC3')6)K*OUL%0)\>:FJ,6$L*FJ+J&%Z='P4:T8:6@= M<)N91VY
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M-!)/VT-E1\)M,+12Z]$;QR/,-KEW:+#UPC/KB,G-!%\4O+@FA>[W.\,A#[T
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M7@..YNPX!XZF8^2LY]ASG>;3XE:2IZJ7LWC)%95:.2E//V%JO%5*"K2H(%^
MI_Q9?S>_WS_>-0T;<WYJ0:^;A=P -S#7F&+FUN'9#4TO!FEY[&@\T:U:DPT,
MKNZW.;^F5"T%9:W4!5.C_/'"Y Y/ N9YL5%NA-6SIO1.;^0%&X%!*3%0(D,O
M[LYXL-[96*'D:(=B-N:H.PTK&/9W#'8WG_HRFG/Z6?[TC_^H?R/_1V6V_N,_
M_A]02P,$%     @ HHM)6-+*/Y1YK0  <#0( !4   !N8FEX+3(P,C,Q,C,Q
M7W!R92YX;6SDO=MVFSF2+GC?3Y%3<SNHQ/G0J[OW\B%=X[6=:2_;6=5[;K@"
M0,#F+HITDY33[J>? *FS1(DB\>N'<V=UVY8L$W'X$(@(!"+^[7]\.YG]]!67
MJ^EB_N]_$7_E?_D)YVF1I_-/__Z7WS^^8OXO_^,__N5?_NW_8NP_G[]_\]/+
M13H]P?GZIQ=+A#7FG_Z8KC__M/Z,/_UCL?SG]"O\]&X&Z[)8GC#V'YM_]F+Q
MY?MR^NGS^B?)I3[_L?._7?XK*&645)H5:3336B@61>$,/7(!/B7TY?_Y]*]>
MF""\-TP)5$RC- Q\C@P-.%5<R1[,YD-GT_D__[7^$F&%/Q%[\]7FRW__R^?U
M^LN__OSS'W_\\==O<3G[ZV+YZ6?)N?KY_*?_<O;CWV[]_!]J\],BA/#SYF\O
M?G0UO>L'Z6/%S__YZYL/Z3.> )O.5VN8I[K :OJOJ\TWWRP2K#=2?Y"NGW;^
M1/V*G?\8J]]B0I*(_OIME?_R'__RTT];<2P7,WR/Y:?Z^^_O7U];<HZGRT5:
M3N?XU[0X^;G^R,\O%@2)=_"I$KSY@/7W+_CO?UE-3[[,+K[W>8GEW_\RC]-O
MM+!40FZ7_;\O__'/EQ1\6>**8+/A^ U]X^PSZFJ'4H/?UCC/N.7S?)W9(EW[
MH5F5\F)Y_B]G$'&V^>XDXW2R^>1G<;5>0EI/D"L5).$OB&B9-F!9S )8D,D[
M+9TOY0;SE? 54;Y1R@K37S\MOOY,'_QS%4C]PT8R&ZG<6FXKG</H/M^%'^EG
M)X*7%+-.S&?!:0-QP2! 9LK;&+6,!$5Y%-E75[M.]56M/ENFGQ;+C$LR(^?+
MP3+=TO!U )_]Q,]?8$D?Q-+GZ2R?_^NR7)RTT-5ZT4!R6[40N7_YB;@NN%QB
M?K/5RD[F-IRMR;CBYB=;:/S9?'X*L_?X9;%<5_J+LC(1ZY%,)R^:@>66"1]4
M#*$$%7P3S5]==2\$R/X1<+ D.T'".UQ.%_F7>7Y)Y_ D@D L$5@2SI T+&?!
M0F'@2O 1(_T7FD#AVK)[84'UCX7#93DR&%Z<+JND7DU7"6;_"V%YSH,7*I)!
MD\RD1.Y2\B01@P3H4# 7KB0 /^XLV['R7I#0_4*BB40[,1$?ES!?3:OLS\Q<
M< J%AL0""L<T*,XB&CK_-(H(WF#@I8VK<&/EO5!A^D5%$XF.C(I?YNOI^ONK
MZ0Q_.SV)N)Q$G97RSK-$D10AFDX^KU,AB0291?96:S@*#3=7W L%ME\4'"7!
M+K3_'C]-JQ#FZ]_@!"?<)2Z]"HP#!Z:++LP[\.0%A^RULT4XUP !UU?="P6N
M=Q0<(<DND/!ZGA9+,F$;P7\@^>.+Q>E\O?S^8I%QHI,4EAO%) 5$3(L$#.J7
MSI.#K*S2P1\7"N]!Q%XX\;WCI)V<NX#-1_CV.I/XIF6Z35^=64+,4B6? TO(
M(^%?2.:A1):3S:!<D,JU.$MV++\75$+O4&DAVRY \BQG4L'J[+<WTSF*2=8E
M*N$-(ZN8F'9T2D(6Q)//6A252Q MCIH[EMXO9<5[1\>Q0NT)&2_HCV^7'Q=_
MS"<Q>C)RT3,>@R8+R,F5=IQ<*&T%A&B\%,<%JCL6W@\5'6<R6PBT)TQLSL:W
MRW?+Q=?I/.'$ (7;F:@'+@732GKF)2 #J8S1Z&70N1TP;JR^'SHZSG(V$VU/
M$'FW6*UA]O]-OVQ\I\2M=RE9EE7VC.)M,GY6 >-D$"&8R+E6[0!R;>W]X-%Q
MXK.16,?.?E8>E@@;NHVL\;;R+(,D+RF#(7@+SF)(64>I8TG'9<"OKK8? 'I.
M<QXJNI%57F_-9^\^+^;G*9@454*?'*.3+1/M7C"O,#*#VH?BK$0X3NTW5]Q/
M]1WG,H\2X<CJ_X#I=$G0%3)^G*YG.(DA\!H?,2Q9$NV:,Z^]9,H4([1$(XZ\
M][JYXG[J[SB)>90(1U;_QR74RJ0/WT_B8C;1$1(:3D=3S"0!1,."BHD)'Q4/
MA6R:$4?I_MIR^RF^X[SEX<+K9-/_\BU]AODGW"1<M0>C"DKF10[DP]8_@3$,
M?3 D!L$S')=PNFO5_3#0<4[R:%%V$0[\ V>S_SFG8/<#PHK.L?QZM3JE@PPL
MJB@\!;S%.Z8=G6:0BV YA^J]TDF6]%&8N'?Y_<#1?1:RA7"[0,G?%[-34L!R
M<V&W7$W(RS$^2DLJ+841Z(D5R((E9U!J8DB5XUR%.Y?=KURJ^^SC,<+L @UG
M=1W;:_MZ#)(23HD/EYTW%IDN16]#GY""H%]2K?3!R.&X$KK[5M\/&]WG(!N(
MM@N(O)[3IY$XIE_Q):SAC*U),L ]CYXIK2DZ=L(1"[%6B685%0H FYK<A=ZU
M^GX0Z3X1V4"T74!D8_U>P!H_+9;?)U! )B#/.4K%F0[9,^"8F!'<<?0(6%K<
M:5U;=#] =)]Z/%R07>#@PPG,9L]/5],YKLC2<6DA0&$H,[E&' .+"I ARF)(
M2D5!"[_SVJ+[X:#C#.2Q@NP"![^<X/(3'7E_6R[^6']^L3CY G."<P*/(4O&
M:Y6HYCXP'VQAT@-XZ27DV.)FXL[%]\-%Q^G)5H(=&1^O4UD^.\U3^HEGZS6N
MMCIX-8-/DV#J8@Z83XI./06<>>4BBTY92!BB3<<]V-F]]G[HZ#A[V4BLG11H
MOYK./ZQ/UK\LEXOEBP41D2ZX*8YK'6)B$@V0]RP\B\E$YK3.'@4/Y"T=!9*'
M:=@/+!UG/!N+N8L3Y\-GG,W.[:'T5GM?L[:I2+*'Y#H'H1VS2@CGK2";V*)&
MXNJ:^X&BXQ3HD6+L @3O3N-LFE[-%K">*%^P*(J<3$B>Y" TR4%)1A&4%IE,
MGRPM,'!ER?T@T'VB\U A=H$ @NY)K2=>I']^^$QB6[T]7=<WYO6&9Q*+T:X^
M9*QLU6<)D85,H!8Z!2V2$LD<YV \3,-^+P.[3WLV$_/!H"%>XJ*AR[&Z+$C'
M_/S[^TH+SA-^Q&_KY_3#_YR =5;$))C#RE8DDQA%R$R!-;$@\J3;>!X/DK(?
MB#K.CPXC])$-T#/B*&_<JNI D84L46@*U GS3"-$!DY;1NS($!SHHLQ1:+FV
MW'Z(Z#@=>KCPN@E9SA_&OJ+OK"8R4.3MN&2 4.K#I\""%9F^5%89HE.%V"A.
MN;;P?DCH. _:0J!=86+[B'[+A!$JE*02*S6[KXT,#(+2M6]/5#(I#/PXJ[!S
MZ?UPT7%>M(U0^W!2B8TES%[/,W[[G_A]XI07X%6M-*+H2A<$YJ4%ACHEGZR@
M$/PX5-RY['Z(Z#XC>HPPFZ'AWWZ^)<0W](W#.TUM<GFOY[5AV.;3KE.\7\.I
M6Y_1J._4_;0=V7ZJLC$YRV1>6>,"+,5:XP2= $9IVNQ@"#:< XL>"OT7K+_Y
M O>V8!Y8XR@G</NIKZ;+D]=Y$E/AP2%%0EECK0;A+"9)%+N:DA?<1C@N9+BV
MW#@]J%HJ[)I'>+ DQXX#MH1O2@B1>P1/=DA1!,QT(-J])J>E^*(@.J.U/JZQ
MR)7%QFE -;#Z'RW%/I3_YJR)X41AMEX8QYPSG&GE$X-4$DM.AL2#L.7(,.#&
M@N-TGAH8! =)L]^S_<5BOEK,IGF3](!9;8#YX3/B>G7((;_[PYIUF=R+VB./
M_=,5^P3P9;)YDEG=_+?EU71.BTW)UU]L6PM=P$FD!!%X8 H"A8*A5M %49@0
MUA>,&:R][VUT@57<Z/QLT>W.PMEZ=?Z=RRWV&+H.M1OG:SQ;K4BL%UPJ;X0I
MEHZ\X,B1E<:SD(E+CZI$ZZ37_KZSXQ NKU,PCC\Q&!+.#4L#<8]XR%RG_JQ@
M\(*) %XD!,<HYLT4_"22ARAT4EH5HB@A175?V>[AF+E!R+C0.4:S=X+D&#%W
M@)47L/K\;)[K;[_\U^GT*\QJ[OW9^@4LE]^G\T]_A]DI3I3 )!$M4Y:VD79
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M#6/?F R"E:,$W0%0GN6\N32"V3N8YM?S%_!E2F?A%;8FR@=AA<S,)#+$6JG
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M]:0@.TH=G8)K,^H^3Y)52GHOF0EH:K(EL^BS8<9$ZZ,%&WEK1VPW-6-GO$8
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M YQ_P-FL=M/'.4EW5GM^YI/I?%HENYY^Q3-93Y"KJ%!;YNJ>U24 "[K4VAF
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M &4FYQ%K'V*OK;)2*<M;FZP'B1K7=1H69VTU,G81S.OY5S+(E?BMI"B2V"1
MZ@Q';AR K=7IGC:(QF"8=T4R46(J(?#L_8V(;4<5S#V+C.L>#8.4IH+MP ;M
ME-*D/H 1$,F$)H],D__(/ C'%'&@>:0_YM9C>W82,VYP/ZS-::.!#F*XR^CS
M_.)].C\EIL["T\5\]1S+8GGVEN(C?,,5F=@ED/JF<UA^WX0PM5]ZO;)?;/)F
MYT[E1!OE8Z:3G2122P)"I, &#+-)\8)%!=I=@SR&&(2=3EX%MXD;>U%[-SN
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M9,4$+[RV[Q',EXATW,O =? @FX\X.(#,_8I5?[2+@*'UU0$D+_H-W*H\20Y
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MF-V@GOYL.4S./8#C'--6R;AQ\U5*3 L9&! GS-%N*9$7G_U>[8GW@<?8UN)
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M<]2Z0^H3Z7OLT_GF[<W$NYBL%XGY@'48G2+B$VU0QX.022'7*/8Z@V]^\G[
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M,X"+T #^11C/F/^_TQ.%3>5H68D@,WV8$KV(R_49/\D\""FU 6&MJX]V)*5
MI4 T65"B+IGD?H#$83_J3@U;G]; 9N1.D$51L&W!Y-IC49"\BBH9(F;C<R!W
MQ%EC >Q!UKC#6P;"S\.8L[5Z.DB47DUGY!<HJOEU1@*Z7H^:J?/LHK*6LXQ
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M4L::4T96TEZKJ?^F':2'X.>8#M)#U--!56%7PYD-6D=C+81@2$Q)(GCI&)2
MFF6=DFG>J'VQ':0'J7S/#M)#Y-\!C)IV2!@92LY"4T3M29XV2(@D2# 8I41+
MQTUN[>*??P?I08 :LH/T$.UV@.S'FQ.EU#HS2]&XK(O!T6IP6(@3M%%$QK-E
MHC%$GWL'Z4&XV*N#]! E=8&TIYH1:\R2UD_X=?:@0C'@I"K@4958-\R%YJMS
M_RX=I*<AKY72.D#@4>V%0D9KO<G@$\EL_6[:,YM!LISH*[7>VSH?^9MWD)Z"
MU\%5W &,#ZOA)8^E, J,5*X],Y85<*$(T-8K:QB7UK9NS7]F':2GY#_#Z:H#
M(#XMO#KX9#J[GE\O'R^XO<;E\OW',./B-_K)C\N),S&DX'(-W.M\=JXA%I)X
M=,Y'$;*2>-ZWPX=R<$F=IP=![: ZT:!Z?W:HOW,UMQGUYY/7@9<:RM<E*O54
M"H8!CS%*+E&EU+HP-2A#E]3DVH]-G(**4:]CVXCC1@Q_+%[/9Q\H0N,R!RD9
MHY"L7D>C+$#2D,!DTCP%A<FWKD>TY>"2>F7',X.3]'[Q1\-#[A\Z 2="L+8^
MW$AU(W1"#X&.3- 4GC++(J7;?<5'/V#HDIIV^[&)4U Q?D_Y?C)Y7!*3R+DQ
M&!WX+(G?; 5XESD87Q #LJCC>0W@<3HOJ==W.%PWT.&(K;ZG\/C00C-F@393
MR,:] V68(@OU#'(=SE>24*:TWH/9@.Q+ZO\]-XI/T?#)/O@!MIMWL-WV4?V&
M87F]V,ZF7"YQM=Q^)8?5M\%\L[=5>/0K/OP4EM/E":UI;3ZX4<_9 %)HU$QV
M^Z&_;);2$2G?VG^DDEIBU,!S-0>;)+B8$E@GF+'TS2!38U_S%#TGM^_<]O2M
M)?]BEE]/0YQ>;:OW&SW\\4WXFQ&JBWNZV!9Q%4:I4( UF4PTN0 AQ@")1V85
MRT*JYB/C6A$_<L=%*[Q]UQLTBG([2!-O&?_IZ^U?_\\4%T34QZ^O\0M>K5M:
M&!U>07 $H;4$I>E4<8685(*;G)F4(;9^V[8?99W@\;RPV07>=CKL"9EW3[WO
M^=M>U#+GC-)! 4?%0169($K-Z8]<+VI-M*+UU?A!!':"TX8(V07"YNKJ"8N_
MSCY?KY9KB?&;X7DI*)>X ^0L@5)T ,4D%5B=':644K'8O'UW-SF=X*P]"';!
M[42-= HN<3-0C.G((F,DD]I75Z_Z@\^Z;MO*O%BFLATLAOZ>G'$OT,8%US$:
MZ0!</X?E1XHZZO_4=QI?PM4Z>:S>7I;,1<H!F+8D(2,DA.0B6.5$4M9H+UO/
M<]M-32?0&C6.:Z2K#E!WLV(<\^,\/?[5FU[B$%36P4,4PI.%^40B]!249)WK
M@G*GL'67V"GTCGOBML+,=TNCSJ3 L2</;!GY;3[#K[^%Q;]P]>J:_KEAI$:]
M-98 )EP!%1SY^J3K+4&)%DF,Q,Z/*HD__)1Q\7,^1<^'D'H'ONYG7*RF94H_
M5GN)?\'/M3"_9<67+#7+#(RMRU)E*>"C*F"DLQ2(AKKRO/41NYN<<<_8LR.M
MM8)ZP-JCCV^$+\I6)JSCY.B%XQ!,O7N/J6@?BC2N=09Z_ NIP1J+QL/7R4KI
M %F[WC)JPS$JDDDI=1L&I3X0D0RD8%(4W:;$9.NER*<\3AX,77UD""VTU '8
MFC[1B=GDY*O/9C71)Z==<WP#*1:TB7/DK+7W>_Y/F \"U)!/F _1;@?(?OJ-
M8M':R$P9F40;B)E@(=81K,6FI U+V34?J'+ZP]++>-)\$$X.>EAZB-(Z0.!1
MKPYMB29;AY!1B3KQBH/C,=6AETI9B2&'UB67P1Z67L9#Z%/P.KB*.X#QPZ%"
M-_D:A>,8HX"0F*[/8RF@QL*@N&2\#QP9:WW-^S@ES^B-\RE0;*"F#L!VYWK\
MSMW2JP7^SS7.TM=U1"2"5!03(7!I$D5$CG+%&!44S>J#;>]0R]:)T(_)&O?=
M0B=)46/M]03(QQC:FJVVC(S))4!D=>!%9!"$1: O273%6XV#70WO)JN3_H-6
M4-BCR>44O70*M>6MQ=[$P-E[SGB$(E&"DJP>$<1=Y'1(Z, C-X-UK#Y!5R=@
M:P6&?3JJ3M%,3V@[X<1X_6TF,)FRTQ2Y9*WJ QX20["L3CQGGLGH..K6RV6;
M,C#NZZS.3N^S(Z(#<[@S3'7"4G+945K&UF/.'6/@O.# HU5H>,JN^7.).Q_?
MB2L]/PCF;332< [X\7#:2.^11Q(3$X*, 0W8*(@5'N@(4H(14U(E37D>I66-
MP;63F,MO]6H#M3;::N;%FC_>^WE.MK1836-]*#F;SA>_SU>X?)'S^MUBK424
M^>)3.'&(_!&?TNA9WJG\-7J#5ZM]W[!S^QI*&Y>UT1YXH5Q'2?)@+M@"3G"F
MD@I&\M8EW<<I:?'L^5O1:AMP,)Z810["1ED?V3+*X1*'H-%C\CYR.\2JK0=D
MC#\N^T2]/_;^^!11=Q!1W6=A<Y>I0[3$-J"L,QQ+IAS,,PLI!,VYB\P/,L6_
MM]'J)RGV2: <+.7N</)[^(3;C%W6[2[*^_IVE$Y<JP5$)^DHM@&C]PFC&6*\
MTV.T](29PW7\)&2.%/C8W<*;<_[.P;\^\M__.7\SGY)=_3E_-?V";W"1B,5?
MZO.1W\)7^NK[C_/KNA;F_9_T]:^OYM<W36(A%IZT45"X5758@X68A:W/2G2P
MUB3]\"7XC@;CQH3UA+QCH3+O1&]C8_:^-#<R6%9-5HLV428OG("2#1T"G'.2
M:+T:%LQ&J[GR4NP%P*<^9?RQNBW.OK;"[!456TNS/!$K7$+QE-*J4.=>V^ @
M1<N+S4$PW,\Q/?TYX_B9QIK<!Q]'B'5LA'PCGASC=$Y.<+[U?L;G["5YOZ04
MN6&.Y(9U'0BJ2\R1>Z\?#O_;]2QFUT=TB(MC-#AO+L[>0/''#+=<H!,J%2'!
MET!'HBZ*N,@(VKJDT'$AL!P%BMN/&.<8.2LHCA-G=^G4M_IH*9IAKD\J4&8Z
M:)4#%V2!)#0C1NH+Q=;/!W:0,F[#UK )^''R[@XVKT*J:]FO9ZN)DSI9S@QP
M7AO(4MW[6I<**59ONX53F(<8K_D8+3WE0D<J^DGP'"GU+BZ\[G/R:VV!Q>7J
M;5CANU4=4+A-Z<('G(CJI)-+8!1;+Z,DA^JR ZLXBSXJ9W'8*N!3U/64(0V!
ML6::Z<YGO<7/UXOT,2PQWS4DSI*T*4"0]?1.MH GMPY"BZQEB:J88>\G'B6K
MIR-P")2=KHL.X$5,A*_K_H/Z5CFN)EFSC+PV(-A(] >/$)E*P(30DI%3MKKU
M4?B0AG&[C(< SDE2[@ E_Z"T8[E9-_['[.5?J^GLP_5T^;%RM&7(449B;2V.
MID(YB<YD )Y2%$\<H22:%&_M@GY(U+C];D/@J*T>^IJ)_S#A71?.OV6L;ZOB
M^"3D:&)P%DR4M0">%/C:^R>U5HY.;QF;MZWM3=RX<\.'/_!:Z67LJM*;Q726
MII_#U>;(_F-VCQN<)%32QD!LB$)_**/I,"<!.B.C,:*V73W V([:T@\^:"^\
MV$O 2W.Q=G#F[8%]XC@AGY"395)8 \XERBBLH(R"^03>9B&=YB[88>_PGR!N
M+XRY2\#8L'H9VR?MQ15^FEY_FE"$F#*1"%$P$E[4#LCW9A YH2[&8F!\+_>T
M_V?NA2)_"2@:4M@=.*UW'TFB:_A/4";RKLD"J_-"E2IU:&C)D&(BNV#,Q>9O
ME[]]^GY53'8)B#E1M!T6+N\ _CUI?OEQ?G6G0/9'>;>:IW^M.7V_F'ZHR^A4
M0BOJA@.TC([NXA2$K!.48%F6#$EP0ZSF/('D_0!XP77T8978@2O;R>[WG.7,
M5;18@&GTM:1;(!@;(%K%2S8>+1_VVN\IZO9#X@57VYNIIF?0W=K8^T7(T]F'
M7\+7Y41S)7-]_LH+#YOF]U"X!6N-8X08Q(&OFW] X'[0N^ 2?$L%703ZZ&M+
M3->KZ1>\PR>?!%&<\%%"4KQ.&5"2PE290%M9@C%&Z^93Z8XF=C]47E1]_SR*
M&SM'_6TZFWZZ_G0WRMCRLG'Y\]=A66_%YHL5YKI"<!,M)\&U5>3S,113E]PS
M\%B3*1.\*-&K&/=KU3KN\_>#VT5< YQ+"]VYPK>8\=/GU4UIYR[O#ZJ.]2?Q
M$^9)01L=%PZ\0N)7U;J/T,2^-,6B+Q)9ZQDBI]*\'U(O^ )A8#5>VMMD I!:
M_Z7Y>^3O?O.@;Y"?YF/8=\=&4 YK5 2#<8T/ X%3P*<198J"%9>'V#!\GG?'
M5A7O.2>C2]5G<TO!@4Y(AAB=#DY:4X:][.SWW?$A>M_GW?$AHN[N>-P,&G->
M%FLR6$-!I'(A0@B1W+3)TAAA#&-F4+#T^>[X(,7^^-WQ(5+N#B=WWC9F%[VW
MI4[+=%B[D#+XH"PXF86U HU4PR:,';\[/DC'^[X[/D3@8R=ZK=^O%B>UR#E2
MZ);(!F76]76)!"LD>L^0K'"_Q49_CW?'!T%ER'?'A^BM.V?W+8%!<OW>!4,Y
MA';UNDX20]8#(RN/*6+ YM.H3GD5=-:GR>V.Q^/DW1UL[K1R6U_G1TL/08A"
MYX!S%&-* U%*SFS@2MEAWW#T_BKH($7O^RKH$*EW<KF^^>#-S'/\>;Y<+7_'
MU23H5)32&9RV$93( 3Q)!9+@*;/$K([M*U"/DM*3VVF%GM-E?FK[<Z,-+K>'
M=973S]>+*E)RRUDE+C,4R4@VS'EPA;RT8-I+.I*+<,V7Y3Y*29^/>$Z!3@.)
M=WAH;:<Z3HANCT4+R%(E"MD\AV"+ .0J$2.%E>8+U':0TN<KGI9'UC$R;WAB
MG:E*??.8\N5?GW&VQ.:UZAV_?]"*]3X\#5NWMB;0694T8"!/HU@I$()40& A
M3T/>1LG6^SW:UJT?;:2]_CR?W<AV@L:)1.@'(XRH,R4*."-8;?I/#G,47A\W
MU.?NIXP?&)^HW"<;DX^69P<G%(7S9'?_N];%[4*@V8=UJ/9BEJO8:KR_G 3!
M47A&[A-]J1O/!+%$S"DEBM#:2<36IK O;>,'SHW0-:A2.@#; X=.ML*2Y=&#
M\.N%DI5\QBR)3&(0B,JJUJL:'I P?N#<&#JGB/AXA,Q7X6K(F.<?\WG^<WIU
M%6:9& RS#S52V(Q*_SDL%E_K2/9U76)>;G[TA CHA$]K% ^UXK=1='3S&2^^
M)^<1^+(2,,0DP$1+@;;U"5ST#)C2=<D;MS&V'C)^$($G/[/??MC;^=75J_GB
MS[#(DUR,SJ+NV6%:@DJ4H0;RS"!<[6 EVTO!#L3S'3+&#;.&0\EW#^Q/U$ '
M1^$-"Q.FLY)%(D0T&51]Q.:+SV#)[XMLN0VE=0WIYK/[@,O12MP!BH,D>C02
M/J]'\[U;A<6J*1Y>I/^YGA(1OUS7Q2*; 8 3:4W6CI((*2/92JE#X8Q"2,PX
MSS!HUGSPV5/TC!MO#X6;DR7?D5<AN>#TPVQ3-4U?UYMAK]8:JK-)ZFB2B;&U
M02)FP*@H,)1)0@S)@7$JVV3)(:O6C4C[4S=N6#X4PAIKI2.\39PNDI-O)1.I
MQ57F WBN#3CI#6;E>6Z^Q/Z@4VRP"O9@I]@A$CWQ%'LYRR,E;P__O2U\8/[C
M"RY>+E?33_4*[Y]++-=7KZ=?3NK!'H*,X=.]-A(:)0\41>EL+(%?FMHBH.AO
M(4>0)4HG(V?HACIASI('ODL?,5]?X1^W.?BF6<<7<M01)1@,];&8H9A!15'-
MWWGDHKC8.A?<04H? 7Y[M'PW]*&!)CHX35]-9],55BO^3F _??TM_/=\\?-5
M6"[7W:^E$ 8B10;26%=G-4GP(2!8(WU@05IN6J>-!Y W+O":P.'A1MJ!=-,W
M[+XQ=J?QE:FZI-KP^L3+4HS*$4(V#EA.:*(7R8K6_NU $D?>6SL45/:'Y,EZ
MZP"6O^ 7O)I_K@,LT\?9_&K^X>O;Z8>/Q-QVW5*6RCFI@6>N06$-D%U]<ZB,
MX]$88T7[9U=/DM0M[$Z'PW<]-NUTTP'4?J78N!Q@M4&BD"PE*'5RJ\I,03!:
MTQ_.%Z[I..&M6XX/)''<$MT0!_"0.NH?@H]:L'%8*Y %; P2E#<>8N8<F.69
M?IN)"5M/M#R"S'&]XJ"P.0RB)^NP"YB^6<P3+I=O28U$R<?:CK(Y#&HOU-;]
M.V>3#L76SB=R_\)*<+((XC&GB,83SZU[ZO<BK&LHG@Z/[^#86E<= /#F0'E]
MVRN<9'&>)0^9,[+86#P$219K1>#"F2J^H:[>7Q_T8FRP^XHACMO3Y-P!4':'
MPS?%TH(3ZXKE.G#@J8)?1O+V#AWD2*&PDDG%U/H$W8>N/NIV1ZI^[RSU2#UT
MC:WE/Q;U&L^3X3%>(H28J]M6=?1L5J"38$I05A_2&4LD:YKZN+0?&E-'R+]O
M/+U(Z?K3]56]Y+G;%3PQ,H1@A" .*7$GG@IE[TZ!%)A$9C9[U[H=^W J^[C&
M'QQS+734-PK7CS9C,=XP#>CK8HBH.(20&/B0L\6Z,$N=$7'[OI<=_.)_<'0=
M*OMF7=R#%3->_I6NKNLHQ-MF!\F+=U8A!"5YG1/EP&-"2D*BMT9S89J/ 3R4
MQG'75+5%VZ#ZZ<"3/6)"W_/$O! &28"Z=O4I;BA&8"Y#PKKRS7%G;.LV]7WH
M&G<]56N<-=;#1;Y0N>W2>3&;7:]'9]Z&"-M7.F6^>.( &*;GJ155P[= #2*_
M43JB<A;.B\@ K:W'N* 37%D#R$R1R3F9ORWWOL2.J*=BY.^U]COIX/V?>/4%
M?YO/5A^7$YX82TA>1AHZ8)1-"ES1Y'D$:C0,!8K6;>ZG4=Q'G:8]]@[)?1KK
MM8/HX3!N_PO#XOV?\PGGW(E:/=?<48CD+(=H*?<37J)Q*B3!6X^X/8K0/NI
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ME E\R!E*$M;)NE*>MY[$OR=I^T'QN=P'G:28GO#VH+%&J,*+R@E<8(D"6,?
M,4JH<M':8HX9Y6 ]!\=T$%_NU<T)@K^(CJ:[3YJ_<]CM'W/O_(AA'VOOQ]D9
MFH6XUERY6H7+!2ED(^BXQ#V83,@R0J3H6[>\#M@L])U8_[&8+[^-28M1.>9+
M!&0\@B*_"TX8"\7*+&V.A6/K/J"G*>JWQ><07.QJXFV@A0Z.O.^XV4Y0F'VH
MES<_A\7B:]G,MEY2]%@B\R)!5(*!0NO 4=!(P61)03!IDF_]K/H \OIX7-,"
M%3\"7",5]8B^V[3['ENW*7@T-H>2"P45=2^!I:#2%QN!!6W0*V=DMD,C\&D2
M^WA0<PX4-E35V$7?[WC[.7R>4E X_5_,-PR]F.5?\ M>S3_7U&82A8A,,58?
MC*\W9$@(SF70&I43B9L@][OU.ORS^W@UTQ!BY]!!I\[NYFO;O.?NW1TQNTV#
MEG5.H4T.(R0?B-.D$+PDLTHI^2R+U'KXDW=O:L?MZSJS"QQ @=UYPV_Q!H8E
M+C=?G&!04<HHH(AZK9Q2!(\I@,@AZZ)]-CX<YP$?_;QQVZK.YO5.EW6/GNX?
M\WG^<WIU12;Q*VEM]J&V+6QYRXPB!)<M!0K6TQ\FD!<OC$)6*[6-4J0P?-JZ
MF[YQ.YW.Z<U:*:E' *XKTQ-FK55.D]W8&C P"AV"9!X24F0:$K&&0XTHN4_)
MN(U*9\U5#Q9\C_!9"VBB;1%!9PFB:%&'50CBPB Y966,2YEC:GT[_S@EXS85
MG=4G'2SX#M[%W^'B]33$Z=5T-;VSSH(+GF(B'HRJUR.610A<&?J;H3#1)U;,
M@ ?>(Q3U^V:M49WV5"UT%)'?8>5!J'CG.Q,C6'(L(6"P)+<D"_@D%&AID;['
MM'+NT-A\KT_NI@A[LLIW1.GMY7]JJ]#[(8Z]NVRN3W!$S>.ZL(S5JR-EL3$(
M#8XSI/0C&!9;MU@\04XW5=96,&NM@OY =>OF[]I)D*@R9QJRJ)N=LJPW_5P!
M<U%Z*0.EMT--:GN,GFXJJT/!ZF0EG(RKDX.LQ\LF=_C9AHS.<BMKLR:KG2,E
M*8A<2OJG89BC+SFS0T_ QS^JW\?4QT1/ XBWKXA\9V\D)2K:."-!:E?-@%OP
M(6I()A3FLG>%L>%.N)-Z64=Y)-VTA^)$??1WW#UF.K_C:D*)L0HN&<C>DNB8
MKMDQ%LIL ^/"H6)L\!OL^R3U^UZY*<).T,-%=!9^6Z'Y:QWS]6G]V]MT%#[Y
MJ]MW$N[/R1DZ"*M,0E(9I*F;PSGSX+TS$#POQ6CKF1VLM;Q=!^']-U:X?!_B
M%4YD*")@35"]+J!BMI1+D+DQ;GQ*J105?PB31W]SOXU_AZCS\0=JQPBO@Y+V
M+?TOKE<?YXOIZNN+OZ;+25UT:+2O;I#5IFUTQ$7=A:"\$!ZC$66P]SWW*!D'
M,@U4NZN3_7@Y=XF67^9U5?E$Q!BDE(*20TMQO_%UDX$U)!HFDE)1%AP>+QM:
M.G$R)^CYA] Y0N@=@.?>P*W_>[V8+O,T5;W\AI\B+B;)VJR<#!!#'>^B P=G
M?8'(K+#.H)"I=3/3#TCJ#4K'Z/WAWO.&2N@ 4]M%J#_/KV>KQ=<M#RK;$DS)
MH(2SM2!J("8G(1BG90E<6&S]NN,Q.CJY/FN)GI/%W0%DUAM#*8EXBU]P=HWO
M</%EFO#7M^^V[*#/1:949[@K01F@4N"DC(!UZX] DM< N[N?)*F32F)+(+54
MPMBWL'?B1,IN<;VD=N*XDHQQ7M\E&F(@TEFOBR &&%)BX9'G!X?9CW.HV]\^
MCF=I%Q2W$5L'OF2?>F7B13A-6:57@LPD&@9.EPB>>94Q*4Q^J+NLDV<A# VA
M(Q5_1-7X$"WT"*P'94H=69'!(UA;MUT7'L$Y*T$6QY$A#[SY-N$6Y>+!?=)
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M)$=_;/L&DS82.$/S29V1QYV70+DF84_K"-Y20D%PU"8H;XL;[%1J/[[JP:S
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M9TGHK7F+G)$OZ!>OSU_%\1I%IW_DKY_?L9BB&WQX?6%*& J62=ANA3\0BH-
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MF 4+T6XS6CLPX/,:]TJ&XJ!H"6SWW'7%4=%]52A9A-G@Q6#!%-A^NB<I!0"
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MOKICJ*H*:/XVE@*H:%F*^J?!60G*GSG:?$M/WN:3+?P1L3]@7#-PAFM]#D;
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M[>:J@%-;>1^%P53<V%8SW!L(8;BKC;*U)+H%9,ZI0^.,$ D/I0H8QRCMTPF
M%J5W5(%[($(O#Y:"UP2;I*@?;FL+$&TXR#3QK[96OA"P%/[ =!!RKL@3%TSA
M^AM4L:BJ\0VJQ,B4?52YJ0B(.#JL'X'#@*/QS'__<_=($&T9DXS@G:H@'-M"
M0-**[K<UQHJ5.*O89'.YK>=> PHV<#@AA_TC;0R/";  2YM:0E,[5,;'RZ@H
MRN(@^$=1#^Z)@Q/8 6NKOKK/<X; U]:&&HI>K/3#/;F1#V,J@/L^'EM@*.>$
M]..I@ZJD#,;GQU_O?SJ^>O^VO6O,W#.,SCVQ/QI\GAQ.SQ$1[Q8+X#(1JUS5
M2Y2"K,);/V87+!6V F*;%C(1YAM^CYV]I_9MUTTL@2S0(H@ +$RU&7:05TN*
M)K *EF'B"F_%^/3PC90Y0>L7=A]:]#9W1 K >K09):76-@C1*^F=*N_T.)+U
M+K#%S9"=%;85*(HYD2YF-8:!S_:Z=#('S9O!.^"95:(L "BF]M3-_G?/IR^/
M+M?[)QM\W#^] &=@0-HW&EJU0JD$T_$**IY*A)Y*A':M9^+QZ)GCP[-77;T=
M_566X&+D^8Z5S"]!)IM;HRJNF^B[LY-.4<<=SI:3VD5CZK#/ [/A"W3B>% .
MQR.;/ ^<K^U\QTG4E#D6>]@*DI2;'_$!54FBOJBPS;6)C4S\)3>KY70OV>][
MZYB*+63MBZ^'B_HG7-7?+^,'7TBR,VOGPT0@N3$>#"]!3EA(8@?KQ%8:DZ[@
MF/U::6MOL#\[<"-K::R9*<-F'YP=50@L6NAY<-9]\V3&X3 <95,L-/;E)(C5
MPW! 0-A4P[$8PBQ !=X\15X8'UV+0I8S$#2<2\235@:/H4D8@]WG9*+)ZTD'
MM6%<O8I!JGLOTI+&]O&#%FOD+C/(Z.//96F;#(D\US0)XL%G8&YLTNCC%7+)
M>(3<R2'9TA];0O/FM#W,Y4Y#D"'-%V*)3!&.7ZM6N 3XG(FV*K%3-/ON^=GY
MY3UHI(.>DQ$%,, ;V-U!]*CF[/#E"2*"@E$D]<!B1QZ7'$?'6"@*:IU2#IEG
M51B2L2!Z),8 $S;1^W5=G#OHQ?;H-^OMY=MH&IZO80-?G)68 *5@%LVU*O+K
M>7K?L+QU<NU&<HCU]\4:'5Y@&>][0..ZF-^U[(8F!:BI8E&'@) *VT;5ND ?
MKUA]*!8;ML^=="*%A)>'B13R2;3-?X^; T?$@F"=DN3N3B^\-Z=8VL_5-5H^
MB6@,M<52\N9683)<?#WXK0$7CFHHM:S=N #,VTQL>23'NV.PCC-EM7.L*Y%B
M2^Z-4+EC)R"\O%I*V:]<G>#%#&ZD?(*4M6VE\\,): $UWWES\&BZ)_;WIB=4
M,]N]-,5+SJ3QW7B/I -OC<V0CL=F<([15=7HA,^RU=*[M1:^L)B",[-3&,C4
MY_A:RQ:YN!W*+Y$8IO9?&M$*S@ H-Y,@S9-$[62>:E7P/(P4/9"Y#9,Q-[)[
M=2?K>7J<=%65$]FAL4_W84ZT''+-.(74W0U82WXOX3:,E-?APVT53=]5X'\N
MO:/3%LD8=^R:BUCBUHV!)U39I.."!&A/^ADPN ;[INY9'%F$/_CZM(58TB+,
MU5J38LBC<04MD[LG;IU?4D35VBM8<KN\Q]#78/S(!GA8W5$(-D'-F.>VY!='
M?0DS1Q!1JM7+ [80:.,FVG,HL\5X<%M3VI^1Q-QE>C5=Q)_V_>NZ[^-I$$;6
MI(O%3*C2<+07A38:SEE38X7J!I#<HV_VD; SJ6@!X"J5F=2XY:1C;P0)X6 6
M#1D&/;G]^AT_FX*V-_M!UX5EI'"*0Y]O$5K*NH.9=AA=K7\I66QWLCRZ%)SP
M;3!=&K"%J_MO#53/$<X0]#K2T>HP373&Y]!2$ZX@9@<%HT  @)ZU+_9(H1<$
M&W$V(YYD4#4Q^;,#4O<L79&'LQV7KB Q8\>0T" 'XZIL#,NLQ&<Q.;V9K.%R
M3^= @P.G.B1R?<%W4RN<XLPU J*0CK*!?:S!S1,?T>Q?G1RM!\<1ULM%JVLW
M"ZO':-_(\=@W-B;R"=-VJ2S*3K]2_[AV:^_T:T6YV:X+M)AI:9W.0(Z 2F@T
M9_E8O'7ZW_P:*V(XO+RN?0W'FO/[) =/PP\+P /B)8X1<^*1Q3=R95FMZ',_
MQ1O)NLY=OUGO& # ] :!=PK<>MDT]AR>7UIEXS5!X'KW8\B>O:TGT@IK$-)6
MFVJIBKC1]%THDM<KUA(5S'N,@M.BFL*P7D*W?5&A04K]F#YN:EI]$<Z(#V#;
MX;B L64K5[^K\Y2M?,I6[EII9>-16F>'1\?\+:45E=4Q4G:KK]Y1QV(1!\W+
M'>C:OD;G$73NY4EU6-S21I/)R>QTA*\D0=OVB%C:UFX:%P?^ DJ0S*H^-UNO
M5UZIVR]*\+]0#J]OHG72DMW/4=@#"4U)/XK.)5/QJS$V:F$=@*[;@X_TIK\-
MF/>-1(PDAS,"[]@'6["^LR2B_D147RVZJ.PY. [ZHI\95,E\0(/G-;@A"MJ%
M^WF,1NML//SOJN+ :K6EKG^MP./X3,$B5^B9$=;'9,"21+"C)U>YPZ:5+7_>
M^T,]ZWSX-5:G%1!VW,*>LN5D%ITS1*=>0:>F;])X%JMMW1VW>''/1,:1LERH
M @'':H-:-QR;"CFT]?Q]))W]U:!!0&M,OQ . H9R8825R -.TE1N(V2-PKM5
MW6!I>(0:'!91,Z>+J;0S-<-7P4H.\0\:O\IPEF_\5<%GXZL*?M=176.6@<,<
M_(';(7$Z"X^G3TBU&EDCW8.&PJ"PHK:9?I=-W"IN&01:NN;*0)B%5U.W&-<A
ME5PEDKO((2><.9]J/[HF@M81ZWWY^IE5OXND4E=]#@&WT0CP>R30W!Q=@TR/
M ,6*/79D:NHXXB_&2<Z8N]K[<(1  ^H6I[KT7TI,' 00$\N>!'&PIX_X@3&M
MV:=MZFT,I]4=8QE9&YY%$#F>[C[*5=*X;9\/IO.Q7W*TR6N6+KX*JV<K4(D4
ME7F #R^-P0^;5)HS!0NMJ*?%V*ZC&BT-V])+D;:D6K3C6GOO"3[W9A98[V4+
M78@X'-ET(LK;18\]-NA)LEA4MRY\V\YF=GG/_L >-Y YI%(1#M$9,)#7IZ=D
M8=9C#4\'3]\?O>V XT\2EO5 9&2OLED<40X:FSZ4N:IG57E3Y3<^7#* BD?P
M/:N7X],65Y),'B+=QZ<K/F:<A.K&$UNJJ3HIPW9"E/5KVG547[0V="C27YN4
MHI&^0JR\$;E*@7ER&A7.*30;%+3A4%=UB!0^<5D96D;?Y[$KJ3:NLYC%2&M!
M"NX?#&:)K:_.=<65=\,7/,3OTQJJ=OR?_RJ$'X9%/-T*!+*GO8G9PVBE.V@/
M7CU^/GTU/C[%W &(>*6=M_(SD<)G/# E?^_W7G;(NI\J5+,S\A/HFT*]KY(R
M+9=5QTG3K8H0AI:B]">^=%8A$W,;9R OR8 V$X68<<(N&/$?:8O CA9UF8N,
M%"/P'[ DO(0M"3(3?0I\16@(K8PSB+ .74?]^2+>/V5@?.YP?5JP%6B^PAPG
MH-!<CA!N;HKFX7E!ZB5Q!7>6"5>A'BC"[B<3@CS&FB[V;@<QJ^7"3JS^[OGI
MJTM.:9"W:&]*P,3,46A@C2;VIW=WRQ]!1GX(2P;[55S^J[1'I\X<NA(Z%J4T
M!S]_S>72S3<]/CHZ'NFPL:N?_Q?A'T'O[G[D9])UXP%#>;H?YTIF0ZV &%RD
M:^U,I_":M?>\1=UI8'3<OO"Q3T<]?F!FJ[NLFFVI;6)K3VPYH?V%2E F+?,'
MWDV0S?11B9"I%,WXI*+C2@]<GP>?3G0F/'U\FRJY7-L]LR:V1B(JX>]N1?$D
MFH.9?\/34$4]A)/>P,E5S]!%FQJK=6EJY19/LK3GI)[K:?G#9T(/>HB#B:0/
M"5A7SGO:(#/!E7I*:_JTYNE36O,IK;EC\_E\?.;S.W1I4):PV/W2VBJ/SW(>
MK,QEIZVUPB1;GOS1X)Y+S"DR/1"@Z_3P4Q2TK[;61(O61U4)KNX[#+;(]*-+
MKN+2?5]P);F'</6[0<;O2KX>'R]<-0DBO=*/T&M<_3 V6 ,N\DWQTB#$X9VT
MH:)(0=S2J>X/K8K/#3Q@>O3^8!H:.[WZ\Y7F)(KI*FW3;0F/7 ?;#OX-_N)I
MXMSW&W+*@%-JI_N2F7*?X4@[HO+IT:%+;?;__.R0^A--&MZ6YCCWO"-':'@G
M0T.U;*@=!6%>\=AL3A[17C>F<[R;U3-F.]7=IG.UY@'-Z^EA!%8HH? _U^'P
M(2]L2TE3)[X8,;\VP+39\ME:N^K_L_MP]N0^[-I]0*I0Z??/5'H2I\?'29;*
ME_'IV7%\/LVRXY/DY/Q$O):9>/6/TV=_DLLQ0)54J+6>9[:U(+XIB0_KJD^R
MT56BL>WN!U691&&)&JCDCV5R[XJQ$6QG3:52,.6 ]<TCW-I/6)Q0A?'%=\EU
M6=WF,IW]GJEW]Y?_W]Z^6I/GY&(!2HMC=1AU.&)XC)/\'BNVT_XC>%U1C+(*
MK 9.I+3==/RH35RPKOIMA:8F04C.?[?4S5G!E">8RA3!X]!HVWY65"G7KZ[Z
MEWL(W2AC]%T^VF6(GDIOR'&Y<1]/H#8=.W8(CA*/I+[%V=9X6U!%3)W&$K\^
M95>%>9HV$EYE&7DC6!)S1W"6;-R-Y#3>([7F_!C.M$T^$/?:E(/_+GOGS%;&
M74]<UR8%2MIC#.8@87;@5F/E4F_(PLH#,:%!8]%]Z[1OIFZ_\>%:E@O[\6H/
M7T!O["3-T/,>U8#7-3(V9*GA6JEH3^!GD;(V7>WVNM\V\[N/.O71NATV>5A:
M+%V/-%]W[6(R[67B>BDAZ07S1QYN[4>MM55AG"SM!-Z"AF5*V@3]V4'PPP-!
M4QG@#5FCV]Z^#9H(26]#]QTK*,S?@XM[*[B><<FM 90I'.[,FVS=FB>'._/N
M3Y)C,Q:&A=H[/ XNI6SM)9G><V[52+<\.,B&K+L4K!.N.KT@\89WK0_FC'Q+
MX*:(PLZ8V.&$H']%Q'Y!.?2$V3\!L^U8E'\1Q#Y]0_U?+;CV(J[2)?PUKXO\
M[?\!4$L! A0#%     @ HHM)6.(1N=UUC@( US(; !$              ( !
M     &YB:7@M,C R,S$R,S$N:'1M4$L! A0#%     @ HHM)6$&4J0HK%0
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M,#(S,3(S,5]G,2YJ<&=02P$"% ,4    " "BBTE8ZH V(+<W  #Q.   %
M            @ %6; , ;F)I>"TR,#(S,3(S,5]G,BYJ<&=02P$"% ,4
M" "BBTE8LL?H.$XT  !Y-@  %               @ $_I , ;F)I>"TR,#(S
M,3(S,5]G,RYJ<&=02P$"% ,4    " "BBTE8AO09M_8?   Q(0  %
M        @ &_V , ;F)I>"TR,#(S,3(S,5]G-"YJ<&=02P$"% ,4    " "B
MBTE8NE>OP-(O  !@,0  %               @ 'G^ , ;F)I>"TR,#(S,3(S
M,5]G-2YJ<&=02P$"% ,4    " "BBTE8N<Z*(3Y= @!*P@( %
M    @ 'K* 0 ;F)I>"TR,#(S,3(S,5]G-BYJ<&=02P$"% ,4    " "BBTE8
M;04AFW8K 0!CGP$ %               @ %;A@8 ;F)I>"TR,#(S,3(S,5]G
M-RYJ<&=02P$"% ,4    " "BBTE8!DDR9_$] 0",4PT %0
M@ $#L@< ;F)I>"TR,#(S,3(S,5]L86(N>&UL4$L! A0#%     @ HHM)6-+*
M/Y1YK0  <#0( !4              ( !)_ ( &YB:7@M,C R,S$R,S%?<')E
M+GAM;%!+ 0(4 Q0    ( **+25BGW(R4\@(  .46   6              "
M =.="0!Q-"TR,#(S>&5X:&EB:70R,3$N:'1M4$L! A0#%     @ HHM)6"\#
MYH,R!   _10  !8              ( !^: ) '$T+3(P,C-X97AH:6)I=#(S
M,2YH=&U02P$"% ,4    " "BBTE8)U<C8K\'  #V)0  %@
M@ %?I0D <30M,C R,WAE>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( **+25C4
M>Q@E=@<  &DF   6              "  5*M"0!Q-"TR,#(S>&5X:&EB:70S
M,3(N:'1M4$L! A0#%     @ HHM)6-V5:\I+!0  62T  !4
M ( !_+0) '$T+3(P,C-X97AH:6)I=#,R+FAT;5!+ 0(4 Q0    ( **+25C[
MPZ['_QD  +JI   5              "  7JZ"0!Q-"TR,#(S>&5X:&EB:70Y
;-RYH=&U02P4&     !, $P#N!   K-0)

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>nbix-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nbix="http://www.neurocrine.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestFourCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestFourCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2019VoyagerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2019VoyagerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2019VoyagerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2019VoyagerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2019VoyagerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2023VoyagerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2023VoyagerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:A2023VoyagerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:BIALPortelaCaSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:ScientificEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:ScientificEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:Amended2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:Amended2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:TwoThousandAndElevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:Amended2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:GeorgeMorrowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:GeorgeMorrowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:EricBenevichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:EricBenevichMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nbix:EricBenevich2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:EricBenevichMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nbix:EricBenevich2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:EricBenevichMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nbix:EricBenevich2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:EricBenevichMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nbix:EricBenevich2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:IngridDelaetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:IngridDelaetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:LeslieNorwalkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:LeslieNorwalkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:ShaliniSharpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:ShaliniSharpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:RichardPopsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:RichardPopsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nbix:EricBenevichMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">nbix:EricBenevich2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>nbix:segment</measure>
    </unit>
    <unit id="non-clinicalstagecompound">
        <measure>nbix:non-clinicalStageCompound</measure>
    </unit>
    <unit id="preclinicalcandidate">
        <measure>nbix:preclinicalCandidate</measure>
    </unit>
    <unit id="undisclosedprogram">
        <measure>nbix:undisclosedProgram</measure>
    </unit>
    <unit id="genetherapyprogram">
        <measure>nbix:geneTherapyProgram</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-32">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0000914475</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList contextRef="c-30" id="f-208">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-52" id="f-374">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-380"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-381"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="c-155" decimals="8" id="f-627" unitRef="number">0.00131711</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-194" id="f-775">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-197" id="f-833">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1022">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <ecd:TrdArrDuration contextRef="c-208" id="f-1076">P337D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-210" id="f-1077">P364D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-215" id="f-1078">P648D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-217" id="f-1079">P366D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-219" id="f-1080">P186D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-221" id="f-1081">P375D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">0-22705</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">12780 El Camino Real,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">San&#160;Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">617-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-8" id="f-29" unitRef="usd">7900000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">99507490</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s definitive proxy statement relating to the registrant&#x2019;s annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days following the end of the registrant&#x2019;s fiscal year ended December&#160;31, 2023 are incorporated by reference into Part III of this Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-36">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-37">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-38">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-39" unitRef="usd">251100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-5" id="f-40" unitRef="usd">262900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-5" id="f-41" unitRef="usd">780500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-5" decimals="-5" id="f-42" unitRef="usd">726400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-4" decimals="-5" id="f-43" unitRef="usd">439300000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-5" decimals="-5" id="f-44" unitRef="usd">350000000.0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-5" id="f-45" unitRef="usd">38300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-5" id="f-46" unitRef="usd">35100000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-5" id="f-47" unitRef="usd">97800000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-5" id="f-48" unitRef="usd">79100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-5" id="f-49" unitRef="usd">1607000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-5" id="f-50" unitRef="usd">1453500000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-4" decimals="-5" id="f-51" unitRef="usd">362600000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-5" decimals="-5" id="f-52" unitRef="usd">305900000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-4" decimals="-5" id="f-53" unitRef="usd">687500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-5" decimals="-5" id="f-54" unitRef="usd">299400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-5" id="f-55" unitRef="usd">276500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-5" id="f-56" unitRef="usd">87000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-4" decimals="-5" id="f-57" unitRef="usd">161900000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-5" decimals="-5" id="f-58" unitRef="usd">102100000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-5" id="f-59" unitRef="usd">70800000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-5" id="f-60" unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-5" id="f-61" unitRef="usd">35500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-5" id="f-62" unitRef="usd">37200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-5" id="f-63" unitRef="usd">49600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-5" id="f-64" unitRef="usd">25000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-5" id="f-65" unitRef="usd">3251400000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-5" id="f-66" unitRef="usd">2368700000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-67" unitRef="usd">448800000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-68" unitRef="usd">347600000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="c-4" decimals="-5" id="f-69" unitRef="usd">170100000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="c-5" decimals="-5" id="f-70" unitRef="usd">169400000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-71" unitRef="usd">35900000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-72" unitRef="usd">20700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-73" unitRef="usd">654800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-74" unitRef="usd">537700000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-5" id="f-75" unitRef="usd">258300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-5" id="f-76" unitRef="usd">93500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-5" id="f-77" unitRef="usd">106300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-5" id="f-78" unitRef="usd">29700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-5" id="f-79" unitRef="usd">1019400000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-5" id="f-80" unitRef="usd">660900000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-81"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-82"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="-5" id="f-83" unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-5" id="f-84" unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-85" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-86" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-87" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-88" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-5" id="f-89" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-5" id="f-90" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-91"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-92"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-5" id="f-93" unitRef="shares">220000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="-5" id="f-94" unitRef="shares">220000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-5" id="f-95" unitRef="shares">98700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-5" id="f-96" unitRef="shares">98700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="-5" id="f-97" unitRef="shares">96500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="-5" id="f-98" unitRef="shares">96500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-5" id="f-99" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-5" id="f-100" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-5" id="f-101" unitRef="usd">2382000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-5" id="f-102" unitRef="usd">2122400000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-5" id="f-103" unitRef="usd">7000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-5" id="f-104" unitRef="usd">-7900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-105" unitRef="usd">-157100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-5" id="f-106" unitRef="usd">-406800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-5" id="f-107" unitRef="usd">2232000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-5" id="f-108" unitRef="usd">1707800000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-5" id="f-109" unitRef="usd">3251400000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-5" id="f-110" unitRef="usd">2368700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-5" id="f-111" unitRef="usd">1860600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-5" id="f-112" unitRef="usd">1440900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-5" id="f-113" unitRef="usd">1090100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-5" id="f-114" unitRef="usd">26500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-5" id="f-115" unitRef="usd">47800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-5" id="f-116" unitRef="usd">43400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-5" id="f-117" unitRef="usd">1887100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-5" id="f-118" unitRef="usd">1488700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-5" id="f-119" unitRef="usd">1133500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-5" id="f-120" unitRef="usd">39700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-12" decimals="-5" id="f-121" unitRef="usd">23200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-13" decimals="-5" id="f-122" unitRef="usd">14300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-5" id="f-123" unitRef="usd">565000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-12" decimals="-5" id="f-124" unitRef="usd">463800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-13" decimals="-5" id="f-125" unitRef="usd">328100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff contextRef="c-1" decimals="-5" id="f-126" unitRef="usd">143900000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff contextRef="c-12" decimals="-5" id="f-127" unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff contextRef="c-13" decimals="-5" id="f-128" unitRef="usd">105300000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-129" unitRef="usd">887600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-12" decimals="-5" id="f-130" unitRef="usd">752700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-13" decimals="-5" id="f-131" unitRef="usd">583300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-5" id="f-132" unitRef="usd">1636200000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-12" decimals="-5" id="f-133" unitRef="usd">1239700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-13" decimals="-5" id="f-134" unitRef="usd">1031000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-5" id="f-135" unitRef="usd">250900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-12" decimals="-5" id="f-136" unitRef="usd">249000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-5" id="f-137" unitRef="usd">102500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-5" id="f-138" unitRef="usd">4600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-12" decimals="-5" id="f-139" unitRef="usd">7100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-13" decimals="-5" id="f-140" unitRef="usd">25800000</us-gaap:InterestExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-5" id="f-141" unitRef="usd">28400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-12" decimals="-5" id="f-142" unitRef="usd">30800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-13" decimals="-5" id="f-143" unitRef="usd">20900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-5" id="f-144" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-12" decimals="-5" id="f-145" unitRef="usd">-70000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-13" decimals="-5" id="f-146" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <nbix:InvestmentIncomeAndOtherNet contextRef="c-1" decimals="-5" id="f-147" unitRef="usd">57400000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet contextRef="c-12" decimals="-5" id="f-148" unitRef="usd">11200000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet contextRef="c-13" decimals="-5" id="f-149" unitRef="usd">3800000</nbix:InvestmentIncomeAndOtherNet>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-150" unitRef="usd">81200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-12" decimals="-5" id="f-151" unitRef="usd">-35100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-13" decimals="-5" id="f-152" unitRef="usd">-1100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-153" unitRef="usd">332100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-5" id="f-154" unitRef="usd">213900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-5" id="f-155" unitRef="usd">101400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-156" unitRef="usd">82400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-157" unitRef="usd">59400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-5" id="f-158" unitRef="usd">11800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-159" unitRef="usd">249700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-5" id="f-160" unitRef="usd">154500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-5" id="f-161" unitRef="usd">89600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-162" unitRef="usd">-2400000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent contextRef="c-12" decimals="-5" id="f-163" unitRef="usd">-2900000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent contextRef="c-13" decimals="-5" id="f-164" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-5" id="f-165" unitRef="usd">12500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-12" decimals="-5" id="f-166" unitRef="usd">-9100000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-13" decimals="-5" id="f-167" unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-5" id="f-168" unitRef="usd">264600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-12" decimals="-5" id="f-169" unitRef="usd">148300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-5" id="f-170" unitRef="usd">86100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">2.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-172"
      unitRef="usdPerShare">1.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-173"
      unitRef="usdPerShare">0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-174"
      unitRef="usdPerShare">2.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-175"
      unitRef="usdPerShare">1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-176"
      unitRef="usdPerShare">0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-177" unitRef="shares">97700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="-5" id="f-178" unitRef="shares">95800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-5" id="f-179" unitRef="shares">94600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-180" unitRef="shares">101000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="-5" id="f-181" unitRef="shares">98900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-5" id="f-182" unitRef="shares">97900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-183"
      unitRef="shares">93500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-5" id="f-184" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-5" id="f-185" unitRef="usd">1849700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-5" id="f-186" unitRef="usd">1800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-5" id="f-187" unitRef="usd">-725400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-5" id="f-188" unitRef="usd">1126200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-5" id="f-189" unitRef="usd">89600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-5" id="f-190" unitRef="usd">89600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-20" decimals="-5" id="f-191" unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-13" decimals="-5" id="f-192" unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-21" decimals="-5" id="f-193" unitRef="usd">134200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-5" id="f-194" unitRef="usd">134200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-22"
      decimals="INF"
      id="f-195"
      unitRef="shares">1400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-21" decimals="-5" id="f-196" unitRef="usd">27500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-13" decimals="-5" id="f-197" unitRef="usd">27500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="c-23"
      decimals="INF"
      id="f-198"
      unitRef="shares">94900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-5" id="f-199" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-5" id="f-200" unitRef="usd">2011400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-5" id="f-201" unitRef="usd">-1700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-5" id="f-202" unitRef="usd">-635800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-5" id="f-203" unitRef="usd">1374000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-5" id="f-204" unitRef="usd">154500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-5" id="f-205" unitRef="usd">154500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-29" decimals="-5" id="f-206" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-12" decimals="-5" id="f-207" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-5" id="f-209" unitRef="usd">-106800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-5" id="f-210" unitRef="usd">74500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-5" id="f-211" unitRef="usd">-32300000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-5" id="f-212" unitRef="usd">173100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-5" id="f-213" unitRef="usd">173100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-35"
      decimals="INF"
      id="f-214"
      unitRef="shares">1600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-34" decimals="-5" id="f-215" unitRef="usd">44700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-12" decimals="-5" id="f-216" unitRef="usd">44700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="c-36"
      decimals="INF"
      id="f-217"
      unitRef="shares">96500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-5" id="f-218" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-5" id="f-219" unitRef="usd">2122400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-5" id="f-220" unitRef="usd">-7900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-5" id="f-221" unitRef="usd">-406800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-5" id="f-222" unitRef="usd">1707800000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-40" decimals="-5" id="f-223" unitRef="usd">249700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-224" unitRef="usd">249700000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-41" decimals="-5" id="f-225" unitRef="usd">14900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-5" id="f-226" unitRef="usd">14900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-42" decimals="-5" id="f-227" unitRef="usd">194300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-5" id="f-228" unitRef="usd">194300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-43"
      decimals="INF"
      id="f-229"
      unitRef="shares">2200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-42" decimals="-5" id="f-230" unitRef="usd">65300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-5" id="f-231" unitRef="usd">65300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="c-44"
      decimals="INF"
      id="f-232"
      unitRef="shares">98700000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-5" id="f-233" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-5" id="f-234" unitRef="usd">2382000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-5" id="f-235" unitRef="usd">7000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-5" id="f-236" unitRef="usd">-157100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-5" id="f-237" unitRef="usd">2232000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-238" unitRef="usd">249700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-5" id="f-239" unitRef="usd">154500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-5" id="f-240" unitRef="usd">89600000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-5" id="f-241" unitRef="usd">194300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-12" decimals="-5" id="f-242" unitRef="usd">173100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="-5" id="f-243" unitRef="usd">134200000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-244" unitRef="usd">17800000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-12" decimals="-5" id="f-245" unitRef="usd">15100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="-5" id="f-246" unitRef="usd">10900000</us-gaap:Depreciation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-5" id="f-247" unitRef="usd">18300000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-12" decimals="-5" id="f-248" unitRef="usd">-3700000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-13" decimals="-5" id="f-249" unitRef="usd">-7400000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-1" decimals="-5" id="f-250" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-12" decimals="-5" id="f-251" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-13" decimals="-5" id="f-252" unitRef="usd">16200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-5" id="f-253" unitRef="usd">700000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-12" decimals="-5" id="f-254" unitRef="usd">1200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-13" decimals="-5" id="f-255" unitRef="usd">1100000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-256" unitRef="usd">3500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-12" decimals="-5" id="f-257" unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-5" id="f-258" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-5" id="f-259" unitRef="usd">28400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-12" decimals="-5" id="f-260" unitRef="usd">30800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-13" decimals="-5" id="f-261" unitRef="usd">20900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-5" id="f-262" unitRef="usd">-56700000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-12" decimals="-5" id="f-263" unitRef="usd">19100000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-13" decimals="-5" id="f-264" unitRef="usd">4300000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-5" id="f-265" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-12" decimals="-5" id="f-266" unitRef="usd">-70000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-13" decimals="-5" id="f-267" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-5" id="f-268" unitRef="usd">-900000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-12" decimals="-5" id="f-269" unitRef="usd">400000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-13" decimals="-5" id="f-270" unitRef="usd">-3000000.0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-5" id="f-271" unitRef="usd">89300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-12" decimals="-5" id="f-272" unitRef="usd">162200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-13" decimals="-5" id="f-273" unitRef="usd">28400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-5" id="f-274" unitRef="usd">-5400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-12" decimals="-5" id="f-275" unitRef="usd">2600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-13" decimals="-5" id="f-276" unitRef="usd">2500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-5" id="f-277" unitRef="usd">64300000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-12" decimals="-5" id="f-278" unitRef="usd">114600000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-13" decimals="-5" id="f-279" unitRef="usd">56800000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-5" id="f-280" unitRef="usd">-47800000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-12" decimals="-5" id="f-281" unitRef="usd">17200000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-13" decimals="-5" id="f-282" unitRef="usd">9200000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-283" unitRef="usd">389900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-12" decimals="-5" id="f-284" unitRef="usd">339400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="-5" id="f-285" unitRef="usd">256500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-5" id="f-286" unitRef="usd">1379900000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-12" decimals="-5" id="f-287" unitRef="usd">621200000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-13" decimals="-5" id="f-288" unitRef="usd">800100000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-5" id="f-289" unitRef="usd">972400000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-12" decimals="-5" id="f-290" unitRef="usd">511000000.0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-13" decimals="-5" id="f-291" unitRef="usd">697900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-5" id="f-292" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-12" decimals="-5" id="f-293" unitRef="usd">42700000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-13" decimals="-5" id="f-294" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi contextRef="c-1" decimals="-5" id="f-295" unitRef="usd">31300000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi contextRef="c-12" decimals="-5" id="f-296" unitRef="usd">7700000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi contextRef="c-13" decimals="-5" id="f-297" unitRef="usd">4600000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-298" unitRef="usd">28300000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-12" decimals="-5" id="f-299" unitRef="usd">16500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-13" decimals="-5" id="f-300" unitRef="usd">23400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-301" unitRef="usd">-467100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-12" decimals="-5" id="f-302" unitRef="usd">-177100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="-5" id="f-303" unitRef="usd">-130200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-5" id="f-304" unitRef="usd">65300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-12" decimals="-5" id="f-305" unitRef="usd">44700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-13" decimals="-5" id="f-306" unitRef="usd">27500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-1" decimals="-5" id="f-307" unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-12" decimals="-5" id="f-308" unitRef="usd">279000000.0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-13" decimals="-5" id="f-309" unitRef="usd">100000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-310" unitRef="usd">65300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-12" decimals="-5" id="f-311" unitRef="usd">-234300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="-5" id="f-312" unitRef="usd">27400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-5" id="f-313" unitRef="usd">300000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="-5" id="f-314" unitRef="usd">-1300000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-5" id="f-315" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-5" id="f-316" unitRef="usd">-11600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-12" decimals="-5" id="f-317" unitRef="usd">-73300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="-5" id="f-318" unitRef="usd">153700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-5" id="f-319" unitRef="usd">270700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-5" id="f-320" unitRef="usd">344000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-5" id="f-321" unitRef="usd">190300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-5" id="f-322" unitRef="usd">259100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-5" id="f-323" unitRef="usd">270700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-5" id="f-324" unitRef="usd">344000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-5" id="f-325" unitRef="usd">2500000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-12" decimals="-5" id="f-326" unitRef="usd">700000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-13" decimals="-5" id="f-327" unitRef="usd">1900000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-5" id="f-328" unitRef="usd">200800000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-12" decimals="-5" id="f-329" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-13" decimals="-5" id="f-330" unitRef="usd">23400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-5" id="f-331" unitRef="usd">3800000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-12" decimals="-5" id="f-332" unitRef="usd">6600000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-13" decimals="-5" id="f-333" unitRef="usd">8600000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-5" id="f-334" unitRef="usd">51500000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-12" decimals="-5" id="f-335" unitRef="usd">14400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-13" decimals="-5" id="f-336" unitRef="usd">5100000</us-gaap:IncomeTaxesPaid>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c-1" id="f-337">Organization and Summary of Significant Accounting Policies&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Business. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurocrine Biosciences, Inc. and its subsidiaries (Neurocrine Biosciences, the Company, we, our or us) is a neuroscience-focused biopharmaceutical company focused on discovering, developing and delivering innovative therapies to help ease the burden of debilitating disorders and diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in a single business segment, which includes all activities related to the research, development and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine and neuropsychiatric disorders and reflects the way in which internally-reported financial information is regularly reviewed by our chief operating decision maker to analyze performance, make decisions and allocate resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Neurocrine Biosciences as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments that are readily convertible into cash without penalty and have an original maturity of three months or less at the time of purchase to be cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks, and any allowance for credit losses. Our estimate for the allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, actual payment patterns of our customers, and individual customer circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We perform an assessment of the recoverability of our inventory on a quarterly basis and write down any excess and obsolete inventory to its net realizable value in the period in which the impairment is first identified. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of investments in certificates of deposit, corporate debt securities and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivables on debt securities available-for-sale were $11.2 million and $4.7 million, respectively, as of December&#160;31, 2023 and 2022. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2023, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents, debt securities available-for-sale and equity security investments at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing data in certain instances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We deem transfers between levels of the fair value hierarchy to have occurred at the end of the reporting period during which the event or change in circumstances that caused the transfer occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Investments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We account for certain equity investments subject to the equity method of accounting, or through which we have the ability to exercise significant influence (but not control) over the operating and financial policies of an investee, under the fair value option. In assessing whether we exercise significant influence, we consider the nature and magnitude of such an investment, the voting and protective rights we hold, any participation in the governance of the investee and other relevant factors, such as the presence of a collaborative or other business relationship. Such investments in publicly traded companies are currently classified within Level 1 of the fair value hierarchy and carried at fair value, with any changes in the fair value of such investments recognized in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $17.8 million for 2023, $15.1 million for 2022 and $10.9 million for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. In addition, costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as selling, general and administrative when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and in-process research and development (IPR&amp;amp;D) and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually, as of October 1, and more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;amp;D asset exceeds its respective fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceed the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets with a finite life are typically comprised of acquired product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We determine if an arrangement is a lease at contract inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that such options will be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As none of our operating leases provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease payments used to determine our ROU assets may include prepaid or accrued lease payments and any lease incentives received and are recognized in ROU assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in lease agreements are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases are reflected in ROU assets, noncurrent operating lease liabilities, and other current liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign currency.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in retained earnings during the period, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income (loss) in the accompanying consolidated statements of stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for such goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Sales.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In the U.S., we sell INGREZZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (valbenazine) primarily to specialty pharmacy providers and distributors. We recognize net product sales when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors, and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#x2019;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant categories of sales discounts and allowances are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Discounts.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We are obligated to pay rebates for discounts including under the Medicaid Drug Rebate Program and Medicare Part D. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations, and relevant contractual terms, as supplemented by management&#x2019;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Payor and Pharmacy Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel, and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient Financial Assistance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; To help patients afford our products, we offer financial assistance to qualified patients with prescription drug copay requirements. We accrue for patient financial assistance based on estimated claims and the cost per claim we expect to receive in connection with inventory that remains in the distribution channel at period end. To date, actual patient financial assistance has not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distributor and Other Fees.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In connection with the sales of our products, we pay distributor and other fees, which are generally recorded as a reduction of revenue, to certain customers that provide us with inventory management, data, and/or distribution services. Costs associated with such services are expensed as selling, general and administrative to the extent we can demonstrate a separable benefit and fair value for such services. To date, actual distributor and other fees have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring product, provided it is within a specified period of the product expiration date, as set forth in the associated distribution agreement. Where actual returns history is not available, we estimate a returns allowance based on benchmarking data for similar products and industry experience. Such estimates are recorded as a reduction of revenue in the period the related sale is recognized. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenues. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into collaboration and license agreements under which we out-license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of the out-licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use, and benefit from, the license. For licenses that are bundled with other promises, we assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestones.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement that includes development, regulatory, and/or commercial milestones, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Amounts for milestones that are not within our control, such as when achievement of a specified event is dependent on the development activities of a third party or approvals from regulators, are not considered probable of being achieved until such specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include sales-based royalties, and under which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, accounts receivable and debt securities available-for-sale. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio with low-risk investment-grade debt securities with maturities of up to three years and by placing our investments with high-credit-quality financial institutions to maintain liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in connection with these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 91% of our total product sales for 2023 and approximately 98% of our accounts receivable balance as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Revenues. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenues includes third-party manufacturing, transportation, freight, and indirect overhead costs primarily for the manufacture and distribution of INGREZZA drug product sold, manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with Mitsubishi Tanabe Pharma Corporation, royalty fees on net sales of elagolix, amortization of intangible assets, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development, or R&amp;amp;D. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses primarily consist of preclinical and clinical trial costs, payroll and benefits costs, including stock-based compensation associated with employees involved in R&amp;amp;D activities, certain facility-based costs, and costs associated with our collaborative arrangements, including event-based milestones. All such costs are expensed as R&amp;amp;D when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Acquisitions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions of assets (or groups of assets) that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets (or group of assets) acquired on the basis of their relative fair value(s) on the measurement date. No goodwill is recognized in an asset acquisition. Intangible assets acquired in an asset acquisition for use in R&amp;amp;D activities which have no alternative future use are expensed as IPR&amp;amp;D on the acquisition date. Future costs to develop these assets are expensed as R&amp;amp;D when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Expense. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $159.9 million for 2023, $149.7 million for 2022 and $139.8 million for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units (RSUs) and performance-based restricted stock units (PRSUs). Additionally, we allow employees to participate in an employee stock purchase plan (ESPP).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. RSUs are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest is recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally &lt;span style="-sec-ix-hidden:f-374"&gt;three&lt;/span&gt; to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP is recognized and amortized on a straight-line basis over the purchase period, which is generally six months. PRSUs vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our income tax provision is computed under the asset and liability method. Significant estimates are required in determining our income tax provision. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share are computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed using the treasury stock and if-converted methods and reflect the weighted average number of common and potentially dilutive shares outstanding during the period, excluding those which effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024 in cash upon conversion and to settle any conversion premium in either cash or shares of our common stock. As a result, only the shares required to settle any conversion premium are considered dilutive under the if-converted method. Further, PRSUs for which the performance condition has not been achieved are excluded from the calculation of diluted earnings per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <nbix:OrganizationAndBusinessDescriptionPolicyPolicyTextBlock contextRef="c-1" id="f-338">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Business. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurocrine Biosciences, Inc. and its subsidiaries (Neurocrine Biosciences, the Company, we, our or us) is a neuroscience-focused biopharmaceutical company focused on discovering, developing and delivering innovative therapies to help ease the burden of debilitating disorders and diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in a single business segment, which includes all activities related to the research, development and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine and neuropsychiatric disorders and reflects the way in which internally-reported financial information is regularly reviewed by our chief operating decision maker to analyze performance, make decisions and allocate resources.&lt;/span&gt;&lt;/div&gt;</nbix:OrganizationAndBusinessDescriptionPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-339">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Neurocrine Biosciences as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-340">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-341">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments that are readily convertible into cash without penalty and have an original maturity of three months or less at the time of purchase to be cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c-1" id="f-342">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks, and any allowance for credit losses. Our estimate for the allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, actual payment patterns of our customers, and individual customer circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-343">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We perform an assessment of the recoverability of our inventory on a quarterly basis and write down any excess and obsolete inventory to its net realizable value in the period in which the impairment is first identified. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-344">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of investments in certificates of deposit, corporate debt securities and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff contextRef="c-4" id="f-345">P90D</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="c-1" id="f-346">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivables on debt securities available-for-sale were $11.2 million and $4.7 million, respectively, as of December&#160;31, 2023 and 2022. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2023, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:InterestReceivableCurrent contextRef="c-4" decimals="-5" id="f-347" unitRef="usd">11200000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="c-5" decimals="-5" id="f-348" unitRef="usd">4700000</us-gaap:InterestReceivableCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff contextRef="c-12" decimals="INF" id="f-349" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff contextRef="c-1" decimals="INF" id="f-350" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff contextRef="c-13" decimals="INF" id="f-351" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-352">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents, debt securities available-for-sale and equity security investments at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing data in certain instances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We deem transfers between levels of the fair value hierarchy to have occurred at the end of the reporting period during which the event or change in circumstances that caused the transfer occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Investments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We account for certain equity investments subject to the equity method of accounting, or through which we have the ability to exercise significant influence (but not control) over the operating and financial policies of an investee, under the fair value option. In assessing whether we exercise significant influence, we consider the nature and magnitude of such an investment, the voting and protective rights we hold, any participation in the governance of the investee and other relevant factors, such as the presence of a collaborative or other business relationship. Such investments in publicly traded companies are currently classified within Level 1 of the fair value hierarchy and carried at fair value, with any changes in the fair value of such investments recognized in earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-353">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $17.8 million for 2023, $15.1 million for 2022 and $10.9 million for 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-48" id="f-354">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-49" id="f-355">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-356" unitRef="usd">17800000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-12" decimals="-5" id="f-357" unitRef="usd">15100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="-5" id="f-358" unitRef="usd">10900000</us-gaap:Depreciation>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-359">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. In addition, costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as selling, general and administrative when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Acquisitions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions of assets (or groups of assets) that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets (or group of assets) acquired on the basis of their relative fair value(s) on the measurement date. No goodwill is recognized in an asset acquisition. Intangible assets acquired in an asset acquisition for use in R&amp;amp;D activities which have no alternative future use are expensed as IPR&amp;amp;D on the acquisition date. Future costs to develop these assets are expensed as R&amp;amp;D when incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-360">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and in-process research and development (IPR&amp;amp;D) and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually, as of October 1, and more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;amp;D asset exceeds its respective fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceed the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets with a finite life are typically comprised of acquired product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-361">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We determine if an arrangement is a lease at contract inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that such options will be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As none of our operating leases provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease payments used to determine our ROU assets may include prepaid or accrued lease payments and any lease incentives received and are recognized in ROU assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in lease agreements are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases are reflected in ROU assets, noncurrent operating lease liabilities, and other current liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-362">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign currency.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in retained earnings during the period, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income (loss) in the accompanying consolidated statements of stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-363">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for such goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Sales.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In the U.S., we sell INGREZZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (valbenazine) primarily to specialty pharmacy providers and distributors. We recognize net product sales when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors, and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#x2019;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant categories of sales discounts and allowances are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Discounts.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We are obligated to pay rebates for discounts including under the Medicaid Drug Rebate Program and Medicare Part D. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations, and relevant contractual terms, as supplemented by management&#x2019;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Payor and Pharmacy Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel, and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient Financial Assistance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; To help patients afford our products, we offer financial assistance to qualified patients with prescription drug copay requirements. We accrue for patient financial assistance based on estimated claims and the cost per claim we expect to receive in connection with inventory that remains in the distribution channel at period end. To date, actual patient financial assistance has not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distributor and Other Fees.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In connection with the sales of our products, we pay distributor and other fees, which are generally recorded as a reduction of revenue, to certain customers that provide us with inventory management, data, and/or distribution services. Costs associated with such services are expensed as selling, general and administrative to the extent we can demonstrate a separable benefit and fair value for such services. To date, actual distributor and other fees have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring product, provided it is within a specified period of the product expiration date, as set forth in the associated distribution agreement. Where actual returns history is not available, we estimate a returns allowance based on benchmarking data for similar products and industry experience. Such estimates are recorded as a reduction of revenue in the period the related sale is recognized. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenues. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into collaboration and license agreements under which we out-license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of the out-licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use, and benefit from, the license. For licenses that are bundled with other promises, we assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestones.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement that includes development, regulatory, and/or commercial milestones, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Amounts for milestones that are not within our control, such as when achievement of a specified event is dependent on the development activities of a third party or approvals from regulators, are not considered probable of being achieved until such specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include sales-based royalties, and under which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-364">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, accounts receivable and debt securities available-for-sale. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio with low-risk investment-grade debt securities with maturities of up to three years and by placing our investments with high-credit-quality financial institutions to maintain liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in connection with these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 91% of our total product sales for 2023 and approximately 98% of our accounts receivable balance as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-50" decimals="2" id="f-365" unitRef="number">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-51" decimals="2" id="f-366" unitRef="number">0.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-367">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Revenues. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenues includes third-party manufacturing, transportation, freight, and indirect overhead costs primarily for the manufacture and distribution of INGREZZA drug product sold, manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with Mitsubishi Tanabe Pharma Corporation, royalty fees on net sales of elagolix, amortization of intangible assets, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-368">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development, or R&amp;amp;D. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses primarily consist of preclinical and clinical trial costs, payroll and benefits costs, including stock-based compensation associated with employees involved in R&amp;amp;D activities, certain facility-based costs, and costs associated with our collaborative arrangements, including event-based milestones. All such costs are expensed as R&amp;amp;D when incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c-1" id="f-369">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Expense. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $159.9 million for 2023, $149.7 million for 2022 and $139.8 million for 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="-5" id="f-370" unitRef="usd">159900000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-12" decimals="-5" id="f-371" unitRef="usd">149700000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-13" decimals="-5" id="f-372" unitRef="usd">139800000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-373">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units (RSUs) and performance-based restricted stock units (PRSUs). Additionally, we allow employees to participate in an employee stock purchase plan (ESPP).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. RSUs are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest is recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally &lt;span style="-sec-ix-hidden:f-374"&gt;three&lt;/span&gt; to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP is recognized and amortized on a straight-line basis over the purchase period, which is generally six months. PRSUs vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-53" id="f-375">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <nbix:ESPPPurchasePeriod contextRef="c-54" id="f-376">P6M</nbix:ESPPPurchasePeriod>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-377">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our income tax provision is computed under the asset and liability method. Significant estimates are required in determining our income tax provision. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-378">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share are computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed using the treasury stock and if-converted methods and reflect the weighted average number of common and potentially dilutive shares outstanding during the period, excluding those which effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024 in cash upon conversion and to settle any conversion premium in either cash or shares of our common stock. As a result, only the shares required to settle any conversion premium are considered dilutive under the if-converted method. Further, PRSUs for which the performance condition has not been achieved are excluded from the calculation of diluted earnings per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-55"
      decimals="INF"
      id="f-379"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-382">Collaboration and License Agreements&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Heptares Therapeutics Limited, or Heptares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We entered into a collaboration and license agreement with Heptares, which became effective in December 2021, to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, for which we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Heptares retains the rights to develop, manufacture, and commercialize all compounds comprised of M1 receptor agonists, subject to certain exceptions. With respect to such rights retained by Heptares, we retain the rights to opt in to profit sharing arrangements, pursuant to which we and Heptares will equally share in the operating profits and losses for such compounds in Japan. Subject to specified conditions, we may elect to exercise such opt-in rights with respect to each such compound either before initiation of the first proof of concept Phase 2 clinical trial for such compound or following our receipt from Heptares of the top-line data from such clinical trial for such compound. We are responsible for all development, manufacturing, and commercialization costs of any collaboration product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Heptares $100.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;amp;D in 2021 as the license had no foreseeable alternative future use. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the FDA's acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in June 2022, we paid Heptares a milestone of $30.0 million, which was expensed as R&amp;amp;D in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Heptares may be entitled to receive potential future payments of up to $2.6 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which the royalty term for such licensed product has expired in such country. On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a licensed product and terminate on the later of (i) the expiration of the last patent covering such licensed product in such country, (ii) a number of years from the first commercial sale of such licensed product in such country and (iii) the expiration of regulatory exclusivity for such licensed product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement in its entirety or with respect to one or more targets upon 180 days&#x2019; written notice to Heptares during the research collaboration term and upon 90 days&#x2019; written notice to Heptares following the expiration of the research collaboration term. Following the expiration of the research collaboration term, Heptares may terminate the agreement on a target-by-target basis in the event that we do not conduct any material development activities outside of Japan with respect to a certain compound or licensed product within the applicable target class for a continuous period of not less than 365 days and do not commence any such activities within 120 days of receiving written notice. Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited, or Takeda.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2020, we entered into an exclusive license agreement with Takeda, pursuant to which we acquired the exclusive rights to develop and commercialize certain early-to-mid stage psychiatry compounds, including luvadaxistat, NBI-1065845, NBI-1065846 and four non-clinical stage compounds. Luvadaxistat and the four non-clinical stage compounds have each been designated as a royalty-bearing product. NBI-1065845 and NBI-1065846 are currently each designated as a profit-share product. We are responsible for all manufacturing, development, and commercialization costs of any royalty-bearing product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to NBI-1065845 and NBI-1065846, we and Takeda will equally share in the operating profits and losses. Takeda retains the rights to opt-out of the profit-sharing arrangements, pursuant to which Takeda would be entitled to receive potential future payments upon the achievement of certain event-based milestones with respect to such compounds and receive royalties on the future net sales of such compounds (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out right for such compound immediately following the completion of a second Phase 2 clinical trial for such compound, or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase 3 clinical trial for such compound.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in 2022, we paid Takeda a milestone of $5.0 million, which was expensed as R&amp;amp;D in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $1.9 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any royalty-bearing product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any royalty-bearing product, the royalty term has expired in such country; and (ii) for any profit-share product, for so long as we continue to develop, manufacture, or commercialize such licensed product.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a royalty-bearing product and terminate on the later of (i) the expiration of the last patent covering such royalty-bearing product in such country, (ii) a number of years from the first commercial sale of such royalty-bearing product in such country and (iii) the expiration of regulatory exclusivity for such royalty-bearing product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement in its entirety or in one or more (but not all) of the U.S., Japan, the European Union (EU) and the United Kingdom (UK) (collectively, the major markets) upon six months&#x2019; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. We may terminate the agreement in its entirety or in one or more (but not all) of the major markets upon 12 months&#x2019; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. Takeda may terminate the agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Idorsia Pharmaceuticals Ltd., or Idorsia.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2020, we entered into a collaboration and license agreement with Idorsia, pursuant to which we acquired the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker in clinical development for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. We are responsible for all manufacturing, development, and commercialization costs of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement, in its entirety or with respect to a particular compound or development candidate, upon 90 days&#x2019; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Xenon Pharmaceuticals Inc., or Xenon. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we entered into a collaboration and license agreement with Xenon to identify, research and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates, which compounds we have the exclusive rights to develop and commercialize. We are responsible for all development and manufacturing costs of any collaboration product, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we purchased approximately 1.4 million shares (at $14.196 per share) of Xenon common stock in 2019. The purchased shares were recorded at a fair value of $14.1 million after considering Xenon&#x2019;s stock price and certain transfer restrictions that were applicable to the shares on the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approval of our clinical trial application in Europe for NBI-921352 for the treatment of focal onset seizures in adults in 2021, we paid Xenon a regulatory milestone of $10.0 million, including a purchase of approximately 0.3 million shares (at $19.9755 per share) of Xenon common stock. The purchased shares were recorded at a fair value of $4.6 million after considering Xenon&#x2019;s stock price and certain transfer restrictions that were applicable to the shares on the measurement date. The remaining $5.4 million of the milestone payment was expensed as R&amp;amp;D in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the FDA's acceptance of our amended KAYAK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;study protocol in 2022, we paid Xenon a regulatory milestone of $15.0 million, including a purchase of approximately 0.3 million shares (at $31.855 per share) of Xenon common stock. The purchased shares were recorded at a fair value of $7.7 million after considering Xenon&#x2019;s stock price on the measurement date. The remaining $7.3 million of the milestone payment was expensed as R&amp;amp;D in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product. Xenon retains the right to elect to co-develop one product in a major indication, pursuant to which Xenon would receive a mid-single digit percentage increase in royalties earned on the future net sales of such product in the U.S. and we and Xenon would equally share in the development costs of such product in the applicable indication, except where such development costs relate solely to the regulatory approval of such product outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular licensed product and country, the license obtained by us with respect to such product and country will become fully paid, royalty free, perpetual and irrevocable. We may terminate the agreement upon 90 days&#x2019; written notice to Xenon, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Voyager Therapeutics, Inc., or Voyager.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Voyager Agreement.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2019, we entered into a collaboration and license agreement with Voyager (the 2019 Voyager Agreement), pursuant to which we retain certain rights to develop and commercialize the Friedreich&#x2019;s ataxia program and two undisclosed programs. We are responsible for all development and commercialization costs of any collaboration product under the 2019 Voyager Agreement, subject to certain co-development and co-commercialization rights retained by Voyager.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the 2019 Voyager Agreement, we purchased approximately 4.2 million shares (at $11.9625 per share) of Voyager common stock (the 2019 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement (defined below). The 2019 Purchased Shares were recorded at a fair value of $54.7 million after considering Voyager&#x2019;s stock price and certain transfer restrictions that were applicable to the shares on the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2019 Voyager Agreement, Voyager may be entitled to receive potential future payments of up to $1.3 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated earlier, the 2019 Voyager Agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product under the agreement or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the 2019 Voyager Agreement. We may terminate the 2019 Voyager Agreement upon 180 days&#x2019; written notice to Voyager prior to the first commercial sale of any collaboration product under the 2019 Voyager Agreement or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product under the 2019 Voyager Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2023 Voyager Agreement.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2023, we entered into a collaboration and license agreement with Voyager (the 2023 Voyager Agreement), pursuant to which we acquired the global rights to the gene therapy products directed to the gene that encodes glucosylceramidase beta 1 (GBA1) for the treatment of Parkinson's disease and other diseases associated with GBA1 (the GBA1 Program), and three gene therapy programs directed to rare central nervous system (CNS) targets, each enabled by Voyager's next-generation TRACER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; capsids. With respect to collaboration products subject to the GBA1 Program, we are responsible for all development and commercialization costs of any such products, including in the U.S., where Voyager retains certain co-development and co-commercialization rights. Voyager may elect to exercise such rights, pursuant to which we and Voyager would equally share in the operating profits and losses of such products in the U.S. (in lieu of Voyager being entitled to receive potential future payments of certain event-based milestones upon their achievement in the U.S. and receive royalties on the future net sales of such products in the U.S.), following Voyager&#x2019;s receipt of the top-line data from a first Phase 1 clinical trial for each such product. Irrespective of Voyager&#x2019;s election to exercise such rights, Voyager may be entitled to receive potential future payments upon the achievement of certain event-based milestones outside the U.S. and would be entitled to receive royalties on the future net sales of any such product outside the U.S. With respect to collaboration products subject to the three gene therapy programs directed to rare CNS targets, we are responsible for all development and commercialization costs for any such products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the 2023 Voyager Agreement, we paid Voyager $175.0 million upfront, including a purchase of approximately 4.4 million shares (at $8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the 2023 Voyager Agreement. In addition, as part of the collaboration, Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine, was appointed to Voyager's board of directors with an initial term expiring in 2024. Mr. Onyia (or another individual designated by us) will be nominated for election to Voyager's board of directors annually for a maximum duration of 10 years from the effective date of the 2023 Voyager Agreement. As a result, our strategic investment in Voyager became subject to the equity method of accounting, and Voyager became a related party under ASC 850, following our purchase of the 2023 Purchased Shares, after which, together with the 2019 Purchased Shares, we owned approximately 19.9% of the voting stock of Voyager. We elected the fair value option to account for our strategic investment in Voyager as we believe it creates greater transparency regarding the investment's fair value at future reporting dates. The 2023 Purchased Shares were recorded at a fair value of $31.3 million after considering Voyager&#x2019;s stock price on the measurement date. The remaining $143.9 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;amp;D in 2023 as the license had no foreseeable alternative future use. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. We recognized unrealized gains of $15.5 million for 2023 and $14.5 million for 2022 and an unrealized loss of $8.7 million for 2021 on our strategic investment in Voyager. As of December&#160;31, 2023, the fair value (Level 1) of our strategic investment in Voyager was $72.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2023 Voyager Agreement, Voyager may be entitled to receive potential future payments of up to $6.1 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated earlier, the 2023 Voyager Agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product under the 2023 Voyager Agreement or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the 2023 Voyager Agreement. We may terminate the 2023 Voyager Agreement upon 180 days&#x2019; written notice to Voyager prior to the first commercial sale of any collaboration product under the 2023 Voyager Agreement or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product under the 2023 Voyager Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIAL &#x2013; Portela &amp;amp; Ca, S.A., or BIAL.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2017, we received from BIAL a license to commercialize and market ONGENTYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (opicapone) in the U.S. and Canada. We launched ONGENTYS in the U.S. as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations in 2020. In 2023, we provided BIAL with written notice of termination of the license agreement to commercialize and market ONGENTYS in the U.S. and Canada, and recognized reserves for ONGENTYS inventory obsolescence totaling $5.2 million in cost of revenues in connection with the termination, which became effective in December 2023, as management determined the cost cannot be recovered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mitsubishi Tanabe Pharma Corporation, or MTPC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015. In 2020, we entered into a commercial supply agreement with MTPC, pursuant to which we supply MTPC with valbenazine drug product for commercial use in such markets. MTPC is responsible for all development, manufacturing, and commercialization costs of valbenazine in such markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MTPC launched DYSVAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (valbenazine) in Japan for the treatment of tardive dyskinesia in June 2022 and subsequently in other select Asian markets, where it is marketed as REMLEAS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (valbenazine). We receive royalties at tiered percentage rates on MTPC net sales of valbenazine. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $20.0 million in 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC&#x2019;s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our license agreement with MTPC, we may be entitled to receive potential future payments of up to $30.0 million upon the achievement of certain sales-based milestones and are entitled to receive royalties at tiered percentage rates on future MTPC net sales of valbenazine for the longer of 10 years or the life of the related patent rights. MTPC may terminate the agreement upon 180 days&#x2019; written notice to us. In such event, all out-licensed product rights would revert to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AbbVie Inc., or AbbVie. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie launched ORILISSA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (elagolix tablets) in the U.S. for the treatment of moderate to severe pain associated with endometriosis in August 2018 and ORIAHNN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $16.7&#160;million for 2023, $21.2&#160;million for 2022 and $22.3&#160;million for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our license agreement with AbbVie, we may be entitled to receive potential future payments of up to $366.0 million upon the achievement of certain event-based milestones and are entitled to receive royalties at tiered percentage rates on future AbbVie net sales of elagolix for the longer of 10 years or the life of the related patent rights. AbbVie may terminate the agreement upon 180 days&#x2019; written notice to us. In such event, all out-licensed product rights would revert to us.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff contextRef="c-56" decimals="-5" id="f-383" unitRef="usd">100000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-57" decimals="-5" id="f-384" unitRef="usd">30000000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:PotentialMilestonePayments contextRef="c-58" decimals="-8" id="f-385" unitRef="usd">2600000000</nbix:PotentialMilestonePayments>
    <nbix:AgreementTerminationMinimalContractualTime contextRef="c-56" id="f-386">P180D</nbix:AgreementTerminationMinimalContractualTime>
    <nbix:AgreementTerminationContractualTimeThreshold contextRef="c-56" id="f-387">P90D</nbix:AgreementTerminationContractualTimeThreshold>
    <nbix:AgreementTerminationByCounterpartyContractualTimeThreshold contextRef="c-56" id="f-388">P365D</nbix:AgreementTerminationByCounterpartyContractualTimeThreshold>
    <nbix:AgreementTerminationByCounterpartyMinimalContractualTime contextRef="c-56" id="f-389">P120D</nbix:AgreementTerminationByCounterpartyMinimalContractualTime>
    <nbix:NumberOfNonClinicalStageCompound
      contextRef="c-59"
      decimals="INF"
      id="f-390"
      unitRef="non-clinicalstagecompound">4</nbix:NumberOfNonClinicalStageCompound>
    <nbix:NumberOfNonClinicalStageCompound
      contextRef="c-59"
      decimals="INF"
      id="f-391"
      unitRef="non-clinicalstagecompound">4</nbix:NumberOfNonClinicalStageCompound>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-60" decimals="-5" id="f-392" unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:PotentialMilestonePayments contextRef="c-61" decimals="-8" id="f-393" unitRef="usd">1900000000</nbix:PotentialMilestonePayments>
    <nbix:AgreementTerminationMinimalContractualTime contextRef="c-59" id="f-394">P6M</nbix:AgreementTerminationMinimalContractualTime>
    <nbix:AgreementTerminationContractualTimeThreshold contextRef="c-59" id="f-395">P12M</nbix:AgreementTerminationContractualTimeThreshold>
    <nbix:PotentialMilestonePayments contextRef="c-62" decimals="-8" id="f-396" unitRef="usd">1700000000</nbix:PotentialMilestonePayments>
    <nbix:AgreementTerminationMinimalContractualTime contextRef="c-63" id="f-397">P90D</nbix:AgreementTerminationMinimalContractualTime>
    <nbix:AgreementTerminationDueToMaterialBreach contextRef="c-63" id="f-398">P90D</nbix:AgreementTerminationDueToMaterialBreach>
    <nbix:NumberOfPreclinicalCandidates
      contextRef="c-64"
      decimals="INF"
      id="f-399"
      unitRef="preclinicalcandidate">3</nbix:NumberOfPreclinicalCandidates>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction contextRef="c-65" decimals="-5" id="f-400" unitRef="shares">1400000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="c-66"
      decimals="3"
      id="f-401"
      unitRef="usdPerShare">14.196</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue contextRef="c-66" decimals="-5" id="f-402" unitRef="usd">14100000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <nbix:MilestonePayment contextRef="c-67" decimals="-5" id="f-403" unitRef="usd">10000000</nbix:MilestonePayment>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction contextRef="c-68" decimals="-5" id="f-404" unitRef="shares">300000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="c-67"
      decimals="4"
      id="f-405"
      unitRef="usdPerShare">19.9755</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue contextRef="c-67" decimals="-5" id="f-406" unitRef="usd">4600000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-69" decimals="-5" id="f-407" unitRef="usd">5400000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:MilestonePayment contextRef="c-70" decimals="-5" id="f-408" unitRef="usd">15000000</nbix:MilestonePayment>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction contextRef="c-71" decimals="-5" id="f-409" unitRef="shares">300000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="c-70"
      decimals="3"
      id="f-410"
      unitRef="usdPerShare">31.855</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-70" decimals="-5" id="f-411" unitRef="usd">7700000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-72" decimals="-5" id="f-412" unitRef="usd">7300000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:PotentialMilestonePayments contextRef="c-73" decimals="-8" id="f-413" unitRef="usd">1700000000</nbix:PotentialMilestonePayments>
    <nbix:AgreementTerminationContractualTimeThreshold contextRef="c-64" id="f-414">P90D</nbix:AgreementTerminationContractualTimeThreshold>
    <nbix:NumberOfUndisclosedPrograms
      contextRef="c-74"
      decimals="INF"
      id="f-415"
      unitRef="undisclosedprogram">2</nbix:NumberOfUndisclosedPrograms>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction contextRef="c-75" decimals="-5" id="f-416" unitRef="shares">4200000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="c-76"
      decimals="4"
      id="f-417"
      unitRef="usdPerShare">11.9625</us-gaap:SharePrice>
    <nbix:VotingRestrictionPeriod contextRef="c-77" id="f-418">P3Y</nbix:VotingRestrictionPeriod>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue contextRef="c-76" decimals="-5" id="f-419" unitRef="usd">54700000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <nbix:PotentialMilestonePayments contextRef="c-78" decimals="-8" id="f-420" unitRef="usd">1300000000</nbix:PotentialMilestonePayments>
    <nbix:AgreementTerminationMinimalContractualTime contextRef="c-74" id="f-421">P180D</nbix:AgreementTerminationMinimalContractualTime>
    <nbix:AgreementTerminationContractualTimeThreshold contextRef="c-74" id="f-422">P1Y</nbix:AgreementTerminationContractualTimeThreshold>
    <nbix:NumberOfGeneTherapyPrograms
      contextRef="c-79"
      decimals="INF"
      id="f-423"
      unitRef="genetherapyprogram">3</nbix:NumberOfGeneTherapyPrograms>
    <nbix:NumberOfGeneTherapyPrograms
      contextRef="c-79"
      decimals="INF"
      id="f-424"
      unitRef="genetherapyprogram">3</nbix:NumberOfGeneTherapyPrograms>
    <nbix:UpfrontPaymentsMade contextRef="c-80" decimals="-5" id="f-425" unitRef="usd">175000000</nbix:UpfrontPaymentsMade>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction contextRef="c-81" decimals="-5" id="f-426" unitRef="shares">4400000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="c-80"
      decimals="2"
      id="f-427"
      unitRef="usdPerShare">8.88</us-gaap:SharePrice>
    <nbix:VotingRestrictionPeriod contextRef="c-79" id="f-428">P3Y</nbix:VotingRestrictionPeriod>
    <nbix:BoardOfDirectorsMaximumDurationTerm contextRef="c-79" id="f-429">P10Y</nbix:BoardOfDirectorsMaximumDurationTerm>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-82" decimals="3" id="f-430" unitRef="number">0.199</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-80" decimals="-5" id="f-431" unitRef="usd">31300000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff contextRef="c-79" decimals="-5" id="f-432" unitRef="usd">143900000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-83" decimals="-5" id="f-433" unitRef="usd">15500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-84" decimals="-5" id="f-434" unitRef="usd">14500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-85" decimals="-5" id="f-435" unitRef="usd">-8700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-86" decimals="-5" id="f-436" unitRef="usd">72400000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <nbix:PotentialMilestonePayments contextRef="c-80" decimals="-8" id="f-437" unitRef="usd">6100000000</nbix:PotentialMilestonePayments>
    <nbix:AgreementTerminationMinimalContractualTime contextRef="c-79" id="f-438">P180D</nbix:AgreementTerminationMinimalContractualTime>
    <nbix:AgreementTerminationContractualTimeThreshold contextRef="c-79" id="f-439">P1Y</nbix:AgreementTerminationContractualTimeThreshold>
    <us-gaap:InventoryValuationReserves contextRef="c-87" decimals="-5" id="f-440" unitRef="usd">5200000</us-gaap:InventoryValuationReserves>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-88" decimals="-5" id="f-441" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nbix:PotentialMilestonePaymentReceipts contextRef="c-89" decimals="-5" id="f-442" unitRef="usd">30000000</nbix:PotentialMilestonePaymentReceipts>
    <nbix:PatentTerm contextRef="c-90" id="f-443">P10Y</nbix:PatentTerm>
    <nbix:AgreementTerminationContractualTimeThreshold contextRef="c-91" id="f-444">P180D</nbix:AgreementTerminationContractualTimeThreshold>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-92" decimals="-5" id="f-445" unitRef="usd">16700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-5" id="f-446" unitRef="usd">21200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-5" id="f-447" unitRef="usd">22300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nbix:PotentialMilestonePaymentReceipts contextRef="c-95" decimals="-5" id="f-448" unitRef="usd">366000000</nbix:PotentialMilestonePaymentReceipts>
    <nbix:PatentTerm contextRef="c-96" id="f-449">P10Y</nbix:PatentTerm>
    <nbix:AgreementTerminationContractualTimeThreshold contextRef="c-97" id="f-450">P180D</nbix:AgreementTerminationContractualTimeThreshold>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-451">Debt Securities&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;382.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;381.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;781.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;780.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;735.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;726.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;486.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;684.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;687.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized losses on our available-for-sale debt security investments were primarily due to changes in interest rates. These investments are of high credit quality, and we do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recognized as of December&#160;31, 2023 or 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2023, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;265.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2022, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;498.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-452">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;382.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;381.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;781.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;780.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;735.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;726.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;486.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;684.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;687.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-98" decimals="-5" id="f-453" unitRef="usd">53500000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent contextRef="c-98" decimals="-5" id="f-454" unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent contextRef="c-98" decimals="-5" id="f-455" unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent contextRef="c-98" decimals="-5" id="f-456" unitRef="usd">53500000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-99" decimals="-5" id="f-457" unitRef="usd">156200000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent contextRef="c-99" decimals="-5" id="f-458" unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent contextRef="c-99" decimals="-5" id="f-459" unitRef="usd">200000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent contextRef="c-99" decimals="-5" id="f-460" unitRef="usd">156000000.0</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-100" decimals="-5" id="f-461" unitRef="usd">382100000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent contextRef="c-100" decimals="-5" id="f-462" unitRef="usd">100000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent contextRef="c-100" decimals="-5" id="f-463" unitRef="usd">1000000.0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent contextRef="c-100" decimals="-5" id="f-464" unitRef="usd">381200000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-101" decimals="-5" id="f-465" unitRef="usd">296200000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent contextRef="c-101" decimals="-5" id="f-466" unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent contextRef="c-101" decimals="-5" id="f-467" unitRef="usd">3200000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent contextRef="c-101" decimals="-5" id="f-468" unitRef="usd">293000000.0</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-102" decimals="-5" id="f-469" unitRef="usd">346100000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent contextRef="c-102" decimals="-5" id="f-470" unitRef="usd">200000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent contextRef="c-102" decimals="-5" id="f-471" unitRef="usd">500000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent contextRef="c-102" decimals="-5" id="f-472" unitRef="usd">345800000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-103" decimals="-5" id="f-473" unitRef="usd">283400000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent contextRef="c-103" decimals="-5" id="f-474" unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent contextRef="c-103" decimals="-5" id="f-475" unitRef="usd">6000000.0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent contextRef="c-103" decimals="-5" id="f-476" unitRef="usd">277400000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-4" decimals="-5" id="f-477" unitRef="usd">781700000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent contextRef="c-4" decimals="-5" id="f-478" unitRef="usd">300000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent contextRef="c-4" decimals="-5" id="f-479" unitRef="usd">1500000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent contextRef="c-4" decimals="-5" id="f-480" unitRef="usd">780500000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-5" decimals="-5" id="f-481" unitRef="usd">735800000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent contextRef="c-5" decimals="-5" id="f-482" unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent contextRef="c-5" decimals="-5" id="f-483" unitRef="usd">9400000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent contextRef="c-5" decimals="-5" id="f-484" unitRef="usd">726400000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent contextRef="c-100" decimals="-5" id="f-485" unitRef="usd">483500000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent contextRef="c-100" decimals="-5" id="f-486" unitRef="usd">2900000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent contextRef="c-100" decimals="-5" id="f-487" unitRef="usd">400000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent contextRef="c-100" decimals="-5" id="f-488" unitRef="usd">486000000.0</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent contextRef="c-101" decimals="-5" id="f-489" unitRef="usd">259500000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent contextRef="c-101" decimals="-5" id="f-490" unitRef="usd">200000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent contextRef="c-101" decimals="-5" id="f-491" unitRef="usd">4300000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent contextRef="c-101" decimals="-5" id="f-492" unitRef="usd">255400000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent contextRef="c-102" decimals="-5" id="f-493" unitRef="usd">201100000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent contextRef="c-102" decimals="-5" id="f-494" unitRef="usd">500000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent contextRef="c-102" decimals="-5" id="f-495" unitRef="usd">100000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent contextRef="c-102" decimals="-5" id="f-496" unitRef="usd">201500000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent contextRef="c-103" decimals="-5" id="f-497" unitRef="usd">45000000.0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent contextRef="c-103" decimals="-5" id="f-498" unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent contextRef="c-103" decimals="-5" id="f-499" unitRef="usd">1000000.0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent contextRef="c-103" decimals="-5" id="f-500" unitRef="usd">44000000.0</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent contextRef="c-4" decimals="-5" id="f-501" unitRef="usd">684600000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent contextRef="c-4" decimals="-5" id="f-502" unitRef="usd">3400000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent contextRef="c-4" decimals="-5" id="f-503" unitRef="usd">500000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent contextRef="c-4" decimals="-5" id="f-504" unitRef="usd">687500000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent contextRef="c-5" decimals="-5" id="f-505" unitRef="usd">304500000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent contextRef="c-5" decimals="-5" id="f-506" unitRef="usd">200000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent contextRef="c-5" decimals="-5" id="f-507" unitRef="usd">5300000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent contextRef="c-5" decimals="-5" id="f-508" unitRef="usd">299400000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-509">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2023, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;265.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2022, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;498.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-100" decimals="-5" id="f-510" unitRef="usd">265100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-100" decimals="-5" id="f-511" unitRef="usd">400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-100" decimals="-5" id="f-512" unitRef="usd">183800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-100" decimals="-5" id="f-513" unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-100" decimals="-5" id="f-514" unitRef="usd">448900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-100" decimals="-5" id="f-515" unitRef="usd">1400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-102" decimals="-5" id="f-516" unitRef="usd">214600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-102" decimals="-5" id="f-517" unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-102" decimals="-5" id="f-518" unitRef="usd">16700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-102" decimals="-5" id="f-519" unitRef="usd">400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-102" decimals="-5" id="f-520" unitRef="usd">231300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-102" decimals="-5" id="f-521" unitRef="usd">600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-99" decimals="-5" id="f-522" unitRef="usd">32100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-99" decimals="-5" id="f-523" unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-99" decimals="-5" id="f-524" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-99" decimals="-5" id="f-525" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-99" decimals="-5" id="f-526" unitRef="usd">32100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-99" decimals="-5" id="f-527" unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-101" decimals="-5" id="f-528" unitRef="usd">199500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-101" decimals="-5" id="f-529" unitRef="usd">1900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-101" decimals="-5" id="f-530" unitRef="usd">299100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-101" decimals="-5" id="f-531" unitRef="usd">5600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-101" decimals="-5" id="f-532" unitRef="usd">498600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-101" decimals="-5" id="f-533" unitRef="usd">7500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-103" decimals="-5" id="f-534" unitRef="usd">107700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-103" decimals="-5" id="f-535" unitRef="usd">2500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-103" decimals="-5" id="f-536" unitRef="usd">198400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-103" decimals="-5" id="f-537" unitRef="usd">4500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-103" decimals="-5" id="f-538" unitRef="usd">306100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-103" decimals="-5" id="f-539" unitRef="usd">7000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-540">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of financial assets, which were measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;867.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;867.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;547.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;547.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;321.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;321.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,889.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,468.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,398.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,025.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-541">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of financial assets, which were measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;867.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;867.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;547.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;547.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;321.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;321.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,889.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,468.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,398.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,025.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:Investments contextRef="c-104" decimals="-5" id="f-542" unitRef="usd">251100000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-105" decimals="-5" id="f-543" unitRef="usd">251100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-106" decimals="-5" id="f-544" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-107" decimals="-5" id="f-545" unitRef="usd">262900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-108" decimals="-5" id="f-546" unitRef="usd">262900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-109" decimals="-5" id="f-547" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-110" decimals="-5" id="f-548" unitRef="usd">8000000.0</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-111" decimals="-5" id="f-549" unitRef="usd">8000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-112" decimals="-5" id="f-550" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-113" decimals="-5" id="f-551" unitRef="usd">7800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-114" decimals="-5" id="f-552" unitRef="usd">7800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-115" decimals="-5" id="f-553" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-116" decimals="-5" id="f-554" unitRef="usd">53500000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-117" decimals="-5" id="f-555" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-118" decimals="-5" id="f-556" unitRef="usd">53500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-119" decimals="-5" id="f-557" unitRef="usd">156000000.0</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-120" decimals="-5" id="f-558" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-121" decimals="-5" id="f-559" unitRef="usd">156000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-122" decimals="-5" id="f-560" unitRef="usd">867200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-123" decimals="-5" id="f-561" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-124" decimals="-5" id="f-562" unitRef="usd">867200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-125" decimals="-5" id="f-563" unitRef="usd">548400000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-126" decimals="-5" id="f-564" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-127" decimals="-5" id="f-565" unitRef="usd">548400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-128" decimals="-5" id="f-566" unitRef="usd">547300000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-129" decimals="-5" id="f-567" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-130" decimals="-5" id="f-568" unitRef="usd">547300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-131" decimals="-5" id="f-569" unitRef="usd">321400000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-132" decimals="-5" id="f-570" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-133" decimals="-5" id="f-571" unitRef="usd">321400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-134" decimals="-5" id="f-572" unitRef="usd">161900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-135" decimals="-5" id="f-573" unitRef="usd">161900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-136" decimals="-5" id="f-574" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-137" decimals="-5" id="f-575" unitRef="usd">102100000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-138" decimals="-5" id="f-576" unitRef="usd">102100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-139" decimals="-5" id="f-577" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-140" decimals="-5" id="f-578" unitRef="usd">1889000000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-141" decimals="-5" id="f-579" unitRef="usd">421000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-142" decimals="-5" id="f-580" unitRef="usd">1468000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-143" decimals="-5" id="f-581" unitRef="usd">1398600000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-144" decimals="-5" id="f-582" unitRef="usd">372800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-145" decimals="-5" id="f-583" unitRef="usd">1025800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-584">Convertible Senior Notes&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% fixed-rate convertible senior notes due May&#160;15, 2024 (the 2024 Notes) and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we repurchased $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. In 2022, we repurchased $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash, which resulted in the recognition of a $70.0 million loss on extinguishment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;295.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the interest expense of the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $1,000 principal amount and equivalent to an initial conversion price of approximately $75.92 per share, reflecting a conversion premium of approximately 42.5% above the closing price of $53.28 per share of our common stock on April&#160;26, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130% of the conversion price then in effect (equal to $98.70 as of December&#160;31, 2023) for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt"&gt;during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price (equal to $98.70 as of December&#160;31, 2023) on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt"&gt;during the&#160;five business-day period immediately after any&#160;five&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2017 Indenture) per&#160;$1,000&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt"&gt;upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt"&gt;if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time. On January 4, 2024, we provided notice to the holders of the 2024 Notes electing to settle all conversions of the 2024 Notes in cash. As such, upon conversion, holders will receive the principal amount of their 2024 Notes and any conversion premium, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the 2017 Indenture) occurs prior to January&#160;15, 2024, we would, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2017 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-55" decimals="INF" id="f-585" unitRef="usd">517500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-55"
      decimals="INF"
      id="f-586"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-146" decimals="-5" id="f-587" unitRef="usd">136200000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt contextRef="c-147" decimals="-5" id="f-588" unitRef="usd">186900000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-148" decimals="-5" id="f-589" unitRef="usd">210800000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt contextRef="c-149" decimals="-5" id="f-590" unitRef="usd">279000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-149" decimals="-5" id="f-591" unitRef="usd">-70000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-592">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;295.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the interest expense of the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-150" decimals="-5" id="f-593" unitRef="usd">170400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-150" decimals="-5" id="f-594" unitRef="usd">300000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleDebtCurrent contextRef="c-150" decimals="-5" id="f-595" unitRef="usd">170100000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:DebtInstrumentFairValue contextRef="c-150" decimals="-5" id="f-596" unitRef="usd">295700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-148" decimals="-5" id="f-597" unitRef="usd">170400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-148" decimals="-5" id="f-598" unitRef="usd">1000000.0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleDebtCurrent contextRef="c-148" decimals="-5" id="f-599" unitRef="usd">169400000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:DebtInstrumentFairValue contextRef="c-148" decimals="-5" id="f-600" unitRef="usd">268000000.0</us-gaap:DebtInstrumentFairValue>
    <nbix:DebtInstrumentCouponInterest contextRef="c-1" decimals="-5" id="f-601" unitRef="usd">3900000</nbix:DebtInstrumentCouponInterest>
    <nbix:DebtInstrumentCouponInterest contextRef="c-12" decimals="-5" id="f-602" unitRef="usd">5900000</nbix:DebtInstrumentCouponInterest>
    <nbix:DebtInstrumentCouponInterest contextRef="c-13" decimals="-5" id="f-603" unitRef="usd">8500000</nbix:DebtInstrumentCouponInterest>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-5" id="f-604" unitRef="usd">700000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-12" decimals="-5" id="f-605" unitRef="usd">1200000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-13" decimals="-5" id="f-606" unitRef="usd">17300000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-5" id="f-607" unitRef="usd">4600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-12" decimals="-5" id="f-608" unitRef="usd">7100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-13" decimals="-5" id="f-609" unitRef="usd">25800000</us-gaap:InterestExpense>
    <nbix:PrincipalAmountOnConversionRate contextRef="c-151" decimals="INF" id="f-610" unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-55"
      decimals="2"
      id="f-611"
      unitRef="usdPerShare">75.92</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nbix:DebtInstrumentConvertibleConversionPremium contextRef="c-55" decimals="3" id="f-612" unitRef="number">0.425</nbix:DebtInstrumentConvertibleConversionPremium>
    <us-gaap:SharePrice
      contextRef="c-55"
      decimals="INF"
      id="f-613"
      unitRef="usdPerShare">53.28</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-152"
      decimals="INF"
      id="f-614"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="c-153"
      decimals="2"
      id="f-615"
      unitRef="usdPerShare">98.70</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-152" decimals="INF" id="f-616" unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-152" decimals="INF" id="f-617" unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-152" decimals="INF" id="f-618" unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-152" decimals="INF" id="f-619" unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-152"
      decimals="INF"
      id="f-620"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="c-153"
      decimals="2"
      id="f-621"
      unitRef="usdPerShare">98.70</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <nbix:PrincipalAmountOnConversionRate contextRef="c-151" decimals="INF" id="f-622" unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice
      contextRef="c-154"
      decimals="INF"
      id="f-623"
      unitRef="number">0.98</nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-152" decimals="INF" id="f-624" unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c-155"
      decimals="INF"
      id="f-625"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c-155"
      decimals="INF"
      id="f-626"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-628">Goodwill and Intangible Assets&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the carrying amount of goodwill. Goodwill is included in other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.843%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill recognized in connection with business combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information relating to our recognized intangible assets as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents approximate future annual amortization expense for our finite-lived intangible assets as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.843%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-629">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.843%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill recognized in connection with business combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-27" decimals="-5" id="f-630" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-12" decimals="-5" id="f-631" unitRef="usd">5200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-12" decimals="-5" id="f-632" unitRef="usd">200000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-5" decimals="-5" id="f-633" unitRef="usd">5400000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-1" decimals="-5" id="f-634" unitRef="usd">400000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-4" decimals="-5" id="f-635" unitRef="usd">5800000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-637">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information relating to our recognized intangible assets as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-636">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information relating to our recognized intangible assets as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-156" id="f-638">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-156" decimals="-5" id="f-639" unitRef="usd">35900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-156" decimals="-5" id="f-640" unitRef="usd">4000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-156" decimals="-5" id="f-641" unitRef="usd">31900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-157" decimals="-5" id="f-642" unitRef="usd">3600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-157" decimals="-5" id="f-643" unitRef="usd">3600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-5" id="f-644" unitRef="usd">35500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-645">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.843%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-5" id="f-646" unitRef="usd">3600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-5" id="f-647" unitRef="usd">3600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-5" id="f-648" unitRef="usd">3600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-5" id="f-649" unitRef="usd">3600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-4" decimals="-5" id="f-650" unitRef="usd">3600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-4" decimals="-5" id="f-651" unitRef="usd">13900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-652">Other Balance Sheet Details&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, net, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less inventory reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tenant improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Scientific equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(83.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales rebates and reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued employee related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current income taxes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent income taxes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent branded prescription drug fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-653">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, net, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less inventory reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c-4" decimals="-5" id="f-654" unitRef="usd">21500000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c-5" decimals="-5" id="f-655" unitRef="usd">12000000.0</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c-4" decimals="-5" id="f-656" unitRef="usd">9700000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c-5" decimals="-5" id="f-657" unitRef="usd">5600000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-4" decimals="-5" id="f-658" unitRef="usd">12300000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-5" decimals="-5" id="f-659" unitRef="usd">17500000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross contextRef="c-4" decimals="-5" id="f-660" unitRef="usd">43500000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c-5" decimals="-5" id="f-661" unitRef="usd">35100000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves contextRef="c-4" decimals="-5" id="f-662" unitRef="usd">5200000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c-5" decimals="-5" id="f-663" unitRef="usd">0</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-5" id="f-664" unitRef="usd">38300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-5" id="f-665" unitRef="usd">35100000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-666">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tenant improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Scientific equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(83.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-158" decimals="-5" id="f-667" unitRef="usd">38100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-159" decimals="-5" id="f-668" unitRef="usd">37900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-160" decimals="-5" id="f-669" unitRef="usd">79600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-161" decimals="-5" id="f-670" unitRef="usd">58800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-162" decimals="-5" id="f-671" unitRef="usd">25200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-163" decimals="-5" id="f-672" unitRef="usd">21500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-164" decimals="-5" id="f-673" unitRef="usd">10900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-165" decimals="-5" id="f-674" unitRef="usd">6700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-5" id="f-675" unitRef="usd">153800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-5" id="f-676" unitRef="usd">124900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-5" id="f-677" unitRef="usd">83000000.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-5" id="f-678" unitRef="usd">66300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-5" id="f-679" unitRef="usd">70800000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-5" id="f-680" unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-681">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales rebates and reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued employee related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current income taxes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="c-4" decimals="-5" id="f-682" unitRef="usd">139300000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="c-5" decimals="-5" id="f-683" unitRef="usd">131900000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-684" unitRef="usd">86200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-685" unitRef="usd">72800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nbix:AccruedBrandedPrescriptionDrugFee contextRef="c-4" decimals="-5" id="f-686" unitRef="usd">45700000</nbix:AccruedBrandedPrescriptionDrugFee>
    <nbix:AccruedBrandedPrescriptionDrugFee contextRef="c-5" decimals="-5" id="f-687" unitRef="usd">27500000</nbix:AccruedBrandedPrescriptionDrugFee>
    <nbix:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-4" decimals="-5" id="f-688" unitRef="usd">44300000</nbix:AccruedResearchAndDevelopmentExpenseCurrent>
    <nbix:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-5" decimals="-5" id="f-689" unitRef="usd">39100000</nbix:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-4" decimals="-5" id="f-690" unitRef="usd">24400000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-5" decimals="-5" id="f-691" unitRef="usd">9000000.0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-692" unitRef="usd">108900000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-693" unitRef="usd">67300000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-694" unitRef="usd">448800000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-695" unitRef="usd">347600000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesTableTextBlock contextRef="c-1" id="f-696">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent income taxes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent branded prescription drug fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesTableTextBlock>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-4" decimals="-5" id="f-697" unitRef="usd">96000000.0</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-5" decimals="-5" id="f-698" unitRef="usd">19800000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <nbix:PrescriptionDrugFeeNoncurrent contextRef="c-4" decimals="-5" id="f-699" unitRef="usd">10300000</nbix:PrescriptionDrugFeeNoncurrent>
    <nbix:PrescriptionDrugFeeNoncurrent contextRef="c-5" decimals="-5" id="f-700" unitRef="usd">9900000</nbix:PrescriptionDrugFeeNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-5" id="f-701" unitRef="usd">106300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-5" id="f-702" unitRef="usd">29700000</us-gaap:OtherLiabilitiesNoncurrent>
    <nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock contextRef="c-1" id="f-703">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-704" unitRef="usd">251100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-5" id="f-705" unitRef="usd">262900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-4" decimals="-5" id="f-706" unitRef="usd">8000000.0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-5" decimals="-5" id="f-707" unitRef="usd">7800000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-5" id="f-708" unitRef="usd">259100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-5" id="f-709" unitRef="usd">270700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-710">Earnings Per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 4.7 million for 2023, 4.6 million for 2022 and 4.1 million for 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-711">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-5" id="f-712" unitRef="usd">249700000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-5" id="f-713" unitRef="usd">249700000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-12" decimals="-5" id="f-714" unitRef="usd">154500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-12" decimals="-5" id="f-715" unitRef="usd">154500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-13" decimals="-5" id="f-716" unitRef="usd">89600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-13" decimals="-5" id="f-717" unitRef="usd">89600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-718" unitRef="shares">97700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="-5" id="f-719" unitRef="shares">95800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-5" id="f-720" unitRef="shares">94600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-5" id="f-721" unitRef="shares">3300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-12" decimals="-5" id="f-722" unitRef="shares">3100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-13" decimals="-5" id="f-723" unitRef="shares">3300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-724" unitRef="shares">101000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="-5" id="f-725" unitRef="shares">98900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-5" id="f-726" unitRef="shares">97900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-727"
      unitRef="usdPerShare">2.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-728"
      unitRef="usdPerShare">1.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-729"
      unitRef="usdPerShare">0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-730"
      unitRef="usdPerShare">2.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-731"
      unitRef="usdPerShare">1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-732"
      unitRef="usdPerShare">0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-166"
      decimals="-5"
      id="f-733"
      unitRef="shares">4700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-167"
      decimals="-5"
      id="f-734"
      unitRef="shares">4600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-168"
      decimals="-5"
      id="f-735"
      unitRef="shares">4100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-736">Stock-Based Compensation&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Equity Incentive Plan.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, our stockholders approved an amendment of the 2020 Equity Incentive Plan (as so amended, the Amended 2020 Plan). The Amended 2020 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other awards. As of December 31, 2023, 10.5&#160;million shares of common stock remain available for future grant under the Amended 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Amended 2020 Plan, the number of shares of common stock available for issuance will be: (i) reduced by (a) one share for each share issued pursuant to an appreciation award (as defined in the Amended 2020 Plan) granted under the Amended 2020 Plan and (b) 2.13 shares for each share issued pursuant to a full value award (as defined in the Amended 2020 Plan) granted under the Amended 2020 Plan on or after May 18, 2022; and (ii) increased by (a) one share for each share subject to an appreciation award that becomes available again for issuance under the terms of the Amended 2020 Plan and (b) 2.13 shares for each share subject to a full value award that becomes available again for issuance under the terms of the Amended 2020 Plan on or after May 18, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2011 Equity Incentive Plan.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2011, we adopted the 2011 Equity Incentive Plan (the 2011 Plan). The 2011 Plan was a stockholder-approved plan pursuant to which outstanding awards have been made, but from which no further awards can or will be made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Stock Purchase Plan.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, our stockholders approved an amendment and restatement of the 2018 Employee Stock Purchase Plan (as so amended and restated, the Amended 2018 ESPP). As of December 31, 2023, 0.5&#160;million shares of common stock remain available for future issuance under the Amended 2018 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effect of stock-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by award-type &lt;span id="iae12b1f8f345443688fcf6efba5f4f06_8127"&gt;&lt;/span&gt;follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, unrecognized stock-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.726%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Recognition Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, stock options have a 10-year term and vest over a &lt;span style="-sec-ix-hidden:f-775"&gt;three&lt;/span&gt; to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, term and interest rates. The weighted-average grant-date fair values of stock options granted were $45.19 for 2023, $32.05 for 2022 and $45.02 for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected option term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average valuation assumptions were determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The expected volatility of common stock is estimated based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The risk-free interest rate for periods within the contractual life of a stock option is based upon observed interest rates appropriate for the expected term of our employee stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We have not historically declared or paid dividends and do not intend to do so in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents summary of activity related to stock options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.808%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of stock options exercised was $39.9 million for 2023, $39.7 million for 2022 and $58.0 million for 2021. Cash received from stock option exercises was $55.5 million for 2023, $37.0 million for 2022 and $20.7 million for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs typically vest over a four-year period and may be subject to a deferred delivery arrangement at the election of eligible employees. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. The total fair value of RSUs that vested was $101.0 million for 2023, $72.4 million for 2022 and $64.3 million for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.808%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-Based Restricted Stock Units. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PRSUs vest based on the achievement of certain predefined Company-specific performance criteria. Any unvested PRSUs will expire if it is determined the related performance criteria has not been met during the applicable &lt;span style="-sec-ix-hidden:f-833"&gt;three&lt;/span&gt; to four-year performance period. The fair value of PRSUs is estimated based on the closing sale price of our common stock on the date of grant. The fair value of PRSUs that vested during 2023 was $34.4 million. No PRSUs vested during 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to PRSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.808%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Amended 2018 ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of 85% of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of common stock on the purchase date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-169"
      decimals="-5"
      id="f-737"
      unitRef="shares">10500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward contextRef="c-170" decimals="0" id="f-738" unitRef="shares">1</nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward>
    <nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted contextRef="c-170" decimals="2" id="f-739" unitRef="shares">2.13</nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted>
    <nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward contextRef="c-170" decimals="0" id="f-740" unitRef="shares">1</nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward>
    <nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward contextRef="c-170" decimals="2" id="f-741" unitRef="shares">2.13</nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-171"
      decimals="INF"
      id="f-742"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-172"
      decimals="-5"
      id="f-743"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-744">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effect of stock-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:&lt;/span&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by award-type &lt;span id="iae12b1f8f345443688fcf6efba5f4f06_8127"&gt;&lt;/span&gt;follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, unrecognized stock-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.726%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Recognition Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-173" decimals="-5" id="f-745" unitRef="usd">126300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-174" decimals="-5" id="f-746" unitRef="usd">115400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-175" decimals="-5" id="f-747" unitRef="usd">85800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-176" decimals="-5" id="f-748" unitRef="usd">68000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-177" decimals="-5" id="f-749" unitRef="usd">57700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-178" decimals="-5" id="f-750" unitRef="usd">48400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-751" unitRef="usd">194300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-5" id="f-752" unitRef="usd">173100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-5" id="f-753" unitRef="usd">134200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-179" decimals="-5" id="f-754" unitRef="usd">91600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-180" decimals="-5" id="f-755" unitRef="usd">62600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-181" decimals="-5" id="f-756" unitRef="usd">60500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-182" decimals="-5" id="f-757" unitRef="usd">93400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-183" decimals="-5" id="f-758" unitRef="usd">86400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-184" decimals="-5" id="f-759" unitRef="usd">62500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-185" decimals="-5" id="f-760" unitRef="usd">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-186" decimals="-5" id="f-761" unitRef="usd">20100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-187" decimals="-5" id="f-762" unitRef="usd">7600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-188" decimals="-5" id="f-763" unitRef="usd">4700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-189" decimals="-5" id="f-764" unitRef="usd">4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-190" decimals="-5" id="f-765" unitRef="usd">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-766" unitRef="usd">194300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-5" id="f-767" unitRef="usd">173100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-5" id="f-768" unitRef="usd">134200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-191" decimals="-5" id="f-769" unitRef="usd">94100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-179" id="f-770">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-192" decimals="-5" id="f-771" unitRef="usd">162400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-182" id="f-772">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-193" decimals="-5" id="f-773" unitRef="usd">22300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-179" id="f-774">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-195" id="f-776">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-777"
      unitRef="usdPerShare">45.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-12"
      decimals="2"
      id="f-778"
      unitRef="usdPerShare">32.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-13"
      decimals="2"
      id="f-779"
      unitRef="usdPerShare">45.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-780">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected option term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-179" decimals="3" id="f-781" unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-180" decimals="3" id="f-782" unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-181" decimals="3" id="f-783" unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-179" decimals="3" id="f-784" unitRef="number">0.408</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-180" decimals="3" id="f-785" unitRef="number">0.426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-181" decimals="3" id="f-786" unitRef="number">0.459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-179" decimals="3" id="f-787" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-180" decimals="3" id="f-788" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-181" decimals="3" id="f-789" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-179" id="f-790">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-180" id="f-791">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-181" id="f-792">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-793">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents summary of activity related to stock options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.808%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="-5" id="f-794" unitRef="shares">9000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-795"
      unitRef="usdPerShare">79.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="-5" id="f-796" unitRef="shares">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-797"
      unitRef="usdPerShare">103.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="-5" id="f-798" unitRef="shares">800000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-799"
      unitRef="usdPerShare">66.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="-5" id="f-800" unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-801"
      unitRef="usdPerShare">98.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="-5" id="f-802" unitRef="shares">10000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-803"
      unitRef="usdPerShare">84.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-804">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-4" decimals="-5" id="f-805" unitRef="usd">467800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-4" decimals="-5" id="f-806" unitRef="shares">6800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-807"
      unitRef="usdPerShare">78.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-808">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-4" decimals="-5" id="f-809" unitRef="usd">361300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-810" unitRef="usd">39900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-12" decimals="-5" id="f-811" unitRef="usd">39700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-13" decimals="-5" id="f-812" unitRef="usd">58000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-5" id="f-813" unitRef="usd">55500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-12" decimals="-5" id="f-814" unitRef="usd">37000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-13" decimals="-5" id="f-815" unitRef="usd">20700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-182" id="f-816">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-182" decimals="-5" id="f-817" unitRef="usd">101000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-183" decimals="-5" id="f-818" unitRef="usd">72400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-184" decimals="-5" id="f-819" unitRef="usd">64300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-820">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.808%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to PRSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.808%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-196"
      decimals="-5"
      id="f-821"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-196"
      decimals="2"
      id="f-822"
      unitRef="usdPerShare">92.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-182"
      decimals="-5"
      id="f-823"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-182"
      decimals="2"
      id="f-824"
      unitRef="usdPerShare">103.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-182"
      decimals="-5"
      id="f-825"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-182"
      decimals="2"
      id="f-826"
      unitRef="usdPerShare">93.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-182"
      decimals="-5"
      id="f-827"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-182"
      decimals="2"
      id="f-828"
      unitRef="usdPerShare">95.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-192"
      decimals="-5"
      id="f-829"
      unitRef="shares">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-192"
      decimals="2"
      id="f-830"
      unitRef="usdPerShare">97.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-182" id="f-831">P1Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested contextRef="c-192" decimals="-5" id="f-832" unitRef="usd">312500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-198" id="f-834">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-185" decimals="-5" id="f-835" unitRef="usd">34400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-186" decimals="-5" id="f-836" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-187" decimals="-5" id="f-837" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-199"
      decimals="-5"
      id="f-838"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-199"
      decimals="2"
      id="f-839"
      unitRef="usdPerShare">101.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-185"
      decimals="-5"
      id="f-840"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-185"
      decimals="2"
      id="f-841"
      unitRef="usdPerShare">97.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-185"
      decimals="-5"
      id="f-842"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-185"
      decimals="2"
      id="f-843"
      unitRef="usdPerShare">98.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-185"
      decimals="-5"
      id="f-844"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-185"
      decimals="2"
      id="f-845"
      unitRef="usdPerShare">115.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-193"
      decimals="-5"
      id="f-846"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-193"
      decimals="2"
      id="f-847"
      unitRef="usdPerShare">89.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-185" id="f-848">P1Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested contextRef="c-193" decimals="-5" id="f-849" unitRef="usd">33000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-200"
      decimals="INF"
      id="f-850"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-851">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents income from continuing operations before provision for income taxes for domestic and international operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;409.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of income tax expense (benefit) for continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(45.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal income taxes at 21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant components of our deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.843%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;530.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;405.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(78.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net of deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(88.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;362.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, our deferred tax assets were primarily the result of net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. As of December 31, 2023 and 2022, we recorded a valuation allowance of $88.9 million and $67.0 million, respectively, against our gross deferred tax asset balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. As of December&#160;31, 2023, management determined there was sufficient positive evidence to conclude that it is more likely than not deferred tax assets of $362.6 million are realizable. The recorded valuation allowance of $88.9 million consisted primarily of state and foreign net operating loss carryforwards and state credit carryforwards for which management cannot conclude it is more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, we had state and foreign income tax net operating loss carryforwards of $286.0 million and $134.3 million, respectively. We had no federal income tax operating loss carryforwards as of December&#160;31, 2023. California net operating losses will begin to expire in 2029 unless previously utilized and the net operating losses related to other states will begin to expire in 2026. Swiss net operating losses will begin to expire in 2030 unless previously utilized. UK net operating losses will carry forward indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, we had state R&amp;amp;D tax credit carryforwards of $85.6 million. California R&amp;amp;D tax credits carry forward indefinitely, while R&amp;amp;D tax credits related to other states will begin to expire in 2033 unless previously utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the future utilization of our net operating loss and R&amp;amp;D tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. No ownership changes have occurred through December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize interest and penalties related to income tax matters in income tax expense. We had accruals for interest related to income tax matters of $3.1 million and $1.2 million, respectively, as of December 31, 2023 and 2022. We had accruals for penalties relates to income tax matters of $2.2 million and $0.4 million, respectively, as of December 31, 2023 and 2022. Accruals for interest and penalties related to income tax matters were not material as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to taxation in the U.S. and various state and foreign jurisdictions. Tax years for 2020 for federal, inception for California, 2016 to 2020 for other significant state jurisdictions, and 2021 and forward for foreign are subject to examination by tax authorities due to the carryforward of unutilized net operating losses and R&amp;amp;D tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease related to prior year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expiration of the statute of limitations for the assessment of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, we had $105.3 million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate, subject to changes in the valuation allowance. We do not expect a significant change in our unrecognized tax benefits in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the OECD announced an Inclusive Framework on Base Erosion and Profit Shifting including Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15%. Subsequently, multiple sets of administrative guidance have been issued. Many non-U.S. tax jurisdictions have either recently enacted legislation to adopt certain components of the Pillar Two Model Rules beginning in 2024 (including EU Member States) with the adoption of additional components in later years or announced their plans to enact legislation in future years. We are continuing to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in the non-U.S. tax jurisdictions we operate in.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-852">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents income from continuing operations before provision for income taxes for domestic and international operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;409.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-5" id="f-853" unitRef="usd">409200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-12" decimals="-5" id="f-854" unitRef="usd">218000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-13" decimals="-5" id="f-855" unitRef="usd">101400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-5" id="f-856" unitRef="usd">-77100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-12" decimals="-5" id="f-857" unitRef="usd">-4100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-13" decimals="-5" id="f-858" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-859" unitRef="usd">332100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-5" id="f-860" unitRef="usd">213900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-5" id="f-861" unitRef="usd">101400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-862">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of income tax expense (benefit) for continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(45.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-863" unitRef="usd">115000000.0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-864" unitRef="usd">17100000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-13" decimals="-5" id="f-865" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-866" unitRef="usd">28100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-867" unitRef="usd">20300000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-13" decimals="-5" id="f-868" unitRef="usd">6300000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-869" unitRef="usd">143100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-870" unitRef="usd">37400000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-13" decimals="-5" id="f-871" unitRef="usd">6300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-872" unitRef="usd">-45200000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-873" unitRef="usd">27500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-5" id="f-874" unitRef="usd">5900000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-875" unitRef="usd">-15500000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-876" unitRef="usd">-5500000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-5" id="f-877" unitRef="usd">-400000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-878" unitRef="usd">-60700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-879" unitRef="usd">22000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-13" decimals="-5" id="f-880" unitRef="usd">5500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-881" unitRef="usd">82400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-882" unitRef="usd">59400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-5" id="f-883" unitRef="usd">11800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-884">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal income taxes at 21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-13"
      decimals="INF"
      id="f-885"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-12"
      decimals="INF"
      id="f-886"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-887" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-5" id="f-888" unitRef="usd">69700000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-12" decimals="-5" id="f-889" unitRef="usd">44900000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-13" decimals="-5" id="f-890" unitRef="usd">21300000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-5" id="f-891" unitRef="usd">17500000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-12" decimals="-5" id="f-892" unitRef="usd">11800000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-13" decimals="-5" id="f-893" unitRef="usd">6200000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee contextRef="c-1" decimals="-5" id="f-894" unitRef="usd">8700000</nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee contextRef="c-12" decimals="-5" id="f-895" unitRef="usd">6500000</nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee contextRef="c-13" decimals="-5" id="f-896" unitRef="usd">4800000</nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee>
    <nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes contextRef="c-1" decimals="-5" id="f-897" unitRef="usd">0</nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes>
    <nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes contextRef="c-12" decimals="-5" id="f-898" unitRef="usd">12000000.0</nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes>
    <nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes contextRef="c-13" decimals="-5" id="f-899" unitRef="usd">0</nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-5" id="f-900" unitRef="usd">-3900000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-12" decimals="-5" id="f-901" unitRef="usd">-2500000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-13" decimals="-5" id="f-902" unitRef="usd">-11300000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost contextRef="c-1" decimals="-5" id="f-903" unitRef="usd">9600000</nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost contextRef="c-12" decimals="-5" id="f-904" unitRef="usd">9200000</nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost contextRef="c-13" decimals="-5" id="f-905" unitRef="usd">7000000.0</nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="-5" id="f-906" unitRef="usd">-2100000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-12" decimals="-5" id="f-907" unitRef="usd">-1300000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-13" decimals="-5" id="f-908" unitRef="usd">200000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <nbix:IncomeTaxReconciliationExpirationOfTaxCredits contextRef="c-1" decimals="-5" id="f-909" unitRef="usd">0</nbix:IncomeTaxReconciliationExpirationOfTaxCredits>
    <nbix:IncomeTaxReconciliationExpirationOfTaxCredits contextRef="c-12" decimals="-5" id="f-910" unitRef="usd">0</nbix:IncomeTaxReconciliationExpirationOfTaxCredits>
    <nbix:IncomeTaxReconciliationExpirationOfTaxCredits contextRef="c-13" decimals="-5" id="f-911" unitRef="usd">600000</nbix:IncomeTaxReconciliationExpirationOfTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-5" id="f-912" unitRef="usd">42200000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-12" decimals="-5" id="f-913" unitRef="usd">29900000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-13" decimals="-5" id="f-914" unitRef="usd">22000000.0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-5" id="f-915" unitRef="usd">22000000.0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="-5" id="f-916" unitRef="usd">7400000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="-5" id="f-917" unitRef="usd">5000000.0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-5" id="f-918" unitRef="usd">3100000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-12" decimals="-5" id="f-919" unitRef="usd">1300000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-13" decimals="-5" id="f-920" unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-921" unitRef="usd">82400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-922" unitRef="usd">59400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-5" id="f-923" unitRef="usd">11800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-924">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant components of our deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.843%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;530.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;405.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(78.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net of deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(88.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;362.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-5" id="f-925" unitRef="usd">36400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-5" id="f-926" unitRef="usd">27400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-4" decimals="-5" id="f-927" unitRef="usd">55300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-5" decimals="-5" id="f-928" unitRef="usd">108900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="c-4" decimals="-5" id="f-929" unitRef="usd">178700000</nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="c-5" decimals="-5" id="f-930" unitRef="usd">91100000</nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-4" decimals="-5" id="f-931" unitRef="usd">52700000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-5" decimals="-5" id="f-932" unitRef="usd">45900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <nbix:DeferredTaxAssetsOperatingLeasesAssets contextRef="c-4" decimals="-5" id="f-933" unitRef="usd">72000000.0</nbix:DeferredTaxAssetsOperatingLeasesAssets>
    <nbix:DeferredTaxAssetsOperatingLeasesAssets contextRef="c-5" decimals="-5" id="f-934" unitRef="usd">26800000</nbix:DeferredTaxAssetsOperatingLeasesAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-4" decimals="-5" id="f-935" unitRef="usd">110000000.0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-5" decimals="-5" id="f-936" unitRef="usd">80700000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-5" id="f-937" unitRef="usd">25000000.0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-5" id="f-938" unitRef="usd">24900000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-5" id="f-939" unitRef="usd">530100000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-5" id="f-940" unitRef="usd">405700000</us-gaap:DeferredTaxAssetsGross>
    <nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities contextRef="c-4" decimals="-5" id="f-941" unitRef="usd">66300000</nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities>
    <nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities contextRef="c-5" decimals="-5" id="f-942" unitRef="usd">21000000.0</nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-4" decimals="-5" id="f-943" unitRef="usd">12300000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-5" decimals="-5" id="f-944" unitRef="usd">11800000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-5" id="f-945" unitRef="usd">78600000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-5" id="f-946" unitRef="usd">32800000</us-gaap:DeferredIncomeTaxLiabilities>
    <nbix:DeferredTaxAssetsLiabilitiesGross contextRef="c-4" decimals="-5" id="f-947" unitRef="usd">451500000</nbix:DeferredTaxAssetsLiabilitiesGross>
    <nbix:DeferredTaxAssetsLiabilitiesGross contextRef="c-5" decimals="-5" id="f-948" unitRef="usd">372900000</nbix:DeferredTaxAssetsLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-5" id="f-949" unitRef="usd">88900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-5" id="f-950" unitRef="usd">67000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-5" id="f-951" unitRef="usd">362600000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-5" id="f-952" unitRef="usd">305900000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-5" id="f-953" unitRef="usd">88900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-5" id="f-954" unitRef="usd">67000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-5" id="f-955" unitRef="usd">362600000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-5" id="f-956" unitRef="usd">88900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-201" decimals="-5" id="f-957" unitRef="usd">286000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-202" decimals="-5" id="f-958" unitRef="usd">134300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-203" decimals="INF" id="f-959" unitRef="usd">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-201" decimals="-5" id="f-960" unitRef="usd">85600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:IncomeTaxExaminationInterestAccrued contextRef="c-4" decimals="-5" id="f-961" unitRef="usd">3100000</us-gaap:IncomeTaxExaminationInterestAccrued>
    <us-gaap:IncomeTaxExaminationInterestAccrued contextRef="c-5" decimals="-5" id="f-962" unitRef="usd">1200000</us-gaap:IncomeTaxExaminationInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAccrued contextRef="c-4" decimals="-5" id="f-963" unitRef="usd">2200000</us-gaap:IncomeTaxExaminationPenaltiesAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAccrued contextRef="c-5" decimals="-5" id="f-964" unitRef="usd">400000</us-gaap:IncomeTaxExaminationPenaltiesAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-965">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease related to prior year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expiration of the statute of limitations for the assessment of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-5" id="f-966" unitRef="usd">84500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-5" id="f-967" unitRef="usd">64600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-18" decimals="-5" id="f-968" unitRef="usd">60800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-5" id="f-969" unitRef="usd">3400000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-12" decimals="-5" id="f-970" unitRef="usd">4700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-13" decimals="-5" id="f-971" unitRef="usd">600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-5" id="f-972" unitRef="usd">36700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-12" decimals="-5" id="f-973" unitRef="usd">15200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-13" decimals="-5" id="f-974" unitRef="usd">4900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-5" id="f-975" unitRef="usd">3600000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-12" decimals="-5" id="f-976" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-13" decimals="-5" id="f-977" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-5" id="f-978" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-12" decimals="-5" id="f-979" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-13" decimals="-5" id="f-980" unitRef="usd">1700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-5" id="f-981" unitRef="usd">121000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-5" id="f-982" unitRef="usd">84500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-5" id="f-983" unitRef="usd">64600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-4" decimals="-5" id="f-984" unitRef="usd">105300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-985">Leases&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases that have commenced have terms that expire beginning 2025 through 2036 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our ROU assets or operating lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental operating lease information for operating leases that have commenced.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash related to letters of credit issued in lieu of cash security deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents approximate future non-cancelable minimum lease payments under operating leases and sublease income as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.843%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sublease&lt;br/&gt;Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments (sublease income)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1022"&gt;Less current operating lease liabilities included in other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Amounts presented in the table above exclude $15.4 million for 2025, $23.6 million for 2026, $24.3 million for 2027, $25.1 million for 2028 and $223.5 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Campus Facility.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, including a six-year option for the construction of a fifth building. This campus facility, comprised of office space and research and development laboratories, will serve as our new corporate headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The construction of the campus facility is phased. We recognized ROU assets of $199.0 million and operating lease liabilities of $189.8 million in association with the commencement of operating leases following the completion of the first phase of construction relating to office space in December 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As we begin to occupy our new campus facility, we will sublease certain of our existing leased premises when we determine there is excess leased capacity. Certain of these subleases contain both lease and non-lease components. Sublease income is recognized as an offset to operating expense on a straight-line basis over the lease term. Income related to non-lease components is recognized in operating expenses as a reduction to costs we incur in relation to the primary lease.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-986">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental operating lease information for operating leases that have commenced.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash related to letters of credit issued in lieu of cash security deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-987" unitRef="usd">17100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-12" decimals="-5" id="f-988" unitRef="usd">16300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-13" decimals="-5" id="f-989" unitRef="usd">15300000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-5" id="f-990" unitRef="usd">700000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-12" decimals="-5" id="f-991" unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-13" decimals="-5" id="f-992" unitRef="usd">0</us-gaap:SubleaseIncome>
    <nbix:OperatingLeaseCostNet contextRef="c-1" decimals="-5" id="f-993" unitRef="usd">16400000</nbix:OperatingLeaseCostNet>
    <nbix:OperatingLeaseCostNet contextRef="c-12" decimals="-5" id="f-994" unitRef="usd">16300000</nbix:OperatingLeaseCostNet>
    <nbix:OperatingLeaseCostNet contextRef="c-13" decimals="-5" id="f-995" unitRef="usd">15300000</nbix:OperatingLeaseCostNet>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-996" unitRef="usd">17900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-12" decimals="-5" id="f-997" unitRef="usd">16900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-13" decimals="-5" id="f-998" unitRef="usd">12600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-999">P10Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1000">P7Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-1001" unitRef="number">0.051</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-1002" unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:RestrictedCash contextRef="c-204" decimals="-5" id="f-1003" unitRef="usd">7800000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-205" decimals="-5" id="f-1004" unitRef="usd">7800000</us-gaap:RestrictedCash>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1005">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents approximate future non-cancelable minimum lease payments under operating leases and sublease income as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.843%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sublease&lt;br/&gt;Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments (sublease income)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1022"&gt;Less current operating lease liabilities included in other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Amounts presented in the table above exclude $15.4 million for 2025, $23.6 million for 2026, $24.3 million for 2027, $25.1 million for 2028 and $223.5 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-5" id="f-1006" unitRef="usd">33000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths contextRef="c-4" decimals="-5" id="f-1007" unitRef="usd">1700000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-5" id="f-1008" unitRef="usd">34700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears contextRef="c-4" decimals="-5" id="f-1009" unitRef="usd">1700000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-5" id="f-1010" unitRef="usd">34000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears contextRef="c-4" decimals="-5" id="f-1011" unitRef="usd">1700000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-5" id="f-1012" unitRef="usd">34800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears contextRef="c-4" decimals="-5" id="f-1013" unitRef="usd">1700000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-5" id="f-1014" unitRef="usd">35600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears contextRef="c-4" decimals="-5" id="f-1015" unitRef="usd">1700000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-5" id="f-1016" unitRef="usd">211400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter contextRef="c-4" decimals="-5" id="f-1017" unitRef="usd">4300000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-5" id="f-1018" unitRef="usd">383500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c-4" decimals="-5" id="f-1019" unitRef="usd">12800000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-5" id="f-1020" unitRef="usd">93200000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-5" id="f-1021" unitRef="usd">290300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-5" id="f-1023" unitRef="usd">32000000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-5" id="f-1024" unitRef="usd">258300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo contextRef="c-4" decimals="-5" id="f-1025" unitRef="usd">15400000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree contextRef="c-4" decimals="-5" id="f-1026" unitRef="usd">23600000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour contextRef="c-4" decimals="-5" id="f-1027" unitRef="usd">24300000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive contextRef="c-4" decimals="-5" id="f-1028" unitRef="usd">25100000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour contextRef="c-4" decimals="-5" id="f-1029" unitRef="usd">223500000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour>
    <nbix:LesseeOperatingLeaseOptionTermToConstructBuilding contextRef="c-206" id="f-1030">P6Y</nbix:LesseeOperatingLeaseOptionTermToConstructBuilding>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-207" decimals="-5" id="f-1031" unitRef="usd">199000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c-207" decimals="-5" id="f-1032" unitRef="usd">189800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1033">Retirement Plan&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a 401(k) defined contribution savings plan for the benefit of all qualifying employees and permits voluntary contributions by employees up to 60% of base salary limited by the IRS-imposed maximum. Employer contributions were $12.5 million for 2023, $10.3 million for 2022 and $8.1 million for 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c-1"
      decimals="INF"
      id="f-1034"
      unitRef="number">0.60</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-5" id="f-1035" unitRef="usd">12500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-12" decimals="-5" id="f-1036" unitRef="usd">10300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-13" decimals="-5" id="f-1037" unitRef="usd">8100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1038">Legal Proceedings&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, 2022, and 2023, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., (iv) Sandoz Inc. and (v) Zydus Pharmaceuticals (USA) Inc. that each company had filed an abbreviated new drug application (ANDA) with the FDA seeking approval of a generic version of INGREZZA. These companies represented that their respective ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by the manufacture, use or sale of the medicine for which the ANDA was submitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We filed suit in the U.S. District Court for the District of Delaware during 2021, 2022 and 2023, against (i) Teva Pharmaceuticals, Inc., Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (entity dismissed), collectively, "Teva", (ii) Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc. and Lupin Atlantis Holdings S.A., collectively, &#x201c;Lupin&#x201d;, (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., collectively, &#x201c;Crystal&#x201d;, (iv) Sandoz Inc., Sandoz International GmbH (entity dismissed) and Sandoz AG (entity dismissed), collectively, &#x201c;Sandoz&#x201d; and (v) Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC (entity dismissed), collectively, &#x201c;Zydus&#x201d;. We also filed suit in the U.S. District Court for the District of New Jersey during 2021, 2022 and 2023 against Zydus.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023 we entered into settlement agreements resolving the foregoing litigation with each of (i) Sandoz and Crystal, collectively, the &#x201c;Sandoz Parties&#x201d;, (ii) Teva, (iii) Lupin and (iv) Zydus. Pursuant to the terms of the respective agreements with the Sandoz Parties, Teva, Lupin, and Zydus, each of Teva, the Sandoz Parties, Lupin, and Zydus has the right to sell generic versions of INGREZZA in the United States beginning March 1, 2038, or earlier under certain circumstances. The settlements with Teva, the Sandoz Parties, Lupin and Zydus resolve all patent litigation brought by us against the companies that filed ANDAs seeking approval to market generic INGREZZA, and all cases have been dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-1" id="f-1039">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the period from October&#160;1, 2023, to December&#160;31, 2023, our executive officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Name and Title&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Action&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trading Arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Shares Authorized &lt;br/&gt;to be Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration &lt;br/&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rule 10b5-1*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-Rule 10b5-1**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;George Morrow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adopt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12/14/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;X&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/15/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Director)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Eric Benevich&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Terminate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/30/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;X&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12/31/2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Chief Commercial Officer)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adopt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/29/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;X&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/27/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ingrid Delaet&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adopt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/29/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;X&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9/7/2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Chief Regulatory Officer)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leslie Norwalk&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adopt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/28/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;X&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/28/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Director)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shalini Sharp&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adopt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/27/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;X&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5/31/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Director)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Richard Pops&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adopt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/21/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;X&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11/30/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Director)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;* Intended to satisfy the affirmative defense of Rule 10b5-1(c)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) On November 30, 2023, Eric Benevich, Chief Commercial Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1 (the &#x201c;Benevich 10b5-1 Plan&#x201d;). The Benevich 10b5-1 Plan was entered into on February 23, 2022, with an expiration date of December 31, 2023.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-208" id="f-1040">George Morrow</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-208" id="f-1041">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-208" id="f-1042">12/14/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-209"
      decimals="0"
      id="f-1043"
      unitRef="shares">40000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndTitle contextRef="c-208" id="f-1044">(Director)</ecd:TrdArrIndTitle>
    <ecd:TrdArrIndName contextRef="c-210" id="f-1045">Eric Benevich</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-211" id="f-1046">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrTerminationDate contextRef="c-211" id="f-1047">11/30/2023</ecd:TrdArrTerminationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-212"
      decimals="0"
      id="f-1048"
      unitRef="shares">131341</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndTitle contextRef="c-210" id="f-1049">(Chief Commercial Officer)</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-213" id="f-1050">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-213" id="f-1051">11/29/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-214"
      decimals="0"
      id="f-1052"
      unitRef="shares">169818</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-215" id="f-1053">Ingrid Delaet</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-215" id="f-1054">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-215" id="f-1055">11/29/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-216"
      decimals="0"
      id="f-1056"
      unitRef="shares">30000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndTitle contextRef="c-215" id="f-1057">(Chief Regulatory Officer)</ecd:TrdArrIndTitle>
    <ecd:TrdArrIndName contextRef="c-217" id="f-1058">Leslie Norwalk</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-217" id="f-1059">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-217" id="f-1060">11/28/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-218"
      decimals="0"
      id="f-1061"
      unitRef="shares">9106</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndTitle contextRef="c-217" id="f-1062">(Director)</ecd:TrdArrIndTitle>
    <ecd:TrdArrIndName contextRef="c-219" id="f-1063">Shalini Sharp</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-219" id="f-1064">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-219" id="f-1065">11/27/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-220"
      decimals="0"
      id="f-1066"
      unitRef="shares">1106</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndTitle contextRef="c-219" id="f-1067">(Director)</ecd:TrdArrIndTitle>
    <ecd:TrdArrIndName contextRef="c-221" id="f-1068">Richard Pops</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-221" id="f-1069">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-221" id="f-1070">11/21/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-222"
      decimals="0"
      id="f-1071"
      unitRef="shares">42100</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndTitle contextRef="c-221" id="f-1072">(Director)</ecd:TrdArrIndTitle>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-223" id="f-1073">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-223" id="f-1074">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-224" id="f-1075">February 23, 2022</ecd:TrdArrAdoptionDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
